Nos. 25-1611, 25-1612

UNITED STATES COURT OF APPEALS FOR THE FIRST CIRCUIT

(No. 25-1611)

AMERICAN PUBLIC HEALTH ASSOCIATION; IBIS REPRODUCTIVE HEALTH; INTERNATIONAL UNION, UNITED AUTOMOBILE, AEROSPACE, AND AGRICULTURAL IMPLEMENT WORKERS (UAW); BRITTANY CHARLTON; KATIE EDWARDS; PETER LURIE; NICOLE MAPHIS,

Plaintiffs-Appellees,

v.

NATIONAL INSTITUTES OF HEALTH; JAY BHATTACHARYA, in his official capacity as Director of the National Institutes of Health; UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; ROBERT F. KENNEDY, JR., in his official capacity as Secretary of Health and Human Services,

Defendants-Appellants.

(Caption continued on inside cover)

Appeals from the U.S. District Court for the District of Massachusetts

PLAINTIFF STATES' RESPONSE BRIEF IN NO. 25-1612

ROB BONTA
Attorney General of California
455 Golden Gate Avenue
San Francisco, CA 94102

ANTHONY G. BROWN
Attorney General of Maryland
200 Saint Paul Place, 20th Floor
Baltimore, MD 21202

NICHOLAS W. BROWN
Attorney General of Washington
800 Fifth Avenue, Suite 2000
Seattle, WA 98104

(Additional counsel listed at pages 67-71)

ANDREA JOY CAMPBELL
Attorney General of Massachusetts
DAVID C. KRAVITZ
State Solicitor
GERARD J. CEDRONE
Deputy State Solicitor
VANESSA A. ARSLANIAN
State Trial Counsel
PHOEBE M. LOCKHART
Assistant Attorney General
One Ashburton Place, 20th Floor
Boston, MA 02108
(617) 963-2282
gerard.cedrone@mass.gov

Counsel for the Plaintiff States

(No. 25-1612)

COMMONWEALTH OF MASSACHUSETTS; STATE OF CALIFORNIA; STATE OF MARYLAND; STATE OF WASHINGTON; STATE OF ARIZONA; STATE OF COLORADO; STATE OF DELAWARE; STATE OF HAWAIʻI; STATE OF MINNESOTA; STATE OF NEVADA; STATE OF NEW JERSEY; STATE OF NEW MEXICO; STATE OF NEW YORK; STATE OF OREGON; STATE OF RHODE ISLAND; STATE OF WISCONSIN,

Plaintiffs-Appellees,

v.

ROBERT F. KENNEDY, JR., in his official capacity as Secretary of Health and Human Services; UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; JAY BHATTACHARYA, in his official capacity as Director of the National Institutes of Health; NATIONAL INSTITUTES OF HEALTH; NATIONAL CANCER INSTITUTE; NATIONAL EYE INSTITUTE; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; NATIONAL HUMAN GENOME RESEARCH INSTITUTE; NATIONAL INSTITUTE ON AGING; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS; NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES; NATIONAL INSTITUTE ON DRUG ABUSE; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES; NATIONAL INSTITUTE OF MENTAL HEALTH; NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; NATIONAL INSTITUTE OF NURSING RESEARCH; NATIONAL LIBRARY OF MEDICINE; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES; JOHN E. FOGARTY INTERNATIONAL CENTER FOR ADVANCED STUDY IN THE HEALTH SCIENCES; NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH; NIH CENTER FOR SCIENTIFIC REVIEW,

Defendants-Appellants.

TABLE OF CONTENTS

Introduction 1

Statement of the Issues 2

Statement of the Case 2

I. Background 2

A. NIH's Support for Biomedical Research 2

B. Adoption of the Challenged Directives 4

1. Secretarial Directive 4

2. Memoli Directive 6

3. Subsequent Directives 7

C. Implementation of the Challenged Directives 9

1. Termination of Existing Grants 10

2. Delay and Denial of Applications for New Grants 15

D. Harms to the Plaintiff States and Public 16

II. Procedural History 17

A. District Court Proceedings 17

B. Stay Proceedings 21

Summary of the Argument 25

Argument 27

I. The district court properly vacated the Challenged Directives. 27

A. The Challenged Directives are arbitrary and capricious. 28

1. The Challenged Directives are not reasonable or reasonably explained. 28

2. Defendants ignored significant reliance interests. 34

B. Defendants identify no impediment to judicial review of the Challenged Directives. 36

1. The plaintiff states have standing. 36

a. Defendants' termination of hundreds of existing research grants conferred standing. 37

b. Defendants' delay and denial of applications for new research grants conferred standing. 38

2. The parties' dispute is not moot. 41

3. The directives constituted final agency action. 46

4. The directives are not committed to agency discretion. 51

II. The district court properly set aside discrete termination decisions premised on the Challenged Directives. 53

A. The Supreme Court's stay decision, while entitled to due weight, is not a final decision on the merits. 53

B. Blackletter jurisdictional principles support the district court's exercise of jurisdiction. 56

C. The parties' complex, ongoing relationship shows that this is an APA suit. 61

D. Defendants' arguments would deprive injured parties of prospective relief. 63

E. If this Court reverses on jurisdiction, it should provide clear guidance for subsequent proceedings. 64

Conclusion 66

TABLE OF AUTHORITIES

Cases:

Abbott Labs. v. Gardner,
387 U.S. 136 (1977) 48, 49, 50

Adams v. Bowater Inc.,
313 F.3d 611 (1st Cir. 2002) 46

Adarand Constructors, Inc. v. Slater,
528 U.S. 216 (2000) 46

Am. Med. Ass'n v. Reno,
57 F.3d 1129 (D.C. Cir. 1995) 52

Am. Pub. Health Ass'n v. NIH,
145 F.4th 39 (1st Cir. 2025) 22, 23, 29, 35, 51

Am. Sci. & Eng'g, Inc. v. Califano,
571 F.2d 58 (1st Cir. 1978) 56

Bennett v. Spear,
520 U.S. 154 (1997) 47

Biden v. Texas,
597 U.S. 785 (2022) 48, 50

Bowen v. Massachusetts,
487 U.S. 879 (1988) 22, 57, 59, 60, 61, 62

City of Waltham v. USPS,
786 F. Supp. 105 (D. Mass. 1992) 5

Conservation Law Found. v. Evans,
360 F.3d 21 (1st Cir. 2004) 44, 45

Crowley Gov't Servs., Inc. v. GSA,
38 F.4th 1099 (D.C. Cir. 2022) 58

Dep't of Education v. California,
145 S. Ct. 966 (2025) 22, 23, 24

Dep't of Homeland Security v. Regents of the Univ. of California,
591 U.S. 1 (2020) 28, 31, 34

Dep't of State v. AIDS Vaccine Advocacy Coal.,
No. 25A269, 2025 WL 2740571 (U.S. Sept. 26, 2025) 27, 54

Doe v. Shibinette,
16 F.4th 894 (1st Cir. 2021) 36

Does 1-3 v. Mills,
142 S. Ct. 17 (2021) 54

FCC v. Fox Television Stations, Inc.,
556 U.S. 502, 515 (2009) 21, 34

Ferreiro v. United States,
501 F.3d 1349 (Fed. Cir. 2007) 63

Firearms Regulatory Accountability Coal., Inc. v. Garland,
112 F.4th 507 (8th Cir. 2024) 50

Friends of the Earth, Inc. v. Laidlaw Env't Servs. (TOC), Inc.,
528 U.S. 167 (2000) 41

Great-West Life & Annuity Insurance Co. v. Knudson,
534 U.S. 204 (2002) 22

L.A. County v. Davis,
440 U.S. 625 (1979) 44

Labrador v. Poe,
144 S. Ct. 921 (2024) 54

Lincoln v. Vigil,
508 U.S. 182 (1993) 52

Match-E-Be-Nash-She-Wish Band v. *Patchak*,
567 U.S. 209 (2012) 60

Md. Dep't of Hum. Res. v. HHS,
763 F.2d 1441 (D.C. Cir. 1985) 57

Me. Cmty. Health Options v. United States,
590 U.S. 296 (2020) 62, 63

Megapulse, Inc. v. Lewis,
672 F.2d 959 (D.C. Cir. 1982) 57

Motor Vehicle Mfrs. Ass'n of the United States, Inc. v. State Farm Mut. Auto. Ins. Co.,
463 U.S. 29 (1983) 33

N.H. Lottery Comm'n v. Rosen,
986 F.3d 38 (1st Cir. 2021) 43

NIH v. Am. Pub. Health Ass'n,
145 S. Ct. 2658 (2025) 27, 37, 38, 49, 53, 54, 55, 57, 58, 60, 64, 65

Ohio v. EPA,
603 U.S. 279 (2024) 28

Trump v. Boyle,
145 S. Ct. 2653 (2025) 53, 54, 55, 56

U.S. Army Corps of Engineers v. Hawkes Co.,
578 U.S. 590 (2016) 47, 49

Union of Concerned Scientists v. Wheeler,
954 F.3d 11 (1st Cir. 2020) 52

Weyerhaeuser Co. v. U.S. Fish & Wildlife Serv.,
586 U.S. 9 (2018) 51, 64

Statutes:

5 U.S.C. §551 20

5 U.S.C. §551(4) 48

5 U.S.C. §551(13) 47

5 U.S.C. §701(a)(2) 51

5 U.S.C. §704 50

5 U.S.C. §706(1) 19, 40, 41

5 U.S.C. §706(2)(A) 19, 20, 21, 50

42 U.S.C. §283p 12

42 U.S.C. §284a(a)(3)(A)(ii) 3

42 U.S.C. §285a-6 11

42 U.S.C. §285t(c) 11

42 U.S.C. §289a(a) 3

Rules:

Fed. R. Civ. P. 54(b) 19, 21

Agency Documents:

NIH Data Book, *Research Project Grants* (last updated Jan. 2025), https://report.nih.gov/nihdatabook/report/20 4

NIH RePORT, No. 1F31DA059262-01A1, *Exploration of the Unique Neurobehavioral Profile of Sequential Opioid-Stimulant Polysubstance Use Disorders*, https://bit.ly/1F31DA059262-01A1 10

NIH RePORT, No. 1K99MD019294-01, *Identifying Unique Biological Factors as Potential Targets to Mitigate Colorectal Cancer Health Disparities in Native Hawaiians*, https://bit.ly/1K99MD019294-01 12

NIH RePORT, No. 3R01AG077579-02S1, *Understanding Biological and Lifestyle Contributions to Alzheimer's Disease Pathology and Clinical Profiles in Black Women: Defining Prevention Targets in High Risk Groups*, https://bit.ly/3R01AG077579-02S1 12

NIH RePORT, No. 3R01AI169543-01S1, *Rapid Response for Pandemics: Single Cell Sequencing and Deep Learning to Predict Antibody Sequences Against an Emerging Antigen*, http://bit.ly/3R01AI169543-01S1 11

NIH RePORT, No. 5R01AI179080-02, *Bacterial and Molecular Determinants of Mycobacterial Impermeability*, https://bit.ly/5R01AI179080-02 11

NIH, *NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity*, pt. 2, §I, https://perma.cc/S83S-H23T 31

NIH, *Questions and Answers for NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity*, https://bit.ly/PAR-23-275-FAQ (archived April 5, 2025) 31

NIH, Statement, *Advancing NIH's Mission Through a Unified Strategy* (Aug. 15, 2025), https://perma.cc/V5E2-4ED2 41

Other Authorities:

United for Med. Rsch., NIH's Role in Sustaining the U.S. Economy (March 2025), https://bit.ly/UMR-2025 3

GLOSSARY

APA	Administrative Procedure Act
App.	Appendix (filed Oct. 9, 2025)
A.R.	Administrative Record
Bhattacharya Statement	NIH, Statement, *Advancing NIH's Mission Through a Unified Strategy* (Aug. 15, 2025), https://perma.cc/V5E2-4ED2
Challenged Directives	Memoli Directive, Secretarial Directive, and several other directives described in State Doc. 151, at 1 n. 1
DEI	diversity, equity, and inclusion
DOJ	Department of Justice
HHS	Department of Health and Human Services
Memoli Directive	Directive on NIH Priorities (Feb. 21, 2025) (App. 2444-2445)
NIH	National Institutes of Health
NOFO	notice of funding opportunity
OMB	Office of Management and Budget
Secretarial Directive	Secretarial Directive on DEI-Related Funding (Feb. 10, 2025) (App. 1639-1640)
State Doc.	document filed in the district court in No. 25-cv-10814 (1st Cir. No. 25-1612)
Supp. App.	Supplemental Appendix (filed Nov. 12, 2025)

REASONS WHY ORAL ARGUMENT SHOULD BE HEARD

The federal government asks this Court to overturn a final judgment in favor of 16 plaintiff states on an issue of significant public importance. Oral argument will materially assist the Court in addressing the federal government's contested legal arguments.

INTRODUCTION

The agency actions underlying this case are, as the district court found, "breathtakingly arbitrary and capricious." Appendix (App.) 163. In a series of directives with virtually no reasoning, defendants prohibited the National Institutes of Health from supporting any scientific research concerning seven topics. Defendants then executed those directives by canceling hundreds of grants to public universities in the 16 plaintiff states for studies on health conditions as varied as heart disease, HIV/AIDS, and Alzheimer's—all without warning.

Defendants do not appear eager to defend their conduct on the merits. They serve up a smorgasbord of threshold issues that supposedly bar the plaintiff states' APA claims; only in the waning pages of their brief do they argue that their actions were not, in fact, arbitrary and capricious. But defendants have identified no substantial impediment to judicial review, and they fail to rebut the district court's determination that both their upstream policies and downstream grant terminations were unlawful. This Court should affirm that judgment in its entirety.

STATEMENT OF THE ISSUES

1. Whether the district court properly vacated a series of NIH policies—the "Challenged Directives"—that defendants promulgated, without reasoning or support, to bar the agency from supporting research on certain subjects.

2. Whether the district court had jurisdiction to vacate the termination of 846 specific grants to the plaintiff states, where the terminations were premised solely on the Challenged Directives.

STATEMENT OF THE CASE

I. Background

A. NIH's Support for Biomedical Research

NIH is the largest public funder of medical research in the world. App. 89. The agency's work has spurred life-changing advances, from the creation of the rubella vaccine to the discovery of the BRCA mutation responsible for various forms of breast and ovarian cancer. App. 460 nn. 3-4 (collecting citations).

While NIH conducts some research in-house, most of its support for biomedical research comes in the form of competitive grants to non-federal scientists. App. 89. These awards not only support the funded projects themselves, but also contribute to our nation's economic security

and prosperity. NIH-funded projects ensure that the next generation of scientists and researchers is trained—and that tomorrow's medical breakthroughs are discovered—in American laboratories. NIH grants also drive economic activity in communities around the country by supporting jobs and the purchase of research-related goods and services. In Fiscal Year 2024, NIH awarded over $36 billion in outside grants.[1]

To secure one of these grants, a researcher must go through a rigorous application process. This process typically begins with a public "notice of funding opportunity" (NOFO), in which NIH invites specific research proposals. App. 90; *see* State Doc.[2] 77-11, §2.3.5, at I-51. The resulting applications must then survive multiple layers of review, including evaluation by experts in the relevant field, who assess the proposal's scientific merit, and evaluation by outside advisors and agency officials, who weigh programmatic considerations. *See* 42 U.S.C. §289a(a) (describing "technical and scientific peer review"); *id.* §284a(a)(3)(A)(ii) (describing review by NIH's "advisory councils"); App. 90. This process

---

[1] United for Med. Rsch., NIH's Role in Sustaining the U.S. Economy, at 5 (March 2025), https://bit.ly/UMR-2025.

[2] This brief uses "State Doc." to refer to documents filed in the district court in No. 25-cv-10814 (1st Cir. No. 25-1612).

is highly competitive: the "success rate" for reviewed applications has hovered around 20% over the past two decades.[3]

B. Adoption of the Challenged Directives

The above-described process for awarding NIH research grants has historically been governed, across presidential administrations, by the apolitical assessment of proposed projects' scientific merit. That changed earlier this year with defendants' adoption of the Challenged Directives—a suite of policies that prohibited NIH from supporting any projects with a perceived connection to seven ill-defined topics. The district court described the evolution of these directives in detail. *See* App. 95-153. This section reviews the development and content of the directives most pertinent to this appeal.

1. Secretarial Directive

On February 10, the Acting Secretary of Health and Human Services issued a memorandum entitled "Secretarial Directive on DEI-Related Funding" (Secretarial Directive). App. 1639-1640; *see* App. 97-99. The directive contained several conclusory statements about "diversity,

[3] NIH Data Book, *Research Project Grants* (last updated Jan. 2025), https://report.nih.gov/nihdatabook/report/20.

equity, and inclusion ('DEI')"—a term the directive did not define. For example, the directive stated, without any elaboration, that "grants that support DEI" are "inconsistent with the Department's policy of improving the health and well-being of all Americans." App. 1639. The directive also stated—again without any support—that "grants [that support DEI] can cause serious programmatic failures." *Id.* Based on these unexplained pronouncements, the directive instructed NIH personnel to pause all payments for grants "related to DEI and similar programs" and advised that "grants may be terminated." *Id.*

Defendants have certified that the "complete administrative record for [the Secretarial Directive] consists" only of the two-page directive itself. State Doc. 118-1 (¶7) (attesting that the record for the directive consists of App. 1639-1640); *accord* App. 99. In other words, defendants admit that they considered no other documents or evidence in promulgating the directive or in reaching the conclusions therein. *See City of Waltham v. USPS*, 786 F. Supp. 105, 116 (D. Mass. 1992) (explaining that the administrative record must contain "all documents and materials directly or indirectly considered by agency decision-makers").

2. Memoli Directive

On February 21, Acting NIH Director Matthew Memoli issued a memorandum entitled "Directive on NIH Priorities" (Memoli Directive). App. 2444-2445; *see* App. 105-110. The first half of the directive offered various conclusions about "studies based on diversity, equity, and inclusion (DEI) and gender identity," including:

> Research programs based primarily on artificial and non-scientific categories, including amorphous equity objectives, are antithetical to the scientific inquiry, do nothing to expand our knowledge of living systems, provide low returns on investment, and ultimately do not enhance health, lengthen life, or reduce illness. Worse, DEI studies are often used to support unlawful discrimination on the basis of race and other protected characteristics, which harms the health of Americans. . . .
>
> Likewise, research programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans. Many such studies ignore, rather than seriously examine, biological realities.

App. 2444. The memorandum gave no support for these factual claims—nor, like the Secretarial Directive, did it explain what qualifies as impermissible "DEI." As with the Secretarial Directive, the administrative record reveals that the agency considered no other documents or evidence in promulgating the directive. The document stated in passing that Memoli "issue[d] th[e] directive based on [his] expertise and experience." *Id.* But

the record shows, and the district court found, that "much, if not all, of the content" of this directive "was provided to [Acting Director Memoli] by [the Department of Health and Human Services (HHS)]." App. 110; *see* App. 589 (stating that pertinent "[l]anguage [was] provided to NIH by HHS").

The second half of the Memoli Directive operationalized the directive's conclusory statements, "direct[ing]" NIH offices to "conduct an internal review of all . . . existing awards" to "ensur[e]" that they "do not fund or support . . . DEI and gender identity research activities and programs." App. 2445. The directive further instructed that any grants "deemed inconsistent with NIH's mission" would be "subject to funding restrictions, terminated or partially terminated, paused, and/or not continued or renewed." *Id.*

3. Subsequent Directives

Starting in March, several follow-on directives expanded upon and implemented the foregoing policies. *See* App. 561-680, 2126-2245; Supplemental Appendix (Supp. App.) 2705-2707 (collecting the directives referred to below as the "Priorities Directive," "Award Revision Guidance," and various "Revised Priorities Directives"); *see also* App. 126-132, 142-

153. Two aspects of these later directives are relevant to this appeal.

First, these directives expanded the list of prohibited research subjects without explanation. As just discussed, the Memoli Directive barred NIH from supporting any projects related to "DEI" or "gender identity." Subsequent directives added "Vaccine Hesitancy," "COVID," "Climate Change," and "Influencing Public Opinion" to the list of forbidden topics. App. 670, 2333.[4] The administrative record does not reveal the origin of, or provide any underlying rationale for, the addition of these new topics.

Second, these additional directives instructed NIH officials to terminate awards with a perceived connection to the offending topics—and even provided the exact language for NIH officials to use in doing so. *See, e.g.*, App. 565-566, 598-599. For example, program officials were told to cancel any grant with a perceived connection to "DEI" using the following boilerplate text, lifted almost verbatim from the Memoli Directive:

> "Research programs based primarily on artificial and non-scientific categories, including amorphous equity objectives, are antithetical to the scientific inquiry, do nothing to expand our knowledge of living systems, provide low returns on investment, and ultimately do not enhance health, lengthen life, or reduce illness. Worse, so-called diversity, equity, and inclusion ("DEI") studies are often used to support unlawful

[4] The district court held that plaintiffs lacked standing to challenge a seventh category, "China." App. 153-154.

> discrimination on the basis of race and other protected characteristics ICO's [*sic*], which harms the health of Americans. Therefore, it is the policy of NIH not to prioritize such research programs."

App. 670 (quotation marks in original); *see, e.g.*, App. 1670, 1708, 1723, 1732, 1740 (termination letters copying this language). Program officials were likewise given text from the Memoli Directive to use when canceling grants with a perceived connection to gender-identity issues:

> "Research programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans. Many such studies ignore, rather than seriously examine, biological realities. It is the policy of NIH not to prioritize these research programs."

App. 670 (quotation marks in original); *see, e.g.*, App. 1672, 1704, 1725, 1771, 1777 (termination letters copying this language). The directives provided similar stock language for the rest of the topics, too. *See* App. 670 (full menu of boilerplate termination language on each topic).

As with the earlier directives, the record shows that defendants did not consider any underlying materials or evidence in promulgating these later directives.

C. Implementation of the Challenged Directives

In the weeks following the promulgation of the Challenged Directives, defendants implemented them by launching an unprecedented

mass termination of grants for existing research projects and delaying and denying pending applications for future research projects.

1. Termination of Existing Grants

The termination of an NIH grant has historically been a rare occurrence: before this year, NIH typically canceled only a handful of grants per decade, usually for serious issues like the death of a researcher or gross misconduct. State Doc. 77-37, ¶¶29-31; State Doc. 77-41, at 44:7-45:23. Starting in January, however, defendants terminated thousands of grants nationwide—including over 800 grants to the plaintiff states' public universities and other instrumentalities. State Doc. 151-1.

The terminated grants, which NIH had awarded after robust review of the projects' scientific merit, supported research benefitting a broad swath of the American public. One University of Washington study, for example, aimed to develop new pharmaceutical treatments by examining how simultaneous use of opioids and stimulants—a "deadl[y] combination[]" that is "increasingly responsible for overdose deaths"—can affect the brain's neural pathways.[5] A canceled University of

[5] NIH RePORT, No. 1F31DA059262-01A1, *Exploration of the Unique Neurobehavioral Profile of Sequential Opioid-Stimulant Polysubstance Use Disorders*, https://bit.ly/1F31DA059262-01A1.

Massachusetts project, meanwhile, sought to analyze the properties of the tuberculosis bacterium's "cell envelope" to better understand why it is relatively impermeable to drug compounds, with a view to improving treatments for the highly contagious disease.[6] And a terminated University of California study aimed to develop a "rigorously tested and fully automated" AI system capable of "rapidly generat[ing] synthetic antibody candidates" to fight new viruses.[7]

Other canceled grants focused on issues impacting more discrete demographic groups, consistent with Congress's express statutory commands. Congress has instructed NIH to undertake research on, among other things, conditions uniquely or disproportionately affecting racial or ethnic minorities, 42 U.S.C. §285t(c)(2)-(3); various women's health conditions, *id.* §§285a-6, §285b-7a(c); and "the health of sexual and gender

---

[6] NIH RePORT, No. 5R01AI179080-02, *Bacterial and Molecular Determinants of Mycobacterial Impermeability*, https://bit.ly/5R01AI179080-02. UMass is a subawardee of the primary grantee, UVA. State Doc. 147-1, at 21.

[7] NIH RePORT, No. 3R01AI169543-01S1, *Rapid Response for Pandemics: Single Cell Sequencing and Deep Learning to Predict Antibody Sequences Against an Emerging Antigen*, http://bit.ly/3R01AI169543-01S1. UC Riverside is a subawardee of the primary grantee, the Keck Graduate Institute. State Doc. 147-1, at 52.

minority populations," *id.* §283p. So, for example, one terminated University of California study examined how inflammation, insulin resistance, and physical activity affect Alzheimer's disease in Black women, a group with "higher rate[s]" and "a more aggressive profile" of the disease than other demographic groups.[8] A terminated University of Hawai'i project, meanwhile, aimed to identify genetic and biological risk factors for colorectal cancer among Native Hawaiians, a population with "increased incidence and mortality rates of" that disease.[9]

Defendants accomplished the mass termination of these grants by dispatching swarms of boilerplate letters to the researchers whose projects were selected for cancellation. Each letter followed the same format, plugging the addressee, grant number, and scripted basis for termination—lifted directly from the Challenged Directives—into a fill-in-the-blank template with no individualized discussion of the relevant project.

---

[8] NIH RePORT, No. 3R01AG077579-02S1, *Understanding Biological and Lifestyle Contributions to Alzheimer's Disease Pathology and Clinical Profiles in Black Women: Defining Prevention Targets in High Risk Groups*, https://bit.ly/3R01AG077579-02S1.

[9] NIH RePORT, No. 1K99MD019294-01, *Identifying Unique Biological Factors as Potential Targets to Mitigate Colorectal Cancer Health Disparities in Native Hawaiians*, https://bit.ly/1K99MD019294-01.

App. 124-125 (blank template); *see, e.g.*, App. 2029-2030 (exemplar of a freestanding termination letter); App. 1848-1849 (exemplar of a "revised" award notice incorporating the termination script).

Defendants issued these terminations with no advance warning, and the administrative record reveals the haste with which defendants carried them out behind the scenes. Throughout March, Acting Director Memoli circulated spreadsheets containing anywhere from a dozen to several hundred grants, demanding that NIH officials terminate the listed projects with extraordinary speed. *E.g.*, App. 2072 ("Please terminate the grants on the attached spreadsheet by COB today."); App. 2097 (demanding termination of 530 grants "by COB next Friday," with "daily evening update[s] on how many were terminated"). The administrative record does not show who selected these awards for termination or what criteria they used. But one thing is clear: Acting Director Memoli did not undertake any independent review. Instead, the record shows that he typically approved terminations within minutes of receiving a list of grants flagged by the agency's black-box process. *See, e.g.*, App. 138 (finding that Memoli approved a list of terminations "within 2 minutes of" receiving it from a staffer).

Given defendants' lack of contemporaneous reasoning, it is impossible to glean from the record how defendants decided any *specific* project was related to one of the prohibited topics. For example, defendants canceled a grant entitled "Faithful Response II: COVID-19 Rapid Test-to-Treat with African American Churches" on the basis that it "focus[ed] on DEI." Administrative Record (A.R.) 2813, 2817-2818.[10] (As the termination letter makes clear, defendants did *not* cancel this grant because it involved COVID treatments. *Id.*) At the same time, defendants boasted in their briefing below that they spared grants entitled "Church Wellness Coordinator-led Intervention to Improve Hypertension Control in the Black Community" and "Engaging Partners in Caring Communities (EPICC): Building Capacity to Implement Health Promotion Programs in African American Churches." State Doc. 95-1. The record does not reveal, and defendants have never explained, why they deemed the first study impermissible "DEI" but view the second and third studies as permissible science.

[10] Electronic copies of A.R. 1-3824 are available on this Court's docket in No. 25-1612 under "Notice of Filing of Courtesy Electronic Copies" (July 8, 2025). Electronic copies of A.R. 3825-4270 are available at State Docs. 131-6 to -15.

2. Delay and Denial of Applications for New Grants

Defendants also enforced the Challenged Directives by delaying and denying pending applications for new research projects.

First, the directives led to extraordinary delay in the grant-award process. As discussed above, NIH follows a rigorous, multi-step process to review applications for research grants. *See supra*, at 3-4. Before the events giving rise to this lawsuit, that process adhered to a predictable timetable with periodic deadlines published well in advance. App. 482 (¶72). Throughout 2025, however, defendants dramatically upended that schedule, systematically delaying the review and disposition of pending applications—including applications that had received favorable marks from the agency's scientific examiners. *See, e.g.*, State Doc. 77-40 fig. 1; State Doc. 77-61, ¶¶5-9; State Doc. 101-3, ¶¶5-11 & figs. As a result of these delays, the plaintiff states were left waiting for the agency to review thousands of applications totaling millions of dollars of potential funding. *See, e.g.*, State Doc. 77-12, ¶¶27-55.

Second, the Challenged Directives caused defendants to deny many grant applications altogether. The plaintiff states have identified—through unrebutted evidence—applications that defendants denied or

"administratively withdrew" as a result of the Challenged Directives. *E.g.*, State Doc. 77-12, ¶56; State Doc. 77-18, ¶52. And in the co-pending case, defendants produced a certification to the private-party plaintiffs on August 19, 2025, admitting that they "administratively withdrew" applications because they had "withdr[awn] the applicable NOFO pursuant to the Challenged Directives." Supp. App. 2772-2799.[11]

D. Harms to the Plaintiff States and Public

Defendants' enforcement of the Challenged Directives caused significant and immediate injuries to the plaintiff states. For example, the termination of plaintiffs' grants threatened unrecoverable loss of scientific knowledge. *See* State Doc. 77-36, ¶21 (explaining that, when longitudinal studies are "stop[ped] in full swing, their partial results often lose validity"); State Doc. 77-33, ¶18(c) (describing the suspension of two such studies). Defendants' actions also imposed severe operational burdens on the plaintiff states' institutions. Planning at research universities often occurs years in advance, and universities organize their affairs around the grants they receive. *See, e.g.*, State Doc. 77-49, ¶9. The

[11] Defendants have agreed to provide a similar certification to the plaintiff states, *see* State Doc. 180, at 2-6, but their deadline to do so has not yet passed.

sudden cancellation and delay of plaintiffs' projects forced them to lay off highly specialized personnel, cut student enrollment, and even withdraw offers of admission. The University of Massachusetts, for example, was forced to lay off or furlough 209 employees at its medical school and cut the incoming fall 2025 graduate medical class by 86%. *See* State Doc. 77-45, ¶10; *see also, e.g.*, State Doc. 77-31, ¶18(b); State Doc. 77-59, ¶31; State Doc. 77-45, ¶15.

Defendants' terminations also harmed the public by eliminating patient-facing clinical programs. For example, a canceled study at San Diego State University had provided clinical care to 85 participants with a history of suicide attempts and current suicidal ideation. A.R. 2977; State Doc. 77-14, ¶¶78-80. Similarly, a terminated study at the University of Hawai‘i had provided advanced screening for HPV, a virus known to cause certain cancers. State Doc. 77-17, ¶44. "[T]here are no other options in a clinical setting in Hawai‘i for this type of important screening." *Id.*

II. Procedural History

A. District Court Proceedings

The plaintiff states' operative complaint asserted several claims,

including APA claims arising out of defendants' adoption of the Challenged Directives, termination of plaintiffs' existing research grants, and undue delay in reviewing applications for new grants. App. 458-549.

On May 12, 2025, the district court (Young, J.) ruled on several threshold issues. The court rejected defendants' argument that it lacked jurisdiction under the APA and that the Tucker Act required plaintiffs to sue in the Court of Federal Claims. App. 9-24. And the court rejected defendants' argument that the challenged decisions were committed to agency discretion. App. 26-27.

The district court then informally consolidated the plaintiff states' case with that of the private plaintiffs in No. 25-1611 and split further proceedings into two phases. In the first phase, the court directed the parties to address the legality of both the Challenged Directives and the resulting grant terminations. App. 733-734 (25:19-26:22).[12] The court

[12] As they did below, defendants argue (Br. 12) that the first phase was "limited" to "NIH's termination of awarded grants"—*i.e.*, that it did not concern the legality of the underlying Challenged Directives. That characterization is wrong, as the district court repeatedly explained. *See* App. 154 (rejecting "attempts to narrow the action to grant terminations"); App. 745 (6:17-20) ("[T]he defense either misunderstood or mischaracterizes the Court's view. I do think the very first issue to be considered is . . . the challenged directives."); App. 764 (25:8-11)

reserved for a second phase the issue of whether defendants' delay in reviewing applications for new or renewed research grants violated 5 U.S.C. §706(1). App. 81, 83, 734 (26:19-22).

Following production of the administrative record, robust briefing, and a bench trial on Phase One, the district court found that the Challenged Directives and resulting grant terminations were arbitrary and capricious under 5 U.S.C. §706(2)(A). The court announced its decision from the bench on June 16, explaining that the directives were "bereft of reasoning virtually in their entirety" and "unsupported by factual development." App. 263 (77:15-18). The court also concluded that the directives arbitrarily ignored "the reliance interests of the many parties affected." *Id.* (77:19-21). The court accordingly ruled that the Challenged Directives violated the APA and ordered that the directives and resulting grant terminations be set aside. App. 264-265 (78:19-79:1). The court reserved decision on other claims and issues.

The district court entered partial final judgment on this single claim on June 23. *See* Fed. R. Civ. P. 54(b). Paragraph I of the judgment

("[Defendants] are wrong to say we're only going to talk about the grant terminations, not these directives.").

set aside the Challenged Directives pursuant to §706(2)(A), declaring them "void, illegal, and of no force and effect." App. 74. Paragraph II set aside the "Resulting Grant Terminations" pursuant to §706(2)(A), declaring them likewise "void, illegal, and of no force and effect." *Id.* Paragraph III directed entry of judgment in favor of plaintiffs on Count 3 of the amended complaint—*i.e.*, the plaintiff states' arbitrary-and-capricious claim. *Id.* Paragraph IV noted the court's retention of jurisdiction to enforce the judgment. *Id.* And an attachment to the judgment identified 846 specific grants falling within the definition of "Resulting Grant Terminations." App. 73 n. 2; *see* State Doc. 151-1.

On July 2, the district court issued a written decision further explaining its reasoning. The court held that both the Challenged Directives and "the resultant, downstream individual terminations" constituted "final agency action[s]" under 5 U.S.C. §551. App. 154. On the merits, the court found that the Challenged Directives were propped up by "sparse pseudo-reasoning" and "wholly unsupported statements." App. 164; *see* App. 160-173. For example, there was "not a shred of evidence" to substantiate the directives' statement that "DEI studies are often used to support unlawful discrimination on the basis of race and other

protected characteristics." App. 169-170 (quoting App. 2444) (emphasis omitted). The court also saw "no evidence that [defendants] even considered the reliance interests that naturally inure to NIH grant process," despite their obligation to "'take[] into account'" any "'serious reliance interests'" when formulating a "'new policy.'" App. 172 (quoting *FCC v. Fox Television Stations, Inc.*, 556 U.S. 502, 515 (2009)). The court thus held that "the Challenged Directives are arbitrary and capricious under Section 706(2)(A), as are the concomitant grant terminations." App. 173.[13]

B. Stay Proceedings

1. Defendants moved the district court for a stay pending appeal, raising only their argument that the court lacked jurisdiction. The district court denied the motion. App. 181-186.

2. This Court likewise denied a stay. *See Am. Pub. Health Ass'n*

[13] The remainder of the district court's opinion addressed plaintiffs' claims that defendants violated certain statutory obligations (Count 1), and that defendants' reliance on certain Office of Management and Budget guidance was contrary to law (Count 2). The district court concluded that it mostly did not need to "dive into" Count 1 because it had already "declared [defendants'] actions arbitrary and capricious," although it did rule against plaintiffs on one discrete aspect of that count (concerning NIH's statutory obligation to develop a strategic plan). App. 178-179. The court found for plaintiffs on Count 2. App. 173-177. Neither count is currently before this Court; the Rule 54(b) judgment on appeal encompasses only Count 3, plaintiffs' arbitrary-and-capricious claim.

v. NIH, 145 F.4th 39 (2025) (*APHA*). The Court explained that the district court "clearly had jurisdiction" to set aside the Challenged Directives—indeed, defendants had "not develop[ed] an argument" otherwise. *Id.* at 50. As for the resulting terminations, the Court held that because plaintiffs' claims did not "depend on the terms or conditions of any contract" and sought "declaratory relief that is unavailable in the Court of Federal Claims," this case was "much closer to *Bowen* [*v. Massachusetts*, 487 U.S. 879 (1988)]," which allowed certain APA claims to proceed in district court, "than *Great-West* [*Life & Annuity Insurance Co. v. Knudson*, 534 U.S. 204 (2002)]," which held that certain ERISA claims could not proceed in district court. *APHA*, 145 F.4th at 50. The Court also explained that this case was distinguishable from *Department of Education v. California*, 145 S. Ct. 966 (2025), because the district court here (1) "did not 'enforce a contractual obligation to pay money,'" and (2) "neither examined any of the plaintiffs' grant terms nor interpreted them in reaching its ruling that the grant terminations must be set aside." *APHA*, 145 F.4th at 52 (quoting *California*, 145 S. Ct. at 968).

The Court next rejected defendants' argument that the challenged grant terminations were committed to agency discretion. *Id.* at 52-53.

As the Court explained, defendants forfeited this argument by failing to raise it in their district-court stay application. *Id.* In any event, the Court explained, plaintiffs' claims did not second-guess discretionary funding decisions, but rather challenged agency decisions using "judicially manageable standards" from statutes and regulations. *Id.* at 53.

As for defendants' likelihood of success on the merits, this Court held that defendants had "failed to carry [their] burden." *Id.* Summarizing the district court's findings, this Court explained that "[defendants'] decisions rested on circular reasoning, included no explanation for the about-face in agency-wide policy, and entirely ignored significant reliance interests." *Id.* at 54.

2. Defendants sought emergency relief from the Supreme Court, which stayed the district court's vacatur of defendants' grant terminations but left in place the vacatur of the Challenged Directives. *APHA*, 145 S. Ct. at 2660. The Court's unsigned order read, in relevant part:

> The application is granted as to the District Court's judgments vacating the Government's termination of various research-related grants. *See Department of Ed. v. California*, 145 S. Ct. 966 (2025) (*per curiam*). The Administrative Procedure Act's "limited waiver of [sovereign] immunity" does not provide the District Court with jurisdiction to adjudicate claims "based on" the research-related grants or to order relief designed to enforce any "'obligation to pay money'" pursuant

> to those grants. *Id.* at 968. . . . The application is otherwise denied.

Id. (brackets in original; parallel citations omitted).

Justice Barrett provided the deciding vote for this split disposition. On the one hand, Justice Barrett explained, "the District Court was likely correct to conclude that it had jurisdiction to entertain an APA challenge to the guidance." *Id.* at 2661. On the other hand, Justice Barrett concluded, "the District Court likely lacked jurisdiction to hear challenges to the grant terminations, which belong in the Court of Federal Claims." *Id.* Justice Barrett acknowledged that her tentative view would mean "[t]wo-track litigation"—*i.e.*, "channeling challenges to the grant terminations and guidance to different forums." *Id.* at 2661-2662. Nevertheless, she explained, her "preliminary judgment [wa]s that the plaintiffs' challenges to the grant terminations belong[ed] in the CFC, and their APA challenges to the guidance belong[ed] in district court." *Id.* at 2663.

No other justices shared Justice Barrett's reasoning. Four justices would have denied defendants' application in full. As the Chief Justice explained, "the District Court's vacatur of the challenged directives . . . ha[d] prospective and generally applicable implications beyond the reinstatement of specific grants," meaning it "f[ell] well within the scope of

the District Court's jurisdiction under the Administrative Procedure Act." *Id.* at 2662-2663. "And if the District Court had jurisdiction to vacate the directives," the Chief Justice reasoned, "it also had jurisdiction to vacate the 'Resulting Grant Terminations.'" *Id.* at 2663. The remaining four justices would have stayed the district court's judgment in full. *See id.* at 2660, 2663-2666.

SUMMARY OF THE ARGUMENT

This Court should affirm the district court's partial final judgment in its entirety.

I. The district court correctly vacated the Challenged Directives as arbitrary and capricious. As the district court found, the directives were "bereft of reasoning virtually in their entirety" (App. 263) and failed to "even consider[] the reliance interests that naturally inure to NIH grant process" (App. 172). On appeal, defendants fail to overcome those deficiencies. To the extent they address the merits, defendants largely ignore the district court's analysis and instead attack strawmen.

Defendants also raise a host of threshold and procedural objections, but they fail to identify any impediment to judicial review. They argue, for example, that plaintiffs lacked standing to contest the Challenged

Directives, or that this case is now moot. But the directives caused concrete injuries that the judgment below alleviates. And the parties' dispute is still live: defendants have never renounced the pertinent directives, and their conduct makes clear that, but for plaintiffs' success below, they would still be enforcing them. Defendants also contend that the Challenged Directives are unreviewable because they are not "final," or because defendants' decisions are committed to their discretion. But defendants cannot seriously claim that policies that impelled them to cancel hundreds of NIH grants *en masse* were interlocutory, and their committed-to-discretion argument fails for reasons this Court gave at the stay stage.

II. The district court also correctly vacated hundreds of identified grant terminations that indisputably flowed from the Challenged Directives. Defendants' sole appellate argument is that, even if the terminations were illegal, only the Court of Federal Claims had jurisdiction to provide relief. But because plaintiffs invoked statutory rights, not contract terms—and because they sought vacatur, not damages—review of the terminations belongs in district court under the APA.

To be sure, a majority of the Supreme Court tentatively agreed with

defendants' contrary argument, and this Court must give due weight to the Supreme Court's interim order. But that order does not short-circuit the usual appellate process. The Supreme Court recently reiterated that its stay orders "should not be read as a final determination on the merits." *Dep't of State v. AIDS Vaccine Advocacy Coal.*, No. 25A269, 2025 WL 2740571, at *1 (Sept. 26, 2025). That admonition is especially apt here, where no rationale persuaded a majority of justices, and the Court's disposition was determined by a concurrence that spoke only for its author, who characterized her reasoning as "preliminary." *NIH v. Am. Pub. Health Ass'n*, 145 S. Ct. 2658, 2662 (2025) (*APHA*) (Barrett, J., concurring). This Court still has a duty to determine who is right on this unsettled legal question. For the reasons explained below, it is the plaintiffs.

ARGUMENT

I. The district court properly vacated the Challenged Directives.

The Court should affirm the district court's determination that the Challenged Directives are unlawful. Defendants fail to rebut the district court's finding that those directives were "breathtakingly arbitrary and capricious." App. 163. And their bevy of threshold and procedural objections—from contentions about standing and mootness to arguments

about finality and agency discretion—are meritless.[14]

A. The Challenged Directives are arbitrary and capricious.

"An agency action qualifies as 'arbitrary' or 'capricious' if it is not reasonable and reasonably explained." *Ohio v. EPA*, 603 U.S. 279, 292 (2024) (quotation marks omitted). An agency's departure from past practice is also arbitrary and capricious if the agency fails to "assess whether there were reliance interests, determine whether they were significant, and weigh any such interests against competing policy concerns." *Dep't of Homeland Security v. Regents of the Univ. of California*, 591 U.S. 1, 33 (2020) (*DHS*). The Challenged Directives fail both of those tests.

1. The Challenged Directives are not reasonable or reasonably explained.

a. In promulgating the Challenged Directives, defendants failed to "offer[] a satisfactory explanation for [their] action[s], including a rational connection between the facts found and the choice made." *Ohio*, 603 U.S. at 292 (quotation marks omitted).

---

[14] Defendants begin (Br. 19-22) by discussing grant terminations, but the Challenged Directives preceded—and precipitated—any individual termination decisions. Consistent with that fact, the plaintiff states' lead argument below focused on the directives (State Doc. 126, at 18-31), and the district court addressed the directives' legality before turning to any specific grant terminations (App. 259-268).

First, nothing backed up the directives' conclusory assertions. As the district court found—and as this Court tentatively agreed at the stay stage—"there was no indication in the record that anyone at NIH performed any analysis to support the conclusion that the forbidden categories of grants . . . were unscientific and/or wasteful." *APHA*, 145 F.4th at 54. Take, for example, the directives' statement that "DEI studies are often used to support unlawful discrimination on the basis of race and other protected characteristics." App. 2444. The record does not contain "a shred of evidence" to substantiate that provocative factual claim. App. 170; *see* App. 246 (60:5-15) (defendants' attorney conceding that, "[b]eyond the statement" itself, "there's nothing" in the record to show "that any particular grant or group of grants [was] used to support unlawful discrimination"). That failure is unsurprising: the record consists almost entirely of the directives and boilerplate letters parroting them. *See supra*, at 5-6, 9, 12-13.

Second, defendants failed to explain the meaning of the standards imposed by the directives. For example, a central feature of the directives is a ban on "so-called diversity, equity, and inclusion ('DEI') studies." App. 670. But nothing in the record clarifies what a "DEI study" *is*. And

defendants' attorneys were unable to explain the concept in court—other than by pointing back to the phrase itself. App. 246 (60:16-18) ("THE COURT: . . . So that's as close to a definition as we've got? MR. PORTS: That is the agency's reasoning."). Plaintiffs are not quibbling about a failure to "define every term in internal guidance" (Defs.' Br. 40); they are challenging defendants' failure to define a *key operative term* in the disputed agency policy.

Defendants' failure of explanation leaves both the plaintiff states and the public with unanswered questions. Why, for example, are some health programs centered on Black churches considered "DEI studies" while others are not? *See supra*, at 14. Why is a study of opioids' effect on the brain, or a study of the tuberculosis bacterium's impermeability to pharmaceutical compounds, a "DEI study"? *See supra*, at 10-11. And how is a researcher supposed to comply with NIH's new policy going forward? The record does not clarify.

Before the Supreme Court, defendants suggested, for the first time, that they terminated some of these studies because they were awarded through "program[s] with an explicit racial preference." Supp. App. 2649-2650 & n. 2. Defendants' opening brief in this Court does not repeat that

contention, and rightly so: the record contains no indication that defendants canceled any grants for this reason. The Challenged Directives—and the termination letters issued pursuant to the directives—centered on projects' *research aims*, not their *application criteria*. *See supra*, at 4-9, 12-13; *see also, e.g.*, A.R. 1389 (canceling one study discussed above on the ground that it was a "so-called [DEI] stud[y]" without mentioning application criteria). Defendants' argument is thus an "impermissible *post hoc* rationalization[]." *DHS*, 591 U.S. at 22.[15]

b. Defendants fail to overcome the directives' fundamental lack of reasoning. They quote the same oft-repeated language from the directives—for example, that "DEI and gender-identities studies are 'low-

[15] Defendants' argument also offers a misleading characterization of the relevant programs' application criteria. The funding notices for these programs "encourage[d]" applications from a broad range of underrepresented groups—including not only certain racial and ethnic groups, but also, for example, first-generation college graduates, individuals with disabilities, and individuals who grew up in rural areas. *E.g.*, NIH, *NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity*, pt. 2, §I, https://perma.cc/S83S-H23T. None of these programs required applicants to fall into a particular racial or ethnic group. *E.g.*, *id.*, §III-1 (defining "Eligible Applicants" and "Eligible Individuals"); NIH, *Questions and Answers for NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity*, https://bit.ly/PAR-23-275-FAQ (archived April 5, 2025) ("Eligibility for this NOFO is only based on new investigator and at-risk investigator status.").

value and off mission'" (Br. 39)—but they do not explain how these labels and conclusions address either of the deficiencies discussed above. If anything, defendants' attempted explanations underscore the directives' lack of reasoning. For example, defendants claim that the Secretarial Directive "explained that DEI initiatives—which focus on specific groups—'are inconsistent with the Department's policy of improving the health and well-being of *all* Americans.'" Br. 39 (quoting App. 563, emphasis defendants'). But that statement just raises the same questions as before: why, for example, are some health programs centered on Black churches thought to impermissibly "focus on specific groups," while others are understood to "improv[e] the health and well-being of *all* Americans"? The directives do not say.

Defendants next suggest that the Challenged Directives were reasonable because they contemplated "that NIH staff would use their scientific background . . . to identify problematic grants." Br. 40 (quotation marks omitted). But plaintiffs are not challenging the method by which defendants selected specific projects for termination; they are challenging the upstream directives that blacklisted certain research topics as a matter of overarching agency policy. As a factual matter, moreover, there

is no evidence that NIH experts ever undertook an individualized, science-based assessment of any terminated grants. To the contrary, the administrative record reveals that defendants canceled grants *en masse* at a speed that precluded any meaningful review. *See supra*, at 13.

Pivoting, defendants argue (Br. 39) that perhaps they do not need to provide any reasoning after all: because the directives make "policy judgments" about "hotly contested issues," they say, it is enough for them to simply pick a side. But that is not how agency decisionmaking is supposed to work. The APA requires an agency to "examine the relevant data," "articulate a satisfactory explanation for its action," and draw "a rational connection between the facts found and the choice made." *Motor Vehicle Mfrs. Ass'n of the United States, Inc. v. State Farm Mut. Auto. Ins. Co.*, 463 U.S. 29, 43 (1983) (quotation marks omitted). That standard governs even—and perhaps especially—when an agency is making a contentious policy judgment. *See id.*

Defendants utterly failed to follow that standard here. Consider, again, the directives' factual assertion that "DEI studies are often used to support unlawful discrimination on the basis of race and other protected characteristics." App. 2444. No one is suggesting—contra

defendants' strawman (Br. 41)—that defendants were required to conduct "empirical or statistical studies" to establish that fact. But the APA required them to provide *some support* to back it up. Yet across the entire record, there is not a single example of "any particular grant or group of grants . . . being used to support unlawful discrimination on the basis of race." App. 246 (60:5-15). The APA demands more.

Finally, defendants argue (Br. 41-42) that the district court improperly treated "shifting policy preferences and the involvement of political appointees as evidence of an APA violation." Not so. The district court's opinion made clear that the APA violation lay in defendants' changing positions *without reasoned explanation*. App. 165-166. Agency action, whether or not undertaken "to reflect the new President's policy priorities" (Defs.' Br. 42) is subject to the APA's constraints—which defendants flouted.

2. Defendants ignored significant reliance interests.

The Supreme Court has repeatedly held that "[w]hen an agency changes course," it must "take[] into account" any "serious reliance interests" that "longstanding policies may have engendered." *DHS*, 591 U.S. at 30 (quotation marks omitted); *accord Fox*, 556 U.S. at 515. As the

district court found—and, again, as this Court tentatively agreed at the stay stage—"there is no evidence that [defendants] even considered the reliance interests that naturally inure to NIH grant process." App. 172; *see APHA*, 145 F.4th at 54. For that reason, too, the directives are arbitrary and capricious.

Defendants respond (Br. 42) that they did not ignore plaintiffs' reliance interests because the termination letters they sent "invited grantees to request transition funds" to phase out their projects. But that bare invitation "does not account for the broad scope of financial and non-financial interests staked on the grant awards, including years of research and millions of hours of work." *APHA*, 145 F.4th at 54. Plaintiffs' public institutions organize their affairs around grant awards: they hire staff, extend admission offers, buy equipment, recruit study participants, etc.—often years in advance. App. 172-173; *see supra*, at 16-17. Defendants gave no consideration to the fact that shuttering hundreds of projects midstream would waste these efforts. *See APHA*, 145 F.4th at 54.

To excuse this failure, defendants suggest (Br. 42-43) that grantees "have no valid . . . reliance interests" because Office of Management and Budget guidance "authorize[s] termination when 'an award no longer

effectuates the program goals or agency priorities.'" Setting aside defendants' misapprehension of OMB's guidance (*see* State Doc. 126, at 27-30; App. 173-177), defendants' argument ignores how significantly they broke from past practice. Historically, NIH has canceled grants only in extreme circumstances—typically a handful of times per decade. *See supra*, at 10. The notion that no one reasonably relies on these awards or the predictable process that has grown up around them is absurd.

For all these reasons, the district court correctly determined that the Challenged Directives were arbitrary and capricious.

B. Defendants identify no impediment to judicial review of the Challenged Directives.

Defendants ask the Court to toss plaintiffs' claim on any of four non-merits grounds: standing, mootness, finality, and agency discretion. The Court should reject each of these attempts to evade review.

1. The plaintiff states have standing.

The doctrine of standing requires a plaintiff to allege a concrete injury that is traceable to the defendant's conduct and redressable by a favorable decision. *Doe v. Shibinette*, 16 F.4th 894, 901 (1st Cir. 2021). This case easily clears that bar. Defendants now argue (Br. 27) that plaintiffs lacked standing "at the time they filed their complaint," but

that contention rests on two mistaken premises: that plaintiffs cannot seek review of the Challenged Directives separate from review of the downstream termination of their grants, and that the directives caused plaintiffs no injury aside from those terminations.[16]

a. Defendants' termination of hundreds of existing research grants conferred standing.

Plaintiffs have standing to seek review of the Challenged Directives because those directives caused the termination of hundreds of research grants for ongoing projects. There is no dispute that the terminations concretely injured the plaintiff states. Nor is there any dispute that the terminations are traceable to the Challenged Directives. *See APHA*, 145 S. Ct. at 2663 (Roberts, C.J., concurring in part and dissenting in part) ("The Government has n[ot] contended that the terminations did not result from the directives[.]"). And there is no dispute that a judicial decision vacating the directives would eliminate the only legal basis for the terminations. On these facts, all the elements of an Article III

[16] None of the seven briefs that defendants previously filed in this case suggested that plaintiffs lacked standing to challenge *any aspect* of the directives; defendants only disputed plaintiffs' standing to challenge *discrete components* of the directives (for example, a portion of the directives barring grants for research in China). *E.g.*, State Doc. 125, at 23.

controversy are present.

Defendants counter (Br. 27-31) that if the district court lacked jurisdiction over grant terminations, those terminations cannot confer standing to challenge the underlying directives. As an initial matter, however, the district court *did* have jurisdiction to review the disputed terminations. *See infra*, at 53-66. And even if this Court were to adopt the Supreme Court's interim conclusion on jurisdiction, Justice Barrett's concurrence expressly contemplated "two-track litigation"—*i.e.*, "channeling challenges to the grant terminations and [challenges to the directives] to different forums." 145 S. Ct. at 2661-2662. Justice Barrett never suggested that the plaintiff states lack standing to challenge the directives in district court; that suggestion appears only in Justice Gorsuch's partial dissent, *see id.* at 2665 n. 2—which, of course, did not command a majority of the Court. Thus, even if the Court of Federal Claims is now the appropriate forum for challenging grant terminations, *but see infra*, at 53-66, the district court remains the right forum to challenge the underlying directives.

b. Defendants' delay and denial of applications for new research grants conferred standing.

In addition to the termination of plaintiffs' existing grants, the

Challenged Directives also led to the delay and denial of plaintiffs' pending applications for new research projects. *See supra*, at 15-16. These unlawful delays and denials are an independent basis for standing.

The harms flowing from these delays and denials satisfy all three of Article III's elements. First, the harms were real and concrete: they involved tangible injuries to plaintiffs' universities, which plaintiffs detailed in numerous unrebutted declarations. *E.g.*, State Doc. 77-18, ¶35 (explaining how delays "forced [the University of Maryland] to implement bridge funding . . . draw[n] from limited discretionary resources"); State Doc. 77-45, ¶12 (explaining how delays contributed to the decimation of the University of Massachusetts's fall 2025 graduate medical program). Second, these delay- and denial-based injuries are traceable to the Challenged Directives. Defendants have conceded that they denied numerous pending applications as a result of the directives, and they have never meaningfully disputed that the directives caused unprecedented delays in NIH's once-orderly grant-review process. *See supra*, at 15. Third, a decision setting aside the Challenged Directives redresses these injuries. Because of the judgment below, defendants can no longer delay or deny plaintiffs' pending applications on the ground that they fail

to comply with the directives.

Defendants' only response (Br. 28-29) is that the district court bifurcated the proceedings below: the district court resolved the legality of the Challenged Directives in the first phase of the case (which resulted in this appeal) but reserved, for a second phase, the question of whether NIH's delay in reviewing grant applications violated 5 U.S.C. §706(1). But the fact that the parties have yet to litigate certain issues related to *delay* overlooks the standing conferred by defendants' *denial* of plaintiffs' applications.[17] Defendants' power to deny future applications based on the Challenged Directives was conclusively adjudicated in Phase One: because the directives have been set aside, defendants cannot use them to deny applications.[18] That conclusion does not depend on any further proceedings—and for that reason alone, plaintiffs' standing is clear.

Regardless, nothing about the district court's deferral of plaintiffs'

---

[17] Again, defendants' *denial* of applications for new grants should not be confused with their *termination* of already-awarded grants. *See supra*, at 37-39.

[18] There are real, non-speculative applications in this category: as discussed above (at 15-16), unrebutted evidence shows, and defendants have admitted, that defendants "administratively withdrew" pending applications because of the Challenged Directives.

§706(1) claim carries Article III implications. The fact that the district court has yet to resolve the particulars of that claim does not require this Court to artificially ignore defendants' injury-causing delay in adjudicating the present standing question. After all, defendants' argument is that plaintiffs lacked standing "at the time they filed their complaint." Br. 27. The district court's post-filing docket-management decisions are irrelevant to that contention.

2. The parties' dispute is not moot.

Defendants next argue (Br. 24-27) that an August 15, 2025, "statement" from NIH's director, Jay Bhattacharya, moots this case. *See* NIH, Statement, *Advancing NIH's Mission Through a Unified Strategy* (Aug. 15, 2025), https://perma.cc/V5E2-4ED2 (Bhattacharya Statement). But a party invoking the doctrine of mootness bears a "heavy burden"—one that is all the more "formidable" when the party claims that its own conduct mooted the case. *Friends of the Earth, Inc. v. Laidlaw Env't Servs. (TOC), Inc.*, 528 U.S. 167, 189-190 (2000). In those circumstances, the party must "show[] that it is *absolutely clear* the allegedly wrongful behavior could not reasonably be expected to recur." *Id.* at 190 (emphasis added). For several reasons, defendants cannot make that showing.

a. As an initial matter, defendants' mootness argument is irreconcilable with their own sworn statements. As discussed above, defendants provided a certification on August 19, 2025, regarding certain research-grant applications then pending before NIH. *See supra*, at 15-16. With respect to at least 18 of those applications, defendants represented that "NIH may apply the Challenged Directives to this application, absent further Court order or judgment." Supp. App. 2772-2799; *see* Supp. App. 2770-2771 (¶¶3-4) (attesting, under penalty of perjury, to the truth and accuracy of these representations). This unequivocal language—offered under oath on *August 19*—fatally undermines defendants' suggestion that this case became moot on *August 15*. If the Bhattacharya Statement had superseded the Challenged Directives, defendants obviously would not have subsequently reserved the right to "apply the Challenged Directives" to other projects.[19]

b. Defendants' prior representations aside, their suggestion of mootness fails because the Bhattacharya Statement did not rescind the

[19] Defendants' certification is troubling for yet another reason: it defies the district court's judgment. By August 19, the district court had long since declared the Challenged Directives "void" and "of no force and effect." App. 74. Against that backdrop, it is unclear how defendants could reserve the right to "apply the Challenged Directives."

Challenged Directives. In *New Hampshire Lottery Commission v. Rosen*, 986 F.3d 38 (1st Cir. 2021), this Court rejected a similar argument from the federal government that a 2019 Department of Justice memo mooted a challenge to a 2018 opinion issued by DOJ's Office of Legal Counsel. *See id.* at 53. As the Court there explained, "[t]he April 2019 Memo d[id] not rescind . . . the 2018 Opinion," and the government had not otherwise "disclaim[ed], in categorical terms, any intent to enforce" the 2018 opinion. *Id.* at 53-54. The same is true here: nothing in the Bhattacharya Statement repeals or disavows any part of the Challenged Directives.

Defendants' brief all but admits the point. The most defendants can bring themselves to say is that the Challenged Directives "have been *effectively* overridden or explicated." Br. 24 (emphasis added). Under this Court's case law, that is not enough. *N.H. Lottery*, 985 F.3d at 53 (observing that "[t]he government refuse[d] to disavow" its 2018 opinion).

c. Even if "effectively" overriding a challenged agency policy *could* moot a case, the Bhattacharya Statement does not even accomplish that much. The statement warns (with emphasis in original) that it is "*not an exhaustive list of all agency priorities*." And a side-by-side comparison of the statement and the Challenged Directives shows that the

two are not mutually exclusive. The bulk of the Bhattacharya Statement consists of discussions about nutrition, artificial intelligence, autism, and other subjects—*i.e.*, discussions that have nothing to do with the seven topics prohibited in the Challenged Directives. And the few portions of the Bhattacharya Statement that *do* touch on the Challenged Directives' proscribed topics tend to reaffirm the directives' proscriptions. For example, the Bhattacharya Statement contains language about "research based on ideologies that promote differential treatment of people based on race or ethnicity." That passage is "largely an extension of" the Challenged Directives' ban on DEI—and so it does nothing to moot the directives' effects. *Conservation Law Found. v. Evans,* 360 F.3d 21, 25 (1st Cir. 2004); *see id.* at 26 (explaining that a challenge is not moot "where a challenged regulation . . . is only superficially altered by a subsequent regulation").

d. Defendants' mootness argument fails for yet another reason: even if the Bhattacharya Statement had replaced the Challenged Directives going forward, defendants have not "completely and irrevocably eradicated the [directives' past] effects." *L.A. County v. Davis*, 440 U.S. 625, 631 (1979). As discussed above (at 10-14), defendants relied on the

Challenged Directives to terminate hundreds of grants to the plaintiff states. Regardless of whether plaintiffs' challenge to those terminations proceeds in district court or must instead go to the Court of Federal Claims (*see infra*, at 53-66), the controversy over these terminations—undertaken pursuant to the directives—confirms that the directives' legality remains a live issue. The same is true of defendants' delay and denial of plaintiffs' applications for new grants: defendants have not unwound those harms, which likewise resulted from the directives. *See supra*, at 15-16, 38-41. The question of whether the directives were lawful is thus still a pertinent one.[20]

e. Finally, even if the Court harbored doubts, it should resolve them against defendants' mootness claim for two additional reasons.

First, as discussed above, when a government agency voluntarily ceases challenged conduct, the government "must demonstrate that it is *absolutely clear* that the allegedly wrongful behavior could not reasonably be expected to recur." *Conservation Law*, 360 F.3d at 24 (emphasis

[20] Defendants' passing argument (Br. 24) that this case is moot as to two specific directives that were "formally rescinded or superseded" fails for the same reason: even if those directives are no longer in force, defendants have not unwound their past effects.

added). That is especially true in a case, like this one, "that has been litigated up to [the Supreme] Court and back down again." *Adarand Constructors, Inc. v. Slater*, 528 U.S. 216, 224 (2000). Even if defendants had managed to raise a colorable claim of mootness, they have not made "absolutely clear" that their illegal conduct is reasonably unlikely to recur.

Second, this Court has previously held that it may weigh "equitable or other considerations" if a mootness question is close. *Adams v. Bowater Inc.*, 313 F.3d 611, 613-614 (1st Cir. 2002). Here, those considerations decisively favor plaintiffs. Defendants "ha[ve] been persistently unwilling either to admit that [their policy] was unlawful or to say that it will not be reintroduced." *Id.* at 614; *see supra*, at 42 & n. 19 (discussing defendants' reservation of the purported right to "apply the Challenged Directives"). And the risk of irreparable harm is high. *See Adams*, 313 F.3d at 614; *see supra*, at 16-17 (describing harms to the plaintiff states). Thus, even if defendants could overcome the hurdles discussed above, the Court should still reject their suggestion of mootness.

3. The directives constituted final agency action.

An agency action is final under the APA if it "mark[s] the consummation of the agency's decisionmaking," and if the action is "one by which

rights or obligations have been determined, or from which legal consequences will flow." *Bennett v. Spear*, 520 U.S. 154, 177-178 (1997) (quotation marks omitted). That standard does not require a particular measure of formality: the Supreme Court "ha[s] long taken" a "pragmatic approach" to this issue. *U.S. Army Corps of Engineers v. Hawkes Co.*, 578 U.S. 590, 599 (2016). The Challenged Directives easily pass this pragmatic test.

a. Both on their face and in practice, the Challenged Directives memorialized defendants' decision to prohibit research on certain topics. In particular, the directives identified the topics that defendants chose to ban, and they detailed the concrete steps that NIH officials needed to take to operationalize that ban. *See supra*, at 4-9. The Memoli Directive, for example, declared "the policy of NIH not to prioritize" so-called "DEI studies" and "direct[ed] NIH personnel" to "terminate[] or partially terminate[]" any offending projects. App. 2444-2445. That language bears all the hallmarks of final action.

The APA's definitions expressly allow a litigant to challenge an overarching agency action with these characteristics. Under 5 U.S.C. §551, the types of reviewable "agency action" include "the whole or a part

of an agency rule." *Id.* §551(13). A "rule," in turn, broadly encompasses "statement[s] of general . . . applicability and future effect designed to implement, interpret, or prescribe law or policy or describing the organization, procedure, or practice requirements of an agency." *Id.* §551(4); *see Abbott Labs. v. Gardner*, 387 U.S. 136, 149 (1977). The Challenged Directives fit this definition to a tee: they prescribe rules of general applicability for future agency conduct.

Controlling precedent confirms the directives' reviewability. In *Biden v. Texas*, 597 U.S. 785 (2022), the Supreme Court held that a memorandum "direct[ing] [agency] personnel to take all appropriate actions to terminate [a federal program]" was final because it "bound [agency] staff by forbidding them to continue the program in any way from that moment on." *Id.* at 793, 808-810 (quotation marks omitted). That reasoning applies with just as much force here: the Challenged Directives compelled agency staff to follow a definitive statement of agency policy. *See supra*, at 4-9.

b. Defendants nevertheless argue (Br. 32-33) that the directives were "interlocutory" communiqués that "merely instructed NIH staff to review existing grants." But defendants' own words and actions prove

otherwise. Before the Supreme Court, defendants admitted that the Challenged Directives reflected a "uniform policy" with "global[]" application. *APHA*, 145 S. Ct. at 2663 (Roberts, C.J., concurring in part and dissenting in part) (quoting Supp. App. 2629). And the factual record establishes that defendants' termination decisions flowed from the directives—not the other way around. *See id.* (noting that defendants have not "contended that the terminations did not result from the directives"). Indeed, the only way defendants' frenzy of grant terminations in the spring of 2025 makes sense is if defendants viewed the directives as final; otherwise, they canceled hundreds of grants *en masse* based on *non*-final policies.

In characterizing the directives as interlocutory, defendants appear to suggest that an agency policy is nonfinal anytime the relevant agency must take subsequent steps to implement the policy. But ample precedent rejects that view. For example, the Supreme Court has held an agency order "giv[ing] notice of how the [agency] interpret[s] the relevant statute" to be final, even though the interpretation "'would have effect only if and when a particular action was brought'" by the agency. *Army Corps*, 578 U.S. at 600-601 (quoting *Abbott Labs.*, 387 U.S. at 150).

Similarly, the Supreme Court concluded that "an FCC regulation announcing a Commission policy that it would not issue a television license to an applicant already owning five such licenses" to be final "even though no specific application [from that applicant] was before the Commission." *Abbott Labs.*, 387 U.S. at 151; *see also Texas*, 597 U.S. at 808-810 (finding a memorandum to be final even though it announced a general policy to be applied later in specific cases). Under this precedent, the Challenged Directives are not deprived of finality merely because the agency carried them out in subsequent termination decisions.

c. Defendants also argue that the Challenged Directives "cannot be final" because the district court found that they were so poorly explained that they "'allow[ed] [defendants] to arrive at whatever conclusion [defendants] wishe[d].'" Br. 34 (quoting App. 166). But an agency policy can be both *final* under 5 U.S.C. §704 and yet *arbitrary and capricious* under §706(2)(A). *See, e.g.*, *Firearms Regulatory Accountability Coal., Inc. v. Garland*, 112 F.4th 507, 525 (8th Cir. 2024) (finding that an agency policy was final, but was nevertheless "arbitrary and capricious because it allow[ed] the [the agency] to arrive at whatever conclusion it wishe[d] without adequately explaining the standard" (brackets and

quotation marks omitted)); App. 166 (citing and quoting that decision). The fact that the Challenged Directives were "breathtakingly arbitrary and capricious," App. 163, does not make them nonfinal.

4. The directives are not committed to agency discretion.

While the APA does not extend to actions "committed to agency discretion by law," 5 U.S.C. §701(a)(2), the Supreme Court has "read [that] exception . . . quite narrowly, restricting it to those rare circumstances" in which "a court would have no meaningful standard" to apply, *Weyerhaeuser Co. v. U.S. Fish & Wildlife Serv.*, 586 U.S. 9, 23 (2018) (quotation marks omitted). This case does not present one of those rare circumstances—as this Court tentatively concluded at the stay stage. *APHA*, 145 F.4th at 53.

Defendants' contrary argument mischaracterizes plaintiffs' claims and the district court's decision. Defendants suggest (Br. 36-37) that the district court engaged in "unbounded arbitrary-and-capricious review of NIH's discretionary funding judgments." But plaintiffs did not challenge, and the district court did not review, any discretionary funding decisions. Instead, this case centers on discrete directives—promulgated, as defendants have admitted, to announce a "uniform policy" with "global[]"

application. Supp. App. 2629. Whatever discretion defendants have to choose among competing grant applicants, they elected to cabin that discretion by promulgating a suite of agencywide policies. Those policies must satisfy the APA's basic requirements. *See Union of Concerned Scientists v. Wheeler*, 954 F.3d 11, 18 n. 5 (1st Cir. 2020) (recognizing that an agency's discretion over "individual hiring decisions" did not preclude review of "an agency-wide policy").

Citing *Lincoln v. Vigil*, 508 U.S. 182 (1993), defendants suggest (Br. 35-37) that *any* decision affecting the "allocation of funds from lump-sum appropriations" is unreviewable. But *Vigil* is not nearly so broad. There, the Court held only that an agency's decision to reallocate funds from one statutorily compliant program to another was committed to the agency's discretion. 508 U.S. at 193-194. The Court did not consider—much less exempt from APA scrutiny—formal directives announcing agencywide policies that agency staff must apply in future cases. Those kinds of global policy directives fall within the heartland of the APA's judicial-review provisions. *See Concerned Scientists*, 954 F.3d at 18 n. 5; *Am. Med. Ass'n v. Reno*, 57 F.3d 1129, 1134-1135 (D.C. Cir. 1995).

For all the foregoing reasons, defendants identify no impediment to

judicial review, and this Court should affirm the vacatur of the Challenged Directives.

II. The district court properly set aside discrete termination decisions premised on the Challenged Directives.

Defendants have never disputed that they terminated hundreds of grants to the plaintiff states on the sole ground that the grants violated the now-vacated Challenged Directives. *See APHA*, 145 S. Ct. at 2663 (Roberts, C.J., concurring in part and dissenting in part). Instead, defendants object only to the district court's jurisdiction to vacate the terminations. For the reasons that follow, however, the district court correctly exercised jurisdiction.

A. The Supreme Court's stay decision, while entitled to due weight, is not a final decision on the merits.

Defendants argue (Br. 19-20) that the Supreme Court's interim decision effectively compels this Court to vacate the district court's judgment. As the Supreme Court has repeatedly stated, however, its "interim orders are not conclusive as to the merits." *Trump v. Boyle*, 145 S. Ct. 2653, 2654 (2025). Indeed, the Supreme Court reiterated that point even *after* issuing the stay decision in this case, cautioning that its stay orders "should not be read as a final determination on the merits." *AIDS*

Vaccine, 2025 WL 2740571, at *1.

There are several reasons why the Court treats its stay decisions as nonfinal. To start, these orders contain only "probabilistic holdings" about whether a particular argument is "*likely* to succeed," *APHA*, 145 S. Ct. at 2664 (Gorsuch, J., concurring in part and dissenting in part) (emphasis added), rather than a final determination of which argument *actually* prevails. Moreover, the Court reaches these probabilistic conclusions on "a short fuse without benefit of full briefing and oral argument." *Does 1-3 v. Mills*, 142 S. Ct. 17, 18 (2021) (Barrett, J., concurring). And the Court's stay orders typically contain little to no reasoning. *See Labrador v. Poe*, 144 S. Ct. 921, 934 (2024) (Kavanaugh, J., concurring) (explaining that a stay order's limited reasoning helps avoid "predetermin[ing] the case's outcome in the proceedings in the lower courts and hamper[ing] percolation across other lower courts on the underlying merits question"). Thus, while the Supreme Court's stay orders "inform how a [lower] court should exercise its equitable discretion in like cases," *Boyle*, 145 S. Ct. at 2654, they do not relieve a lower court of its obligation to determine which party prevails on the disputed legal question.

This principle applies with even greater force in this case, because

there is a higher than usual likelihood that the Supreme Court's tentative ruling will *not* match its final outcome. In deciding defendants' stay application, no single rationale commanded the support of a majority of justices; the Court instead splintered 4–1–4. The bottom-line result—that review of the directives likely belongs in district court, while review of terminations likely belongs in the Court of Federal Claims—was one that no party advanced (or even briefed), that no lower court adopted (or even suggested), and that eight of the nine justices disagreed with. The one justice who did support the result, meanwhile, cautioned that the disposition reflected only her "preliminary judgment." *APHA*, 145 S. Ct. at 2662 (Barrett, J., concurring). In this context, there is good reason to think the Supreme Court's final word on the issue, after full briefing and argument and further percolation, will differ from its interim order.

Defendants counter (Br. 19) that the Supreme Court's recent stay order in *Boyle* compels this Court to treat the interim order in this case as final, but defendants misunderstand what *Boyle* said. There, the Court explained that its interim orders "inform how a [lower] court should exercise its equitable discretion in like cases." 145 S. Ct. at 2653. That statement simply means that, once the Supreme Court has issued

a stay in one case, a lower court should typically issue a stay (*i.e.*, "exercise its equitable discretion") in "like cases." *Id.* But this case is no longer in a stay posture, and defendants are not asking this Court to "exercise its equitable discretion." Instead, the Court is finally confronted with the merits of the parties' legal dispute. On that question, *Boyle* was clear: the Court's "interim orders are not conclusive as to the merits." *Id.*

Accordingly, this Court has a duty to review the pertinent legal authorities—including, as applicable, any reasoning in the Supreme Court's interim decisions—and decide the merits.

B. Blackletter jurisdictional principles support the district court's exercise of jurisdiction.

The pertinent legal authorities do not support defendants' narrow conception of jurisdiction. A party injured by an agency decision may sue under the APA for "relief other than money damages" unless another statute "impliedly forbids the relief which is sought." 5 U.S.C. §702. In determining whether the Tucker Act impliedly forbids an APA claim, courts ask whether the claim is "essentially a contract dispute." *Am. Sci. & Eng'g, Inc. v. Califano*, 571 F.2d 58, 61 (1st Cir. 1978). To answer that question, courts often examine (1) "the source of the rights upon which the plaintiff bases its claims," and (2) "the type of relief sought."

Megapulse, Inc. v. Lewis, 672 F.2d 959, 968 (D.C. Cir. 1982); *see* Defs.' Br. 20 (adopting that test). Here, both of these elements show that plaintiffs' challenge to the termination of their grants belonged in district court.

First, the source of plaintiffs' rights is noncontractual. In challenging the termination of their grants, plaintiffs did not invoke their rights under any contract clause. Instead, plaintiffs argued that the terminations were based exclusively on agencywide policies that were arbitrary and capricious under the APA. The resolution of that claim in no way "depend[ed] on the terms or conditions of any contract." *APHA*, 145 F.4th at 50. Indeed, defendants did not even include grant agreements for many of the terminated projects in the administrative record—an inexplicable choice if this case "self-evidently arises from the grant agreements." Defs.' Br. 20. Nor did the courts below have to parse any contract terms to resolve plaintiffs' challenge. *See Md. Dep't of Hum. Res. v. HHS*, 763 F.2d 1441, 1449 (D.C. Cir. 1985) (*MDHR*) (Bork, J.) (explaining that claims that "turn[ed] on the interpretation of statutes and regulations rather than on the interpretation of an agreement" were "not contract claims for Tucker Act purposes"); *Bowen*, 487 U.S. at 894-901 (adopting *MDHR*'s reasoning).

The Supreme Court's interim order nevertheless suggested that plaintiffs' APA claims were likely "'based on' [plaintiffs'] research-related grants." 145 S. Ct. at 2660. The Court did not explain why it thought that was so; defendants, for their part, argued that "[w]ithout a grant agreement, [plaintiffs] would have had no right to payment in the first place." Supp. App. 2617. But plaintiffs have never asserted a "right to payment." And the fact that plaintiffs would have no claim *but for* a grant agreement does not mean plaintiffs' claim is *based on* the grant agreement. *See Crowley Gov't Servs., Inc. v. GSA*, 38 F.4th 1099, 1110 (D.C. Cir. 2022) (rejecting "a 'but-for' test for identifying the source of the right"). An employee who brings a Title VII claim alleging that her employer terminated her employment agreement on the basis of a protected characteristic is not bringing a "contract claim," even though the claim would not have existed absent the parties' contractual relationship. So too here. The source of plaintiffs' rights is the APA's guarantee of freedom from arbitrary and capricious agency decisionmaking—not plaintiffs' grant agreements.

Second, the nature of the relief sought and awarded below confirms that plaintiffs' claims are not contractual. The district court's judgment

was declaratory, not injunctive or monetary; it simply set aside the Challenged Directives and resulting grant terminations. App. 73-74. That mirrors the relief in *Bowen*. There, as here, Massachusetts did not receive money "in *compensation* for the damage sustained by the failure of the Federal Government to pay as mandated." 487 U.S. at 900. Instead, as in this case, it obtained "specific relief" setting aside challenged government action—which a district court has jurisdiction to grant. *Id.* at 895; *see also Dep't of the Army v. Blue Fox, Inc.*, 525 U.S. 255, 262 (1999) (explaining that "*Bowen*'s interpretation of § 702 . . . hinged on the distinction between specific relief and substitute relief").

Defendants argue (Br. 21-22) that *Bowen* is inapposite because it "did not involve a contract claim and did not address the APA provision in 5 U.S.C. §702 that bars suits 'expressly or impliedly forbid[den]' by another statute." But everything the *Bowen* Court said about *why* the Tucker Act was inadequate vis-à-vis the APA—including that the Tucker Act is "tailored" to provide "compensation" for "particular categories of past injuries or labors," 487 U.S. at 904 n. 39—makes clear that the Tucker Act does not contemplate the forward-looking, specific relief awarded here. And the Supreme Court has since confirmed that a

"statute cannot prevent an APA suit" by implication if it "'is not addressed to the type of grievance which the plaintiff seeks to assert.'" *Match-E-Be-Nash-She-Wish Band v. Patchak*, 567 U.S. 209, 216 (2012) (quoting May 10, 1976, letter of then-A.A.G. Scalia). Thus, *Bowen*'s recognition that the Tucker Act is "addressed to" a different "type of grievance" than the one the plaintiffs here "seek[] to assert," *id.*, defeats defendants' reliance on §702's "impliedly forbids" language.

The Supreme Court's interim decision, for its part, suggested that the district court functionally compelled the payment of money. *APHA*, 145 S. Ct. at 2660. But nothing in the judgment below orders the government to disburse any funds—much less "past due sums" (Defs.' Br. 21). Rather, because the district court found that the termination decisions, like the Challenged Directives, were arbitrary and capricious, the court simply vacated the terminations as having "no force and effect," App. 74, thus returning the parties to the status quo ante. To be sure, that vacatur allows the plaintiff states' universities once again to seek reimbursement for their work. But they must do so consistent with the usual rules and regulations for any payments to occur. *E.g.*, A.R. 3987-4025. As *Bowen* makes clear, an "action for specific relief" under the APA

does not seek damages merely because a judgment might "require the payment of money by the federal government." 487 U.S. at 893-894; *see also id.* at 910 (observing that HHS would likely "abide by [the District Court's] declaration and reimburse Massachusetts," but explaining that, "to the extent that the District Court's judgment engender[ed] this result," it was "a mere byproduct of that court's primary function of reviewing [HHS]'s interpretation of federal law").

The Congress that enacted the current version of §702 "understood that [the statute] would authorize judicial review of the administration of Federal grant-in-aid programs." *Bowen*, 487 U.S. at 898 (quotation marks omitted). The district court's vacatur of defendants' unlawful terminations was a straightforward exercise of that jurisdiction.

C. The parties' complex, ongoing relationship shows that this is an APA suit.

The Supreme Court has also looked to the nature of the parties' relationship to assess whether a claim properly arises under the Tucker Act or the APA. As the Court recently reiterated, "the Administrative Procedure Act is tailored to managing the relationships between States and the Federal Government that occur over time and that involve constantly shifting balance sheets, while the Tucker Act is suited to

remedying particular categories of past injuries or labors for which various federal statutes provide compensation." *Me. Cmty. Health Options v. United States*, 590 U.S. 296, 327 (2020) (quotation marks and brackets omitted) (quoting *Bowen*, 487 U.S. at 904 n. 39). So whereas "the litigants' 'complex ongoing relationship'" in *Bowen* supported jurisdiction in the district court, *id.* (quoting *Bowen*, 487 U.S. at 905), the claim for "sums already calculated, past due, and designed to compensate for completed labors" in *Maine Community* "l[ay] in the Tucker Act's heartland," *id.*

That dichotomy confirms that the district court properly exercised jurisdiction here. As in *Bowen*, this case arises out of a "complex ongoing relationship" with "constantly shifting balance sheets" between the plaintiff states and the federal government. *Id.* The University of California, for example, receives thousands of NIH grants every year and, at any given time, has thousands more applications pending. Defendants' adoption and implementation of the Challenged Directives touched virtually every aspect of that dynamic partnership. *See* State Doc. 77-36, ¶¶4-12, State Doc. 77-65, ¶5. And that is just *one* of several public universities in *one* of the 16 plaintiff states. The APA is "tailored" to provide a

uniform answer to the intricate legal issues arising from the Challenged Directives' impact on those relationships. *Me. Cmty.*, 590 U.S. at 327. A multiplicity of separate Tucker Act suits is not. *See id.*

D. Defendants' arguments would deprive injured parties of prospective relief.

Defendants' contrary arguments not only contradict the governing statutes and established legal tests—they would deprive parties of their ability to seek meaningful relief for arbitrary agency decisionmaking and myriad other forms of illegality external to any contractual relationship. Defendants argue that federal district courts lack the jurisdiction to reinstate unlawfully terminated grants. But they have maintained that the Court of Federal Claims is equally powerless to award that relief. Supp. App. 2645; *see Ferreiro v. United States*, 501 F.3d 1349, 1353 n. 3 (Fed. Cir. 2007). The upshot: on defendants' view, *no* court can reinstate grants canceled in light of an illegal policy.

That has some startling implications. Imagine, for example, that NIH were to cancel all grants to a particular group of politically disfavored researchers—say, Black doctors, or religious colleges, or veterans, or pregnant women, or firearms owners. According to defendants (Supp. App. 2644-2645), those researchers would have no recourse—a result

that violates the APA's "basic presumption of judicial review." *Weyerhaeuser*, 586 U.S. at 22.

For that reason, too, the government's jurisdictional objection is untenable.

E. If this Court reverses on jurisdiction, it should provide clear guidance for subsequent proceedings.

For the reasons just discussed, this Court should affirm the district court's judgment with respect to grant terminations. If, however, the Court adopts defendants' jurisdictional arguments, it should provide three important clarifications that are necessary to avoid gamesmanship and ensure meaningful judicial review.

First, and as already discussed, the Court should reiterate that the district court has jurisdiction to review and set aside the Challenged Directives and any other agencywide policies upstream of the agency's termination decisions. *See supra*, at 37-38. Defendants want to avoid that kind of review, but the very opinion on which they rely expressly contemplated "two-track litigation," with the Challenged Directives reviewed in district court. *APHA*, 145 S. Ct. at 2661-2662 (Barrett, J., concurring).

Second, the Court should make clear that vacatur of the Challenged Directives—and other agencywide policies—restores the pre-directive

status quo. So even if plaintiffs must pursue damages for any "past due sums" in the Court of Federal Claims (Defs.' Br. 21), the vacatur of the directives bars defendants from otherwise implementing or enforcing the directives, including by delaying or denying grant applications or terminating active projects in reliance on the directives.[21] And if defendants violate that judgment by taking new actions premised on the directives, the district court has tools—including contempt proceedings—to secure compliance.

Third, the Court should clarify that any follow-on damages lawsuit in the Court of Federal Claims is not an opportunity to relitigate the lawfulness of the directives. The upshot of defendants' position, if adopted, is that "APA challenges to [agencywide policies] belong in district court," while "challenges to the grant terminations belong in the CFC." *APHA*, 145 S. Ct. at 2662 (Barrett, J., concurring). The CFC litigation, in other words, is not a second bite at the apple.

---

[21] Of course, one would expect a federal agency acting in good faith not to wait for a separate action in the Court of Federal Claims. Upon receipt of a final judgment setting aside a policy that prompted unlawful terminations, an agency operating in good faith would quickly restore grantees to the position they occupied before the wrongful terminations.

***

Again, these clarifications are necessary only if the Court adopts defendants' jurisdictional contentions. As discussed, however, blackletter principles make clear that the district court properly exercised jurisdiction. Like the district court's vacatur of the Challenged Directives, therefore, the district court's vacatur of the resulting grant terminations should be affirmed.

CONCLUSION

The Court should affirm the district court's judgment in full.

November 12, 2025

Respectfully submitted.

ANDREA JOY CAMPBELL
Attorney General of Massachusetts

/s/ *Gerard J. Cedrone*
DAVID C. KRAVITZ
State Solicitor
GERARD J. CEDRONE
Deputy State Solicitor
VANESSA A. ARSLANIAN
State Trial Counsel
PHOEBE M. LOCKHART
Assistant Attorney General
One Ashburton Place, 20th Floor
Boston, MA 02108
(617) 963-2282
gerard.cedrone@mass.gov

Counsel for Massachusetts

(Listing of counsel continued on next page)

ROB BONTA
Attorney General of California

/s/ *Emilio Varanini*
EMILIO VARANINI
Supervising Deputy Attorney General
NIMROD PITSKER ELIAS
DANIEL D. AMBAR
SOPHIA TONNU
Deputy Attorneys General
455 Golden Gate Avenue
San Francisco, CA 94102
(415) 510-3541
emilio.varanini@doj.ca.gov

Counsel for California

ANTHONY G. BROWN
Attorney General of Maryland

/s/ *Adam D. Kirschner*
JULIA DOYLE
Solicitor General
ADAM D. KIRSCHNER
MICHAEL DREZNER
JAMES C. LUH
Senior Assistant Attorneys General
200 Saint Paul Place, 20th Floor
Baltimore, MD 21202
(410) 576-6959
mdrezner@oag.state.md.us

Counsel for Maryland

NICHOLAS W. BROWN
Attorney General of Washington

/s/ *Andrew Hughes*
ANDREW HUGHES
Assistant Attorney General
800 Fifth Avenue, Suite 2000
Seattle, WA 98104
(206) 464-7744
andrew.hughes@atg.wa.gov

Counsel for Washington

KRISTIN K. MAYES
Attorney General of Arizona

/s/ *Joshua G. Nomkin*
JOSHUA G. NOMKIN
Assistant Attorney General
2005 N. Central Avenue
Phoenix, AZ 85004
(602) 542-3333
joshua.nomkin@azag.gov

Counsel for Arizona

(Listing of counsel continued on next page)

PHILIP J. WEISER
Attorney General of Colorado

/s/ *Shannon Stevenson*
SHANNON STEVENSON
Solicitor General
1300 Broadway, 10th Floor
Denver, CO 80203
(720) 508-6000
shannon.stevenson@coag.gov

Counsel for Colorado

KATHLEEN JENNINGS
Attorney General of Delaware

/s/ *Vanessa L. Kassab*
IAN R. LISTON
Director of Impact Litigation
VANESSA L. KASSAB
Deputy Attorney General
820 N. French Street
Wilmington, DE 19801
(302) 683-8899
vanessa.kassab@delaware.gov

Counsel for Delaware

ANNE E. LOPEZ
Attorney General of Hawai'i

/s/ *Kaliko'onālani D. Fernandes*
DAVID D. DAY
Special Assistant
to the Attorney General
KALIKO'ONĀLANI D. FERNANDES
Solicitor General
425 Queen Street
Honolulu, HI 96813
(808) 586-1360
kaliko.d.fernandes@hawaii.gov

Counsel for Hawai'i

KEITH ELLISON
Attorney General of Minnesota

/s/ *Elizabeth Kramer*
ELIZABETH KRAMER
Solicitor General
445 Minnesota Street, Suite 600
St. Paul, Minnesota, 55101
(651) 757-1010
liz.kramer@ag.state.mn.us

Counsel for the State of Minnesota

(Listing of counsel continued on next page)

AARON D. FORD
Attorney General of Nevada

/s/ *Heidi Parry Stern*
HEIDI PARRY STERN
Solicitor General
1 State of Nevada Way, Suite 100
Las Vegas, NV 89119
hstern@ag.nv.gov

Counsel for Nevada

MATTHEW J. PLATKIN
Attorney General of New Jersey

/s/ *Angela Cai*
ANGELA CAI
Executive Assistant
Attorney General
BRYCE K. HURST
Deputy Attorney General
25 Market Street
Trenton, NJ 08611
(609) 414-5954
angela.cai@njoag.gov

Counsel for New Jersey

RAÚL TORREZ
Attorney General of New Mexico

/s/ *Amy Senier*
AMY SENIER
Senior Counsel,
Impact Litigation Division
408 Galisteo Street
Santa Fe, NM 87501
(505) 637-1737
asenier@nmdoj.gov

Counsel for New Mexico

LETITIA JAMES
Attorney General of New York

/s/ *Judith N. Vale*
JUDITH N. VALE
Deputy Solicitor General
28 Liberty Street
New York, NY 10005
(212) 416-6274
judith.vale@ag.ny.gov

Counsel for New York

(Listing of counsel continued on next page)

DAN RAYFIELD
Attorney General of Oregon

/s/ *Robert Koch*
ROBERT KOCH
Senior Assistant Attorney General
1162 Court Street, NE
Salem, OR 97301
(503) 378-4402
robert.a.koch@doj.oregon.gov

Counsel for Oregon

PETER F. NERONHA
Attorney General of Rhode Island

/s/ *Jordan Broadbent*
JORDAN BROADBENT
Special Assistant Attorney General
150 South Main Street
Providence, RI 02903
(401) 274-4400, Ext. 2060
jbroadbent@riag.ri.gov

Counsel for Rhode Island

JOSHUA L. KAUL
Attorney General of Wisconsin

/s/ *Lynn K. Lodahl*
LYNN K. LODAHL
Assistant Attorney General
17 West Main Street
P.O. Box 7857
Madison, WI 53707
(608) 264-6219
lynn.lodahl@wisdoj.gov

Counsel for Wisconsin

CERTIFICATE OF COMPLIANCE

This brief complies with the word limits of Federal Rule of Appellate Procedure 32(a)(7) because, excluding the parts of the document exempted by Rule 32(f), it contains 12,981 words.

This brief complies with the typeface requirements of Rule 32(a)(5) and the type-style requirements of Rule 32(a)(6) because it has been prepared using Microsoft Word in Century Schoolbook, a proportionally spaced typeface.

November 12, 2025 /s/ *Gerard J. Cedrone*

Nos. 25-1611, 25-1612

UNITED STATES COURT OF APPEALS
FOR THE FIRST CIRCUIT

(No. 25-1611)

AMERICAN PUBLIC HEALTH ASSOCIATION; IBIS REPRODUCTIVE HEALTH; INTERNATIONAL UNION, UNITED AUTOMOBILE, AEROSPACE, AND AGRICULTURAL IMPLEMENT WORKERS (UAW); BRITTANY CHARLTON; KATIE EDWARDS; PETER LURIE; NICOLE MAPHIS,

Plaintiffs-Appellees,

v.

NATIONAL INSTITUTES OF HEALTH; JAY BHATTACHARYA, in his official capacity as Director of the National Institutes of Health; UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; ROBERT F. KENNEDY, JR., in his official capacity as Secretary of Health and Human Services,

Defendants-Appellants.

(Caption continued on inside cover)

Appeals from the U.S. District Court for the District of Massachusetts

SUPPLEMENTAL APPENDIX – VOLUME I

JESSIE J. ROSSMAN
SUZANNE SCHLOSSBERG
JENNIFER M. HERRMANN
American Civil Liberties Union Foundation of Massachusetts, Inc.
One Center Plaza, Suite 801
Boston, MA 02018
617-482-3170

Counsel for APHA Plaintiffs
Additional counsel for APHA Plaintiffs and Plaintiff States listed in Answering Briefs

(No. 25-1612)

COMMONWEALTH OF MASSACHUSETTS; STATE OF CALIFORNIA; STATE OF MARYLAND; STATE OF WASHINGTON; STATE OF ARIZONA; STATE OF COLORADO; STATE OF DELAWARE; STATE OF HAWAIʻI; STATE OF MINNESOTA; STATE OF NEVADA; STATE OF NEW JERSEY; STATE OF NEW MEXICO; STATE OF NEW YORK; STATE OF OREGON; STATE OF RHODE ISLAND; STATE OF WISCONSIN,

Plaintiffs-Appellees,

v.

ROBERT F. KENNEDY, JR., in his official capacity as Secretary of Health and Human Services; UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; JAY BHATTACHARYA, in his official capacity as Director of the National Institutes of Health; NATIONAL INSTITUTES OF HEALTH; NATIONAL CANCER INSTITUTE; NATIONAL EYE INSTITUTE; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; NATIONAL HUMAN GENOME RESEARCH INSTITUTE; NATIONAL INSTITUTE ON AGING; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS; NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES; NATIONAL INSTITUTE ON DRUG ABUSE; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES; NATIONAL INSTITUTE OF MENTAL HEALTH; NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; NATIONAL INSTITUTE OF NURSING RESEARCH; NATIONAL LIBRARY OF MEDICINE; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES; JOHN E. FOGARTY INTERNATIONAL CENTER FOR ADVANCED STUDY IN THE HEALTH SCIENCES; NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH; NIH CENTER FOR SCIENTIFIC REVIEW,

Defendants-Appellants.

_____

TABLE OF CONTENTS

VOLUME I – COURT FILINGS AND CASE DOCUMENTS

Memorandum of Points and Authorities in Support of Defendants' Motion to Dismiss Plaintiffs' Phase 2 Claims (25-cv-10787 Dkt. No. 131)……A2563

Notice of Production (25-cv-10787 Dkt. No. 170)……A2591

Application to Stay the Judgments of the United States District Court for the District of Massachusetts and Request for an Immediate Administrative Stay (Sup. Ct. 25A103, July 24, 2025)……A2593

Reply in Support of Application for Stay (Sup. Ct. 25A103, Aug. 4, 2025)……A2636

Grant Termination Appeal Packet, dated April 21, 2025 (NIH_GRANTS_005706–22)…. ……....A2665

Plaintiff Ibis Reproductive Health Grant Termination Appeal Packet, dated April 15, 2025 (NIH_GRANTS_005879–85)……A2684

Grant Termination Appeal Letter, dated April 18, 2025 (NIH_GRANTS_006712–13) ...…A2691

Memoli Grant Termination Appeal Response Letters, dated May 27, 2025 (NIH_GRANTS_006955–56)……A2693

Non-Overlapping APHA Grants and Appeals Spreadsheet (NIH_GRANTS_006957–59……..…A2695

OPERA Analysis of Non-Overlapping APHA Grants (NIH_GRANTS_006960–62)…...…A2698

NIH Grants Policy Statement – §§ 6.0, 6.1, 6.2, 7.3 (NIH_GRANTS_003987–3988; 3990–3991)……A2701

PDF Copy of NIH_GRANTS_001959……..…….A2705

PDF Copy of NIH_GRANTS_001968……. A2707

PDF Copy of NIH_GRANTS_002046……. A2708

PDF Copy of NIH_GRANTS_002296……. A2714

PDF Copy of NIH_GRANTS_002311……. A2717

PDF Copy of NIH_GRANTS_002353……. A2720

PDF Copy of NIH_GRANTS_002470……...……A2726

PDF Copy of NIH_GRANTS_002489……...……A2730

PDF Copy of NIH_GRANTS_002497……...…A2732

PDF Copy of NIH_GRANTS_002564……...…A2740

PDF Copy of NIH_GRANTS_003123……...…A2742

PDF Copy of NIH_GRANTS_003463……...……A2750
PDF Copy of NIH_GRANTS_003512……...……A2756
PDF Copy of NIH_GRANTS_003588……...……A2758
PDF Copy of NIH_GRANTS_003632……...……A2761
PDF Copy of NIH_GRANTS_003807……...……A2764

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

AMERICAN PUBLIC HEALTH ASSOCIATION, *et al.*, Plaintiffs, v. NATIONAL INSTITUTES OF HEALTH, *et al.*, Defendants.	Civil Action No. 1:25-cv-10787-WGY

MEMORANDUM OF POINTS AND AUTHORITIES IN SUPPORT OF DEFENDANTS' MOTION TO DISMISS PLAINTIFFS' UNREASONABLE DELAY CLAIMS

Table of Contents

Introduction 1

Background 2

Procedural History 5

Legal Standard 6

Argument 7

I. Plaintiffs lack standing to challenge alleged agency delay related to grant applications. .. 7

A. Plaintiffs cannot enforce the rights of nonparties 9

B. Plaintiffs also lack Article III standing 11

II. Plaintiffs' claims under 5 U.S.C. § 706(1) should be dismissed for three independent reasons 12

A. Plaintiffs' claims that NIH should be compelled to resume holding meetings and deciding awards are moot because NIH resumed before Plaintiffs sued 12

B. Any claims that NIH should not apply the Challenged Directives when considering and deciding Plaintiffs' applications about de-prioritized research topics are properly § 706(2) claims, not § 706(1) claims 133

C. The Court cannot compel NIH to decide applications because doing so is not a discrete and mandatory duty 15

III. Any unreasonable delay claim under 5 U.S.C. § 706(2) should be dismissed. 177

A. Plaintiffs did not allege sufficient facts to state a plausible claim for relief from delay in considering specific applications. 177

B. In any event, an application remaining under review is not a final agency action ... 177

IV. All phase 2 claims should be dismissed because the consideration of applications is committed to agency discretion by law. 188

Conclusion 19

TABLE OF AUTHORITIES

Page(s)

Cases

AAUP, et al. v. U.S. Dep't of Justice, et,
No. 25-cv-2429 (MKV), 2025 WL 1684817 (S.D.N.Y. June 16, 2025) 10, 11

ABC, Inc. v. Stewart,
360 F.3d 90 (2d Cir. 2004) 13

Ahadian & Fathollahzadeh v. Rubio,
No. 24-cv-12168, 2025 WL 1617224 (D. Mass. June 6, 2025) 14

Ashcroft v. Iqbal,
556 U.S. 662 (2009) 7

Associated Builders & Contractors, Inc. v. Herman,
976 F. Supp. 1 (D.D.C. 1997) 13

Barrett v. United States,
105 F.3d 793 (2d Cir. 1996) 13

Bell Atl. Corp. v. Twombly,
550 U.S. 544 (2007) 7

Bennett v. Spear,
520 U.S. 154 (1997) 18

Clapper v. Amnesty Int'l USA,
568 U.S. 398 (2013) 11, 12

Delta Data Sys. Corp. v. Webster,
744 F.2d 197 (D.C. Cir. 1984) 19

Dep't of Educ. v. California,
604 U.S. ---, 145 S. Ct. 966 (2025) 11

Dosmetova v. USCIS,
No. 3:24-cv-7409, 2025 WL 1663661 (D.S.C. Feb. 7, 2025) 19

Edwards v. Aurora Loan Servs.,
791 F. Supp. 2d 144 (D.D.C. 2011) 9

FDIC v. Meyer,
510 U.S. 471 (1994) 7

Friends of the Wild Swan, Inc. v. EPA,
130 F. Supp. 2d 1184 (D. Mont. 1999) 13

Funds for Animals, Inc. v. U.S. Bureau of Land Mgmt.,
460 F.3d 13 (D.C. Cir. 2006) 16

Gonzalez v. Cuccinelli,
985 F.3d 357 (4th Cir. 2021) 20

Haaland v. Brackeen,
599 U.S. 255 (2023) 11

Hells Canyon Pres. Council v. U.S. Forest Serv.,
593 F.3d 923 (9th Cir. 2010) 14

Hillside Metro Assocs., LLC v. JPMorgan Chase Bank, Nat. Ass'n,
747 F.3d 44 (2d Cir. 2014) 9

Karst Env't Educ. and Prot., Inc. v. U.S. Env't Prot. Agency,
403 F. Supp. 2d 74 (D.D.C. 2005) 19

Klamath Water Users Protective Ass'n v. Patterson,
204 F.3d 1206 (9th Cir. 1999) 9, 10

Kowalski v. Tesmer,
543 U.S. 125 (2004) 10

Lujan v. Def. of Wildlife,
504 U.S. 555 (1992) 8, 12

Maldonado-Coronel v. McElroy,
943 F. Supp. 376 (S.D.N.Y. 1996) 19

Merlonghi v. United States,
620 F.3d 50 (1st Cir. 2010) 7

Murphy v. United States,
45 F.3d 520 (1st Cir. 1995) 7

Murthy v. Missouri,
603 U.S. 43 (2024) 11

Nat'l Parks Conservation Ass'n v. U.S. Dep't of the Interior,
No. 1:20-cv-3706, 2024 WL 1344450 (D.D.C. Mar. 29, 2024) 14

Norton v. S. Utah Wilderness All.,
542 U.S. 67 (2004)..... 13, 15, 16

Planned Parenthood of Wisc., Inc. v. Azar,
316 F. Supp. 3d 291 (D.D.C. 2018)..... 18

Powers v. Ohio,
499 U.S. 410 (1991)..... 8

Rattlesnake Coal. v. EPA,
509 F.3d 1095 (9th Cir. 2007)..... 18

Rezaii v. Kennedy,
No. 1:24-cv-10838, 2025 WL 750215 (D. Mass. Feb. 24, 2025)..... 13

Sardarian v. Fed. Emergency Mgmt. Agency,
No. 3:19-cv-00910, 2022 WL 4080325 (D. Conn. Apr. 1, 2022)..... 10

Scarborough Citizens Protecting Res. v. U.S. Fish & Wildlife Serv.,
674 F.3d 97 (1st Cir. 2012)..... 15

Taber Partners, I v. Merit Builders, Inc.,
987 F.2d 57 (1st Cir. 1993)..... 7

Touarsi v. Mueller,
538 F. Supp. 2d 447 (D. Mass. 2008)..... 19

Vermont Yankee Nuclear Power Corp. v. Natural Resources Defense Council, Inc.,
435 U.S. 519, (1978)..... 19

Warth v. Seldin,
422 U.S. 490 (1975)..... 8

West v. Lynch,
845 F.3d 1228 (D.C. Cir. 2017)..... 12

Statutes

5 U.S.C. § 551(13)..... 16

5 U.S.C. § 701..... 19

5 U.S.C. § 706(1)..... 1, 12, 14, 16

5 U.S.C. § 706(2)..... 1, 18

5 U.S.C. § 1009..... 4

42 U.S.C. § 241 2

42 U.S.C. § 282 2

42 U.S.C. § 284a 3, 13

42 U.S.C. § 284 19

Rules

Fed. R. Civ. P. 12(b)(6) 7

Regulations

42 C.F.R. § 52h.2 3

42 C.F.R. § 52h.8 3

42 C.F.R. § 52.5 ..... 4, 17

42 C.F.R. § 52.6 ..... 2, 4

Other Authorities

90 Fed. Reg. 11175-01 (Mar. 4, 2025) 5, 12

90 Fed. Reg. 11323-02 (Mar. 5, 2025) 5, 12

90 Fed. Reg. 11324-01 (Mar. 5, 2025) 5

90 Fed. Reg. 11422-01 (Mar. 6, 2025) 5, 12

90 Fed. Reg. 12325 (Mar. 17, 2025) 5, 12

90 Fed. Reg. 12333 (Mar. 17, 2025) 5, 12

90 Fed. Reg. 13175 13

90 Fed. Reg. 13182 (Mar. 20, 2025) 5, 12

90 Fed. Reg. 13187 (Mar. 20, 2025) 5, 12

90 Fed. Reg. 13376 13

90 Fed. Reg. 13379 13

90 Fed. Reg. 13604 13

90 Fed. Reg. 13755 13

90 Fed. Reg. 14143 13

90 Fed. Reg. 14267 13

90 Fed. Reg. 14454 13

90 Fed. Reg. 15009 13

INTRODUCTION

Defendants respectfully move under Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6) to dismiss Plaintiffs' Phase 2 claims.

First, Plaintiffs lack both Article III and prudential standing to raise these claims. Plaintiffs attempt to assert the legal rights of nonparties, and their allegations of harm are too attenuated to support jurisdiction.

Plaintiffs' 5 U.S.C. § 706(1) claim should also be dismissed for three independent reasons. First, Plaintiffs acknowledge that NIH's delay in holding meetings and approving applications ended before Plaintiffs sued, thus rendering Plaintiffs' § 706(1) claim moot. Second, Plaintiffs' § 706(1) claim is an improper attempt to circumvent the final agency action requirement. Alternatively, if the Court rules that its phase 1 order under § 706(2) about the challenged Directives encompasses NIH's consideration of Plaintiffs' grant applications, applying the phase 1 ruling would remedy the alleged harms that Plaintiffs seek to redress in phase 2. This would mean—if phase 2 can proceed at all—the Court would need to consider Plaintiffs' remaining claims under 5 U.S.C. § 706(2), which courts recognize is the appropriate and preferred approach. Finally, even if the foregoing were not true, and the Court applies § 706(1), Plaintiffs cannot compel the actions that they seek to compel because those actions are not discrete and mandatory.

Any unreasonable delay claim pursued under 5 U.S.C. § 706(2) should also be dismissed. First, continued consideration of an application is not a final agency action. Second, to the extent Plaintiffs intend to argue that NIH has delayed or ended consideration of certain grants because of the challenged Directives, that claim should be dismissed under Rule 12(b)(6) because Plaintiffs failed to plead facts sufficient to state a claim for relief. They failed to put NIH on notice of which applications they allege are unreasonably delayed because Plaintiffs did not identify the allegedly delayed applications, and the few examples provided are insufficient.

Finally, all claims should be dismissed for phase 2 because considering applications and entering grant agreements is committed to agency discretion by law.

BACKGROUND

NIH's mission is to "seek fundamental knowledge about the nature and behavior of living systems" in order to enhance health, lengthen life, and reduce illness and disability.[1] To further this mission, NIH spent more than $35 billion in Fiscal Year 2023 on almost 50,000 competitive grants to more than 300,000 researchers at more than 2,500 universities, medical schools, and other research institutions across all 50 states and the District of Columbia. *See* Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates, NOT-OD-25-068 (Feb. 7, 2025).

Congress gave NIH broad discretion in awarding grants. 42 U.S.C. § 241(a)(3); 42 U.S.C. § 282(b)(3), (12). The Health and Human Services ("HHS") Secretary awards grants "to those applicants whose approved projects will *in the Secretary's judgment* best promote the purposes of the statute authorizing the grant and the regulations of this part." 42 C.F.R. § 52.6(a) (emphasis added). NIH also maintains broad discretion when administering grants. *See, e.g.*, 42 C.F.R. § 52.6(f).

Before approving any grant, NIH subjects grant applications to two levels of review; the first, by "peer review groups" and the second, by the funding institute's "Advisory Council." Peer review groups are composed of "primarily nongovernment experts qualified by training and experience in particular scientific or technical fields, or as authorities knowledgeable in the various disciplines and fields related to the scientific areas under review, to give expert advice on the scientific and technical merit of grant applications or contract proposals, or the concept of contract

[1] NIH, Mission and Goals, available at https://www.nih.gov/about-nih/what-we-do/mission-goals (last visited Feb. 14, 2025).

projects[.]" 42 C.F.R. § 52h.2(k). Annually, NIH engages roughly 25,000 peer reviewers. Advisory Councils are also composed of primarily non-government experts, and they "advise, assist, consult with, and make recommendations to the Secretary and the Director of such institute on matters related to the activities carried out by and through the institute and the policies respecting such activities." 42 U.S.C. § 284a. Among other responsibilities, Advisory Councils "review applications for grants and cooperative agreements for research or training and for which Advisory Council approval is required . . . and recommend for approval applications for projects which show promise of making valuable contributions to human knowledge[.]" *Id*.

The regulations governing the first level of NIH peer review process provide, in part, that each "scientific peer review group shall assess the overall impact that the project could have on the research field involved, taking into account a variety of factors." 42 C.F.R. § 52h.8. If the peer review group advises approval, the recommendation of the proposal then goes to the Advisory Councils. These bodies are *not* subject to specific review criteria identified in regulation; their role focuses on the prioritization of funding in light of NIH's budget and other competing grant applications. The Advisory Councils broadly consider whether applications "show promise of making valuable contributions to human knowledge," 42 U.S.C. § 284a, consistent with the priorities, missions, and purposes of the institute they advise.

Following review, if a project is approved by the relevant peer review group and Advisory Council, NIH may award that grant. 42 C.F.R. § 52.5(b). For any grant, NIH may also deny the application or take additional time to review. *Id*.

When NIH awards a grant, it enters an agreement with the grantee through the issuance of a Notice of Award (NOA), and the terms of that NOA govern the relationship between the grantee and NIH. Although a grant agreement permits the grantee to draw funds, it does not "commit[] or

obligate[] the United States in any way to make any additional, supplemental, continuation, or other award with respect to any approved application or portion of an approved application." 42 CFR § 52.6(c)(3).

Following the 2024 Presidential election, NIH's priorities shifted. Consistent with past practice when NIH comes under new management, on January 21, 2025, the Administration issued a temporary freeze on the publication of any documents in the Federal Register until they had been reviewed by a presidential appointee. NIH_GRANTS_000001. Because NIH must post a notice to the Federal Register when it schedules a peer review meeting for grant applications, it scheduled no meetings for the duration of the temporary pause. 5 U.S.C. § 1009(a)(2). NIH also cancelled all peer review meetings for that brief period.

NIH also began exercising its broad discretion to make and administer grants in alignment with its priorities. On February 10, 2025, the Acting Secretary of Health and Human Services directed agency personnel to "briefly pause all payments made to contractors, vendors, and grantees related to DEI and similar programs" to allow time for an internal review, including "to determine whether those contracts or grants are in the best interest of the government and consistent with current policy priorities." Feb. 10, 2025 Secretarial Directive, NIH_GRANTS_000004.[2] On February 21, 2025, then-Acting Director Dr. Matthew Memoli announced a shift in NIH's priorities. NIH_GRANTS_002930-1. Consistent with these priorities, the head of NIH, exercising the delegated authority of the Secretary, reviewed lists of grants and directed the termination of grants that did not effectuate agency priorities. *See, e.g.*,

[2] NIH stopped and re-started its processes to comply with court orders. See Feb. 12, 2025 NIH Review of Agency Priorities Based on the New Administration's Goals, NIH_GRANTS_000009 (directing agencies to resume issuing grants without restriction); Feb. 13, 2025 Supplemental Guidance, NIH_GRANTS_00016 (providing guidance about NIH priorities review).

NIH_GRANTS_003752–3. Additionally, various Institutes and Centers did not award renewals of certain grants following their investigation and review of individual grants. *See, e.g.*, NIH_GRANTS_001444-50.

While NIH continued to review and terminate grants, by March 23, 2025, NIH's pause on holding peer review meetings and awarding new grants ended.[3] Working to make up for lost time, NIH increased the rate at which it scheduled and held peer review meetings. From March 23, 2025, to June 30, 2025, NIH scheduled 837 peer review group meetings, according to publicly available NIH data.[4] That is a faster pace than NIH maintained in 2023 or 2024. For comparison, during the same period in 2024, NIH held 651 peer review group meetings. In 2023, it held 665. *Id.* Publicly available public documents thus show that, at present, NIH is not delaying consideration and award of grants, in general.

Plaintiffs nonetheless allege that NIH has delayed consideration of Plaintiffs' grants due to the challenged Directives. Compl. Doc No. 1 ¶¶ 237-40.

PROCEDURAL HISTORY

Plaintiffs sued on April 2, 2025, over a month after grant terminations started and after NIH resumed holding meetings and deciding grants. *See* Compl., Doc No. 1. More than three weeks later, Plaintiffs moved for a Preliminary Injunction. *See* Doc No. 37. Defendants opposed the Preliminary Injunction Motion on May 12, 2025. Doc. No. 66. On May 22, 2025, the Court collapsed the request for a Preliminary Injunction with a trial on the merits and treated the

[3] *See, e.g.*, 90 Fed. Reg. 11175-01 (Mar. 4, 2025); 90 Fed. Reg. 11324-01 (Mar. 5, 2025); 90 Fed. Reg. 11323-02 (Mar. 5, 2025); 90 Fed. Reg. 11422-01 (Mar. 6, 2025); 90 Fed. Reg. 12333 (Mar. 17, 2025); 90 Fed. Reg. 12325 (Mar. 17, 2025); 90 Fed. Reg. 13187 (Mar. 20, 2025); 90 Fed. Reg. 13182 (Mar. 20, 2025).

[4] https://www.csr.nih.gov/RevPanelsAndDates/RevDates.aspx

Defendants' Opposition as a Motion to Dismiss. Doc No. 77. On May 30, the Court entered a Order dismissing Counts IV, VI, and VII, but allowing the remaining Counts to proceed.

On June 3, 2025, the Court held a status conference in which it consolidated the proceedings in *Massachusetts, et al. v. Kennedy, et al.*, 1:25-cv-10814 (D. Mass.), with this case. *See* Doc No. 87. The Court decided that it would consider Plaintiffs' allegations in two phases, with the first phase considering the "challenged Directives" and terminations and the second phase considering Plaintiffs' unreasonable delay claims. Defendants timely filed administrative records by June 13, 2025. Doc No. 117. On the phase 2 proceedings, the Court ordered Defendants to produce an administrative record by July 9 and allowed Defendants to file this Motion to Dismiss by June 20. Doc. No. 87. [5]

On June 16, 2025, after briefing and a hearing on phase 1, the Court ruled from the bench that the challenged Directives, taken as a whole, and related grant terminations were arbitrary, capricious, and unlawful under the APA. It ruled that it would vacate the grant terminations listed on Plaintiffs' spreadsheets.

LEGAL STANDARD

A district court must dismiss claims under Rule 12(b)(1) when it lacks subject-matter jurisdiction to decide them. That includes claims for which the United States has not waived its sovereign immunity. *See FDIC v. Meyer*, 510 U.S. 471, 475 (1994) ("Sovereign immunity is jurisdictional in nature"). "When a district court considers a Rule 12(b)(1) motion, it credits the plaintiff's well-pled factual allegations and draws all reasonable inferences in the plaintiff's favor"

[5] Defendants understand the Court's scheduling order provided Defendants the opportunity to file a proper motion to dismiss in this case, not just the States case. Although APHA disagrees, Defendants file this motion because—regardless—12(b)(1) arguments can be raised at any time and many remaining arguments apply to APHA as well as the States, thus APHA should have opportunity to respond.

Merlonghi v. United States, 620 F.3d 50, 54 (1st Cir. 2010). "A plaintiff, however, may not rest merely on unsupported conclusions or interpretations of law." *Murphy v. United States*, 45 F.3d 520, 522 (1st Cir. 1995) (citation omitted). Moreover, "the party invoking the jurisdiction of a federal court carries the burden of proving its existence." *Taber Partners, I v. Merit Builders, Inc.*, 987 F.2d 57, 60 (1st Cir. 1993).

A suit also must be dismissed if the complaint fails to "state a claim upon which relief can be granted." Fed. R. Civ. P. 12(b)(6). To defeat a Rule 12(b)(6) motion to dismiss, a plaintiff must plead sufficient facts "to 'state a claim to relief that is plausible on its face.'" *Ashcroft v. Iqbal*, 556 U.S. 662, 678 (2009) (quoting *Bell Atl. Corp. v. Twombly*, 550 U.S. 544, 570 (2007)). A claim is facially plausible when the pleaded facts allow a court "to draw the reasonable inference that the defendant is liable for the misconduct alleged." *Id.* at 678. When evaluating a Rule 12(b)(6) motion, the Court must accept all material factual allegations in the complaint as true and draw any reasonable inferences in the non-moving party's favor. *Id.* However, the Court is "not bound to accept as true a legal conclusion couched as a factual allegation," or to credit "mere conclusory statements" or "[t]hreadbare recitals of the elements of a cause of action." *Id.* (quoting *Twombly*, 550 U.S. at 555).

ARGUMENT

I. Plaintiffs lack standing to challenge alleged agency delay related to grant applications.

As an initial matter, the Court should dismiss all of Plaintiffs' claims because Plaintiffs lack both prudential and Article III standing. At its "irreducible constitutional minimum," Article III standing requires a plaintiff, as the party invoking the Court's jurisdiction, to establish three elements: (1) a concrete and particularized injury-in-fact, either actual or imminent, and not conjectural or hypothetical, (2) a causal connection between the injury and defendants' challenged

conduct, and (3) a likelihood that the injury suffered will be redressed by a favorable decision. *Lujan v. Def. of Wildlife*, 504 U.S. 555, 560-61 (1992). Moreover, courts adhere to the rule that a party "generally must assert his own legal rights and interests, and cannot rest his claim to relief on the legal rights or interests of third parties." *Warth v. Seldin,* 422 U.S. 490, 499 (1975). Court disfavor granting third-party standing in the absence of a "hindrance to the third party's ability to protect his or her own interests." *Powers v. Ohio*, 499 U.S. 410, 411 (1991).[6]

A. Plaintiffs cannot enforce the rights of nonparties.[7]

Plaintiffs allege that the Defendants are delaying or suspending review of grant applications in which neither Plaintiffs nor their members have a legally cognizable interest. Indeed, all of Plaintiffs' § 706(1) claims are aimed at challenging NIH's handling of grant applications for *other nonparty entities*. Therefore, Plaintiffs lack prudential standing to assert these claims.

"In order to establish standing to" enforce rights related to a government contract, a plaintiff must show that they are party to the putative contract or an intended third-party beneficiary. *Edwards v. Aurora Loan Servs.*, 791 F. Supp. 2d 144, 150 (D.D.C. 2011); *see also Hillside Metro Assocs., LLC v. JPMorgan Chase Bank, Nat. Ass'n*, 747 F.3d 44, 49 (2d Cir. 2014) (holding that plaintiff lacked prudential standing because it could not "enforce the terms of" an agreement "as to which it is neither a party nor a third-party beneficiary"); *Klamath Water Users Protective Ass'n v. Patterson*, 204 F.3d 1206, 1210 (9th Cir. 1999), *opinion amended on denial of reh'g*, 203 F.3d 1175 (9th Cir. 2000) ("Before a third party can recover under a contract, it must

[6] As the Court has already ruled that associational Plaintiffs have associational standing, Defendants do not reassert those arguments here but preserve the issue for any potential appeal.

[7] Although not raised in "phase 1" of this case, the same reasoning for Plaintiffs' lack of standing here applies to all grant terminations at issue in phase 1 for all Plaintiffs other than Ibis. And, importantly, as it is a jurisdictional matter, standing cannot be waived.

show that the contract was made for its direct benefit—that it is an intended beneficiary of the contract."). Plaintiffs can show neither.

Other than Ibis, each Plaintiff in this case is either a researcher that works for a nonparty entity or membership organization whose members are individual researchers. None of the individual or associational Plaintiffs or their members have directly applied for a grant themselves; rather, they work for institutions who may have applied for NIH grants. They therefore have no legally cognizable interest in the grant applications. Ibis has not itself submitted a grant application consideration of which was delayed. Doc No. 1 ¶¶ 20, 160-61. [8]

As the Administrative Record in Phase 1 of this case makes clear, each of the grant applications that Plaintiffs claim to have an interest in are for grants that would be awarded to *their employer* institutions, none of which are parties to this suit. *See, e.g.*, NIH_Grants_004271; 5570.; *see also* Doc No. 38-21 (Maphis Decl.) ¶ 20 ("*My institution* (UNM) has lost out on the opportunity to train me for the next two years"); Doc No. 38-26 (Berg Decl) at ¶ 13 (noting that Congress authorized grants to "universities, hospitals, laboratories, and other public or private institutions" – but not to researchers); ¶ 28 (noting that a scientist submits a grant "*through their organization*" (emphasis added)). Plaintiffs and their members were not party to any of the grant applications whose consideration they allege were delayed.

Nor have Plaintiffs alleged in their complaint or elsewhere that they are intended beneficiaries. *See Klamath*, 204 F.3d at 1211 ("[T]he third party must show that the contract reflects the express or implied intention of the parties to the contract to benefit the third party.").

[8] The only named individual Plaintiff who alleges that they submitted a grant application that NIH refuses to consider is Plaintiff Nicole Maphis. *See* Doc No. 1 ¶ 18. However, any such grant is awarded to the institution for which she works, University of New Mexico School of Medicine, and not Plaintiff Maphis. *Id.*; *see also* Doc No. 38-21 at ¶ 20. And, as explained below, as a "Principal Investigator," she is not an intended beneficiary of the grant.

While the nonparty institutions may list an individual researcher as a "Principal Investigator or Project Director" on their grants, *see, e.g.*, NIH_Grants_004278, the researchers are not themselves intended beneficiaries of any awarded contract. *See AAUP v. U.S. Dep't of Justice*, No. 25-cv-2429, 2025 WL 1684817, at *5, 6, 12 n.7 (S.D.N.Y. June 16, 2025) (finding "principal investigators" lacked legal interest in terminated NIH grants). The researchers therefore lack standing to sue for NIH's alleged delay in considering their employers' grant applications. *See Kowalski v. Tesmer*, 543 U.S. 125, 129 (2004) (noting that only parties, or select nonparties (intended beneficiaries), may seek to enforce their rights); *see also Sardarian v. Fed. Emergency Mgmt. Agency*, No. 3:19-CV-00910 (OAW), 2022 WL 4080325, at *1–2 (D. Conn. Apr. 1, 2022) (dismissing suit for lack of standing because FEMA awarded "the grant in question" to the State of Connecticut and to the Town of Westport, and plaintiff was not the recipient of the Federal grant).

Recently, the Southern District of New York dismissed a similar jurisdictional overreach by Plaintiff UAW and another organizational plaintiff claiming their members had an interest in Columbia University's terminated NIH research grants. *See AAUP v. U.S. Dept' of Justice*, No. 25-cv-02429-MKV, 2025 WL 1684817 (S.D.N.Y. June 16, 2025). The district court recognized that these associational plaintiffs lack prudential standing to challenge NIH grant terminations:

> Neither the Executive Branch nor the Legislature ever awarded the grants and contracts at issue to Plaintiffs or any of their members. The funding that Plaintiffs ask this Court to commandeer was awarded to Columbia, which is conspicuously absent from this case. If any funds have been wrongfully withheld, such funds may be recovered at the end of a successful lawsuit by the appropriate plaintiff in an appropriate forum. *See Dep't of Educ. v. California*, 604 U.S. ---, 145 S. Ct. 966, 969 (2025).

Id. at *1. Here too, the institutions that employ Plaintiffs may themselves file suit (and in some instances have in the related matter), but Plaintiffs and their members lack prudential standing.

B. Plaintiffs also lack Article III standing

Plaintiffs alleged harms are also too attenuated to support jurisdiction because any asserted harms must flow from independent choices made by their employers, or their injury is otherwise too speculative. A "federal court cannot redress 'injury that results from the independent action of some third party not before the court.'" *See Murthy v. Missouri*, 603 U.S. 43, 57 (2024). Courts are "'reluctant to endorse standing theories that require guesswork as to how independent decisionmakers will exercise their judgment,'" *id.* (quoting *Clapper v. Amnesty Int'l USA*, 568 U.S. 398, 413 (2013)), and have rejected theories of redressability that depend on such guesswork, *id.*, 603 U.S. at 73; *Haaland v. Brackeen*, 599 U.S. 255, 293-94 (2023).

Plaintiffs claim that NIH delays in considering may cause "large numbers of current and future biomedical researchers risk unexpected job loss that will harm them personally." Doc No. 1 ¶ 240. It is, however, the choice of *their employers*, nonparties to this case who are taking such actions. *See, e.g.*, Doc No. 38-21 ("My institution . . . may not have the money to support my salary."). If, for example, their employer chooses to continue funding their project despite any delays on the part of NIH, then no harm flows to Plaintiffs' members. Thus, the choices of nonparties who have "broad and legitimate discretion," interrupt any link between any alleged harms. *See Lujan*, 504 U.S. at 562. When this kind of "conjecture is necessary, redressability is lacking." *West v. Lynch*, 845 F.3d 1228, 1237 (D.C. Cir. 2017) (internal citation omitted).

Plaintiffs also contend that "they may not be able to continue their projects," have had to "take on additional responsibilities," are in "administrative limbo," and other vague and undefined alleged harms. *See* Doc No. 41 at 33-34. But such claims are far too speculative to satisfy Article III standing. *See Clapper*, 568 U.S. at 409 (explaining that any allegation of "threatened injury must be *certainly impending*" (citation omitted)); *see also* Doc No. 41 at 34 (noting that Plaintiffs' members are trying to secure replacement fund but "do not anticipate" being able to raise enough).

II. Plaintiffs' claims under 5 U.S.C. § 706(1) should be dismissed for three independent reasons.

A. Plaintiffs' claims that NIH should be compelled to resume holding meetings and deciding awards are moot because NIH resumed before Plaintiffs sued.

Plaintiffs cannot obtain an order requiring NIH to "refrain from delaying" meetings and procedural steps needed to issue awards "based on the Challenged Directives" because the relevant directives ended before Plaintiffs even sued. Defendants have resumed holding meetings and taking the procedural steps needed to review new applications and issue awards. NIH did cancel previously scheduled meetings and refrained from setting new meetings based on the January 21, 2025 Notice Pause Directive. APHA Doc No. 66-1 ¶ 20. But that Directive—by its own terms—expired on February 1, 2025. NIH_GRANTS_000001. Since then, from March 24 through June 30, NIH has scheduled or held 837 peer review meetings. This is 186 more peer review meetings than NIH held for this same time period last year.[9] NIH is also on track to complete at least three advisory council meetings this fiscal year, as contemplated by 42 U.S.C. § 284a(e).[10] APHA Doc No. 66-1 ¶ 24. Peer reviews are also ongoing. APHA Doc No. 66-1 ¶ 22. So, although NIH briefly paused certain processes upon the change in administrations, NIH has been conducting all necessary steps in the review and disposition of grant applications.

Once an agency resolves a challenged delay, the issue becomes moot. *See Norton v. S. Utah Wilderness All.*, 542 U.S. 67, 68 (2004) (holding two claims moot because they sought creation of Bureau of Land Management plans, which were later created); *Friends of the Wild Swan, Inc. v.*

[9] This is shown by searching the relevant date range through NIH's public calendar of peer review meetings: https://www.csr.nih.gov/RevPanelsAndDates/RevDates.aspx; see also, e.g., 90 Fed. Reg. 11175; 90 Fed. Reg. 11324; 90 Fed. Reg. 11323; 90 Fed. Reg. 11422; 90 Fed. Reg. 12333; 90 Fed. Reg. 12325; 90 Fed. Reg. 13187; 90 Fed. Reg. 13182.

[10] *See, e.g.*, 90 Fed. Reg. 14267; 90 Fed. Reg. 13755; 90 Fed. Reg. 13175; 90 Fed. Reg. 14454; 90 Fed. Reg. 13376; 90 Fed. Reg. 15009; 90 Fed. Reg. 14143; 90 Fed. Reg. 13379; 90 Fed. Reg. 13604.

EPA, 130 F.Supp.2d 1184, 1192 (D. Mont. 1999) (APA claim moot when the EPA, thirteen years after its alleged duty arose, cured its failure to act by finally acting); *Associated Builders & Contractors, Inc. v. Herman,* 976 F. Supp. 1, 8 (D.D.C. 1997) (holding an APA claim challenging an agency's delay moot because the agency had finally acted). The Second Circuit has explained that "if an event occurs while a case is pending on appeal that makes it impossible for the court to grant any effectual relief whatever to a prevailing party, [the court] must dismiss the case" as moot "rather than issue an advisory opinion." *ABC, Inc. v. Stewart*, 360 F.3d 90, 97 (2d Cir. 2004); *see also Barrett v. United States*, 105 F.3d 793, 794 (2d Cir. 1996); *Rezaii v. Kennedy*, No. 1:24-cv-10838, 2025 WL 750215 at *3 (D. Mass. Feb. 24, 2025) (holding unreasonable delay claim moot where agency took the allegedly delayed action). The Challenged Directives relating to the pause about which Plaintiffs complain have expired, and so too have the temporary pauses themselves. This claim is moot and should be dismissed.

B. Any claims that NIH should not apply the Challenged Directives when considering and deciding Plaintiffs' applications about de-prioritized research topics are properly § 706(2) claims, not § 706(1) claims.

Plaintiffs cannot evade the § 706(2)'s final-agency-action requirement by disguising § 706(2) claims as § 706(1) claims. Courts routinely reject such efforts, especially when plaintiffs bring both § 706(2) claims and § 706(1) claims that are based on the same legal theory. *Hells Canyon Pres. Council v. U.S. Forest Serv.*, 593 F.3d 923, 934 (9th Cir. 2010) (rejecting effort to bring a § 706(1) claim where the "argument is better phrased as" a § 706(2) claim.); *see Ahadian & Fathollahzadeh v. Rubio.*, No. 24-cv-12168, 2025 WL 1617224 at *4 (D. Mass. June 6, 2025) (refusing to "separately consider" claims brought pursuant to § 706(1) and § 706(2) where the two claims rely "on the same theory."); *Nat'l Parks Conservation Ass'n v. United States Dep't of the Interior*, No. 20-cv-3706, 2024 WL 1344450 at *9 (D.D.C. Mar. 29, 2024) (emphasizing that "because [plaintiff's] Section 706(2)(A) claims assert that what [defendant] has already done is

impermissible, it is better to resolve that question before deciding whether [defendant] must be compelled to do anything else under Section 706(1)."). *Hells Canyon Preservation Council v. U.S. Forest Service*, is instructive. 593 F.3d 923 (9th Cir. 2010). There, the Ninth Circuit rejected an effort to cast a § 706(2) claim as a § 706(1) claim. *Id.* at 933. In doing so, it emphasized that the defendant *had* engaged in final agency action, and that plaintiffs' contentions under § 706(1) were actually a challenge to a final agency action. *Id.* at 930. As such, § 706(2), not § 706(1), was the only proper avenue for relief. *Id.* at 933.

Ultimately, Plaintiffs' § 706(1) claims are simply another assault on the Challenged Directives. They styled their admitted § 706(2) claims as attacks on these directives in phase 1. APHA Compl. Doc No. 1 ¶ 215; Sates Am. Compl. Doc No. 75 ¶ 215. And their purported § 706(1) claims are just another volley on that front in phase 2. State Plaintiffs' § 706(1) claim in their amended complaint emphasizes "in implementing the *Challenged Directives*, defendants have cancelled and/or substantially delayed … NIH's advisory councils and study sections—a significant and unprecedented departure from the NIH's published review process and the agency's past practice." States' Am. Compl. Doc No. 75 ¶ 264 (emphasis added). Indeed, the *entirety* of Count 7, State Plaintiffs' § 706(1) claim, emphasizes that the delays flow from the Challenged Directives. *Id.* ¶ 264-66. APHA plaintiffs take the same approach. APHA Compl. Doc No. 1 ¶ 239. Just as in *Hells Canyon Preservation Council*, Plaintiffs here are still attacking the Challenged Directives, which the Court has already determined to be final agency action.[11] If so, law of the case holds that the Court's recent conclusion in phase 1 extends to the alleged delays to be examined in phase 2. Thus, at this stage, no § 706(1) claim exists.

[11] Defendants respectfully disagree with this conclusion and include a no-final-agency-action argument below to preserve their arguments.

C. The Court cannot compel NIH to decide applications because doing so is not a discrete and mandatory duty.

To establish a claim under § 706(1), Plaintiffs must show that the agency "failed to take a discrete agency action that it is required to take." *Scarborough Citizens Protecting Res. v. U.S. Fish & Wildlife Serv.*, 674 F.3d 97, 99 (1st Cir. 2012) (quoting *Norton v. S. Utah Wilderness All.*, 542 U.S. 55, 64 (2004)). As the Supreme Court recognized, "[t]his is a high standard," and the "central question in evaluating such a claim is whether the agency's delay is so egregious that mandamus is warranted." APHA Doc. 84 at 29 (quotations omitted). Plaintiffs have failed to identify a discrete and mandatory agency action that the Court can compel under § 706(1).

Plaintiffs assert that NIH was required to (1) hold study section and advisory council meetings to consider and make final recommendations on grant applications, and (2) make a final decision on grant applications and requests for renewals. States Doc No. 75 at 85-87; APHA Doc No. 1 at 74. In previous briefing, Plaintiffs maintained that they also assert that the withholding of consideration of grant applications for withdrawn Notices of Funding Opportunities was unlawful.[12] APHA Doc No. 66 at 18-19. Putting aside that NIH is holding meetings and deciding applications, none of these is a discrete and mandatory agency action.

First, holding meetings is not "agency action" at all. As the Supreme Court explained in *Norton*, a failure to act under § 706(1) is "properly understood as a failure to take an agency action—that is, a failure to take one of the agency actions (including their equivalents) earlier defined in § 551(13)." 542 U.S. at 62. That earlier APA section, 5 U.S.C. § 551(13), defines "agency action" as "the whole or a part of an agency rule, order, license, sanction, relief, or the

[12] In fact, Plaintiffs omit this theory in the portions of their complaints that asserted a § 706(1) claim. *See* States Doc No. 75 at 84-87; APHA Doc No. 1 at 74.

equivalent or denial thereof, or failure to act." Holding meetings—even meetings established by statute—fall well outside this definition.

Moreover, holding meetings is not a *discrete* action. It is part of NIH's "common business of managing government programs," rather than a discrete action that can be compelled. *Funds for Animals, Inc. v. U.S. Bureau of Land Mgmt.*, 460 F.3d 13, 19-20 (D.C. Cir. 2006) ("Much of what an agency does is in anticipation of agency action."). Plaintiffs acknowledge that NIH resumed holding the study section and advisory council meetings, but Plaintiffs still take issue and ask this Court to monitor how many meetings are being scheduled and how quickly. This is precisely the sort of invasive supervision that the Supreme Court has said to avoid. *Norton*, 542 U.S. at 67 ("The prospect of pervasive oversight by federal courts over the manner and pace of agency compliance with such congressional directives is not contemplated by the APA."). The APA does not permit the Court to compel the pace of NIH's meetings.

Second, making a final decision on grant applications and requests for renewal is not a mandatory agency action. To the contrary, HHS regulations expressly authorize the agency to "defer" making a final decision "because of either lack of funds or a need for further evaluation." 42 C.F.R. § 52.5(b). That is exactly what NIH briefly did here (before resuming issuing notices of award): NIH deferred decisions on grant applications due to a need to evaluate whether such applications were consistent with revised agency priorities following a change in administration. Making a final decision cannot be mandatory when the regulations permit deferring that decision.

Finally, Plaintiffs argued in previous briefing that, even though NIH had resumed holding meetings and resumed issuing notices of award, NIH continued to withhold consideration of certain applications. *See* APHA Doc No. 71 at 18. Specifically, Plaintiffs alleged that NIH had "begun to 'administratively withdraw' applications for some programs purged as a result of the

Directives." *Id*. This allegation refers to applications that were mooted when NIH withdrew the Notice of Funding Opportunity ("NOFO"). But maintaining a NOFO is neither discrete nor mandatory. A NOFO is merely a notice that invites applications for a *potential* grant, not an agency action. And Plaintiffs do not cite any authority that requires NIH to maintain—and that denies NIH any discretion to withdraw—a NOFO. Thus, no basis exists for the Court to compel NIH to restore a NOFO and revive a mooted application.[13]

III. Any unreasonable delay claim under 5 U.S.C. § 706(2) should be dismissed.

A. Plaintiffs did not allege sufficient facts to state a plausible claim for relief from delay in considering specific applications.

Plaintiffs fail to state a claim for relief related to unreasonable delay because they do not allege that Ibis Reproductive Health—the only plaintiff that applies for and receives grants—submitted an application that has been delayed. *See* APHA Compl., Doc No. 1 ¶¶ 20, 160, 161. The Complaint alleges delayed applications related only to Plaintiff Maphis, APHA Members 1 and 6, UAW Members 1-8, and UAW Pre-Members 1-6. *See* APHA Compl., Doc No. 1 ¶¶ 162-194. As explained above, none of these people have standing to challenge alleged agency inaction related to the grants. *See supra* Part I. Accordingly, Plaintiffs have failed to state any claim for which relief could be granted, and their complaint should be dismissed for purposes of phase 2.

B. In any event, an application remaining under review is not a final agency action.

Even if Plaintiffs had sufficiently alleged that NIH has not scheduled reviews for certain applications, doing so is not a final agency action subject to judicial review because it neither (1) "marks the consummation of the agency's decision-making process," nor (2) is "one by which rights or obligations have been determined, or from which legal consequences will flow." *Bennett*

[13] Following the Court's entry of partial judgment on phase 1, absent a stay, NIH will restore NOFOs related to terminated programs listed on Plaintiffs' spreadsheet.

v. Spear, 520 U.S. 154, 177-78 (1997). In the context of agency grant-making in particular, no final agency action exists "until the [agency] has reviewed a grant application and decided to disburse the funds." *Rattlesnake Coal. v. EPA*, 509 F.3d 1095, 1103-04 (9th Cir. 2007); *Planned Parenthood of Wisc., Inc. v. Azar*, 316 F. Supp. 3d 291, 300-01 (D.D.C. 2018), *vacated as moot on other grounds*, 942 F.3d 512, 519 (D.C. Cir. 2019) (emphasizing that, in the grant application context, "courts usually recognize final agency action only after grant awards issue."). Before the agency makes an award, 'the federal money is but an expectancy that has not yet materialized.'" *Karst Env't Educ. and Prot., Inc. v. U.S. Env't Prot. Agency*, 403 F. Supp. 2d 74, 81 (D.D.C. 2005); *see Delta Data Sys. Corp. v. Webster*, 744 F.2d 197, 206 (D.C. Cir. 1984) ("award procedures are not designed to establish private entitlements to public contracts but to produce the best possible contracts for the government."). Indeed, State Plaintiffs admit that while a review is not scheduled "the grant remains under review." States Doc No. 75 at 44, ¶ 183. Not scheduling review of an application neither denies nor establishes any rights, obligations, or legal consequences since NIH can schedule review at any time.

IV. All phase 2 claims should be dismissed because the consideration of applications is committed to agency discretion by law.

For many of the same reasons that holding meetings does not constitute a discrete agency action, NIH's management of its grant review process is also "committed to agency discretion by law." 5 U.S.C. § 701(a)(2). "Internal agency procedures are committed to the agency's discretion." *Maldonado-Coronel v. McElroy*, 943 F. Supp. 376, 381 (S.D.N.Y. 1996) (citing *Vermont Yankee Nuclear Power Corp. v. Natural Resources Defense Council, Inc.*, 435 U.S. 519, 524, (1978)). In the context of application processes, Plaintiffs must show that NIH "has a nondiscretionary duty to adjudicate" grant applications "within a certain timeframe. *Dosmetova v. USCIS*, No. 3:24-cv-7409, 2025 WL 1663661 *2 (D.S.C. Feb. 7, 2025) (collecting cases).

Otherwise, the APA provides no opportunity to review. *Id.*; *see Touarsi v. Mueller*, 538 F. Supp. 2d 447,452 (D. Mass. 2008) (holding claim to compel agency action under 706(1) precluded where statute imposed no timing requirements on agency).

NIH has no nondiscretionary duty to process applications, or hold peer review meetings, within a certain timeframe. Indeed, it need not process grant applications *at all*. 42 U.S.C. §§ 284(b)(2) ("Support for an activity or program under this subsection *may* be provided through grants, contracts, and cooperative agreements.") (emphasis added); 284(b)(2)(A)–(B) (providing that the agency "*may* enter into a contract for research" and "*may* make grants and cooperative agreements") (emphasis added). This statutorily discretionary approach to grant review is fatal to Plaintiffs' 706(1) claims, because "where an agency is not required to do something, [the Court] cannot compel the agency to act—let alone to act faster." *Gonzalez v. Cuccinelli*, 985 F.3d 357, 466 (4th Cir. 2021). And even if the Court determines NIH must process grant applications, Plaintiffs can point to nothing that requires it to do so on any particular timeline.

CONCLUSION

For the foregoing reasons, the Court should dismiss all Plaintiffs' phase 2 claims.

Defendants respectfully request that the Court enter an expedited deadline for Plaintiffs' response of June 26, 2025, which is the same amount of time the Court provided for Defendants to move to dismiss after the phase 1 hearing concluded. Defendants had four business days (and four calendar days) to move. Defendants propose that Plaintiffs be provided four business days (six calendar days) to respond. This promotes the interests of justice and efficiency, since the Court's ruling on the motion to dismiss could impact the administrative record that is being prepared for phase 2. Plaintiffs informed Defendants' counsel that they oppose the request for expedited briefing.

Defendants respectfully submit ten days as proposed by Defendants' in the related case is inappropriate based on the expedited nature of this case and because Defendants in that case proposed more reciprocal deadlines (Defendants had 7 days to move while Plaintiffs had 10 days to respond) which Plaintiffs opposed. Most important, in Defendants' proposal, the decision on the motion to dismiss triggered the deadline for the administrative record. Without an expedited response deadline, Defendants will need to produce the administrative record shortly after Plaintiffs' respond to their motion to dismiss, and potentially before the Court has opportunity to rule.

Respectfully submitted,

BRETT A. SHUMATE
Assistant Attorney General

LEAH B. FOLEY
United States Attorney

KIRK T. MANHARDT
Director

MICHAEL J. QUINN
Senior Litigation Counsel

Dated: June 20, 2025

/s/ Anuj Khetarpal

ANUJ KHETARPAL
Assistant U.S. Attorney
1 Courthouse Way, Suite 9200
Boston, MA 02210
(617) 748-3658
anuj.khetarpal@usdoj.gov

THOMAS W. PORTS, Jr. (Va. Bar No. 84321)
Trial Attorney
U.S. Department of Justice
Civil Division, Corporate/Financial Section
P.O. Box 875
Ben Franklin Stations
Washington D.C. 20044-0875
(202) 307-1105
thomas.ports@usdoj.gov

Attorneys for Defendants

CERTIFICATE OF SERVICE

I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF).

Dated: June 20, 2025

/s/ Anuj Khetarpal
Anuj Khetarpal

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

AMERICAN PUBLIC HEALTH ASSOCIATION, *et al.*, Plaintiffs, v. NATIONAL INSTITUTES OF HEALTH, *et al.*, Defendants.	Civil Action No. 1:25-cv-10787-WGY

NOTICE OF PRODUCTION

Pursuant to the joint stipulation entered into between the parties on July 25, 2025, Doc. No. 163, Doc. No. 167, and the Court's order approving it on August 14, 2025, Doc. No. 168, defendants have produced a spreadsheet containing explanations for the status of various grant applications included on the list that Plaintiffs provided to Defendants on June 30, 2025, and each of the Notices of Funding Opportunity on the list that Plaintiffs provided to Defendants on July 29, 2025. The content of the spreadsheet is described in the attached Certification.

The spreadsheet includes sensitive information about the status of various grant applications. The parties are in the process of entering a protective order to shield that sensitive information. Defendants have therefore produced the spreadsheet by sending an email to Plaintiffs and submitting it electronically to the court's clerk.

Respectfully submitted,

BRETT A. SHUMATE
Assistant Attorney General

LEAH B. FOLEY
United States Attorney

KIRK T. MANHARDT
Director

MICHAEL J. QUINN
Senior Litigation Counsel

Dated: August 19, 2025

/s/ Anuj Khetarpal
ANUJ KHETARPAL
Assistant U.S. Attorney
1 Courthouse Way, Suite 9200
Boston, MA 02210
(617) 748-3658
Anuj.Khetarpal@usdoj.gov

Attorneys for Defendants

No. 25A

In the Supreme Court of the United States

NATIONAL INSTITUTES OF HEALTH, ET AL., APPLICANTS

v.

AMERICAN PUBLIC HEALTH ASSOCIATION, ET AL.

ROBERT F. KENNEDY, JR., ET AL., APPLICANTS

v.

COMMONWEALTH OF MASSACHUSETTS, ET AL.

APPLICATION TO STAY THE JUDGMENTS OF THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS AND REQUEST FOR AN IMMEDIATE ADMINISTRATIVE STAY

D. JOHN SAUER
Solicitor General
Counsel of Record
Department of Justice
Washington, D.C. 20530-0001
SupremeCtBriefs@usdoj.gov
(202) 514-2217

TABLE OF CONTENTS

Statement 6

A. Factual background 6

B. Procedural history 12

Argument 17

A. The government is likely to succeed on the merits 18

1. The district court lacked subject-matter jurisdiction to compel the government to pay terminated grants 18

2. NIH grant decisions are committed to agency discretion by law 27

3. The grant terminations were not arbitrary or capricious 29

B. The other factors support a stay 34

1. The issues raised by this case warrant this Court's review 34

2. The district court's order irreparably harms the government 36

3. The balance of the equities strongly favors the government 37

C. This Court should issue an administrative stay 38

Conclusion 39

PARTIES TO THE PROCEEDING

Applicants (defendants-appellants below) in *National Institutes of Health* v. *American Public Health Association* are the National Institutes of Health; Jay Bhattacharya, in his official capacity as Director of the National Institutes of Health; United States Department of Health and Human Services; and Robert F. Kennedy, Jr., in his official capacity as Secretary of the United States Department of Health and Human Services.

Respondents (plaintiffs-appellees below) in *National Institutes of Health* v. *American Public Health Association* are the American Public Health Association, IBIS Reproductive Health, United Auto Workers, Brittany Charlton, Katie Edwards, Peter Lurie, and Nicole Maphis.

Applicants (defendants-appellants below) in *Kennedy* v. *Massachusetts* are Robert F. Kennedy, Jr., in his official capacity as Secretary of the United States Department of Health and Human Services; United States Department of Health and Human Services; Jayanta Bhattacharya, in his official capacity as Director of the National Institutes of Health; National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Drug Abuse; National Institute of Environmental Health Sciences;

National Institute of General Medical Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke; National Institute of Nursing Research; National Library of Medicine; National Center for Advancing Translational Sciences; John E. Fogarty International Center for Advanced Study in the Health Sciences; National Center for Complementary and Integrative Health; and NIH Center for Scientific Review.

Respondents (plaintiffs-appellees below) in *Kennedy* v. *Massachusetts* are the Commonwealth of Massachusetts, State of California, State of Maryland, State of Washington, State of Arizona, State of Colorado, State of Delaware, State of Hawaii, State of Minnesota, State of Nevada, State of New Jersey, State of New Mexico, State of New York, State of Oregon, State of Rhode Island, and State of Wisconsin.

RELATED PROCEEDINGS

United States District Court (D. Mass.):

American Public Health Association v. *National Institutes of Health*, No. 25-cv-10787 (June 24, 2025) (denying stay)

Massachusetts v. *Kennedy*, No. 25-cv-10814 (June 24, 2025) (denying stay)

American Public Health Association v. *National Institutes of Health*, No. 25-cv-10787 (June 23, 2025) (partial final judgment)

Massachusetts v. *Kennedy*, No. 25-cv-10814 (June 23, 2025) (partial final judgment)

United States Court of Appeals (1st Cir.):

American Public Health Association v. *National Institutes of Health*, No. 25-1611 (July 18, 2025)

Massachusetts v. *Kennedy*, No. 25-1612 (July 18, 2025)

In the Supreme Court of the United States

No. 25A

NATIONAL INSTITUTES OF HEALTH, ET AL., APPLICANTS

v.

AMERICAN PUBLIC HEALTH ASSOCIATION, ET AL.

ROBERT F. KENNEDY, JR., ET AL., APPLICANTS

v.

COMMONWEALTH OF MASSACHUSETTS, ET AL.

APPLICATION TO STAY THE JUDGMENTS OF THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS AND REQUEST FOR AN IMMEDIATE ADMINISTRATIVE STAY

Pursuant to Rule 23 of the Rules of this Court and the All Writs Act, 28 U.S.C. 1651, the Solicitor General—on behalf of National Institutes of Health, et al., and Robert F. Kennedy, Jr., Secretary of Health and Human Services, et al.—respectfully files this application to stay the judgments of the United States District Court for the District of Massachusetts (App., *infra*, 148a-150a, 151a-152a), pending the consideration and disposition of the government's appeal to the United States Court of Appeals for the First Circuit and, if the court of appeals affirms the judgments, pending the timely filing and disposition of a petition for a writ of certiorari and any further proceedings in this Court. In addition, the Solicitor General respectfully requests an

immediate administrative stay pending the Court's consideration of this application.

This application presents a particularly clear case for this Court to intervene and stop errant district courts from continuing to disregard this Court's rulings. Cf. *Trump* v. *Boyle*, No. 25A11 (July 23, 2025); *Department of Homeland Security* v. *D.V.D.*, No. 24A1153, 2025 WL 182186 (July 3, 2025). Over three months ago, on April 4, 2025, this Court stayed the District of Massachusetts' order blocking the government from terminating a host of discretionary grants that the Administration deemed contrary to its policies and priorities. *Department of Educ.* v. *California*, 145 S. Ct. 966, 968-969 (2025) (per curiam). This Court explained that the district court likely "lacked jurisdiction to order the payment of money under the" Administrative Procedure Act (APA), because "[t]he APA's limited waiver of immunity does not extend to orders 'to enforce a contractual obligation to pay money' along the lines of what the District Court ordered here." *Id.* at 968 (quoting *Great-West Life & Annuity Ins. Co.* v. *Knudson*, 534 U.S. 204, 212 (2002)). Further, this Court recognized, the government suffered irreparable harm because it was "unlikely to recover the grant funds once they are disbursed." *Id.* at 969. And the grantees suffered no countervailing harm because they could "recover any wrongfully withheld funds through suit in an appropriate forum." *Ibid.*

Notwithstanding this Court's decision in *California*, the District of Massachusetts declined to stay a materially identical order. The same day as this Court's *California* decision, the same plaintiffs (seven States, now joined by nine other States plus private parties suing separately) brought the same APA claims against the government—this time to stop the National Institutes of Health (NIH) from terminating $783 million in grants that contravened the Administration's policy positions on diversity, equity, and inclusion (DEI) and gender ideology. For instance, the NIH ter-

minated grants to study "Buddhism and HIV stigma in Thailand"; "intersectional, multilevel and multidimensional structural racism for English- and Spanish-speaking populations"; and "anti-racist healing in nature to protect telomeres of transitional age BIPOC for health equity." 25-cv-10814 D. Ct. Doc. 151, at 5, 7, 25 (June 23, 2025) (capitalization omitted). Grants like these, the NIH explained, rely "on artificial and non-scientific categories" that "are antithetical to the scientific inquiry, do nothing to expand our knowledge of living systems, provide low returns on investment, and ultimately do not enhance health, lengthen life, or reduce illness." App., *infra*, 85a. As in *California*, respondents sought reinstatement of the terminated grants.

When the government pointed out that respondents' challenges to those grant terminations belong in the Court of Federal Claims under *California*, the district court recognized with serious understatement that *California* was a "somewhat similar case." App., *infra*, 221a. Yet the district court dismissed this Court's ruling as "not final" and "without full precedential force," "agree[d] with the Supreme Court dissenters," and "consider[ed] itself bound" by the First Circuit ruling that *California* repudiated. *Ibid.*; *see id.* at 229a (*California* "is not binding on this Court"). The First Circuit then reprised the reasoning of its *California* ruling, insisting that respondents brought an action for "declaratory relief under the APA," not a contract claim that belongs in the Court of Federal Claims. *Id.* at 23a; cf. *California* v. *United States Dep't of Educ.*, 132 F.4th 92, 97 (2025) ("The States' claims are, at their core, assertions that the Department acted in violation of federal law -- not its contracts.").

The lower courts thus required the government to continue paying out over $783 million in grants that the Administration considers contrary to its policy objectives, even though forcing the government "to keep paying up" is the essence of a

contractual suit against the government that Congress barred district courts from adjudicating. See *United States Conference of Catholic Bishops* v. *United States Dep't of State*, 770 F. Supp. 3d 155, 163 (D.D.C. 2025). And the lower courts did so even though *California* recognizes that jurisdiction is likely lacking; that the government is irreparably harmed when forced to pay out millions of dollars on discretionary grants, with no guarantee of recouping the money; and that a stay was warranted in materially similar circumstances. 145 S. Ct. at 968-969.

On top of that, the lower courts held that they could review the NIH's allocation of lump-sum appropriations under the APA even though Congress left grant decisions to agency discretion. App., *infra*, 24a-26a, 238a-239a; cf. *California*, 132 F.4th at 97-98. And the lower courts deemed those terminations arbitrary and capricious by substituting their own political and policy judgments for those of the Executive Branch—asserting, for instance, that the President had "set [DEI] up as some sort of boogeyman" and unleashed "partisan appointed public officials" on an agency with a "historical norm" of "apolitic[ism]." App., *infra*, 52a, 127a; cf. *California*, 132 F.4th at 98-100. In every respect, this sequel poses an even bigger affront to bedrock legal principles than the original.

Worse, this case is no outlier. District-court defiance of this Court's decision in *California* has grown to epidemic proportions, as courts have issued nearly two dozen decisions asserting jurisdiction over claims challenging grant or funding terminations since *California*.[1] Meanwhile, other courts properly recognize that this

[1] *E.g.*, *New York* v. *Kennedy*, No. 25-cv-196, 2025 WL 1803260, at *10 (D.R.I. July 1, 2025); *American Ctr. for Int'l Labor Solidarity* v. *Chavez-DeRemer*, No. 25-cv-1128, 2025 WL 1795090, at *19-*20 (D.D.C. June 30, 2025); *Louisiana Delta Serv. Corps* v. *Corporation for Nat'l & Cmty. Serv.*, No. 25-cv-378, 2025 WL 1787429, at *18-*22 (M.D. La. June 27, 2025); *National Job Corps Ass'n* v. *Department of Labor*, No. 25-cv-4641, 2025 WL 1752414, at *5 n.5 (S.D.N.Y. June 25, 2025); *Thakur* v. *Trump*, No. 25-cv-4737, 2025 WL 1734471, at *20-*21 (N.D. Cal. June 23, 2025), ap-

Court's precedent vests jurisdiction in the Court of Federal Claims alone, creating a sharp conflict between courts that follow this Court's rulings and those that do not.[2]

---

peal pending, No. 25-4249 (9th Cir. filed July 10, 2025); *Green & Healthy Home Initiatives, Inc.* v. *EPA*, No. 25-cv-1096, 2025 WL 1697463, at *14 (D. Md. June 17, 2025); *San Francisco A.I.D.S. Found.* v. *Trump*, No. 25-cv-1824, 2025 WL 1621636, at *12 (N.D. Cal. June 9, 2025); *Maryland* v. *Corporation for Nat'l & Cmty. Serv.*, No. 25-cv-1363, 2025 WL 1585051, at *27 (D. Md. June 5, 2025); *Southern Educ. Found.* v. *United States Dep't of Educ.*, No. 25-cv-1079, 2025 WL 1453047, at *8-*9 (D.D.C. May 21, 2025), appeal pending, No. 25-5262 (D.C. Cir. filed July 21, 2025); *Colorado* v. *United States Dep't of Health & Human Servs.*, No. 25-cv-121, 2025 WL 1426226, at *9 (D.R.I. May 16, 2025), appeal pending, No. 25-1671 (1st Cir. filed July 16, 2025); *American Bar Ass'n* v. *United States Dep't of Justice*, No. 25-cv-1263, 2025 WL 1388891, at *6 (D.D.C. May 14, 2025); *AIDS Vaccine Advocacy Coal.* v. *United States Dep't of State*, No. 25-cv-400, 2025 WL 1380421, at *2-*3 (D.D.C. May 13, 2025); *Rhode Island* v. *Trump*, No. 25-cv-128, 2025 WL 1303868, at *6 (D.R.I. May 6, 2025), appeal pending, No. 25-1477 (1st Cir. filed May 20, 2025); *Community Legal Servs. in E. Palo Alto* v. *United States Dep't of Health & Human Servs.*, No. 25-cv-2847, 2025 WL 1233674, at *7 (N.D. Cal. Apr. 29, 2025), appeal pending, No. 25-2808 (9th Cir. filed May 1, 2025); *Sustainability Inst.* v. *Trump*, No. 25-cv-2152, 2025 WL 1486978, at *5*-6 (D.S.C. Apr. 29, 2025), appeal pending, No. 25-1575 (4th Cir. filed May 22, 2025); *San Francisco Unified Sch. Dist.* v. *Americorps*, No. 25-cv-2425, 2025 WL 1180729, at *8 (N.D. Cal. Apr. 23, 2025); *Widakuswara* v. *Lake*, No. 25-cv-1015, 2025 WL 1166400, at *9 (D.D.C. Apr. 22, 2025), appeal pending, No. 25-5144 (D.C. Cir. filed Apr. 24, 2025); *Community Legal Servs. in E. Palo Alto* v. *United States Dep't of Health & Human Servs.*, No. 25-cv-2847, 2025 WL 1168898, at *3-*4 (N.D. Cal. Apr. 21, 2025); *Climate United Fund* v. *Citibank, N.A.*, No. 25-cv-698, 2025 WL 1131412, at *11-*12 (D.D.C. Apr. 16, 2025), appeal pending, No. 25-5122 (D.C. Cir. filed Apr. 16, 2025), and No. 25-5123 (D.C. Cir. filed Apr. 17, 2025); *Woonasquatucket River Watershed Council* v. *USDA*, No. 25-cv-97, 2025 WL 1116157, at *14-*15 (D.R.I. Apr. 15, 2025), appeal pending, No. 25-1428 (1st Cir. filed May 1, 2025); *New York* v. *Trump*, No. 25-cv-39, 2025 WL 1098966, at *1-*3 (D.R.I. Apr. 14, 2025), appeal pending, No. 25-1413 (1st Cir. filed Apr. 28, 2025); *Maine* v. *USDA*, No. 25-cv-131, 2025 WL 1088946, at *19 n.8 (D. Me. Apr. 11, 2025).

[2] *E.g.*, *Sustainability Inst.* v. *Trump*, No. 25-1575, 2025 WL 1587100, at *1-*2 (4th Cir. June 5, 2025); *American Ass'n of Colls. for Teacher Educ.* v. *McMahon*, No. 25-1281, 2025 WL 1232337, at *1 (4th Cir. Apr. 10, 2025); *Board of Educ. for Silver Consolidated Schs.* v. *McMahon*, No. 25-cv-586, 2025 WL 2017177, at *7-*8 (D.N.M. July 18, 2025); *American Ass'n of Univ. Professors* v. *United States Dep't of Justice*, No. 25-cv-2429, 2025 WL 1684817 (S.D.N.Y. June 16, 2025), appeal pending, No. 25-1529 (2d Cir. filed June 17, 2025); *Child Trends, Inc.* v. *United States Dep't of Educ.*, No. 25-cv-1154, 2025 WL 1651148, at *6-*8 (D. Md. June 11, 2025); *American Library Ass'n* v. *Sonderling*, No. 25-cv-1050, 2025 WL 1615771, at *4-*11 (D.D.C. June 6, 2025); *Solutions in Hometown Connections* v. *Noem*, No. 25-cv-885, 2025 WL 1530318, at *11-*13 (D. Md. May 29, 2025), appeal pending, No. 25-1640 (4th Cir. filed June 2, 2025); *Pippenger* v. *United States DOGE Serv.*, No. 25-cv-1090, 2025 WL 1148345, at *5 (D.D.C. Apr. 17, 2025); *Massachusetts Fair Hous. Ctr.* v. *Department of Hous. & Urb. Dev.*, No. 25-cv-30041, 2025 WL 1225481 (D. Mass. Apr. 14, 2025), appeal pend-

For good reason, the Constitution vests the "judicial Power" in "one supreme Court," to which all others are "inferior Courts." U.S. Const. Art. III, § 1. As this Court explained yesterday, when lower courts face materially identical stay requests, this Court's emergency orders "squarely control[]." *Boyle*, slip op. 1. Our judicial system rests on vertical *stare decisis*, not a lower-court free-for-all where individual district judges feel free to elevate their own policy judgments over those of the Executive Branch, and their own legal judgments over those of this Court.

STATEMENT

A. Factual Background

1. Immediately after his inauguration, President Trump issued a trio of executive orders announcing policy directives relevant to the grants at issue.

On January 20, 2025, the President issued Executive Order No. 14,151, 90 Fed. Reg. 8339 (Jan. 29, 2025), titled *Ending Radical and Wasteful Government DEI Programs and Preferencing*, to eliminate "illegal and immoral discrimination programs, going by the name 'diversity, equity, and inclusion' (DEI)" from the government. *Id.* § 1. That Executive Order rescinded President Biden's Executive Order that mandated "an ambitious whole-of-government equity agenda" and instructed federal agencies to "allocate resources to address the historic failure to invest sufficiently, justly, and equally in underserved communities," *i.e.*, "populations sharing a partic-

---

ing, No. 25-1368 (1st Cir. filed Apr. 16, 2025); *Solutions in Hometown Connections* v. *Noem*, No. 25-cv-885, 2025 WL 1103253, at *8-*11 (D. Md. Apr. 14, 2025); see *Catholic Bishops*, 770 F. Supp. 3d at 162-165 (reaching same conclusion pre-*California*); see also *United States Vera Inst. of Justice* v. *United States Dep't of Justice*, No. 25-cv-1643, 2025 WL 1865160, at *7-*14 (D.D.C. July 7, 2025) (holding that *California* forecloses APA claims but not constitutional claims), appeal pending, No. 25-5248 (D.C. Cir. filed July 8, 2025); *Harris County* v. *Kennedy*, No. 25-cv-1275, 2025 WL 1707665, at *6, *14-*15 (D.D.C. June 17, 2025) (same); *Amica Ctr. for Immigrant Rights* v. *United States Dep't of Justice*, No. 25-cv-298, 2025 WL 1852762, at *11-*15, *17 (D.D.C. July 6, 2025) (similar), appeal pending, No. 25-5254 (D.C. Cir. filed July 14, 2025).

ular characteristic * * * that have been systematically denied a full opportunity to participate in aspects of economic, social, and civic life." *Advancing Racial Equity and Support for Underserved Communities Through the Federal Government*, Exec. Order No. 13,985, 86 Fed. Reg. 7009 §§ 1, 2, 6 (Jan. 25, 2021). President Trump instead directed "[e]ach agency, department, or commission head" to "terminate, to the maximum extent allowed by law, all * * * 'equity-related' grants or contracts." Exec. Order No. 14,151, § 2(b)(i).

On January 21, 2025, President Trump issued Executive Order No. 14,173, 90 Fed. Reg. 8633 (Jan. 31, 2025), titled *Ending Illegal Discrimination and Restoring Merit-Based Opportunity*, "to enforce our longstanding civil-rights laws and to combat illegal private-sector DEI preferences, mandates, policies, programs, and activities." *Id.* § 2. That Executive Order instructs each agency head to "include in every contract or grant award * * * [a] term requiring [the] counterparty or recipient to certify that it does not operate any programs promoting DEI that violate any applicable Federal anti-discrimination laws." *Id.* § 3(b)(iv)(B). And that Order directs the head of the Office of Management and Budget (OMB) to "[e]xcise references to DEI * * * principles, under whatever name they may appear, from Federal acquisition, contracting, grants, and financial assistance procedures." *Id.* § 3(c)(ii).

On January 20, 2025, the President also issued Executive Order No. 14,168, 90 Fed. Reg. 8615 (Jan. 30, 2025), titled *Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government*. That Executive Order affirms "the immutable biological reality of sex" and rejects its replacement "with an ever-shifting concept of self-assessed gender identity" via "'[g]ender ideology.'" *Id.* §§ 1, 2(f). The Executive Order directs federal agencies to "take all necessary steps, as permitted by law, to end the Federal funding of gender ideology." *Id.*

§ 3(e). And the Order directs agencies to "ensure grant funds do not promote gender ideology." *Id.* § 3(g).

2. This case involves grant terminations at the NIH, a subagency of the Department of Health and Human Services (HHS). The NIH is made up of two dozen national research institutes or centers that generally focus on specific diseases or body systems, like the National Institute of Allergy and Infectious Diseases. 42 U.S.C. 281(b). The NIH and its constituent institutes make grants to fund research at universities, hospitals, laboratories, and other research institutions. See 42 U.S.C. 241(a)(1), 284(b)(1)-(2). Congress supports that research via lump-sum appropriations. For example, in 2024 Congress appropriated $6.5 billion for the National Institute of Allergy and Infectious Diseases to carry out the Public Health Service Act "with respect to allergy and infectious diseases." Further Consolidated Appropriations Act, 2024, Pub. L. No. 118-47, Div. D, Tit. II, 138 Stat. 656; see Full-Year Continuing Appropriations and Extensions Act, 2025, § 1101(a)(8), Pub L. No. 119-4, 139 Stat. 11 (carrying forward HHS's 2024 appropriation into 2025).

Because funding is finite, NIH grants are "highly competitive," and the agency approves only 20 percent of applications. NIH, *Grants & Funding* (Oct. 15, 2024), https://grants.nih.gov/new-to-nih. NIH grants are typically discretionary and the funding decision is ultimately up to the head of the relevant NIH research institute. 42 U.S.C. 284(b)(2); Administrative Record (A.R.) 3860[3]; see 25-cv-10787 Compl. ¶ 57 (acknowledging that "[f]inal authority to make an award belongs to the Director of the [national research institute] responsible for the grant"); App., *infra*, 51a (district court acknowledging same).

---

[3] A.R. 3825-4270, which includes the NIH Grants Policy Statement, is available at 25-cv-10814 D. Ct. Doc. 131 (June 11, 2025).

Once those discretionary grants obtain agency approval, NIH entities memorialize the grant terms in a Notice of Award—a formal legal document issued by the NIH entity to the recipient. A.R. 3982. The Notice of Award sets out "the amount of funds awarded" and the "terms and conditions" of the award, which the recipient accepts "by drawing or requesting funds." *Id.* at 3984-3986. The NIH's standard grant terms incorporate express caveats that awards can be terminated if they do not support agency objectives or policies. For instance, all NIH grants incorporate by reference the NIH Grants Policy Statement, which in turn incorporates OMB's guidance for federal financial assistance in 2 C.F.R. Pt. 200. A.R. 3924, 4078. OMB's guidance states that a "Federal award may be terminated" by the agency, "to the extent authorized by law, if an award no longer effectuates the program goals or agency priorities." 2 C.F.R. 200.340(a)(4). Further, all NIH grants are subject to HHS's uniform administrative requirements for federal awards. 45 C.F.R. 75.101; see, *e.g.*, Gov't C.A. App. 366 (sample Notice of Award incorporating the NIH Grants Policy Statement and 45 C.F.R. Pt. 75). Those HHS requirements mandate that NIH grants be administered "so as to ensure that Federal funding is expended and associated programs are implemented in full accordance with U.S. statutory and public policy requirements," including those against "prohibiting discrimination." 45 C.F.R. 75.300(a).

3. Beginning in February 2025, the NIH moved to terminate grants that do not align with the Administration's policy priorities.

On February 10, 2025, the Acting HHS Secretary issued a "Secretarial Directive on DEI-Related Funding." App., *infra*, 59a-60a (capitalization altered). That directive ordered a review of all HHS payments "related to DEI and similar programs" to ensure that all payments were "consistent with current policy priorities"

and "improv[ed] the health and well-being of all Americans." *Id.* at 59a. Consistent with that directive, NIH paused all grants supporting "diversity, equity, and inclusion * * * initiatives or any other initiatives that discriminate on the basis of race, color, religion, sex, national origin, or any other protected characteristic." *Id.* at 64a.

On February 21, 2025, the Acting NIH Director directed his staff to ensure that NIH grants "do not fund or support low-value and off-mission research activities or projects – including DEI and gender identity research activities and programs." App., *infra*, 70a. As the Acting Director explained "based on [his] expertise and experience" and "consistent with recent Executive Orders," "amorphous equity objectives[] are antithetical to the scientific inquiry, do nothing to expand our knowledge of living systems, provide low returns on investment, and ultimately do not enhance health, lengthen life, or reduce illness." *Id.* at 69a. Likewise, gender-identity studies may "ignore * * * biological realities," "are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans." *Ibid.* Accordingly, "it is the policy of NIH not to prioritize such research programs." *Ibid.*

Ensuing guidance documents directed NIH staff to review "the specific aims" of each project for compliance with the NIH's priorities. App., *infra*, 88a, 104a. Where "[t]he sole purpose of the project" contradicts those priorities, like a grant for a conference about "diversity," funding may not issue. *Ibid.* But if the project only "partially supports" impermissible activities, staff were directed to negotiate out those terms. *Id.* at 88a, 105a. For example, if a scientific conference limited to specific minority groups sought funding, the NIH would ask the conference hosts to remove the racially restrictive term and open the conference to all comers. *Id.* at 107a. If they agreed, the grant could proceed. *Ibid.* The guidance also identified other research topics inconsistent with NIH priorities. For instance, grants supporting Chi-

nese universities "contravene[] American national-security interests and hinder[] America's foreign-policy objectives." *Id.* at 90a. And COVID research has outlasted its "limited purpose" of "ameliorat[ing] the effects of the pandemic." *Id.* at 111a.

The NIH terminated numerous grants pursuant to that guidance, with appointees at HHS helping identify the ineligible grants. App., *infra*, 99a, 102a-103a, 114a.[4] For example, the NIH terminated grants involving:

- "Buddhism and HIV Stigma in Thailand," 25-cv-10814 D. Ct. Doc. 151, at 5;
- "the effects of intersectional stigma on HIV prevention among Latino MSM [men who have sex with men]," *id.* at 8;
- "intersectional, multilevel and multidimensional structural racism for English- and Spanish-speaking populations," *id.* at 25;
- "anti-racist healing in nature to protect telomeres of transitional age BIPOC [Black, Indigenous, and People of Color] for health equity," *id.* at 7 (capitalization omitted);
- "[c]ontrolled puberty in transgender adolescents," *id.* at 15; and
- "[t]he role of gender-affirming hormones in transgender women's immune response to COVID-19 vaccines," *id.* at 21.

The NIH sent letters to affected grant recipients explaining that the OMB guidelines incorporated into their grants permit termination "if an award no longer effectuates the program goals or agency priorities." App., *infra*, 85a. The letters identified why the grantees' projects "no longer effectuate[] agency priorities" using

---

[4] The court of appeals' decision incorrectly states "that [Department of Government Efficiency (DOGE)] staffers (who had no affiliation with either NIH or HHS) decided which grants to terminate." App., *infra*, 11a. The official that the court of appeals identified is a detailee from DOGE who is employed by HHS.

standardized language tracking the Acting Director's guidance. *Id.* at 85a-86a. For example, researchers working on DEI-related grants were informed that "it is the policy of NIH not to prioritize such research" because "[r]esearch programs based primarily on artificial and non-scientific categories, including amorphous equity objectives, are antithetical to the scientific inquiry." *Ibid.* And those studying "[t]ransgender issues" were informed of the NIH's conclusion that "[r]esearch programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans." *Id.* at 86a. The letters explained how the grantees could appeal the decision to the NIH Director or his designee. *Ibid.*; see 45 C.F.R. 75.374.

B. Procedural History

1. On April 4, 2025, this Court granted a stay pending appeal of a temporary restraining order from the District of Massachusetts enjoining the Department of Education from terminating DEI-related grants. *California*, 145 S. Ct. at 968-969. The Court explained that such claims likely belonged in the Court of Federal Claims, that the district court accordingly lacked jurisdiction, and that the government faced irreparable harm absent a stay, while the recipients' claimed monetary injuries were not irreparable. *Ibid.*

On the eve of this Court's *California* ruling, on April 2 and 4, 2025, two sets of plaintiffs challenged the NIH's grant terminations in the District of Massachusetts. App., *infra*, 5a. Research and advocacy organizations, a union, and individual researchers filed *American Public Health Ass'n* v. *National Institutes of Health*, No. 25-cv-10787 (D. Mass.). And 16 States—including all but one of the *California* respondents—filed *Massachusetts* v. *Kennedy*, No. 25-cv-10814 (D. Mass.), asserting the rights of their public universities. As in *California*, both suits alleged that the grant

terminations were arbitrary and capricious in violation of the APA. 25-cv-10787 Compl. ¶¶ 196-215; 25-cv-10814 Am. Compl. ¶¶ 225-233. And much like in *California*, respondents asked the court to enjoin the NIH from "terminating any grants" pursuant to the challenged guidance documents and "[o]rder NIH to restore the grant awards, retroactive to the respective termination date." 25-cv-10787 Compl. 76; accord 25-cv-10814 Am. Compl. 88-89; cf. Compl. at 52, *California* v. *U.S. Dep't of Educ.*, No. 25-cv-10548 (D. Mass. filed Mar. 6, 2025) (requesting injunction against "terminating any individual * * * grant for recipients in Plaintiff States" and order that the government "restore recipients in Plaintiff States to the pre-existing status quo prior to the termination").

2. The district court informally consolidated the cases and issued a series of decisions:

a. First, on May 12, 2025, the district court held that it had subject-matter jurisdiction in *Massachusetts*. App., *infra*, 213a-240a. The court acknowledged that, in *California*, this Court had stayed a district-court decision "enjoining the Department of Education from terminating certain grants" because such contract disputes can likely only be brought in the Court of Federal Claims under the Tucker Act. *Id.* at 224a-225a. But in the district court's view, *California* was "not binding on this Court" and "of little assistance to the district courts" because it was "an emergency interlocutory order." *Id.* at 221a, 229a, 232a. The court instead "agree[d] with the Supreme Court dissenters" and followed the First Circuit decision that this Court had effectively overruled in *California*. *Id.* at 221a, 235a.

Separately, the district court rejected the government's argument that NIH funding decisions are committed to agency discretion by law and thus not reviewable under the APA. App., *infra*, 239a (citing 5 U.S.C. 701(a)(2)). In the court's view, there

was "arguably" law to apply because respondents alleged that the grant terminations "conflict with authorizing statutes and applicable regulations." *Ibid.* (citation omitted). But the court did not identify what those statutory or regulatory requirements might be or conclude that the agency had violated them. *Ibid.*

b. In *American Public Health Ass'n*, the district court construed the parties' preliminary-injunction briefing as a motion to dismiss, which the court denied in relevant part on May 30, 2025. App., *infra*, 169a-212a. The court rejected the government's Tucker Act argument "substantially for the same reasons" as in *Massachusetts* and concluded that the organizational plaintiffs had standing. *Id.* at 182a; see *id.* at 182a-189a. On the merits, the court held that respondents had adequately pleaded an arbitrary-and-capricious claim because the termination notices read "more like a political statement than reasoning about the grants." *Id.* at 199a.

c. The district court held a joint hearing and bench trial in the two cases, largely limited to respondents' arbitrary-and-capricious claims. App., *infra*, 44a. At the end of the hearing, on June 16, 2025, the court orally vacated the NIH guidance and respondents' grant terminations as arbitrary and capricious and promised that "a full written opinion" would follow. *Id.* at 153a-168a. The court concluded its oral ruling by equating DEI grant terminations with "palpable" "racial discrimination," expressed its "unutterabl[e] sad[ness]," and asked, "of our society as a whole, have we fallen so low? Have we no shame?" *Id.* at 166a, 168a.

The court issued partial final judgments in both cases reflecting the court's oral ruling, *id.* at 148a-152a, and denied the government's request for a stay pending appeal, *id.* at 142a-147a. In denying a stay, the district court lauded its own "rigorous" fact-finding as reflecting "the true glory of our trial courts" and asserted that funding delays "destroy[] the unmistakable legislative purpose from its accomplish-

ment." *Id.* at 144a-146a & n.1 (citation omitted).

d. Over two weeks after the bench ruling, on July 2, 2025, the district court issued its promised written decision holding that the challenged decisions were arbitrary and capricious. App., *infra*, 39a-141a. Relying on Justice Jackson's *California* dissent, the court concluded that the NIH had engaged in "no reasoned decision-making * * * in the 'robotic rollout' of this grant-termination action." *Id.* at 125a (quoting 145 S. Ct. at 975-976). The court principally objected to the NIH's failure to define the term "DEI," which the court found "purely circular." *Id.* at 52a, 125a-134a.

More broadly, the court faulted the "new Administration" for breaking "a historical norm of a largely apolitical scientific research agency" and "weaponizing what should not be weaponized." App., *infra*, 51a-52a. The court criticized the President's DEI Order as "rudderless" and "set[ting] [DEI] up as some sort of boogeyman" for "partisan appointed public officials" to expunge. *Id.* at 127a. And the court characterized the President's Order on gender ideology as a "fiat" that induced "extensive discrimination against everyone whose lived experience of their sexuality is in any way different from the executive orthodoxy." *Id.* at 46a n.4. The court described the NIH's decision to terminate gender-identity grants as "a truly hold-my-beer-and-watch-this moment." *Id.* at 129a. And the court viewed "[t]he lack of any demonstrable pushback" from agency staff as proof of "the tremendous bureaucratic pressure at play." *Id.* at 129a n.15.

The district court further objected to NIH's reliance on OMB guidance permitting termination of grants that "no longer effectuate[] the program goals or agency priorities" because HHS had not yet adopted that guidance as its own. App., *infra*, 134a-137a (quoting 2 C.F.R. 200.340(a)(4)). Nonetheless, the court did not dispute that the OMB guidance is incorporated by reference into all NIH grants. *Id.* at 137a-

138a. Given its arbitrary-and-capricious holding, the court declined to resolve respondents' other statutory challenges to the terminations. *Id.* at 139a.

The government sought a stay from the court of appeals the next day, July 3.

3. The court of appeals denied an administrative stay on July 4, 2025, promising a stay decision "as soon as practicable." App., *infra*, 35a, 38a. The court noted that the government filed its "motion the day after the district court had entered a promised memorandum reflecting its legal reasoning, and our denial of immediate relief therefore is not based on the timing of relevant filings." *Ibid.*

Two weeks later, on July 18, 2025, the court of appeals denied a stay. App., *infra*, 1a-34a. On jurisdiction, the court treated the district court's vacatur of NIH's guidance and the subsequent grant terminations as two separate declaratory judgments. *Id.* at 19a. The court held that the government had waived any argument that the district court lacked jurisdiction to vacate the guidance. *Ibid.* In any event, the court held, "the district court clearly had jurisdiction to grant 'prospective relief' that will govern 'the rather complex ongoing relationships'" between the parties. *Ibid.* (quoting *Bowen* v. *Massachusetts*, 487 U.S. 879, 905 (1988)). The court acknowledged that the grant terminations posed "a closer question," but thought that this case could proceed because the district court provided "declaratory relief that is unavailable in the Court of Federal Claims" and does not "depend on the terms or conditions of any contract." *Id.* at 19a-20a. The court of appeals distinguished *California* as limited to an order "to pay out past-due grant obligations." *Id.* a 21a (quoting 145 S. Ct. at 968). In the court's view, the district court here had "simply declared that the Department unlawfully terminated certain grants" without relying on any particular grant terms. *Id.* at 22a-23a.

The court of appeals also rejected the government's argument that NIH fund-

ing allocations are committed to agency discretion by law. App., *infra*, 24a-26a. The court deemed this argument forfeited because the government had not specifically reiterated it in its district-court stay motion. *Id.* at 24a-25a. But the court of appeals went on to hold that "numerous statutory provisions" and an HHS regulation provide "'judicially manageable standards'" for review. *Id.* at 25a-26a (citation omitted).

The court of appeals further held that the grant terminations were likely arbitrary and capricious. App., *infra*, 26a-30a. The court saw "no obvious error" in the district court's conclusion that the NIH engaged in an unexplained "about-face" that "entirely ignored significant reliance interests." *Id.* at 27a-28a.

The court of appeals concluded that the other factors disfavored a stay. App., *infra*, 30a-34a. The court acknowledged the government's irreparable harm in paying unrecoverable grants. *Id.* at 31a. But the court reasoned that, because the challenged agency action was unlawful, the government had no interest in "the President's ability to execute core Executive Branch policies." *Id.* at 30a. The court found the government's injury outweighed by respondents' "non-monetary harms" from an "abrupt cutoff in funding." *Id.* at 31a-32a. And the court held that the balance of equities supported a stay given the importance of "scientific and medical advancements" and the "substantial public interest" in agencies following the law. *Id.* at 33a-34a.

ARGUMENT

Under Rule 23 of the Rules of this Court and the All Writs Act, 28 U.S.C. 1651, the Court may stay a final judgment entered by a federal district court. See, *e.g.*, *Trump* v. *Wilcox*, 145 S. Ct. 1415 (2025); *Merrill* v. *Alabama*, 141 S. Ct. 25 (2020). To obtain a stay, an applicant must show a likelihood of success on the merits, a reasonable probability of certiorari, and a likelihood of irreparable harm. See *Hollingsworth* v. *Perry*, 558 U.S. 183, 190 (2010) (per curiam). In "close cases," "the Court will bal-

ance the equities and weigh the relative harms." *Ibid.* Those factors overwhelmingly support a stay here, not least because the lower courts are systematically ignoring a recent, controlling ruling of this Court that resolves those factors in the government's favor.

A. The Government Is Likely To Succeed On The Merits

The same district that produced the *California* order has again asserted jurisdiction to order the government to continue paying unrecoverable grants contrary to the current Administration's priorities. That order is, if anything, even more legally flawed than the order that this Court stayed in *California*. First, as this Court held in *California*, the Tucker Act likely precludes district-court jurisdiction over suits challenging grant terminations. The district court flouted that decision, declaring "[t]he views of the dissenters" more "persuasive." App., *infra*, 232a. But under our system of vertical *stare decisis*, the majority's opinion controls. Second, NIH grant decisions are committed to agency discretion by law and not reviewable under the APA. Given limited research funding, Congress has appropriated lump sums for the NIH to award as it sees fit. Third, the challenged decisions were not arbitrary or capricious. Following the change in Administration, the NIH identified, explained, and pursued new funding priorities. That is democracy at work, not, as the district court thought, proof of inappropriate "partisan[ship]"—let alone a permissible basis for setting agency action aside under the APA. *Id.* at 127a.

1. The district court lacked subject-matter jurisdiction to compel the government to pay terminated grants

The government is likely to succeed in showing that the district court lacked jurisdiction to order the government to pay out some $783 million in terminated grants, as this Court recognized in *California*, 145 S. Ct. at 968. This Court's renewed

intervention is essential to ensure that district courts stop asserting jurisdiction that they lack and that contract disputes over government grant terminations proceed where Congress said they belong: in the Court of Federal Claims. See 28 U.S.C. 1491(a)(1).

a. *California* should have conclusively resolved this case. There, as here, the Administration conducted a comprehensive internal review "to 'ensure that Department grants do not fund discriminatory practices—including in the form of DEI—that are either contrary to law or to the Department's policy objectives.'" Appl. at 6, *California*, *supra* (No. 24A910) (*California* Appl.) (citation omitted). There, as here, the agency subsequently rescinded DEI-related grants that "no longer effectuate[d] the program goals or agency priorities"—an authority incorporated by reference into the grant contract. *Ibid.* (quoting 2 C.F.R. 200.340(a)(4)). There, as here, grant recipients—all but one of whom is also a respondent here—sued, alleging that the grant terminations were arbitrary and capricious in violation of the APA. *Id.* at 7. There, as here, the district court ordered the government to continue to pay, holding that the Tucker Act did not preclude jurisdiction because the plaintiffs invoked federal statutes and regulations and did not style their action as one for money damages. *Id.* at 9. And there, as here, the First Circuit denied an administrative stay, promised further action "as soon as practicable," and then sat on the case (here, for two weeks) before concluding that the APA authorized district-court jurisdiction. *Id.* at 9-10 (citation omitted).

In *California*, this Court issued a stay. 145 S. Ct. at 968. As the Court explained, the District of Massachusetts had "enjoin[ed] the Government from terminating various education-related grants" and "require[d] the Government to pay out past-due grant obligations and to continue paying grant obligations as they accrue."

Ibid. But the district court likely lacked jurisdiction because the APA's waiver of sovereign immunity "does not extend to orders 'to enforce a contractual obligation to pay money' along the lines of what the District Court ordered." *Ibid.* (quoting *Great-West*, 534 U.S. at 212). Instead, such suits must be brought in the Court of Federal Claims, in which Congress vested "jurisdiction over suits based on 'any express or implied contract with the United States.'" *Ibid.* (quoting 28 U.S.C. 1491(a)(1)).

That ruling reflects black-letter jurisdictional principles. Given the federal government's sovereign immunity, federal courts generally lack jurisdiction over "suits against the United States absent Congress's express consent." *United States* v. *Miller*, 145 S. Ct. 839, 849 (2025). The APA provides a limited waiver of sovereign immunity for claims "seeking relief other than money damages." 5 U.S.C. 702. But the APA's waiver "comes with an important carve-out": It does not apply "'if any other statute that grants consent to suit expressly or impliedly forbids the relief which is sought.'" *Match-E-Be-Nash-She-Wish Band of Pottawatomi Indians* v. *Patchak*, 567 U.S. 209, 215 (2012) (quoting 5 U.S.C. 702).

Thus, parties that seek funds that the government is allegedly obligated to pay by contract—including via grant agreements, which are a species of contract—must typically proceed under the Tucker Act, not the APA. The Tucker Act provides that the "United States Court of Federal Claims shall have jurisdiction to render judgment upon any claim against the United States founded" on "any express or implied contract with the United States." 28 U.S.C. 1491(a). The D.C. Circuit has thus "held that the Tucker Act 'impliedly forbids'" bringing "contract actions" against "the government in a federal district court" under the APA. *Albrecht* v. *Committee on Emp. Benefits of the Fed. Reserve Emp. Benefits Sys.*, 357 F.3d 62, 67-68 (2004) (citation omitted). *California* implicitly endorsed that principle, 145 S. Ct. at 968, and re-

spondents do not dispute it, States C.A. Opp. 18-20; APHA C.A. Opp. 7-9.

To determine which court has jurisdiction, the question is whether "an action is in 'its essence' contractual," *Perry Capital LLC* v. *Mnuchin*, 864 F.3d 591, 618-619 (2017) (citation omitted), cert. denied, 583 U.S. 1115 (D.C. Cir. 2018), which "depends both on the source of the rights upon which the plaintiff bases its claims, and upon the type of relief sought," *Megapulse, Inc.* v. *Lewis*, 672 F.2d 959, 968 (D.C. Cir. 1982). If a plaintiff's claim rests on the notion that the government purportedly breached its contract and seeks to compel the government to pay sums due under the contract, that is a Tucker Act claim, not an APA claim. See *id.* at 967-971.

In *California*, those principles established that the respondents' putative APA claim was just a disguised breach-of-contract claim that belonged in the Court of Federal Claims. The Department of Education's grant agreements had "the essential elements of a contract"—offer, acceptance, and consideration. See *Henke* v. *United States Dep't of Commerce*, 83 F.3d 1445, 1450-1451 (D.C. Cir. 1996). And those grant agreements were "the source of the rights upon which" the respondents based their claims. *Megapulse*, 672 F.2d at 968. Without a grant agreement, the respondents would have had no right to payment in the first place.

That contract-based right readily distinguishes *Bowen* v. *Massachusetts*, 487 U.S. 879 (1988), because *Bowen* did not involve a contract claim at all, let alone the APA provision in 5 U.S.C. 702 precluding claims that are impliedly forbidden by another statute. See *Great-West*, 534 U.S. at 212 (noting that *Bowen* did not involve any "contractual obligation"). Instead, *Bowen* involved two separate provisions: (1) part of 5 U.S.C. 702 precluding APA claims for "money damages," and (2) part of 5 U.S.C. 704 requiring "no other adequate remedy in a court" for an agency action to be subject to APA review. *Bowen* held that a State's APA claim for adjusted reimburse-

ment rates under the Medicaid Act was not a "money damages" claim under 5 U.S.C. 702 just because it might result in the payment of money. 487 U.S. at 891-901. And *Bowen* added that a Tucker Act suit was not an alternative "adequate remedy" for the State's Medicaid reimbursement-rate suit so as to preclude review under 5 U.S.C. 704. 487 U.S. at 901-908. Nothing in *Bowen* addresses the separate bar in 5 U.S.C. 702 on suits "expressly or impliedly forbid[den]" by other statutes, which is presumably why this Court cited *Bowen* approvingly in *California* before concluding that grant-termination suits like this one are disguised breach-of-contract claims that likely belong in the Court of Federal Claims. 145 S. Ct. at 968.

b. *California* "squarely control[s]" this materially identical case. *Boyle*, slip op. 1. Here too, the district court relied on the APA's waiver of sovereign immunity to bar the government from terminating grant agreements. App., *infra*, 150a, 152a, 235a. The court "set aside" specific grant terminations, *id.* at 150a, 152a (capitalization omitted), while recognizing that doing so would require the "forthwith * * * disbursement of funds both appropriated by the Congress of the United States and allocated heretofore by the defendant agencies," *id.* at 160a-161a. In substance, that order compelled "specific performance of the grant agreements—a quintessentially contractual remedy." *Widakuswara* v. *Lake*, No. 25-5144, 2025 WL 1288817, at *4 (D.C. Cir. May 3, 2025) (per curiam), reh'g granted and stay denied, 2025 WL 1521355, at *1 (D.C. Cir. May 28, 2025) (en banc) (per curiam). While *California* is an interim decision that is "not conclusive as to the merits," it is still a precedent of this Court which "inform[s] how a court should exercise its equitable discretion in like cases." *Boyle*, slip op. 1. Where a "case does not otherwise differ * * * in any pertinent respect," lower courts must treat like cases alike. *Ibid.* Yet here, despite failing to meaningfully distinguish *California*, the district court denied a stay by re-upping

its earlier jurisdictional analysis without elaboration. App., *infra*, 144a.

The district court's earlier analysis was extraordinarily candid in its disagreement with this Court. The district court declared this Court's decision "not binding," instead finding the First Circuit decision this Court effectively reversed "more compelling." App., *infra*, 229a, 232a. The district court then spent pages quoting the *California* dissents, deeming them "persuasive authority" for its decision. *Id.* at 226a-228a, 232a. The district court declared that it "agree[d] with the Supreme Court dissenters"—a result the court acknowledged was "somewhat awkward." *Id.* at 221a.

The district court also briefly endeavored to distinguish *California* as "somewhat different" on the ground that it involved only "'sums awarded * * * in previously awarded discretionary grants.'" App., *infra*, 228a (quoting *Widakuswara*, 2025 WL 1288817, at *13 (Pillard, J., dissenting)). But that cursory point is clearly incorrect. The district court's order here also involves only previously awarded discretionary grants. See *id.* at 149a n.1, 151a n.2 (describing the terminated grants which respondents challenge).

For its part, the court of appeals attempted to distinguish *California* by describing this Court's decision as addressing only an order "to pay out past-due grant obligations." App., *infra*, 21a (quoting 145 S. Ct. at 968). In fact, the order in *California* "require[d] the Government to pay out past-due grant obligations *and to continue paying obligations as they accrue*." 145 S. Ct. at 968 (emphasis added). That forward- and backward-looking relief is identical to the order here, which declared the grant terminations to be "of no effect" and accordingly required the ongoing payment of funds "forthwith." App., *infra*, 150a, 160a-161a; see *id.* at 152a; cf. *Community Legal Servs. in E. Palo Alto* v. *United States Dep't of Health & Human Serv.*, 135 F.4th 852, 855 (9th Cir. 2025) (Bumatay & VanDyke, JJ., dissenting from the denial

of rehearing en banc) (*California* "cannot be distinguished on the ground that the Plaintiffs here instead seek forward-looking injunctive relief * * * rather than monetary relief for past-due contractual breaches.").

The court of appeals also observed that the *California* respondents, unlike respondents here, did not dispute that grants are contracts. App., *infra*, 22a. But this Court recognized that *California* involved "grants," yet did not hesitate to characterize the claim as one "to enforce a contractual obligation to pay money." 145 S. Ct. at 968 (citation omitted). Regardless, respondents' grant agreements are plainly contracts. They reflect "offer, acceptance, consideration, mutuality of intent, and action by an official with authority to bind the government." *Widakuswara*, 2025 WL 1288817, at *3; see *Columbus Reg'l Hosp. v. United States*, 990 F.3d 1330, 1338 (Fed. Cir. 2021) ("[F]ederal grant agreements [are] contracts when the standard conditions for a contract are satisfied, including that the federal entity agrees to be bound."). The NIH offers federal funding to perform agreed-upon research subject to extensive terms and conditions. A.R. 3924-3925. And the grant "recipient indicates acceptance of an NIH award and its associated terms and conditions by drawing or requesting funds." A.R. 3984. While respondents note that some authorities describe NIH grants and contracts separately, APHA C.A. Opp. 12, those labels have no bearing on whether respondents' claims are founded "upon any express or implied contract with the United States" as required by the Tucker Act, 28 U.S.C. 1491(a)(1).

The court of appeals also cast the claims in *California* as "depend[ing] on the terms and conditions of the grant awards," while the district court here supposedly "neither examined any of the plaintiffs' grant terms nor interpreted them in reaching its ruling." App., *infra*, 22a-23a (citing *California* Appl. at 16; Reply Br. at 9, *California*, *supra* (No. 24A910) (*California* Reply Br.)). But the claims in *California* de-

pended on the grant contracts in the exact same way as the claims here: "The ultimate source of grantees' asserted right to payment is the grant awards, not the grant-making statutes or grant-termination regulations that respondents claim the government violated." *California* Appl. at 16. And "the relevant regulatory language," including the OMB guidance authorizing termination for grants that "no longer effectuate[] the program goals or agency priorities," 2 C.F.R. 200.340(a)(4), is incorporated into respondents' contracts, "confirming the inescapably contractual nature of the dispute." *California* Reply Br. at 9. Indeed, the district court here considered whether the OMB guidance gave the NIH the right to terminate respondents' grants on the assumption that the guidance "has been incorporated into the terms and conditions of the grantees' awards"—a fact the court of appeals seemingly overlooked. App., *infra*, 137a. This is a contract dispute through and through.

c. The court of appeals' other arguments for jurisdiction are unavailing. In an effort to cast the relief here as non-contractual, the court of appeals sought to sever the district court's vacatur of NIH's internal grant-making guidance from its vacatur of the termination of respondents' grants. App., *infra*, 19a. The court asserted that the government had waived any challenge to the former remedy, which, in the court's view, "the district court clearly had jurisdiction to grant." *Ibid.*

But those two remedies merge here. The district court correctly limited relief "only to the parties before it" and focused only on the termination of *existing* grants. *Id.* at 140a (citing *Trump* v. *CASA, Inc.*, 145 S. Ct. 2540, 2562 (2025)); see *id.* at 148a-149a, 151a (addressing "Resulting Grant Terminations"). The district court did not suggest that the agency would have to award DEI- and gender-identity grants to respondents going forward—claims which would be lacking in both standing and ripeness given the highly discretionary nature of NIH grant decisions. See *id.* at 160a

(reserving claims related to notices of funding opportunities, *i.e.*, future grants, for "further consideration"). Indeed, the court bracketed claims that the government had unreasonably delayed issuing new grants for a separate "Phase Two" hearing that has yet to occur. *Id.* at 42a, 207a-208a. Ordering the government not to apply the guidance to respondents' grants and ordering the government to reinstate those grants are thus effectively the same remedy: To comply with those rulings, the government must perform the grant contracts instead of terminating them. That claim belongs in the Court of Federal Claims, not the District of Massachusetts.

The court of appeals also analogized this case to *Bowen*, asserting that respondents, like the State in *Bowen*, simply seek "declaratory relief that is well within the scope of the APA." App., *infra*, 20a-21a. But the same was true in *California*: The respondents "sought declaratory and injunctive relief to set aside the termination of the previously awarded grants." 145 S. Ct. at 971 (Jackson, J., dissenting). Regardless, the critical difference in *Bowen* was that the State had no contractual claim to payment; they were thus not seeking to enforce contractual rights and their suit could not have been impliedly precluded by the Tucker Act provisions at issue here. *Great-West*, 534 U.S. at 212; see *Middle E. Broad. Networks, Inc.* v. *United States*, No. 25-5150, 2025 WL 1378735, at *3 (D.C. Cir. May 7, 2025) (en banc) (Katsas, J., dissenting). If plaintiffs could evade the Tucker Act just by requesting declaratory relief, virtually any contract suit could be transmuted into an APA claim. As the D.C. Circuit has observed, "[i]t is hard to conceive of a claim falling no matter how squarely within the Tucker Act which could not be urged to involve as well agency error subject to review under the APA." *Megapulse*, 672 F.2d at 967 n.34 (brackets and citation omitted); see *Catholic Bishops*, 770 F. Supp. 3d at 165 ("Sure, the [plaintiff] seeks to set aside agency action. But the agency action that it asks the Court to reverse is the

Government's decision to cease a financial relationship with the [plaintiff]. This is not standard injunctive fare.").

When claims like respondents' are "[s]tripped of [their] equitable flair," the "requested relief seeks one thing: * * * [T]he Court to order the Government to stop withholding the money due" under their grant agreements. *Catholic Bishops*, 770 F. Supp. 3d at 163. "In even plainer English: [They] want[] the Government to keep paying up." *Ibid.* Such a claim for "the classic contractual remedy of specific performance" "must be resolved by the Claims Court." *Ibid.* (citations omitted). This Court has already resolved in a similar stay posture that such claims belong in the Court of Federal Claims. This Court should not allow lower courts to continue to deny preliminary relief by defying basic jurisdictional principles—and this Court's authority.

2. NIH grant decisions are committed to agency discretion by law

Even if the district court had jurisdiction, the government's decision to terminate specific NIH grants is "committed to agency discretion by law" and not subject to APA review. 5 U.S.C. 701(a)(2).

a. Consistent with the "'basic presumption of judicial review,'" the APA "instructs reviewing courts to set aside agency action that is 'arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.'" *Department of Commerce* v. *New York*, 588 U.S. 752, 771 (2019) (quoting *Abbott Labs.* v. *Gardner*, 387 U.S. 136, 140 (1967); then quoting 5 U.S.C. 706(2)(A)). But that presumption comes with a key caveat: The APA does not apply when agency action is "committed to agency discretion by law." 5 U.S.C. 701(a)(2). That exception applies when a "statute is drawn so that a court would have no meaningful standard against which to judge the agency's exercise of discretion." *Heckler* v. *Chaney*, 470 U.S. 821, 830 (1985).

One paradigmatic decision "traditionally regarded as committed to agency discretion" is "[t]he allocation of funds from a lump-sum appropriation." *Lincoln* v. *Vigil*, 508 U.S. 182, 192 (1993). "After all, the very point of a lump-sum appropriation is to give an agency the capacity to adapt to changing circumstances and meet its statutory responsibilities in what it sees as the most effective or desirable way." *Ibid.* Lump-sum appropriations thus leave it to the agency to decide how "'resources are best spent'" and "whether a particular program 'best fits the agency's overall policies.'" *Id.* at 193 (quoting *Heckler*, 470 U.S. at 831). While Congress may set outer guardrails on "permissible statutory objectives," courts have "no leave to intrude" so long as agencies adhere to those limits in allocating funding. *Ibid.*

This case falls in the heartland of that exception. As explained, NIH grants come from lump-sum appropriations. See p. 8, *supra*. The only guidance the appropriations acts provide is that each national research institute must spend the money on its assigned topic, like "cancer" or "neurological disorders and stroke." *E.g.*, 138 Stat. 656. That level of discretion makes sense given that the NIH receives five times as many proposals as it could possibly fund. See p. 8, *supra*. Congress did not decide for itself which studies on "dental and craniofacial diseases" warrant federal support, instead delegating that decision to the unreviewable discretion of the National Institute of Dental and Craniofacial Research. 138 Stat. 656. "[T]he 'agency is far better equipped than the courts to deal with the many variables involved in'" prioritizing competing scientific grant applications. See *Lincoln*, 508 U.S. at 193 (quoting *Heckler*, 470 U.S. at 831-832).

b. The court of appeals disagreed, citing an HHS regulation and the "numerous statutory provisions that direct NIH to prioritize or to consider certain research objectives." App., *infra*, 25a-26a. But Congress's delineation of "permissible

statutory objectives" does not rescind an agency's discretion to allocate lump-sum appropriations. *Lincoln*, 508 U.S. at 193. "'[T]o [the] extent'" the agency complies with those objectives, "§ 701(a)(2) gives the courts no leave to intrude." *Ibid.* (quoting 5 U.S.C. 701(a)(2)) (first alteration in original). Here, the district court notably did not find any deviation from Congress's statutory objectives, so the NIH's decisions about how to act within those objectives were the NIH's alone. App., *infra*, 139a-140a. Regardless, the cited statutes merely require the NIH to, *e.g.*, disaggregate data by race, sex, and age and support "basic research" on "pathogens of pandemic concern." 42 U.S.C. 282(b)(4)(B); 42 U.S.C. 285f-5(b)(1). And the cited regulation states that grants "may be terminated * * * for cause" without purporting to limit the agency's discretion to terminate grants under other authorities, like 2 C.F.R. 200.340(a)(4), or suggesting that a violation of the agency's priorities would not constitute "cause," 45 C.F.R. 75.372(a)(2). Those provisions hardly obligate the NIH to fund studies on anti-racism and intersectionality.

The court of appeals also reasoned that the government forfeited its argument that lump-sum appropriations are committed to agency discretion by law by not expressly raising it in the district-court stay motion. App., *infra*, 24a-25a. But the district court had already considered and rejected the point, *id.* at 238a-239a, so the government's stay motion incorporated by reference "the other reasons argued by Defendants" in previous briefs rather than relitigate rejected points, D. Ct. Stay Mot. 6. Regardless, the court of appeals "passed upon" the discretion question notwithstanding its forfeiture concerns, making this Court's ability to review clear. *United States* v. *Williams*, 504 U.S. 36, 41 (1992); see App., *infra*, 25a-26a.

3. The grant terminations were not arbitrary or capricious

Even were APA review appropriate, the challenged grant terminations were

manifestly proper under settled APA precedents.

a. Under the APA, courts set aside agency action that is "arbitrary, capricious, an abuse of discretion or otherwise not in accordance with law." 5 U.S.C. 706(2)(A). The arbitrary-and-capricious "standard is deferential." *FCC* v. *Prometheus Radio Project*, 592 U.S. 414, 423 (2021). The court "ensures that the agency has acted within a zone of reasonableness," taking care not to "substitute its own policy judgment for that of the agency." *Ibid.* So long as the agency action "is rational, based on consideration of the relevant factors, and within the scope of the authority delegated to the agency by the statute," the action will be upheld. *Motor Vehicle Mfrs. Ass'n of the U.S., Inc.* v. *State Farm Mut. Auto. Ins. Co.*, 463 U.S. 29, 42 (1983).

The grant terminations here fall well within that wide band of reasonableness. The Acting Secretary explained that DEI initiatives—which focus on specific groups—"are inconsistent with the Department's policy of improving the health and well-being of *all* Americans." App., *infra*, 59a (emphasis added). And the Acting NIH Director explained, "based on [his] expertise and experience," that DEI and gender-identities studies are "low-value and off-mission." *Id.* at 69a. He added that the categories underlying DEI can be "artificial and non-scientific" and, at worst, may be "used to support unlawful discrimination on the basis of race and other protected characteristics." *Ibid.* He further reasoned that gender-identity research—which targets a narrow slice of the population—does "nothing to enhance the health of many Americans" and ignores "biological realities." *Ibid.*

Those decisions reflect quintessential policy judgments on hotly contested issues that should not be subject to judicial second-guessing. It is hardly irrational for agencies to recognize—as members of this Court have done—that paeans to "diversity" often conceal invidious racial discrimination. *E.g.*, *Students for Fair Admis-*

sions, Inc. v. *President & Fellows of Harv. Coll.*, 600 U.S. 181, 257 (2023) (Thomas, J., concurring). And transgender issues are "an evolving field" involving "fierce scientific and policy debates." *United States* v. *Skrmetti*, 145 S. Ct. 1816, 1837 (2025). The Executive Branch reasonably took a side on those questions in line with the President's policy pronouncements and clearly articulated disagreement with his predecessor's approach. Exec. Order No. 14,151, § 1; Exec. Order No. 14,168, § 7.

The NIH then implemented those democratically accountable policy decisions. Staff worked with grant recipients to excise impermissible grant terms wherever possible. App., *infra*, 88a-89a. But where the grant solely funded initiatives inconsistent with the agency's stated priorities, the NIH sent the affected grant recipient a letter explaining why the NIH had chosen not to prioritize that research. *Id.* at 85a-86a. For example, a researcher offering "[a] novel approach for equitable characterization of gender" received a letter informing her that her "award no longer effectuates agency priorities" because it was impermissibly "based on gender identity." Gov't C.A. App. 414; see 25-cv-10814 D. Ct. Doc. 151, at 21. Such "reasonabl[e] expla[nations]" for the agency's decision are exemplars of *permissible* agency decision-making. *Prometheus Radio*, 592 U.S. at 423.

b. The district court's principal objection was that the NIH never defined the term "DEI." App., *infra*, 125a-134a. But there is no APA rule that agencies define every term in every internal guidance document, particularly when that guidance steers highly discretionary decisions over how to allocate limited agency resources. Thus, when another district court declared the President's direction to terminate "equity-related" grants impermissibly vague, a court of appeals stayed that preliminary injunction on appeal. *National Ass'n of Diversity Officers in Higher Educ.* v. *Trump*, 767 F. Supp. 3d 243, 277-280 (D. Md. 2025), stay granted, No. 25-1189 (4th Cir. Mar.

14, 2025). When the government provides "selective subsidies" which frequently rely on subjective criteria, perfect "clarity" "is not always feasible." *National Endowment for the Arts* v. *Finley*, 524 U.S. 569, 589 (1998).

Here, the NIH's guidance described the Administration's general priorities on research funding and instructed implementation on a grant-by-grant basis. App., *infra*, 69a-70a, 88a-90a, 104a-114a. As the record reflects, NIH staff then used their "scientific background" and knowledge of "their programs" to identify problematic grants. *Id.* at 65a n.8. If any grantee felt that her grant was miscategorized, the termination notice explained how to pursue an administrative appeal. *Id.* at 86a.

In any event, it is hardly a mystery that grants on topics like "structural racism and discrimination" and "daily diar[ies]" for "bisexual+ young adults" involve DEI and fall within the category of grants that the Administration views as highly problematic for a litany of policy reasons. 25-cv-10814 D. Ct. Doc. 151, at 5, 41 (capitalization omitted). The President's January 20 Executive Order on DEI repudiated the prior Administration's order that spent pages delineating the kinds of policies that the current Administration rejects. See Exec. Order 13,985. Agency guidance documents do not need to come with glossaries just to avoid APA invalidation.

The district court also cast aspersions on having "partisan appointed public officials" help draft termination letters and identify grants inconsistent with the Administration's priorities. App., *infra*, 127a. The court accused political appointees of "force-fe[eding] unworkable 'policy'" to the NIH and insinuated that there was something nefarious about employees of what the court labeled the "so-called Department of Government Efficiency" being copied on emails. *Id.* at 71a, 101a-102a, 125a. The court then dismissed NIH's explanation for the grant terminations because it struck the court as "look[ing] more like a political statement than reasoning about the

grants." *Id.* at 199a.

But courts may not set aside agency action under the APA just "because it might have been influenced by political considerations or prompted by an Administration's priorities." *Department of Commerce*, 588 U.S. at 781. "Under our Constitution, the 'executive Power'—all of it—is 'vested in a President.'" *Seila Law LLC* v. *CFPB*, 591 U.S. 197, 203 (2020) (citations omitted). That politically accountable officials would shift an agency's priorities after a change in administration to reflect the new President's policy priorities is a feature, not a bug, of democracy. And that a district court would consider shifting policy preferences or the involvement of political appointees as near-dispositive proof of an APA violation is grounds for reversal, not vindication.

Additionally, the district court criticized the NIH's use of "boilerplate language" in termination letters. App., *infra*, 89a, 91a, 129a. The *California* respondents made the same objection. Opp. at 1, 8, 31, *California*, *supra* (No. 24A910). But that is a reason to uphold the agency's decision under the APA, not to reject it, because it underscores that the agency properly treated like cases alike. See *National Cable & Telecomm. Ass'n* v. *Brand X Internet Servs.*, 545 U.S. 967, 981 (2005) ("Unexplained inconsistency is, at most, a reason for holding an interpretation to be an arbitrary and capricious change from agency practice under the Administrative Procedure Act."). The APA does not perversely require agencies to fiddle with verbiage when they implement a uniform policy globally on an even-handed basis.

For its part, the court of appeals opined that the government insufficiently considered grantees' reliance interests—a point to which the district court devoted two sentences. App., *infra*, 27a-29a, 133a. But the NIH invited grantees to request transition funds "to support an orderly phaseout of the project," mitigating any reli-

ance concerns. *E.g.*, Gov't C.A. App. 367. Moreover, the terms of the contracts do not support any claim of valid reliance interests. The grant contracts authorize termination when "an award no longer effectuates the program goals or agency priorities." 2 C.F.R. 200.340(a)(4). Grantees can hardly claim unfair surprise when the new Administration took a different view of the NIH's priorities.

At bottom, the district court disagreed with the Administration's view that federal science funding should not support DEI or gender ideology and accused "[t]he new Administration" of "weaponizing what should not be weaponized." App., *infra*, 52a. But the district court politicized what should not be politicized: the Judiciary. When courts criticize executive-branch officials for "their haste to appease the Executive," *id.* at 140a, and dismiss the President's goal of "'making America great'" as a "guise," *id.* at 53a (citation omitted), they impermissibly "substitute [their] own policy judgment for that of the agency." *Prometheus Radio*, 592 U.S. at 423.

B. The Other Factors Support A Stay

In deciding whether to grant emergency relief, this Court also considers whether the underlying issues warrant its review, whether the applicant likely faces irreparable harm, and, in close cases, the balance of the equities. See *Hollingsworth*, 558 U.S. at 190. Those factors overwhelmingly support relief here.

1. The issues raised by this case warrant this Court's review

The district court's order directs the NIH to continue paying $783 million in federal grants that are undisputedly counter to the Administration's priorities. This Court has already intervened to stay a materially identical order, *California*, 145 S. Ct. at 968, and the same course is even more warranted here given the district court's brazen refusal to follow controlling Supreme Court precedent.

The need for this Court's intervention is especially acute given lower courts'

ongoing disagreement over the proper venue for grant-termination suits. Notwithstanding this Court's guidance in *California*, the circuits are "divided" over when grant-termination suits belong in the Court of Federal Claims. Order at 3, *New York* v. *United States Dep't of Educ.*, No. 25-1424 (2d Cir. June 20, 2025). The Fourth Circuit has held that, when—as here—the Executive terminates grants "awarded by federal executive agencies to specific grantees from a generalized fund," challenges to that termination belong in the Court of Federal Claims. *Sustainability Inst.*, 2025 WL 1587100, at *2. A D.C. Circuit panel reached a similar conclusion, though the en banc court disagreed over four judges' dissent. *Widakuswara*, 2025 WL 1288817, at *4; see *Widakuswara*, 2025 WL 1521355, at *1; *id.* at *2 & n.* (Katsas, J., joined by Henderson, Rao & Walker, JJ., dissenting in part). Following *California*, numerous district courts have also held that they lack jurisdiction. See p. 5, n.2, *supra*.

By contrast, the First Circuit joined the Second and Ninth Circuits in allowing funding-termination suits to proceed in district court—with the Ninth Circuit denying en banc review at an early stage of the case over ten judges' dissent. App., *infra*, 23a-24a; Order at 3, *New York*, *supra*; *Community Legal Servs. in E. Palo Alto* v. *United States Dep't of Health & Human Servs.*, 137 F.4th 932, 937-939; *Community Legal Servs.*, 135 F.4th at 852-855 (Bumatay & VanDyke, JJ., joined by Callahan, Ikuta, Bennett, R. Nelson, Bade, Collins, Lee & Bress, JJ., dissenting from the denial of rehearing en banc). Numerous district courts have asserted jurisdiction in similar cases, relying on tenuous or nonexistent distinctions of *California*. See p. 4 n.1, *supra*. For example, one district court ordered the EPA to resume $180 million in "climate justice" grants on the dubious theory that *California* does not apply to claims seeking declaratory relief. *Green & Healthy*, 2025 WL 1697463, at *3, *14. Another court ordered the government to restore $2.8 billion in climate funding, characteriz-

ing plaintiffs as seeking "equitable relief" in the form of "reinstatement of their grants and the recovery of specific money"—even though that was the exact remedy sought in *California*. *Climate United*, 2025 WL 1131412, at *1, *11. And a third court ordered HHS to resume 23 States' share of $11 billion in COVID grants only by dismissing *California* as a "cursory" "three-page stay order." *Colorado*, 2025 WL 1426226, at *9, *24.

As the en banc D.C. Circuit has observed, the jurisdictional question is an "important issue" that has been "recurren[t]" in recent months. *Widakuswara*, 2025 WL 1521355, at *1. Likewise, the lower courts' holdings that grant terminations based on new policy priorities are reviewable and arbitrary and capricious reflect an impermissible intrusion into executive-branch policy-making that warrant this Court's intervention. See, *e.g.*, *Heckler* v. *Lopez*, 463 U.S. 1328, 1329 (1983) (Rehnquist, J., in chambers) (stay of order requiring Secretary of Health and Human Services "immediately to reinstate benefits to the applicants"). Moreover, this Court's review is clearly and urgently needed to stop lower courts from continuing to defy this Court's *California* decision.

2. The district court's order irreparably harms the government

As the court of appeals correctly acknowledged, the district court's order irreparably harms the government by obligating it to disburse grant funds that it may never recover. App., *infra*, 31a. The government has a strong interest in safeguarding the public fisc. See *Mathews* v. *Eldridge*, 424 U.S. 319, 348 (1976). In *California*, this Court thus found irreparable harm where the government risked paying millions in grants and "[n]o grantee 'promised to return withdrawn funds should its grant termination be reinstated.'" 145 S. Ct. at 969. Respondents likewise make no such promise here. App., *infra*, 31a. While the States identify tools by which the govern-

ment could attempt to claw back "improperly paid" funds, States C.A. Opp. 27, respondents would presumably argue that any funds issued while the district court's order remains in effect were proper and not recoverable. The high likelihood that respondents will continue to drain hundreds of millions of dollars from the Treasury absent a stay establishes clear irreparable harm.

Beyond that fiscal burden, the district court's order "improperly intrudes on a coordinate branch of the Government and prevents the Government from enforcing its policies." *CASA*, 145 S. Ct. at 2561 (cleaned up). The decisions below force the Administration to continue supporting research projects that are clearly antithetical to its policies and the deeply held values of countless Americans. That alone "is enough to justify interim relief." *Ibid.*

3. The balance of the equities strongly favors the government

The balance of the equities also supports a stay. Respondents' claims for terminated grant funds are monetary, contractual disputes that they may take up later in the Court of Federal Claims without any cognizable irreparable harm. See pp. 18-27, *supra*. The government, by contrast, has an overriding interest in ensuring that discretionary funding decisions align with the President's priorities.

The court of appeals deemed respondents' asserted injuries "non-monetary" because an "abrupt cutoff in funding" might permanently disrupt research and research careers. App., *infra*, 31a-32a. But most of the respondents—which include 16 States—plainly "have the financial wherewithal to keep their programs running." See *California*, 145 S. Ct. at 969. For those who do not, the government may authorize additional funds "to support an orderly phaseout of the project," including "to support patient safety and animal welfare." Gov't C.A. App. 367.

The court of appeals largely collapsed the public-interest factor with the mer-

its, asserting that "there is a substantial public interest 'in having governmental agencies abide by the federal laws that govern their existence and operations.'" App., *infra*, 33a (quoting *League of Women Voters of the U.S.* v. *Newby*, 838 F.3d 1, 12 (D.C. Cir. 2016)). But, as explained, the grant terminations were entirely lawful and, in any event, not properly challenged here. See pp. 18-34, *supra*.

The court of appeals also invoked the importance of "funding for 'urgent public health issues'" and "the scientific and medical advancements of the United States." App., *infra*, 33a-34a. But the Administration has determined that the terminated projects, covering topics from intersectionality to puberty in transgender teens, do *not* meaningfully advance public health. That is a policy determination for the Executive Branch, not the Judicial Branch. Moreover, federal science funding is inherently finite. A stay would not end scientific research in America; it would allow the NIH to reallocate funds to projects that better align with current priorities and that, in the Administration's view, *actually* advance public health. Courts are ill-equipped to second-guess the NIH's judgment about which scientific research best serves the American people. See *Lincoln*, 508 U.S. at 193.

C. This Court Should Issue An Administrative Stay

The Solicitor General respectfully requests that this Court grant an administrative stay while it considers this application. The district court orally directed the government to reinstate respondents' grants over a month ago. App., *infra*, 159a-160a. Yet the court waited over two weeks to issue a reasoned written decision, and the court of appeals took two weeks after that to deny a stay. Meanwhile, the government has been compelled to restore $783 million of grant money for respondents to draw down—taxpayer money that the government may well never see again. Each day the district court's order remains in place, respondents can continue to liquidate

that money from the Treasury. Given that this Court has already addressed the jurisdictional question here in a decision the district court openly defied, an administrative stay is warranted.

CONCLUSION

This Court should stay the district court's preliminary injunction. In addition, the Solicitor General respectfully requests an immediate administrative stay of the district court's order pending the Court's consideration of this application.

Respectfully submitted.

D. JOHN SAUER
Solicitor General

JULY 2025

No. 25A103

In the Supreme Court of the United States

NATIONAL INSTITUTES OF HEALTH, ET AL., APPLICANTS

v.

AMERICAN PUBLIC HEALTH ASSOCIATION, ET AL.

ROBERT F. KENNEDY, JR., ET AL., APPLICANTS

v.

COMMONWEALTH OF MASSACHUSETTS, ET AL.

REPLY IN SUPPORT OF APPLICATION FOR A STAY

D. JOHN SAUER
Solicitor General
Counsel of Record
Department of Justice
Washington, D.C. 20530-0001
SupremeCtBriefs@usdoj.gov
(202) 514-2217

TABLE OF CONTENTS

A. The government is likely to succeed on the merits 2

1. The Tucker Act precludes jurisdiction 3

2. The grant terminations were committed to agency discretion 9

3. The grant terminations were not arbitrary or capricious 10

B. The remaining factors support a stay 14

In the Supreme Court of the United States

No. 25A103

NATIONAL INSTITUTES OF HEALTH, ET AL., APPLICANTS

v.

AMERICAN PUBLIC HEALTH ASSOCIATION, ET AL.

ROBERT F. KENNEDY, JR., ET AL., APPLICANTS

v.

COMMONWEALTH OF MASSACHUSETTS, ET AL.

REPLY IN SUPPORT OF APPLICATION FOR A STAY

"Th[is] application is squarely controlled by" the Court's stay ruling in *Department of Education* v. *California*, 145 S. Ct. 966 (2025) (per curiam). *Trump* v. *Boyle*, No. 25A11 (July 23, 2025), slip op. 1. When the government terminates millions of dollars in discretionary grants founded on contracts and is sued to force their resumption, that suit belongs in the Court of Federal Claims, not district court, because only the former court has jurisdiction over most contract claims against the government. This Court in *California* stayed an order from the United States District Court for the District of Massachusetts that would have forced the Department of Education to pay out $65 million in grants related to diversity, equity, and inclusion (DEI) that the agency terminated as contrary to the Administration's priorities. When most of the

same respondents brought the same claims to force a different agency—the National Institutes of Health (NIH)—to resume $783 million in grants that were terminated for the same reasons, the District of Massachusetts should have followed this Court's precedent. Instead, the court disavowed *California*, embraced the dissents, hewed to arguments this Court rejected, and again exercised jurisdiction that it lacked to force the government to pay out millions of dollars in discretionary grants antithetical to the Administration's policy objectives. Respondents, for their part, have no real answers to *California*; they too just repackage the *California* dissenters' arguments.

This case differs from *California* only in being even more manifestly cert-worthy. The lower courts are commandeering the Executive into continuing grant payments based on precedent-defying Administrative Procedure Act (APA) rationales that would independently warrant review. Meanwhile, lower courts have responded to *California* by openly disagreeing with that decision and each other, creating a 3-1 circuit split and sowing lower-court chaos in the dozens of cases raising this issue. This Court should not countenance this ongoing defiance of its decisions. The Court should grant a stay because this case—like many others—"does not * * * differ from [*California*] in any pertinent respect." *Boyle*, slip op. 1.

A. The Government Is Likely To Succeed On The Merits

Three independent flaws in the lower courts' opinions make the government likely to succeed on the merits and would each warrant review: (1) The district court's exercise of jurisdiction over these grant-termination claims flouts the Tucker Act and defies *California*; (2) the district court transgressed the APA's bar on review of agencies' discretionary decisions to reallocate lump-sum appropriations; and (3) the district court's finding of APA violations contravenes bedrock APA precepts and ignores that the NIH's decision to terminate grants inconsistent with Administration priori-

ties was reasonable and reasonably explained.

1. The Tucker Act precludes jurisdiction

California controls this stay application. The essence of respondents' claim is that the government should not have terminated their grant agreements and must continue performing those contracts. That is a contractual dispute which Congress channeled to the Court of Federal Claims, not an APA suit for district courts. Appl. 18-27.

a. Respondents barely address the lower courts' defiance of *California*, which the States—many of whom were *California* respondents—relegate to page 30. In both cases, plaintiffs brought APA claims alleging that across-the-board cuts to DEI-related grants were arbitrary and capricious. Appl. 19. There too, the States purported to "challenge a programmatic decision" based on "statutes and regulations, not contracts," and sought "equitable relief," not money damages. Opp. at 22, 25, *California*, 145 S. Ct. 966 (24A910) (*California* Opp.); cf. States Opp. 22-23, 25-27; APHA Opp. 22-25. Yet this Court held that those were disguised breach-of-contract claims that belonged in the Court of Federal Claims. *California*, 145 S. Ct. at 968.

Respondents say that *California* turned on "the terms and conditions of each individual grant award," citing the First Circuit's characterization of that case. States Opp. 30 (quoting *California* v. *United States Dep't of Educ.*, 132 F.4th 92, 96-97 (2025)); accord APHA Opp. 24. But just as here, the *California* district court did not "examine[] any of the plaintiffs' grant terms nor interpret[] them." APHA Opp. 24 (quoting Appl. App. 22a); see *California* v. *United States Dep't of Educ.*, 769 F. Supp. 3d 72 (D. Mass. 2025). In both cases, the grant terms gave respondents a right to payment, and they allowed the government to terminate grants that "no longer effectuate[] the program goals or agency priorities" via Office of Management and

Budget guidance incorporated into every contract. 2 C.F.R. 200.340(a)(4); Appl. 24-25. And in both cases, that contract term was the basis for the contested termination, making clear that the crux of the dispute was whether the government breached the grant contracts.

Respondents emphasize (States Opp. 31; APHA Opp. 19-22) that the *California* district court awarded injunctive relief, while the district court here awarded declaratory relief. That distinction is meritless. Respondents offer no principled reason why declaratory claims would escape the Tucker Act's jurisdictional bar when, under *California*, injunctive claims do not. Both are "quintessentially equitable remed[ies]" (APHA Opp. 14) that are generally unavailable in the Court of Federal Claims. See *North Star Alaska* v. *United States*, 9 F.3d 1430, 1432 (9th Cir. 1993) (en banc) (per curiam). If plaintiffs could evade the Tucker Act by asking district courts to declare their rights under a contract, every contractual dispute could be reformulated as an APA suit, contrary to Congress's jurisdiction-channeling scheme. Appl. 26-27.

The similarities were not lost on the district court, which recognized that *California* "may be an indicator of how the Supreme Court *might* someday view the merits" but declared that decision "not binding on this Court." Appl. App. 229a. That was erroneous. This Court's interim orders "squarely control[]" lower courts when faced with materially identical facts. *Boyle*, slip op. 1. The district court's refusal to follow *California* and grant a stay should be dispositive.

b. Respondents portray (States Opp. 22-23; APHA Opp. 2, 20 n.3) the district court as issuing two distinct orders—one vacating the NIH's guidance, and one vacating the grant terminations. They assert that the government challenges only the latter and that the district court could vacate the guidance even if it lacked jurisdiction to vacate the grant terminations. But the government seeks a stay of the

district court's judgments in full, because the two are inseparable here. Appl. 25-26.

The entire point of respondents' attack on the guidance is to get back their terminated grants. Without the termination of their own funding, respondents would lack standing to challenge the guidance documents in the first place. Each set of respondents thus brings a single arbitrary-and-capricious claim attacking the NIH's guidance and the grant terminations as a package because the guidance led to the termination of *their* grants (or their instrumentalities' or members'). 25-cv-10814 Am. Compl. ¶¶ 225-233; 25-cv-10787 Compl. ¶¶ 196-215. Private respondents asserted that the grant terminations and the guidance underlying those terminations were arbitrary and capricious "[f]or the same reasons." 25-cv-10787 Compl. ¶ 215. And the States sought an order "holding unlawful and setting aside the Challenged Directives," *i.e.*, the guidance, "and enjoining any action taken to enforce or implement the Challenged Directives," *i.e.*, the grant terminations. 25-cv-10814 Am. Compl. ¶ 233. Before *California*, the States did not even challenge the guidance. Their original arbitrary-and-capricious claim was limited "to termination of the Terminated Grants." 25-cv-10814 Compl. ¶ 234. The States added their artfully pleaded attack on the NIH's guidance only after *California* issued (the same day they filed their original complaint).

Even if the district court's remedy applies prospectively to future grant applications, States Opp. 22-23, the core of this suit is contractual, and the judgments should be stayed in full. In *California*, the States likewise insisted that they were also "seeking prospective relief," to no avail. *California* Opp. at 26 n.3; accord *id.* at 25, 27. Respondents' effort to plead around the Tucker Act should fail here too.

c. Rather than engage with *California*, respondents largely defend the district court's exercise of jurisdiction over their grant-terminations claims under court-

of-appeals precedent. Those contentions are meritless, and the cited lower-court precedents support the government, not respondents.

The parties start from common ground: With exceptions not relevant here, the Tucker Act impliedly precludes district-court jurisdiction over contract suits against the United States. Appl. 20-21; States Opp. 24; APHA Opp. 20. The key question is whether the action is in essence contractual, which "depends both on the source of the rights upon which the plaintiff bases its claims, and upon the type of relief sought." Appl. 21 (quoting *Megapulse, Inc.* v. *Lewis*, 672 F.2d 959, 968 (D.C. Cir. 1982)); accord States Opp. 24; APHA Opp. 22.

Here, the "source of rights upon which the plaintiff bases its claims" is the grant contract. *Megapulse*, 672 F.2d at 968. Without the contracts, respondents would have no right to payment in the first place. When "[t]he right to the[] payments is created in the first instance by the contract," that is a contract claim that belongs in the Court of Federal Claims. *Spectrum Leasing Corp.* v. *United States*, 764 F.2d 891, 894 (D.C. Cir. 1985). Parties cannot evade that jurisdictional requirement by claiming that the government's breach of contract violated the "procedural requirements" of another statute, like the APA, *ibid.*, particularly when, as here, the basis for termination was spelled out in the contract. See pp. 3-4, *supra.*

Respondents counter that the "source of their rights is * * * the APA's guarantee of freedom from arbitrary and capricious agency decisionmaking." States Opp. 25-26; accord APHA Opp. 25. But "a plaintiff may not avoid the jurisdictional bar * * * merely by alleging violations of regulatory or statutory provisions rather than breach of contract"; the jurisdictional inquiry instead depends on the "essential aspects" of the claim. *Ingersoll-Rand Co.* v. *United States*, 780 F.2d 74, 77-78 (D.C. Cir. 1985). Otherwise, every plaintiff could evade the Tucker Act by insisting that the

government arbitrarily breached its contract in violation of the APA. See *Megapulse*, 672 F.2d at 967 n.34.

The States worry (Opp. 26) about nullifying the APA's application to "grant[s] of money." 5 U.S.C. 551(11)(A). But not every grant is accompanied by a contract covered by the Tucker Act—for example, when the government offers money without enforceable conditions. When plaintiffs seek "to enforce a contractual obligation to pay money" though, jurisdiction lies in the Court of Federal Claims. *California*, 145 S. Ct. at 968 (citation omitted).

Respondents note (States Opp. 26-28; APHA Opp. 20, 22-24) that they, like the State in *Bowen* v. *Massachusetts*, 487 U.S. 879 (1988), seek declaratory relief authorized by the APA, not money damages. But *Bowen* involved neither a contract claim nor the APA's bar on suits impliedly forbidden by another statute. Appl. 21-22, 26. Plaintiffs cannot "sidestep" jurisdictional preclusion "merely by avoiding a request for damages." *Ingersoll-Rand*, 780 F.2d at 79. The key inquiry is "the essence" of the claim, and when that essence "is a request for specific performance of the original contract," that request belongs in the Court of Federal Claims however pleaded. *Ibid.*

The States assert (Opp. 28-29) that their "complex, ongoing relationship" with the federal government makes this "a quintessential APA suit" like *Bowen*. But in a huge number of contract claims, the parties have an ongoing relationship, and those claims still belong in the Court of Federal Claims. *Ingersoll-Rand*, 780 F.2d at 80. Even if the court must review an agency's decision, contract claims are fundamentally not "quintessential APA suit[s]."

The States bemoan (Opp. 29-30) the creation of "an intolerable jurisdictional void" whereby no court could "prospectively reinstate grants." But the idea that a particular form of relief would not be available against the United States should be

neither surprising nor intolerable. The APA retains the United States' sovereign immunity for relief that Congress impliedly precluded elsewhere to "prevent[] plaintiffs from exploiting the APA's waiver to evade limitations on suit contained in other statutes." *Match-E-Be-Nash-She-Wish Band of Pottawatomi Indians* v. *Patchak*, 567 U.S. 209, 215 (2012). One such limitation is in the Tucker Act, which allows money damages but "foreclose[s] specific performance of government contracts." *Spectrum*, 764 F.2d at 893 n.2 (quoting H.R. Rep. No. 1656, 94th Cong., 2d Sess. 12-13 (1976)). Plaintiffs' inability to compel specific performance is an inherent feature of Congress's design for contract claims generally, not a license to resort to the APA.

Respondents raise (States Opp. 30; APHA Opp. 29) the specter of discriminatory government contract terminations and assert that it would be intolerable if no court could enjoin such action. But the reason *why* the government breached a contract does not alter whether a dispute is contractual. If the government refused to pay $25,000 owed to a construction contractor, that contractual dispute would obviously belong in the Court of Federal Claims regardless of the reason for the breach. Discrimination might give the contractor a winning equal-protection claim, but it would not change the fundamentally contractual nature of the dispute.

d. Private respondents, but not the States, question (Opp. 25-30) whether NIH grant agreements are contracts. The lower courts did not embrace that argument for good reason. NIH grant agreements entitle recipients to "request[]" awarded funds "from the designated [Department of Health and Human Services (HHS)] payment system" in exchange for conducting research pursuant to detailed "terms and conditions" which "are binding on the recipient." Administrative Record 3982, 3984. That is a textbook contract.

Private respondents invoke (Opp. 26-28) irrelevant Federal Circuit and Court

of Federal Claims cases looking to agency practice to inform whether plaintiffs have "implied-in-fact contract[s]" with the government. *E.g.*, *Hanlin* v. *United States*, 316 F.3d 1325, 1328 (Fed. Cir. 2003); *Adia Holdings, Inc.* v. *United States*, 170 Fed. Cl. 296, 300 (2024). Respondents have *express*, not implied, contracts with the NIH—the notices of award.

Private respondents assert (Opp. 28-29) that the grant agreements are not backed by adequate consideration because they did not directly benefit the government. But "consideration[] turns on the conditions attached to [the] grants." *Columbus Regional Hosp.* v. *United States*, 990 F.3d 1330, 1340 (Fed. Cir. 2021). When the grant agreement "impose[s] a variety of duties on" the grantee—as is plainly true here—adequate consideration exists. *Ibid.* *California* treated materially identical DEI-related grants as contracts, 145 S. Ct. at 968; they remain contracts here too.

2. The grant terminations were committed to agency discretion

Even if the Tucker Act did not foreclose jurisdiction, the NIH's decisions about how to allocate lump-sum appropriations to grantees are "committed to agency discretion by law" and not reviewable under the APA. 5 U.S.C. 701(a)(2); Appl. 27-29.

The States claim (Opp. 33) that lump-sum appropriations are generally subject to arbitrary-and-capricious review. This Court has held otherwise: "The allocation of funds from a lump-sum appropriation is * * * traditionally regarded as committed to agency discretion" and "is accordingly unreviewable under § 701(a)(2)." *Lincoln* v. *Vigil*, 508 U.S. 182, 192-193 (1993); Appl. 28. The States' cited court-of-appeals cases (Opp. 33) do not involve lump-sum appropriations and are thus beside the point.

Private respondents at least acknowledge (Opp. 35-38) *Lincoln*'s rule, but they claim that various statutes and an HHS regulation make the agency's discretion reviewable here. But "as long as the agency allocates funds from a lump-sum appropri-

ation to meet permissible statutory objectives, * * * the decision to allocate funds 'is committed to agency discretion by law.'" *Lincoln*, 508 U.S. at 193 (quoting 5 U.S.C. 701(a)(2)). Respondents' own authority confirms this: "*Lincoln* stands for the principle that once that initial level of judicial review is passed," *i.e.*, that the agency complied with statutory objectives, "the specific execution by the agency to meet those objectives may still be left entirely within its discretion." *Raymond Proffitt Found.* v. *U.S. Army Corps of Engineers*, 343 F.3d 199, 208 (3d Cir. 2003) (cited at APHA Opp. 38). While respondents' contrary-to-law claims remain pending in district court, this appeal proceeds on the assumption that the NIH complied with all statutory objectives. Appl. App. 139a. The NIH's discretionary allocation of lump-sum appropriations within those bounds is not subject to arbitrary-and-capricious review.

Respondents also claim (States Opp. 32; APHA Opp. 34-35) that the government forfeited this argument by not *re*-raising it in the district-court stay motion. But respondents do not dispute that the government raised it when litigating the merits in district court. Regardless, the First Circuit passed upon this argument, so it is preserved for *this* Court's review. Appl. 29.

3. The grant terminations were not arbitrary or capricious

Even if they were reviewable, the grant terminations pass muster under the APA. The Administration has clearly articulated its opposition to supporting DEI and gender ideology, and the NIH realigned its grants with those priorities and reasonably explained that it was doing so. Appl. 29-31. By definition, agency decision-making is "prompted by an Administration's priorities." *Department of Commerce* v. *New York*, 588 U.S. 752, 781 (2019); Appl. 33. The district court opined otherwise, but respondents do not defend the court's openly political disagreements, Appl. 14-15, 32-34, and the States distance (Opp. 17 n.10) themselves from the court's baseless

accusation of race and sex discrimination.[1]

Respondents instead demand (States Opp. 34; APHA Opp. 31-32) "data" and "empirical" support for the Administration's opposition to DEI. But "the APA imposes no general obligation on agencies to conduct or commission their own empirical or statistical studies." *FCC* v. *Prometheus Radio Project*, 592 U.S. 414, 423 (2021). Regardless, it is unclear what empirical support respondents would have the government offer to demonstrate, *e.g.*, that DEI does not "expand our knowledge of living systems." APHA Opp. 31 (quoting Appl. App. 130a).

Respondents echo (States Opp. 34-35; APHA Opp. 32) the district court's criticism of the guidance documents' failure to explicitly define DEI. Respondents ignore case law holding that grant criteria need not define terms with exacting precision. Appl. 31-32. And respondents themselves seem to know what DEI is. *E.g.*, Cal. Gov't Operations, *Diversity, Equity and Inclusion*, https://perma.cc/JR3N-YR82; APHA, *Equity Diversity & Inclusion Survey* (Oct. 2021), https://perma.cc/3UFG-JTPE. They clearly recognize (States Opp. 35) that DEI encompasses inquiries into "structural racism and discrimination." And they do not dispute that intersectionality, "anti-

[1] After the government filed its application, the district court announced that it intends to press forward with its race- and sex-discrimination theory even if this Court grants a stay on the Tucker Act argument and even though no party has advanced such a claim. App., *infra*, 5a-6a; see generally 25-cv-10787 Compl.; 25-cv-10814 Am. Compl. The district court stated that, "as a court of equity," it "surely * * * retains jurisdiction" to enjoin discrimination. App., *infra*, 5a. The court thus announced its plan to "immediately * * * convene a hearing" to "impose an injunction that's not only prospective" but would order the NIH to "reevaluate[]" "a subset" of grants "forthwith * * * without regard to racial or gender issues of any sort, to see whether those grants, as a scientific matter, are not appropriate to go forward." *Id.* at 6a. In addition to violating the party-presentation rule, see *United States* v. *Sineneng-Smith*, 590 U.S. 371, 375-376 (2020), such an injunction would be plainly improper. Respondents have attempted (States Opp. 31; APHA Opp. 19-22) to distinguish *California* on the ground that that case involved an injunction while this case involves declaratory relief. If this Court stays the district court's declaratory relief on jurisdictional grounds, it would be highly inappropriate for the court to turn around and immediately issue a materially similar injunction.

racist healing," and "Buddhism and HIV stigma in Thailand" all qualify. Appl. 11. Instead, they point (States Opp. 34-35) to a small sample of studies with less facially DEI-related titles and assert a scientific basis for a study involving "daily diar[ies] for bisexual+ young adults" while feigning confusion over why that grant was terminated. To the extent that respondents contend that individual grants were misclassified, they can ask the agency to review that decision, see Pet. App. 86a, not pursue a blunderbuss arbitrary-and-capricious challenge to every grant termination.

Further, respondents' retail-level broadsides about what certain studies have to do with DEI are deeply misleading. Their study of "how aging is affected by HIV" (APHA Opp. 18) is titled "Structural Racism and Discrimination in Older Men's Health Inequities." 25-cv-10787 D. Ct. Doc. 38-33 ¶ 11 (Apr. 25, 2025). Their description of "equip[ping] peers with the tools to respond effectively and compassionately to disclosures of sexual violence" (APHA Opp. 18) omits that the study was limited to "SGM [sexual and gender minority]-specific sexual violence." 25-cv-10787 D. Ct. Doc. 38-34 ¶ 11 (Apr. 25, 2025).

Many of the highlighted grants were funded through a racially discriminatory process that the current Administration abhors. For example, the States' grant on "Bacterial and Molecular Determinants of Mycobacterial Impermeability" (Opp. 10 n.4, 34-35) came through a program with an explicit racial preference for "Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians, and other Pacific Islanders," *i.e.*, not whites or Asians. NIH, *NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity*, https://perma.cc/S83S-H23T; see NIH RePORT, *Bacterial and Molecular Determinants of Mycobacterial Impermeability*, https://bit.ly/5R01AI179080-02 (showing funding via "PAR-22-241," this diversity program). Numerous other cited studies

were funded via similarly discriminatory programs.[2] And one of the named respondents described having her department chair certify that she was "dedicated to a career that champions and fosters DEI" to apply for the previous Administration's diversity grants. *E.g.*, 25-cv-10787 D. Ct. Doc. 38-21 ¶15.b (Apr. 25, 2025). The NIH reasonably identified such grants resulting from a racially discriminatory application process as incompatible with Administration priorities.

Respondents also attack (States Opp. 36; APHA Opp. 32-33) the process by which individual grants were identified for termination. That focus on individual

---

[2] *E.g.*, NIH, *Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research*, https://perma.cc/U3CW-ESQR (PA-21-052) (same racial preference for grants on "Exploration of Unique Neurobehavioral Profile of Sequential Opioid-Stimulant Polysubstance Use Disorders" (States Opp. 10 n.3, 34) and "Understanding the Role of Coiled-Coil Domains in Regulating Liquid-Liquid Phase Separation of Protein Assemblies in Cell Division" (APHA Opp. 3)); NIH, *NCI Cancer Moonshot Scholars Diversity Program*, https://perma.cc/A4YP-JSF4 (RFA-CA-22-050) (same for grant on "Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings" (APHA Opp. 18)); NIH, *Research Supplements to Promote Diversity in Health-Related Research*, https://perma.cc/BP5N-KH4K (PA-21-071) (same for grant on "Understanding Biological and Lifestyle Contributions to Alzheimer's Disease Pathology and Clinical Profiles in Black Women" (States Opp. 11 n.6)); NIH, *NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity*, https://perma.cc/W8XD-KQ9E (RFA-DC-23-001) (same for grant on "family language planning and language acquisition among deaf and hard of hearing children" (APHA Opp. 10)); NIH, *Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity*, https://perma.cc/K3QE-CXM6 (PA-21-271) (similar for grants on "Identifying Unique Biological Factors as Potential Targets to Mitigate Colorectal Cancer Health Disparities in Native Hawaiians" (States Opp. 11 n.7), "Alzheimer's Disease and Related Dementia Neuropathologies and Exposures to Traffic Pollution Mixtures" (APHA Opp. 3), "An Adaptive Framework to Synthesize and Reconfigure Bacterial Viruses (Phages) to Counter Antibiotic Resistance" (*ibid.*), "Delineating the Role of the Homocysteine-Folate-Thymidylate Synthase Axis and Uracil Accumulation in African American Prostate Tumors" (APHA Opp. 10), and "Molecular Understanding of Maternal Humoral Responses to Pregnancy" (APHA Opp. 18)); NIH, *Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists*, https://perma.cc/2U8T-F2EZ (PAR-20-236) (same for grant on "Preparing Indigenous Scientists to Lead Innovative Substance Use Research" (States Opp. 11 n.8)). Other highlighted grants, like the States' "Rapid Response for Pandemics" example (Opp. 10 n.5), supported COVID-19 research that the NIH has deprioritized.

terminations, despite respondents' claim to challenge a "centralized policy decision" (States Opp. 36), confirms that this is a contract dispute for the Court of Federal Claims. See pp. 3-9, *supra*. While embracing the district court's findings elsewhere, respondents run away from the court's finding that the NIH's chief grants official testified "[c]onsistent with the Administrative Record" that NIH staff were to use their "scientific background" and knowledge of their programs "to identify DEI activities." Appl. App. 65a n.8. Respondents' main objection (APHA Opp. 32-33) is that "individuals outside of NIH" (*i.e.*, government officials at NIH's parent agency, HHS) helped identify disqualified grants. But respondents identify no rule of administrative law that prevents agencies from working together to carry out shared goals, particularly when the NIH Director reports to the HHS Secretary. 42 U.S.C. 282.

Finally, respondents claim (States Opp. 36-37; APHA Opp. 31, 33-34) that the NIH gave inadequate weight to reliance interests. But the NIH invited respondents to request transition funding for an orderly wind-down. Appl. 33-34. While respondents dismiss such funding as inadequate, agencies need only take "serious reliance interests * * * into account," *FCC* v. *Fox Television Stations, Inc.*, 556 U.S. 502, 515 (2009), not mitigate every harm. Regardless, the grant contracts enshrine the NIH's authority to terminate awards that "no longer effectuate[] the program goals or agency priorities." 2 C.F.R. 200.340(a)(4). Though previous administrations may not have exercised that authority, States Opp. 37, any reliance would be objectively unreasonable given the contracts' clear terms. Appl. 34. Such clear and explicit "disclaimers are surely pertinent in considering the strength of any reliance interests." See *DHS* v. *Regents of the Univ. of Cal.*, 591 U.S. 1, 31 (2020).

B. The Remaining Factors Support A Stay

Certworthiness. Certworthiness is obvious: The Tucker Act question impli-

cates (at least) tens of billions of dollars, the circuits are split 3-1, and dozens of district courts have reached conflicting results. And the APA questions reflect a trend of district-court intrusion on executive-branch decision-making, with this case alone implicating $783 million in grant money that lower-court orders are forcing the Executive Branch to continue disbursing over the Administration's strong policy objections. Appl. 34-36. The States claim (Opp. 40) that the split may resolve itself, while private respondents implausibly dismiss (Opp. 39) the split as fact-bound. But the Second Circuit has acknowledged the split, the en banc D.C. Circuit has recognized the question's "recurren[t]" "important[ce]," and ten Ninth Circuit judges have called out for review. *Widakuswara* v. *Lake*, No. 25-5144, 2025 WL 1521355, at *1 (D.C. Cir. May 28, 2025) (en banc) (per curiam); see Appl. 35. Moreover, lower-court defiance of interim orders itself warrants intervention, as recent decisions confirm. *Boyle*, slip op. 1; *DHS* v. *D.V.D.*, No. 24A1153, 2025 WL 1832186 (July 3, 2025).

Irreparable Harm. The States ignore the First Circuit's conclusion (Appl. App. 31a) that the government has irreparable harm because it will be forced to pay unrecoverable grants. Respondents dismiss (States Opp. 31, 37; APHA Opp. 17) that harm as not "quantif[iable]" and note that they can only withdraw funds for "specific project-related costs." But respondents have ongoing access to $783 million in federal funds that they have every incentive to draw down and never return. That is the same harm this Court accepted in *California*, 145 S. Ct. at 969. Appl. 36-37.

The States point (Opp. 37-38) to contractual and regulatory terms allowing the government to recoup "unallowable" payments. But they do not explain why those provisions would apply to grants whose termination a district court vacated, and they conspicuously have not "promised to return withdrawn funds should [the] grant termination[s] be reinstated." *California*, 145 S. Ct. at 969 (citation omitted).

The government is also irreparably harmed by the blockade of a key executive-branch priority. Appl. 37 (citing *Trump* v. *CASA, Inc.*, 145 S. Ct. 2540, 2561 (2025)). Respondents claim (States Opp. 38; APHA Opp. 17-18) that *CASA*'s irreparable-harm analysis is limited to universal injunctions. But an "improper intrusion by a federal court into the workings of a coordinate branch of Government" is an irreparable harm. *INS* v. *Legalization Assistance Project of L.A. Cnty. Fed'n of Labor*, 510 U.S. 1301, 1306 (1993) (O'Connor, J., in chambers); cf. *Maryland* v. *King*, 567 U.S. 1301, 1303 (2012) (Roberts, C.J., in chambers) ("[A]ny time a State is enjoined by a court from effectuating statutes enacted by representatives of its people, it suffers a form of irreparable injury.") (citation omitted).

Balance of the Equities. Respondents' asserted harms do not outweigh the government's paramount interest in overseeing the Executive Branch. Appl. 37-38. Respondents and their amici present the loss of federal funding as a cataclysm for American science. The States in *California* offered similar rhetoric about the devastation of "programs vital to the education of our youth." *California* Opp. at 40. Yet this Court recognized that those assertions did not refute the need for a stay. 145 S. Ct. at 969. Those respondents could seek any funds to which they were legally entitled in the Court of Federal Claims. *Ibid.* And any harms from terminating programs in the meantime was "self-imposed" because the States could use their own money to keep the programs running. *Ibid.* (citation omitted).

Despite also being respondents in *California*, the States assert (Opp. 31-32, 39) that they now suddenly lack money to plug the gap. Accord APHA Opp. 16-17. That defies credulity. California collected $86 billion in revenue this year, from personal income taxes alone. Cal. State Controller's Office, *April 2025 California Personal Income Tax Daily Revenue Tracker*, https://perma.cc/VZF7-C6XR. While California

might prefer that the federal government pay for research at its state universities, California's choice to shutter research rather than keep the lights on while litigating in the Court of Federal Claims is just that—a choice. As for private respondents, their highlighted examples (APHA Opp. 17) include affidavits stating that researchers *are* using "reserve funding to make up the difference," 25-cv-10787 D. Ct. Doc. 38-33 ¶ 23 (Apr. 25, 2025), or have received "short-term funding" from their university, 25-cv-10787 D. Ct. Doc. 38-34 ¶ 25 (Apr. 25, 2025). And some named respondents work at institutions like Harvard and the University of Michigan, with 11-figure endowments. See 25-cv-10787 Compl. ¶¶ 15-16. Any interim injury is self-inflicted.

Respondents' focus on public health also ignores that NIH research funding is finite. Money not spent on respondents' DEI-related research can be reallocated to projects that, in the Administration's view, advance public health. Appl. 38. The NIH denies 80% of grant applications; the public does not have any inherent interest in having one study funded over another. Which studies best serve the public is a discretionary decision Congress reserved to the NIH.

In any event, private respondents mischaracterize (Opp. 15) this factor as "the most crucial." This Court considers the equities only in "close cases." *Hollingsworth* v. *Perry*, 558 U.S. 183, 190 (2010) (per curiam). Given the on-point decision in *California*, this case is not close. The district court flouted vertical *stare decisis* by following this Court's dissenters over the majority. Appl. App. 221a. That alone should warrant a swift rebuke.

* * * * *

For the foregoing reasons and those stated in the government's application, the Court should stay the district court's judgments.

Respectfully submitted.

D. JOHN SAUER
Solicitor General

AUGUST 2025

APPENDIX

Status conference transcript (July 28, 2025) 1a

UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS (Boston)

No. 1:25-cv-10814-WGY

COMMONWEALTH OF MASSACHUSETTS, et al,
Plaintiffs
vs.

ROBERT F. KENNEDY, JR., et al,
Defendants

No. 1:25-cv-10787-WGY

AMERICAN PUBLIC HEALTH ASSOCIATION, et al,
Plaintiffs
vs.

NATIONAL INSTITUTES OF HEALTH, et al,
Defendants

****

For Hearing Before:
Judge William G. Young

Status Conference

United States District Court
District of Massachusetts (Boston.)
One Courthouse Way
Boston, Massachusetts 02210
Monday, July 28, 2025

****

REPORTER: RICHARD H. ROMANOW, RPR
Official Court Reporter
United States District Court
One Courthouse Way, Room 5510, Boston, MA 02210
rhr3tubas@aol.com

A P P E A R A N C E S

GERARD J. CEDRONE, ESQ.
KATHERINE B. DIRKS, ESQ.
PHOEBE LOCKHART, ESQ.
Massachusetts Attorney General's Office
One Ashburton Place, 20th Floor
Boston, MA 02108
E-mail: Gerard.cedrone@mass.gov
For the Commonwealth of Massachusetts plaintiffs

SUZANNE SCHLOSSBERG, ESQ.
OLGA AKSELROD, ESQ.
American Civil Liberties Union Foundation
125 Broad Street
New York, NY 10004
Email: Oakselrod@aclu.org
and
KENNETH PARRENO, ESQ.
Protect Democracy Project
15 Main Street, Suite 312
Watertown, MA 02472
Email: Kenneth.parreno@protectdemocracy.org
and
MAX ROLLER SELVER, ESQ.
Emery Celli Brinkerhoff Abad Ward & Maazel, LLC
1 Rockefeller Plaza, Suite 8th Floor
New York, NY 10020
Email: Imaazel@ecbawm.com
For the APHA plaintiffs

SAMUEL HOBBS, ESQ.
DOJ-Civ
Corporate Financial Litigation
1100 L St NW, Room 7210
Washington, DC 20005
Email: Samuel.hobbs@usdoj.gov
and
ANUJ K. KHETARPAL, ESQ.
United States Attorney's Office
1 Courthouse Way, Suite 9200
Boston, MA 02210
Email: Anuj.khetarpal@usdoj.gov
For all defendants

advance of the trial, just a little bit later than the August 4th date we proposed.

THE COURT: That's the order. You proposed it. You're held to it.

All right. There's one other aspect of this that I need to speak to, and again I speak only because I think it's helpful.

The, um, defendant public officials, quite properly, as they have every right, have made applications for an emergency stay to the Supreme Court of the United States. I am not going to speak to it or make any arguments with respect to it at all. But that fact, um, raises in my mind a possible outcome that I consider I ought make an indicative ruling with respect to, and it has to do with this matter of discrimination.

The -- I've read the Solicitor General's brief and I understand that the plaintiffs will get a chance to oppose. I've said my say with respect to those matters and have nothing further to say.

I just can conceive of really three possible outcomes to the application for a stay and they are these.

One, the stay may be denied. If it's denied, what we've done here this afternoon of course -- this morning, governs the further proceedings in the further

aspect of this case.

Two, the stay may be granted but without, um, specificity as to the grounds on which the, um, Supreme Court is acting. As I read the Solicitor General's brief, he raises two arguments. One, he raises the Tucker Act argument, it's a respectable argument, though I've rejected it, as has the Court of Appeals. But he also raises an argument that these matters are committed to agency discretion and, um, the DOGE -- I'll call them the "DOGE directives," are within agency discretion.

Well wanting and believing it was in the interests of the parties to get a prompt resolution, I purposely have focused my actions on serving up to the Court of Appeals what I've called a "clean APA," um, "based determination," and indeed I've entered a partial final judgment under the appropriate civil rule.

In addition to this Phase 2, I have made it clear on the record, in a conclusory way, that I have found that the DOGE directives, um, direct racial, gender, and, um, what I call "LGBTQ discrimination." I have not entered any, um, equitable decision, and indeed as the footnote to this Court's comprehensive written opinion indicates, in light of decisions of the Supreme Court, I now include that it would be improvident for me to do so as to LGBTQ discrimination, though discrimination there

was. But as to racial and sexist discrimination, I intend, and I've intended throughout, to enter a prospective injunction against the public officials from prospectively engaging in any such discrimination.

I have thought that such -- and I think that's clear on the record, I'm simply reiterating it, and I'm at work now in, um, writing up the factual basis for entering such an injunction and considering the language that I will use in fashioning such an injunction.

In the unlikely event that the Supreme Court indicates that there is a stay -- and this is what I have not thought through and I take the opportunity now to explain it, so that -- so that everyone understands. I don't want to be in a position, and I don't want to be seen to be in a position of, um, in any way disregarding or getting around an order of the Supreme Court of the United States. That -- I would never do that.

So I guess what I'm saying is that if the Supreme Court enters a stay and the stay is reasonably limited to the Tucker Act issue, surely this Court then retains jurisdiction, as a court of equity, which the Court of Federal Claims is not, to address the discrimination, which this Court has unequivocally found.

If -- so now I'm saying that were that to be the way it plays out before the Supreme Court, I will

immediately convene -- because we can't wait on my written decision, I will convene a hearing and I will impose an injunction that's not only prospective, but would say -- and it would be a subset of the grants to which the, um -- well what I have called the "DOGE directives," which I've declared invalid and have no force and effect, a subset of those, which in this Court's mind evidence the racial and gender discrimination, um, and I will enjoin -- forthwith in this wise, I will instruct the officials and the Cabinet Secretary that those grants are to be reevaluated at once forthwith, um, without regard to racial or gender issues of any sort, to see whether those grants, as a scientific matter, are not appropriate to go forward. It shouldn't take long, because of course the scientists have already reviewed these grants and allocated the funds and such that the grants may go forward.

To reiterate. If there's no stay, I will get to this discrimination business with a prospective injunction in the ordinary course, and we have our, um, framework to proceed on Phase 2. If there is a "blanket stay" or anything that fairly can be construed as a "blanket stay," all orders in this case are suspended until that stay is lifted. And the only thing left appropriately for this Court is to, um, file, as the

Rules of Civil Procedure require, its written findings of racial, gender, and I can still find LGBTQ discrimination, though I've decided it would be improvident to enter an order, that I'm going to go ahead with anyway. Only if the Tucker Act is stayed but the issue of whether it's committed to agency discretion is not stayed, fairly read, would I have the need promptly to enter an injunction, since my written opinion presumes this Court has subject matter jurisdiction over the APA claim.

Questions as to what I just said. And we'll go around.

Any questions?

MS. DIRKS: None from the state plaintiffs, your Honor.

THE COURT: APHA?

MS. SCHLOSSBERG: No, your Honor.

THE COURT: Questions, Mr. Hobbs?

MR. HOBBS: Your Honor, it's not a question, but we do have a comment on the discrimination --

THE COURT: Well feel free, but you'll understand I'm not arguing it, I simply am trying to explain the Court's position. But I will hear you, sir.

MR. HOBBS: Yeah. No, I understand the Court's position, I just think it's important for the defendants

to note, um, that since the plaintiffs never asserted discrimination claims, we've never had an opportunity to be heard on the discrimination claims. And so at the very least, we would seek an opportunity to submit, um, briefing on why we think the Court doesn't have jurisdiction to, um, issue any rulings or injunctions related to the discrimination claims.

THE COURT: Then I urge you to file such briefs, because I -- assuming no stay, which is what I'm assuming, I'm working on it right now. So the sooner I get your views on that, the better it will be. For me it's palpable and the Court must deal with it. But of course I will entertain your briefs.

MR. HOBBS: Understood, your Honor. Thank you.

THE COURT: Thank you.

All right, it's good to see you all. We'll stand in recess.

(Ends, 11:50 a.m.)

UCSF
University of California
San Francisco

Winona L. Ward, CRA
Assistant Vice Chancellor
Office of Sponsored Research

Office of the Executive
Vice Chancellor and Provost
UCSF Campus Box 0962
San Francisco, CA 94143

winona.ward@ucsf.edu

www.ucsf.edu

April 21, 2025

Dr. Matthew Memoli
Acting Director
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892

Subject: Appeal of Early NIH Termination Notice for 1U19AI171110-01, QCRG Pandemic Response Program

Dear Dr. Memoli,

On behalf of Dr. Nevan J. Krogan, Ph.D. and the University of California San Francisco (UCSF), we want to thank the NIH for the tremendous amount of support for the UCSF research mission and the subject research project. UCSF shares the NIH mission to improve the health of Americans, extend life, and reduce illness by conducting research to develop new therapeutic approaches with panviral activity that target SARS-CoV-2 and other viral families of pandemic potential.

In accordance with the 2024 Policy Statement 8.7[1], we are writing to exercise our first level appeal rights to request a review in response to the Termination Notice issued March 24, 2025, for FAIN# U19AI171110. This request is submitted within the 30-day timeframe to request a review.[2]

We acknowledge the notice of termination which includes the following statement: *The end of the pandemic provides cause to terminate COVID-related grant funds. These grant funds were issued for a limited purpose: to ameliorate the effects of the pandemic. Now that the pandemic is over, the grant funds are no longer necessary*

We respectfully object to the subject grant termination on the grounds that:

The reasoning that the AViDD program's fundamental scientific and public health objectives no longer align with the agency's priorities. Specifically, we dispute the conclusions that:

1. The end of the COVID-19 pandemic reduces the importance of developing antiviral drugs for future pandemic threats.
2. The initial purpose of the award is no longer necessary or compatible with NIH program goals.
3. No corrective action or scope modification could be implemented to realign the project with current agency priorities.

While the AViDD program was established in response to the COVID-19 pandemic, it was clear from the outset that its scope included leveraging insights from coronaviruses to advance research on other viruses with pandemic potential. A critical aspect of this preparedness was to create enduring infrastructure and capabilities, ensuring our nation is equipped to handle future threats.

Alignment with Enduring NIH and HHS Priorities:
We support the restructuring of the Department of Health and Human Services (HHS) to enhance disease prevention efforts and are committed to collaborating with the current administration to align on shared goals. The termination letter implies a shift in NIH priorities without indicating the nature of the change, although we assume that public health remains a top priority. The AViDD program's core objectives are to be ready to respond to emerging public health threats, and our center's established infrastructure and pipeline are well-suited to meet this challenge.

Corrective or Adaptive Actions Are Possible:
Although the termination letter states that "no corrective action is possible," we respectfully assert our ability to revise our Specific Aims or timeline to align with any changes in agency priorities. If NIH aims to modify the AViDD program to exclude activities related to SARS-CoV-2 specifically, the scope can be adjusted to focus on variants resistant to current therapies, underscoring the need for improved drugs. This can be done without halting work on relevant projects and NIH precedent supports scope revisions over terminations when program evolution occurs.

Impact on Scientific Progress and National Capabilities:
Over the past three years, this project has achieved significant milestones, leading to the discovery and development of multiple drug-like candidates poised for pre-clinical development and subsequent clinical trials. Premature termination risks losing all this progress, wasting the substantial monetary investment NIH has already made in these programs, and undermining the broader NIH mission to ensure the nation is prepared to treat or prevent future outbreaks.

Facts supporting our request:
The QCRG AViDD Center spans ~50 research labs across 13 institutions (8 within the US, 5 international) under the leadership of Director Dr. Nevan Krogan. Almost 200 lab-based scientists and researchers are associated with this award. The five QCRG projects (listed below) are heavily supported by nine technology cores. As an integrated unit, they work together to carry forward the Center's vision and enable development of the following projects:
Project 1: Targeting Viral RNA Using a Sequence Programmable Small Molecule-Oligonucleotide Conjugate
Project 2: Developing Antivirals Targeting Proteases and Polymerases of Coronaviruses, Picornaviruses and Bunyavirales
Project 3: Targeting Viroporins and Coronavirus Envelope (E) and Membrane (M) Protein
Project 4: Development of Novel Antivirals Targeting Viral RNA Methylation
Project 5: Inhibiting Viral Macrodomains Using Structure-Based Design

From the five projects, four research areas have progressed to IND-enabling studies, focusing on inhibitors targeting the viral proteins Major Protease (Mpro), Envelope (E), Membrane (M), and Macrodomain (Mac1). In the context of COVID-19, Mpro is a key enzyme critical for viral replication. Current treatments, such as Paxlovid (approved in the US) and Ensitrelvir (approved in Japan), both target Mpro. However, the compounds developed by QCRG are more potent and demonstrate efficacy against SARS-CoV-2 variants that are resistant to current therapies and are also efficacious against MERS.

The SARS-CoV-2 Mac1 is a novel target due to the macrodomain's role in helping the virus evade the host immune response, making it an important focus for therapeutic development not only for COVID-19 but also for other viruses of pandemic potential such as Chikungunya. This first-in-class inhibitor boasts an excellent pharmacokinetic and pharmacodynamic profile, with no observed human off-target effects. We are poised to explore how this could be used as part of a drug cocktail with the Mpro inhibitor.

QCRG's pipeline of verified drug-like antiviral molecules also includes potent inhibitors targeting the envelope (E) and membrane (M) proteins. The QCRG program also has a project focused on developing therapies that target the viral RNA itself, which has the potential to be highly efficient in suppressing viral infection and, if successful, would allow researchers to program the therapy for any newly emerging virus.

As of March 31st, all 9 AViDD centers have published a total of 228 scientific papers in <3 years. QCRG AViDD has published 60 papers (~1/4th of all scientific publications) as evidence of our tremendous scientific output. Despite all this progress, our AViDD Center scientists now lack the means to advance these projects to completion, preventing their transition to pharmaceutical partners for clinical trials. This lamentable circumstance not only underscores the potential squandering of many millions in taxpayer funds but also portends a critical deficit in the development of urgently needed antiviral medications.

This request includes supporting documents, as follows:
1. A copy of the adverse determination (termination letter)

2. Revised Notice of Award
3. Letter from Scientific Advisory Board Chair supporting this appeal
4. Total amount in dispute

Based on the proposed realignment of NIH priorities mentioned in the termination letter, we suggest advancing our most promising projects as follows:
Project 1: Targeting Viral RNA Using a Sequence Programmable Small Molecule-Oligonucleotide Conjugate (*no change in scope*)
Project 2: Developing Antivirals Targeting Proteases of MERS-CoV and SARS-CoV resistant to current treatments (*focus on commercially validated Protease target, elimination of the Polymerase sub-project*)
Project 3: Targeting Coronavirus Membrane (M) Protein (*focus on Membrane protein, elimination of Envelope protein sub-project,*)
Project 5: Inhibiting Viral Macrodomains Using Structure-Based Design (*no change in scope)*

Projects eliminated:
Project 2: Developing Antivirals Targeting Polymerases
Project 3: Targeting Viroporins and Coronavirus Envelope (E) Protein
Project 4: Development of Novel Antivirals Targeting Viral RNA Methylation

Request for Review:

We respectfully request the opportunity to discuss possible alternatives to termination, including project modification or scope adjustment, which may better reflect current agency direction while preserving the value and intent of this significant federal investment. For the reasons outlined in our appeal here, we request that the NIH reconsider the termination of Grant Award U19AI171110. We remain committed to working in partnership with NIH to align our efforts with national public health goals and scientific priorities.

Please do not hesitate to contact me at *Nevan.Krogan@ucsf.edu* should you need any further information or clarification. We respectfully request that NIH reconsider its decision to terminate this award and provide a fair opportunity to demonstrate our commitment to the project's success. We appreciate NIH's support of UCSF's research programs and look forward to a favorable response.

Sincerely,

DocuSigned by:
Nevan Krogan
071FBFAE7EA8463...
Nevan J. Krogan, Ph.D.
Professor & QBI Director

DocuSigned by:
D863E139BF08463...
Winona Ward
Assistant Vice Chancellor
Office of Sponsored Research

Attachments
Cc:
Dr. Harold Collard, UCSF Vice Chancellor of Research
Dr. Kathy Giacomini, Ph.D., Dean of the School of Pharmacy

---

[1] https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.7_grant_appeals_procedures.htm
[2] https://www.ecfr.gov/current/title-2/subtitle-A/chapter-II/part-200#200.342 and 42 CFR 50.406(a)

From: Bulls, Michelle G. (NIH/OD) [E] <michelle.bulls@nih.gov>
Sent: Monday, March 24, 2025 12:52 PM
To: Rynne, Gavin <Gavin.Rynne@ucsf.edu>
Subject: Grant Termination Notification

This Message Is From an External Sender

This message came from outside your organization.

3/24/2025

Rynne, Gavin
University Of California, San Francisco

gavin.rynne@ucsf.edu

Dear Rynne, Gavin:

Effective with the date of this letter, funding for Project Number 1U19AI171110-01 is hereby terminated pursuant to the Fiscal Year 2022 National Institutes of Health ("NIH") Grants Policy Statement,[1] and 2 C.F.R. § 200.340(a)(2). This letter constitutes a notice of termination.[2]

The 2022 Policy Statement applies to your project because NIH approved your grant on 5/16/2022, and "obligations generally should be determined by reference to the law in effect when the grants were made."[3]

The 2022 Policy Statement "includes the terms and conditions of NIH grants and cooperative agreements and is incorporated by reference in all NIH grant and cooperative agreement awards.[4]" According to the Policy Statement, "NIH may … terminate the grant in whole or in part as outlined in 2 CFR Part 200.340.[5]" At the time your grant was issued, 2 C.F.R. § 200.340(a)(2) permitted termination "[b]y the Federal awarding agency or pass-through entity, to the greatest extent authorized by law, if an award no longer effectuates the program goals or agency priorities."

The end of the pandemic provides cause to terminate COVID-related grant funds. These grant funds were issued for a limited purpose: to ameliorate the effects of the pandemic. Now that the pandemic is over, the grant funds are no longer necessary.

Although "NIH generally will suspend (rather than immediately terminate) a grant and allow the recipient an opportunity to take appropriate corrective action before NIH makes a termination decision,"[6] no corrective action is possible here. The premise of this award is incompatible with agency priorities, and no modification of the project could align the project with agency priorities.

Costs resulting from financial obligations incurred after termination are not allowable.[7]

Nothing in this notice excuses either NIH or you from complying with the closeout obligations imposed by 2 C.F.R. §§ 75.381-75.390. NIH will provide any information required by the Federal Funding Accountability and Transparency Act or the Office of Management and Budget's regulations to *USAspending.gov*.[8]

Administrative Appeal

You may object and provide information and documentation challenging this termination.[9]

NIH has established a first-level grant appeal procedure that must be exhausted before you may file an appeal with the Departmental Appeals Board.[10]

You must submit a request for such review to Dr. Matt Memoli no later than 30 days after the written notification of the determination is received, except that if you show good cause why an extension of time should be granted, Dr. Memoli may grant an extension of time.[11]

The request for review must include a copy of the adverse determination, must identify the issue(s) in dispute, and must contain a full statement of your position with respect to such issue(s) and the pertinent facts and reasons in support of your position. In addition to the required written statement, you shall provide copies of any documents supporting your claim.[12]

Sincerely,

Michelle G. Bulls, on behalf of Emily Linde, Chief Grants Management Officer, NIAID
Director, Office of Policy for Extramural Research Administration
Office of Extramural Research

---

[1] https://grants.nih.gov/grants/policy/nihgps/nihgps.pdf.

[2] 2 C.F.R. § 200.341(a); 45 C.F.R. § 75.373

[3] *Bennett v. New Jersey*, 470 U.S. 632, 638 (1985).

[4] NIH Grants Policy Statement at IIA-1.

[5] *Id.* at IIA-155.

[6] NIH Grants Policy Statement at IIA-156.

[7] *See* 2 C.F.R. § 200.343 (2024).

[8] 2 C.F.R. § 200.341(c); 45 C.F.R. § 75.373(c)

[9] *See* 45 C.F.R. § 75.374.

[10] See 42 C.F.R. Part 50, Subpart D

[11] 11 *Id.* § 50.406(a)

[12] 12 *Id.* § 50.406(b)

Recipient Information

1. Recipient Name
REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE
1855 FOLSOM ST STE 425
SAN FRANCISCO, CA 94103

2. Congressional District of Recipient
11

3. Payment System Identifier (ID)
1946036493A6

4. Employer Identification Number (EIN)
946036493

5. Data Universal Numbering System (DUNS)
094878337

6. Recipient's Unique Entity Identifier
KMH5K9V7S518

7. Project Director or Principal Investigator
Nevan J Krogan, PHD
Professor
nevan.krogan@ucsf.edu
415-476-2980

8. Authorized Official
Gavin Rynne
gavin.rynne@ucsf.edu
415-502-1846

Federal Agency Information

9. Awarding Agency Contact Information
KATHERINE ANNE Matheson

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
katherine.matheson@nih.gov
301-594-4218

10. Program Official Contact Information
DIPANWITA Basu
Program Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
dipanwita.basu@nih.gov
(240) 627-3469

Federal Award Information

11. Award Number
1U19AI171110-01

12. Unique Federal Award Identification Number (FAIN)
U19AI171110

13. Statutory Authority
42 USC 241 31 USC 6305 42 CFR 52

14. Federal Award Project Title
QCRG Pandemic Response Program

15. Assistance Listing Number
93.855

16. Assistance Listing Program Title
Allergy and Infectious Diseases Research

17. Award Action Type
New Competing (REVISED)

18. Is the Award R&D?
Yes

Summary Federal Award Financial Information	
19. Budget Period Start Date 05/16/2022 **– End Date** 03/24/2025	
20. Total Amount of Federal Funds Obligated by this Action	$0
20 a. Direct Cost Amount	$0
20 b. Indirect Cost Amount	$0
21. Authorized Carryover	
22. Offset	
23. Total Amount of Federal Funds Obligated this budget period	$67,452,049
24. Total Approved Cost Sharing or Matching, where applicable	$0
25. Total Federal and Non-Federal Approved this Budget Period	$67,452,049
26. Project Period Start Date 05/16/2022 **– End Date** 03/24/2025	
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	$67,452,049

28. Authorized Treatment of Program Income
Additional Costs

29. Grants Management Officer - Signature
Emily Linde

30. Remarks

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Version:25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

A2670

NIH_GRANTS_005711

RESEARCH PROJECT COOPERATIVE AGREEMENT
Department of Health and Human Services
National Institutes of Health

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 1U19AI171110-01 REVISED

Principal Investigator(s):
Nevan J Krogan, PHD

Award e-mailed to: cgrasteam@ucsf.edu

Dear Authorized Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to The Regents of the UCSF in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number U19AI171110. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Emily Linde
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

Salaries and Wages	$12,922,347
Fringe Benefits	$3,760,061
Personnel Costs (Subtotal)	$16,682,408
Consultant Services	$9,600
Equipment	$1,616,522
Materials & Supplies	$3,104,202
Travel	$2,372,584
Other	$6,101,516
Subawards/Consortium/Contractual Costs	$19,617,425
Publication Costs	$94,850
Tuition Remission	$116,244
Federal Direct Costs	$49,715,351
Federal F&A Costs	$17,736,698
Approved Budget	$67,452,049
Total Amount of Federal Funds Authorized (Federal Share)	$67,452,049
TOTAL FEDERAL AWARD AMOUNT	$67,452,049
AMOUNT OF THIS ACTION (FEDERAL SHARE)	$0

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	**THIS AWARD**	**CUMULATIVE TOTALS**
1	$67,452,049	$67,452,049

Fiscal Information:

Payment System Identifier:	1946036493A6
Document Number:	UAI171110AC6
PMS Account Type:	P (Subaccount)
Fiscal Year:	2022

IC	CAN	2022
AI	8051125	$67,452,049

NIH Administrative Data:
PCC: M51E SR / **OC**: 41026 / **Released**: 03/25/2025
Award Processed: 03/26/2025 12:03:02 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1U19AI171110-01 REVISED

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – STANDARD TERMS AND CONDITIONS – 1U19AI171110-01 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
c. 45 CFR Part 75.
d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

definition of “Research and Development” at 45 CFR Part§ 75.2**.** As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

This institution is a signatory to the Federal Demonstration Partnership (FDP) Phase VII Agreement which requires active institutional participation in new or ongoing FDP demonstrations and pilots.

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

MULTI-YEAR FUNDED AWARD: This is a multi-year funded award. A progress report is due annually on or before the anniversary of the budget/project period start date of the award, in accord with the instructions posted at: http://grants.nih.gov/grants/policy/myf.htm.

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) U19AI171110. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: http://grants.nih.gov/grants/policy/policy.htm#gps.

A final expenditure Federal Financial Report (FFR) (SF 425) must be submitted through the Payment Management System (PMS) within 120 days of the period of performance end date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/policy.htm#gps, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the real-time cash drawdown data in PMS. NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final FFR on expenditures. It is important to note that for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date. The HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm. This paragraph does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, D42, D43, D71, DP7, G07, G08, G11, K12, K16, K30, P09, P40, P41, P51, R13, R25, R28, R30, R90, RL5, RL9, S10, S14, S15, U13, U14, U41, U42, U45, UC6, UC7, UR2, X01, X02.

Unless an application for competitive renewal is submitted, a Final Research Performance Progress Report (Final RPPR) must also be submitted within 120 days of the period of performance end date. If a competitive renewal application is submitted prior to that date, then an Interim RPPR must be submitted by that date as well. Instructions for preparing an Interim or Final RPPR are at: https://grants.nih.gov/grants/rppr/rppr_instruction_guide.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the Interim or Final RPPR. *Note that data*

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

reported within Section I of the Interim and Final RPPR forms will be made public and should be written for a lay person audience.

NIH requires electronic submission of the final invention statement through the Closeout feature in the Commons.

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final RPPR is not required. However, a final expenditure FFR is required and must be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html and https://www.lep.gov.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see https://grants.nih.gov/grants/policy/harassment.htm.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see https://www.hhs.gov/conscience/conscience-protections/index.html and https://www.hhs.gov/conscience/religious-freedom/index.html.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 1U19AI171110-01 REVISED

Clinical Trial Indicator: No
This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

Revised Award: The end of the pandemic provides cause to terminate COVID-related grant funds. These grant funds were issued for a limited purpose: to ameliorate the effects of the pandemic. Now that the pandemic is over, the grant funds are no longer necessary. Therefore, this project is terminated.

Please be advised that your organization, as part of the orderly closeout process will need to submit the necessary closeout documents (i.e., Final Research Performance Progress Report, Final Invention Statement, and the Final Federal Financial Report (FFR), as applicable within 120 days of the end of this grant.

NIH is taking this enforcement action in accordance with 2 C.F.R. § 200.340 as implemented in NIH GPS Section 8.5.2. This revised award represents the final decision of the NIH. It shall be the final decision of the Department of Health and Human Services (HHS) unless within 30 days after receiving this decision you mail or email a written notice of appeal to Dr. Matthew Memoli. Please include a copy of this decision, your appeal justification, total amount in dispute, and any material or documentation that will support your position. Finally, the appeal must be signed by the institutional official authorized to sign award applications and must be dated no later than 30 days after the date of this notice.

Supersedes previous Notice of Award dated **09/12/2023**. All other terms and conditions still apply to this award.

****

REVISED AWARD: This award is revised to update the terms and conditions of award that have been accepted by the recipient on 9/7/2023.

TERM 1 – Redirection of funds & Clarification of Experimental Approaches- What work may be conducted and what may require further review

No funds provided by this award may be used to support research reasonably anticipated to create, transfer, or use an enhanced potential pandemic pathogen per the Department of Health and Human Services (HHS) Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (HHS P3CO Framework). Detailed descriptions of all proposed experiments that are determined to or may be reasonably anticipated to meet this scope, must be submitted to NIAID for review and approval prior to any work commencing. Any work that is conducted without prior approval could result in improper payments of such work that is charged to the project. If NIAID determines that HHS review of the proposed studies is required, NIAID may request additional information for inclusion in materials, including but not limited to, supporting evidence for the anticipated phenotypic characteristics of each resulting pathogen, for submission to HHS.

The following studies have been approved by NIAID:

- Studies, including resistance studies, involving the creation, use, or transfer of SARS-CoV-2 viruses that use the Δ3678 SARS-CoV-2 or double ORF-deficient (Δ3a/Δ6, Δ3a/Δ7a, and Δ3a/Δ7b) SARS-CoV-2 viruses as a backbone. Any work with an attenuated virus different from those identified above requires prior approval from NIAID, and may require HHS review.
- Use or transfer of naturally-occurring clinical isolates of circulating viruses.

The following studies, when conducted using strains other than the Δ3678 SARS-CoV-2 or double ORF-deficient (Δ3a/Δ6, Δ3a/Δ7a, and Δ3a/Δ7b) SARS-CoV-2 viruses as backbones, meet the scope of the HHS P3CO Framework, require review by HHS, and no funds from this award may be used to support this research:

- Studies involving the creation, use, or transfer of viruses, that are resistant to approved or authorized drugs, or components thereof, including, but not limited to, Paxlovid™/nirmatrelvir, Lageviro™/molnupiravir, and Veklury™/remdesivir.
- Studies with candidate compounds that bind to the same active site and/or have similar chemical structure to approved or authorized drugs, or components thereof, including but not limited to Paxlovid™/nirmatrelvir, Lageviro™/molnupiravir, and Veklury™/remdesivir, that may generate viruses, that are resistant to approved or authorized drugs, or components thereof.

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

TERM 2 – Potential Unanticipated Viral Outcomes

The currently proposed research funded under this award is not reasonably anticipated to create, transfer, or use an enhanced potential pandemic pathogen. However, should research conducted under this award have unanticipated outcomes potentially falling within this scope, the recipient must stop work immediately on the day the potential unanticipated outcome(s) are observed. On that same day, the institution must notify the NIAID Program Officer, Grants Management Specialist, and appropriate institutional biosafety committee. After review of the unanticipated outcomes, NIAID will communicate to the institution what, if any, actions should be taken with respect to the virus and research-related virus containing materials. NIAID funds cannot be used to resume these experiments unless a revised Notice of Award (NOA) with the approval has been received. Examples of unanticipated outcomes that would meet this scope include:

In vitro Studies

- If applicable - Experiments that result in a virus that has increased infectivity as assessed by assays in cell culture when compared to a parental strain in the presence or absence of an approved or authorized drug. Evidence of increased infectivity can include but is not limited to, a one (1) log decrease in the multiplicity of infection (m.o.i) required to observe clear cytopathic effect, a 50% increase in cell syncytia formation, and/or changes in cell morphology not observed with the parental virus, such as rounding, detaching, and/or clumping of adherent cells.

In vivo Studies

- If applicable - Experiments involving vertebrate animals infected with a modified/mutated virus (e.g., viruses generated during the course of deep mutational scanning studies or viruses with resistance to a therapeutic candidate in development) that display unanticipated increases in disease severity (e.g., weight loss, viral titer, disease progression, or mortality) and/or transmissibility when compared to parental strains in the presence or absence of an approved or authorized drug.

TERM 3 – Publication Notification

- The recipient is strongly encouraged to submit to the NIAID Program Officer all materials to be published or publicly disseminated, and to inform the NIAID Program Officer about the deposition of genomic data in publicly available databases, resulting from this award at least 10 business days prior to submission or public dissemination. The acknowledgement section should state the specific research studies that were supported by this award.

Supersedes previous Notice of Award dated 05/17/2022. All other terms and conditions still apply to this award.

*****

TRANSITION APPLICATION: Continuation of the program for years 4 and 5 is dependent upon an expected appropriation. If funds are available, to be considered for additional funding after the end of the current project period, the recipient must submit a Non-competing Continuation Progress Report form. Recipients must follow the instructions for the PHS 2590
found at https://grants.nih.gov/grants/funding/2590/2590.htm ;;;;;;to complete the form. All applicable sections must be completed.

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

The continuation application package is due 03/15/2025 and should be sent via email to the **NIAID GMP Inbox** at niaidgmpinbox@mail.nih.gov and vandhana.khrauna@nih.gov. When submitting the continuation application package please include "**AViDD Application"** in the subject line of the email and copy the program official identified on the Notice of Award.

Funding for the continuation application will be contingent upon 1) availability of supplemental funds; and then 2) assessment of the progress report and determination if the goals were achieved, 3) review and approval of other documents necessary for continuation. If the extension request is not approved, the awardee will be advised of the decision in writing.

***

This award provides funds to prevent, prepare for, and respond to coronavirus, domestically or internationally. These funds are restricted for the emergency response to COVID-19 only and may not be rebudgeted or used for any other purpose without NIAID prior approval.

***

This award is issued as a Cooperative Agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award set forth in Section VI: Award Administrative Information of RFA-AI-21-050, which are hereby incorporated by reference as special terms and conditions of award.

The RFA may be accessed at: http://grants.nih.gov/grants/guide/index.html

***

This award is issued with direct costs based on NIAID recommended funding levels.

***

In accordance with the NIAID Financial Management Plan, NIAID does not provide funds for inflationary increases. Future budget year(s) committed amounts were adjusted accordingly. See: https://www.niaid.nih.gov/grants-contracts/financial-management-plan.

***

This Notice of Award (NoA) includes funds for J. David Gladstone Institutes in the amount of **$433,629**
This Notice of Award (NoA) includes funds for Icahn School of Medicine at Mount Sinai in the amount of **$1,774,500**
This Notice of Award (NoA) includes funds for Texas Biomedical Research Institute in the amount of **$1,782,000**
This Notice of Award (NoA) includes funds for University of California, Berkeley in the amount of **$722,250**
This Notice of Award (NoA) includes funds for Icahn School of Medicine at Mount Sinai in the amount of **$1,521,000**
This Notice of Award (NoA) includes funds for J. David Gladstone Institutes in the amount of **$1,379,961**
This Notice of Award (NoA) includes funds for J. David Gladstone Institutes in the amount of **$855,993**
This Notice of Award (NoA) includes funds for Icahn School of Medicine at Mount Sinai in the amount of **$2,281,500**
This Notice of Award (NoA) includes funds for University of California, Berkeley in the amount of **$1,685,250**
This Notice of Award (NoA) includes funds for Rutgers in the amount of **$1,150,224**
This Notice of Award (NoA) includes funds for Northwestern University in the amount of **$480,000**

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

This Notice of Award (NoA) includes funds for J. David Gladstone Institutes in the amount of **$567,000**
This Notice of Award (NoA) includes funds for Massacusetts Institute of Technology in the amount of **$1,534,892**

***

This Notice of Award (NoA) includes funds for Instituto Gulbenkian de Ciencia - PORTUGAL in the amount of **$372,600**
This Notice of Award (NoA) includes funds for University College of London - UNITED KINGDOM in the amount of **$971,466**
This Notice of Award (NoA) includes funds for Institute Pasteur Paris - FRANCE in the amount of **$485,580**
This Notice of Award (NoA) includes funds for Institute Pasteur Paris - FRANCE in the amount of **$485,580**
This Notice of Award (NoA) includes funds for University of Alberta - CANADA in the amount of **$486,000**
This Notice of Award (NoA) includes funds for University of Toronto - CANADA in the amount of **$648,000**

***

Research conducted at the following site(s) must be reported in the Research Performance Progress Report (RPPR), Section G.9 (Foreign component):

- University of Alberta, CANADA
- University of Toronto, CANADA
- Insitut Pasteur, FRANCE
- Instituto Gulbenkian De Ciencia, PORTUGAL
- University College London, UNITED KINGDOM

***

Dissemination of study data must be in accord with the recipient's genomic data sharing plan as stated in the letter/e-mail from Gavin Rynne of UCSF dated April 15, 2022. Failure to adhere to the sharing plan may result in Enforcement Actions as described in the NIH Grants Policy Statement.

***

Recipients conducting research involving Select Agents (see 42 CFR 73 for the relevant human Select Agents and Toxins; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant Select Agents and Toxins at https://www.selectagents.gov/regulations/) must complete registration with CDC (or APHIS, depending on the agent) before using NIH funds. No funds can be used for research involving Select Agents if the final registration certificate is denied.

Prior to conducting a restricted experiment with a Select Agent or Toxin, recipients must notify the NIAID and must request and receive approval from CDC or APHIS.

Be advised that the recipient is responsible for having its subrecipients comply with the requirements pertaining to the use of Select Agents and/or Highly Pathogenic Agents.

***

Highly Pathogenic Agents:
NIAID defines a Highly Pathogenic Agent as an infectious Agent or Toxin that may warrant a biocontainment safety level of BSL3 or higher according to the current edition of the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) (https://www.cdc.gov/labs/BMBL.html). Research funded under this grant must adhere to the BMBL, including using the BMBL-recommended biocontainment level at a minimum. If the Institutional Biosafety Committee (IBC) (or equivalent body) or designated institutional

Version: 25 - 2/15/2024 9:51 AM | Generated on: 3/26/2025 12:03 AM

biosafety official recommends a higher biocontainment level, the higher recommended containment level must be used.
When submitting future Progress Reports indicate at the beginning of the report:

If no research with a Select Agent (see 42 CFR 73 for the relevant human Select Agents and Toxins; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant Select Agents and Toxins at https://www.selectagents.gov/regulations/ and https://www.selectagents.gov/sat/list.htm) and/or has been performed or is planned to be performed under this grant.

If the IBC or equivalent body or official has determined, for example, by conducting a risk assessment, that the work being planned or performed under this grant may be conducted at a biocontainment safety level that is lower than BSL3.

If the work involves Select Agents and/or Highly Pathogenic Agents, also address the following points:

Any NIAID pre-approved changes in the use of the Select Agents and/or Highly Pathogenic Agents including its restricted experiments that have resulted in a change in the required biocontainment level, and any resultant change in location, if applicable, as determined by the IBC or equivalent body or official.

If work with a new or additional Select Agents and/or Highly Pathogenic Agents is proposed in the upcoming project period, provide:

- A list of the new and/or additional Agent(s) that will be studied;
- A description of the work that will be done with the Agent(s), and whether or not the work is a restricted experiment;
- The title and location for each biocontainment resource/facility, including the name of the organization that operates the facility, and the biocontainment level at which the work will be conducted, with documentation of approval by the IBC or equivalent body or official. It is important to note if the work is being done in a new location;
- Any biosafety incidents that occurred and were reported to NIH/NIAID.

SPREADSHEET SUMMARY
AWARD NUMBER: 1U19AI171110-01 REVISED

INSTITUTION: The Regents of the UCSF

Budget	Year 1
Salaries and Wages	$12,922,347
Fringe Benefits	$3,760,061
Personnel Costs (Subtotal)	$16,682,408
Consultant Services	$9,600
Equipment	$1,616,522
Materials & Supplies	$3,104,202
Travel	$2,372,584
Other	$6,101,516
Subawards/Consortium/Contractual Costs	$19,617,425
Publication Costs	$94,850
Tuition Remission	$116,244
TOTAL FEDERAL DC	$49,715,351
TOTAL FEDERAL F&A	$17,736,698
TOTAL COST	$67,452,049

Facilities and Administrative Costs	Year 1
F&A Cost Rate 1	61.5%
F&A Cost Base 1	$28,840,160
F&A Costs 1	$17,736,698

April 14, 2025

To Whom It May Concern at NIH Regarding the Cancellation of the AViDD Grant:

I am writing to appeal the decision to terminate the AViDD research grant awarded to UCSF – a decision I believe is a grave mistake, and one I urge you to reconsider. The COVID-19 pandemic exposed just how unprepared we were, resulting in over one million U.S. deaths with devastating human and economic consequences.

About me

As the former Chief Scientific Officer of Gilead Sciences and CEO of Kronos Bio, I have dedicated my career to the fight against global infectious diseases. Over my 28 years at Gilead, I focused extensively on the treatment and prevention of viral diseases, contributing to the development of therapies for HIV, Hepatitis B and C, Influenza and COVID-19. It was this same commitment that led me to accept the role of Chair of the AViDD Scientific Advisory Committee, a position I took on without any form of compensation.

About AViDD

The AViDD research initiative is a critical effort to ensure we are better prepared for the next pandemic, an event that is not a matter of if, but when. Terminating this grant would significantly undermine these efforts. It would not only diminish our pandemic preparedness, but also further weaken U.S. leadership in antiviral drug discovery at a time when other nations, particularly China, are investing aggressively and advancing rapidly in biotechnology.

The projects funded under this grant are focused on a number of viral targets and the potential benefit extends beyond Covid to other future pandemic threats. The scientific progress to date has been highly encouraging, and we maintain an active process of review and reprioritization to ensure that resources are directed toward the most promising and impactful research efforts.

The next pandemic

It is my strong belief that another pandemic is inevitable. Viruses frequently circulate in animal reservoirs, constantly mutating and, at times, gaining the ability to infect humans. HIV is thought to have originated from the African green monkey, MERS from camels, Covid from bats and recently flu from birds, and M-pox from monkeys. That's the reason why it is close to certain that we will face another viral pandemic in the future.

Given this reality, the cost of canceling the AViDD grant far outweighs any perceived savings. The funds involved are relatively modest, but the potential cost of inaction is enormous. We cannot afford to risk repeating the devastation of COVID-19 due to a lack of foresight or investment.

Sincerely,



Norbert Bischofberger, Ph.D.
Chief Executive Officer
NextQuest LLC
3 E 3rd Avenue, Suite 208
San Mateo, CA 94401

QCRG AViDD Total Amount in Dispute:

Awarded amount	$ 67,452,049.00
Invoiced	$ 60,207,252.41
Total unbilled	$ 854,701.59
Unobligated Balance	$ 6,390,095.00
Pending expenses (Subs and UCSF)	$ 4,460,865.00
Total Amount in Dispute	**$ 1,929,230.00**

Name
image002.png

Comment	Size	Modified
	26,555	



April 16, 2025

Jay Battacharya, MD, PhD, Director
jayanta.bhattacharya@nih.gov

Matthew J. Memoli, MD MS, Principal Deputy Director (former Acting Director)
memolimj@nih.hhs.gov

National Institutes of Health
1 Center Drive
Bethesda, MD 20892

By mail and email

Subject: Appeal of Grant Termination – R01HD109320

Dear Dr. Battacharya and Dr. Memoli:

I am writing to challenge the termination of NIH Grant R01HD109320 titled "*Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality*" as communicated in your notice dated March 20, 2025 signed by Michelle Bulls on behalf of Margaret Young, utilizing the first level grant appeal procedure under 45 C.F.R. § 75.374. The termination notice is attached as Exhibit A.

This abrupt decision in the middle of an awarded grant year unjustly disrupts vital research with significant public health implications and contradicts the NIH's mission to support biomedical and behavioral research that improves the health of all Americans. The rationale provided in the termination is vague and not scientifically accurate. Further, the harm is particularly acute for our small, nonprofit research organization and has implications for staff retention, obligated funds, contributions of the research, and more. The termination letter received was generic, widely disseminated, and not based on the merit of the science or progress of this project.

Issue in Dispute

1. The issue in dispute is NIH's violation of the Administrative Procedure Act by terminating the Project funding in an arbitrary and capricious manner and violating constitutional rights

Statement of Position with respect to the Issue in Dispute

Agency actions that are not "reasonable and reasonably explained" do not meet the arbitrary and capricious standard that is required under the Administrative Procedure Act ("APA"), *FCC v. Prometheus Radio Project*, 592 U.S. 414, 424 (2021). For an agency action to not be considered arbitrary and capricious, the agency must have "acted within a zone of reasonableness and, in particular, has reasonably considered the relevant issues and reasonably explained the decision." Id. "Normally, an agency rule would be arbitrary and capricious if the agency has relied on factors which Congress has not intended it to consider, entirely failed to consider an important aspect of the problem, offered an explanation for its decision that runs counter to the evidence before the agency, or is so implausible that it could not be ascribed to a difference in view or the product of agency expertise." *Motor Vehicle Mfrs. Ass'n v. State Farm Mut. Auto. Ins. Co.*, 463 U.S. 29, 43, 103 S. Ct. 2856, 2867 (1983).

The NIH's termination is unreasonable and does not explain how the agency decision was made, relies on factors that Congress has not intended it to consider, entirely fails to consider important aspects of the funded research, and offers no explanation for its decision that runs counter to any evidence.

The following pertinent facts and reasons should have been factors and aspects of the project that were considered before this agency action:

1. Alignment with NIH's Mission and Strategic Plan

The NIH has long been committed to fostering health equity, advancing scientific knowledge, and improving the well-being of all Americans. The NIH-Wide Strategic Plan for DEIA (2023–2027) explicitly recognizes the need for inclusive research to better address health disparities. Additionally, NIH's core mission is to seek fundamental knowledge that enhances health, lengthens life, and reduces illness and disability, which our project directly supports by focusing on methodological innovations to improve data quality across health topics for all Americans. This grant collects data on how we can improve the accuracy of eligibility screening for reproductive health research among all people, as well as needed epidemiological data on the reproductive health needs and preferences of understudied populations. Terminating this grant contradicts these foundational commitments and impedes efforts to ensure equitable healthcare advancements. (nih.gov)

2. Alignment with the NICHD's Strategic Plan 2025

In addition to alignment with the overall NIH's priorities, this grant specifically advances and is in close alignment with the priorities of the funding institute – the NICHD - as stated in their 2025 Strategic Plan (nichd.nih.gov). For example, this grant is designed to contribute evidence toward "Advancing Gynecologic, Andrologic, and Reproductive Health" and "Setting the Foundation for Healthy Pregnancies and Lifelong Wellness", two of the five core priorities of the 2025 Strategic Plan. By terminating this grant, the NIH precludes the collection of urgently needed data on the gynecologic, andrologic, and reproductive health needs, preferences, and experiences of all reproductive age Americans, as well as data needed to support healthy pregnancies.

3. Compliance with NIH Inclusion Policies and Research Priorities

Our grant fully complies with NIH Inclusion Policies, which mandate the participation of women, minorities, and individuals across all age groups in clinical research to ensure broad applicability of findings. Additionally, our project aligns with NIH priorities in addressing disparities in healthcare access and outcomes among underserved populations, including LGBTQ+ communities, as articulated in the NICHD 2025 Strategic Plan as follows: "Understanding the full range of social, economic, and structural factors that contribute to differences in health outcomes across various communities will inform research to develop innovative solutions to wide-ranging health problems." Termination of this grant disrupts vital progress in these areas and contradicts NIH's stated objectives. (orwh.od.nih.gov)

4. Public Health and Scientific Impact

This research is critical to improving reproductive health outcomes for all Americans, including LGBTQ+ Americans as well as cisgender and heterosexual Americans. The NIH has historically funded and supported groundbreaking research that addresses disparities and advances health equity, recognizing that research that includes diverse populations of people benefits all Americans. Termination of this grant not only halts essential research but also undermines broader national health objectives and diminishes the NIH's ability to address critical public health concerns, including care needed to support healthy pregnancies.

5. Procedural and Ethical Concerns

The termination notice did not follow the NIH's own procedures for termination and inaccurately references aspects of the policy statement that are not in effect, specifically with regard to 2 C.F.R. § 200.340. NIH policies require transparency in funding decisions, and this abrupt termination without clear, evidence-based reasoning raises concerns regarding procedural fairness. The OMB Uniform Guidance (2 CFR part 200) currently in effect allows for termination of a federal award solely under three limited conditions: (1) if the award recipient "fails to comply with the terms and conditions of a Federal award," (2) "for cause", or (3) "with the consent" of the grantee. None of these conditions apply to this award. The implementation of this grant to date has been in full compliance with the terms and the conditions of the award, and the research is in full alignment with the stated priorities of the NIH broadly, and the NICHD specifically. Nor has the awardee, our organization, provided consent for the termination. Given the significant impact of this decision, I request that NIH provide a detailed rationale, including any identified deficiencies in our adherence to NIH policies, and how they were identified or assessed. We have been informed of no such deficiencies.

6. Harms to the organization and study partners

The early termination of this award during an awarded grant year (year two of a five-year award) causes harm to our small, nonprofit research organization, and to our study partners. With the early termination of this grant in the middle of a grant year, we are suddenly left without funding to support commitments to staff salary and benefits, and subaward costs. Nor can we complete the urgently needed research that the NIH has invested $1,047,555 in over the past 22 months, leading to a

potentially significant wasted investment in research that was scored in the highest 2 percent of reviewed proposals. This score indicates the assessment of the value of the research among our peers, experts, and the broader scientific community. The $1.4 million in research funding that was committed to us in our Notice of Award for the remaining years 3-5 of the grant was an important proportion of our small, nonprofit organization's $8 million annual operating budget.

Further, termination was improper because NIH summarily terminated the Award, rather than allowing Ibis Reproductive Health an opportunity to modify the project or take other appropriate action. In addition, NIH exceeded its statutory authority, and violated constitutional rights, including the Fifth Amendment by terminating the Project funding based on an unconstitutionally vague directive.

Requested Action

I respectfully request that NIH withdraw the termination notice and reinstate funding for R01HD109320. If the termination decision is upheld, I request:

- A written justification detailing the specific reasons for termination.
- A formal hearing to present additional evidence demonstrating this project's alignment with NIH priorities.

The NIH plays a critical role in ensuring that research advances serve all Americans equitably. Reinstating this grant would reaffirm the NIH's commitment to scientific integrity, inclusion, and its mission to improve the health of all Americans.

Ibis Reproductive Health does not concede that termination was proper under 2 C.F.R. § 200.340 and does not waive any arguments and reserves its rights to include additional grounds of appeal under 45 C.F.R. § 75.374 with the Departmental Appeals Board or other tribunals.

I appreciate your prompt attention to this appeal and look forward to your response. Please confirm receipt of this appeal and advise on the next steps in the review process.

Sincerely,

Kelly Blanchard, MSc
President | Ibis Reproductive Health

kblanchard@ibisreproductivehealth.org
+1 617.349.0027

Encl: Exhibit A, Termination Notice of NIH Grant R01HD109320 dated March 20, 2025

Cc (via email): Office of the Director, NIH (odocplinquiries@od.nih.gov)

Michelle Bulls (michelle.bulls@nih.gov)

Dr. Heidi Moseson, Senior Research Scientist and Principal Investigator at Ibis Reproductive Health

National Institutes of Health
Office of Extramural Research

03/20/2025

Kelly Blanchard
IBIS REPRODUCTIVE HEALTH
kblanchard@ibisreproductivehealth.org

Dear Kelly Blanchard:

Effective with the date of this letter, funding for Project Number 5R01HD109320-02 is hereby terminated pursuant to the Fiscal Year 2024 National Institutes of Health ("NIH") Grants Policy Statement,[1] and 2 C.F.R. § 200.340(a)(2). This letter constitutes a notice of termination.[2]

The 2024 Policy Statement applies to your project because NIH approved your grant on 06/01/2024, and "obligations generally should be determined by reference to the law in effect when the grants were made."[3]

The 2024 Policy Statement "includes the terms and conditions of NIH grants and cooperative agreements and is incorporated by reference in all NIH grant and cooperative agreement awards.[4]" According to the Policy Statement, "NIH may … terminate the grant in whole or in part as outlined in 2 CFR Part 200.340.[5]" At the time your grant was issued, 2 C.F.R. § 200.340(a)(2) permitted termination "[b]y the Federal awarding agency or pass-through entity, to the greatest extent authorized by law, if an award no longer effectuates the program goals or agency priorities."

This award no longer effectuates agency priorities. Research programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans. Many such studies ignore, rather than seriously examine, biological realities. It is the policy of NIH not to prioritize these research programs. Although "NIH generally will suspend (rather than immediately terminate) a grant and allow the recipient an opportunity to take appropriate corrective action before NIH makes a termination decision,"[6] no corrective action is possible here. The premise of this award is incompatible with agency priorities, and no modification of the project could align the project with agency priorities.

---

[1] https://grants.nih.gov/grants/policy/nihgps/nihgps.pdf.
[2] 2 C.F.R. § 200.341(a); 45 C.F.R. § 75.373
[3] *Bennett v. New Jersey*, 470 U.S. 632, 638 (1985).
[4] 2024 Policy Statement at IIA-1.
[5] *Id.* at IIA-155.
[6] 2024 Policy Statement at IIA-156.

Costs resulting from financial obligations incurred after termination are not allowable.[7] Nothing in this notice excuses either NIH or you from complying with the closeout obligations imposed by 2 C.F.R. §§ 75.381-75.390. NIH will provide any information required by the Federal Funding Accountability and Transparency Act or the Office of Management and Budget's regulations to *USAspending.gov*.[8]

Administrative Appeal

You may object and provide information and documentation challenging this termination.[9] NIH has established a first-level grant appeal procedure that must be exhausted before you may file an appeal with the Departmental Appeals Board.[10]

You must submit a request for such review to Dr. Matt Memoli no later than 30 days after the written notification of the determination is received, except that if you show good cause why an extension of time should be granted, Dr. Memoli may grant an extension of time.[11]

The request for review must include a copy of the adverse determination, must identify the issue(s) in dispute, and must contain a full statement of your position with respect to such issue(s) and the pertinent facts and reasons in support of your position. In addition to the required written statement, you shall provide copies of any documents supporting your claim.[12]

Sincerely,

Michelle G. Bulls -S Digitally signed by Michelle G Bulls -S
Date: 2025.03.20 16:30:00 -04'00'

Michelle G. Bulls, on behalf of Margaret Young, Chief Grants Management Officer,
National Institute of Child Health & Human Development
Director, Office of Policy for Extramural Research Administration
Office of Extramural Research

---

[7] *See* 2 C.F.R. § 200.343 (2024).
[8] 2 C.F.R. § 200.341(c); 45 C.F.R. § 75.373(c)
[9] *See* 45 C.F.R. § 75.374.
[10] See 42 C.F.R. Part 50, Subpart D
[11] 11 *Id.* § 50.406(a)
[12] 12 *Id.* § 50.406(b)

April 18, 2025

Matthew J. Memoli, M.D, M.S.
Principal Deputy Director
National Institutes of Health (NIH)
The U.S. Department of Health and Human Services (HHS)
9000 Rockville Pike
Bethesda, MD 20892
Matthew.Memoli@nih.gov
NIHExecSec@nih.gov

Re: First Level Administrative Appeal

Dear Dr. Memoli,

I am writing to formally appeal the termination of NIH Grant 5R01MD015256-05 (the "Project"), as communicated in the attached NIH notice dated March 21, 2025.

Issues in Dispute

The termination is solely based on the conclusory finding that the award no longer effectuates agency priorities without further detail or explanation. Termination of this award disrupts vital research with significant public health implications and contradicts the NIH's mission to support biomedical and behavioral research that improves the health of all Americans.

NIH cites grounds for termination that refer to HHS regulations that will not become effective until October 2025. However, even if NIH had authority to terminate for the reason stated in its notice – i.e., the award no longer effectuates agency priorities -- the termination notice did not provide sufficient justification outlining how this research fails to meet NIH's rigorous funding criteria. NIH policies require transparency in funding decisions, and this termination without clear, evidence-based reasoning raises concerns regarding procedural fairness. Further, our study has already incurred expenditures of approximately $3,170,850. Early termination of this study undermines the investment NIH has already made in this work.

Requested Action

I respectfully request that NIH reconsider its decision and reinstate funding for Project Number 5R01MD015256-05.

If NIH does not do so, and given the significant impact of the termination decision, I respectfully request that NIH provide a detailed rationale for its termination decision, including any identified deficiencies in our adherence to NIH policies, to allow for a fair and evidence-based review.

I also respectfully request an opportunity to take appropriate corrective action, such as modification to the scope of the Project, to cure any identified deficiencies in accordance with NIH's 2024 Grants Policy Statement (GPS), § 8.5.2.

In tandem with this appeal, we are working through federal award closeout procedures for the Project, including financial and progress reporting requirements, and are doing so only due to and only as required by the Termination Notice. *See* Termination Notice at page 2; *see* NIH GPS (2024), § 8.6. Notwithstanding, we preserve all legal and equitable remedies to appeal the Termination Notice and, if such appeal ultimately is successful, or if any applicable court order invalidates the termination, to continue carrying out the award in accordance with the then-current Notice of Award and NIH-approved Project plan.

I appreciate your prompt attention to this appeal and look forward to your response. Please confirm receipt of this appeal and advise on the next steps in the review process.

Sincerely,

DocuSigned by:
Cary Williams
3337A8319694424...

Cary Williams
Director, Office of Sponsored Programs
Harvard Pilgrim Health Care, Inc.
Research_admin@point32health.org

Cc: Michelle Bulls

Enclosure

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

www.nih.gov

May 27, 2025

Ms. Amanda Amescua
Icahn School of Medicine at Mount Sinai
grants@mssm.edu

Dear Ms. Amanda Amescua:

On April 10 2025, the National Institutes of Health (NIH) terminated your project entitled "NIH FIRST Cohort Cluster Hiring Initiative at Icahn School of Medicine at Mount Sinai" under grant U54CA267776-04 to Icahn School of Medicine at Mount Sinai.

NIH terminated the project on the grounds that the research activities do not align with the agency's priorities. You have submitted an appeal requesting NIH to reconsider its award action. As such, NIH has conducted a careful assessment of your request for reconsideration of the determination, and have identified the following:

The program that supported this award was terminated because it no longer aligned with NIH/HHS priorities. Consequently, awards made through this program can no longer be supported and the request for reinstatement cannot be granted. NIH encourages the awardee to submit a new application that aligns with NIH's priorities under one of NIH's active NOFOs.

We appreciate your patience while we reassessed this matter.

Sincerely,

Matthew J. Memoli, M.D., M.S.
Principal Deputy Director, NIH

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

www.nih.gov

May 27, 2025

Ms. Pamela Caudill
Yale University
pamela.caudill@yale.edu

Dear Ms. Pamela Caudill:

On April 7 2025, the National Institutes of Health (NIH) terminated your project entitled "ComPASS Health Equity Research Hub at Yale" under grant UC2CA293786-01 to Yale University.

NIH terminated the project on the grounds that the research activities do not align with the agency's priorities. You have submitted an appeal requesting NIH to reconsider its award action. As such, NIH has conducted a careful assessment of your request for reconsideration of the determination, and have identified the following:

The program that supported this award (ComPASS) was terminated because it no longer aligned with NIH/HHS priorities. Consequently, awards made through this program can no longer be supported and the request for reinstatement cannot be granted. NIH encourages the awardee to submit a new application that aligns with NIH's priorities under one of NIH's active NOFOs.

We appreciate your patience while we reassessed this matter.

Sincerely,

Matthew J. Memoli, M.D., M.S.
Principal Deputy Director, NIH

KEY: RED = APPEALS
GREEN = WILL BE REINSTATED
BLUE = NON-GRANTS

LAST UPDATED 6.10.25

Grant Number	Date of Appeal Submission	Category of Termination	
1R61HD117134-01	4/11/2025	Gender Identity	
R01DA054236	4/9/2025	Gender Identity	
R01HD115551	01 - 4/18/25	Gender Identity	
5R01MD015256-05	4/18/2025	DEI	
5R01MD015256-05S1	SI 4/18/2025	DEI	
5R01HD109320-02	4/16/2025	Gender Identity	
3R01HD109320-02S1			
5R01MD016384-03			
5R21MD018509-02			
1R15AA030898-01A1			
1R34AA030662-01A1			
1R21MH136855-01	4/18/2025	Gender Identity	
5R33TW011665-06	4/18/2025	DEI	
3U24MD017250-04S1			
5T32MH019139-35			
3U01MD019398-03S1			
3U01MD019398-03S2			
3U01MD019398-03S3	4/16/2025	DEI	
1R01MD020284-01			
3R01AA029076-04S1	4/18/2025	Gender Identity	
5R01AA029076-04	4/18/2025	Gender Identity	
5R01AA030017	4/18/2025	Gender Identity	
1R01AA031637-01A1	4/15/2025	Gender Identity	
1T32DA057926-01A1	4/17/2025	DEI	
1R01DA059240-01A1	4/18/2025	DEI -	WILL BE RESINTATATED
R01DA059480-01A1			
1R01DA060066-01			
1R01DA061661-01	4/16/2025	Gender Identity	
R21DA062591	4/15/2025	DEI	
3R01AG063771-05S1			
5R01AG063771-05			
3R01AG077934-03S1	4/9/2025	DEI	
R34MH126894			
5R01MH128049-04			
5R34MH129208-03	4/15/2025	DEI	
3R24NS132283-01S1			
1R24NS132283-01	3/24/2025	DEI	
1RF1MH132360-01	4/9/2025	Vaccine Hesitancy	
5K23DK139454-02	4/3/2025	DEI	
5T32GM141862-04			
1R01GM155395-01	4/17/2025	DEI	
1K99GM155594-01			
1U19AI171110-01	4/22/2025	COVID-19	
5K99NS129753-02			
F31GM151838-02			
1F31DA060046-01			
U54DA060049-02			
1R24DA061190-01			
1F31DA061593-01	6/4/2025	DEI	
1K99DA062328-01			
8K00DA062570-02			
R01AG073440-03	4/18/2025	Gender Identity	
R01HD105655-04S1	5/29/2025	DEI	
5K12GM106996-09			
5U01HD108738-03	4/16/2025	DEI	WILL BE RESINTATATED
R21HD109536	4/8/2025	Vaccine Hesitancy	
1R01HD110428-01A1			
1R01HD115985-01			
R25HD116367			
3P30AI117943-10S1	3/17/2025	DEI	
5R01MH118245-05			
5R01MH121194-04	4/11/2025	DEI	
5K99NS126639/R00NS126639			
5R25MH126703-05			
5T32MH126772-04	4/11/2025	DEI	
5R21MH128114-02			
5R01MH128130-04			
3R01MH128729-03S2			
7R01MH129175-03	4/18/2025	Gender Identity	
R34MH129187			
5R34MH129189-03			
5R01MH130375-02	4/16/2025	DEI	
5R01MH132415	4/8/2025	Vaccine Hesitancy	
5R01MH133543-02	4/17/2025	Gender Identity	
4R00DK133804			
1K23MH134111-01			
1F31MH134720-01A1	4/15/2025	DEI	
1R21DK134815-01A1	5/27/2025	DEI	

1R34MH134912-01A1			
5K99MH135061-02			
3R01DK135099-02S1			
R36MH135619			
5F32MH135634-02			
R01MH135738			
5F99NS135767-02			
1K99MH135993-01			
1R21DK136084-01A1			
1F31MH136729-01A1	4/16/2025	DEI	
5U01DK137259-02	5/28/2025	DEI	
1U01DK137262			
5U01DK137269-02	5/28/2025	DEI	
K23MH137389-01	4/21/2025	Gender Identity	
1R01MH137695-01	4/18/2025	Gender Identity	
1R34MH137753-01	4/17/2025	Gender Identity	
1R01MH140023-01	4/18/2025	DEI	
5R00GM140269-04	4/30/2025	DEI*	UPHELD
1K99DK140511-01			
5T34GM141986-04			
5K99GM146016/4R00GM146016-03			
K99GM146243-01			
5K99GM148819-02			
5R01HL149778-05			
K99GM151467-02			
K99GM151473			
5K99GM152834-02/4R00GM152834-03			
5K99GM152835-02			
K99GM154061			
3R01AI155739-04S1			
1K99GM157463-01			
K99GM157504			
1K99GM159354-01A1			
3P01AI165075-01S1			
5K99HL169908-02			
5K99AI173544-02	5/30/2025	DEI	
1K99HL173668-01			
R01CA237670	4/17/2025	Gender Identity	
1U54CA267730-01			
5U54CA267776-04	5/7/2025	DEI	UPHELD
1UC2CA293786	5/7/2025	DEI	UPHELD
1R01HG013145-01			
5R01MD013495-05			
5R01MD016864-03			
4R00MD016964-03	5/28/2025	DEI	
P50MD017349	4/18/2025	DEI	
5R01MD017364-03			
1K99MD018451-01A1			
R01MD018523	4/14/2025	DEI	
5K99MD019060	4/17/2025	Gender Identity	
1K99MD019292-01			
R21MD019345-01A1			
1P50MD019475-01	4/11/2025	DEI	
1R21MD019829-01	4/1/2025	Gender Identity	
1F31MD019996-01			
1F31MD020261-01			
5R01NR020309-04	4/16/2025	Gender Identity	
5K99DC020570-02/4R00DC020570-03			
5R01NR020846-02	4/9/2025	Gender Identity	
1U24NR021014-02			
5R01AA029044-04	4/18/2025	DEI	
4R00AA030601-03			
1F31AA031420-01A1	4/16/2025	Gender Identity	
1K99EB036553-01			
5U01DA036939-10	4/17/2025	DEI	
3P30AI050409-26S1			
R03DA052651			
3R01DA055673-03S1	5/2/2025	DEI - Upheld	
R01DA056235	4/10/2025	Gender Identity	
5R01DA056287-02			
5R01DA056888-03			
5R01DA058642-02	4/2/2025	Gender Identity	
5R01MD012793-05			
3R01MD015165-04S1			
5T32MH020004			
1R01NR020583-01			
R01NR021098			
1F31NR021239-01			
R00AA028049	4/18/2025	Gender Identity	

T32DA031099-13			
1K01DE033040-01A1			
U01OD033248			
5UM1AI068619-19			
1K23HD112599-01A1	4/9/2025	Vaccine Hesitancy	
1R21HD116080-01	4/18/2025	Gender Identity	
R01MH130007			
5K99MH133994-02			
1R36MH135609-01			
5K99NS135649-02			
5K99GM144750-02			
5K99GM148723-02			
1R15GM152943-01			
5K99GM153720-02			
1K99GM154060-01			
1K99GM157508-01			
5K99HL166700-02			
5P01AI168148-02			
1U19AI171401-01	4/4/2025	COVID-19	
R01CA251478			
R34CA283483-02	4/30/2025	Vaccine Hesitancy	
5K99MD018629-02			
5R24AG066599-03	3/27/2025	Gender Identity	
2T32GM135742-06	5/22/2025	DEI	
5R01MD018250-03			
5R01CA274564-03			
OT2OD035659-01	4/7/2025	DEI	UPHELD
3OT2OD035592			

Grant Number	Category	OPERA Notes	Documents Provided
1F31AA031420-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1F31DA060046-01	IC Type 5 early termination		NOA
1F31DA061593-01	IC Type 5 early termination	NOFO unpublished	NOA
1F31MD019996-01	IC Type 5 early termination		NOA
1F31MD020261-01	IC Type 5 early termination		NOA
1F31MH134720-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1F31MH136729-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1F31NR021239-01	OPERA effectuated via OD or termination via letter	Columbia	NOA
1K01DE033040-01A1	Active pending termination	NOFO unpublished	N/A
1K23HD112599-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/10/2025	Letter. NOA.
1K23MH134111-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1K99DA062328-01	Active pending termination	NOFO unpublished	N/A
1K99DK140511-01	Active pending termination	NOFO unpublished	N/A
1K99EB036553-01	IC Type 5 early termination		NOA
1K99GM154060-01	Active pending termination		N/A
1K99GM155594-01	Active pending termination	NOFO unpublished	N/A
1K99GM157463-01	ActivePending Termination	NOFO unpublished	N/A
1K99GM157508-01	Active pending termination		N/A
1K99GM159354-01A1	ActivePending Termination	NOFO unpublished	N/A
1K99HL173668-01	Active pending termination	NOFO unpublished	N/A
1K99MD018451-01A1	Active pending termination	NOFO unpublished	N/A
1K99MD019292-01	IC Type 5 early termination		NOA
1K99MH135993-01	Active pending termination	NOFO unpublished	N/A
1P50MD019475-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01AA031637-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01DA059240-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01DA060066-01	IC Type 5 early termination		NOA
1R01DA061661-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01GM155395-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01HD110428-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/10/2025	Letter. NOA.
1R01HD115551-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01HD115985-01	IC Type 5 early termination	NOFO unpublished	NOA
1R01HG013145-01	OPERA effectuated via OD or termination via letter	HHS 3/13/2025	Letter. NOA.
1R01MD020284-01	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
1R01MH137695-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01MH140023-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R01NR020583-01	OPERA effectuated via OD or termination via letter	Columbia	NOA
1R15AA030898-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R15GM152943-01	OPERA effectuated via OD or termination via letter	HHS List 3/10/2025	Letter. NOA.
1R21DA062591-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R21DK134815-01A1	IC Type 5 early termination		NOA
1R21DK136084-01A1	IC Type 5 early termination		NOA
1R21HD116080-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R21MD019829-01	OPERA effectuated via OD or termination via letter	HHS 3/13/2025	Letter. NOA.
1R21MH136855-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025.	Letter. NOA.
1R24DA061190-01	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
1R24NS132283-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R34AA030662-01A1	Active - Reinstated.	HHS List 3/13/2025. Terminated 3/26. Reinstated 5/6.	Termination letter. Termination NOA. Reinstatement NOA.
1R34MH134912-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R34MH137753-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1R36MH135609-01	IC Type 5 early termination		NOA
1R61HD117134-01	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
1RF1MH132360-01	OPERA effectuated via OD or termination via letter	HHS List 3/10/2025	Letter. NOA.
1T32DA057926-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
1U01DK137262	IC Type 5 early termination		NOA
1U19AI171110-01	OPERA effectuated via OD or termination via letter	HHS List 3/24/2025	Letter. NOA.
1U19AI171401-01	Active - Reinstated.	HHS List 3/24/2025	Letter. NOAs
1U24NR021014-02	OPERA effectuated via OD or termination via letter	COMPASS	Letter. NOA.
1U54CA267730-01	OPERA effectuated via OD or termination via letter	FIRST Program	Letter. NOA.
1UC2CA293786	OPERA effectuated via OD or termination via letter	COMPASS	Letter. NOA.
2T32GM135742-06	IC Type 5 early termination		NOA
3OT2OD035592	OPERA effectuated via OD or termination via letter	COMPASS	Letter. NOA.
3P01AI165075-01S1	Not Active - Project Period Ended	Project ended 12/31/24	
3P30AI050409-26S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
3P30AI117943-10S1	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
3R01AA029076-04S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
3R01AG063771-05S1	OPERA effectuated via OD or termination via letter	HHS List 2/28/2025	Letter. NOA.
3R01AG077934-03S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
3R01AI155739-04S1	IC Type 5 early termination	Diversity Supplement	NOA
3R01DA055673-03S1	IC Type 5 early termination		NOA
3R01DK135099-02S1	IC Type 5 early termination	Diversity Supplement	NOA
3R01HD109320-02S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	See letter for parent grant. NOA.
3R01MD015165-04S1	IC Type 5 early termination		NOA
3R01MH128729-03S2	IC Type 5 early termination	Diversity Supplement	NOA
3R24NS132283-01S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
3U01MD019398-03S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
3U01MD019398-03S2	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
3U01MD019398-03S3	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
3U24MD017250-04S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025.	Letter. NOA.
4R00AA030601-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
4R00DK133804	Active pending termination	NOFO unpublished	N/A
4R00MD016964-03	IC Type 5 early termination		NOA
5F32MH135634-02	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
5F99NS135767-02	Active pending termination	NOFO unpublished	N/A
5K12GM106996-09	Active pending termination	NOFO unpublished	N/A
5K23DK139454-02	IC Type 5 early termination		NOA
5K99AI173544-02	IC Type 5 early termination		NOA
5K99DC020570-02/4R00DC020570-03	Active pending termination	NOFO unpublished	N/A

5K99GM144750-02	Active pending termination	NOFO unpublished	N/A
5K99GM146016/4R00GM146016-03	Active pending termination	NOFO unpublished	N/A
5K99GM148723-02	Active pending termination	NOFO unpublished	N/A
5K99GM148819-02	Active pending termination	NOFO unpublished	N/A
5K99GM152834-02/4R00GM152834-03	Active pending termination	NOFO unpublished	N/A
5K99GM152835-02	Active pending termination	NOFO unpublished	N/A
5K99GM153720-02	Active pending termination	NOFO unpublished	N/A
5K99HL166700-02	Active pending termination	NOFO unpublished	N/A
5K99HL169908-02	Active pending termination	NOFO unpublished	N/A
5K99MD018629-02	IC Type 5 early termination		NOA
5K99MD019060	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5K99MH133994-02	ActivePending Termination	NOFO unpublished	N/A
5K99MH135061-02	Active pending termination	NOFO unpublished	N/A
5K99NS126639/R00NS126639	Active pending termination	NOFO unpublished	N/A
5K99NS129753-02	Active pending termination	NOFO unpublished	N/A
5K99NS135649-02	Active pending termination	NOFO unpublished	N/A
5P01AI168148-02	Active	Year 2 ended 4/30/2025. Year 3 is pending.	N/A
5R00GM140269-04	Active pending termination	NOFO unpublished	N/A
5R01AA029044-04	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01AA029076-04	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01AA030017	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01AG063771-05	OPERA effectuated via OD or termination via letter	HHS List 2/28/2025	Letter. NOA.
5R01CA274564-03	OPERA effectuated via OD or termination via letter	Columbia	NOA
5R01DA054236-04	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
5R01DA056287-02	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01DA056888-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01DA058642-02	OPERA effectuated via OD or termination via letter	HHS List 3/11/2025	Letter. NOA.
5R01HD109320-02	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01HL149778-05	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter
5R01MD012793-05	OPERA effectuated via OD or termination via letter	HHS List 2/28/2025	Letter. NOA.
5R01MD013495-05	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01MD015256-05	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01MD015256-05S1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01MD016384-03	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
5R01MD016864-03	OPERA effectuated via OD or termination via letter	HHS List 3/31/2025	Letter. NOA.
5R01MD017364-03	OPERA effectuated via OD or termination via letter	HHS List 3/31/2025	Letter. NOA.
5R01MD018250-03	OPERA effectuated via OD or termination via letter	Columbia	NOA
5R01MH118245-05	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01MH121194-04	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
5R01MH128049-04	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01MH128130-04	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01MH130375-02	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01MH132415	OPERA effectuated via OD or termination via letter	HHS List 3/10/2025	Letter. NOA.
5R01MH133543-02	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01NR020309-04	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R01NR020846-02	OPERA effectuated via OD or termination via letter	HHS List 3/11/2025	Letter. NOA.
5R21MD018509-02	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
5R21MH128114-02	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R24AG066599-03	OPERA effectuated via OD or termination via letter	HHS List 2/28/2025	Letter. NOA.
5R25MH126703-05	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R33TW011665-06	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025.	Letter. NOA.
5R34MH126894-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R34MH129189-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5R34MH129208-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5T32GM141862-04	IC Type 5 early termination		NOA
5T32MH019139-35	OPERA effectuated via OD or termination via letter	Columbia	Letter. NOA.
5T32MH020004	OPERA effectuated via OD or termination via letter	Columbia	NOA
5T32MH126772-04	OPERA effectuated via OD or termination via letter	HHS List 3/12/2025	Letter. NOA.
5T34GM141986-04	Active pending termination	NOFO unpublished	N/A
5U01DA036939-10	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5U01DK137259-02	IC Type 5 early termination		NOA
5U01DK137269-02	IC Type 5 early termination		NOA
5U01HD108738-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
5U54CA267776-04	OPERA effectuated via OD or termination via letter	FIRST Program	Letter. NOA.
5UM1AI068619-19	Active	Award was renegotiated	NOA with renegotiation terms
7R01MH129175-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
8K00DA062570-02	IC Type 5 early termination	NOFO unpublished	NOA
F31GM151838-02	IC Type 5 early termination		NOA
K23MH137389-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
K99GM146243-01	OPERA effectuated via OD or termination via letter	Harvard	NOA
K99GM151467-02	Active pending termination	NOFO unpublished	N/A
K99GM151473	Active pending termination	NOFO unpublished	N/A
K99GM154061	IC Type 5 early termination		NOA
K99GM157504	Active pending termination	NOFO unpublished	N/A
OT2OD035659-01	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
P50MD017349	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R00AA028049	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R01AG073440-03	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R01CA237670	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R01CA251478	Active	Award issued with term stating no DEI activities.	NOA
R01DA056235	OPERA effectuated via OD or termination via letter	HHS List 3/13/25	Letter. NOA.
R01DA059480-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R01HD105655-04S1	IC Type 5 early termination	Diversity Supplement	NOA
R01MD018523	OPERA effectuated via OD or termination via letter	HHS List 3/13/25	Letter. NOA.
R01MH130007	IC Type 5 early termination	Diversity Supplement	NOAs for 2 supplements.
R01MH135738	Active	Year 1 ended 3/31/2025. Year 2 pending in 'to be paid' status. South Africa.	N/A
R01NR021098	Active pending termination	Harvard. NOA not yet issued.	N/A

R03DA052651	OPERA effectuated via OD or termination via letter	HHS List 3/13/25	Letter. NOA.
R21HD109536	OPERA effectuated via OD or termination via letter	HHS List 3/10/2025	Letter. NOA.
R21MD019345-01A1	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R25HD116367	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R34CA283483-02	OPERA effectuated via OD or termination via letter	HHS List 3/31/2025	Letter. NOA.
R34MH129187	OPERA effectuated via OD or termination via letter	HHS List 3/13/2025	Letter. NOA.
R36MH135619	IC Type 5 early termination	NOFO unpublished	NOA
T32DA031099-13	OPERA effectuated via OD or termination via letter	Columbia. NOA not issued.	
U01OD033248	OPERA effectuated via OD or termination via letter	Award transferred to MH in 2021. 5U01MH136558-03.	NOA. Letter
U54DA060049-02	OPERA effectuated via OD or termination via letter	HHS List 3/13	Letter. NOA.

6 PAYMENT

The PMS is a centralized grants payment and cash management system, operated by HHS PSC, PMS. HHS grant payments may be made by one of several advance payment methods, including SMARTLINK II/ACH, cash request, or by cash request on a reimbursement basis, as specified in the NoA and as described in this chapter. Payments under NIH grants generally are made as advance payments. NIH grant payments are made by PMS, operated by PSC, in accordance with Department of the Treasury and OMB requirements, as implemented by 2 CFR Part 200.305. These requirements are intended to minimize the time elapsing between the transfer of funds from the Federal government and disbursement by a recipient. Therefore, although the grant may be financed by advance payments, the intent is that recipients draw funds on an as-needed basis—specifically, no more than 3 business days before the funds are needed.

All Federal funds deposited by PMS in a recipient's bank account as an unrestricted advance payment should be fully disbursed (checks written, signed, and issued to the payees) by the close of business the next workday after receipt of the funds. The potential for excessive Federal cash on hand exists each time a recipient does not disburse Federal funds in this manner. The recipient is responsible for determining when the Federal funds have been deposited into its bank account for each drawdown, ensuring that the funds are fully disbursed by the close of business the next workday after they are received, and immediately returning all undisbursed Federal funds to PMS.

The Treasury and OMB policies also establish accountability for interest earned on advances of grant funds and provide for use of the reimbursement method if cash management requirements are not met. Advances made by recipients to consortium participants and contractors under grants must conform to substantially the same standards of timing and amount that govern advances to the recipient.

Operational guidance for recipients is provided through a training CD from PSC. Inquiries regarding drawdown requests, cash management rules, and the disbursement of funds through the Federal Financial Report (SF 425) should be directed to PSC/PMS (see Part III).

6.1 SMARTLINK II/ACH

The SMARTLINK II/ACH method of advance payment makes direct deposit of funds to a recipient's bank account and requires recipients to have Internet access to submit a request for funds to PMS. SMARTLINK II/ACH provides funds the day following the request with direct deposit using the Federal Reserve Bank's (Richmond, Virginia) ACH process.

6.2 CASH REQUEST

Recipients not eligible for an unrestricted advance of funds by SMARTLINK II/ACH must submit a cash request, usually monthly. The cash request may be on either an advance or reimbursement basis, as specified by the NIH awarding IC. Cash requests are used when a recipient's cash management must be closely monitored (for example, recipients whose financial management systems do not meet the standards specified in 2 CFR Part 200.302) or under programs where reimbursement financing is appropriate. A recipient also may be converted from an unrestricted advance payment method to a cash request basis if, during post-award administration, the GMO determines that a recipient is not complying with the cash management requirements or other requirements of the award, including the submission of complete and timely reports (see Administrative Requirements—Monitoring—Reporting and Administrative Requirements—Enforcement Actions—Modification of the Terms of Award).

If the cash request is for an advance payment, the recipient may request grant funds from PMS monthly on the basis of expected disbursements during the succeeding month and the amount of Federal funds already on hand. A request for reimbursement may be submitted more often, if authorized. For timely receipt of cash, a recipient must submit the request through the awarding IC early enough for it to be forwarded to PMS at least 2 weeks before the cash is needed. PMS makes payment to the recipient electronically through the ACH process upon receipt of the approved payment request from the awarding IC.

6.3 INTEREST EARNED ON ADVANCES OF GRANT FUNDS

Except as provided in 2 CFR Part 200.305(b)(8), any NIH recipient subject to the requirements of 2 CFR Part 200 that receives advance payments must maintain those advances in an interest-bearing account.

Recipients are expected to promptly return any funds not spent within three business days. As provided in 2 CFR Part 200.305(b)(9) subject to the requirements of 2 CFR Part 200 and to the extent required by law, interest earned on Federal advance payments deposited in interest-bearing accounts must be remitted annually to the Department of Health and Human Services, Payment Management System, Rockville, MD 20852. Interest amounts up to $500 per year may be retained by the non-Federal entity for administrative expense.

6.4 IMPROPER PAYMENTS ELIMINATION AND RECOVERY IMPROVEMENT ACT

The Improper Payments Elimination and Recovery Improvement Act of 2012 (IPERIA) (PL 112-248), signed into law on January 10, 2013, established the Do Not Pay Initiative to reduce improper payments or awards. Improper payments occur when funds go to the wrong recipient, the recipient receives the incorrect amount of funds (including overpayments and underpayments), documentation is not available to support a payment, or the recipient uses funds in an improper manner. Incorrect amounts are overpayments or underpayments that are made to eligible recipients (including inappropriate denials of payment or service, any payment that does not account for credit for applicable discounts, payments that are for an incorrect amount, and duplicate payments). When an agency's review is unable to discern whether a payment was proper as a result of insufficient or lack of documentation, this payment should also be considered an improper payment. When establishing documentation requirements for payments, agencies should ensure that all documentation requirements are necessary and should refrain from imposing additional burdensome documentation requirements. Interest or other fees that may result from an underpayment by an agency are not considered an improper payment if the interest was paid correctly. These payments are generally separate transactions and may be necessary under certain statutory, contractual, administrative, or other legally applicable requirements.

HHS has implemented provisions of IPERIA through integrating use of the Do Not Pay system into the current payment processes managed by the PMS, HHS.

- ***Reasonableness (Including Necessity).*** A cost may be considered reasonable if the nature of the goods or services acquired or applied and the associated dollar amount reflect the action that a prudent person would have taken under the circumstances prevailing when the decision to incur the cost was made. The cost principles elaborate on this concept and address considerations such as whether the cost is of a type generally necessary for the organization's operations or the grant's performance, whether the recipient complied with its established organizational policies in incurring the cost or charge, and whether the individuals responsible for the expenditure acted with due prudence in carrying out their responsibilities to the Federal government and the public at large as well as to the organization.
- ***Allocability.*** A cost is allocable to a specific grant, function, department, or other component, known as a cost objective, if the goods or services involved are chargeable or assignable to that cost objective in accordance with the relative benefits received or other equitable relationship. A cost is allocable to a grant if it is incurred solely in order to advance work under the grant; it benefits both the grant and other work of the institution, including other grant-supported projects; or it is necessary to the overall operation of the organization and is deemed to be assignable, at least in part, to the grant. A cost is allocable as a direct cost to a grant if it is incurred solely in order to advance work under the grant or meets the criteria for closely related projects determination (see Cost Considerations—Allocation of Costs and Closely Related Work).
- ***Consistency.*** Recipients must be consistent in assigning costs to cost objectives. Costs may be charged as either direct costs or F&A costs, depending on their identifiable benefit to a particular project or program, but all costs must be treated consistently for all work of the organization under similar circumstances, regardless of the source of funding.
- ***Conformance.*** This test of allowability—conformance with limitations and exclusions as contained in the terms and conditions of award, including those in the cost principles—varies by the type of activity, the type of recipient, and other characteristics of individual awards. Cost Considerations—Allowability of Costs/Activities provides information common to most NIH grants and, where appropriate, specifies some of the distinctions if there is a different treatment based on the type of grant or recipient. IIB contains additional information on allowability of costs for particular types of grants, recipients, and activities.

These four tests apply regardless of whether the particular category of costs is one specified in the cost principles or one governed by other terms and conditions of an award. These tests also apply regardless of treatment as a direct cost or an F&A cost. The fact that a proposed cost is awarded as requested by an applicant does not indicate a determination of allowability.

7.3 DIRECT COSTS AND FACILITIES AND ADMINISTRATIVE COSTS

Direct costs are any cost that can be identified specifically with a particular sponsored project, an instructional activity, or any other institutional activity, or that can be directly assigned (allocated) to such activities relatively easily with a high degree of accuracy. Direct costs may include, but are not limited to, salaries, travel, equipment, and supplies directly supporting or benefiting the grant-supported project or activity. If directly related to a specific award, certain costs that otherwise would be treated as indirect costs may also be considered direct costs.

Most organizations also incur costs for common or joint objectives that cannot be readily identified with an individual project or program. These are referred to as indirect costs, also called Facilities and Administrative costs (F&A). Facilities operation and maintenance costs, depreciation, and administrative

expenses are examples of costs that usually are treated as F&A costs. The organization is responsible for the management and accounting of costs consistently and must not include costs associated with its F&A rate as direct costs. Note, the term facilities and administrative costs and the term indirect costs may be used interchangeably to determine applicable policies. For NIH purposes, including the NIHGPS, these costs will be referred to as F&A costs; however, other documents or non-NIH entities may refer to them as indirect costs.

Project costs consist of the allowable direct costs directly related to the performance of the grant plus the allocable portion of the allowable F&A costs of the organization, less applicable credits (as described below and in the cost principles).

The amount NIH awards for each budget period will reflect the total approved budget for the grant, including direct costs and, if applicable, F&A costs. (SBIR and STTR awards also may include a fee as specified in Grants to For-Profit Organizations—Small Business Innovation Research and Small Business Technology Transfer Programs in IIB.) If a recipient waives reimbursement of full F&A costs, NIH will either not award F&A costs or will award only partial F&A costs, as appropriate. The NIH award amount shown in the NoA constitutes NIH's maximum financial obligation to the recipient under that award.

7.4 REIMBURSEMENT OF FACILITIES AND ADMINISTRATIVE COSTS

For grant programs that can provide F&A cost reimbursement, NIH will generally not provide F&A costs unless the recipient has established an F&A cost rate covering the applicable activities and period of time, except for awards under which F&A costs are reimbursed at a fixed rate.

In addition, NIH will not require a recipient to establish an F&A rate if the organization's total operations consist of a single grant-supported project or if the organization appropriately and consistently treats all costs as direct costs to projects and accounts for them as such. In the latter case, the GMO must be satisfied that the organization's accounting system can adequately identify and support all costs as direct costs to the project. This includes being able to identify and segregate costs on the basis of a process that assigns costs commensurate with the benefits provided to individual projects (see Administrative Requirements—Management Systems and Procedures—Financial Management System Standards).

F&A rates are negotiated by CAS, DFAS in the Office of Acquisition Management and Policy, NIH (responsible for negotiating F&A cost rates for for-profit entities receiving awards from HHS), or other agency with cognizance for F&A/indirect cost rate (and other special rate) negotiation. If an applicant is advised by the GMO of the need to establish a rate, the GMO will indicate the responsible office to be contacted.

F&A cost proposals must be prepared in accordance with the applicable cost principles and guidance provided by the cognizant office or agency for indirect costs and must conform to cost policies in the NIHGPS. Further information concerning the establishment of F&A rates and the reimbursement of F&A costs may be obtained from DCA or DFAS (see Part III). CAS should be consulted to determine the need to submit a Disclosure Statement (DS-2) pursuant to the requirements of 2 CFR Part 200, Subpart E-Cost Principles.

Consistent with 2 CFR Part 200.414(f), any non-Federal entity, including for-profit organizations, that does not have a current negotiated (including provisional) F&A rate, except for those non-Federal entities described in 2 CFR Part 200, Appendix VII, Section D(1)(b) and 45 CFR Part 75, Appendix VII may elect to charge a de minimis rate of 10% of modified total direct costs (MTDC) which may be used indefinitely. No documentation is required to justify the 10% de minimis indirect cost rate. As described in 2

PDF COPY OF NIH_GRANTS_001959
NATIVE FILE PROVIDED TO COURT

	A	B	E	H	I
1					
2		Sex Hormones and Identity affect Nociceptive Expression (SHINE)	3R01NR019417-03S1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$50,000
3	Project SummaryThe COVID-19 pandemic and the co-occurrin	Unequal Parenthoods: Population Perspectives on Gender Race and Sexual Minority Disparities in Family Stress and Health During Crises	5U01HD108779-04	UNIVERSITY OF MINNESOTA	$225,000
4	PROJECT SUMMARYThis project seeks to use real-time geospat	Impact of Social Cohesion and Social Capital in PrEP Uptake and Adherence Among Transwomen of Color	5R01MD013554-05	COLUMBIA UNIVERSITY HEALTH SCIENCES	$507,062
5	PROJECT SUMMARYThe goal of the proposed research is to dev	Measures of structural stigmatization and discrimination for HIV research with Latine sexual and gender minorities	1R01MD020284-01	DREXEL UNIVERSITY	$812,946
6	PROJECT SUMMARY/ABSTRACTDisparities continue to persist	Exploring Stigma Social Support and Cancer Screenings among Sexual and Gender Diverse People Living with HIV in Georgia	3R01NR020154-04S1	EMORY UNIVERSITY	$87,833
7	The All of Us Research Program has an explicit goal to enroll at	PRIDEnet for the All of Us Research Program	4OT2OD025276-03	STANFORD UNIVERSITY	$1,444,263
8	PROJECT SUMMARY/ABSTRACT An unprecedented number of r	Supportive and restrictive factors and mental health in LGBT adolescent and young adult populations	1R61HD117134-01	HARVARD PILGRIM HEALTH CARE, INC.	$838,837
9	PROJECT SUMMARY.Sexual and gender minority (SGM) youth i	Project SMART: Social Media Anti-vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens	5R01DA054236-04	UNIVERSITY OF PENNSYLVANIA	$681,337
10	Project SummaryTransgender and other gender minority youth	Development and Pilot Evaluation of an Online Mentoring Program to Prevent Adversities Among Trans and Other Gender Minority Youth	5R21MD018509-02	UNIVERSITY OF NEBRASKA LINCOLN	$236,949
11	Project summary/abstractThe 2024 National LGBTQ Health Co	National LGBT Health Conference 2024	1R13MH138043-01	EMORY UNIVERSITY	$20,000
12	The All of Us Research Program has an explicit goal to enroll at	PRIDEnet for the All of Us Research Program	4OT2OD025276-03	STANFORD UNIVERSITY	$1,444,263
13	Project SummaryBackground/Objective: Transgender adolesce	Development of a School-Based Prevention Intervention to Promote Adolescent Mental Health Equity	1R34MH136018-01A1	BOSTON COLLEGE	$139,551
14	PROJECT SUMMARYNo changes being proposed.INTRODUCTIO	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	3R01AG063771-05S1	VANDERBILT UNIVERSITY	$99,998
15	Project SummaryThe goal of this study is to test the efficacy of a theo	Efficacy of a Multi-level School Intervention for LGBTQ Youth	5R01MD016082-04	WASHINGTON UNIVERSITY	$565,297
16	Project SummarySexual and gender minorities (SGM) are heav	Training Program in Translational Science HIV and Sexual and Gender Minority Health	5T32MH130325-03	NORTHWESTERN UNIVERSITY AT CHICAGO	$497,664
17	Project SummaryNearly half of sexual minority (SM) men exper	An Innovative Prospective Model to Understand Risk and Protective Factors for Sexual Assault Experiences and Outcomes Among Sexual Minority Men	5R01MD016384-03	UNIVERSITY OF NEBRASKA LINCOLN	$767,135
18	The "Patient-Responsive Initiatives for Diverse Engagement LG	PRIDE-CARES Center: Patient-Responsive Initiatives for Diverse Engagement - LGBTQ+ Community Action in Research to Eliminate Substance Use Disorder	1R24DA061190-01	UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA	$503,095
19	Project SummaryCategorization is a fundamental aspect of hu	Views of Gender in Adolescence	3R01HD092347-08S1	PRINCETON UNIVERSITY	$97,554
20	ABSTRACTOne in two Black men who have sex with men (MSM)	Intersectional Discrimination and Sexual Health Among Young Black Men who Have Sex with Men: A Mixed Methods Study	1F31MH138075-01	DUKE UNIVERSITY	$42,014
21	PROJECT SUMMARYRacial ethnic and sexual and gender minor	SILOS: Structural Inequities across Layers Of Social-Context as Drivers of HIV and Substance Use	1R01DA061247-01	NORTHWESTERN UNIVERSITY AT CHICAGO	$777,568
22	Project Summary/AbstractThe Stanford Genomics Diversity Su	Genomics Diversity Summer Program (GDSP) at Stanford	5R25HG010857-05	STANFORD UNIVERSITY	$285,283
23	Project SummaryThis proposal seeks continued support to exp	A Longitudinal Examination of Mechanisms Underlying Intersectional Health Disparities in the United States	2R01HD094081-06A1	UNIVERSITY OF MINNESOTA	$672,168
24	PROJECT SUMMARYTHIRD COAST CFAR DEI PROGRAM CORE	Partnering and Programming for a BIPOC SGM Pathway to HIV Research	3P30AI117943-10S1	NORTHWESTERN UNIVERSITY AT CHICAGO	
25	PROJECT SUMMARYDiversity enhances creativity and innovati	Faculty Initiative for Improved Recruitment Retention and Experience (FIIRRE)	5U54CA272171-03	UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA	$4,386,670
26	Project SummaryThe scope of this study is to engage Ryan Whit	Ending the HIV Epidemic with Equity: An All-facility Intervention to Reduce Structural Racism and Discrimination and Its Impact on Patient and Healthcare Staff Wellbeing	5R01NR020583-03	COLUMBIA UNIVERSITY HEALTH SCIENCES	$798,648
27	The University at Buffalo (UB) NIMHD Center of Excellence in I	Igniting Hope in Buffalo New York communities: Training the Next Generation of Health Equity Researchers	1P50MD019473-01	STATE UNIVERSITY OF NEW YORK AT BUFFALO	
28	Project Summary/AbstractBackground: Structural racism defir	Developing Modules to Address Microaggressions and Discriminatory Behaviors	5R25GM149980-02	CHILDREN'S HOSP OF PHILADELPHIA	$91,048
29	Background: Black women represent the largest group of wome	Monitoring Microaggressions and Adversities to Generate Interventions for Change (MMAGIC) for Black Women Living with HIV	3R01MH121194-04S1	UNIVERSITY OF MIAMI CORAL GABLES	$72,588
30	Background: Black women represent the largest group of wome	Monitoring Microaggressions and Adversities to Generate Interventions for Change (MMAGIC) for Black Women Living with HIV	5R01MH121194-04	UNIVERSITY OF MIAMI CORAL GABLES	$642,346
31	Project SummaryStress is associated with HIV risk behaviors in	Health disparities stress pathways and stress-related comorbidities among MSM living with HIV	5R01MD013495-05	JOHNS HOPKINS UNIVERSITY	$1,285,395
32	Project Summary Overdose deaths are exponentially rising for	Exploring Historical Trauma Racial Discrimination PTSD and Substance Use Among Black Young Adults	1R36DA058830-01A1	NEW SCHOOL UNIVERSITY	$53,501
33	AbstractTransgender and gender diverse adults (TGDAs) experiences s	An intersectional approach linking Minority Stressors Experienced by Transgender and Gender Diverse Adults to Alcohol and Drug Use and comorbid Mental and Physical Health Outcomes	5R01AA030275-02	GEORGIA STATE UNIVERSITY	$501,825
34	PROJECT SUMMARY/ABSTRACTStructural racism and discrimi	Universal basic income and structural racism in the US South: Differences in health service utilization between older African American men with and without experiences of recent incarceration	5R01MD017509-03	UNIV OF ARKANSAS FOR MED SCIS	$760,276
35	Project Summary/ AbstractSocial justice is the primary ethical	Securing Health Equity: Philosophical Foundations for Equality and Social Justice in Public Health and Health Care	1G13LM014426-01	UNIVERSITY OF WASHINGTON	$47,535
36	Project SummaryBlack and Latinx gay and bisexual men are at highes	Theoretically Informed Behavioral Intervention to Enhance QOL and Prevent HIV-related Comorbidities in Ethnic and Racial Sexual Minority Men	1R01MD019956-01	YALE UNIVERSITY	$1,054,907
37	Project Summary/Abstract The goal of this R01 is to build upon	Identifying multilevel facilitators of care outcomes among Positive Deviants to design an intervention for Black sexual minority men living with HIV	1R01NR021691-01A1	GEORGE WASHINGTON UNIVERSITY	$676,457
38	PROJECT SUMMARY Inequities in health manifest as a result of	Multilevel Racism & Discrimination and PrEP Outcomes Among Black SMM in the Southeastern U.S.	5R01MH130166-03	US HELPING US, PEOPLE INTO LIVING, INC.	$601,194
39	PROJECT SUMMARY/ABSTRACTIt is estimated that more than d	Understanding the effects of cross-sex hormone therapy on vaginal mucosal immunity	5R21AI178913-02	BOSTON MEDICAL CENTER	$222,500
40	Project SummaryBlack cisgender women (hereafter Black wom	A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation among Black Women	5R01MD019178-02	JOHNS HOPKINS UNIVERSITY	$1,105,281
41	PROJECT SUMMARY/ABSTRACTThere is evidence of a growing h	A multi-level study of the link between fear of deportation and mental health in Latinx young adults: The role of systemic inflammation and related risk and protective factors	1F31MD019521-01A1	UNIVERSITY OF HOUSTON	$36,978
42	Sex differences in immunity are dynamic throughout the lifespan and	Understanding transgender women's immune and behavioral responses to seasonal COVID-19 vaccines to improve their uptake	1R21AI183544-01A1 Already terminated	NEW YORK BLOOD CENTER	$267,121
43	PROJECT ABSTRACTHeadache has been one of the top three causes	Effect of pubertal hormones on Headache in Transmasculine Adolescents	5K23NS130143-02	UNIVERSITY OF COLORADO DENVER	$224,924
44	Project SummaryThis project will elucidate the psychological proces	The psychological underpinnings of gender disparities in adolescent mental health	5F32MH135634-02	PRINCETON UNIVERSITY	$73,828
45	Sex Hormones and Identity affect Nociceptive Expression (SHINE)Pro	Sex Hormones and Identity affect Nociceptive Expression (SHINE)	5R01NR019417-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$473,872
46	PROJECT SUMMARYThis R01 proposal responds to Notice of Sp	Androgen effects on the reproductive neuroendocrine axis	5R01HD111650-02 already terminate	UNIVERSITY OF CALIFORNIA, SAN DIEGO	$581,671
47	This proposal will undertake preclinical studies to address brea	Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes	1R56CA284564-01	BETH ISRAEL DEACONESS MEDICAL CENTER	$299,940
48	PROJECT ABSTRACTWounds have a sizable impact on public he	Molecular Mechanisms of Hormone-Mediated Sex Differences in Wound Healing	1R35GM157032-01	BRIGHAM AND WOMEN'S HOSPITAL	$442,444
49	The University of Georgia (UGA) proposes a renewal of PREP@UGA th	PREP at University of Georgia	2R25GM109435-10	UNIVERSITY OF GEORGIA	$343,158
50	Project Summary/Abstract Science is failing minorities in the US by 1	Culturally-focused HIV Advancements through the Next Generation for Equity (CHANGE) Training Program	5T32MH126772-04	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$286,511
51	ABSTRACTThe vision of the Utah Clinical & Translational Science Inst	CTSA UM1 Program at University of Utah	5UM1TR004409-02	UNIVERSITY OF UTAH	$5,424,809
52	Project SummaryThe goal of this study is to test the efficacy of a	Efficacy of a Multi-level School Intervention for LGBTQ Youth	5R01MD016082-04	WASHINGTON UNIVERSITY	$565,297
53	PROJECT SUMMARY/ABSTRACTSexual minorities (i.e. individua	The Socioecology of Sexual Minority Stigma: Data Harmonization to Address Confounding Bias and Investigate Cross-Level MentalHealth Effects	5R01MH133821-02	SAN DIEGO STATE UNIVERSITY	$447,178
54					$32,563,719

Termination Categories

- China: Bolstering Chinese universities does not enhance the American people's quality of life or improve America's position in the world. On the contrary, funding research in China contravenes American national-security interests and hinders America's foreign-policy objectives.
- DEI: Research programs based primarily on artificial and non-scientific categories, including amorphous equity objectives, are antithetical to the scientific inquiry, do nothing to expand our knowledge of living systems, provide low returns on investment, and ultimately do not enhance health, lengthen life, or reduce illness. Worse, so-called diversity, equity, and inclusion ("DEI") studies are often used to support unlawful discrimination on the basis of race and other protected characteristics, which harms the health of Americans. Therefore, it is the policy of NIH not to prioritize such research programs.
- Gender: Research programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans. Many such studies ignore, rather than seriously examine, biological realities. It is the policy of NIH not to prioritize these research programs.
- Vaccine Hesitancy: It is the policy of NIH not to prioritize research activities that focuses gaining scientific knowledge on why individuals are hesitant to be vaccinated and/or explore ways to improve vaccine interest and commitment. NIH is obligated to carefully steward grant awards to ensure taxpayer dollars are used in ways that benefit the American people and improve their quality of life. Your project does not satisfy these criteria.

PDF COPY OF NIH_GRANTS_002046
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
1	Project Title	Public Health Relevance	Administering	Application ID	Award Notice	Opportunity Number	Project Numb	Serial Numbe	Program Official Informa	Project Start I	Project End D	Study Section	Contact PI Pe	Contact PI / P	Other PI or Pr	Department	Organization I	Budget Start D	Budget End Da	Funding Mech	Fiscal Year	Total Cost	Funding IC(s)	Direct Cost IC	Indirect Cost	Total Cost IC
2	Creation of an Institution	n/a	OD	10129786	9/19/20	PAR-20-086	1C06OD030	30152	CHEN, YONG	9/21/20	5/31/25	Scientific and	6205023	REILLY, MUR	Not Applicab	INTERNAL ME	COLUMBIA U	9/21/20	5/31/25	Construction	2020	$8,000,000	OD	$8,000,000	$0	$8,000,000
3	Center to Improve Chror	NARRATIVE:The COMMU	NIMHD	10897775	8/1/24	RFA-MD-21-007	5P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$4,048,432	NIMHD	$2,674,989	$1,373,443	$4,048,432
4	Center for Environmenta	PROJECT NARRATIVE OV	NIEHS	10851719	5/10/24	RFA-ES-20-006	5P30ES00908	9089	THOMPSON, CLAUDIA	7/1/98	4/30/28	Environmenta	7839598	PERZANOWS	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$1,631,206	NIEHS	$1,020,275	$610,931	$1,631,206
5	Climate and Health: Act	Overall NarrativeClimat	NIA	10981243	9/20/24	RFA-ES-23-007	1P20AG0939	93975	KWOK, RICHARD K	9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	BERHANE, KI	PUBLIC HEAL	COLUMBIA U	9/30/24	8/31/25	Research Ce	2024	$1,397,411	NIA	$849,890	$547,521	$1,397,411
6	Advanced training in env	Project NarrativeColum	NIEHS	10843247	6/7/24	PA-18-403	5T32ES00732	7322	SHREFFLER, CAROL A.	7/1/00	6/30/25	Environmenta	1862308	MILLER, GARY	FACTOR-LITV	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$1,343,565	NIEHS	$1,561,132	$95,611	$1,343,565
7	Anga Center for Climate	PROJECT NARRATIVE Eas	FIC	10982425	9/19/24	RFA-ES-23-007	1P20TW0128	12808	NEWSOME, BRAD	9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	NDETEI, DAV	Unavailable	COLUMBIA U	9/23/24	8/31/25	Research Ce	2024	$1,061,973	NIEHS	$860,247	$201,725	$1,061,972
8	Center to Improve Chror	NARRATIVE:The COMMU	NIMHD	10939527	8/27/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,025,313	NIMHD	$787,662	$237,651	$1,025,313
9	Resilient Emotion Regula	Project NarrativeResilie	NIMH	10898037	7/15/24	PA-20-185	5R01MH1305	130578	SMITH, ASHLEY	8/2/23	6/30/28	Child Psycho	9514113	TOTTENHAM,	SEEDAT, SOR	PSYCHOLOG	COLUMBIA U	7/15/24	6/30/25	Non-SBIR/ST	2024	$992,759	NIMH	$904,808	$87,951	$992,759
10	Comparing a Novel Teleh	PROJECT NARRATIVECar	NIMHD	10981223	9/17/24	PA-20-183	1R01MD019	19189	PADGETT, LYNNE SLAU	9/20/24	5/31/29	Clinical Mana	15008881	DURAN, AND	Not Applicab	INTERNAL ME	COLUMBIA U	9/20/24	5/31/25	Non-SBIR/ST	2024	$821,694	NIMHD	$499,510	$322,184	$821,694
11	A daily diary examination	PROJECT NARRATIVEStig	NHLBI	10801457	1/22/24	PA-20-185	1R01HL1684	168489	CAMPO, REBECCA A.	9/1/24	5/31/28	Biobehaviora	12508902	CACERES, BI	Not Applicab	OTHER HEAL	COLUMBIA U	9/1/24	5/31/25	Non-SBIR/ST	2024	$813,579	NHLBI	$494,577	$319,002	$813,579
12	Ending the HIV Epidemic	Project NarrativeThe pro	NINR	10819558	4/16/24	RFA-MD-21-004	5R01NR0205	20583	WILLIS, LEIGH ANDREV	7/1/22	4/30/27	ZMD1-KNL(J1	10397136	LELUTIU-WEI	BROWNE, FE	OTHER HEAL	COLUMBIA U	5/1/24	4/30/25	Non-SBIR/ST	2024	$798,648	NINR	$615,060	$183,588	$798,648
13	Disability diversity and t	Project NarrativeStudies	NHGRI	10653189	9/1/23	PA-17-444	5R01HG0108	10868	KAUFMAN, DAVE J	3/12/21	6/30/25	Special Emph	12453587	SABATELLO, N	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/23	6/30/25	Non-SBIR/ST	2023	$795,723	NHGRI	$498,920	$296,803	$795,723
14	Just Inclusion and Equity	PROJECT NARRATIVEThis	NHGRI	10910148	9/23/24	PAR-20-254	5R01HG0128	12841	STERLING, RENE	9/1/23	6/30/27	Special Emph	6597920	LEE, SANDRA	CALLIER, SHA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$737,573	NHGRI	$577,866	$159,707	$737,573
15	Estimating the impact of	PROJECT NARRATIVEAgg	NIDA	10840302	3/12/24	PA-20-185	5R01DA0580	58028	DUNSTON, SHEBA KIN	5/15/23	3/31/28	Social Scienc	11076659	PRINS, SETH	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$716,003	NIDA	$473,109	$242,894	$716,003
16	Harnessing digital health	Only one in four depresse	NCI	10945367	8/26/24	PAR-22-105	1R01CA2940	294004	RANDHAWA, GURVAN	9/1/24	7/31/29	Science of Im	12100576	MOISE, NATH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/24	7/31/25	Non-SBIR/ST	2024	$696,140	NCI	$436,637	$259,503	$696,140
17	SPECTRUM (Studying PR	NARRATIVEThe SPECTRU	NCI	10801508	4/5/24	PA-20-185	1R01CA2791	279145	DEAN, DAVID WORTH	4/5/24	3/31/29	Cancer and H	14146562	HOUGHTON,	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/5/24	3/31/25	Non-SBIR/ST	2024	$694,771	NCI	$532,535	$162,236	$694,771
18	Late Life Learning Demer	Project NarrativeThis pro	NIA	10845557	6/13/24	PAR-21-311	5R01AG0740	74076	CHATTERJI, MINKI	9/1/22	5/31/27	Special Emph	11055051	ZEKI AL HAZZ	ELBEJJANI , M	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$704,282	NIA	$592,671	$101,611	$694,282
19	Reducing Health Dispari	PROJECT NARRATIVEThe	NINR	10864979	5/22/24	PA-20-142	5T32NR0079	7969	KEHL, KAREN	8/1/02	6/30/27	ZNR1-REV-M	9765581	SCHNALL, RE	BAKKEN, SUZ	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$691,597	NINR	$689,848	$44,588	$691,597
20	GENETIC ATTRIBUTIONS	The proposed research w	NHGRI	10932235	8/7/24	PAR-20-254	5R01HG0128	12868	KAUFMAN, DAVE J	9/20/23	6/30/27	Special Emph	14884731	LEBOWITZ, M	PEARL, REBE	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$689,893	NHGRI	$634,610	$55,283	$689,893
21	Preventing Drug Abuse a	PROJECT NARRATIVE Add	NIDA	10425383	7/7/22	PA-15-261	5R01DA0435	43512	ROMBERG, ALEXA RUT	7/1/18	6/30/25	Interventions	8585554	SCHWINN, T	Not Applicab	OTHER HEAL	COLUMBIA U	7/1/22	6/30/25	Non-SBIR/ST	2022	$680,444	NIDA	$433,039	$247,405	$680,444
22	Health Disparities in Ho	PROJECT NARRATIVERad	NINR	10912788	6/17/24	PA-20-185	5R01NR0206	20601	KEHL, KAREN	8/23/23	6/30/27	Healthcare a	1872031	STONE, PATR	DHINGRA, LA	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$655,106	NINR	$545,221	$109,885	$655,106
23	Intervention toiMProveA	RELEVANCEThere are lor	NIMHD	10897800	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	6405748	HERSHMAN,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$654,071		$405,673	$248,398	$654,071
24	Evaluating Medicaid Pos	Project NarrativeSustain	NIMHD	11003869	4/8/24	PA-21-268	7R01MD018	18180	OLADEINDE, YEWAND	6/4/23	11/30/28	Organization	8963719	JANEVIC, TER	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/8/24	11/30/25	Non-SBIR/ST	2024	$642,775	NIMHD	$563,130	$79,645	$642,775
25	Project 1: Addressing Sle	NARRATIVE:Sleep health	NIMHD	10897794	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	12346337	MAKAREM, N	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$628,419		$396,689	$231,730	$628,419
26	Temperature shade and a	Temperatures are rising (	NIMH	10863844	6/20/24	PA-20-185	5R01MH1287	128734	THOMAS, LAURA A.	9/15/21	6/30/26	Behavioral G	9555896	KEYES, KATH	RUNDLE, AN	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$621,780	NIMH	$408,959	$212,821	$621,780
27	Social Connectedness a	PROJECT NARRATIVEGer	NIMHD	11004310	12/22/24	PAR-21-350	5R01MD0170	17085	HERREN, OLGA MARIN	7/15/23	12/31/27	Special Emph	6832127	BOCKTING, W	Not Applicab	OTHER HEAL	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$612,485	NIMHD	$449,844	$162,641	$612,485
28	Assessing Cervical Canc	PROJECT NARRATIVEThe	NIMHD	10982514	12/17/24	PAR-20-310	5R01MD0182	18250	PADGETT, LYNNE SLAU	5/5/23	11/30/27	Organization	10513738	LLANOS, ADA	TSUI, JENNIF	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$610,020	NIMHD	$528,633	$81,387	$610,020
29	Policy levers to reduce ra	Project NarrativeGestat	NIDDK	11094148	2/21/25	PA-20-185	5R01DK1347	134725	LAWRENCE, JEAN M	12/9/23	2/29/28	Community I	8963719	JANEVIC, TER	Not Applicab	PUBLIC HEAL	COLUMBIA U	3/1/25	2/28/26	Non-SBIR/ST	2025	$570,471	NIDDK	$391,471	$179,000	$570,471
30	Enhancing Alzheimer's-re	PROJECT NARRATIVEIncr	NIA	11033614	1/31/25	RFA-AG-24-027	1UG3AG0905	90558	GHALEH, MARYAM X	2/1/25	1/31/28	Special Emph	7891222	BRICKMAN, A	MNGOMEZU	NEUROLOGY	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$539,352	NIA	$420,681	$118,671	$539,352
31	Impact of Social Cohesio	PROJECT NARRATIVEThis	NIMHD	10397977	5/8/22	RFA-MD-18-003	5R01MD0135	13554	STINSON, NATHANIEL	9/11/18	4/30/25	ZMD1-RP(O1	11872940	DUNCAN, DU	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/22	4/30/25	Non-SBIR/ST	2022	$507,062	NIMHD	$340,488	$166,574	$507,062
32	Policy solutions for addre	n/a	NICHD	10908630	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	1970408	LI, GUOHUA	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$503,613		$365,317	$138,296	$503,613
33	2/3 Genomics of Schizop	PROJECT NARRATIVEAfri	NIMH	11085137	12/19/24	PAR-20-027	5U01MH1250	125058	PEVSNER, JONATHAN	1/1/21	12/31/25	ZMH1-ERB-C	1911330	SUSSER, EZR	Not Applicab	PUBLIC HEAL	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$447,238	NIMH	$336,053	$111,185	$447,238
34	The Behavioral Cost of C	PROJECT NARRATIVEThe	OD	10923510	9/18/24	RFA-RM-23-007	1DP5OD0374	37400	MILLER, BECKY	9/18/24	7/31/29	Special Emph	78943744	MINOR, KELT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/24	7/31/25	Non-SBIR/ST	2024	$411,250	OD	$249,999	$161,250	$411,249
35	Network biology-based n	n/a	NIA	10981246	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	1862308	MILLER, GARY	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$384,800		$233,921	$150,879	$384,800
36	Columbia Population Re	Project NarrativeThe Co	NICHD	10895753	8/14/24	RFA-HD-24-008	2P2CHD0584	58486	CLARK, REBECCA L	8/15/09	6/30/29	Special Emph	1892638	TEITLER, JULI	HIRSCH, JEN	OTHER HEAL	COLUMBIA U	9/1/24	6/30/25	Other Resear	2024	$359,265	NICHD	$218,398	$140,867	$359,265
37	Cannabis use PrEP and H	PROJECT NARRATIVEThis	NIDA	10838513	8/6/24	RFA-DA-21-024	5R01DA0545	54553	JENKINS, RICHARD A	8/1/21	5/31/26	ZDA1-TXT-V((	11872940	DUNCAN, DU	KNOX, JUSTIN	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$715,456	NIAID	$297,359	$60,370	$357,729
38	Cannabis use PrEP and H	PROJECT NARRATIVEThis	NIDA	10838513	8/6/24	RFA-DA-21-024	5R01DA0545	54553	JENKINS, RICHARD A	8/1/21	5/31/26	ZDA1-TXT-V((	11872940	DUNCAN, DU	KNOX, JUSTIN	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$715,456	NIDA	$297,358	$60,369	$357,727
39	Training in Health Equity	NarrativeThe mission of t	NCI	10884327	7/22/24	RFA-CA-21-020	5R25CA2741	274180	GHOSH, SANGEETA AH	8/15/22	7/31/27	Institutional	10534314	MCDONALD,	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$342,806	NCI	$317,416	$25,393	$342,806
40	Nationwide Associations	n/a	NIA	10981245	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$281,937		$171,790	$110,147	$281,937
41	Investigating pathways b	n/a	FIC	10982427	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$275,863		$218,939	$56,924	$275,863
42	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	OD	$242,040	$7,885	$249,925
43	Novel Assessments of the	PROJECT NARRATIVEIn t	NIEHS	10832126	4/1/24	PA-20-188	5R00ES0337	33742	LAWRENCE, KAITLYN G	5/1/23	4/30/26	NSS	77863179	PARKS, ROBB	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Non-SBIR/ST	2024	$249,000	NIEHS	$151,368	$97,632	$249,000
44	Training West African Pu	Project narrative:We pro	FIC	10899280	9/2/24	PAR-21-120	1D43TW0127	12737	SINA, BARBARA J	9/1/24	4/30/29	Special Emph	6434515	WICKISER, JO	DOUMBIA, SE	PUBLIC HEAL	COLUMBIA U	9/1/24	4/30/25	Other Resear	2024	$248,793	NIAID	$240,575	$5,946	$246,521
45	Racial Disparity in Diagn	Uterine cancer is the mo	NIMHD	10831829	4/19/24	PA-20-185	5R01MD0163	16386	PADGETT, LYNNE SLAU	8/27/21	4/30/26	Healthcare a	7568885	XU, XIAO	WRIGHT, JAS	OBSTETRICS	COLUMBIA U	5/1/24	4/30/26	Non-SBIR/ST	2024	$232,654	NIMHD	$152,337	$80,317	$232,654
46	Center to Improve Chror	NARRATIVE:The COMMU	NIMHD	10939526	8/26/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$226,727	NIMHD	$137,828	$88,899	$226,727
47	India - Factors of CKDu i	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J(	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	NIDDK	$205,661	$79,103	$199,334
48	Youth-PRIDES: Impleme	Mental disorders are the	NIMH	10669228	7/19/23	PA-18-363	5K01MH1202	120258	ALLISON, SUSANNAH	8/15/19	7/31/25	Mental Healt	9614976	LOVERO, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/23	7/31/25	Other Resear	2023	$181,675	NIMH	$169,700	$11,975	$181,675
49	Racial Inequities in Opio	PROJECT NARRATIVEThe	NIDA	10821454	3/21/24	PA-20-190	5K01DA0580	58085	ZUR, JULIA BETH	4/15/23	3/31/28	Social Scienc	12407723	PAMPLIN, JO	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Other Resear	2024	$177,962	NIDA	$164,780	$13,182	$177,962
50	Subtyping sepsis in Ugan	PROJECT NARRATIVEThe	NIAID	11009064	1/17/25	PA-20-205	5K23AI16336	163364	ERNST, NANCY L.	2/2/22	1/31/26	Microbiology	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	2/1/25	1/31/26	Other Resear	2025	$173,996	NIAID	$161,107	$12,889	$173,996
51	Just Inclusion and Equity	PROJECT NARRATIVEThis	NHGRI	11064335	9/24/24	PA-20-272	3R01HG0128	12841	STERLING, RENE	9/1/23	6/30/27	Special Emph	6597920	LEE, SANDRA	CALLIER, SHA	INTERNAL ME	COLUMBIA U	9/24/24	6/30/25	Non-SBIR/ST	2024	$164,087	NHGRI	$115,703	$48,384	$164,087
52	Leveraging Latinx Adoles	PROJECT NARRATIVECur	NIMH	10919831	8/26/24	RFA-MH-23-116	5R21MH1354	135489	SMITH, ASHLEY	9/4/23	8/31/25	ZMH1-ERB-R	11732940	DUPONT, ME	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	$163,665	NIMH	$110,800	$52,865	$163,665
53	Establishing a unified eva	Project NarrativeExtrem	NIEHS	11055056	12/13/24	PAR-21-172	1K01ES0362(	36202	QUINN, ASHLINN KO	12/16/24	11/30/27	Special Emph	78417944	WU, XIAO	Not Applicab	BIOSTATISTIC	COLUMBIA U	12/16/24	11/30/25	Other Resear	2025	$157,841	NIEHS	$146,149	$11,692	$157,841
54	Investigating association	PROJECT NARRATIVEClir	NIMH	10592335	3/23/23	PA-21-235	5R21MH1273	127356	CAMPBELL-ROSEN, HC	4/1/22	3/31/25	Community I	16325196	WINTER, SAM	Not Applicab	OTHER HEAL	COLUMBIA U	4/1/23	3/31/25	Non-SBIR/ST	2023	$157,500	NIMH	$125,000	$32,500	$157,500
55	India - Factors of CKDu i	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J(	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	NIEHS	$150,290	$57,804	$145,666
56	Summer Program for Und	PROJECT NARRATIVEThe	NINDS	11004622	12/23/24	PAR-21-168	5R25NS0764	76445	MATTHEWS, MARGUER	4/1/12	12/31/27	ZNS1-SRB-D	8613268	GRUEBER, W	SIEGELBAUM	PHYSIOLOGY	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$135,000	NINDS	$125,000	$10,000	$135,000
57	Support Mentoring of Ear	The regulation of body we	NIDDK	10917344	5/21/24	RFA-DK-22-012	5K26DK1384	138418	SASLOWSKY, DAVID E	9/1/23	5/31/28	ZDK1-GRB-1	1869280	GALLAGHER,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$132,845	NIDDK	$123,116	$9,729	$132,845
58	DYnamics of Contracept	PROJECT NARRATIVEAdo	NICHD	10846589	5/17/24	PA-20-190	5K01HD1086	108636	CHINN, JUANITA JEANN	5/24/23	4/30/28	Population Sc	14766811	GREENLEAF,	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Other Resear	2024	$130,810	NICHD	$121,120	$9,690	$130,810
59	Advancing equitable imp	Project narrative/Public	NIDDK	10906807	8/28/24	PA-20-190	5K01DK1324	132495	RANKIN, TRACY L	9/15/22	8/31/27	Kidney, Urolo	14313406	MILO RASOU	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$128,938	NIDDK	$119,743	$9,195	$128,938
60	Spatiotemporal effects a	PROJECT NARRATIVEWil	NIEHS	10984277	7/24/24	PAR-21-271	1K99ES0358	35895	CUI, YUXIA	8/1/24	7/31/26	Special Emph	78428836	CERNA-TURC	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$126,333	NIEHS	$116,975	$9,358	$126,333
61	Mentoring clinical invest	PROJECT NARRATIVEThe	NIDA	10863840	6/4/24	PA-19-122	5K24DA0513	51328	LAO, GUIFANG	4/1/23	6/30/25	Population ar	9421939	SEVELIUS, JAE	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Other Resear	2024	$125,114	NIDA	$115,846	$9,268	$125,114
62	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	NIEHS	$96,846	$3,154	$100,000
63	BEST-DP: Biostatistics &	Biomedical scientists es	NHLBI	10658980	5/3/23	RFA-HL-16-008	5R25HL0962	96260	WOLZ, MICHAEL	5/15/09	4/30/25	ZHL1-CSR-M	10781196	GOLDSMITH,	BEGG, MELIS	BIOSTATISTIC	COLUMBIA U	5/1/23	4/30/25	Other Resear	2023	$82,944	NHLBI	$76,800	$6,144	$82,944
64	Development and Testin	PROJECT NARRATIVETra	NIMH	10744754	11/15/23	PA-20-141	5R34MH128	128163	GREENWOOD, GREGC	1/1/22	11/30/25	HIV/AIDS Intr	9765581	SCHNALL, RE	GAROFALO, F	OTHER HEAL	COLUMBIA U	12/1/23	11/30/25	Non-SBIR/ST	2024	$72,743	NIMH	$62,125	$10,618	$72,743
65	Disparities in Deaths of [	PROJECT NARRATIVEThe	NIEHS	11100635	8/8/24	PA-23-189	3R00ES0337	33742	LAWRENCE, KAITLYN G	5/1/23	4/30/26		77863179	PARKS, ROBB	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/9/24	4/30/25	Non-SBIR/ST	2024	$67,927	NIEHS	$44,672	$23,255	$67,927
66	Youth-PRIDES: Impleme	Mental disorders are the	NIMH	10900850	8/31/23	PA-20-272	3K01MH1202	120258	ALLISON, SUSANNAH	8/15/19	7/31/25	Mental Healt	9614976	LOVERO, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/23	7/31/25	Other Resear	2023	$65,315	NIMH	$60,477	$4,838	$65,315
67	Skeletal Health in Youth	Our parent study is show	NIDDK	10772814	8/28/23	PA-20-272	3R01DK1225	122564	MALOZOWSKI, SAUL N	9/12/19	6/30/25	ZDK1(M3)-S	7373765	RUBIN, MISH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/23	6/30/25	Non-SBIR/ST	2023	$100,000	NIDDK	$30,395	$19,605	$50,000
68	Skeletal Health in Youth	Our parent study is show	NIDDK	10772814	8/28/23	PA-20-272	3R01DK1225	122564	MALOZOWSKI, SAUL N	9/12/19	6/30/25	ZDK1(M3)-S	7373765	RUBIN, MISH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/23	6/30/25	Non-SBIR/ST	2023	$100,000	OD	$30,395	$19,605	$50,000
69	Diversity in Practice: the	PROJECT NARRATIVEThis	NLM	11009933	12/13/24	PAR-21-046	5G13LM0141	14176	YOON, SUNG SUG SUG	1/1/23	12/31/25	ZLM1-JL-P(01	6597920	LEE, SANDRA	SHIM, JANET	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$49,795	NLM	$49,795	$0	$49,795
70	Personal Healthcare Net	PROJECT NARRATIVETra	NINR	10900078	6/24/24	PA-21-051	1F31NR0212	21239	WILLIS, LEIGH ANDREV	7/1/24	3/31/26	National Inst	79192449	GAEDECKE, T	Not Applicab	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,974	NINR	$48,974	$0	$48,974
71	Applying a multidimensio	PROJECT NARRATIVEMo	NIMH	10909057	8/15/24	PA-21-051	5F31MH1346	134699	ALLISON, SUSANNAH	9/1/23	8/31/25	Special Emph	16592276	KHALIFA, ALE	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$47,324	NIMH	$47,324	$0	$47,324
72	Neighborhood Social Env	PROJECT NARRATIVEDep	NIMH	10833481	4/25/24	PA-21-051	5F31MH1322	132290	AVENILLA, FRANK	5/1/23	4/30/25	Special Emph	15898106	DIAZ, SARAH	Not Applicab	NONE	COLUMBIA U	5/1/24	4/30/25	Training, Indi	2024	$39,146	NIMH	$39,146	$0	$39,146
73	An equity-focused evalua	PROJECT NARRATIVEThis	NIEHS	10930696	8/9/24	PA-21-052	5F31ES03528	35280	LAWRENCE, KAITLYN G	9/15/23	8/14/25	Special Emph	77847681	FLORES, NIN	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/15/24	8/14/25	Training, Indi	2024	$36,053	NIEHS	$36,053	$0	$36,053
74	Late Life Learning Demer	Project NarrativeThis pro	NIA	10845557	6/13/24	PAR-21-311	5R01AG0740	74076	CHATTERJI, MINKI	9/1/22	5/31/27	Special Emph	11055051	ZEKI AL HAZZ	ELBEJJANI , M	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$704,282	FIC	$8,537	$1,463	$10,000
75	India - Factors of CKDu i	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J(	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	FIC	$5,158	$1,984	$5,000
76	Training West African Pu	Project narrative:We pro	FIC	10899280	9/2/24	PAR-21-120	1D43TW0127	12737	SINA, BARBARA J	9/1/24	4/30/29	Special Emph	6434515	WICKISER, JO	DOUMBIA, SE	PUBLIC HEAL	COLUMBIA U	9/1/24	4/30/25	Other Resear	2024	$248,793	FIC	$2,218	$54	$2,272
77	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	FIC	$2	$0	$2
78	Anga Center for Climate	PROJECT NARRATIVE Eas	FIC	10982425	9/19/24	RFA-ES-23-007	1P20TW0128	12808	NEWSOME, BRAD	9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	NDETEI, DAV	Unavailable	COLUMBIA U	9/23/24	8/31/25	Research Ce	2024	$1,061,973	FIC	$1	$0	$1
79	The Behavioral Cost of C	PROJECT NARRATIVEThe	OD	10923510	9/18/24	RFA-RM-23-007	1DP5OD0374	37400	MILLER, BECKY	9/18/24	7/31/29	Special Emph	78943744	MINOR, KELT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/24	7/31/25	Non-SBIR/ST	2024	$411,250	NIDCR	$1	$0	$1
80	Medical Scientist Trainin	PROJECT NARRATIVEThe	NIGMS	10877873	6/4/24	PAR-21-189	5T32GM1454	145440	MCINTYRE, JEREMY C(	7/1/22	6/30/27	Training and V	1864040	REINER, STEV	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$1,558,334	NIGMS	$1,489,124	$69,210	$1,558,334
81	Postdoctoral Training in (	Our training program see	NHLBI	10890104	7/15/24	PA-18-403	5T32HL00785	7854	WEBB, STEPHANIE JOH	7/1/96	6/30/26	NHLBI Institu	8052876	MARX, STEVE	ABDALLA, MA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$900,800	NHLBI	$862,704	$58,096	$900,800
82	Training in Cellular Mole	PROJECT NARRATIVEThe	NIGMS	10868599	4/22/24	PAR-20-213	5T32GM1457	145766	AIYEGBO, MOHAMMED	7/1/22	6/30/27	Training and V	1884281	LIEM, RONAL	HAEUSLER, R	PATHOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$878,975	NIGMS	$836,384	$42,591	$878,975
83	NRSA Training Core	n/a	NCATS	10894261	6/12/24	PAR-18-940	5TL1TR00187	1875	ATIENZA, AUDIE A	7/1/16	5/31/26	ZTR1-SRC(99	8870151	SPANN, MAR	TAYLOR, JAC(	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Inst	2024	$749,022	NCATS	$895,872	$53,150	$749,022
84	Postdoctoral Training in	Project NarrativeThis is a	NHLBI	10824211	8/5/24	PA-20-142	5T32HL00734	7343	WANG, WAYNE C.	7/1/78	7/31/28	NHLBI Institu	1857723	GINSBERG, H	REILLY, MUR	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$673,488	NHLBI	$698,140	$50,131	$673,488
85	Patient Safety and Healt	Despite a heightened foc	AHRQ	10875422	6/26/24	RFA-HS-22-010	5T32HS0261	26121	DESOTO, MAUSHAMI	7/1/18	6/30/28	ZHS1-HSR-A	10386412	ADELMAN, JA	BARR, R GRA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$620,443	AHRQ	$596,592	$38,847	$620,443
86	Training Program on HIV a	PROJECT NARRATIVE Thi	NIDA	10918691	5/16/24	PA-23-048	2T32DA0378(	37801	DUCHARME, LORI	7/1/14	6/30/29	Special Emph	1891871	EL-BASSEL, N	METSCH, LIS	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$557,156	NIDA	$522,404	$34,752	$557,156
87	Substance Abuse Epiden	Substance use and subst	NIDA	10836582	5/20/24	PA-20-142	5T32DA0310	31099	LOPEZ, MARSHA	7/1/12	6/30/27	ZDA1-SKM-D	1879601	HASIN, DEBC	MARTINS, SIL	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$510,748	NIDA	$545,048	$35,700	$510,748
88	Behavioral Sciences Res	Major biomedical advan(	NIMH	10874650	6/28/24	PA-18-403	5T32MH0191	19139	ALLISON, SUSANNAH	7/1/89	6/30/25	ZMH1-ERB-M	8188389	MELLINS, CL	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$500,315	NIMH	$564,140	$43,451	$500,315
89	Systems Science and Co	PROJECT NARRATIVEThe	NINR	10861745	5/16/24	PA-20-142	5T32NR0142	14205	KEHL, KAREN	7/1/13	6/30/28	ZNR1-REV-W	9844694	POGHOSYAN	STONE, PATR	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$487,419	NINR	$485,994	$31,920	$487,419
90	Molecular Oncology Trai	PROJECT NARRATIVECar	NCI	10880432	6/25/24	PA-18-403	5T32CA2037(	203703	LIM, SUSAN E	7/18/16	6/30/26	Institutional	6405748	HERSHMAN,	CREW, KATH	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$483,880	NCI	$514,752	$39,740	$483,880
91	Translational Research T	We urgently need to sust	NIMH	10836376	6/3/24	PA-18-403	5T32MH0164	16434	BECHTHOLT, ANITA J	9/25/80	6/30/25	ZMH1-ERB-G	8746379	VEENSTRA-V	FITZGERALD,	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$462,630	NIMH	$514,596	$37,568	$462,630
92	Training in Schizophrenia	PROJECT NARRATIVEThis	NIMH	10894080	6/7/24	PA-18-403	5T32MH0188	18870	CHAVEZ, MARK	8/1/88	6/30/25	ZMH1-ERB-G	9574679	KELLENDON	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$458,786	NIMH	$532,584	$39,007	$458,786
93	Global Mental Health (G	People in Low and Middle	NIMH	10911009	8/19/24	PA-20-142	5T32MH0967	96724	ALLISON, SUSANNAH	8/21/12	7/31/28	ZMH1-ERB-E	6072016	WAINBERG, M	Not Applicab	PSYCHIATRY	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$443,114	NIMH	$416,948	$31,532	$443,114
94	Genetic Approaches to D	PROJECT NARRATIVEThis	NIGMS	10866352	4/9/24	PAR-17-341	5T32GM1418	141882	STAMM, JOYCE CHIN-(	7/1/21	6/30/26	Training and V	1940239	SHIRASU-HIZ	BERCHOWIT	GENETICS	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$439,487	NIGMS	$418,192	$21,295	$439,487
95	Research Training Progra	Project narrativePsychia	NIMH	10863869	6/20/24	PA-20-142	5T32MH0130	13043	CHAVEZ, MARK	7/1/72	6/30/27	ZMH1-ERB-M	9555896	KEYES, KATH	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$432,394	NIMH	$423,188	$29,069	$432,394

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
96	Translational Clinical Re	Project Narrative:Substa	NIDA	10837720	5/22/24	PA-20-142	5T32DA0072	7294	LAO, GUIFANG	7/20/93	6/30/28	Career Deve	1866589	LEVIN, FRANC	MARTINEZ, D	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$412,899	NIDA	$542,736	$40,163	$412,899
97	Multidisciplinary Trainin	Project NarrativeWhile c	NIDDK	10849176	6/26/24	PA-23-048	2T32DK08325	83256	DENSMORE, CHRISTIN	7/1/09	6/30/29	Special Emph	1873597	WANG, TIMO	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$400,571	NIDDK	$487,904	$32,352	$400,571
98	Genome and Epigenome	Two fundamental but me	NCI	10910046	8/6/24	PA-20-142	5T32CA26582	265828	LIM, SUSAN E	9/1/22	8/31/27	Institutional	7931342	ZHANG, ZHIG	SYMINGTON,	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$373,349	NCI	$409,146	$26,372	$373,349
99	Neuroepidemiology Trair	The goal of this proposal	NINDS	10620288	7/24/23	PA-18-403	5T32NS00715	7153	WEIGAND, LETITIA ALEX	7/1/80	6/30/25	ZNS1-SRB-L(	9875866	WILLEY, JOSH	GU, YIAN	NEUROLOGY	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$373,048	NINDS	$348,916	$24,132	$373,048
100	Research Training in Mod	PROJECT NARRATIVEThis	NIMH	10849196	6/5/24	PA-23-048	2T32MH0151	15144	CHAVEZ, MARK	7/1/78	6/30/29	Special Emph	1925580	LEONARDO,	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$363,642	NIMH	$443,432	$32,475	$363,642
101	Anesthesiology Research	NarrativeThe proposed p	NIGMS	10876234	6/18/24	PA-20-142	5T32GM0084	8464	PAUL, MOUSHUMI	7/1/92	6/30/28	ZGM1-TWD-X	1864643	EMALA, CHAR	HUA, MAY	ANESTHESIO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$350,862	NIGMS	$326,028	$24,834	$350,862
102	Dental-Biomedical Engir	Project NarrativeIn the U	NIDCR	10880369	6/27/24	PAR-20-056	5T90DE03212	32123	MCGUIRL, MICHELE	7/1/23	6/30/28	ZDE1-NB(13)	6952080	WADHWA, SU	LU, HELEN H	DENTISTRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$329,548	NIDCR	$312,804	$16,744	$329,548
103	Graduate Training in Nut	The discipline of nutritio	NIDDK	10887599	8/8/24	PA-18-403	5T32DK00764	7647	DENSMORE, CHRISTIN	9/15/90	8/31/25	ZDK1-GRB-T	1952696	FERRANTE, A	ZELTSER, LOR	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$319,578	NIDDK	$317,844	$16,308	$319,578
104	The Columbia University	PROJECT NARRATIVEThe	NHLBI	10899556	7/15/24	PA-20-142	5T32HL10532	105323	KALANTARI, ROYA	7/1/11	6/30/26	NHLBI Institu	1861590	BHATTACHAR	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$309,544	NHLBI	$384,180	$26,702	$309,544
105	Training in Translational	Project NarrativeThe aim	NIAID	10744233	11/7/23	PA-18-403	5T32AI14809	148099	GONDRE-LEWIS, TIMO	2/1/20	8/31/25	Allergy, Immu	1887410	SYKES, MEGA	Not Applicab	INTERNAL ME	COLUMBIA U	2/1/24	8/31/25	Training, Inst	2024	$302,148	NIAID	$317,734	$23,948	$302,148
106	Research Training in Late	Project NarrativeThere i	NIMH	10591549	6/9/23	PA-18-403	5T32MH0200	20004	CHAVEZ, MARK	7/1/98	6/30/25	ZMH1-ERB-G	10355138	BROWN, PAT	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$299,068	NIMH	$322,536	$24,139	$299,068
107	Training Grant in Diabete	The Training Grant in Dia	NIDDK	10848883	6/17/24	PA-23-048	1T32DK13195	131952	CASTLE, ARTHUR	7/1/24	5/31/29	Diabetes, End	6564579	ACCILI, DOM	PAJVANI, UTP	INTERNAL ME	COLUMBIA U	7/1/24	5/31/25	Training, Inst	2024	$298,427	NIDDK	$279,692	$18,735	$298,427
108	Global HIV Implementat	PROJECT NARRATIVEDes	NIAID	11006928	7/9/24	PA-23-048	2T32AI11439	114398	REFSLAND, ERIC WILL	9/1/14	8/31/29	Acquired Imm	8438960	HOWARD, AN	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$286,928	NIAID	$317,844	$16,308	$286,928
109	Neurobiology and Behav	PROJECT NARRATIVENeu	NIMH	10917221	8/23/24	PAR-17-096	5T32MH1260	126036	VAN'T VEER, ASHLEE V	9/1/20	8/31/25	ZNS1-SRB-X(	8613268	GRUEBER, W	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$425,050	NIGMS	$265,646	$13,078	$267,698
110	Training Grant in Pediatr	NARRATIVEMore pediatr	NIDDK	10865098	6/12/24	PA-18-403	5T32DK06552	65522	CASTLE, ARTHUR	7/1/05	6/30/25	Diabetes, End	1918410	OBERFIELD, S	Not Applicab	PEDIATRICS	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$260,271	NIDDK	$260,040	$19,003	$260,271
111	Social Determinants of H	Columbia University Mai	NIMH	10873117	6/14/24	PA-20-142	5T32MH1283	128395	ALLISON, SUSANNAH	7/1/21	6/30/26	ZAA1-GG(35)	2109075	WINGOOD, G	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$259,320	NIMH	$263,620	$13,490	$259,320
112	Hormones: Molecular Me	Project NarrativeThe goa	NIDDK	10849844	6/21/24	PA-20-142	5T32DK00732	7328	CASTLE, ARTHUR	9/15/78	6/30/26	Diabetes, End	7752388	KOUSTENI, ST	Not Applicab	PHYSIOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$225,297	NIDDK	$232,870	$13,590	$225,297
113	Vision Sciences Training	Project NarrativeThe goa	NEI	10909050	9/6/24	PA-20-142	5T32EY01393	13933	CLAYTON, EDWIN C	9/30/01	8/31/26	ZEY1-VSN(04	1879090	MASON, CAR	TROY, CARO	PATHOLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$222,768	NEI	$211,896	$10,872	$222,768
114	Advanced Graduate Trai	The complexity of neuros	NINDS	10615158	7/10/23	PA-18-403	5T32NS06492	64929	WEIGAND, LETITIA ALEX	7/1/09	6/30/25	ZNS1-SRB-L(	2201944	ABBOTT, LAU	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$213,078	NINDS	$202,776	$10,302	$213,078
115	Columbia University Gra	This competing renewal	NIAID	10841618	5/15/24	PA-18-403	5T32AI10671	106711	GONDRE-LEWIS, TIMO	6/1/14	6/30/25	Allergy, Immu	9235902	BASU, UTTIYA	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$212,360	NIAID	$211,896	$10,872	$212,360
116	Short Term Training Gran	PROJECT NARRATIVEThis	NHLBI	10833526	4/4/24	PA-18-404	5T35HL0076	7616	HILL-PRYOR, CRYSTAL	5/1/81	4/30/26	ZHL1-CSR-B	7057421	LEIBEL, RUDO	Not Applicab	PEDIATRICS	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$210,933	NHLBI	$195,308	$15,625	$210,933
117	Training in Pediatric Infe	Project NarrativeThis is a	NIAID	10661019	7/21/23	PA-18-403	5T32AI00753	7531	COOMES, STEPHANIE	9/30/98	8/31/25	Microbiology	1935964	SAIMAN, LISA	PRINCE, ALIC	PEDIATRICS	COLUMBIA U	9/1/23	8/31/25	Training, Inst	2023	$206,884	NIAID	$282,096	$18,128	$206,884
118	Advanced Graduate Trai	The goal of the proposed	NINDS	10878700	6/19/24	PAR-19-211	5T32NS06492	64928	WEIGAND, LETITIA ALEX	7/1/10	6/30/25	ZNS1-SRB-D	8737737	HENGST, ULR	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$200,104	NINDS	$249,288	$13,863	$200,104
119	Obesity Research Cente	Obesity is now among the	NIDDK	10896924	6/28/24	PA-20-142	5T32DK00755	7559	DENSMORE, CHRISTIN	7/1/89	7/31/27	ZDK1-GRB-T	1869280	GALLAGHER,	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$197,244	NIDDK	$289,676	$19,174	$197,244
120	Integrated Musculoskele	PROJECT NARRATIVEThe	NIAMS	10804662	5/3/24	PA-20-142	5T32AR08074	80744	VINCENT, ISAAH S	5/1/23	4/30/28	ZAR1-KM(M1	1880521	GUO, X. EDW	CHAHINE, N	BIOMEDICAL	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$197,168	NIAMS	$186,296	$10,872	$197,168
121	Multidisciplinary Trainin	PROJECT NARRATIVEGas	NCI	10769254	8/23/24	PA-20-142	1T32CA28527	285274	LIM, SUSAN E	9/1/24	8/31/29	Institutional	9047196	ABRAMS, JUL	RUSTGI, ANIL	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$193,144	NCI	$180,800	$12,344	$193,144
122	Columbia Integrated Tra	PROJECT NARRATIVEThis	NIAID	10814938	5/7/24	PA-20-142	5T32AI10085	100852	COOMES, STEPHANIE	6/1/13	5/31/28	Microbiology	9733196	UHLEMANN,	SOBIESZCZY	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Inst	2024	$188,707	NIAID	$198,216	$12,817	$188,707
123	Brief Research In Aging a	Project NarrativeThe Bri	NIA	10834985	6/6/24	PA-20-162	5T35AG04430	44303	WAGSTER, MOLLY V.	5/1/13	4/30/28	ZAG1-ZIJ-U(J	9773845	NOBLE, JAME	AGARWAL, SA	NEUROLOGY	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$187,816	NIA	$173,904	$13,912	$187,816
124	Research Training in Bio	PROJECT NARRATIVEThis	NIMH	10844537	7/1/24	PA-20-142	5T32MH0966	96679	CHAVEZ, MARK	6/1/13	6/30/28	ZMH1-ERB-E	6487748	ATTIA, EVELYN	WALSH, B. TI	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$176,220	NIMH	$265,308	$19,425	$176,220
125	Neurobiology and Behav	PROJECT NARRATIVENeu	NIMH	10917221	8/23/24	PAR-17-096	5T32MH1260	126036	VAN'T VEER, ASHLEE V	9/1/20	8/31/25	ZNS1-SRB-X(	8613268	GRUEBER, W	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$425,050	NIMH	$156,146	$7,686	$157,352
126	Multidisciplinary Trainin	Project NarrativeThe aim	NIAMS	10849865	6/26/24	PA-20-142	5T32AR07695	76953	VINCENT, ISAAH S	7/1/21	6/30/26	ZAR1-FY(M1)	1964244	BATHON, JOA	WINCHESTE	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$137,882	NIAMS	$169,720	$12,378	$137,882
127	GSH Training Grant	PROJECT NARRATIVENat	NICHD	10892748	5/29/24	PA-20-142	5T32HD0493	49339	CAPPS, RANDOLPH CH	5/9/06	4/30/27	ZHD1-DSR-R	1950424	HIRSCH, JEN	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$115,696	NICHD	$209,896	$10,712	$115,696
128	Research Training Progra	Project Narrative:Menta	NIMH	10847982	6/5/24	PA-23-048	1T32MH1358	135856	CHAVEZ, MARK	7/1/24	6/30/29	Special Emph	8874378	WANG, YUAN	OGDEN, TOD	BIOSTATISTIC	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$110,844	NIMH	$105,448	$5,396	$110,844
129	Training Medical Student	Project NarrativeThe ma	NIDDK	10820478	5/1/24	PA-20-162	5T35DK09343	93430	CASTLE, ARTHUR	3/15/12	4/30/27	Kidney, Urolo	1860269	AL-AWQATI, Q	PAJVANI, UTP	INTERNAL ME	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$103,318	NIDDK	$98,922	$7,914	$103,318
130	Functional interrogation	PROJECT NARRATIVEThis	NIMH	10915447	8/28/24	RFA-MH-20-620	5F32MH1300	130023	VAN'T VEER, ASHLEE V	9/1/22	8/31/25	ZMH1-ERB-L	78260336	YI, JANE	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$84,254	NINDS	$84,254	$0	$84,254
131	Unraveling the neural me	PROJECT NARRATIVETo r	NIDA	10902676	3/14/24	PA-21-048	1F32DA0607	60751	LIN, YU	5/1/24	4/30/27	Special Emph	77856830	SHEN, JIA	Not Applicab	NEUROSCIEN	COLUMBIA U	5/1/24	4/30/25	Training, Indi	2024	$82,192	NIDA	$82,192	$0	$82,192
132	Understanding the indivi	PROJECT NARRATIVEHaz	NIAAA	10867417	8/7/24	PA-21-048	5F32AA02995	29957	KERRIDGE, BRADLEY T	8/1/22	7/31/25	ZAA1-GG(32)	14982558	BOCHICCHIO	Not Applicab	OTHER HEALT	COLUMBIA U	8/1/24	7/31/25	Training, Indi	2024	$78,892	NIAAA	$78,892	$0	$78,892
133	Fast and Flexible Conjun	Project NarrativeThe hur	NEI	10809777	4/3/24	PA-21-048	5F32EY03365	33654	AGARWAL, NEERAJ	4/16/22	4/15/25	Special Emph	78107930	TAYLOR, JOH	Not Applicab	PSYCHOLOG	COLUMBIA U	4/16/24	4/15/25	Training, Indi	2024	$74,284	NEI	$74,284	$0	$74,284
134	Photocatalytic Generati	PROJECT NARRATIVE Ne	NIGMS	11014961	12/23/24	PA-21-048	5F32GM1530	153032	STAMM, JOYCE CHIN-C	1/10/24	1/9/27	Special Emph	15873294	KARIOFILLIS,	Not Applicab	CHEMISTRY	COLUMBIA U	1/10/25	1/9/26	Training, Indi	2025	$74,284	NIGMS	$74,284	$0	$74,284
135	Caregiver influences on	PROJECT NARRATIVEMe	NICHD	10997094	8/22/24	PA-23-262	1F32HD1144	114417	MANN KOEPKE, KATHY	11/1/24	10/31/27	Special Emph	79078686	YATES, TRIST	Not Applicab	PSYCHOLOG	COLUMBIA U	11/1/24	10/31/25	Training, Indi	2024	$73,828	NICHD	$73,828	$0	$73,828
136	Discovering how emergir	PROJECT NARRATIVE We	NICHD	10996977	7/27/24	PA-23-262	1F32HD1166	116657	MILLER, BRETT	11/16/24	11/15/27	Special Emph	16076737	FOREST, TESS	Not Applicab	PSYCHOLOG	COLUMBIA U	11/16/24	11/15/25	Training, Indi	2024	$73,828	NICHD	$73,828	$0	$73,828
137	Integrating biomaterials	Project NarrativeGlycan	NIBIB	11071622	11/27/24	PA-23-262	1F32EB03692	36927	GUTEKUNST, DAVID JO	1/1/25	12/31/28	Special Emph	12489535	HINCAPIE, RO	Not Applicab	BIOMEDICAL	COLUMBIA U	1/1/25	12/31/25	Training, Indi	2025	$73,828	NIBIB	$73,828	$0	$73,828
138	Striatal Dopamine's Role	Project NarrativeImpaire	NIMH	10824454	9/13/23	PA-21-048	1F32MH1355	135597	PINARD, COURTNEY	3/2/24	10/31/28	Special Emph	14218632	DECORTE, BE	Not Applicab	PSYCHIATRY	COLUMBIA U	3/2/24	10/31/26	Training, Indi	2023	$73,580	NIMH	$73,580	$0	$73,580
139	Resting state connectivi	PROJECT NARRATIVEObs	NIMH	10904864	8/7/24	PA-21-049	5F30MH1265	126504	BECHTHOLT, ANITA J	9/1/21	8/31/25	Special Emph	15267921	SHI, TRACEY	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$56,974	NIMH	$56,974	$0	$56,974
140	Alzheimer's Disease Gen	PROJECT NARRATIVEGer	NIA	10906795	8/30/24	PA-21-049	5F30AG0746	74618	SARE, RACHEL	9/1/21	8/31/25	Special Emph	15267909	CHATILA, ZEN	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$53,974	NIA	$53,974	$0	$53,974
141	Quantifying the interacti	NarrativePreterm birth i	NICHD	10914690	8/8/24	PA-21-049	5F30HD1088	108886	GIRARDI, GUILLERMIN	9/15/22	9/14/26	Special Emph	15827843	KINDSCHUH	Not Applicab	BIOCHEMIST	COLUMBIA U	9/15/24	9/14/25	Training, Indi	2024	$53,974	NICHD	$53,974	$0	$53,974
142	Contribution of PAG to In	PROJECT NARRATIVEDes	NCI	10888994	6/17/24	PA-21-049	5F30CA2716	271624	ODEH, HANA M	7/15/22	7/14/26	Special Emph	15827894	MOORE, EMI	Not Applicab	INTERNAL ME	COLUMBIA U	7/15/24	7/14/25	Training, Indi	2024	$53,974	NCI	$53,974	$0	$53,974
143	Leveraging CRISPR RNA-	PROJECT NARRATIVEDes	NHLBI	11005254	12/23/24	PA-21-052	5F31HL16753	167530	REYES, MADELYN	2/1/23	1/31/27	Special Emph	15074693	KING, REBEC	Not Applicab	BIOCHEMIST	COLUMBIA U	2/1/25	1/31/26	Training, Indi	2025	$53,974	NHLBI	$53,974	$0	$53,974
144	Targeting Neuron-Microg	PROJECT NARRATIVENea	NCI	10875397	5/31/24	PA-19-191	5F30CA2577	257768	PURI, ANU	6/15/21	6/14/25	Special Emph	15271056	GOLDBERG,	Not Applicab	PATHOLOGY	COLUMBIA U	6/15/24	6/14/25	Training, Indi	2024	$53,974	NCI	$53,974	$0	$53,974
145	Deciphering mechanism	PROJECT NARRATIVEPat	NIDCD	10906823	8/27/24	PA-21-049	5F30DC0209	20900	SCHURMAN, JACLYN R	9/1/22	8/31/26	ZDC1-SRB-E	15827862	POURMORAD	Not Applicab	BIOCHEMIST	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$53,974	NIDCD	$53,974	$0	$53,974
146	Adipocyte-derived exoso	Project NarrativeAdipose	NIDDK	10902095	8/7/24	PA-21-049	5F30DK1290	129008	CASTLE, ARTHUR	9/15/21	9/14/25	ZDK1-GRB-2	15267915	GOODMAN, J	Not Applicab	INTERNAL ME	COLUMBIA U	9/15/24	9/14/25	Training, Indi	2024	$53,974	NIDDK	$53,974	$0	$53,974
147	Elucidating the role of Fr	PROJECT NARRATIVEAcu	NIDDK	10862718	6/17/24	PA-21-049	5F30DK1341	134109	DENSMORE, CHRISTIN	7/1/22	6/30/26	ZDK1-GRB-7	15827849	LI, ALINA LIN	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$53,974	NIDDK	$53,974	$0	$53,974
148	Modulation of Heterome	PROJECT NARRATIVEThe	NINDS	11031948	2/13/25	PA-21-051	5F31NS1325	132554	UMANAH, GEORGE KW	2/1/24	1/31/27	Special Emph	77858962	YEN, LAURA Y	Not Applicab	PHYSIOLOGY	COLUMBIA U	2/1/25	1/31/26	Training, Indi	2025	$51,974	NINDS	$51,974	$0	$51,974
149	Induction and maintenar	PROJECT NARRATIVEVac	NIAID	10891422	6/4/24	PA-21-049	5F30AI17478	174785	ARNOLD, MICHELLE M	7/1/23	6/30/27	Special Emph	16529540	DAVIS-PORAD	Not Applicab	SURGERY	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$50,974	NIAID	$50,974	$0	$50,974
150	Multiscale imaging of co	PROJECT NARRATIVERea	NIMH	10901194	3/8/24	PA-21-049	1F30MH1356	135661	VAN'T VEER, ASHLEE V	3/15/24	3/14/28	Special Emph	16529550	GRUSKIN, DA	Not Applicab	NEUROSCIEN	COLUMBIA U	3/15/24	3/14/25	Training, Indi	2024	$50,937	NIMH	$50,937	$0	$50,937
151	Impact of Species-Speci	PROJECT NARRATIVESyn	NIMH	10899947	3/8/24	PA-21-049	1F30MH1366	136683	DRISCOLL, JAMIE	7/1/24	6/30/27	Special Emph	78213242	RECUPERO, A	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$50,937	NIMH	$50,937	$0	$50,937
152	Engineering a strategy fo	PROJECT NARRATIVEThe	NHLBI	10998065	9/10/24	PA-23-260	1F30HL1740	174098	MEADOWS, TAWANNA	9/15/24	9/14/27	Special Emph	78213224	CORDOVES,	Not Applicab	INTERNAL ME	COLUMBIA U	9/15/24	9/14/25	Training, Indi	2024	$50,937	NHLBI	$50,937	$0	$50,937
153	Mechanisms of reverse t	PROJECT NARRATIVE Wit	NIAID	10901546	1/25/24	PA-21-049	1F30AI18383	183830	ERNST, NANCY L.	7/1/24	6/30/27	Special Emph	78213245	TANG, STEPH	Not Applicab	BIOCHEMIST	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$50,937	NIAID	$50,937	$0	$50,937
154	Targeting Purinergic Sign	PROJECT NARRATIVEGlic	NCI	10825218	3/11/24	PA-21-049	1F30CA2880	288006	PURI, ANU	3/15/24	3/14/28	Special Emph	16529573	PEREIRA, BRI	Not Applicab	PATHOLOGY	COLUMBIA U	3/15/24	3/14/25	Training, Indi	2024	$50,937	NCI	$50,937	$0	$50,937
155	Improving bacterial canc	PROJECT NARRATIVEBac	NCI	11112287	2/28/25	PA-21-049	5F30CA2877	287792	PURI, ANU	3/1/24	2/28/28	Special Emph	16529535	CHEN, NOAH	Not Applicab	MICROBIOLO	COLUMBIA U	3/1/25	2/28/26	Training, Indi	2025	$50,937	NCI	$50,937	$0	$50,937
156	Disentangling the roles o	PROJECT NARRATIVECel	NIDCD	11165197	12/9/24	PA-23-260	1F30DC0227	22796	SCHURMAN, JACLYN R	1/15/25	1/14/29	Special Emph	78213239	MIHAILA, TIB	Not Applicab	BIOCHEMIST	COLUMBIA U	1/15/25	1/14/26	Training, Indi	2025	$50,928	NIDCD	$50,928	$0	$50,928
157	Investigating the Impact	PROJECT NARRATIVEAlzh	NIA	10902945	7/3/24	PA-21-049	1F30AG0843	84312	MACKIEWICZ, MIROSL	7/3/24	7/2/28	Special Emph	16529554	JIN, MICHELL	Not Applicab	PSYCHIATRY	COLUMBIA U	7/3/24	7/2/25	Training, Indi	2024	$50,414	NIA	$50,414	$0	$50,414
158	Epigenetic and Neurona	PROJECT NARRATIVERet	NICHD	10902891	9/10/24	PA-21-049	1F30HD1153	115371	OREILLY, JULIA JIAQI	9/16/24	9/15/28	Special Emph	16529563	PAN, RICHAR	Not Applicab	PHYSIOLOGY	COLUMBIA U	9/16/24	9/15/25	Training, Indi	2024	$50,414	NICHD	$50,414	$0	$50,414
159	RNA Decay of LINE-1 Ret	PROJECT NARRATIVEIn o	NIAID	10902832	7/9/24	PA-21-049	1F30AI17918	179182	GONDRE-LEWIS, TIMO	7/15/24	7/14/27	Special Emph	16529555	LAURING, MA	Not Applicab	MICROBIOLO	COLUMBIA U	7/15/24	7/14/25	Training, Indi	2024	$50,414	NIAID	$50,414	$0	$50,414
160	Transcriptional regulatio	PROJECT NARRATIVEHur	NIDCR	10908411	7/26/24	PA-21-051	5F31DE0319	31970	FUQUA, CHANTEL FAYS	9/1/22	8/31/25	National Inst	16077152	ANDERSON,	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$49,774	NIDCR	$49,774	$0	$49,774
161	ECM remodeling and cro	PROJECT NARRATIVE Joi	NIDCR	10979141	7/26/24	PA-21-051	5F31DE0332	33220	FUQUA, CHANTEL FAYS	9/1/23	8/31/26	Special Emph	77792546	MO, JULIA	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$49,774	NIDCR	$49,774	$0	$49,774
162	Testing competing mode	Project Narrative:Halluc	NIMH	10869925	6/21/24	PA-21-051	5F31MH1346	134617	AVENILLA, FRANK	7/1/23	6/30/25	Special Emph	16104095	BUCK, JUSTIN	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,994	NIMH	$48,994	$0	$48,994
163	Acetylation as a novel po	PROJECT NARRATIVE-ce	NIDDK	10903057	2/14/24	PA-21-051	1F31DK1376	137600	CASTLE, ARTHUR	6/1/24	5/31/26	Fellowships i	77823297	CHIRIKJIAN,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Indi	2024	$48,974	NIDDK	$48,974	$0	$48,974
164	Immature neutrophil mig	PROJECT NARRATIVEObe	NIDDK	11071091	12/24/24	PA-23-272	1F31DK1425	142531	CASTLE, ARTHUR	12/24/24	12/23/26	Fellowships i	77812251	QUIN WATER	Not Applicab	INTERNAL ME	COLUMBIA U	12/24/24	12/23/25	Training, Indi	2025	$48,974	NIDDK	$48,974	$0	$48,974
165	The genomic and synapti	Project NarrativeLearne	NIDCD	11071726	8/20/24	PA-23-272	1F31DC0221	22183	SCHURMAN, JACLYN R	9/1/24	8/31/27	Special Emph	79511585	NARAYANAN,	Not Applicab	ENGINEERIN	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIDCD	$48,974	$0	$48,974
166	Synergistic contribution	PROJECT NARRATIVEThis	NIA	10998809	8/13/24	PA-23-272	1F31AG0900	90091	SARE, RACHEL	9/1/24	8/31/27	Special Emph	79142637	EDWARDS, N	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIA	$48,974	$0	$48,974
167	The impact of Alzheimer'	PROJECT NARRATIVEAlzh	NIA	10997953	8/19/24	PA-23-272	1F31AG0900	90071	WAGSTER, MOLLY V.	9/1/24	8/31/26	Special Emph	15977956	BULTHUIS, N	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIA	$48,974	$0	$48,974
168	Brain-wide neural mecha	PROJECT NARRATIVE Cry	NICHD	10903156	4/5/24	PA-21-052	1F31HD1144	114466	MANN KOEPKE, KATHY	4/5/24	9/4/26	Special Emph	77842692	MCRAE, BRIA	Not Applicab	NEUROSCIEN	COLUMBIA U	4/5/24	4/4/25	Training, Indi	2024	$48,974	NICHD	$48,974	$0	$48,974
169	Impact of developmenta	PROJECT NARRATIVEPre	NIMH	11071345	8/30/24	PA-23-271	1F31MH1381	138134	PINARD, COURTNEY	9/1/24	2/28/27	Special Emph	78316229	ANQUEIRA, A	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIMH	$48,974	$0	$48,974
170	Impact of social environm	PROJECT NARRATIVEThe	NIMH	10902956	3/5/24	PA-21-052	1F31MH1368	136812	PINARD, COURTNEY	7/1/24	6/30/27	Special Emph	78640196	BRAVO, ISAB	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,974	NIMH	$48,974	$0	$48,974
171	Regeneration of Thalamo	Project Narra+veThis pro	NINDS	11070946	11/21/24	PA-23-272	1F31NS1416	141628	OSBORNE, LESLIE CAR	12/1/24	9/30/27	Special Emph	79678097	CHUA, JIANM	Not Applicab	BIOLOGY	COLUMBIA U	12/1/24	11/30/25	Training, Indi	2025	$48,974	NINDS	$48,974	$0	$48,974
172	The Cellular and Neural (	PROJECT NARRATIVEFlex	NINDS	10903100	3/20/24	PA-21-051	1F31NS1377	137735	GREENWELL, THOMAS	4/1/24	3/31/27	Special Emph	77842705	WOOD, ABBY	Not Applicab	NEUROSCIEN	COLUMBIA U	4/1/24	3/31/25	Training, Indi	2024	$48,974	NINDS	$48,974	$0	$48,974
173	Determining how a single	Project Narrative1. PKR	NINDS	10997698	6/27/24	PA-23-271	1F31NS1396	139626	SIEBER, BETH-ANNE	7/1/24	6/30/28	Special Emph	14938537	GERTIE, JAKE	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,974	NINDS	$48,974	$0	$48,974
174	Interrogation of non-can	PROJECT NARRATIVEVolt	NINDS	10902910	3/29/24	PA-21-052	1F31NS1377	137770	MATOS GALICIA, HEID	9/1/24	8/31/27	Special Emph	15147704	HELMS, KYLE	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NINDS	$48,974	$0	$48,974
175	Elucidating the complex	PROJECT NARRATIVEAllo	NIAID	10903188	8/6/24	PA-21-051	1F31AI18413	184134	XU, ZUOYU	9/1/24	8/31/27	Special Emph	78329645	SUNDBERG,	Not Applicab	BIOCHEMIST	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIAID	$48,974	$0	$48,974
176	Mechanistic insights into	Project NarrativePhosph	NIAID	10826774	7/22/24	PA-21-051	1F31AI18155	181556	GU, XIN-XING	9/1/24	8/31/26	Special Emph	16104164	ZINKLE, ALLE	Not Applicab	PHYSIOLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIAID	$48,974	$0	$48,974
177	Biomechanics and mech	PROJECT NARRATIVEUte	NICHD	10902995	8/8/24	PA-21-051	1F31HD1144	114449	AHN, HELENA HYESOO	9/1/24	8/31/26	Special Emph	15967517	FODERA, DA	Not Applicab	BIOMEDICAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NICHD	$48,974	$0	$48,974
178	Investigating the role of c	PROJECT NARRATIVEThe	NIAID	11071146	11/26/24	PA-23-272	1F31AI18888	188882	GONDRE-LEWIS, TIMO	12/1/24	11/30/27	Special Emph	79078562	WHISENANT,	Not Applicab	MICROBIOLO	COLUMBIA U	12/1/24	11/30/25	Training, Indi	2025	$48,974	NIAID	$48,974	$0	$48,974
179	Host Factors Required b	Project NarrativeThe Par	NIAID	10824958	3/6/24	PA-21-051	1F31AI17676	176760	KIM, SONNIE	3/6/24	3/5/26	Special Emph	77858958	STEARNS, KY	Not Applicab	PHYSIOLOGY	COLUMBIA U	3/6/24	3/5/25	Training, Indi	2024	$48,974	NIAID	$48,974	$0	$48,974
180	Investigating the Geneti	PROJECT NARRATIVEBas	NHLBI	10998862	8/13/24	PA-23-272	1F31HL17616	176168	SOOD, BEENA G	9/1/24	8/31/27	Special Emph	78335692	DIRVIN, BRO	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NHLBI	$48,974	$0	$48,974
181	Type I Interferon Mediate	PROJECT NARRATIVEVas	NINDS	11003276	12/9/24	PA-21-051	5F31NS1309	130983	HEWETT, SANDRA JEAN	1/15/23	1/14/26	Special Emph	15827872	TUOHY, MARY	Not Applicab	NEUROLOGY	COLUMBIA U	1/15/25	1/14/26	Training, Indi	2025	$48,974	NINDS	$48,974	$0	$48,974
182	Therapeutic Editing of Rc	PROJECT NARRATIVEPho	NEI	11042742	1/22/25	PA-21-051	5F31EY03366	33660	AGARWAL, NEERAJ	2/1/23	1/31/26	Special Emph	78103980	NOLAN, NICH	Not Applicab	OPHTHALMO	COLUMBIA U	2/1/25	1/31/26	Training, Indi	2025	$48,974	NEI	$48,974	$0	$48,974
183	Interactions between mc	PROJECT NARRATIVEThe	NIMH	10928756	8/29/24	PA-21-051	5F31MH1333	133351	PINARD, COURTNEY	9/8/23	9/7/25	Special Emph	16366203	GASSER, CAM	Not Applicab	PSYCHOLOG	COLUMBIA U	9/8/24	9/7/25	Training, Indi	2024	$48,974	NIMH	$48,974	$0	$48,974
184	Inhibition of CD33-sialic	PROJECT NARRATIVEWh	NIA	10928124	8/27/24	PA-21-051	5F31AG0796	79613	SARE, RACHEL	9/1/23	8/31/26	Special Emph	16177782	GREEN, JENN	Not Applicab	PHARMACOL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIA	$48,974	$0	$48,974
185	Understanding and Cont	Project NarrativeMecha	NICHD	10914666	8/7/24	PA-20-246	5F31HD1054	105405	MUKHOPADHYAY, MAH	9/1/21	8/31/25	Special Emph	16124527	CUPO, CHRIS	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NICHD	$48,974	$0	$48,974
186	Mechanisms underlying t	Project Narrative While	NIA	10909146	8/26/24	PA-21-051	5F31AG0796	79601	FRIDELL, YIH-WOEI	9/1/22	8/31/25	Special Emph	16077168	GATTO, JARED	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIA	$48,974	$0	$48,974
187	A Novel Long Noncoding	PROJECT NARRATIVESys	NIAID	10886817	6/5/24	PA-21-051	5F31AI17231	172316	GONDRE-LEWIS, TIMO	7/1/22	6/30/25	Special Emph	78206283	TIAN, RUXIAO	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,974	NIAID	$48,974	$0	$48,974
188	Mechanisms controlling	Project narrativeMany tr	NICHD	11099655	7/9/24	PA-21-051	5F31HD1102	110242	STEIN, KATHRYN K	7/1/23	6/30/26	Special Emph	16027869	MUNCE, ROS	Not Applicab	GENETICS	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,974	NICHD	$48,974	$0	$48,974
189	Chromosomal instability	PROJECT NARRATIVEBra	NCI	10842249	6/6/24	PA-21-049	5F30CA2811	281104	BIAN, YANSONG	7/1/23	6/30/28	Special Emph	16529522	CAPRIO, LIND	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,974	NCI	$48,974	$0	$48,974
190	Prenatal exposure to pht	PROJECT NARRATIVEPht	NIEHS	10923843	7/25/24	PA-21-051	5F31ES03497	34972	BOYLES, ABEE	9/1/23	8/31/25	Special Emph	78596921	SIDDIQ, SHA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIEHS	$48,974	$0	$48,974

A2710

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
191	Examining Individuals' Ex	PROJECT NARRATIVERes	NIAAA	10908296	8/2/24	PA-21-051	5F31AA0311	31193	BLOSS, GREGORY	9/1/23	8/31/25	ZAA1-GG(32)	78548327	MEHRANBOD	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIAAA	$48,974	$0	$48,974
192	Auditory cortical tuning t	Project Narrative Deficit	NIDCD	10904727	7/10/24	PA-21-051	5F31DC0209	20904	SCHURMAN, JACLYN R	9/1/22	8/31/25	ZDC1-SRB-Y	78565715	EDWARDS, JA	Not Applicab	PSYCHOLOG	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIDCD	$48,974	$0	$48,974
193	Data-Driven Discovery o	PROJECT NARRATIVEThis	NIA	10915420	8/9/24	PA-21-051	5F31AG0796	79627	MARTIN, DAMALI	9/1/23	8/31/25	Special Emph	16354815	JAWADEKAR,	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,214	NIA	$48,214	$0	$48,214
194	Regulation and function	Project NarrativeMitoch	NINDS	10888185	6/17/24	PA-21-051	5F31NS1291	129199	MILLER, DANIEL L	7/1/22	6/30/25	Special Emph	16486772	DONOVAN, E	Not Applicab	BIOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,123	NINDS	$48,123	$0	$48,123
195	Associations among mat	PROJECT NARRATIVETho	NICHD	10898330	7/23/24	PA-21-051	1F31HD1153	115324	GRIFFIN, JAMES	8/1/24	7/31/26	Special Emph	78158033	SPERBER, JES	Not Applicab	PSYCHOLOG	COLUMBIA U	8/1/24	7/31/25	Training, Indiv	2024	$42,574	NICHD	$42,574	$0	$42,574
196	Linking endoplasmic reti	Project NarrativeNeurot	NEI	11002649	11/29/24	PA-21-052	5F31EY03516	35165	AGARWAL, NEERAJ	12/16/23	12/15/26	Special Emph	15050727	DELGADO, KA	Not Applicab	BIOLOGY	COLUMBIA U	12/16/24	12/15/25	Training, Indiv	2025	$42,574	NEI	$42,574	$0	$42,574
197	Parent-adolescent inforr	PROJECT NARRATIVESuic	NICHD	10996097	2/20/25	PA-21-051	5F31HD1112	111295	ESPOSITO, LAYLA E	1/1/24	1/1/27	Special Emph	78597909	SPEARS, ANG	Not Applicab	PSYCHOLOG	COLUMBIA U	1/2/25	1/1/26	Training, Indiv	2025	$41,294	NICHD	$41,294	$0	$41,294
198	Investigating the potenti	PROJECT NARRATIVEMat	NIAID	10824991	3/22/24	PA-21-051	1F31AI17685	176851	BOZICK, BROOKE ALLIS	8/1/24	7/31/26	Special Emph	77847671	GORIN, EMM	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Training, Indiv	2024	$36,053	NIAID	$36,053	$0	$36,053
199	Long-term exposure to ai	PROJECT NARRATIVEThis	NIEHS	10922694	8/12/24	PA-21-051	5F31ES03530	35306	JOUBERT, BONNIE	9/1/23	8/31/26	Special Emph	78344631	MEDGYESI, D	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$35,958	NIEHS	$35,958	$0	$35,958
200	Examining Social Ecolog	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEALT	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NIAID	$1,700,392	$849,988	$2,550,380
201	Examining Social Ecolog	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEALT	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NICHD	$233,353	$116,647	$350,000
202	Examining Social Ecolog	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEALT	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NIAAA	$100,009	$49,991	$150,000
203	NY Community-Hospital	OVERALL PROJECT NARR	NICHD	10908625	7/17/24	RFA-HD-23-035	5U54HD1131	113172	FABIYI, CAMILLE	8/17/23	7/31/30	Special Emph	15745999	REDDY, UMA	BROWN, SEV	OBSTETRICS	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$2,265,444	NICHD	$1,825,476	$439,968	$2,265,444
204	The Empilisweni Center f	Project NarrativeAlthoug	NCI	10931463	7/29/24	RFA-CA-22-019	5U54CA2840	284030	SIVARAM, SUDHA	9/19/23	8/31/28	ZCA1-SRB-2(	7012821	CASTOR, DEL	ARENDSE, JU	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,068,363	NCI	$850,447	$217,916	$1,068,363
205	MyPEEPS Mobile Plus: A N	PROJECT NARRATIVEHIV	NIMHD	10933040	3/22/24	RFA-MD-23-008	5R01MD019	19181	FERNANDEZ, ANGELA	9/21/23	3/31/28	ZMD1-IN(A1)	9765581	SCHNALL, RE	GAROFALO, R	OTHER HEALT	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$989,833	NIMHD	$754,827	$235,006	$989,833
206	Integrated Supportive Ca	Policy solutions that cen	NINR	10933006	6/26/24	RFA-NR-23-002	5R01NR0211	21108	GIVENS-BRADLEY, SHA	9/21/23	6/30/28	Special Emph	15823607	DAW, JAMIE R	DORVAL-MO	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$743,447	NINR	$505,099	$238,348	$743,447
207	Mental Health of Latino A	Exposures to deprivation	NIMHD	10839331	11/29/23	PAR-21-080	5R01MD0172	17273	STINSON, NATHANIEL	5/9/23	11/30/28	Psychosocial	1869481	ORJUELA, MA	LEWIS-FERN	PUBLIC HEAL	COLUMBIA U	12/1/23	11/30/25	Non-SBIR/ST	2024	$687,188	NIMHD	$422,830	$264,358	$687,188
208	Multidimensional and lo	PROJECT NARRATIVEThe	NIAID	10938759	9/12/24	PA-20-185	1R01AI18499	184997	MINNICOZZI, MICHAE	9/12/24	7/31/29	Population ba	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	9/12/24	7/31/25	Non-SBIR/ST	2024	$615,891	NIAID	$425,191	$190,700	$615,891
209	Strategies for Reaching a	Project NarrativeAdvanc	NCI	10856030	3/13/24	PAR-22-105	1R01CA2892	289295	MARCUS, PAMELA M.	4/1/24	3/31/29	Special Emph	9837872	SHELTON, RA	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$542,964	NCI	$396,853	$146,111	$542,964
210	Reframing personal and c	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RO	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	NIEHS	$159,622	$70,683	$230,305
211	Reframing personal and c	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RO	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	NHGRI	$69,309	$30,691	$100,000
212	Reframing personal and c	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RO	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	OD	$69,309	$30,691	$100,000
213	CADRE Program for Post	PROJECT NARRATIVEIt is	NINDS	10987061	11/29/24	RFA-NS-22-035	5R25NS1309	130961	MATTHEWS, MARGUER	12/1/22	11/30/26	ZNS1-SRB-D	8613268	GRUEBER, W	HENGST, ULF	PHYSIOLOGY	COLUMBIA U	12/1/24	11/30/25	Other Resear	2025	$424,202	NINDS	$392,780	$31,422	$424,202
214	SEARCH: SMS Electronic	PUBLIC HEALTH RELEVAN	NCI	10919236	7/19/24	PAR-19-376	5R33CA2536	253604	PEARLMAN, PAUL C	8/1/20	7/31/26	Special Emph	9013927	STOCKWELL,	KITAKA, SABR	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$246,609	NCI	$195,292	$46,317	$241,609
215	SEARCH: SMS Electronic	PUBLIC HEALTH RELEVAN	NCI	10919236	7/19/24	PAR-19-376	5R33CA2536	253604	PEARLMAN, PAUL C	8/1/20	7/31/26	Special Emph	9013927	STOCKWELL,	KITAKA, SABR	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$246,609	FIC	$4,042	$958	$5,000
216	Multimodal immune prof	PROJECT NARRATIVEThe	NIAID	10651894	5/16/23	PA-20-195	5R21AI17124	171249	PLIMACK, MARY KATHE	6/23/22	5/31/25	Clinical Rese	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$236,190	NIAID	$151,692	$84,498	$236,190
217	Training in Cardiovascula	PROJECT NARRATIVEThe	NHLBI	10863934	4/1/24	RFA-HL-19-024	5R25HL1560	156002	MEADOWS, TAWANNA	5/1/21	4/30/26	ZHL1-CSR-A(	1859027	MARKS, AND	Not Applicab	PHYSIOLOGY	COLUMBIA U	5/1/24	4/30/25	Other Resear	2024	$123,984	NHLBI	$114,800	$9,184	$123,984
218	The Role of Social Deterr	PROJECT NARRATIVEOve	NINR	10995462	7/2/24	PA-23-272	1F31NR0213	21330	WILLIS, LEIGH ANDREV	9/1/24	8/31/26	National Inst	15467797	HAHN, ALEXA	Not Applicab	OTHER HEALT	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$51,974	NINR	$51,974	$0	$51,974
219	Does self-reported psych	PROJECT NARRATIVEHyp	NICHD	11105757	8/6/24	PA-21-052	5F31HD1102	110257	MITCHELL, MEGAN S	9/1/23	8/31/25	Special Emph	15784692	CLEMONS, A	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,214	NICHD	$48,214	$0	$48,214
220	Brain Research Apprenti	PROJECT NARRATIVEThe	NINDS	11058915	12/20/24	PAR-21-168	2R25NS1155	115551	MATTHEWS, MARGUER	12/5/20	1/31/30	Special Emph	9307525	SHOHAMY, D	EL-SHAMAYL	PSYCHOLOG	COLUMBIA U	2/1/25	1/31/26	Other Resear	2025	$135,000	NINDS	$125,000	$10,000	$135,000
221	Summer Institute for Tra	PROJECT NARRATIVETec	NHLBI	11011475	1/2/25	RFA-HL-22-009	5R25HL1617	161786	COADY, SEAN	1/15/22	12/31/26	ZHL1-CSR-A(	7347011	BERHANE, KI	MAURO, CHR	BIOSTATISTIC	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$238,222	NHLBI	$155,181	$8,041	$163,222
222	Summer Institute for Tra	PROJECT NARRATIVETec	NHLBI	11011475	1/2/25	RFA-HL-22-009	5R25HL1617	161786	COADY, SEAN	1/15/22	12/31/26	ZHL1-CSR-A(	7347011	BERHANE, KI	MAURO, CHR	BIOSTATISTIC	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$238,222	OD	$71,306	$3,694	$75,000
223	The linkage between Rac	Elevated expression of th	NCI	10891394	9/11/24	PAR-18-654	5R01CA2533	253368	MERCER, NATALIA	9/24/20	6/30/25	Special Emph	1926891	GARDNER, K	Not Applicab	PATHOLOGY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$625,704	NCI	$482,854	$142,850	$625,704
224	A Multilevel Investigation	Project NarrativeMexico	NIA	10979824	8/26/24	RFA-AG-24-028	1R01AG0891	89174	BANDIERA, FRANK	9/1/24	5/31/29	Special Emph	11055051	ZEKI AL HAZZ	GLYMOUR, M	PUBLIC HEAL	COLUMBIA U	9/1/24	5/31/25	Non-SBIR/ST	2024	$839,262	NIA	$608,095	$231,167	$839,262
225	The SDOH-Homecare Int	Project Narrative: Stroke	NINDS	11012850	2/19/25	PA-20-183	5U01NS1355	135533	SANKAR, CHERYSE A	2/1/24	1/31/29	Health Servic	8840097	WILLIAMS, O	MARSHALL, R	NEUROLOGY	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$1,086,080	NINDS	$710,421	$375,659	$1,086,080
226	CE24-001 Columbia Cen	Columbia Center for Inju	NCIPC	10762286	7/29/24	RFA-CE-24-001	1R49CE0035	3555		8/1/24	7/31/29	Special Emph	1974739	BRANAS, CH	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other	2023	$849,985	NCIPC			$849,985
227	Dissecting the role of lon	PROJECT NARRATIVELon	NIDA	11003839	7/22/24	PAR-23-194	1R36DA0616	61635	DUNSTON, SHEBA KIN	8/1/24	7/31/26	Special Emph	78302176	MARZIALI, ME	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$51,390	NIDA	$48,116	$3,274	$51,390
228	Drinking water contamin	PROJECT NARRATIVEClin	NIEHS	10727706	9/8/23	PA-20-200	1R03ES0355(	35509	BOYLES, ABEE	9/10/23	8/31/25	Reproductive	14259321	GOIN, DANA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/10/23	8/31/25	Non-SBIR/ST	2023	$185,979	NIEHS	$124,036	$61,943	$185,979
229	HIV Intervention Science	PROJECT NARRATIVE The	NIMH	10442449	8/21/23	PAR-15-145	5R25MH0806	80665	ALLISON, SUSANNAH	4/16/07	6/30/25	ZMH1-ERB-X	1891871	EL-BASSEL, N	WU, ELWIN	OTHER HEALT	COLUMBIA U	7/1/23	6/30/25	Other Resear	2023	$132,524	NIMH	$245,414	$19,633	$132,524
230	GLASS-AD: Global Latino	NARRATIVE.Hispanics/La	NIA	10935947	8/29/24	PAR-21-212	5U01AG0818	81817	BENNANI-BAITI, MICH	9/30/23	8/31/28	ZAG1-ZIJ-4(J	11677901	TOSTO, GIUS	MARTIN, EDE	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	$2,682,382	NIA	$2,341,785	$340,597	$2,682,382
231	Pediatric Heart Network	PROJECT NARRATIVEThe	NHLBI	11005047	12/24/24	RFA-HL-24-001	5UM1HL1727	172720	OJESE, OLANREWAJU C	1/1/24	12/31/30	ZHL1-CSR-Q	14396086	RICHMOND,	ANDERSON,	PEDIATRICS	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$419,349	NHLBI	$298,514	$120,835	$419,349
232	Prenatal Exposure to Air	NARRATIVEThis proposal	NIEHS	10981407	9/5/24	PA-20-185	1R01ES0357	35792	GRAY, KIMBERLY A	9/6/24	6/30/29	Social and En	10550576	MARGOLIS, A	FOX, NATHAN	PSYCHIATRY	COLUMBIA U	9/6/24	6/30/25	Non-SBIR/ST	2024	$701,902	NIEHS	$494,571	$207,331	$701,902
233	Strengthening Healthcar	Project NarrativeThe pro	NINDS	11062246	9/10/24	PA-20-272	3R01NS1236	123639	YIN, XILING	6/15/21	6/30/25	Acute Neural	11309584	MASTERSON	GAUDINO, M	OTHER HEALT	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$157,869	OD	$95,969	$61,900	$157,869
234	Summer Biomechanics E	NARRATIVEThe 2023-202	NIBIB	10836043	5/29/24	PA-21-151	5R13EB0350	35037	GUTEKUNST, DAVID JO	6/1/23	5/31/26	ZEB1-OSR-E(	7075581	THOMOPOUL	Not Applicab	ORTHOPEDIC	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$10,000	NIBIB	$10,000	$0	$10,000
235	Doxy4STICare - Doxycyc	Narrative: This study aim	NIAID	11035852	3/11/24	PA-20-185	1R56AI18234	182347	HUEBNER, ROBIN E	3/11/24	2/28/26	HIV Comorbi	14634337	ZUCKER, JAS	Not Applicab	INTERNAL ME	COLUMBIA U	3/11/24	2/28/26	Non-SBIR/ST	2024	$837,185	NIAID	$508,927	$328,258	$837,185
236	Characterizing Sleep AR	PROJECT NARRATIVEUsi	NHLBI	10920401	8/27/24	RFA-HL-21-018	5R01HL1603	160325	DIXIT, SHILPY	9/15/21	7/31/26	ZHL1-CSR-Q	11872940	DUNCAN, DU	SCHNEIDER,	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$774,324	NHLBI	$654,575	$119,749	$774,324
237	The impact of a culturally	Preterm birth occurs at u	NIMHD	10992173	11/28/24	PAR-21-100	5R01MD0168	16899	MUJURU, PRISCAH	4/16/23	11/30/27	ZNS1-SRB-E(	1916168	CORWIN, ELI	LOEWY, JOAN	OTHER HEALT	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$618,862	NIMHD	$530,964	$87,898	$618,862
238	A randomized trial of Imp	PROJECT NARRATIVENea	NIMH	10615902	6/7/23	PA-18-274	5R01MH118(	118004	SENN, THERESA ELAIN	8/23/19	5/31/25	Population ar	1893302	SIKKEMA, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$607,390	NIMH	$480,303	$127,087	$607,390
239	Preparing for pre-exposu	Project NarrativeTo stem	FIC	10884348	7/8/24	PAR-19-376	5R33TW0117	11752	NEWSOME, BRAD	9/9/20	6/30/25	Special Emph	10397136	LELUTIU-WEI	PACHANKIS,	OTHER HEALT	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$327,558	FIC	$246,265	$81,293	$327,558
240	Stress hazardous drinking a	PROJECT NARRATIVEStudi	NIAAA	10911104	8/5/24	PA-20-190	5K01AA02853	28532	FREEMAN, ROBERT	9/1/21	8/31/26	Clinical, Treatn	14429074	FORD, JESSIE	Not Applicable	PUBLIC HEALT	COLUMBIA UN	9/1/24	8/31/25	Other Researc	2024	$140,687	NIAAA	$130,266	$10,421	$140,687
241	MyPEEPS Mobile LITE: Li	PROJECT NARRATIVEAdd	NIAID	11081972	8/1/24	RFA-AI-21-018	4UH3AI16965	169658	ZIMAND, LORI B.	9/1/22	7/31/27	ZAI1-KSW-A(J	9765581	SCHNALL, RE	DUNCAN, DU	OTHER HEALT	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$2,497,744	NIAID	$2,615,064	$1,015,363	$2,497,744
242	Building mobile HIV preven	Project NarrativeThis projec	NIMH	10632778	8/10/22	PA-21-268	7R01MH1168	116829	GREENWOOD, GREGORY	9/5/18	6/30/25	Behavioral and	10397136	LELUTIU-WEIN	PACHANKIS, J	OTHER HEALT	COLUMBIA UN	8/11/22	6/30/25	Non-SBIR/STT	2022	$768,346	NIMH	$542,762	$225,584	$768,346
243																										
244	Obesogenic origins of ma	PROJECT NARRATIVEThe	NICHD	10850865	7/15/24	PA-19-056	5R01HD1045	104599	MAJJI, SAI PRASANNA	9/25/20	6/30/25	Special Emph	8345946	ABRAMS, ELA	JAO, JENNIFE	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$2,452,419	NICHD	$2,380,040	$72,379	$2,452,419
245	Trial of Human Milk Oligo	Project Narrative:Childr	NICHD	10857315	6/21/24	PA-18-480	5R01HD1054	105492	MAJJI, SAI PRASANNA	6/1/21	5/31/26	HIV Comorbi	12518193	SHIVAKOTI, R	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$732,299	NICHD	$580,457	$151,842	$732,299
246	Targeting TB transmission h	Project NarrativeA critical ba	NIAID	10827921	5/6/24	PA-20-185	5R01AI15117	151173	LACOURCIERE, KAREN A	5/11/21	4/30/26	Infectious Dise	10783316	MATHEMA, BA	NAIDOO, KOG	PUBLIC HEALT	COLUMBIA UN	5/1/24	4/30/25	Non-SBIR/STT	2024	$632,098	NIAID	$525,367	$106,731	$632,098
247	Automated Digital Imagi	Project NarrativeWe pro	NCI	10880245	6/5/24	PA-19-056	5R01CA2545	254576	VILLALOBOS, AUBREY V	7/6/20	6/30/25	HIV Comorbi	1872852	KUHN, LOUIS	Not Applicab	NEUROLOGY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$470,853	NCI	$329,527	$141,326	$470,853
248	Strengthening informed co	Public Health Relevance: S	NICHD	11008251	8/6/24	PA-20-194	1R21HD1154	115480	ESBER, ALLAHNA LAURE	8/6/24	7/31/26	Population and	1872852	KUHN, LOUISE	Not Applicable	NEUROLOGY	COLUMBIA UN	8/6/24	7/31/25	Non-SBIR/STT	2024	$295,355	NICHD	$238,798	$56,557	$295,355
249	Emergence of bedaquilin	PROJECT NARRATIVEBed	NIAID	10977076	10/30/24	PA-20-185	5R01AI16993	169938	LACOURCIERE, KAREN	11/25/22	10/31/27	Special Emph	10783316	MATHEMA, B	GANDHI, NE	PUBLIC HEAL	COLUMBIA U	11/1/24	10/31/25	Non-SBIR/ST	2025	$722,084	NIAID	$585,910	$136,174	$722,084
250	mHealth and Mobile Ultras	PROJECT NARRATIVEThe p	NICHD	10693537	8/3/23	PA-21-268	7R21HD1030	103053	WEINBERG, DAVID H.	9/3/22	8/31/25	Special Empha	11309584	MASTERSON C	Not Applicable	Unavailable	COLUMBIA UN	9/3/22	8/31/25	Non-SBIR/STT	2022	$174,031	NICHD	$120,785	$48,246	$169,031
251	Sleep health of preschoo	This K01 International Re	FIC	10931620	9/14/24	PAR-21-105	5K01TW0124	12425	HAYES, UNJA	9/21/23	8/31/28	Special Emph	12203848	SANIA, AYESH	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$151,698	FIC	$141,855	$9,843	$151,698
252	International Workshops	PROJECT NARRATIVEThe	NICHD	10884394	6/26/24	PA-21-151	5R13HD1103	110322	LEE, SONIA S	8/1/22	7/31/25	Pediatrics St	8345946	ABRAMS, ELA	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$74,999	NICHD	$74,999	$0	$74,999
253	Fragile Families Summer	PROJECT NARRATIVEThis	NICHD	10919203	7/15/24	PAR-18-217	5R25HD0745	74544	JEKIELEK, SUSAN	2/7/13	7/31/25	Population Sc	10237406	MINCY, RON	GARFINKEL,	OTHER HEALT	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$161,460	NICHD	$149,592	$11,868	$161,460
254	mHealth and Mobile Ultr	PROJECT NARRATIVEThe	NICHD	10693537	8/3/23	PA-21-268	7R21HD1030	103053	WEINBERG, DAVID H.	9/3/22	8/31/25	Special Emph	11309584	MASTERSON	Not Applicab	Unavailable	COLUMBIA U	9/3/22	8/31/25	Non-SBIR/ST	2022	$174,031	FIC	$3,573	$1,427	$5,000
255	An effectiveness trial of WIN	The proposed study interve	NIAAA	10923881	8/5/24	RFA-AA-21-016	7R01AA03046	30462	FREEMAN, ROBERT	9/1/22	6/30/27	ZAA1-DD(17)V	11496912	DASGUPTA, A	GILBERT, LOU	PUBLIC HEALT	COLUMBIA UN	7/1/24	6/30/25	Non-SBIR/STT	2024	$717,423	NIAAA	$454,525	$262,898	$717,423
256	The TAIL-PrEP Study: Acc	Project NarrativePotent	NIMH	10700242	9/18/23	PA-20-145	1R21MH1337	133755	STIRRATT, MICHAEL J	9/18/23	9/17/25	HIV/AIDS Intr	11019999	MEYERS, KAT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/23	9/17/25	Non-SBIR/ST	2023	$483,983	OD	$164,981	$100,051	$265,032
257	Guyana Research in Inju	Although Guyana has the	FIC	10900711	8/16/24	RFA-TW-21-003	5D43TW0121	12189	LEVINTOVA, MARYA	9/15/21	8/31/26	Special Emph	7947406	HOVEN, CHR	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$262,065	FIC	$253,858	$8,207	$262,065
258	The TAIL-PrEP Study: Acc	Project NarrativePotent	NIMH	10700242	9/18/23	PA-20-145	1R21MH1337	133755	STIRRATT, MICHAEL J	9/18/23	9/17/25	HIV/AIDS Intr	11019999	MEYERS, KAT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/23	9/17/25	Non-SBIR/ST	2023	$483,983	NIMH	$136,297	$82,654	$218,951
259	Using wastewater survei	Project NarrativeSARS-C	NIAID	10762470	12/12/23	PA-20-195	5R21AI17574	175747	BOZICK, BROOKE ALLIS	1/10/23	12/31/25	Modeling and	11805024	YANG, WAN	Not Applicab	PUBLIC HEAL	COLUMBIA U	1/1/24	12/31/25	Non-SBIR/ST	2024	$205,625	NIAID	$125,000	$80,625	$205,625
260	Harnessing Bioinformatics	Project Narrative:Pre-expos	NIAID	10886003	7/12/24	PA-19-119	5K23AI15037	150378	MCKAIG, ROSEMARY G	8/1/20	7/31/25	Acquired Imm	14634337	ZUCKER, JASO	Not Applicable	INTERNAL ME	COLUMBIA UN	8/1/24	7/31/25	Other Researc	2024	$192,024	NIAID	$178,200	$13,824	$192,024
261	Bronx Environmental Healt	Project NarrativeThe propo	NIEHS	11058265	1/30/25	PAR-21-168	1R25ES0360	36012	HUMBLE, MICHAEL C.	2/1/25	1/31/30	Special Empha	11722514	HILPERT, MAR	VAN HORNE, Y	PUBLIC HEALT	COLUMBIA UN	2/1/25	1/31/26	Other Researc	2025	$132,347	NIEHS	$124,988	$7,359	$132,347
262	A Multi-site Multi-Setting RC	Public Health RelevanceInj	NIDA	10217065	8/3/22	PAS-16-018	5R01DA0457	45713	LAO, GUIFANG	9/30/17	7/31/25	ZDA1-HXO-H(1	1955316	METSCH, LISA	BRUNEAU, JU	PUBLIC HEALT	COLUMBIA UN	8/1/22	7/31/25	Non-SBIR/STT	2022	$1,217,167	NIDA	$1,156,400	$60,767	$1,217,167
263	RFA-PS-21-003: PrEP Ch	PROJECT NARRATIVEMe	NCHHSTP	10844338	6/25/24	RFA-PS-21-003	5U01PS0052	5229		9/30/21	9/29/26	ZPS1-GCA(48	9765581	SCHNALL, RE	Not Applicab	NONE	COLUMBIA U	9/30/24	9/29/25	Non-SBIR/ST	2024	$1,038,792	NCHHSTP			$1,038,792
264	ICAP Clinical Trials Unit	PROJECT NARRATIVEThe	NIAID	10975364	11/11/24	RFA-AI-19-045	5UM1AI1544	154468	GUBB, STEPHANIE MA	12/1/20	11/30/27	ZAI1-RCU-A(	1871336	EL-SADR, WA	JUSTMAN, JES	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$820,936	NIAID	$615,399	$157,021	$772,420
265	ICAP Clinical Trials Unit	PROJECT NARRATIVEThe	NIAID	10975364	11/11/24	RFA-AI-19-045	5UM1AI1544	154468	GUBB, STEPHANIE MA	12/1/20	11/30/27	ZAI1-RCU-A(	1871336	EL-SADR, WA	JUSTMAN, JES	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$820,936	NIDA	$38,654	$9,862	$48,516
266	Center for High-Through	This Program represents	NIAID	10891553	7/19/24	RFA-AI-19-012	5U19AI06777	67773	TALIAFERRO, LANYN P.	8/31/05	7/31/25	ZAI1-JA-I(J1)	1868601	BRENNER, D	Not Applicab	RADIATION-D	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$5,348,648	OD	$4,286,746	$1,061,902	$5,348,648
267	A Tolerance Approach to	Project NarrativeThis is a	NIAID	10991705	12/20/24	PAR-20-072	5P01AI04589	45897	NABAVI, NASRIN N.	9/15/00	12/31/26	ZAI1-LAR-X(M	1887410	SYKES, MEGA	SACHS, DAVI	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$3,181,738	NIAID	$1,964,036	$1,217,702	$3,181,738
268	Opportunities Fund Man	n/a	NIAID	10891556	7/19/24	RFA-AI-19-012	5U19AI06777	67773		8/31/05	7/31/25	ZAI1-JA-I	1942267	AMUNDSON,	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024			$2,781,929	$391,796	$3,173,725
269	Engineering protease-re	The outbreak of SARS-Co	NIAID	11177103	9/4/24	PAR-20-178	4R01AI16096	160961	PLIMACK, MARY KATHE	8/1/21	7/31/26	ZAI1-ZL-W(J2	1878831	MOSCONA, A	Not Applicab	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$714,282	NIAID	$569,159	$145,123	$714,282
270	Fusion inhibitors that blo	The recent and ongoing o	NIAID	11177101	9/4/24	PAR-20-178	4R01AI16095	160953	BASU, DIPANWITA	8/1/21	7/31/26	ZAI1-ZL-W(J2	8439631	POROTTO, M	DE SWART, R	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$711,960	NIAID	$545,111	$166,849	$711,960
271	Quantifying Error Growth	PROJECT NARRATIVEIn t	NIAID	10623347	5/3/23	PA-20-185	5R01AI16302	163023	GEZMU, MISRAK	6/9/21	5/31/27	Special Emph	8466769	SHAMAN, JEF	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$649,085	NIAID	$403,484	$245,601	$649,085
272	COVID-19 Mother Baby O	NARRATIVEThe devastat	NIMH	11073000	1/22/25	PA-20-185	5R01MH1265	126531	ZEHR, JULIA L	4/12/21	1/31/26	Development	8077959	DUMITRIU, D	MARSH, RAC	PEDIATRICS	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$644,816	NIMH	$455,455	$189,361	$644,816
273	Immunologic and Predict	Multisystem inflammato	NICHD	10866496	8/7/24	PA-20-185	5R01HD1084	108467	MAJJI, SAI PRASANNA	7/18/22	6/30/27	Special Emph	10812148	BOGUNOVIC	Not Applicab	PEDIATRICS	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$531,183	NICHD	$359,936	$171,247	$531,183
274	Elucidating the impact o	PROJECT NARRATIVE:The	NIAID	10785394	8/15/24	PA-20-203	1K08AI18034	180347	ARNOLD, MICHELLE M	8/15/24	7/31/29	Allergy, Immu	10786718	BOWEN, ANT	Not Applicab	INTERNAL ME	COLUMBIA U	8/15/24	7/31/25	Other Resear	2024	$193,644	NIAID	$179,300	$14,344	$193,644
275	Evaluating the Epidemio	PROJECT NARRATIVENeu	NIAID	10894841	8/22/24	PA-20-205	5K23AI17126	171263	GONDRE-LEWIS, TIMO	8/16/22	7/31/26	Microbiology	15670222	PURPURA, LA	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$192,260	NIAID	$178,200	$14,060	$192,260
276	Neurocognitive & neurop	Public Health Relevance	NIDCD	10846774	5/22/24	PA-20-205	5K23DC0196	19678	RIVERA-RENTAS, ALBE	6/1/21	5/31/26	Communicat	9698876	OVERDEVEST	Not Applicab	OTOLARYNG(	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$178,610	NIDCD	$165,380	$13,230	$178,610
277	Enhancing Nurse Practit	PROJECT NARRATIVEAdd	NINR	11012314	2/14/25	PAR-20-310	5R01NR0210	21007	MCNAMARA, KAREN M	4/7/23	1/31/27	Healthcare a	9844694	POGHOSYAN	Not Applicab	OTHER HEALT	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$717,434	NINR	$476,613	$240,821	$717,434
278	Communicating Narrativ	Project NarrativeIn this r	NINR	11018608	1/28/25	PA-20-185	5R01NR0169	16941	MCNAMARA, KAREN M	4/6/17	1/31/27	Clinical Infor	8414539	ROSSETTI, SA	CATO, KENRI	INTERNAL ME	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$715,057	NINR	$569,395	$145,662	$715,057
279	Clinical Operations and	n/a	NIA	10924048	8/20/24	PAR-19-374	5U19AG0785	78558		9/1/22	8/31/27	ZAG1-ZIJ-5	10523321	TEMPROSA, N	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	##########		##########	$115,984	##########
280	Clinical and Translationa	Project Narrative Page 2	NCATS	10893961	6/12/24	PAR-18-940	5UL1TR00187	1873	ATIENZA, AUDIE A	8/1/22	5/31/26		6205023	REILLY, MUR	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	##########	NCATS	$6,379,791	$3,908,575	##########
281	Cancer Center Support C	OVERALL: NARRATIVECa	NCI	10880379	6/6/24	PAR-17-095	5P30CA0136	13696	BELIN, PRECILLA L.	7/4/97	6/30/25	Cancer Cent	1868587	RUSTGI, ANIL	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$5,302,111	NCI	$3,272,908	$2,029,203	$5,302,111
282	Alzheimer's Disease Res	OVERALL NARRATIVEThe	NIA	10885042	6/21/24	RFA-AG-20-004	5P30AG0664	66462	SILVERBERG, NINA B.	6/15/20	4/30/25	ZAG1-ZIJ-G(J	1884949	SMALL, SCOT	Not Applicab	NEUROLOGY	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$3,035,934	NIA	$1,926,030	$1,109,904	$3,035,934
283	A Multi-scale Atlas of Ser	OVERALL: PROJECT NAR	NIA	10898652	8/12/24	RFA-RM-21-008	5U54AG0760	76040	FRIDELL, YIH-WOEI	9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	CHRISTIANO	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,587,409	OD	$2,156,497	$925,931	$2,587,409
284	Prospective Genetic Ris	PROJECT NARRATIVEThe	NICHD	10916374	8/26/24	RFA-HD-22-008	5P50HD1098	109879	KAU, ALICE S	9/6/22	8/31/27	Special Emph	8746379	VEENSTRA-V	CHUNG, WE	PEDIATRICS	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,373,156	NICHD	$1,481,345	$641,811	$2,123,156
285	Prospective Genetic Ris	PROJECT NARRATIVEThe	NICHD	10916374	8/26/24	RFA-HD-22-008	5P50HD1098	109879	KAU, ALICE S	9/6/22	8/31/27	Special Emph	8746379	VEENSTRA-V	CHUNG, WE	PEDIATRICS	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,373,156	NIEHS	$174,428	$75,572	$250,000

A2711

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
286	Center for Solutions for N	NARRATIVEThe Center fo	NINDS	10878252	9/2/24	RFA-NS-24-022	1U54NS1371	137199	DALEY, WILLIAM PATRI	9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/3/24	8/31/25	Research Ce	2024	$1,968,142	NINDS	$697,351	$270,791	$968,142
287	Center for Solutions for N	NARRATIVEThe Center fo	NINDS	10878252	9/2/24	RFA-NS-24-022	1U54NS1371	137199	DALEY, WILLIAM PATRI	9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/3/24	8/31/25	Research Ce	2024	$1,968,142	NCCIH	$180,075	$69,925	$250,000
288	Columbia University and	NarrativeHazardous met	NIEHS	10877756	6/25/24	RFA-ES-20-014	5P42ES0337	33719	CARLIN, DANIELLE J.	9/21/22	6/30/27	ZES1-LAT-S(S	8696712	NAVAS-ACIEN	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,791,523	NIEHS	$1,273,206	$518,317	$1,791,523
289	Center for Cancer Syste	PROJECT NARRATIVEThe	NCI	10931548	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-F	7827402	CALIFANO, A	HONIG, BAR	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,736,052	NCI	$1,093,908	$642,144	$1,736,052
290	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NINDS	$1,573,209	$635,680	$796,311
291	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NCATS	$1,036,744	$418,912	$524,769
292	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NICHD	$395,124	$159,655	$200,000
293	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	OD	$98,781	$39,913	$50,000
294	New York Obesity Resea	PROJECT NARRATIVEThe	NIDDK	10817164	5/9/24	RFA-DK-19-002	5P30DK0266	26687	EVANS, MARY	12/1/96	3/31/26	ZDK1-GRB-2	1869280	GALLAGHER,	FERRANTE, A	INTERNAL ME	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,221,081	NIDDK	$820,033	$401,048	$1,221,081
295	The Columbia University	NARRATIVEThe Columbia	NIDDK	10818417	5/7/24	RFA-DK-19-004	5P30DK1327	132710	SERRANO, KATRINA JA	4/30/22	3/31/27	ZDK1-GRB-7	8447367	SCHWABE, R	Not Applicab	INTERNAL ME	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,204,298	NIDDK	$732,096	$472,202	$1,204,298
296	Investigating the Geneti	OVERALL: NARRATIVELov	NIDDK	10897733	7/24/24	RFA-DK-20-008	5U54DK1043	104309	NIHALANI, DEEPAK	9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	BARASCH, JC	UROLOGY	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$1,200,000	NIDDK	$769,851	$430,149	$1,200,000
297	Molecular Correlates of	PROJECT NARRATIVEPed	NINDS	10878254	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IA	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,186,570		$777,943	$408,627	$1,186,570
298	NAMDC Clinical Registry	n/a	NINDS	10699998	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,179,830		$840,296	$339,534	$1,179,830
299	Columbia Roybal Center	Project NarrativeMost a	NIA	10875092	8/12/24	RFA-AG-24-006	2P30AG0641	64198	ONKEN, LISA	9/15/19	5/31/29	Special Emph	9193205	KRONISH, IA	MOISE, NATH	INTERNAL ME	COLUMBIA U	8/15/24	5/31/25	Research Ce	2024	$1,121,471	NIA	$817,721	$303,750	$1,121,471
300	Administrative Core	n/a	NIMHD	11177217	8/27/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	7/1/24	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,025,313		$787,662	$237,651	$1,025,313
301	Project 3: Developmenta	n/a	NICHD	10916387	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	8465923	AMSO, DIMA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,009,214		$613,504	$395,710	$1,009,214
302	Columbia-Cornell-Einste	Disparities in healthcare	AHRQ	11004283	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	10386412	ADELMAN, JA	ALCANTARA,	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$996,724	AHRQ	$699,385	$297,339	$996,724
303	Biological Analysis Core	n/a	NIA	10898662	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$967,665		$626,730	$340,935	$967,665
304	Living Healthy for Moms	n/a	NICHD	10908626	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	11628850	OSBORNE, L	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$941,193		$803,483	$137,710	$941,193
305	Clinical Core	n/a	NIA	10885045	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	9773845	NOBLE, JAME	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$841,656		$519,541	$322,115	$841,656
306	Roybal Center for Fearle	n/a	NIA	10875094	8/12/24	RFA-AG-24-006	2P30AG0641	64198		9/15/19	5/31/29	Special Emph	12100576	MOISE, NATH	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$827,484		$639,005	$188,479	$827,484
307	Core Facilities for Vision	Project NarrativeVision i	NEI	10896239	8/23/24	PAR-20-051	5P30EY0190	19007	GOVER, TONY DOUGL	7/1/10	6/30/26	ZEY1-VSN(07	7367717	GOLDBERG,	Not Applicab	OPHTHALMO	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$808,380	NEI	$499,000	$309,380	$808,380
308	Administrative Core	n/a	NIA	10898653	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$778,367		$480,474	$297,893	$778,367
309	Administrative Core	n/a	NIA	10885044	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	1884949	SMALL, SCOT	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$769,214		$474,823	$294,391	$769,214
310	Research and Data Analy	n/a	AHRQ	11004299	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	11309584	MASTERSON	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$767,567		$543,123	$224,444	$767,567
311	Administrative Core	n/a	NINDS	10699995	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$755,914		$538,375	$217,539	$755,914
312	Investigator Developmer	n/a	NIMHD	10897790	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	7120933	SHIMBO, DA	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$654,700		$419,210	$235,490	$654,700
313	Columbia Center for Inte	PROJECT NARRATIVEThe	NIA	10909374	7/25/24	RFA-AG-23-025	5P30AG0593	59303	BANDIERA, FRANK	9/1/18	6/30/28	ZAG1-ZIJ-4(M	2261261	MANLY, JENN	BRICKMAN, A	NEUROLOGY	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$641,307	NIA	$515,243	$126,064	$641,307
314	Project 3-CommunityHe	NARRATIVEThe CHURCH	NIMHD	10897805	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	8840097	WILLIAMS, O	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$634,066		$425,098	$208,968	$634,066
315	Administrative Core	n/a	NIMHD	10897780	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$633,012		$406,263	$226,749	$633,012
316	CONNECTOME-Commu	n/a	NIMHD	10897786	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$629,596		$490,982	$138,614	$629,596
317	Career Enhancement Pr	n/a	NINDS	10700016	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880694	HAAS, RICHA	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$615,493		$438,365	$177,128	$615,493
318	Translational Research S	n/a	NIEHS	10851724	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8853211	CHILLRUD, S	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$532,335		$328,674	$203,661	$532,335
319	Mitochondrial functiona	n/a	NINDS	10700003	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1973197	VAN HOVE, J	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$497,390		$354,250	$143,140	$497,390
320	Biospecimen Core	n/a	NIA	10898656	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	1894412	OWENS, DAV	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$455,184		$307,959	$147,225	$455,184
321	Tissue Engineering Resou	n/a	NIBIB	10848083	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Emph	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$445,884		$307,242	$138,642	$445,884
322	Administrative Core	n/a	NIEHS	10851720	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8651962	BACCARELLI,	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$440,749		$267,933	$172,816	$440,749
323	Genotypic Analysis of ME	PROJECT NARRATIVEA he	NINDS	10878255	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	11229447	PONTING, CH	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$437,634		$431,876	$5,758	$437,634
324	NY-CHAMP Community	n/a	NICHD	10908634	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	9403946	HALL, KELLI S	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$435,249		$355,191	$80,058	$435,249
325	Project 1: Identifying and	n/a	NICHD	10916384	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	1890713	CHUNG, WE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$400,487		$243,457	$157,030	$400,487
326	Data Analysis Core	n/a	NIA	10898660	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	14885882	MENON, VILA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$386,193		$296,267	$89,926	$386,193
327	Career Development and	n/a	NICHD	10908637	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	9807979	TAYLOR, JAC	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$385,389		$301,485	$83,904	$385,389
328	Genomic Testing for Mol	n/a	NINDS	10700001	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	11003865	KARAA, AMEL	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$374,245		$266,544	$107,701	$374,245
329	Human phenotype (Core	n/a	NIDDK	10817169	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1869280	GALLAGHER,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$356,448		$229,999	$126,449	$356,448
330	Tissue Engineering Resou	n/a	NIBIB	10848082	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Emph	1943583	HUNG, CLAR	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$352,774		$218,392	$134,382	$352,774
331	Biomarker Core	n/a	NIA	10885054	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	7891222	BRICKMAN, A	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$343,652		$212,131	$131,521	$343,652
332	Expanded Access Deoxy	There are no FDA-approv	NINDS	10700011	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$334,868		$238,499	$96,369	$334,868
333	Administrative and Enga	n/a	NCI	10931473	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	7012821	CASTOR, DEL	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$331,893		$238,874	$93,019	$331,893
334	Advanced Genetic Study	n/a	NINDS	10700006	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1927769	BEDOYAN, JI	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$331,873		$236,366	$95,507	$331,873
335	Imaging Histology and Fu	n/a	NEI	10896247	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	1933579	SPARROW, JA	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$322,638		$199,159	$123,479	$322,638
336	Research Project 1	n/a	NCI	10931482	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	16051833	SAIDU, RAKIY	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$318,356		$268,072	$50,284	$318,356
337	Neuropathology Core	n/a	NIA	10885050	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	10450717	TEICH, ANDR	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$312,508		$192,906	$119,602	$312,508
338	Tissue Engineering Resou	n/a	NIBIB	10848081	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Emph	2059300	KAPLAN, DAV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$304,639		$288,514	$16,125	$304,639
339	Roybal Center for Fearle	n/a	NIA	10875093	8/12/24	RFA-AG-24-006	2P30AG0641	64198		9/15/19	5/31/29	Special Emph	9193205	KRONISH, IA	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$293,987		$178,716	$115,271	$293,987
340	Research Education Cor	n/a	NIA	10909378	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	7033495	AIELLO, ALLIS	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$291,715		$278,009	$13,706	$291,715
341	Anga Center Capacity Bu	n/a	FIC	10982429	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	79487238	MUITA, RICH	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$277,209		$237,419	$39,790	$277,209
342	High Resolution Models	Project 1 NarrativeThere	NIEHS	10877757	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8853211	CHILLRUD, S	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$272,919		$172,836	$100,083	$272,919
343	Anga Center Community	n/a	FIC	10982428	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	79391762	MUHANGUZI	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$271,971		$215,850	$56,121	$271,971
344	Causal Molecular Mecha	Project 4 NarrativeArsen	NIEHS	10877761	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	10403982	PEARSON, BF	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$270,683		$176,497	$94,186	$270,683
345	Pilot	n/a	NINDS	10700012	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$268,405		$191,163	$77,242	$268,405
346	Computer Core	n/a	NEI	10896243	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	6619355	ALLIKMETS, R	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$267,182		$164,927	$102,255	$267,182
347	Pilot Project Program	n/a	NIEHS	10851731	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8875879	RE, DIANE BE	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$262,970		$159,860	$103,110	$262,970
348	Advanced Single Cell Tec	n/a	NCI	11171868	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-F	10946359	SIMS, PETER	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$259,748		$157,902	$101,846	$259,748
349	Leadership and Administ	n/a	NIA	10909375	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	2261261	MANLY, JENN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$257,034		$170,438	$86,596	$257,034
350	Administrative Core	n/a	NIDDK	10817165	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	7057421	LEIBEL, RUD	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$254,749		$167,223	$87,526	$254,749
351	Administrative Core	n/a	NIDDK	10897735	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$253,820		$156,679	$97,141	$253,820
352	Integrated Data and Exp	n/a	NIA	10981248	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	7347011	BERHANE, KI	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$250,250		$152,128	$98,122	$250,250
353	The Administrative Core	n/a	NIDDK	10818418	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	8447367	SCHWABE, R	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$246,248		$149,695	$96,553	$246,248
354	Core C: Assessment Cor	n/a	NICHD	10916382	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	1884921	KANNE, STEP	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$245,768		$170,672	$75,096	$245,768
355	A Novel Metabolic Pathw	n/a	NIDDK	10897761	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	8228433	BARASCH, JC	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$243,194		$160,708	$82,486	$243,194
356	Administrative Core	n/a	NIA	10981244	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$242,814		$147,607	$95,207	$242,814
357	Human genetic approac	n/a	NIDDK	10897749	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	3169385	GHARAVI, ALI	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$241,161		$159,121	$82,040	$241,161
358	Research Capacity Build	n/a	NCI	10931477	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	14456149	DENNY, LYNE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$238,827		$192,143	$46,684	$238,827
359	Community Engagement	n/a	NIA	10981247	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	9509976	ZOTA, AMI R	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$237,610		$144,444	$93,166	$237,610
360	Anga Center Administrat	n/a	FIC	10982426	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	14103745	MUSYIMI, CH	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$236,930		$188,040	$48,890	$236,930
361	Community Engagement	n/a	NIEHS	10851729	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	9509976	ZOTA, AMI R	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$235,283		$166,623	$68,660	$235,283
362	Microbial Genomics Bio	n/a	NIDDK	10897744	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	9733196	UHLEMANN,	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$233,244		$143,978	$89,266	$233,244
363	Transcriptional regulatio	n/a	NIDDK	10897757	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$228,581		$149,365	$79,216	$228,581
364	Administrative Core	n/a	NINDS	10878253	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IA	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$228,352		$137,986	$90,366	$228,352
365	Administrative Core	n/a	NIMHD	11177216	8/26/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	7/1/24	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$226,727		$137,828	$88,899	$226,727
366	Data Management and A	NarrativeThe DMAC will	NIEHS	10877764	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	10781196	GOLDSMITH,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$221,085		$146,163	$74,922	$221,085
367	The Bioimaging Core	n/a	NIDDK	10818427	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	3127300	OLIVE, KENN	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$216,525		$131,626	$84,899	$216,525
368	The Clinical Biospecime	n/a	NIDDK	10818421	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9047196	ABRAMS, JUL	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$216,188		$131,421	$84,767	$216,188
369	Admin Core	n/a	NIMHD	10934597	8/1/24	RFA-MD-21-007	5P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	HERSHMAN,	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$214,568		$131,074	$83,494	$214,568
370	Molecular Biology/Molec	n/a	NIDDK	10817183	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	14183064	EGLI, DIETER	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$207,281		$147,276	$60,005	$207,281
371	Core B: Statistical and C	n/a	NICHD	10916379	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	7740764	WALL, MELAN	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$205,785		$145,313	$60,472	$205,785
372	Light-Based Approaches	Project 5 NarrativeExpos	NIEHS	10877762	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8270461	BOSTICK, BE	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$195,766		$143,409	$52,357	$195,766
373	Pilot and Feasibility Prog	n/a	NIDDK	10817190	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1927452	KORNER, JUD	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$194,306		$129,913	$64,393	$194,306
374	Instrumentation Fabrica	n/a	NEI	10896241	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	2093726	SILVERMAN,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$191,176		$118,010	$73,166	$191,176
375	Project 2: Psychosocial i	n/a	NICHD	10916385	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	8236828	APPELBAUM,	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$186,214		$144,914	$41,300	$186,214
376	Administrative Core	n/a	AHRQ	11004290	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	10386412	ADELMAN, JA	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$183,870		$123,085	$60,785	$183,870
377	Research Project 2	n/a	NCI	10931485	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	12114400	MOODLEY, JE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$179,287		$151,358	$27,929	$179,287
378	Neuroimmunology Core	n/a	NIA	10885057	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	1925223	DE JAGER, PH	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$176,063		$108,681	$67,382	$176,063
379	Isotopic Tracing of Sourc	Project 2 NarrativeProje	NIEHS	10877759	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	77993292	HALLIDAY, AL	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$175,669		$141,496	$34,173	$175,669
380	Data Management and S	n/a	NIA	10885048	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	2076195	ANDREWS, H	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$173,189		$125,570	$47,619	$173,189

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
381	The Bioinformatics and S	n/a	NIDDK	10818422	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	10946359	SIMS, PETER	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$169,960		$103,319	$66,641	$169,960
382	Core D: Dissemination a	n/a	NICHD	10916377	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Empl	8746379	VEENSTRA-V	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$165,343		$103,404	$61,939	$165,343
383	The Organoid and Cell C	n/a	NIDDK	10818425	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	7132013	NAKAGAWA,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$165,030		$100,322	$64,708	$165,030
384	Studying the evolution of	PROJECT NARRATIVEThe	NCI	11072772	9/3/24	PA-20-272	3U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1(M2)	7827402	CALIFANO, A	HONIG, BAR	INTERNAL MB	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$164,500	NCI	$100,000	$64,500	$164,500
385	Genetics Core	n/a	NIA	10885056	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	9349727	REITZ, CHRIS	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$164,206		$101,362	$62,844	$164,206
386	Clinical and Translationa	Project NarrativeIn this a	NCATS	11064191	8/7/24	PA-20-272	3UL1TR0018	1873	ATIENZA, AUDIE A	8/1/22	5/31/26		6205023	REILLY, MUR	Not Applicab	INTERNAL MB	COLUMBIA U	8/7/24	5/31/25	Research Ce	2024	$161,384	OD	$98,106	$63,278	$161,384
387	Core A: Administrative C	n/a	NICHD	10916375	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Empl	1890713	CHUNG, WE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$160,345		$97,474	$62,871	$160,345
388	Study Design and Data S	n/a	NIEHS	10851726	5/10/24	RFA-ES-20-006	5P30ES0090	9089		7/1/98	4/30/28	Environment	2409522	FACTOR-LITV	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$159,869		$97,185	$62,684	$159,869
389	Animal Phenotyping (Cor	n/a	NIDDK	10817174	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	6361245	SCHWARTZ,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$151,772		$100,760	$51,012	$151,772
390	Outreach Recruitment a	n/a	NIA	10885052	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	12570380	ARCE, MIGUI	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$147,446		$91,016	$56,430	$147,446
391	Administrative Core	Administrative Core - Na	NIEHS	10877763	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8696712	NAVAS-ACIEN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$133,652		$83,031	$50,621	$133,652
392	Pathogen Discovery Thro	NARRATIVEWhat causes	NINDS	10878256	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Empl	12386930	MISHRA, NIS	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$115,586		$69,845	$45,741	$115,586
393	Pilot and Feasibility Prog	n/a	NIDDK	10818429	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9695780	PAJVANI, UTP	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$113,773		$69,163	$44,610	$113,773
394	Research Education Cor	n/a	NIA	10885058	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	8152373	COSENTINO,	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$108,000		$100,000	$8,000	$108,000
395	Outreach Core	n/a	NCI	11171867	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-I	1878184	MURRAY, DIA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$106,850		$64,955	$41,895	$106,850
396	Tissue Engineering Resou	n/a	NIBIB	10848080	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Empl	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$96,810		$58,851	$37,959	$96,810
397	Analysis Core	n/a	NIA	10909376	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	8735029	TERESI, JEAN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$92,558		$66,796	$25,762	$92,558
398	Community Engagement	Community Engagement	NIEHS	10877765	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	7698320	O'LEARY, MA	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$77,823		$73,818	$4,005	$77,823
399	The Enrichment Program	n/a	NIDDK	10818430	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9365956	QUE, JIANWE	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$76,574		$46,550	$30,024	$76,574
400	Enrichment Program	n/a	NIDDK	10817197	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1952696	FERRANTE, A	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$56,525		$44,862	$11,663	$56,525
401	Tissue Engineering Resou	n/a	NIBIB	10848084	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Empl	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$55,247		$33,585	$21,662	$55,247
402	Research Experience an	RETCC NarrativeThe Res	NIEHS	10877766	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8696712	NAVAS-ACIEN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$53,698		$33,360	$20,338	$53,698
403	Administrative Core	n/a	NCI	11171863	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-I	7827402	CALIFANO, A	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$49,932		$30,353	$19,579	$49,932
404	Research Education Cor	n/a	AHRQ	11004294	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	12100576	MOISE, NATH	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$45,287		$33,177	$12,110	$45,287
405	Administrative Core	n/a	NEI	10896240	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	7367717	GOLDBERG,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$27,384		$16,904	$10,480	$27,384
406																										
407																										
408																					Total	##########				

PDF COPY OF NIH_GRANTS_002296
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G
1	**Project Abstract**	**Project Title**	**Administe**	**Project End Date**	**FIPS**	**Organization Name**	**Total Cost IC**
2	Abstract A plethora of research exists highlighting the disproportionate disparities faced by sexual and gender minorities (SGM) of all ages, such as increased levels of homelessness, lack of access to healthcare, and negative physical and psychological outcomes. While there have been significant efforts to address systemic racism and social determinants of health (SDOHs) at the	Leveraging a community-driven approach to address the impact of social determinants of health on structural inequities among Miami-Dade County's intergenerational LGBTQ+ Community	OD	09/20/2028	US	URBAN HEALTH PARTNERSHIPS	$ 1,125,000
3	PROJECT SUMMARY No changes being proposed. INTRODUCTION This application is for an Administrative Supplement for Research on Sexual and Gender Minority (SGM) Populations (NOT-OD-22-032) to the parent award, ""Effects of Social Networks and Policy Context on Health	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	NIA	06/30/2025	US	VANDERBILT UNIVERSITY	$ 99,998
4	7. Project Summary/Abstract Consistent with NIAAA's expressed goal to understand sex differences in risk of problem alcohol use and target mechanisms that contribute to known disparities within high-risk communities, the current proposal seeks to examine the role of internal sources of minority stress (i.e., stress unique to those from marginalized communities) in potentiating heavy alcohol use, particularly among female	Internal Sources of Minority Stress and Alcohol Consumption	NIAAA	07/31/2025	US	TEXAS TECH UNIVERSITY	$ 397,892
5	PROJECT SUMMARY Mobile health (mHealth) interventions are a promising modality for overcoming barriers and providing culturally appropriate treatment among transgender individuals. mHealth interventions may be appropriate among transgender individuals, as emergent evidence suggests that virtual spaces are used to access gender affirming support and resources. Moreover, mHealth interventions may enable	TRANSforma Tu Salud Dejando de Fumar: Advancing smoking cessation among transgender individuals	NCI	08/31/2025	US	UNIVERSITY OF ROCHESTER	$ 2,000
6	ABSTRACT Age is the greatest risk factor for Alzheimer's disease and related dementia (AD/ADRD) and an estimated 2.7 million LGBTQ+ Americans are older adults. LGBTQ+ older adults face discrimination and persecution throughout their lives, with only some recent legal protections for their sexual orientation and/or gender identification statuses in the United States. LGBTQ+ individuals with	SilverBills: A Legal, Technical and Financial Tool for Aging LGBTQ+ Individuals with Impaired Cognition.	NIA	08/31/2025	US	SILVERBILLS INC.	$ 1,080,149
7	Transgender individuals are disproportionately burdened by chronic (e.g., interpersonal rejection) and acute (victimization) discrimination. According to minority stress theory, both forms of discrimination are associated with adverse mental health outcomes including PTSD, a stress sensitive disorder that may arise from exposure to life-threatening events, serious injury, or sexual assault. While PTSD effects an estimated 6.8% of the U.S.	Trajectories of Adaptation to Traumatic Stress in a Vulnerable Population	NIGMS	08/31/2025	US	HUNTER COLLEGE	$ 117,000
8	Project Summary Sexual minority women (SMW) consistently report higher rates of alcohol use than heterosexual women. In fact, SMW are more likely to be current alcohol users, binge drinkers, and heavy drinkers than heterosexual women1 and are 11 times more likely to meet the threshold for alcohol use disorder.1-6 While research on SMW's alcohol use has grown in recent years, a scoping review of the literature	Health Effects of Intersectional Stigma among Sexual Minority Women	NIAAA	08/31/2025	US	UNIVERSITY OF CALIFORNIA SANT	$ 180,704
9	Abstract By 2030, there will be nearly six million sexual and gender minority (SGM) older adults aged 50 and older in the U.S. who identify as lesbian, gay, bisexual, transgender, and/or queer. This number will more than double by 2050. Approximately 350,000 SGM older adults in the U.S. currently are living with Alzheimer's disease and related dementias (ADRD), with projections nearing one million by 2030.	Building Community and Research Engagement among Sexual and Gender Minority Older Adults at Risk for Alzheimer's Disease and Related Dementias	NIA	08/31/2025	US	EMORY UNIVERSITY	$ 727,284
10	ABSTRACT Black and Latino trans women and men who have sex with men – or sexual and gender minorities of color (SGMoC) - account for at least half of all new HIV infections in the United States (U.S.). At the same time there is a significant disparity in knowledge of, access to and uptake of pre-exposure prophylaxis (PrEP) among SGMoC is disproportionately low compared to white MSM and trans	One Ballroom: Understanding Intersectional Stigma to Optimize the HIV Prevention Continuum among Vulnerable Populations in the United States	NIAID	08/31/2027	US	UNIVERSITY OF CALIFORNIA-IRVI	$ 426,660
11	PROJECT SUMMARY Transgender and gender nonbinary (TGNB) people are diverse and have distinct healthcare needs, yet demonstrate lower levels of healthcare utilization and greater likelihood of delaying needed care than their cisgender counterparts. Further, TGNB young adults experience more barriers to healthcare utilization and are more likely to delay care than TGNB adolescents and older adults. Though	Facilitators of and barriers to healthcare utilization among racially and ethnically diverse transgender and gender nonbinary young adults	NIMHD	02/28/2025	US	UNIVERSITY OF CENTRAL FLORID	$ 188,746
12	ABSTRACT Older sexual and gender minority (SGM) populations experience significant disparities in morbidity and disability compared with their heterosexual and cisgender counterparts. There are two primary explanations as to why physical health, mental health, and disability outcomes may differ for older SGM adults compared to older heterosexual and cisgender	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	NIA	06/30/2025	US	VANDERBILT UNIVERSITY	$ 362,818
13	PROJECT SUMMARY The use of virtual sociosexual networking venues (e.g., mobile apps and websites) to find intimate partners is near ubiquitous among young sexual minority (SM) men. However, little attention has been paid to the unique discriminatory phenomena that occur in online spaces, and how these experiences impact the mental health of young sexual minority men of color (YSMMoC). One such phenomenon that	Racialized Sexual Discrimination (RSD) and Psychological Well-being among Young Sexual Minority Men of Color (YSMMoC)	NIMHD	02/28/2025	US	UNIVERSITY OF ILLINOIS AT URBA	$ 159,646

	A	B	C	D	E	F	G
14	PROJECT SUMMARY/ABSTRACT During the COVID-19 pandemic, up to 81% of adults in the United States experienced worsening mental health. A major cause was the social isolation triggered by the pandemic due to quarantining, loss of family or friends, and loss of work. For individuals who lost social connections or were unable to adapt to maintain their connections, social support decreased and loneliness worsened, putting	Improving mental health among the LGBTQ+ community impacted by the COVID-19 pandemic	NIMH	08/31/2025	US	BROWN UNIVERSITY	$ 2,368,492
15	Project Summary Our study seeks to advance methods to measure and analyze multiple types of discrimination for population health research. We will compare novel implicit vs. conventional explicit (self-report) measures of exposure, investigate different approaches to modeling exposure to multiple types of discrimination, and test novel hypotheses using causal mediation analyses. We are motivated by profound	Advancing novel methods to measure and analyze multiple types of discrimination for population health research	NIMHD	01/31/2026	US	HARVARD SCHOOL OF PUBLIC HE	$ 648,444
16	Abstract By 2030, there will be nearly six million sexual and gender minority (SGM) older adults aged 60 and older in the U.S. who identify as lesbian, gay, bisexual and transgender. Approximately 350,000 SGM older adults in the U.S. currently have Alzheimer's disease and related dementias (ADRD), with projections nearing one million by 2030. Yet, almost nothing is known about the prevalence or risk	The Epidemiology of Alzheimer's Disease and Related Dementias in Sexual and Gender Minority Older Adults: Identifying Risk and Protective Factors	NIA	06/30/2025	US	UNIVERSITY OF NEVADA LAS VEG	$ 126,738
17	Abstract Public awareness of the diversity of experiences of gender identities has climbed sharply. The specific issues of those with gender dysphoria (GD) related to self-identity, body image, and medical interventions are challenges for the 21st century, particularly given the high risk of suicide. Gender identity is tightly linked to one's bodily features, particularly readily observable sexual characteristics.	Personalized 3D avatar tool development for measurement of body perception across gender identities	NIBIB	03/31/2025	CA	CENTRE FOR ADDICTION AND ME	$ 120,174

PDF COPY OF NIH_GRANTS_002311
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G
1	**Project Abstract**	**Project Title**	**Administe**	**Project End Date**	**FIPS**	**Organization Name**	**Total Cost IC**
2	Abstract A plethora of research exists highlighting the disproportionate disparities faced by sexual and gender minorities (SGM) of all ages, such as increased levels of homelessness, lack of access to healthcare, and negative physical and psychological outcomes. While there have been significant efforts to address systemic racism and social determinants of health (SDOHs) at the	Leveraging a community-driven approach to address the impact of social determinants of health on structural inequities among Miami-Dade County's intergenerational LGBTQ+ Community	OD	09/20/2028	US	URBAN HEALTH PARTNERSHIPS	$ 1,125,000
3	PROJECT SUMMARY No changes being proposed. INTRODUCTION This application is for an Administrative Supplement for Research on Sexual and Gender Minority (SGM) Populations (NOT-OD-22-032) to the parent award, ""Effects of Social Networks and Policy Context on Health	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	NIA	06/30/2025	US	VANDERBILT UNIVERSITY	$ 99,998
4	7. Project Summary/Abstract Consistent with NIAAA's expressed goal to understand sex differences in risk of problem alcohol use and target mechanisms that contribute to known disparities within high-risk communities, the current proposal seeks to examine the role of internal sources of minority stress (i.e., stress unique to those from marginalized communities) in potentiating heavy alcohol use, particularly among female	Internal Sources of Minority Stress and Alcohol Consumption	NIAAA	07/31/2025	US	TEXAS TECH UNIVERSITY	$ 397,892
5	PROJECT SUMMARY Mobile health (mHealth) interventions are a promising modality for overcoming barriers and providing culturally appropriate treatment among transgender individuals. mHealth interventions may be appropriate among transgender individuals, as emergent evidence suggests that virtual spaces are used to access gender affirming support and resources. Moreover, mHealth interventions may enable	TRANSforma Tu Salud Dejando de Fumar: Advancing smoking cessation among transgender individuals	NCI	08/31/2025	US	UNIVERSITY OF ROCHESTER	$ 2,000
6	ABSTRACT Age is the greatest risk factor for Alzheimer's disease and related dementia (AD/ADRD) and an estimated 2.7 million LGBTQ+ Americans are older adults. LGBTQ+ older adults face discrimination and persecution throughout their lives, with only some recent legal protections for their sexual orientation and/or gender identification statuses in the United States. LGBTQ+ individuals with	SilverBills: A Legal, Technical and Financial Tool for Aging LGBTQ+ Individuals with Impaired Cognition.	NIA	08/31/2025	US	SILVERBILLS INC.	$ 1,080,149
7	Transgender individuals are disproportionately burdened by chronic (e.g., interpersonal rejection) and acute (victimization) discrimination. According to minority stress theory, both forms of discrimination are associated with adverse mental health outcomes including PTSD, a stress sensitive disorder that may arise from exposure to life-threatening events, serious injury, or sexual assault. While PTSD effects an estimated 6.8% of the U.S.	Trajectories of Adaptation to Traumatic Stress in a Vulnerable Population	NIGMS	08/31/2025	US	HUNTER COLLEGE	$ 117,000
8	Project Summary Sexual minority women (SMW) consistently report higher rates of alcohol use than heterosexual women. In fact, SMW are more likely to be current alcohol users, binge drinkers, and heavy drinkers than heterosexual women1 and are 11 times more likely to meet the threshold for alcohol use disorder.1-6 While research on SMW's alcohol use has grown in recent years, a scoping review of the literature	Health Effects of Intersectional Stigma among Sexual Minority Women	NIAAA	08/31/2025	US	UNIVERSITY OF CALIFORNIA SANT	$ 180,704
9	Abstract By 2030, there will be nearly six million sexual and gender minority (SGM) older adults aged 50 and older in the U.S. who identify as lesbian, gay, bisexual, transgender, and/or queer. This number will more than double by 2050. Approximately 350,000 SGM older adults in the U.S. currently are living with Alzheimer's disease and related dementias (ADRD), with projections nearing one million by 2030.	Building Community and Research Engagement among Sexual and Gender Minority Older Adults at Risk for Alzheimer's Disease and Related Dementias	NIA	08/31/2025	US	EMORY UNIVERSITY	$ 727,284
10	ABSTRACT Black and Latino trans women and men who have sex with men – or sexual and gender minorities of color (SGMoC) - account for at least half of all new HIV infections in the United States (U.S.). At the same time there is a significant disparity in knowledge of, access to and uptake of pre-exposure prophylaxis (PrEP) among SGMoC is disproportionately low compared to white MSM and trans	One Ballroom: Understanding Intersectional Stigma to Optimize the HIV Prevention Continuum among Vulnerable Populations in the United States	NIAID	08/31/2027	US	UNIVERSITY OF CALIFORNIA-IRVI	$ 426,660
11	PROJECT SUMMARY Transgender and gender nonbinary (TGNB) people are diverse and have distinct healthcare needs, yet demonstrate lower levels of healthcare utilization and greater likelihood of delaying needed care than their cisgender counterparts. Further, TGNB young adults experience more barriers to healthcare utilization and are more likely to delay care than TGNB adolescents and older adults. Though	Facilitators of and barriers to healthcare utilization among racially and ethnically diverse transgender and gender nonbinary young adults	NIMHD	02/28/2025	US	UNIVERSITY OF CENTRAL FLORID	$ 188,746
12	ABSTRACT Older sexual and gender minority (SGM) populations experience significant disparities in morbidity and disability compared with their heterosexual and cisgender counterparts. There are two primary explanations as to why physical health, mental health, and disability outcomes may differ for older SGM adults compared to older heterosexual and cisgender	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	NIA	06/30/2025	US	VANDERBILT UNIVERSITY	$ 362,818
13	PROJECT SUMMARY The use of virtual sociosexual networking venues (e.g., mobile apps and websites) to find intimate partners is near ubiquitous among young sexual minority (SM) men. However, little attention has been paid to the unique discriminatory phenomena that occur in online spaces, and how these experiences impact the mental health of young sexual minority men of color (YSMMoC). One such phenomenon that	Racialized Sexual Discrimination (RSD) and Psychological Well-being among Young Sexual Minority Men of Color (YSMMoC)	NIMHD	02/28/2025	US	UNIVERSITY OF ILLINOIS AT URBA	$ 159,646

	A	B	C	D	E	F	G
14	PROJECT SUMMARY/ABSTRACT During the COVID-19 pandemic, up to 81% of adults in the United States experienced worsening mental health. A major cause was the social isolation triggered by the pandemic due to quarantining, loss of family or friends, and loss of work. For individuals who lost social connections or were unable to adapt to maintain their connections, social support decreased and loneliness worsened, putting	Improving mental health among the LGBTQ+ community impacted by the COVID-19 pandemic	NIMH	08/31/2025	US	BROWN UNIVERSITY	$ 2,368,492
15	Project Summary Our study seeks to advance methods to measure and analyze multiple types of discrimination for population health research. We will compare novel implicit vs. conventional explicit (self-report) measures of exposure, investigate different approaches to modeling exposure to multiple types of discrimination, and test novel hypotheses using causal mediation analyses. We are motivated by profound	Advancing novel methods to measure and analyze multiple types of discrimination for population health research	NIMHD	01/31/2026	US	HARVARD SCHOOL OF PUBLIC HE	$ 648,444
16	Abstract By 2030, there will be nearly six million sexual and gender minority (SGM) older adults aged 60 and older in the U.S. who identify as lesbian, gay, bisexual and transgender. Approximately 350,000 SGM older adults in the U.S. currently have Alzheimer's disease and related dementias (ADRD), with projections nearing one million by 2030. Yet, almost nothing is known about the prevalence or risk	The Epidemiology of Alzheimer's Disease and Related Dementias in Sexual and Gender Minority Older Adults: Identifying Risk and Protective Factors	NIA	06/30/2025	US	UNIVERSITY OF NEVADA LAS VEG	$ 126,738
17	Abstract Public awareness of the diversity of experiences of gender identities has climbed sharply. The specific issues of those with gender dysphoria (GD) related to self-identity, body image, and medical interventions are challenges for the 21st century, particularly given the high risk of suicide. Gender identity is tightly linked to one's bodily features, particularly readily observable sexual characteristics.	Personalized 3D avatar tool development for measurement of body perception across gender identities	NIBIB	03/31/2025	CA	CENTRE FOR ADDICTION AND ME	$ 120,174

PDF COPY OF NIH_GRANTS_002353
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H	I	J	K
1	**IC**	**NIH POC**	**Type of Project (grant, intramural research, NOFO, etc.)**	**Name of Project**	**Institution**	**Short Description of Project**	**Timeframe**	**Grant or NOFO Number (optional)**	**Budget (optional)**	**Link to Project (optional)**	**Notes**
2	NIAID	Brooke Bozick	Grant	Alaska Native Communities Advancing Vaccine Uptake	SOUTHCENTRAL FOUNDATION	This project will form a consortium of Tribal health leaders and ANAI community vaccine advocates to systematically characterize and address barriers to COVID-19 vaccine uptake in ANAI communities in Alaska. The goal is to increase COVID-19 vaccine uptake among AN/AI population in Alaska through training and support of community members to serve as community vaccine advocates.	8/18/2022-7/31/2027	5R01AI170946-03			
3	NIAID	Brooke Bozick	Grant	PROmotion of COVid-19 VA(X)ccination in the Emergency Department - PROCOVAXED	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	This project aims to understand principal barriers to vaccination, especially vaccine hesitancy, in vulnerable populations whose health care access primarily occurs in emergency departments (EDs). The clinical trial will develop and implement the PROCOVAXED intervention, a trusted messaging informational platform, to determine whether it can increase COVID-19 and influenza vaccine uptake in this population.	5/24/2021-4/30/2025	5R01AI166967-03			
4	NIAID	Brooke Bozick	Grant	Population-level assessment of early childhood vaccination timeliness, parental vaccine hesitancy, and immunization schedule adherence in the United States, including rural-urban disparities	UNIVERSITY OF MONTANA	This project's objectives are to quantify national and state trends in and factors associated with four novel measures of early childhood immunization services quality: (1) vaccine timeliness, (2) immunization schedule adherence, (3) undervaccination due to parental vaccine hesitancy, and (4) undervaccination due to other access barriers.	9/21/2021-8/31/2025	5R01AI165768-04			
5	NIAID	Brooke Bozick	Grant	COVID-19 Vaccine Uptake and Risk Mitigation Behaviors: Understanding the Role of Institutional Trust	BENTLEY UNIVERSITY	This project will investigate the extent to which trust in social institutions impacts individual adherence to public health recommendations, including vaccine uptake, and how this relationship evolved over the pandemic.	2/9/2023-1/31/2026	1R15AI176375-01			
6	NIAID	Brooke Bozick	Grant	Understanding transgender women's immune and behavioral responses to seasonal COVID-19 vaccines to improve their uptake	NEW YORK BLOOD CENTER	This project aims to understand the effect of sex hormones on the immune response to COVID-19 vaccination and SARS-CoV-2 infection by comparing immune response between cis-gender and transgender women (TW) using gender-affirming hormone therapy. The study will combine the immunological data with behavioral science data to develop a tailored draft intervention strategy, OptimizeVax, that will facilitate uptake of the updated seasonal COVID-19 vaccines by TW, a population that is traditionally hesitant to use biomedical products in the absence of TW-specific biomedical and behavioral data.	12/16/2024 – 11/30/2026	1R21AI183544-01A1			
7	NIAID	Brooke Bozick	Grant	COVID-19 transmission, testing, and vaccination dynamics within migrant worker social networks	UNIVERSITY OF CHICAGO	This project will characterize the social and transmission networks of migrant workers in Greece to mitigate ongoing and future coronavirus epidemics among vulnerable populations in diverse contexts. Outcomes will enable a better understanding of COVID-19 prevention, testing, treatment, vaccination, seroprevalence and immunogenicity in order to address facilitators and barriers to COVID-19 transmission mitigation.	03/05/2024 – 01/31/2026	5R21AI182822-02			
8	NIAID	Brooke Bozick	Grant	Uptake, Safety and Effectiveness of COVID-19 Vaccines during Pregnancy	UNIVERSITY OF SAN FRANCISCO	Drawing from national, linked health information for over 870,000 mother-infant pairs, this research will provide large-scale evidence on the uptake, safety and effectiveness of maternal COVID-19 vaccination in terms of perinatal, neonatal and infant health outcomes. Completion of this research will facilitate informed decision-making among pregnant persons, those planning pregnancy and their healthcare providers.	04/08/2022 – 03/31/2025	5R01AI169239-03			
9	NIAID	Brooke Bozick	Grant	Text4Vax: Understanding the Effectiveness and Implementation of Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines	COLUMBIA UNIVERSITY HEALTH SCIENCES	This project will conduct a pragmatic Hybrid Type 2 effectiveness/implementation trial with national scope to understand the effectiveness and implementation of behaviorally-informed COVID-19 and influenza text message reminders across parents with varied backgrounds and whose children are cared for in diverse practice settings. On a national scale, understanding the effectiveness and implementation of influenza and COVID-19 vaccine text message reminders among a diverse pediatric population will provide key information to clinicians, health systems, health departments and policymakers to bolster vaccine receipt and counter vaccine hesitancy.	04/15/2024 – 02/29/2028	1R01AI182165-01			
10	NIAID	Thomas Hiltke	Grant	Starve and Kill: Engineered Antigens Targeting Nutrient Acquisition Pathways Essential for Gonococcal Infection and Disease	GEORGIA STATE UNIVERSITY	This is a multiproject grant focused on the discovery and development of a vaccine for the sexually transmitted infection gonorrhea. The majority of the grant includes experiments to identify vaccine antigens and test them for immunogenicity and effectiveness in animal models of infection. One of the 3 Projects is looking at modelling the impact of a hypothetical vaccine on gonorrhea rates. One of the Aims in this Project is to evaluate healthcare worker's and potential patient's attitudes towards acceptance of a gonorrhea vaccine if one is developed.	03/25/2019-02/28/2025	1U19AI144182			This grant has ended, however there is a pending 2nd No Cost Extension request. if it is granted the grant will resume.
11	NIAID	Eleanore Chuang	Grant	Identifying the multi-level factors influencing provider recommendations of adolescent vaccines: A mixed methods study	YALE UNIVERSITY	This proposal is examining how provider recommendations vary across individual, interpersonal and community characteristics and how these factors influence recommendation quality. Results are being used to develop and target interventions to improve uptake of adolescent vaccines.	6/1/2022-05/31/2025	5F31AI167626-03			Trainee has switched institutions. Therefore grant is being terminated early.

	A	B	C	D	E	F	G	H	I	J	K
12	NIAID	Eleanore Chuang	Grant	Evaluating Heterogeneities in Initiation and Completion of Human Papilloma Virus (HPV) Vaccine among Adolescents	EMORY UNIVERSITY	The project proposes to examine risk factors and heterogeneity at the individual and geographic level, associated with initiation or completion of HPV vaccination among children and adolescents between ages 9 and 17 in the US and the state of Georgia. The research could inform state and local public health departments regarding targeted intervention design and delivery to increase HPV vaccine uptake .	Post-Council To Be Paid	1F31AI191734-01			This grant has not yet been awarded pending final council review.
13	NIAID	Eleanore Chuang	Grant	Epidemiological factors related to human monkeypox virus (MPOX) in men who have sex with men (MSM) in the United States	JOHNS HOPKINS UNIVERSITY	The study proposes to assess factors associated with monkeypox (MPOX) vaccination, testing, and stigma among men who have sex with men (MSM) in the United States (US).	6/1/2024-5/31-2025	1F31AI178878-01A1			
14	NEI	EVERETT, DONALD F	Grant	The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Abs	01/01/2018 - 5/31/2028	EY028739-07	$623,881	RePORT Proj Info	
15	NICHD	Sarah Glavin	Grant	ENHANCING K-12 SCHOOL SAFETY DURING A RESPIRATORY VIRAL PANDEMIC	YALE UNIVERSITY	The overall objective of the research is to understand K-12 school experience, vaccination and safety strategies during the Covid19 pandemic and would also examine the implementation outcomes of an institutional-level Bluetooth Digital Contact Tracing intervention.	2/16/2023 to 2/15/2025	F30HD107932-02			
16	NICHD	Sarah Glavin	Grant	DIGITAL STORYTELLING TO REDUCE PEDIATRIC INFLUENZA VACCINATION DISPARITIES: A PILOT PRAGMATIC TRIAL	DENVER HEALTH AND HOSPITAL AUTHORITY	Exploring, developing, and testing a Digital Storytelling (DST) intervention tailored to Black families to improve influenza vaccination equity in children 6 months to 5 years.	9/1/2022 to 8/31/2027	K23HD107184-03			
17	NICHD	Sarah Glavin	Grant	IMPROVING VACCINE DELIVERY IN HOSPITALIZED CHILDREN	SEATTLE CHILDREN'S HOSPITAL	This proposal will engage with nurses, pharmacists, physicians and parents to develop and test a technology-based intervention to identify undervaccinated children and improve vaccine delivery during hospitalization.	9/21/2023 to 8/31/2028	K23HD111624-02			
18	NICHD	Sarah Glavin	Grant	CAREGIVER DECISION MAKING FOR SEASONAL RESPIRATORY VACCINES FOR CHILDREN	CHILDREN'S RESEARCH INSTITUTE	The proposed project will identify the factors influencing parental hesitancy for seasonal respiratory vaccines.	8/13/2024 to 7/31/2029	K23HD112599-01A1			
19	NICHD	Sarah Glavin	Grant	MATERNAL COVID-19 VACCINATION AND LACTATION OUTCOMES	HEALTHPARTNERS INSTITUTE	To evaluate the vaccination safety: determine the association of COVID-19 vaccination during pregnancy and postpartum and the risk of adverse infant and lactation-related outcomes.	7/1/2022 to 4/30/2026	R01HD107753-03			
20	NICHD	Sarah Glavin	Grant	MODELING ADOLESCENT HEALTH CARE DECISION-MAKING FOR VACCINES: A COMMUNITY- BASED PARTICIPATORY APPROACH	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	The overall objective for this application is to understand the impact that Vaccine Consent laws for minors have on the overall spread of COVID-19.	9/16/2024 to 5/31/2029	R01HD110428-01A1			
21	NICHD	Sarah Glavin	Grant	COVID19 VACCINE HESITANCY AMONG PERINATAL WOMEN AT RISK FOR HEALTH DISPARITIES	BUTLER HOSPITAL (PROVIDENCE, RI)	This study will involve in-depth assessments with pregnant and postpartum women, and with prenatal care providers, in order to help identify reasons for the low rate of COVID-19 vaccination among perinatal women, as well as possible solutions.	1/1/2023 to 12/31/2025	R21HD110912-02			
22	NICHD	Sarah Glavin	Grant	UNIVERSITY OF SOUTH FLORIDA SITE CONSORTIUM - ADOLESCENT MEDICINE TRIALS NETWORK FOR HIV/AIDS INTERVENTIONS (ATN) OPERATIONS AND COLLABORATIONS CENTER (UM2 CLINICAL TRIAL OPTIONAL) [Parent Title: ADOLESCENT MEDICINE TRIALS NETWORK FOR HIV/AIDS INTERVENTIONS (ATN) OPERATIONS AND COLLABORATIONS CENTER (UM2 CLINICAL TRIAL OPTIONAL)]	UNIVERSITY OF SOUTH FLORIDA	The USF Adolescent HIV Consortium will collaborate with the Adolescent Trials Network (ATN) Operations and Collaborations Center (OCC) by engaging, enrolling, and retaining adolescents and young adults, both at risk of and living with HIV, in care and research through a well-established clinical and research infrastructure. One of the aim is to leverage the consortium's expertise in vaccine trials to address pressing public health issues such as understanding community COVID-19 vaccine hesitancy, which may improve future HIV vaccination efforts.	9/22/2022 to 6/30/2029	UM2HD111076-03			
23	NICHD	Sarah Glavin	Grant	EVALUATING TEEN-PARENT DYNAMICS IN ADOLESCENT COVID-19 VACCINE ACCEPTANCE AND UPTAKE	UNIVERSITY OF SAN FRANCISCO	Developing a tool to measure vaccine hesitancy among adolescents and evaluate how adolescent vaccine hesitancy aligns with their parents and how adolescent and parental vaccine hesitancy interact in the decision to vaccinate against COVID-19.	8/15/2022 to 4/30/2025	R21HD109536-02			
24	NICHD	Sarah Glavin	Grant	REDUCING VACCINE HESITANCY AMONG HISPANIC PARENTS OF COVID-19 VACCINE-ELIGIBLE CHILDREN	ARIZONA STATE UNIVERSITY-TEMPE CAMPUS	This community-based study aims to create and evaluate a disseminable, low-cost intervention to reduce Hispanic parents' vaccine hesitancy.	9/1/2023 to 8/31/2025	R21HD110837-01A1			
25	NIDCR	Jill Mattia	Grant	Investigating Behavioral Mechanisms and Efficacy of a Provider-Directed Intervention for HPV Vaccine Promotion in Real-World Dental Settings	HealthPartners Institute	Human papillomavirus (HPV) is the leading cause of oropharyngeal cancers in the United States. This NIDCR-funded project will develop an intervention for dental provider training including tailored scripts for the promotion of the HPV vaccine in a real-world dental clinic setting.	2023/02/01 - 2029/02/28	UH3DE030063		https://reporter.nih.gov/search/Dk1rInSaTEiMKp1dHBAAvg/project-details/10769887	

	A	B	C	D	E	F	G	H	I	J	K
26	OD	Claudia Thompson	grant supplement	RADx COVID-19 Supplement	University of California Davis	The aims of this study are to: (1) reduce vaccine hesitancy, improve vacc	Sept 2021 to March 2024	P30ES023513-07S1	No NIEHS funds were used. Project was supported through RADx funding from OD.		
27	OD	Kim McAllister	grant supplement	Community-Engaged Covid-19 Interventions to Protect and Monitor Children	Baylor College of Medicine	This partnership of academic and community health disparities experts	Sept 2021 to July 2023	R01ES028615-07S1	No NIEHS funds were used. Project was supported through RADx funding from OD.		
28	NIGMS	LAWRENCE A. BECK (beckl@mail.nih.gov)	grant	One Health Education: Connecting Humans, Animals, and the Environment	UNIVERSITY OF ROCHESTER	The goal of this Science Education Partnership Award (SEPA), is to create and disseminate educational materials about human health, animal health and environmental health are interrelated, such as through zoonotic transmission of pathogens from animal to human hosts. The grantees are aiming to educate adolescents as ambassadors for health literacy in was that would address COVID-19 vaccine hesitancy.	Project Start Date: 01-August-2019 Project End Date: 30-June-2025	GM132758-03S1	FY: 2021; Total Award: $53,996	RePORTER link	This project is likely relevant: it is focused on education to generate ambassadors to reduce vaccine hesitancy
29	NIGMS	GARTRELL, KYUNGSOOK (kyungsook.gartrell@nih.gov)	grant	An examination of childhood vaccine hesitancy in Brazil	UNIVERSITY OF VERMONT & ST AGRIC COLLEGE	The University of Vermont's Translational Global Infectious Diseases Research (TGIR) Center of Biomedical Research Excellence (COBRE) aims to support and develop the research careers of the next generation of scientists and to build institutional strength in global infectious disease research. One subproject under this COBRE is focused on understand the factors underlying vaccine hesitancy in Brazil.	Project Start Date: 15-September-2018 Project End Date: 31-July-2028	GM125498-07	FY: 2024: Total Award: $208,911	RePORTER link	This project may be relevant: it studies mechanisms underlying vaccine hesitancy using Brazil as a model given their successful childhood vaccination program.
30	NIGMS	GUOQIN YU (guoqin.yu@nih.gov)	grant	Digital data streams and machine learning for real-time modeling of vaccine-preventable infectious diseases	BOSTON CHILDREN'S HOSPITAL	This project focuses on developing tools for computational epidemiology of vaccine-preventable diseases, and proposes methods to monitor and measure behaviors that affect transmissibility, which include vaccine hesitancy, as a way to improve epidemic modeling.	Project Start Date: 01-September-2022 Project End Date: 31-August-2027	GM146974-03	FY: 2024; Total Award: $442,337	RePORTER link	This project is likely not relevant: grantees wish to incorporate vaccine hesitancy, among several other factors, into the parameters of mathematical modeling.
31	NIGMS	HAN NGUYEN (han.nguyen@nih.gov)	grant	Mathematical Modeling and Scientific Computing for Infectious Disease Research	UNIVERSITY OF TENNESSEE CHATTANOOGA	The overall objective of this proposal is to establish a new mathematical and computational modeling framework for infectious diseases, with a focus on COVID-19, that integrates novel mathematical modeling, extensive numerical simulation, and rigorous data validation. The grantees mention that vaccine hesitancy has not been fully addressed in prior mathematical modeling, and that they would like to make their model more accurate to a variety of real-world conditions.	Project Start Date: 22-September-2023 Project End Date: 31-August-2026	GM152943-01	FY: 2023; Total Award: $331,246	RePORTER link	This project is likely not relevant: grantees wish to incorporate vaccine hesitancy, among several other factors, into the parameters of mathematical modeling.
32	NIGMS	Unknown	grant	Community Engagement and Outreach Core	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	The primary mission of the Oklahoma Shared Clinical and Translational Resources (OSCTR) is to improve health by catalyzing clinical and translational research (CTR) that addresses the top health concerns experienced in the state. The Oklahoma Primary Healthcare Improvement Cooperative (OPHIC), the subset of the OSCTR that performs community engagement, had also received a RADx-UP award during the pandemic which included research to address vaccine hesitancy.	Community Engagement and Outreach Core: Project Start Date: 01-September-2013 Project End Date: 30-June-2028	GM104938-12	FY: 2024: Total Award: $808,911	RePORTER link	This project is likely not relevant: grantees are describing historically funded work on vaccine hesitancy to highlight past accomplishments of the currently-funded program.
33	NIGMS	Unknown	grant	Clinical Resources Core	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	The primary mission of the Oklahoma Shared Clinical and Translational Resources (OSCTR) is to improve health by catalyzing clinical and translational research (CTR) that addresses the top health concerns experienced in the state. During the pandemic, the Clinical Resources Core of the OSCTR was involved in the aforementioned RADx-UP awards which partially addressed vaccine hesitancy.	Clinical Research Resources Core: Project Start Date: 01-September-2013 Project End Date: 30-June-2028	GM104938-12	FY: 2024: Total Award: $636,668	RePORTER link	This project is likely not relevant: grantees are describing historically funded work on vaccine hesitancy to highlight past accomplishments of the currently-funded program.
34	NIGMS	Unknown	grant	Core 07: Clinical Research Resources Core	LSU PENNINGTON BIOMEDICAL RESEARCH CTR	The Louisiana Clinical and Translational Science (LA CaTS) Center is a consortium of the major academic and biomedical research centers in the State of Louisiana to build capacity for clinical and translational research that addresses the health needs of the state of Louisiana. The clinical research resources core was part of the implementation of several awards from RADx, one of which was addressing vaccine hesitancy.	Clinical Research Resources Core: Project Start Date: 15-August-2012 Project End Date: 30-June-2027	GM104940-09	FY: 2024: Total Award: $431,320	RePORTER link	This project is likely not relevant: grantees are describing historically funded work on vaccine hesitancy to highlight past accomplishments of the currently-funded program.
35	NIGMS	Unknown	grant	Northern New England Clinical and Translational Research Network	MAINEHEALTH	The long-term goal of the Northern New England Clinical and Translational Research Network (NNE-CTR), composed of MaineHealth, the University of Vermont, and the University of Southern Maine, is to sustain a clinical and translational research infrastructure that supports improvements in community health for northern New England inhabitants. The NNE-CTR funds a variety of pilot projects—one historical project was on vaccine hesitancy.	Pilot Project Program: Project Start Date: 03-July-2017 Project End Date: 30-June-2027	GM115516-08	FY: 2024: Total Award: $531,209	RePORTER link	This project is likely not relevant: grantees are describing historically funded work on vaccine hesitancy to highlight past accomplishments of the currently-funded program.
36	NIGMS	Unknown	grant	Northern New England Clinical and Translational Research Network - Equipment	MAINEHEALTH	supplement for equipment		GM115516-08S1		supplement for equipment	This project is likely not relevant: grantees are describing historically funded work on vaccine hesitancy to highlight past accomplishments of the currently-funded program.
37	NIGMS	LAWRENCE A. BECK (beckl@mail.nih.gov)	grant	Partnerships for Prevention: A plan for managing student stress, anxiety, and pain through interactive media.	DUQUESNE UNIVERSITY	The goal of this Science Education Partnership Award (SEPA), is to educate children and teens on the biology of the brain, body and emotions, as well as how to develop healthy habits, in order to help them navigate challenges related to anxiety and stress in their daily life. The abstract mentions COVID-19 and vaccination as a source of recent increases in stress and anxiety.	Project Start Date: 01-August-2019 Project End Date: 31-July-2025	GM132910-05S1	FY: 2023; Total Award: $215,227	RePORTER link	This project is not relevant: grantees mention vaccine hesitancy as a source of anxiety.

	A	B	C	D	E	F	G	H	I	J	K
38	NIMH	Jennifer Humensky	Grant	Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depression	Graduate School of Public Health and Health Policy	Despite increased risk of COVID-19 infection, severe complications, hospitalizations, and death, people with mental health disorders report greater vaccine hesitancy and have lower COVID vaccination levels than the general population. This research will adapt, pilot, and test a brief attitudinal inoculation intervention to increase COVID-19 vaccination and boosting among US adults with symptoms of anxiety or depression. Findings will rapidly generate evidence to inform the development and implementation of strategies to increase vaccination uptake and mitigate the impact of COVID-19 among mental health populations.	Project Start Date: September 1, 2022; Project End Date: August 31, 2025	1RF1MH132360-01	$3,296,734	https://reporter.nih.gov/project-details/10613750	
39	NIMH	Maggie Sweeney	Grant	Using Data Science to Quantify the Impact of Misinformation, Mistrust, and Other Key Psychosocial Factors on Vaccine Hesitancy Amon g Vulnerable People Experiencing Psychopathology	University of Minnesota	Although people with severe mental illness (SMI) are 3-10 times more likely to contract and die from vaccine- preventable disease, it remains unclear how best to address vaccine hesitancy in this population, largely because it is not known whether and how unique features of SMI impact hesitancy. This project aims to characterize unique aspects of hesitancy among people with SMI; use cutting-edge machine-learning methods to learn what causes people with SMI to be vaccine hesitant and identify, in a data-driven manner, the most promising targets for hesitancy-reducing interventions; and test whether education about herd immunity, which improves willingness to vaccinate in the general population, is differentially efficacious for people with SMI vs. healthy people.	Project Start Date: June 1, 2024; Project End Date: May 31, 2028	1K01MH132899-01A1	$187,261	https://reporter.nih.gov/project-details/10885682	
40	NIMH	Michael Stirratt	Grant	Understanding the Regional Ecology of a Future HIV Vaccine	University of Pennsylvania	This project will investigate the influence of vaccine characteristics, information in the community, vaccination norms, and public health policies on the intention to receive an HIV vaccine, should it be approved. It will inform vaccination policy and communications more generally with respect to other adolescent and adult vaccines.	Project Start Date: August 1, 2023; Project End Date: May 31, 2028	5R01MH132415-02	$790,033	https://reporter.nih.gov/project-details/10894613	
41	NINR	dionne.godette@nih.gov	Grant	Leveraging community-based behavioral health to increase vaccine uptake in Latinx adults with mental illness	Boston College	In collaboration with East Boston Neighborhood Health Center this study is evaluating the effectiveness of a motivational interviewing-based behavioral intervention to reduce vaccine hesitancy and increase vaccine uptake.	2022-2027	R01NR020482			
42	NIDDK	JUNICHI ISHIGAMI	training award	Implementation research to improve the uptake of influenza vaccination in CKD	JOHNS HOPKINS UNIVERSITY	ABSTRACT/ PROJECT SUMMARY Dr. Junichi Ishigaki, MD, MPH seeks a N	2024	5K01DK125616-04	$144,955		Awarded. Non-fellowships only
43	NHGRI	Dave Kaufman	Grant	Religion and support for genomic healthcare: An exploratory study of the US public and faith leaders	Washington University	Survey of 4800 adults in the US to examine the association of religious variables with support for genomics and genomic healthcare activities such as prenatal genetic testing, gene editing, and mRNA vaccines.	9/22/2022-6/30/2025	R01HG012830	$458,341 (for FY24)	https://reporter.nih.gov/project-details/10866483	
44	NIMHD	LINARES, DEBORAH ELIZABETH; DAGHER, RADA	Notice of Special Interest (NOSI)	NOT-MD-23-008: Research to Address Vaccine Uptake and Implementation Among Populations Experiencing Health Disparities	NIMHD	This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the U.S. and its territories. This NOSI is focused on individuals across the life span. The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.	Release Date, 2023/03/31; Expiration Date, 2026/06/06			Notice of Special Interest	

	A	B	C	D	E	F	G	H	I	J	K
1	**IC**	**NIH POC**	**Type of Project (grant, intramural research, NOFO, etc.)**	**Name of Project**	**Institution**	**Short Description of Project**	**Timeframe**	**Grant or NOFO Number (optional)**	**Budget (optional)**	**Link to Project (optional)**	**Notes**
2	NHGRI	Peter McGuire	Intramural research	Metabolism, infection and immunity in inborn errors of mitochondrial metabolism	NHGRI	Examination of vaccine attitudes among families with a child with a mitochondrial disease.	FY2012-present (for the whole research program)	ZIAHG200381	$2,108,935 (for FY23)	https://reporter.nih.gov/project-details/10920205	This is one very small aspect of the overall research program, the goal of which is to understand the mechanisms involved in host-pathogen interactions in children with mitochondrial disease.
3	NIMHD	ALVAREZ PRIVADO, CHRISTIAN	Intramural Research	The COVID-19's Unequal Racial Burden (CURB) survey	NIMHD	The COVID-19's Unequal Racial Burden (CURB) survey is an online, nationally representative survey of adults living in the United States. The CURB survey included a total of 8,500 unique participants. Baseline data was collected between December 2020 and February 2021, and 6-	Data collection completed in 2020-2021. Data analysis is ongoing.				
4	NIMHD	FORDE, ALLANA	Intramural Research	Weighing Factors in COVID Health Decisions Survey	NIMHD	The Weighing Factors in COVID Health Decisions survey was conducted from December 2020 to December 2021 at the University of Maryland, College Park on students who were 18 years of age or older. The self-administered online survey included questions related	Data collection completed in 2020-2021. Data analysis is ongoing.				
5	NIMHD	FORDE, ALLANA	Intramural Research	Race-Related Experiences Associated with COVID-19 and Health in the United States (REACH-US) Study	NIMHD	REACH-US is a nationally representative online survey of a large, sample of U.S. adults 18 years and older, from seven racial and/or ethnic groups living in the U.S. The survey included questions about COVID-19 vaccine willingness and vaccine uptake. This cross-sectional study was	Data collection completed in 2021. Data analysis is ongoing.				

PDF COPY OF NIH_GRANTS_002470
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G
1	**Project Abstract**	**Project Title**	**Administer**	**Project End Date**	**FIPS**	**Organization Name**	**Total Cost IC**
2	Abstract A plethora of research exists highlighting the disproportionate disparities faced by sexual and gender minorities (SGM) of all ages, such as increased levels of homelessness, lack of access to healthcare, and negative physical and psychological outcomes. While there have been significant efforts to address systemic racism and social determinants of health (SDOHs) at the	Leveraging a community-driven approach to address the impact of social determinants of health on structural inequities among Miami-Dade County's intergenerational LGBTQ+ Community	OD	09/20/2028	US	URBAN HEALTH PARTNERSHIPS	$ 1,125,000
3	PROJECT SUMMARY No changes being proposed. INTRODUCTION This application is for an Administrative Supplement for Research on Sexual and Gender Minority (SGM) Populations (NOT-OD-22-032) to the parent award, ""Effects of Social Networks and Policy Context on Health	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	NIA	06/30/2025	US	VANDERBILT UNIVERSITY	$ 99,998
4	7. Project Summary/Abstract Consistent with NIAAA's expressed goal to understand sex differences in risk of problem alcohol use and target mechanisms that contribute to known disparities within high-risk communities, the current proposal seeks to examine the role of internal sources of minority stress (i.e., stress unique to those from marginalized communities) in potentiating heavy alcohol use, particularly among female	Internal Sources of Minority Stress and Alcohol Consumption	NIAAA	07/31/2025	US	TEXAS TECH UNIVERSITY	$ 397,892
5	PROJECT SUMMARY Mobile health (mHealth) interventions are a promising modality for overcoming barriers and providing culturally appropriate treatment among transgender individuals. mHealth interventions may be appropriate among transgender individuals, as emergent evidence suggests that virtual spaces are used to access gender affirming support and resources. Moreover, mHealth interventions may enable	TRANSforma Tu Salud Dejando de Fumar: Advancing smoking cessation among transgender individuals	NCI	08/31/2025	US	UNIVERSITY OF ROCHESTER	$ 2,000
6	ABSTRACT Age is the greatest risk factor for Alzheimer's disease and related dementia (AD/ADRD) and an estimated 2.7 million LGBTQ+ Americans are older adults. LGBTQ+ older adults face discrimination and persecution throughout their lives, with only some recent legal protections for their sexual orientation and/or gender identification statuses in the United States. LGBTQ+ individuals with	SilverBills: A Legal, Technical and Financial Tool for Aging LGBTQ+ Individuals with Impaired Cognition.	NIA	08/31/2025	US	SILVERBILLS INC.	$ 1,080,149
7	Transgender individuals are disproportionately burdened by chronic (e.g., interpersonal rejection) and acute (victimization) discrimination. According to minority stress theory, both forms of discrimination are associated with adverse mental health outcomes including PTSD, a stress sensitive disorder that may arise from exposure to life-threatening events, serious injury, or sexual assault. While PTSD effects an estimated 6.8% of the U.S.	Trajectories of Adaptation to Traumatic Stress in a Vulnerable Population	NIGMS	08/31/2025	US	HUNTER COLLEGE	$ 117,000

	A	B	C	D	E	F	G
8	Project Summary Sexual minority women (SMW) consistently report higher rates of alcohol use than heterosexual women. In fact, SMW are more likely to be current alcohol users, binge drinkers, and heavy drinkers than heterosexual women1 and are 11 times more likely to meet the threshold for alcohol use disorder.1-6 While research on SMW's alcohol use has grown in recent years, a scoping review of the literature	Health Effects of Intersectional Stigma among Sexual Minority Women	NIAAA	08/31/2025	US	UNIVERSITY OF CALIFORNIA SANT	$ 180,704
9	Abstract By 2030, there will be nearly six million sexual and gender minority (SGM) older adults aged 50 and older in the U.S. who identify as lesbian, gay, bisexual, transgender, and/or queer. This number will more than double by 2050. Approximately 350,000 SGM older adults in the U.S. currently are living with Alzheimer's disease and related dementias (ADRD), with projections nearing one million by 2030.	Building Community and Research Engagement among Sexual and Gender Minority Older Adults at Risk for Alzheimer's Disease and Related Dementias	NIA	08/31/2025	US	EMORY UNIVERSITY	$ 727,284
10	ABSTRACT Black and Latino trans women and men who have sex with men – or sexual and gender minorities of color (SGMoC) - account for at least half of all new HIV infections in the United States (U.S.). At the same time there is a significant disparity in knowledge of, access to and uptake of pre-exposure prophylaxis (PrEP) among SGMoC is disproportionately low compared to white MSM and trans	One Ballroom: Understanding Intersectional Stigma to Optimize the HIV Prevention Continuum among Vulnerable Populations in the United States	NIAID	08/31/2027	US	UNIVERSITY OF CALIFORNIA-IRVI	$ 426,660
11	PROJECT SUMMARY Transgender and gender nonbinary (TGNB) people are diverse and have distinct healthcare needs, yet demonstrate lower levels of healthcare utilization and greater likelihood of delaying needed care than their cisgender counterparts. Further, TGNB young adults experience more barriers to healthcare utilization and are more likely to delay care than TGNB adolescents and older adults. Though	Facilitators of and barriers to healthcare utilization among racially and ethnically diverse transgender and gender nonbinary young adults	NIMHD	02/28/2025	US	UNIVERSITY OF CENTRAL FLORIDA	$ 188,746
12	ABSTRACT Older sexual and gender minority (SGM) populations experience significant disparities in morbidity and disability compared with their heterosexual and cisgender counterparts. There are two primary explanations as to why physical health, mental health, and disability outcomes may differ for older SGM adults compared to older heterosexual and cisgender	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	NIA	06/30/2025	US	VANDERBILT UNIVERSITY	$ 362,818
13	PROJECT SUMMARY The use of virtual sociosexual networking venues (e.g., mobile apps and websites) to find intimate partners is near ubiquitous among young sexual minority (SM) men. However, little attention has been paid to the unique discriminatory phenomena that occur in online spaces, and how these experiences impact the mental health of young sexual minority men of color (YSMMoC). One such phenomenon that	Racialized Sexual Discrimination (RSD) and Psychological Well-being among Young Sexual Minority Men of Color (YSMMoC)	NIMHD	02/28/2025	US	UNIVERSITY OF ILLINOIS AT URBA	$ 159,646

	A	B	C	D	E	F	G
14	PROJECT SUMMARY/ABSTRACT During the COVID-19 pandemic, up to 81% of adults in the United States experienced worsening mental health. A major cause was the social isolation triggered by the pandemic due to quarantining, loss of family or friends, and loss of work. For individuals who lost social connections or were unable to adapt to maintain their connections, social support decreased and loneliness worsened, putting	Improving mental health among the LGBTQ+ community impacted by the COVID-19 pandemic	NIMH	08/31/2025	US	BROWN UNIVERSITY	$ 2,368,492
15	Project Summary Our study seeks to advance methods to measure and analyze multiple types of discrimination for population health research. We will compare novel implicit vs. conventional explicit (self-report) measures of exposure, investigate different approaches to modeling exposure to multiple types of discrimination, and test novel hypotheses using causal mediation analyses. We are motivated by profound	Advancing novel methods to measure and analyze multiple types of discrimination for population health research	NIMHD	01/31/2026	US	HARVARD SCHOOL OF PUBLIC HE	$ 648,444
16	Abstract By 2030, there will be nearly six million sexual and gender minority (SGM) older adults aged 60 and older in the U.S. who identify as lesbian, gay, bisexual and transgender. Approximately 350,000 SGM older adults in the U.S. currently have Alzheimer's disease and related dementias (ADRD), with projections nearing one million by 2030. Yet, almost nothing is known about the prevalence or risk	The Epidemiology of Alzheimer's Disease and Related Dementias in Sexual and Gender Minority Older Adults: Identifying Risk and Protective Factors	NIA	06/30/2025	US	UNIVERSITY OF NEVADA LAS VEGA	$ 126,738
17	Abstract Public awareness of the diversity of experiences of gender identities has climbed sharply. The specific issues of those with gender dysphoria (GD) related to self-identity, body image, and medical interventions are challenges for the 21st century, particularly given the high risk of suicide. Gender identity is tightly linked to one's bodily features, particularly readily observable sexual characteristics.	Personalized 3D avatar tool development for measurement of body perception across gender identities	NIBIB	03/31/2025	CA	CENTRE FOR ADDICTION AND ME	$ 120,174

PDF COPY OF NIH_GRANTS_002489
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X
1	FY	Appl Id	Actv	Admin IC	Grant	Budget Start	Budget End	Proj Start	Proj End	PI Name	Title	Abs	Abstract Text	Active	Org Id	Institution	Awd Tot $	Is the work in the covered areas?	Whole Project or Subproject?	Notes				
2	2024	10849875	K01	AG	5 K01 AG065	2024/06/01	2025/05/31	2020/08/01	2025/05/31	SCHERER, AA	Creating Innc	Abs	PROJECT SUM	Y	3972901	UNIVERSITY O	$122,211	Yes						
3	2024	10840830	R01	AR	5 R01 AR080	2024/05/01	2025/04/30	2022/05/10	2027/04/30	FELDMAN, CA	Leveraging C	Abs	PROJECT SUM	Y	6144650	NORTHWESTE	$709,413	Yes	Whole					
4	2024	10840830	R01	AR	5 R01 AR080	2024/05/01	2025/04/30	2022/05/10	2027/04/30	RAMSEY-GOL	Leveraging C	Abs	PROJECT SUM	Y	6144650	NORTHWESTE	$709,413	Yes	Whole					
5	2024	10813728	R37	CA	5 R37 CA259	2024/04/01	2025/03/31	2022/04/12	2027/03/31	KORNIDES, MI	An inoculatio	Abs	Project Summ	Y	6463801	UNIVERSITY O	$592,790	Yes	Whole					
6	2024	10900605	R34	CA	5 R34 CA283	2024/08/01	2025/07/31	2023/08/07	2026/07/31	BUTLER, LISA	Multi-level sct	Abs	PROJECT SUM	Y	1080401	BRIGHAM AN	$241,234	Yes	Sub	The specific				
7	2024	10900605	R34	CA	5 R34 CA283	2024/08/01	2025/07/31	2023/08/07	2026/07/31	KATZ, INGRID	Multi-level sct	Abs	PROJECT SUM	Y	1080401	BRIGHAM AN	$241,234	Yes	Sub	The specific				
8	2024	10923945	R00	CA	5 R00 CA248	2024/09/01	2025/08/31	2023/09/01	2026/08/31	SWIRE-THOM	Cancer misin	Abs	Project Summ	Y	6116101	NORTHEASTER	$244,981	Yes	Whole	focuses on				
9	2024	10923996	K22	CA	5 K22 CA258	2024/08/01	2025/07/31	2022/08/02	2025/07/31	KOHLER, RAC	Addressing H	Abs	PROJECT SUM	Y	10034168	RUTGERS BIO	$219,899	Yes	Whole	focuses on				
10	2024	10929945	R01	CA	5 R01 CA273	2024/07/01	2025/06/30	2022/09/01	2027/06/30	BICKMORE, TI	Conversation	Abs	Universal Hun	Y	130301	TUFTS MEDICA	$648,684	Yes	Whole	focuses on				
11	2024	10929945	R01	CA	5 R01 CA273	2024/07/01	2025/06/30	2022/09/01	2027/06/30	PAASCHE-OR	Conversation	Abs	Universal Hun	Y	130301	TUFTS MEDICA	$648,684	Yes	Whole	The research				
12	2024	10929945	R01	CA	5 R01 CA273	2024/07/01	2025/06/30	2022/09/01	2027/06/30	PERKINS, REBE	Conversation	Abs	Universal Hun	Y	130301	TUFTS MEDICA	$648,684	Yes	Whole	Repayment				
13	2024	11062095	R01	CA	3 R01 CA248	2024/08/01	2025/07/31	2021/08/01	2026/07/31	LU, QIAN	Promoting HF	Abs	PROJECT SUM	Y	578407	UNIVERSITY O	$128,021	Yes	Whole					
14	2024	10880678	R25	GM	5 R25 GM150	2024/06/01	2025/05/31	2023/07/03	2028/05/31	ROBISON, BA	Eradicating M	Abs	Project Summ	Y	3543501	UNIVERSITY O	$261,005	Yes	Whole					
15	2024	10890031	R25	GM	5 R25 GM150	2024/07/01	2025/06/30	2023/07/20	2028/06/30	CLAPMAN, LE	PBS NewsHou	Abs	Project Summ	Y	10032008	WETA TV 26	$270,000	Yes	Whole					
	2025	11078765	R37	CA	5 R37CA259210-04		CA			Kornides, Mel	An inoculation	https://reporter.nih.gov/search/Q0mHQ0/project-details/11078765#publications			10000493	LOAN REPAY	$548,283	Yes	Whole					
16																								
17	2024	10885911	R01	MH,OD	5 R01MH132500-02					Andrasik, Mich	Evaluating a M	https://reporter.nih.gov/search/	$643,002					No	Whole					
18	2024	10842257	R37	CA	5 R37 CA253	2024/05/01	2025/04/30	2020/08/10	2025/04/30	CALO, WILLIA	HPV ECHO: Ir	Abs	ABSTRACT De	Y	1524204	PENNSYLVAN	$351,690	No		focuses on				
19	2024	10864335	K22	CA	1 K22 CA288	2024/07/01	2025/06/30	2024/07/01	2027/06/30	FRIDMAN, ILO	Cancer Misin	Abs	Abstract Patie	Y	3117901	HACKENSACK	$194,400	No						
20	2024	10977489	R37	CA	3 R37 CA253	2024/05/01	2025/04/30	2020/08/10	2025/04/30	CALO, WILLIA	HPV ECHO: Ir	Abs	ABSTRACT De	Y	1524204	PENNSYLVAN	$63,731	No						
21	2024	10988903	L40	CA	2 L40 CA220	2024/07/01	2025/06/30	2024/07/01	2025/06/30	KORNIDES, MI	An inoculatio	Abs	Background: T	Y	10000493	LOAN REPAY	$7,411	No		extensive				
22	2024	11094263	R01	DA	7 R01 DA054	2024/05/24	2026/04/30	2021/06/01	2026/04/30	ARONSON, IA	Community D	Abs	Project Summ	Y	10056635	NDRI-USA, INC	$461,653	No						
23	2024	10814317	R01	MD	5 R01	2024/02/01	2026/01/31	2021/04/20	2026/01/31	BUDHWANI,	A	Abs	PROJECT SUM	Y	513804	FLORIDA	$692,762	No	Whole	This project				
24	2024	10854799	R01	MD	5 R01	2024/06/01	2025/05/31	2022/09/22	2025/05/31	CARPENTER,	Addressing	Abs	PROJECT SUM	Y	578206	UNIV OF	$569,232	No	Whole	This project				
25	2024	10908996	R01	MD	7 R01	2024/04/17	2025/05/31	2023/08/17	2028/05/31	RITCHWOO	Advancing	Abs	Abstract As w	Y	9021205	WAKE	$766,932	No	Whole	This project				
26	2024	10944038	R01	MD	1 R01	2024/09/22	2025/05/31	2024/09/22	2028/05/31	GWADZ,	Community -	Abs	PROJECT SUM	Y	5998301	NEW YORK	$688,573	No	Whole	This project				
27	2024	10759403	R01	MD	5 R01	2024/02/01	2026/01/31	2021/04/23	2026/01/31	BICKMORE,	Community-	Abs	PROJECT SUM	Y	6116101	NORTHEASTE	$677,130	No	Whole	This project				
28	2024	10947101	R21	MD	1 R21	2024/08/24	2025/03/31	2024/08/24	2026/03/31	REITER, PAUL	COVID-19	Abs	PROJECT SUM	Y	6218701	OHIO STATE	$196,875	No	Whole	This project				
29	2024	10909015	R01	MD	5 R01	2024/03/01	2025/05/31	2023/08/17	2028/05/31	DANILA,	Improving	Abs	PROJECT SUM	Y	1288803	UNIVERSITY	$603,165	No	Whole	This project				
30	2024	10881752	R01	MD	5 R01	2024/05/01	2025/04/30	2022/08/21	2025/04/30	CRESPO,	Increasing	Abs	Project Summ	Y	513614	SAN DIEGO	$609,078	No	Whole	This project				
31	2024	10946664	R01	MD	1 R01	2024/09/20	2025/04/30	2024/09/20	2029/04/30	YOUNG,	Influence of	Abs	Abstract One	Y	577504	UNIVERSITY	$683,352	No	Whole	This project				
32	2024	10933019	R21	MD	5 R21	2024/07/01	2025/06/30	2023/09/21	2025/06/30	KHANNA,	Integrated	Abs	Project Summ	Y	1003201	BROWN	$207,669	No	Whole	This project				
33	2024	10884906	R01	MD	5 R01	2024/04/01	2025/03/31	2022/07/15	2027/03/31	CARDARELLI,	K-VAC:	Abs	ABSTRACT Va	Y	2793601	UNIVERSITY	$607,507	No	Whole	This project				
34	2024	10845547	R01	MD	5 R01	2024/06/01	2025/05/31	2022/09/20	2027/05/31	KANAMORI	LatiNET: a	Abs	PROJECT SUM	Y	5221250	UNIVERSITY	$719,232	No	Whole	This project				
35	2024	10771048	R01	MD	5 R01	2024/01/01	2025/06/30	2022/04/13	2027/06/30	PAGE,	REDES: a	Abs	Project Summ	Y	4134401	JOHNS	$714,762	No	Whole	This project				
36																								
37																								
38	Grants above in red should be terminated per MM. Grants below in yellow should be renegotiated (if possible). The notes in column U describe the goals of the renegotiations. (Note one grant is duplicated because it is MPI).																							
39																								
40																								
41	2024	10918275	R01	CA	5 R01 CA268	2024/09/01	2025/08/31	2022/09/08	2027/08/31	BULLER, DAVI	#4Corners4H	Abs	Several risk fa	Y	4368501	KLEIN BUENDE	$998,970	Yes	Sub		Renegotiate to remove vaccine hesitancy work			
42	2024	10918275	R01	CA	5 R01 CA268	2024/09/01	2025/08/31	2022/09/08	2027/08/31	SUSSMAN, AN	#4Corners4H	Abs	Several risk fa	Y	4368501	KLEIN BUENDE	$998,970	Yes	Sub		Renegotiate to remove vaccine hesitancy work			
43	2024	10855130	R01	CA	1 R01 CA289	2024/04/03	2025/03/31	2024/04/03	2029/03/31	POPOVA, LYU	Communicat	Abs	ABSTRACT Sn	Y	676604	GEORGIA STA	$593,747	No		focuses on	Change title to emphasize smoking cessation			

PDF COPY OF NIH_GRANTS_002497
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H
1	Project Abstra	in NJ	Administering IC	Project Number	Program Official Information	Contact PI / Project Leader	Organization Name	Total Cost
2	Poor cardiova	Cardiovascular Health and Inflammation: Intersectional Impact of Structural Racism Structural Sexism and Structural Classism	NIGMS	5P20GM135007-05		BERNAL, FEDERICO	UNIVERSITY OF VERMONT & ST AGRIC COLLEGE	
3	ABSTRACT Ch	Children's Hospital Los Angeles Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Coll		5UM2HD111076-03		BELZER, MARVIN E	WESTAT, INC.	
4	Research Pro	Administrative Core	NIMHD	2U54MD007582-39			FLORIDA AGRICULTURAL AND MECHANICAL UNIV	
5	Project Summ	Community Outreach and Engagement		2U54MD007598-16		DEL PINO, HOMERO ERWIN	CHARLES R. DREW UNIVERSITY OF MED & SCI	
6	ABSTRACT: PF	Amplifying the menthol cigarette bans impact in priority populations with a quit smoking campaign	NIDA	5U54DA060049-02			UNIV OF NORTH CAROLINA CHAPEL HILL	
7	PROJECT SUM	Recruitment and Retention Core	NINDS	5U19NS120384-04			UNIVERSITY OF CALIFORNIA AT DAVIS	
8	FIU-RCMI Adr	Administrative Core	NIMHD	5U54MD012393-08			FLORIDA INTERNATIONAL UNIVERSITY	
9	SUMMARYThe	Stanford Cancer Institute (SCI) is a national and international leader in cancer research across the cancercontrol cont	NCI	5P30CA124435-16			STANFORD UNIVERSITY	
10	PROJECT SUM	Core A: Administrative	NIAID	3P30AI050409-26S1		DEL RIO, CARLOS	EMORY UNIVERSITY	
11	PROJECT SUM	AIDS prevention;Acquired Immunodeficiency Syndrome;Address;Adherence;Adolescence;Adolescent;Adolescent and Y	NIAID	5P30AI042853-26			MIRIAM HOSPITAL	
12	PROJECT SUM	PROJECT NARRATIVEThe global HIV epidemic affects the lives of millions of individuals around the world many of whom f	NIAID	5UM1AI068619-19	DEJLI, JAMAL	COHEN, MYRON SCOTT	FAMILY HEALTH INTERNATIONAL	$12,774,001.00
13	PROJECT SUM	Clinical and Translational Science Collaborative of Northern Ohio Catalyzing Linkages to Equity in Health (CLE Health)	NCATS	5UM1TR004528-02	DOYLE, JAMIE MIHOKO	MCCOMSEY, GRACE A	CASE WESTERN RESERVE UNIVERSITY	$8,041,152.00
14	Abstract. Clir	University of Minnesota Clinical and Translational Science Institute (UMN CTSI)	NCATS	5UM1TR004405-02	KRASNOVA, IRINA N	BLAZAR, BRUCE R	UNIVERSITY OF MINNESOTA	$7,699,733.00
15	ABSTRACT O	PROJECT NARRATIVE OVERALLThe Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) will develop an	NICHD	5UM2HD111076-03	RUSSO, DENISE	DRIVER, BARBARA	WESTAT, INC.	$7,583,126.00
16	Scientific wor	Vanderbilt FIRST - Elevating Excellence and Transforming Institutional Culture	NCI	5U54CA280915-02	HUSSAIN, SHADAB FATIMA	WILKINS, CONSUELO HOPKINS	VANDERBILT UNIVERSITY MEDICAL CENTER	$5,475,798.00
17	Research sho	PURPOSE: Positively Uniting Researchers of Pain to Opine Synthesize and Engage	NINDS	1R24NS132283-01	WANDNER, LAURA DOVER	COVERSTONE, JACOB SUTTON	NEUROVATIONS	$5,142,623.00
18	PROJECT SUM	Catalyzing Systemic Change at Drexel University to Support Diverse Faculty in Health Disparities Research	NCI	5U54CA267735-04		CALZOLA, JESSICA MARIE	DREXEL UNIVERSITY	$4,642,999.00
19	SUMMARYSig	Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases (RCC RD-MCD)	NIMHD	5U24MD017250-04	STINSON, NATHANIEL	GANSKY, STUART A	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$4,475,000.00
20	The RCMI Pro	The RCMI Program in Health Disparities Research at Meharry Medical College	NIMHD	5U54MD007586-38	DAS, RINA	ADUNYAH, SAMUEL EVANS	MEHARRY MEDICAL COLLEGE	$4,434,185.00
21	No Abstract	All of Us Southern California Consortium (AoUSCC): Engagement Enrollment and Retention of Diverse Populations	OD	1OT2OD036428-01	PRABHUDAS, IRENE	ANTON-CULVER, HODA A	UNIVERSITY OF CALIFORNIA-IRVINE	$4,000,000.00
22	PROJECT SUM	Chicago Chronic Condition Equity Network (C3EN)	NIMHD	5P50MD017349-04	SOLIS SANABRIA, CAROLINA VANESSA	HUANG, ELBERT S.	UNIVERSITY OF CHICAGO	$3,998,319.00
23	ABSTRACT: O	Advancing Tobacco Regulatory Science to Reduce Health Disparities	NIDA	5U54DA060049-02	ROMBERG, ALEXA RUTH	RIBISL, KURT M.	UNIV OF NORTH CAROLINA CHAPEL HILL	$3,855,746.00
24	Project Summ	Asian Americans & Racism: Individual and Structural Experiences (ARISE)	NIA	1R56AG079510-01A1	BANDIERA, FRANK	PARK, VAN MY TA	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$3,432,146.00
25	The U.S. has s	AIDS prevention;Accounting;Address;Adherence;Administrative Supplement;African American;Age;Age Years;American	NIDA	5U01DA036926-10		JENKINS, RICHARD A	CHILDREN'S HOSPITAL OF LOS ANGELES	$2,909,986.00
26	The U.S. has s	Using Longitudinal Research to Engage African American and Latinx Sexual- and Gender-Minority Youth in the HIV Preve	NIDA	5U01DA036926-10	JENKINS, RICHARD A	KIPKE, MICHELE D.	CHILDREN'S HOSPITAL OF LOS ANGELES	$2,909,986.00
27	In this compe	20 year old;AIDS prevention;Address;Adolescence;Adolescent and Young Adult;Adult;Age;Age Years;Aging;Agreement;Ar	NIDA	5U01DA036939-10		DUNSTON, SHEBA KING	NORTHWESTERN UNIVERSITY AT CHICAGO	$2,747,259.00
28	In this compe	Multilevel Influences on HIV and Substance Use in a YMSM cohort	NIDA	5U01DA036939-10	DUNSTON, SHEBA KING	MUSTANSKI, BRIAN	NORTHWESTERN UNIVERSITY AT CHICAGO	$2,747,259.00
29	This proposal	Penn Innovation in Suicide Prevention Implementation Research (INSPIRE) Center	NIMH	5P50MH127511-04	MAVANDADI, SHAHRZAD	BROWN, GREGORY K	UNIVERSITY OF PENNSYLVANIA	$2,710,637.00
30	PROJECT SUM	Examining Social Ecological and Network Factors to Assess Epidemiological Risk in a Large National Cohort of Cisgende	NIAID	5R01AI172469-02	ROE, JOANAD'ARC C	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$2,550,380.00
31	PROJECT SUM	18 year old;AIDS prevention;Accounting;Address;Advertisements;Advertising;Affect;Age;Age Years;Alcohol consumption	NIAID	4UH3AI169658-03		ZIMAND, LORI B.	COLUMBIA UNIVERSITY HEALTH SCIENCES	$2,497,744.00
32	PROJECT SUM	MyPEEPS Mobile LITE: Limited Interaction Efficacy Trial of MyPEEPS Mobile to Reduce HIV Incidence and Better Underst	NIAID	4UH3AI169658-03	ZIMAND, LORI B.	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$2,497,744.00
33	AbstractFor p	Limited interaction cohort to identify determinants of viral suppression in MSM and transfeminine individuals living with	NIAID	5UG3AI176853-02	ZIMAND, LORI B.	SULLIVAN, PATRICK SEAN	EMORY UNIVERSITY	$2,496,734.00
34	PROJECT SUM	Examining Non-Congregate Shelter Effects on Mental Health Crises through Community Health Partnerships in Connecticut	NINR	1R01NR021461-01	MCNAMARA, KAREN MARIE	WONG, AMBROSE H	YALE UNIVERSITY	$2,432,517.00
35	PROJECT SUM	Improving mental health among the LGBTQ+ community impacted by the COVID-19 pandemic	NIMH	1RF1MH132348-01	BARRERA LOUCHEUR, ALINNE ZOE	MOITRA, ETHAN	BROWN UNIVERSITY	$2,368,492.00
36	Background:	TENTRUST - economic navigation and strengthening to realize unrestricted services for transgender women	NIDA	1DP2DA058436-01	JENKINS, RICHARD A	CYRUS, ELENA	UNIVERSITY OF CENTRAL FLORIDA	$2,280,000.00
37	Sexual minori	Harnessing the power of text messaging to reduce HIV incidence in adolescent males across the United States	NICHD	5U01HD108738-03	YATES, FRANKLIN WILLEM	YBARRA, MICHELE L.	CENTER FOR INNOVATIVE PUBLIC HEALTH RESEARCH	$2,154,708.00
38	People living v	Evaluation of anal self-sampling in HIV men-who-have-sex-with-men (HIV MSM) populations	NCI	1ZIACP101240-01		CLARKE, MEGAN	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS	$2,134,016.00
39	PROJECT SUM	Increasing financial and health equity among low income black youth and young adults	NIMHD	5U01MD019398-03	JOHNSON, JARRETT AINSWORTH	LIPPMAN, SHERI ANN	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$2,126,891.00
40	PROJECT SUM	1/4 Asian Bipolar Genetics Network (A-BIG-NET)	NIMH	5R01MH130675-03	PEVSNER, JONATHAN	HUANG, HAILIANG	BROAD INSTITUTE, INC.	$2,093,614.00
41	Project Summ	Meharry HIV/AIDS Research and Training Facility	OD	1C06OD034042-01	CHEN, YONG	BERTHAUD, VLADIMIR	MEHARRY MEDICAL COLLEGE	$2,000,000.00
42	Project Summ	Texas Minority Health Research and Outreach (MiHERO)	NIMHD	5S21MD012472-07	JONES, NANCY LYNNE	VISHWANATHA, JAMBOOR K.	UNIVERSITY OF NORTH TEXAS HLTH SCI CTR	$2,000,000.00
43	AbstractChar	Charles R. Drew University of Medicine and Science Research Endowment Program	NIMHD	5S21MD018960-02	JONES, NANCY LYNNE	CARLISLE, DAVID M	CHARLES R. DREW UNIVERSITY OF MED & SCI	$2,000,000.00
44	Project Summ	Developing a Community-Based Facility to Support Next Generation Biomedical HIV Research	OD	1C06OD034040-01	LI, XIANG-NING	RENDINA, H. JONATHON	WHITMAN-WALKER INSTITUTE, INC.	$2,000,000.00
45	Stimulant dru	RP7 Impact	NICHD	5UM2HD111102-03		HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	$1,989,068.00
46	Project Summ	Autism Center of Excellence Network: Neurodevelopmental Biomarkers of Late Diagnosis in Female and Gender Diverse Autism	NIMH	5R01MH100028-14	GILOTTY, LISA	PELPHREY, KEVIN A	UNIVERSITY OF VIRGINIA	$1,896,210.00
47	Project Summ	Establishing the science behind Alzheimer's recruitment registries: opportunities for increasing diversity and accelerating enrollmen	NIA	5R01AG063954-05	ELLIOTT, CERISE	LANGBAUM, JESSICA BROOKE	BANNER HEALTH	$1,842,475.00
48	Research sho	PURPOSE: Positively Uniting Researchers of Pain to Opine Synthesize and Engage	NINDS	1R24NS132283-01	WANDNER, LAURA DOVER	COVERSTONE, JACOB SUTTON	NEUROVATIONS	$1,739,582.00
49	PROJECT SUM	ALACRITY for Early Screening and Treatment of High Risk Youth (eSToRY)	NIMH	5P50MH126283-04	ACRI-MARRO, MARY	COOK, BENJAMIN LE	CAMBRIDGE HEALTH ALLIANCE	$1,634,609.00
50	Sexually trans	The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness investigate asso	NIAID	1R01AI181732-01A1	CHUANG, ELEANORE JENNIFER	LUETKEMEYER, ANNE FREY	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$1,628,180.00
51	Project Summ	The Optics of Health: Race Skin Tone Minority Health and Health Disparities in the U.S.	NIMH	1DP2MH132941-01	TALKOVSKY, ALEXANDER M	MONK, ELLIS	HARVARD UNIVERSITY	$1,521,000.00
52	Project Summ	Pediatric Scientist Development Program	NICHD	5K12HD000850-40	WINER, KAREN	PERMAR, SALLIE R.	WEILL MEDICAL COLL OF CORNELL UNIV	$1,501,572.00
53	PROJECT SUM	PROJECT NARRATIVEThe global HIV epidemic affects the lives of millions of individuals around the world many of whom f	NIAID	5UM1AI068619-19	DEJLI, JAMAL	COHEN, MYRON SCOTT	FAMILY HEALTH INTERNATIONAL	$1,500,000.00
54	ABSTRACT - C	Center for HIV Identification Prevention and Treatment Services	NIMH	5P30MH058107-29	GORDON, CHRISTOPHER M.	SHOPTAW, STEVEN J	UNIVERSITY OF CALIFORNIA LOS ANGELES	$1,499,315.00
55	PROJECT SUM	Center for AIDS Prevention Studies (CAPS)	NIMH	5P30MH062246-24	GORDON, CHRISTOPHER M.	JOHNSON, MALLORY O	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$1,498,873.00
56	AbstractPregi	Center to Advance Reproductive Justice and Behavioral Health among Black Pregnant/Postpartum Women and Birthing People (CO	NICHD	5U54HD113292-02	FABIYI, CAMILLE	HERNANDEZ, NATALIE DOLORES	MOREHOUSE SCHOOL OF MEDICINE	$1,474,219.00
57	In the United	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$1,411,882.00
58	In the United	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$1,411,882.00
59	Adaptable Co	Adaptable Community-Engaged Intervention for Violence Prevention: Michigan Model	NICHD	1UG3HD115253-01	GILBERT, LEAH KAYE	WU, TSU-YIN	EASTERN MICHIGAN UNIVERSITY	$1,410,608.00
60	PROJECT SUM	Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma	NIMH	1DP2MH132938-01	TALKOVSKY, ALEXANDER M	PEARL, REBECCA L	UNIVERSITY OF FLORIDA	$1,372,500.00
61	PROJECT SUM	PROJECT NARRATIVEThe global HIV epidemic affects the lives of millions of individuals around the world many of whom f	NIAID	5UM1AI068619-19	DEJLI, JAMAL	COHEN, MYRON SCOTT	FAMILY HEALTH INTERNATIONAL	$1,353,261.00
62	Transgender a	TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults Using Interventions to Drive Equity	NIMH	5U01MH136558-03	ACRI-MARRO, MARY	XU, RENA	BOSTON CHILDREN'S HOSPITAL	$1,344,044.00
63	The United St	Digital Phenotyping & Deep Learning: Substance Use Impact on PrEP Adherence among Black Sexual and Gender Minori	NIDA	1ZIADA000646-02		CURTIS, BRENDA	NATIONAL INSTITUTE ON DRUG ABUSE	$1,337,600.00
64	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$1,286,124.00
65	Project Summ	Acute;Adrenal Glands;Affect;Behavior;Biological Markers;Buffers;Cardiovascular Diseases;Cellular Phone;Chronic;Cr	NIMHD	5R01MD013495-05		DAS, RINA	JOHNS HOPKINS UNIVERSITY	$1,285,395.00
66	PROJECT ABS	Cerebral small vessel disease burden and racial disparity in vascular cognitive impairment and Alzheimers disease and its related de	NIA	5R01AG072592-04	GHALEH, MARYAM X	HYACINTH, HYACINTH IDU	UNIVERSITY OF CINCINNATI	$1,233,404.00
67	PROJECT SUM	NNLM Region 5: Reaching More People in More Ways	NLM	5UG4LM013725-04	YOON, SUNG SUG SUG	MUILENBURG, JENNY	UNIVERSITY OF WASHINGTON	$1,227,997.00
68	PROJECT SUM	Third Coast Center for AIDS Research	NIAID	3P30AI117943-10S1	REFSLAND, ERIC WILLIAM	MUSTANSKI, BRIAN	NORTHWESTERN UNIVERSITY AT CHICAGO	$1,200,000.00
69	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
70	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
71	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
72	SUMMARY/A	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
73	ABSTRACTAlz	Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population	NINDS	5R01NS101483-06	YIN, XILING	GALVIN, JAMES E	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$1,143,639.00
74	AbstractThis p	Scaling Up Implementation Strategies to Improve the DIAGNOSE and PREVENT Pillars for Young MSM in Florida	NIMH	5R01MH132147-03	POLLARD-BRANCHARD, SUZY	NAAR, SYLVIE	FLORIDA STATE UNIVERSITY	$1,128,033.00
75	AbstractAple	Leveraging a community-driven approach to address the impact of social determinants of health on structural inequities among Mi	OD	1OT2OD035935-01	MADDEN, EBONY B	IGLESIAS, ANDREA	URBAN HEALTH PARTNERSHIPS	$1,125,000.00
76	My Brothers K	Achieving Optimal Sexual and Reproductive Health (SRWH Project)	OD	1OT2OD035877-01	MADDEN, EBONY B	GIPSON, JUNE ARNESSA	MY BROTHER'S KEEPER, INC.	$1,125,000.00
77	Project Summ	Asian Community-Led Health Equity Structural Intervention (Asian CHESI)	OD	1OT2OD035669-01	MADDEN, EBONY B	WU, DUNLI	ASIAN COMMUNITY HEALTH COALITION	$1,124,986.00
78	ComPASS: Co	Addressing Systemic Barriers Impacting Health in CHC Communities	OD	1OT2OD035834-01	MADDEN, EBONY B	CARACOSTIS, ANDREA	ASIAN AMERICAN HEALTH COALITION/HOUSTON	$1,123,685.00
79	DEVELOPMEN	Developmental Core	NIAID	5P30AI027763-33		JOHNSON, MALLORY O	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$1,081,769.00
80	ABSTRACTAge	SilverBills: A Legal Technical and Financial Tool for Aging LGBTQ+ Individuals with Impaired Cognition.	NIA	5R44AG080843-02	JOHN, DINESH	LOBEL-ESRIG, MARCI	SILVERBILLS INC.	$1,080,149.00
81	Microlevel int	Macro-level Health Considerations of Community and Criminal Justice System Relationships in North Texas	OD	1OT2OD035659-01	MADDEN, EBONY B	FULMER, LINDA	HEALTHY TARRANT COUNTY COLLABORATION	$1,075,664.00
82	ABSTRACTRa	Improving Inclusivity of Alzheimers Disease and Related Dementias Research for Asian Americans and Latinx through Nationally Re	NIA	5R01AG082080-02	PHILLIPS, JOHN	LEE, SUNG-HEE	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$1,072,668.00

	A	B	C	D	E	F	G	H
83	SUMMARYIt is	NARRATIVEThe goal of this proposed research is to examine psycho social risk and protective factors for Alzheimersdisease and rela	NIA	1R01AG087121-01A1	BANDIERA, FRANK	MEZUK, BRIANA	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$1,059,015.00
84	Project Summ	Theoretically Informed Behavioral Intervention to Enhance QOL and Prevent HIV-related Comorbidities in Ethnic and Ra	NIMHD	1R01MD019956-01	LINARES, DEBORAH ELIZABETH	RAMOS, SILVIA RAQUEL	YALE UNIVERSITY	$1,054,907.00
85	ABSTRACTIn t	A multi-level approach to improve HIV prevention and care for transgender women of color	NIMH	7R01MH129285-02	ALLISON, SUSANNAH		NEW YORK STATE PSYCHIATRIC INSTITUTE	$1,052,842.00
86	Project Summ	Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness / Implemen	NICHD	5UG1HD113160-02	RUSSO, DENISE	GAROFALO, ROBERT	NORTHWESTERN UNIVERSITY AT CHICAGO	$1,044,010.00
87	PROJECT SUM	Faithful Response II: COVID-19 Rapid Test-to-Treat with African American Churches	NIMHD	1U01MD018310-01	BARKSDALE, CRYSTAL	BERKLEY-PATTON, JANNETTE YVONNE	UNIVERSITY OF MISSOURI KANSAS CITY	$1,016,780.00
88	No Abstract	NATIONAL LATINO NETWORK (NLN) FOR PRECISION MEDICINE AND HEALTH DISPARITIES RESEARCH	OD	1OT2OD037880-01	ALFARANO, ALEXANDRIA SKYE	COLON, VIVIAN	COMPREHENSIVE CANCER CENTER/ UNIV/PR	$1,000,000.00
89	No Abstract	NATIONAL LATINO NETWORK (NLN) FOR PRECISION MEDICINE AND HEALTH DISPARITIES RESEARCH	OD	1OT2OD037880-01	ALFARANO, ALEXANDRIA SKYE		COMPREHENSIVE CANCER CENTER/ UNIV/PR	$1,000,000.00
90	The Preventio	DP24-004 PRC Core: University of Iowa Prevention Research Center for Rural Health	NCCDPHP	1U48DP006812-01	DARLING, NATALIE	AFIFI, RIMA	UNIVERSITY OF IOWA	$1,000,000.00
91	The Preventio	DP24-004 PRC Core: University of Iowa Prevention Research Center for Rural Health	NCCDPHP	1U48DP006812-01	AFIFI, RIMA	UNIVERSITY OF IOWA	IOWA CITY	$1,000,000.00
92	To respond to	DP24-004 PRC Core: UCSF Prevention Research Center: Reducing social isolation among older LGBTQ+ adults	NCCDPHP	1U48DP006806-01	RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISC	SAN FRANCISCO	$999,852.00
93	PROJECT SUM	MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM	NIMHD	5R01MD019181-02	FERNANDEZ, ANGELA R		COLUMBIA UNIVERSITY HEALTH SCIENCES	$989,833.00
94	PROJECT ABS	Integrated Networks of Scholars in Global Health Research Training (INSIGHT)	FIC	5D43TW012274-03	HAYES, UNJA	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$986,244.00
95	PROJECT SUM	Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals with Eating Disorders	NIMH	1R61MH133710-01A1	CHAVEZ, MARK		AUBURN UNIVERSITY AT AUBURN	$978,986.00
96	Abstract:The	Screening strategies and social determinants of health among people with high risk of anal cancer	NCI	5R01CA285198-02	SAHASRABUDDHE, VIKRANT V		EMORY UNIVERSITY	$976,498.00
97	ABSTRACTThe	Center for Health Equity Research (CHER)	NIMHD	3U54MD012523-05S1	STINSON, NATHANIEL		UNIVERSITY OF ILLINOIS AT CHICAGO	$950,000.00
98	ABSTRACTBa	Phase IIB: Development of TruT Algorithm for Commercialization in Androgen Disorders	NIA	5R44AG045011-05	JOSEPH, LYNDON		FUNCTION PROMOTING THERAPIES, LLC	$948,808.00
99	7. Project Sur	Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication	NIAID	5UM1AI069463-19	SANNE, IAN MATTHIAS	WITS HEALTH CONSORTIUM (PTY), LTD	PARKTOWN	$943,730.00
100	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$927,251.00
101	ABSTRACT: W	NARRATIVE: We propose to conduct research that will determine the impact of relevant behaviors on HIVprevention am	NIDA	5R01DA057351-03	LAO, GUIFANG		UNIVERSITY OF CHICAGO	$924,073.00
102	AbstractIn th	Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substanc	NIDA	5R01DA056888-03	WEBB, CANDACE KARONDELETTE		FRIENDS RESEARCH INSTITUTE, INC.	$912,089.00
103	AbstractTrans	Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women	NIDA	5R01DA056287-02	REBACK, CATHY J	FRIENDS RESEARCH INSTITUTE, INC.	BALTIMORE	$896,441.00
104	ABSTRACTIn t	RP4 LEAP	NICHD	5UM2HD111102-03	HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	TALLAHASSEE	$895,147.00
105	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$887,718.00
106	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$887,718.00
107	Enter the text	Promoting Inclusive Excellence	NIGMS	1R01GM155395-01	NELSON, SHAKIRA M		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$879,690.00
108	ABSTRACTDe	AIDS prevention;Address;Adherence;Adolescent and Young Adult;Age;Area;Articulation;Award;Behavior;Biological;Bise	NIAID	4UH3AI169631-03		ZIMAND, LORI B.	UNIVERSITY OF ILLINOIS AT CHICAGO	$877,431.00
109	ABSTRACTDe	Keeping it LITE 2: Exploring HIV Risk in Vulnerable Youth with Limited Interaction and Digital Health Intervention (LITE-2)	NIAID	4UH3AI169631-03	ZIMAND, LORI B.	HOSEK, SYBIL	UNIVERSITY OF ILLINOIS AT CHICAGO	$877,431.00
110	Project Abstr	Step UP for STEM and Health Careers: An Intervention to Reduce STEM-related biases and improve high school STEM learning envi	NICHD	5R44HD103517-03	GALLEN, COURTNEY LEIGH		RESILIENT GAMES STUDIO, LLC	$863,909.00
111	PROJECT SUM	CE24-001 Injury Prevention Research Center at Emory (IPRCE).	NCIPC	1R49CE003553-01	RUPP, JONATHAN D.	EMORY UNIVERSITY	ATLANTA	$850,000.00
112	Sexually trans	Doxy4STICare - Doxycycline for Sexually Transmitted Infections; A Comprehensive Assessment of Antimicrobial Resista	NIAID	1R56AI182347-01A1	HUEBNER, ROBIN E		COLUMBIA UNIVERSITY HEALTH SCIENCES	$837,185.00
113	PROJECT SUM	Still Climbin': A Randomized Controlled Trial of an Intervention to Improve Coping with Discrimination Address Medical Mistrust an	NIMHD	5R01MD014722-05	GILLMAN, ARIELLE SAMANTHA		RAND CORPORATION	$829,836.00
114	PROJECT SUM	Bisexual adolescents' and young adults' risk for depression and suicidal ideation: Developmental trajectories risk and protective fac	NIMH	1R01MH138335-01	MURPHY, ERIC ROUSSEAU		OHIO STATE UNIVERSITY	$815,881.00
115	PROJECT SUM	Bisexual adolescents' and young adults' risk for depression and suicidal ideation: Developmental trajectories risk and protective fac	NIMH	1R01MH138335-01		DYAR, CHRISTINA	OHIO STATE UNIVERSITY	$815,881.00
116	Hypertension	A daily diary examination of the influence of intersectional stigma on blood pressure	NHLBI	1R01HL168489-01A1	CAMPO, REBECCAA.		COLUMBIA UNIVERSITY HEALTH SCIENCES	$813,579.00
117	Project Summ	Identifying socioecological profiles that impact changes in care outcomes among Black Sexual minority men living with	NIMH	5UG3MH133258-02	STIRRATT, MICHAEL J		GEORGE WASHINGTON UNIVERSITY	$811,432.00
118	PROJECT SUM	Sexual orientation-related disparities in obstetrical and perinatal health	NIMHD	5R01MD015256-05	MUJURU, PRISCAH		HARVARD PILGRIM HEALTH CARE, INC.	$802,428.00
119	PROJECT SUM	Sexual orientation-related disparities in obstetrical and perinatal health	NIMHD	5R01MD015256-05		CHARLTON, BRITTANY MICHELLE	HARVARD PILGRIM HEALTH CARE, INC.	$802,428.00
120	AbstractThe h	Structural Racism and Discrimination in Older Men's Health Inequities	NIA	5R01AG077934-03	GERALD, MELISSA S		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$800,878.00
121	Transgender a	The effects of gender-affirming sex steroids on brain development in adolescents	NICHD	1R01HD115921-01	WINER, KAREN		BOSTON CHILDREN'S HOSPITAL	$800,403.00
122	PROJECT SUM	Implementing sustainable evidence-based mental healthcare in low-resource community settings nationwide to advance mental h	NIMH	5R01MH133543-02	MAVANDADI, SHAHRZAD		YALE UNIVERSITY	$798,034.00
123	PROJECT SUM	Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)	NIAID	5R01AI174862-03	SHARMA, USHA K.		HARVARD PILGRIM HEALTH CARE, INC.	$790,624.00
124	Project Summ	Resource Centers for Minority Aging Research National Coordinating Center (RCMARs NCC)	NIA	5U24AG083253-02	GERALD, MELISSA S		GERONTOLOGICAL SOCIETY OF AMERICA	$789,806.00
125	Abstract. In re	Leveraging a Strategic Alliance of Community-Based Implementers and Researchers to Characterize Protocolize and S	NIMH	1R01MH138237-01	POLLARD-BRANCHARD, SUZY		UNIVERSITY OF MIAMI CORAL GABLES	$788,119.00
126	PROJECT SUM	Trans/Forming Genomics: Guidance for Research Involving Transgender and Gender Diverse People	NHGRI	5R01HG013145-02	LOCKHART, NICOLE C		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	$787,406.00
127	Sexual minori	Young Sexual Minority Women's Mental Health: Developmental Trajectories Mechanisms of Risk and Protective Factors.	NIMH	5R01MH132692-02	MORRIS, SARAH E		UNIVERSITY OF CINCINNATI	$786,630.00
128	PROJECT SUM	Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP	NIAID	1R01AI186641-01	SPINELLI, MATTHEW A.	UNIVERSITY OF CALIFORNIA, SAN FRANCISC	SAN FRANCISCO	$781,821.00
129	PROJECT SUM	Promoting Reductions in Intersectional Stigma to Improve HIV Testing and PrEP Use Among Latino Sexual Minority Men	NIMH	5R01MH121256-05	GREENWOOD, GREGORY		RAND CORPORATION	$780,958.00
130	AbstractThe d	Public Health Relevance StatementLatinx gay/bisexual men and men who have sex with men experience disproportiona	NIMH	5U01MH136574-02	POLLARD-BRANCHARD, SUZY		SAN FRANCISCO STATE UNIVERSITY	$780,747.00
131	Transgender a	Cardiometabolic Impact of Gender-Affirming Hormone Therapy in Transmasculine Young Adults	NHLBI	1R01HL177518-01	WIDLANSKY, MICHAEL E	MEDICAL COLLEGE OF WISCONSIN	MILWAUKEE	$779,771.00
132	Project Summ	Michigan Center for Diabetes Translational Research	NIDDK	5P30DK092926-14	HEISLER, MARY ELLEN MICHELE	UNIVERSITY OF MICHIGAN AT ANN ARBOR	ANN ARBOR	$779,000.00
133	PROJECT SUM	Behavior;Black race;Chicago;Cities;Collaborations;Communicable Diseases;Communities;Complex;Data;Disadvanta	NIDA	1R01DA061247-01		BIRKETT, MICHELLE	NORTHWESTERN UNIVERSITY AT CHICAGO	$777,568.00
134	PROJECT SUM	Characterizing Sleep ART Adherence and Viral Suppression Among Black Sexual Minority Men	NHLBI	5R01HL160325-04	DIXIT, SHILPY		COLUMBIA UNIVERSITY HEALTH SCIENCES	$774,324.00
135	ABSTRACT CH	Optimizing a Just-in-Time Adaptive Intervention to Increase Uptake of Chemsex Harm Reduction Services in MSM: A Mic	NIDA	1R01DA061661-01	JENKINS, RICHARD A		UNIVERSITY OF CONNECTICUT STORRS	$773,845.00
136	PROJECT SUM	ICAP Clinical Trials Unit	NIAID	5UM1AI154468-05	GUBB, STEPHANIE MAJER		COLUMBIA UNIVERSITY HEALTH SCIENCES	$772,420.00
137	Project Summ	Network-based study design statistical and modeling solutions for HIV among populations that use illicit substances: Int	NIDA	1R01DA058994-01A1	JENKINS, RICHARD A		UNIVERSITY OF RHODE ISLAND	$771,618.00
138	Summary/Abs	Impact of Gender Affirming Hormone Therapy on HIV Viral Dynamics and Immune Responses in Transgender Women	NIAID	1R01AI189309-01	SCULLY, EILEEN PATRICIA	JOHNS HOPKINS UNIVERSITY	BALTIMORE	$771,490.00
139	PROJECT SUM	Investigating and identifying the heterogeneity in COVID-19 misinformation exposure on social media among Black and Rural comm	NIMHD	5R01MD018340-03	GILLMAN, ARIELLE SAMANTHA		UNIVERSITY OF PENNSYLVANIA	$771,159.00
140	Chlamydia tra	A seek test and treat intervention to reduce Chlamydia trachomatis disparities in Black youth living in the deep South	NIAID	1R01AI186142-01A1	CHUANG, ELEANORE JENNIFER		TULANE UNIVERSITY OF LOUISIANA	$770,842.00
141	The goal of thi	Characterizing intersecting sexual gender and race-based stigmas affecting communities of US transgender women and	NINR	5R01NR020437-04	WILLIS, LEIGH ANDREW		JOHNS HOPKINS UNIVERSITY	$768,731.00
142	Project Summ	Building mobile HIV prevention and mental health support in low-resource settings	NIMH	7R01MH116829-06	LELUTIU-WEINBERGER, CORINA		COLUMBIA UNIVERSITY HEALTH SCIENCES	$768,346.00
143	What we know	A Multilevel Multiphase Optimization Strategy for PrEP: Patients and Providers in Primary Care	NIMHD	5R01MD018523-02	BARKSDALE, CRYSTAL		HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCE	$768,126.00
144	Project Summ	Developing and pilot testing an eHealth decision support tool for young trans women to improve informed decision maki	NIMH	1R34MH137753-01	SENN, THERESA ELAINE		TEMPLE UNIV OF THE COMMONWEALTH	$766,765.00
145	7.PROJECTSU	Acquired Immunodeficiency Syndrome;Adult;Affect;Age;Aging;Alzheimer's disease related dementia;Alzheimer's dise	NIA	5R01AG069041-04		BOCKTING, WALTER O.	NEW YORK STATE PSYCHIATRIC INSTITUTE	$765,460.00
146	7.PROJECTSU	Social Convoys Cognitive Reserve and Resilience and Risk for Alzheimer's Disease and Related Dementias	NIA	5R01AG069041-04	GERALD, MELISSA S		NEW YORK STATE PSYCHIATRIC INSTITUTE	$765,460.00
147	SUMMARYAd	Assessing intersectional multilevel and multidimensional structural racism for English- and Spanish-speaking populations in the U	NIMHD	5R01MD019029-02	GILLMAN, ARIELLE SAMANTHA		UNIVERSITY OF MARYLAND BALTIMORE	$764,870.00
148	PROJECT SUM	The Institute for Health Equity Research Catalyst Center	NIMHD	1P50MD019475-01	STINSON, NATHANIEL		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	$759,917.00
149	Project Summ	Feasibility acceptability and preliminary efficacy of an adapted group-based and online HIV prevention intervention for	NIMH	1R34MH134603-01A1	POLLARD-BRANCHARD, SUZY		UNIVERSITY OF ILLINOIS AT CHICAGO	$759,489.00
150	Project Summ	Social-Affective Vulnerability to Suicidality among LGBTQ Young Adults: Proximal and Distal Factors	NIMH	5R01MH124900-04	LEITMAN, DAVID I		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$759,447.00
151	PROJECT SUM	Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV	NIDA	5R01DA058965-02	WEBB, CANDACE KARONDELETTE		UNIVERSITY OF CHICAGO	$758,812.00
152	PROJECT SUM	A Strengths-Based Intersectional Approach to Suicide Prevention Among Black Sexual and Gender Minority Youth	NIMH	5R01MH134051-02	MURPHY, ERIC ROUSSEAU		UNIVERSITY OF CENTRAL FLORIDA	$756,237.00
153	PROJECT SUM	A Strengths-Based Intersectional Approach to Suicide Prevention Among Black Sexual and Gender Minority Youth	NIMH	5R01MH134051-02		TALIAFERRO, LINDSAY A	UNIVERSITY OF CENTRAL FLORIDA	$756,237.00
154	Project Abstra	A randomized clinical trial of client-centered care coordination to improve pre-exposure prophylaxis use for Black men	NIMH	5R01MH134721-02	STIRRATT, MICHAEL J		UNIVERSITY OF MARYLAND BALTIMORE	$753,802.00
155	In this Resear	Engaging Diverse Stakeholders in Genomic/Precision Medicine Research: The All of Us Research Program Engagement Core	OD	3OT2OD035980-01S1	ALTON, ANGELICA SUZETTE		VANDERBILT UNIVERSITY MEDICAL CENTER	$750,528.00
156	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$750,000.00
157	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01	GERALD, MELISSA S	BOGART, LAURA M	RAND CORPORATION	$750,000.00
158	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01		GERALD, MELISSA S	RAND CORPORATION	$750,000.00
159	ABSTRACTDe	AIDS prevention;Address;Adherence;Adolescent and Young Adult;Age;Area;Articulation;Award;Behavior;Biological;Bise	NIAID	4UH3AI169631-03		ZIMAND, LORI B.	UNIVERSITY OF ILLINOIS AT CHICAGO	$750,000.00
160	ABSTRACTDe	Keeping it LITE 2: Exploring HIV Risk in Vulnerable Youth with Limited Interaction and Digital Health Intervention (LITE-2)	NIAID	4UH3AI169631-03	ZIMAND, LORI B.	HOSEK, SYBIL	UNIVERSITY OF ILLINOIS AT CHICAGO	$750,000.00
161	Project Summ	THE IMPACT OF PUBERTAL SUPPRESSION ON ADOLESCENT NEURAL AND MENTAL HEALTH TRAJECTORIES - Resubmission - 1	NIMH	5R01MH123746-04	MURPHY, ERIC ROUSSEAU		RESEARCH INST NATIONWIDE CHILDREN'S HOSP	$738,171.00
162	PROJECT SUM	A unified protocol to address sexual minority women's minority stress mental health and hazardous drinking	NIAAA	5R01AA029088-03	FREEMAN, ROBERT		YALE UNIVERSITY	$737,885.00
163	PROJECT ABS	Synergistic epidemics of non-communicable diseases stigma depression and material insecurities among sexual and ge	NHLBI	5R01HL165686-03	KUNZ, JOHN FREDERIC		UNIVERSITY OF MARYLAND BALTIMORE	$734,579.00
164	Project Summ	Enhancing Structural Competency in School-Based Health Centers to Address LGBTQ+ Adolescent Health Equity	NINR	5R01NR021019-03	GODETTE, DIONNE		PACIFIC INSTITUTE FOR RES AND EVALUATION	$734,567.00

	A	B	C	D	E	F	G	H
165	PROJECT SUM	Long-term and Daily Associations among Intersectional Minority Stress Structural Oppression and Alcohol Use and Misuse among	NIAAA	5R01AA029989-04	RUFFIN, BEVERLY		UNIV OF MARYLAND, COLLEGE PARK	$729,606.00
166	AbstractBy 2(	Building Community and Research Engagement among Sexual and Gender Minority Older Adults at Risk for Alzheimers Disease and	NIA	5R24AG066599-03	GERALD, MELISSA S		EMORY UNIVERSITY	$727,284.00
167	PROJECT SUM	A longitudinal and experience sampling investigation of rejection sensitivity and its role in sexual minority adolescents' mental healt	NIMH	5R01MH130375-02	SMITH, ASHLEY		ROSALIND FRANKLIN UNIV OF MEDICINE & SCI	$726,126.00
168	PROJECT SUM	Suicide Prevention for Sexual and Gender Minority Youth	NIMH	5R33MH120236-04	O'CONNOR, STEPHEN		SAN DIEGO STATE UNIVERSITY	$724,430.00
169	PROJECT SUM	Mental Health Effects of Marriage Policy: Evidence from Linked Administrative Data in New Zealand	NIMH	1R01MH140023-01	TALKOVSKY, ALEXANDER M		VANDERBILT UNIVERSITY	$722,293.00
170	PROJECT SUM	Understanding multilevel predictors affecting family formation among sexual and gender minority couples	NICHD	1R01HD115551-01	POPKIN, RONNA		NORTHWESTERN UNIVERSITY AT CHICAGO	$718,900.00
171	PROJECT SUM	A Multi-Level Integrated Strategy to Optimize PrEP Adherence for Black MSM and Accelerate Implementation at Scale	NIMH	1R01MH138225-01	POLLARD-BRANCHARD, SUZY		YALE UNIVERSITY	$709,213.00
172	Project Summ	Sex hormone effects on neurodevelopment: Controlled puberty in transgender adolescents	NIMH	5R01MH115349-05	SMITH, ASHLEY		STANFORD UNIVERSITY	$707,054.00
173	SUMMARYSe	Enhancing Measurement and Characterization of Roles and Experiences of Sexual and Gender Minority Caregivers of Persons living	NIA	5R01AG083177-02	GERALD, MELISSA S		UNIVERSITY OF NEVADA LAS VEGAS	$702,329.00
174	PROJECT SUM	Characterizing Intersectional Geospatial Stigma and Affirmation Landscapes and Their Influence on Black and Latino Bi	NIDA	1R01DA059240-01A1	DUNSTON, SHEBA KING		FLORIDA STATE UNIVERSITY	$701,204.00
175	PROJECT SUM	Equitable Measurement of Care Disparities and Needs in Intersex Youth/Youth with Variations in Sex Development	NICHD	5R01HD114134-02	POPKIN, RONNA		CHILDREN'S RESEARCH INSTITUTE	$699,796.00
176	Project Summ	Intervention to improve parent communication about sexuality with sexual minority male adolescents	NICHD	1R01HD111516-01A1	POPKIN, RONNA		UNIVERSITY OF PENNSYLVANIA	$698,557.00
177	PROJECT SUM	A Randomized Controlled Trial of a Game-Based Intervention to Reduce Alcohol Use among Sexual and Gender Minority Youth	NIAAA	5R01AA030017-02	KERRIDGE, BRADLEY TOWNSEND		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$695,237.00
178	AbstractRece	Testing Effective Methods to Recruit Sexual and Gender Minority Cancer Patients for Cancer Studies	NCI	5R01CA265945-03	BERRIGAN, DAVID		UNIVERSITY OF MINNESOTA	$694,803.00
179	PROJECT SUM	Structural Influences on Methamphetamine Use among Black Gay and Bisexual Men in Atlanta	NIDA	5R01DA056235-03	DUNSTON, SHEBA KING		EMORY UNIVERSITY	$683,730.00
180	PROJECT SUM	A multidimensional investigation of social support for transgender and nonbinary people and its impacts on health and well-being	NIMHD	5R01MD018571-02	BARKSDALE, CRYSTAL		UNIVERSITY OF WISCONSIN-MADISON	$681,042.00
181	ABSTRACT Th	Preventing Drug Abuse among Sexual-Minority Youth	NIDA	5R01DA043512-05	ROMBERG, ALEXA RUTH		COLUMBIA UNIV NEW YORK MORNINGSIDE	$680,444.00
182	220.7 PROJEC	NEXUS: A novel social network approach to study the effects of intersectional stigma on HIV prevention among Latino MS	NIMH	5R01MH123282-05	GREENWOOD, GREGORY		UNIVERSITY OF CALIFORNIA, SAN DIEGO	$678,582.00
183	Project Summ	Long-term trajectories of psychosocial functioning among transgender youth and their parents.	NICHD	5R01HD112418-02	POPKIN, RONNA		UT SOUTHWESTERN MEDICAL CENTER	$678,490.00
184	PROJECT SUM	Strategies to Prevent HIV Acquisition Among Transgender MSM in the US	NIMH	7R01MH129175-03	STIRRATT, MICHAEL J		UNIVERSITY OF MICHIGAN AT ANN ARBOR	$676,347.00
185	Project Summ	The Collaborative Care PrTNER (Prevention Treatment NavigationEngagement Resource) Project	NIDA	7R01DA059022-02	WEBB, CANDACE KARONDELETTE		CHILDREN'S HOSP OF PHILADELPHIA	$674,186.00
186	ABSTRACTNo	The Role of Local Structural Stigma in Alcohol Related Inequities among SGM Young Adults	NIAAA	1R01AA031637-01A1	FREEMAN, ROBERT		PACIFIC INSTITUTE FOR RES AND EVALUATION	$668,532.00
187	Project Summ	An Online Family-based Program to Prevent Alcohol Use and Dating and Sexual Violence among Sexual and Gender Minority Youth	NIAAA	1R34AA030662-01A1	BALACHOVA, TATIANA NIKOLAYEVNA		UNIVERSITY OF COLORADO	$653,281.00
188	PROJECT SUM	Biopsychosocial mechanisms underlying internalizing psychopathology in a prospective population-based cohort of sexual minor	NIMH	5R01MH118245-05	MORRIS, SARAH E		YALE UNIVERSITY	$652,487.00
189	PROJECT SUM	Measuring and Mapping Trajectories of Risk and Resilience for Suicidal Thoughts and Behaviors in Sexual and Gender Minority Prete	NIMH	1R01MH137695-01	MURPHY, ERIC ROUSSEAU		VANDERBILT UNIVERSITY	$651,915.00
190	Project Summ	Sexual Assault Recovery Among Sexual Minority Women: A Longitudinal Multi-Level Study	NIMHD	5R01MD017573-03	MUJURU, PRISCAH		UNIVERSITY OF WASHINGTON	$645,353.00
191	PROJECT SUM	Geographically-Explicit Ecological Momentary Assessment Protocol to Assess the Linkages Between Intersectional Discrimination,	NHLBI	1R01HL169503-01A1	BROWN, ALISON GWENDOLYN MARY		NEW YORK UNIVERSITY	$636,567.00
192	PROJECT SUM	Sexual minority couples' health during the transition to marriage	NIMHD	5R01MD018167-03	GILLMAN, ARIELLE SAMANTHA		UNIVERSITY OF DENVER (COLORADO SEMINARY)	$632,717.00
193	7. PROJECT S	Female Sexual Orientation GWAS	NICHD	5R01HD100180-05	POPKIN, RONNA		ENDEAVOR HEALTH CLINICAL OPERATIONS	$624,192.00
194	Project Summ	Cardiovascular Health of Sexual and Gender Minorities in the Hispanic Community Health Study/Study of Latinos (SGM HCHS/SOL	NHLBI	5R01HL149778-05	KUNZ, JOHN FREDERIC		UNIV OF NORTH CAROLINA CHAPEL HILL	$615,646.00
195	PROJECT SUM	Social Connectedness and Health among Gender Minority People of Color	NIMHD	5R01MD017085-03	HERREN, OLGA MARINA		COLUMBIA UNIVERSITY HEALTH SCIENCES	$612,485.00
196	PROJECT SUM	Project Recognize: Improving Measurement of Alcohol Use and Other Disparities by Sex Sexual Orientation and Gender Identity thro	NIAAA	5R01AA029076-04	FREEMAN, ROBERT		NORTHWESTERN UNIVERSITY AT CHICAGO	$604,760.00
197	PROJECT SUM	Examining the Mechanisms and Consequences of Sleep Health Inequities Affecting Black Sexual Minority Men	NIMHD	5R01MD019278-02	GILLMAN, ARIELLE SAMANTHA		RAND CORPORATION	$599,087.00
198	PROJECT SUM	AIDS/HIV problem;Accidental Injury;Address;Adult;Affect;Age;Alcohol consumption;Alcohols;Area;Biological Markers;Bisexual;B	NIDA	5R01DA045773-05		DUNSTON, SHEBA KING	GEORGE WASHINGTON UNIVERSITY	$592,421.00
199	Project Summ	Psychosocial Predictors of Risk for Suicidal Behavior Among Gender Minority Adolescents	NIMHD	1R01MD018582-01A1	BURNS, PAUL ANTHONY		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$585,097.00
200	Improving the	Looking Back to Look Forward: Social Environment Across the Life Course Epigenetics and Birth Outcomes in Black Families	NIA	7R01AG069003-04	BRAUDT, DAVID BRUCE		UNIV OF NORTH CAROLINA CHAPEL HILL	$584,035.00
201	PROJECT SUM	Understanding the Role of Structural Oppression for Suicide Risk among Black Sexual and Gender Minority Adolescents and Young	NIMHD	5R01MD018679-02	BARKSDALE, CRYSTAL		RUTGERS BIOMEDICAL AND HEALTH SCIENCES	$582,847.00
202	PROJECT SUM	Violence and viral suppression among men living with HIV	NIMH	5R01MH123388-05	SENN, THERESA ELAINE		UNIVERSITY OF MICHIGAN AT ANN ARBOR	$582,129.00
203	People living \	Evaluation of anal self-sampling in HIV men-who-have-sex-with-men (HIV MSM) populations	NCI	1ZIACP101240-01		CLARKE, MEGAN	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS	$580,000.00
204	Project Abstra	Feasibility and Effectiveness of Gamified Digital Intervention to Prevent Alcohol and Mental Health Risks	NIAAA	5R01AA031175-02	KERRIDGE, BRADLEY TOWNSEND		LOYOLA MARYMOUNT UNIVERSITY	$576,285.00
205	Transgender (	AIDS prevention;Address;Adherence;Adult;Affect;Anus;Behavioral;Biological;Birth;Blood;Caring;Categories;Centers fo	NIMH	5R01MH115765-05		ALLISON, SUSANNAH	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$573,588.00
206	PROJECT SUM	AIDS prevention;Ablation;Address;Adherence;Adult;Age;Anal Sex;Area;Behavioral;Blood;Caring;Clinical;Clinical Trials;	NIAID	5R01AI145675-05		PORTER, KRISTEN AMY	JOHNS HOPKINS UNIVERSITY	$567,621.00
207	PROJECT SUM	UnBIASED: Understanding Biased patient-provider Interaction And Supporting Enhanced Discourse	NLM	5R01LM013301-05	MISQUITTA, LEONIE		UNIVERSITY OF WASHINGTON	$561,008.00
208	Abstract Lesb	Peer Victimization and Risky Alcohol Use among Sexual Minority Youth: Understanding Mechanisms and Contexts	NIAAA	5R01AA028810-04	FREEMAN, ROBERT		STATE UNIVERSITY OF NEW YORK AT BUFFALO	$553,693.00
209	Project Abstra	Public Health Relevance Health disparities adversely affecting sexual and gender minority (SGM) adolescents and youth of colorare	NIMHD	5R01MD015722-04	BARKSDALE, CRYSTAL		UNIVERSITY OF MINNESOTA	$550,391.00
210	Project Summ	Autism Center of Excellence Network: Neurodevelopmental Biomarkers of Late Diagnosis in Female and Gender Diverse Autism	NIMH	5R01MH100028-14	GILOTTY, LISA	PELPHREY, KEVIN A	UNIVERSITY OF VIRGINIA	$550,000.00
211	PROJECT SUM	Examining Health Comorbidities and Healthcare Utilization Disparities among Older Transgender and Cisgender Adults in the U.S.	NIA	5R01AG073440-03	NOVAK, PRISCILLA JOY		BROWN UNIVERSITY	$538,794.00
212	PROJECT SUM	Health and economic consequences of changing federal and state policies on reproductive health.	NICHD	1R01HD112464-01A1	POPKIN, RONNA		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$538,719.00
213	Project Summ	The Impact of Minority Stress on Alcohol-Related Sexual Assault among Sexual Minority College Students: An Intersectional Mixed	NIAAA	5R01AA031213-02	FREEMAN, ROBERT		UNIVERSITY OF WISCONSIN MILWAUKEE	$538,377.00
214	PROJECT SUM	Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Messag	NCI	5R01CA237670-06	BLAKE, KELLY D		UNIVERSITY OF PENNSYLVANIA	$536,922.00
215	ABSTRACTThe	Modeling Resilience as a Multidimensional Protective Factor for Transgender Health Disparities: Measure Development and Longitu	NIMHD	5R01MD018051-03	GILLMAN, ARIELLE SAMANTHA		MICHIGAN STATE UNIVERSITY	$534,452.00
216	Recent data e	Reproductive Consequences of Steroid Hormone Administration	NICHD	5R01HD098233-05	JOHNSTON, DANIEL STEPHEN		UNIVERSITY OF MICHIGAN AT ANN ARBOR	$532,185.00
217	Project Summ	Sex Gender and the Immunopathogenesis of HIV	NIAID	5R01AI154541-04		NOVAK, LEIA KAYE	JOHNS HOPKINS UNIVERSITY	$531,596.00
218	AbstractUpta	Evaluating the effectiveness of a mobile HIV prevention app to increase HIV and STI testing and PrEP initiation among run	NIMH	5R01MH134267-02	POLLARD-BRANCHARD, SUZY		EMORY UNIVERSITY	$531,589.00
219	Project Summ	Addressing the continuum of care among high-risk Thai men	NIMH	5R01MH119015-05	GREENWOOD, GREGORY		MAHIDOL UNIVERSITY	$531,153.00
220	PROJECT SUM	Intersectional Approaches to Population-Level Health Research: Role of HIV Risk and Mental Health in Alcohol Use Disp	NIAAA	5R01AA029044-04	FREEMAN, ROBERT		NORTHWESTERN UNIVERSITY AT CHICAGO	$530,894.00
221	ABSTRACTTra	Skeletal Health and Bone Marrow Composition Among Youth	NICHD	5R01HD101421-05		RUSSO, DENISE	BOSTON CHILDREN'S HOSPITAL	$529,742.00
222	PROJECT SUM	PrEParados: A Multi-Level Social Network Model to Increase PrEP Enrollment by Latino MSM Self-Identified as Gay Bisex	NIMH	5R01MH125727-03	STIRRATT, MICHAEL J		UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$524,517.00
223	Project Summ	MyPrEP Plus: Development and Pilot Testing of Novel Pre-Exposure Prophylaxis Support Tools for Transgender Women	NIMH	1R34MH132405-01	STIRRATT, MICHAEL J		PUBLIC HEALTH FOUNDATION ENTERPRISES	$521,875.00
224	PROJECT SUM	Stress hazardous drinking and intimate partner aggression in a diverse sample of women and their partners	NIAAA	5R01AA027252-05	FREEMAN, ROBERT		COLUMBIA UNIVERSITY HEALTH SCIENCES	$520,468.00
225	Project Summ	Alcohol minority stress and intimate partner violence: Temporal and prospective associations in sexual minority young adults	NIAAA	5R01AA027248-05	FREEMAN, ROBERT		UNIVERSITY OF WISCONSIN MILWAUKEE	$519,398.00
226	ABSTRACTSTI	STI Response and Recommendations Under PrEP (STIRRUP)	NIMH	5R01MH128130-04	SCOTT-SHELDON, LORI		EMORY UNIVERSITY	$518,619.00
227	SUMMARYThe	Community Outreach and Engagement	NCI	5P30CA124435-16			STANFORD UNIVERSITY	$512,726.00
228	Men who have	Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex with Men	NIAID	5U01AI156874-04	ZIMAND, LORI B.		NORTHWESTERN UNIVERSITY AT CHICAGO	$500,000.00
229	AbstractThe c	RFA-PS-23-006 De Confianza: Creating Medical Trust with Latinx Communities	NCHHSTP	5U01PS005248-02		RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$499,674.00
230	ABSTRACTOv	Acquired Immunodeficiency Syndrome;Address;Adherence;Aging;Area;Biological Markers;Blood;Caring;Chronic;Cohort Studies;Complex;C	NIH	5R01HL160326-05	COADY, SEAN	FRIEDMAN, MACKEY R	RUTGERS BIOMEDICAL AND HEALTH SCIENCES	$497,040.00
231	Enhancing Po	Confidentiality in use of health insurance coverage for reproductive health services	NICHD	1R21HD116080-01	POPKIN, RONNA	JANIAK, ELIZABETH	BRIGHAM AND WOMEN'S HOSPITAL	$495,307.00
232	PROJECT SUM	A Randomized Controlled Trial of an HPV Vaccine Intervention for Young Sexual Minority Men	NCI	5R37CA226682-06	KOBRIN, SARAH	REITER, PAUL L	OHIO STATE UNIVERSITY	$490,264.00
233	PROJECT SUM	Over-the-Counter PrEP: Acceptability Feasibility and Potential Impact of Access without a Prescription (OFFSCRIPT)		1R21MH136855-01	STIRRATT, MICHAEL J	MARCUS, JULIA L.	HARVARD PILGRIM HEALTH CARE, INC.	$489,120.00
234	PROJECT SUM	Choice-Based PrEP Delivery for Transgender People in Uganda	NIMH	5R01MH130208-02	STIRRATT, MICHAEL J	MUJUGIRA, ANDREW	INFECTIOUS DISEASES INSTITUTE	$478,540.00
235	Estimates sug	Harnessing the power of technology to develop a population-based HIV prevention program for trans girls	NINR	5R01NR020309-04	WILLIS, LEIGH ANDREW	YBARRA, MICHELE L.	CENTER FOR INNOVATIVE PUBLIC HEALTH RESEARCH	$472,086.00
236	Project Summ	3-Dimensional;AIDS prevention;Accounting;Address;Adherence;Affect;Age;Area;Behavioral;Black race;Blood;California;Clinic;Clinic Visits	NIMH	5R01MH119956-05	STIRRATT, MICHAEL J	BUCHBINDER, SUSAN	PUBLIC HEALTH FOUNDATION ENTERPRISES	$471,332.00
237	Project Summ	AIDS prevention;Address;Adherence;Africa;Age;Bisexual;Caring;Clinical;Communities;Consultations;Control Groups;Country;Data;Discrir	NIH	5R01NR021170-02	WILLIS, LEIGH ANDREW	ABU-BA'ARE, GAMJI RABIU	UNIVERSITY OF ROCHESTER	$465,030.00
238	PROJECT SUM	Development and Initial Trial of Brief Interventions to Help Parents of Stigmatized Youth Reduce Distress and Strengthen Attachmer	NICHD	1R21HD110617-01A1	POPKIN, RONNA	PACHANKIS, JOHN EDWARD	YALE UNIVERSITY	$463,689.00
239		Development and Evaluation of a Multilevel Socio-Culturally Contextualized Digital Health Decision Intervention to Reduce Medical Mistru		5U01PS005283-02			GUILAMO-RAMOS, VINCENT M.	$460,246.00
240	PROJECT SUM	Implementation of PrEP Care Among Women in Family Planning Clinics	NIMH	5R01MH134264-02	POLLARD-BRANCHARD, SUZY		RUSH UNIVERSITY MEDICAL CENTER	$458,824.00
241	Project Abstra	Sampling Strategies and Measure Development for the LGBT Aging Project (SAMLAP)		5R01AG070059-03	PHILLIPS, JOHN	O'MUIRCHEARTAIGH, COLM AONGUS	NATIONAL OPINION RESEARCH CENTER	$458,823.00
242	Summary: Sex	Reconstruction of an SGM-specific sexual violence peer support program (SSS+)		1R15AA030898-01A1	ROACH, DEIDRA	MOXIE, JESSAMYN	UNIVERSITY OF NORTH CAROLINA CHARLOTTE	$458,269.00
243	ABSTRACTKn	STEM-Coaching and Resources for Entrepreneurial Women (CREW)		5R25GM147291-03	BLATCH, SYDELLA ANNE	FEGHALI-BOSTWICK, CAROL A.	MEDICAL UNIVERSITY OF SOUTH CAROLINA	$457,484.00
244	Hispanic/Lati	Exploring and Intervening on Multilevel Factors of Medical Mistrust among Hispanic/Latino Gay Bisexual and Other Men Who Have Sex with I		5U01PS005250-02			RHODES, SCOTT D	$456,915.00
245	ABSTRACTYou	AIDS prevention;Acquired Immunodeficiency Syndrome;Adolescent Development;Adverse event;Affect;Age;Area;Attention;Awareness;Beha		1R21MH130302-01A1	ALLISON, SUSANNAH	BOYD, DONTE T	OHIO STATE UNIVERSITY	$450,125.00
246	AbstractThe c	Building a Diverse Network to Support and Build Pathways for Historically Underrepresented Students in Quantitative-Focused Research Areas Within the A		1OT2OD037655-01	ALFARANO, ALEXANDRIA SKYE	COOK, STEPHANIE HAZEL	NEW YORK UNIVERSITY	$450,000.00

	A	B	C	D	E	F	G	H
247	PROJECT SUN	Activities of Daily Living;Address;Adherence;Advocate;Age;Ally;Anti-Retroviral Agents;Bereavement;Bisexual;Caring;Child;Cognitive;Cognitive Therapy;Co		1R21AG087792-01	GERALD, MELISSA S	BATCHELDER, ABIGAIL WINSTON	FENWAY COMMUNITY HEALTH CENTER	$443,875.00
248	Despite the S	Adapting and testing a smoking cessation intervention for transgender and gender-diverse individuals	NCI	1R21CA292185-01	RODITIS, MARIA LEIA	O'CLEIRIGH, CONALL MICHAEL	MASSACHUSETTS GENERAL HOSPITAL	$439,966.00
249	Appalachia is	Harnessing the power of peer navigation and mHealth to reduce health disparities in Appalachia		5R01NR019512-05	GODETTE, DIONNE	RHODES, SCOTT D	WAKE FOREST UNIVERSITY HEALTH SCIENCES	$439,496.00
250	ABSTRACTIt is	Race & Place: The Impacts of Racial Inequality on Substance Use and HIV Outcomes in Los Angeles		1R01DA061345-01	WEBB, CANDACE KARONDELETTE	GORBACH, PAMINA MAE	UNIVERSITY OF CALIFORNIA LOS ANGELES	$439,153.00
251	PROJECT SUN	RP3 PrEP Choice	NICHD	5UM2HD111102-03		HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	$429,460.00
252	PROJECT SUN	Feasibility study for assessing processes and outcomes related to gender affirming care		1R21HD115838-01	POPKIN, RONNA	HUTCHENS, KENDRA	UNIVERSITY OF COLORADO DENVER	$429,000.00
253	Project Summ	Restoring equity to measuring and preventing perinatal intimate partner violence (Remap-IPV)	NICHD	1R25HD116367-01	CHINN, JUANITA JEANNE	HATCHER, ABIGAIL MAE	UNIV OF NORTH CAROLINA CHAPEL HILL	$428,270.00
254	PROJECT SUN	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality		5R01HD109320-02	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$427,618.00
255	ABSTRACTBla	One Ballroom: Understanding Intersectional Stigma to Optimize the HIV Prevention Continuum among Vulnerable Populations in the United States		5DP2AI164315-04	SHARP, GERALD B.	ARAYASIRIKUL, SEAN	UNIVERSITY OF CALIFORNIA-IRVINE	$426,660.00
256	Project Abstra	The Next Generation of Black Women Scientists		5R25GM060566-22	HARTON, MARIE DEBORAH GAYNELLE	BLANKSON, ARABA NAYENA	SPELMAN COLLEGE	$424,969.00
257	Project Summ	Using digital photovoice to explore the relationships between social media content and suicidality among transgender adolescents	NIMH	1R01MH135498-01A1	MURPHY, ERIC ROUSSEAU	NAMBISAN, PRIYA	UNIVERSITY OF WISCONSIN MILWAUKEE	$423,369.00
258	PROJECT ABS	VCU National Coordinating Center for Advancing Gender Inclusive Excellence	NIDDK	1U24DK138889-01	SERRANO, KATRINA JANE		VIRGINIA COMMONWEALTH UNIVERSITY	$421,354.00
259	SUMMARYThi	AIDS prevention;Address;Adherence;Affect;Affordable Care Act;Architecture;Behavioral;Black race;Caring;Clinic;Computer Assisted;Comp		1R21DA062591-01	JENKINS, RICHARD A	GROV, CHRISTIAN	GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY	$420,319.00
260	ABSTRACTSe	Cultural Consensus Modeling to Identify Culturally Relevant Risk and Protective Factors for Suicide among Sexual Minority Youth		1R21MH135130-01A1	MURPHY, ERIC ROUSSEAU	HILL, RYAN	LOUISIANA STATE UNIV A&M COL BATON ROUGE	$417,730.00
261	PROJECT SUN	RP5 MPT Study	NICHD	5UM2HD111102-03		HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	$416,416.00
262	PROJECT SUN	Design of a Lay Health Worker Training Intervention to Promote Mental Health Care Access for Racially Diverse Transgender Youth	NIMH	1R21MH135234-01A1	LUSHIN, VICTOR	BARNETT, MIYA	UNIVERSITY OF CALIFORNIA SANTA BARBARA	$416,299.00
263	Project Summ	Effects of exogenous testosterone therapy on communication in gender diverse speakers	NIDCD	5R01DC020061-04	KOPF, LISA MARIE		BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)	$415,942.00
264	PROJECT SUN	Abstinence;Arousal;Attenuated;Behavior Therapy;Behavioral;Clinical;Cocaine use disorder;Control Groups;Cues;Development;Drug usage;Electroence		5R61DA056779-02	PARIYADATH, VANI	PARVAZ, MUHAMMAD ADEEL	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	$415,322.00
265	PROJECT SUN	Substance use and DNA methylation at the intersection of sex and gender		5R01DA052016-04	LOSSIE, AMY C	FLENTJE, ANNESA	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$415,223.00
266	PROJECT SUN	Center for AIDS Prevention Studies (CAPS)	NIMH	5P30MH062246-24	GORDON, CHRISTOPHER M.	JOHNSON, MALLORY O	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$411,982.00
267	ABSTRACTThe	Recruiting & Retaining Older African Americans into Research (ROAR)		5R24AG065151-03	ELLIOTT, CERISE	MITCHELL, JAYMIA ANN	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$410,803.00
268	PROJECT SUN	18 year old;Address;Adult;Age;Awareness;Behavioral Risk Factor Surveillance System;Bisexual;Cessation of life;Cigarette Smoker;Data;Data Set;Data Sou		5R01CA276500-02	REYES-GUZMAN, CAROLYN	VELIZ, PHILIP T	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$407,963.00
269	PROJECT SUN	Using mixed methods to evaluate self- and other-generated TDM content as predictors of socioemotional well-being in sexual and g	NICHD	5P01HD109850-03		SELKIE, ELLEN MARIE	UNIVERSITY OF WISCONSIN-MADISON	$407,284.00
270	SUMMARY/AB	Elucidating minority stress influences on tobacco use at the intersection of sexual orientation and rurality		1R01DA059480-01A1	DUNSTON, SHEBA KING	ROMM, KATELYN	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$406,246.00
271	PROJECT SUN	Social and structural violence and HIV care continuum outcomes: Developing a trauma-informed HIV care intervention	NIMH	5R01MH123349-05	SENN, THERESA ELAINE	SHANNON, KATE	UNIVERSITY OF BRITISH COLUMBIA	$401,871.00
272	PROJECT SUN	Boosting Mentor Effectiveness iN Training of Research Scientists (MENTORS) Using Social Cognitive Career Theory to Support Entry of Women & Minorities		5U01GM132375-05	GAMMIE, ALISON	ARORA, VINEET	UNIVERSITY OF CHICAGO	$400,242.00
273	Project Summ	Charting Trajectories of Sexual Identity Development and Mental Health Disparities Among Sexual Minority Youth		5R01MD015109-04	BARKSDALE, CRYSTAL	HALL, WILLIAM JAMES	UNIV OF NORTH CAROLINA CHAPEL HILL	$386,605.00
274	PROJECT SUN	Intervention to Enhance PrepPersistence Among African American Men Who Have Sex With Men	NIMH	5R01MH131475-02	STIRRATT, MICHAEL J		BROWN UNIVERSITY	$379,617.00
275	Abstract My B	Achieving Optimal Sexual and Reproductive Health (SRWH Project)	OD	3OT2OD035877-01S1	MADDEN, EBONY B	GIPSON, JUNE ARNESSA	MY BROTHER'S KEEPER, INC.	$375,000.00
276	Virginia Tech	Virginia Tech Postbaccalaureate Research Education Program (VT PREP)		5R25GM066534-20	AKACEM, LAMEESE DANA	SMITH, EDWARD J	VIRGINIA POLYTECHNIC INST AND ST UNIV	$374,968.00
277	PROJECT SUN	Intermountain PREP		5R25GM144253-03	STEPANEK, LAURIE ELIZABETH	MURTAUGH, LEWIS C	UNIVERSITY OF UTAH	$369,845.00
278	PROJECT SUN	Experiences of Rural Sexual and Gender Minority Couples: Does Alcohol Use Explain the Link Between Minority Stress and Intimate	NIAAA	5R01AA030558-02	FREEMAN, ROBERT		UNIVERSITY OF NEBRASKA LINCOLN	$350,000.00
279	PROJECT SUN	Intervention to Enhance PrepPersistence Among African American Men Who Have Sex With Men	NIMH	5R01MH131475-02	STIRRATT, MICHAEL J		BROWN UNIVERSITY	$350,000.00
280	PROJECT SUN	Examining Social Ecological and Network Factors to Assess Epidemiological Risk in a Large National Cohort of Cisgende	NIAID	5R01AI172469-02	ROE, JOANAD'ARC C	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$350,000.00
281		Sailing PrEP: Tailoring PrEP navigation for sexual and gender minorities in Puerto Rico		1U01PS005284-01			KARVER, TAHILIN SANCHEZ	$349,959.00
282	ABSTRACTPol	A novel approach for equitable characterization of gender and its use in exposing subgroup discrepancies in polygenic score associ	NHGRI	5R01HG012697-03	RIVERS, ROBERT C		UNIVERSITY OF IOWA	$348,982.00
283	Abstract:Orop	HPV Oropharyngeal cancer and screening in Gay and Bisexual Men		5R01CA253244-03	CHOLLETTE, VERONICA	ROSS, MICHAEL W	UNIVERSITY OF MINNESOTA	$347,351.00
284	The RCMI Pro	The RCMI Program in Health Disparities Research at Meharry Medical College	NIMHD	5U54MD007586-38	DAS, RINA	ADUNYAH, SAMUEL EVANS	MEHARRY MEDICAL COLLEGE	$345,550.00
285	Project Summ	Stanford Women's Reproductive Health Research Career Development Program		5K12HD103084-05	KAUFMAN, STEVEN	SUBAK, LESLEE L	STANFORD UNIVERSITY	$336,279.00
286	AbstractDeca	How Spouses Influence Each Other's Health in Same- and Different-Sex Marriages: A Dyadic and Longitudinal Assessment from Mid to Later Life		5R37AG076057-04	GERALD, MELISSA S	UMBERSON, DEBRA J.	UNIVERSITY OF TEXAS AT AUSTIN	$329,102.00
287	There is a den	Supporting the Tufts BIRCWH Program with an Additional Scholar Position		3K12AR084217-09S1	TIGNO, XENIA	FREUND, KAREN	TUFTS UNIVERSITY BOSTON	$327,390.00
288	ABSTRACTThi	UCSF-Kaiser Department of Research Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Program		3K12AR084219-26S1	TIGNO, XENIA	HARPER, CYNTHIA C	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$325,591.00
289	SUMMARY MI	PREP-MT: Providing Research Education for Postbaccalaureate Trainees in Montana		5R25GM152359-02	STEPANEK, LAURIE ELIZABETH	BIMCZOK, DIANE	MONTANA STATE UNIVERSITY - BOZEMAN	$325,205.00
290	PROJECT SUN	A Multidimensional Aging Science Program: MSTEM Scholars Trained in Aging Research (MSTEM STAR)		5R25AG076390-03	TORRES, DELANY	PIAZZA, JENNIFER	CALIFORNIA STATE UNIVERSITY FULLERTON	$325,034.00
291	Belonging is a	Bridges: A digital intervention to increase workplace belonging		1R43MD019197-01	JOHNSON, JARRETT AINSWORTH	EVERS, KERRY	PRO-CHANGE BEHAVIOR SYSTEMS, INC.	$324,381.00
292	PROJECT SUN	TRANSforma Tu Salud Dejando de Fumar: Advancing smoking cessation among transgender individuals		1R21CA284313-01	PEARLMAN, PAUL C	CARTUJANO, FRANCISCO	UNIVERSITY OF ROCHESTER	$323,032.00
293	Abstract HIV (	AIDS prevention;Address;Adherence;Affect;Birth;Bisexual;Caring;Central America;Communities;Complex;Country;Data;Destinations;Diag		1R21MH136915-01A1	STENSON, ANAIS FERN	TIEU, HONG VAN NHU	NEW YORK BLOOD CENTER	$308,371.00
294	Our commitm	Bachelor's Degree;Behavioral;Biology;Biomedical Research;CCL7 gene;Career Choice;Collaborations;County;Data;Development Plans;Disciplin		5R25GM050070-22	STEPANEK, LAURIE ELIZABETH	MOLONEY, DANIEL J	STATE UNIVERSITY NEW YORK STONY BROOK	$305,137.00
295	Abstract Mala	Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM	FIC	5R33TW011665-06	NEWSOME, BRAD	SHRESTHA, ROMAN	UNIVERSITY OF CONNECTICUT STORRS	$293,778.00
296	Contextual D	Contextual Determinants of Sexual Minority Health in the United States	NIMHD	5R01MD016417-03		MUJURU, PRISCAH	UNIVERSITY OF TEXAS SAN ANTONIO	$291,186.00
297	ABSTRACT Ga	GHB Toxicokinetics: Role of sex hormone dependent monocarboxylate transporter regulation and potential for altered overdose ris	NIDA	5SC1DA052120-04	LE, HOANG VAN	FELMLEE, MELANIE	UNIVERSITY OF THE PACIFIC-STOCKTON	$290,624.00
298	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01	GERALD, MELISSA S	BOGART, LAURA M	RAND CORPORATION	$290,387.00
299	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01		GERALD, MELISSA S	RAND CORPORATION	$290,387.00
300	Project Summ	18 year old;Advertisements;Affect;Age;Baltimore;Bisexual;Black race;Caring;Clinic;Communication;Communities;Cyb	NIMH	5R21MH129186-02		ALLISON, SUSANNAH	JOHNS HOPKINS UNIVERSITY	$286,563.00
301	Abstract Hist	Evidence-based Parent Training for Diverse Families (PTDF)	NICHD	1R44HD106855-01A1		GALLEN, COURTNEY LEIGH	IRIS MEDIA, INC.	$283,526.00
302	PROJECT SUN	Sexual Fluidity and Longitudinal Changes in Alcohol Misuse and Associated Health Consequences	NIAAA	5R01AA030243-03		KERRIDGE, BRADLEY TOWNSEND	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$280,253.00
303	In the general	Youth Empowerment and Safety Intervention for Systems-involved Sexual and Gender Minority Youth at Risk of Suicide	NIMH	1R34MH134912-01A1		O'CONNOR, STEPHEN	CASE WESTERN RESERVE UNIVERSITY	$279,366.00
304	Transgender v	Optimizing an mHealth intervention to improve uptake and adherence of the HIV pre-exposure prophylaxis (PrEP) in vuln	NICHD	5R33HD107988-04	YATES, FRANKLIN WILLEM	WANG, BO	UNIV OF MASSACHUSETTS MED SCH WORCESTER	$278,952.00
305	A health work	Sexual and Gender Minority Cancer Curricular Advances for Research and Education (SGM Cancer CARE)	NCI	5R25CA265802-03		RADAEV, SERGEY	UNIVERSITY OF TX MD ANDERSON CAN CTR	$277,181.00
306	PROJECT SUN	Integrated Alcohol and Sexual Assault Prevention for Bisexual Women	NIAAA	5R34AA030035-03		KERRIDGE, BRADLEY TOWNSEND	RHODE ISLAND HOSPITAL	$275,273.00
307	Project Summ	14 year old;Address;Adolescent;Age;Attitude;Behavior;Cause of Death;Child;Communities;Complex;Data;Development;Distress	NIMHD	1R21MD019829-01		GOGINENI, ARUNDHATI	UNIVERSITY OF SOUTHERN CALIFORNIA	$269,438.00
308	PROJECT SUN	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$267,000.00
309	PROJECT SUN	Cardiometabolic effects of gender-affirming hormone therapy in transgender adolescents	NICHD	5R21HD107609-02	WINER, KAREN	WEINZIMER, STUART ALAN	YALE UNIVERSITY	$266,081.00
310	Project Abstra	Examining reproductive and sexual health during the transition to adulthood	NICHD	1R56HD113725-01A1		POPKIN, RONNA	INNOVATION RESEARCH AND TRAINING, INC.	$263,996.00
311	PROJECT ABS	The BH-Works Suicide Prevention Program for Sexual and Gender Minority Youth	NIMH	5R34MH129785-03		O'CONNOR, STEPHEN	VIRGINIA POLYTECHNIC INST AND ST UNIV	$263,102.00
312	PROJECT ABS	Adapting the FOCUS Program for Sexual and Gender Minority (SGM) Cancer Patients and Caregivers	NCI	5R34CA283408-02		DEAN, DAVID WORTH	UNIVERSITY OF ROCHESTER	$261,095.00
313	PROJECT SUN	AIDS prevention;Address;Adherence;Adult;Age;Awareness;Cicatrix;Continuity of Patient Care;Data;Decision Making;D	NIAID	1R21AI183907-01A1		MATHIAS, CHERLYNN	UNIVERSITY OF WASHINGTON	$259,807.00
314	Project Summ	Adaptation and feasibility of Many Men Many Voices (3MV) an HIV prevention intervention to reduce intersectional stigr	FIC	5R01TW012671-02		BANSAL, GEETHA PARTHASARATHY	UNIVERSITY OF ROCHESTER	$257,515.00
315	PROJECT SUN	Training in Genomics Research (TiGeR)	NHGRI	5R25HG012330-03	XIRASAGAR, SANDHYA		ARIZONA STATE UNIVERSITY-TEMPE CAMPUS	$252,692.00
316	Project Summ	Advancing help-seeking and recovery measures for sexual and gender minority survivors of gender-based violence	NIMHD	1R21MD019089-01A1		MUJURU, PRISCAH	TEMPLE UNIV OF THE COMMONWEALTH	$250,709.00
317	PROJECT SUN	ADVANCE SGM Health for Research Diversity	NIMHD	1T32MD019780-01		BARKSDALE, CRYSTAL	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$250,060.00
318	Men who have	Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex with Men	NIAID	5U01AI156874-04	ZIMAND, LORI B.		NORTHWESTERN UNIVERSITY AT CHICAGO	$250,000.00
319	PROJECT SUN	Development and Preliminary Trial of a Digital Transdiagnostic CBT Intervention for Transgender Adolescents	NIMH	1R34MH133768-01A1	BURSTEIN, MARCY ELLEN	CHEN, DIANE	LURIE CHILDREN'S HOSPITAL OF CHICAGO	$249,765.00
320	Individuals ra	Transdisciplinary Health Disparities Research Training for Native Hawaiians and Pacific Students	NIMHD	5T37MD008636-10	OLADEINDE, YEWANDE A	SY, ANGELA U	UNIVERSITY OF HAWAII AT MANOA	$249,400.00
321	PROJECT	Event-level Antecedents of Heavy Drinking Among Bisexual and Heterosexual Women with and without Histories of Sexual Assault	NIAAA	4R00AA030079-03	KERRIDGE, BRADLEY TOWNSEND	LOPEZ, GABRIELA	RHODE ISLAND HOSPITAL	$249,000.00
322	PROJECT SUN	Event-level Antecedents of Heavy Drinking Among Bisexual and Heterosexual Women with and without Histories of Sexual Assault	NIAAA	4R00AA030079-03		KERRIDGE, BRADLEY TOWNSEND	RHODE ISLAND HOSPITAL	$249,000.00
323	PROJECT SUN	Sexually Transmited Infection Testing Risk and Prevention among Trans Women (STRIP-T)	NIMHD	4R00MD017967-03		HERREN, OLGA MARINA	UNIVERSITY OF CENTRAL FLORIDA	$249,000.00
324	PROJECT SUN	Stigma Romantic Relationships and Alcohol Use Among Transgender and Nonbinary Young Adults	NIAAA	4R00AA030601-03	KERRIDGE, BRADLEY TOWNSEND	MURCHISON, GABRIEL R	BOSTON UNIVERSITY MEDICAL CAMPUS	$249,000.00
325	The applicant	AIDS prevention;Address;Area;Attitude;Award;Behavior;Behavior Therapy;Behavioral;Caring;Collaborations;Communi	NIDA	4R00DA055508-03		JENKINS, RICHARD A	ILLINOIS INSTITUTE OF TECHNOLOGY	$249,000.00
326	PROJECT SUN	Testing the effect of anti-tobacco message framing on polytobacco use in lesbian gay bisexual and transgender young adults	NCI	5R00CA260718-04		MAYER, MARGARET ELIZABETH	OHIO STATE UNIVERSITY	$248,993.00
327	PROJECT SUN	AIDS prevention;Achievement;Acquired Immunodeficiency Syndrome;Address;Admission activity;Affect;Area;Arts;Awar	NIMH	5R25MH126703-04		ALLISON, SUSANNAH	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$247,641.00
328	ABSTRACT AN	The Role of Testosterone on Mediating Sex and Gender Influences on Chronic Orofacial Pain Conditions	NIDCR	5R01DE032225-02	GHIM, MELISSA M	RO, JIN Y	UNIVERSITY OF MARYLAND BALTIMORE	$246,556.00
329	PROJECT SUN	Population-Specific Eating Disorder Risk Factors in Sexual Minority Women	NIMHD	5R00MD015770-04		JOHNSON, JARRETT AINSWORTH	UNIVERSITY OF COLORADO DENVER	$244,716.00

	A	B	C	D	E	F	G	H
330	Project Summ	Enhancing Engagement with Online Health Messaging about Oral and Injectable PrEP Among Young-Adult MSM	NIMH	5R21MH133487-02		GREENWOOD, GREGORY	PENNSYLVANIA STATE UNIVERSITY, THE	$241,500.00
331	Project Summ	Defining the neovaginal microbiome after gender affirming vaginoplasty	NIAID	1R21AI178840-01A1	CHUANG, ELEANORE JENNIFER	FARR ZUEND, CHRISTINA	CASE WESTERN RESERVE UNIVERSITY	$241,500.00
332	PROJECT SUM	A mixed-methods approach to understanding stress and hazardous drinking among same-sex female couples	NIAAA	5R00AA028049-05		ZHA, WENXING	NORTHWESTERN UNIVERSITY AT CHICAGO	$241,466.00
333	PROJECT SUM	An intervention to promote healthy relationships among transgender and gender expansive youth	NICHD	5R21HD107311-02		POPKIN, RONNA	SEATTLE CHILDREN'S HOSPITAL	$240,544.00
334	The aim of thi	In-depth Understanding of HIV Risk Behavior among Men Who Have Sex With Men in Sub-Saharan Africa: Secondary Ana	NIMH	5R21MH130217-02		SCOTT-SHELDON, LORI	NEW YORK STATE PSYCHIATRIC INSTITUTE	$240,219.00
335	AbstractTrans	Tcher Take Charge: Increasing PrEP Awareness Uptake and Adherence Through Health Care Empowerment and Address	NIMH	5R01MH128049-04	POLLARD-BRANCHARD, SUZY		PUBLIC HEALTH FOUNDATION ENTERPRISES	$237,100.00
336	AbstractTrans	Tcher Take Charge: Increasing PrEP Awareness Uptake and Adherence Through Health Care Empowerment and Address	NIMH	5R01MH128049-04	POLLARD-BRANCHARD, SUZY		PUBLIC HEALTH FOUNDATION ENTERPRISES	$237,100.00
337	PROJECT SUM	Brothers building brothers by breaking barriers (B6): A resilience-focused intervention for young Black gay and bisexual men living w	NIMH	5R34MH129187-03		ALLISON, SUSANNAH	EMORY UNIVERSITY	$234,600.00
338	PROJECT SUM	ESTEEMED Scholars Program at the University of Rhode Island	NIBIB	5R25EB034489-02		GATLIN, TINA L.	UNIVERSITY OF RHODE ISLAND	$234,392.00
339	Project Summ	Proud to Quit (P2Q): A Person-centered mobile technology intervention for smoking cessation among transgender adults	NIDA	5R34DA058191-02	FITZ-RANDOLPH, MARCY ESTHER	SUN, CHRISTINA JIAYI	UNIVERSITY OF COLORADO DENVER	$234,262.00
340	Project Summ	Identifying Community-Informed DoxyPEP Implementation Strategies to Guide Equitable Delivery of Syphilis Prevention	NIMHD	5R21MD018707-02		FERNANDEZ, ANGELA R	UNIVERSITY OF CHICAGO	$232,669.00
341	Pre-exposure	AIDS prevention;Address;Adherence;Agreement;Appointment;Awareness;Behavioral;Biological;Bisexual;Black race;Bl	NIMH	5R34MH129279-03		STIRRATT, MICHAEL J	SAN DIEGO STATE UNIVERSITY	$230,997.00
342	PROJECT ABS	Reframing personal and community report back of consumer products by centering intersectionality		1R01ES036258-01	MCALLISTER, KIMBERLY A.	ZOTA, AMI R	COLUMBIA UNIVERSITY HEALTH SCIENCES	$230,305.00
343	Project Summ	Buddhism and HIV Stigma in Thailand: An Intervention Study	FIC	5R01TW012392-03	BANSAL, GEETHA PARTHASARATHY	CHEN, WEI-TI	UNIVERSITY OF CALIFORNIA LOS ANGELES	$224,971.00
344	PROJECT SUM	AIDS prevention;Adherence;Appointment;Behavioral;Cities;Code;Data;Data Collection;Development;Effectiveness;E	NIDA	7R21DA058575-02		JENKINS, RICHARD A	HARVARD PILGRIM HEALTH CARE, INC.	$220,370.00
345	Project Summ	Daily Impact of Sexual Minority Stress on Alcohol-Related Intimate Partner Violence among Bisexual+ Young Adults: A Couples' Da	NIAAA	1R21AA031548-01A1		FREEMAN, ROBERT	VIRGINIA POLYTECHNIC INST AND ST UNIV	$218,293.00
346	Project Summ	The All-or-Nothing Marriage? Marital Functioning and Health Among Individuals in Same and Different-Gender Marriages	NIA	5R01AG060944-05		BRAUDT, DAVID BRUCE	UNIVERSITY OF MINNESOTA	$218,169.00
347	Project Abstra	Strengthening the HIV care continuum for transgender women living with HIV in Malaysia	NIMH	5R21MH128114-02	ALLISON, SUSANNAH	WICKERSHAM, JEFFREY ALLEN	YALE UNIVERSITY	$218,127.00
348	PROJECT SUM	Ecological momentary assessment of daily minority stressors and cannabis and tobacco co-use among sexual minority young adu	NIMHD	1R21MD019345-01A1		GOGINENI, ARUNDHATI	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$216,772.00
349	PROJECT SUM	Short Trainings on Methods for Recruiting Sampling and Counting Hard-to-Reach Populations: The H2R Training Program	NIMH	5R25MH129290-03	ALLISON, SUSANNAH	MIRZAZADEH, ALI	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$216,249.00
350	ABSTRACT AN	The Role of Testosterone on Mediating Sex and Gender Influences on Chronic Orofacial Pain Conditions	NIDCR	5R01DE032225-02	GHIM, MELISSA M	RO, JIN Y	UNIVERSITY OF MARYLAND BALTIMORE	$215,441.00
351	ABSTRACTSui	CA-LINC: A Culturally Adapted Care Coordination Suicide Detection and Intervention Model for Black Youth	NIMH	5R34MH129782-03		ACRI-MARRO, MARY	UNIVERSITY OF NORTH CAROLINA CHARLOTTE	$214,271.00
352	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$214,000.00
353	PROJECT SUM	AIDS prevention;Adoption;Advocate;Bisexual;Caring;Chlamydia;Clinic;Collaborations;Communication difficulty;Comm	NIMH	5R34MH129208-03		SENN, THERESA ELAINE	MEDICAL COLLEGE OF WISCONSIN	$213,959.00
354	PROJECT SUM	Intersectional minority stress mental health and HIV treatment and care among MSM living with HIV in Ghana	NIMH	5K01MH130270-03		SENN, THERESA ELAINE	STATE UNIVERSITY OF NEW YORK AT BUFFALO	$211,430.00
355	ABSTRACTIn S	Formative work for the development of an intervention to support combined HIV/syphilis self-testing and linkage to prev	NIMH	1R21MH135779-01A1	GREENWOOD, GREGORY	RAEL, CHRISTINE TAGLIAFERRI	UNIVERSITY OF COLORADO DENVER	$211,326.00
356	PROJECT SUM	18 year old;Address;Adopted;Adult;Advisory Committees;Affect;Anxiety;Anxiety Disorders;Area;Attention;Bisexual;Clinical;Clinica	NIMH	1K23MH137389-01		SWEENEY, MAGGIE	HUNTER COLLEGE	$211,103.00
357	PROJECT SUM	Understanding Breast Cancer Risk and Screening in Transgender Persons through a Pilot Breast Cancer Screening Program	NCI	5K08CA276706-02		BIAN, YANSONG	MEDICAL COLLEGE OF WISCONSIN	$210,062.00
358	Men who have	Integration of Electronic SBI(RT) into an HIV Testing Program to Reduce Substance Use and HIV risk Behavior among MSI	NIDA	5R34DA055503-03	LEE-WINN, ANGELA EUNJI	BALAN, IVAN C	FLORIDA STATE UNIVERSITY	$209,449.00
359	ABSTRACTIn t	Formative work to develop differentiated communication tools to facilitate transgender women's recruitment enrollme	NIMH	5R21MH132421-02	STIRRATT, MICHAEL J	RAEL, CHRISTINE TAGLIAFERRI	UNIVERSITY OF COLORADO DENVER	$208,242.00
360	7. Project Sur	Intersectional discrimination and linkage to HIV prevention and care in transgender women in Ecuador	NIMH	5K01MH134764-02	GREENWOOD, GREGORY	AGUAYO ROMERO, RODRIGO ARMANDO	WHITMAN-WALKER INSTITUTE, INC.	$207,691.00
361	PROJECT SUM	Building Interdisciplinary Research Careers in Women's Health at UC Davis	NIAMS	3K12AR084220-21S1	TIGNO, XENIA	LANE, NANCY E	UNIVERSITY OF CALIFORNIA AT DAVIS	$206,172.00
362	PROJECT SUM	Using youth-engaged methods to develop and evaluate a measure for disordered eating behaviors in transgender and gender-diver	NIMH	1K23MH134111-01		BECHTHOLT, ANITA J	VIRGINIA COMMONWEALTH UNIVERSITY	$205,308.00
363	Young men ha	Adapting effective mhealth interventions to improve uptake and adherence of the HIV pre- exposure prophylaxis (PrEP)	NIMH	5R34MH124081-03	ALLISON, SUSANNAH	WANG, BO	UNIV OF MASSACHUSETTS MED SCH WORCESTER	$202,639.00
364	Project Summ	Building an interprofessional and diverse workforce in substance use and pain	NIDA	1T32DA057926-01A1		LIN, YU	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$202,337.00
365	PROJECT SUM	CHAMPION - Combining HIV And Stimulant Prevention and Treatment Interventions Optimized for HIV-Negative MSM	NIDA	1R21DA060856-01A1	JENKINS, RICHARD A	TSUYUKI, KIYOMI	UNIVERSITY OF CALIFORNIA, SAN DIEGO	$202,308.00
366	Background. S	19 year old;Address;Adherence;Age;Agreement;Anti-Retroviral Agents;Appointment;Attention;Behavioral;Behavioral M	NIMH	5R34MH126894-03		ALLISON, SUSANNAH	BROWN UNIVERSITY	$202,013.00
367	Project Summ	Data-driven peer-led messaging using social media influencers to increase PrEP awareness and uptake among transgen	NIMH	5R34MH129189-03	SCOTT-SHELDON, LORI	BASS, SARAH B	TEMPLE UNIV OF THE COMMONWEALTH	$201,803.00
368	Significance.	AIDS prevention;AIDS/HIV problem;Address;Adherence;Affect;Back;Behavior;Behavior Therapy;Behavioral Research;B	NIDA	5R21DA053156-02		HARTSOCK, PETER	NEW YORK STATE PSYCHIATRIC INSTITUTE	$200,782.00
369	Project Summ	Psychosocial Predictors of Risk for Suicidal Behavior Among Gender Minority Adolescents	NIMHD	1R01MD018582-01A1	BURNS, PAUL ANTHONY		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$200,000.00
370	Project Summ	Two-Spirit Films in Indigenous Cancer Health	NCI	3P30CA016056-47S1		HE, MIN	ROSWELL PARK CANCER INSTITUTE CORP	$200,000.00
371	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$200,000.00
372	In the United	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$200,000.00
373	In the United	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$200,000.00
374	AbstractUpta	Evaluating the effectiveness of a mobile HIV prevention app to increase HIV and STI testing and PrEP initiation among run	NIMH	5R01MH134267-02	POLLARD-BRANCHARD, SUZY		EMORY UNIVERSITY	$200,000.00
375	PROJECT SUM	Experiences of Rural Sexual and Gender Minority Couples: Does Alcohol Use Explain the Link Between Minority Stress and Intimate	NIAAA	5R01AA030558-02	FREEMAN, ROBERT		UNIVERSITY OF NEBRASKA LINCOLN	$177,063.00
376	ABSTRACTPol	A novel approach for equitable characterization of gender and its use in exposing subgroup discrepancies in polygenic score associ	NHGRI	5R01HG012697-03	RIVERS, ROBERT C		UNIVERSITY OF IOWA	$160,444.00
377	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$160,000.00
378	SUMMARY/AB	Kabawil: Adapting an Intervention to Reduce Intersectional Stigmas among Indigenous Sexual Minority Men and Traditional Healers	FIC	1R01TW012904-01		BANSAL, GEETHA PARTHASARATHY	UNIVERSITY OF WASHINGTON	$157,738.00
379	PROJECT SUM	Sexual Fluidity and Longitudinal Changes in Alcohol Misuse and Associated Health Consequences	NIAAA	3R01AA030243-03S1	KERRIDGE, BRADLEY TOWNSEND	EVANS-POLCE, REBECCA J.	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$155,941.00
380	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$150,000.00
381	PROJECT SUM	Examining Social Ecological and Network Factors to Assess Epidemiological Risk in a Large National Cohort of Cisgende	NIAID	5R01AI172469-02	ROE, JOANAD'ARC C	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$150,000.00
382	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$150,000.00
383	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$150,000.00
384	Project Summ	Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness / Implemen	NICHD	5UG1HD113160-02	RUSSO, DENISE	GAROFALO, ROBERT	NORTHWESTERN UNIVERSITY AT CHICAGO	$150,000.00
385	Despite an ar	Malaysian Implementation Science Training (MIST) Program in HIV	FIC	5D43TW011324-05	BANSAL, GEETHA PARTHASARATHY	ALTICE, FREDERICK LEWIS	YALE UNIVERSITY	$147,920.00
386	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$147,825.00
387	PROJECT SUM	Predicting acute and dynamic suicide risk in rural sexual minorities	NIMHD	5K08MD019314-03	JONES, NANCY LYNNE	FORREST, LAUREN NICOLE	UNIVERSITY OF OREGON	$139,738.00
388	Project Summ	Stigma Reduction and Gender Affirmation to Promote HIV Prevention/Testing in Trans Women	FIC	7R21TW012010-03	BANSAL, GEETHA PARTHASARATHY	OPERARIO, DON	EMORY UNIVERSITY	$139,298.00
389	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$118,365.00
390	ABSTRACTTra	Improving the accessibility of transgender voice training with visual-acoustic biofeedback	NIDCD	5R21DC021537-02	KOPF, LISA MARIE	NOVAK, VESNA DOMINIKA	UNIVERSITY OF CINCINNATI	$114,998.00
391	PROJECT SUM	Implementation of PrEP Care Among Women in Family Planning Clinics	NIMH	5R01MH134264-02	POLLARD-BRANCHARD, SUZY		RUSH UNIVERSITY MEDICAL CENTER	$100,000.00
392	PROJECT ABS	Reframing personal and community report back of consumer products by centering intersectionality		1R01ES036258-01	MCALLISTER, KIMBERLY A.	ZOTA, AMI R	COLUMBIA UNIVERSITY HEALTH SCIENCES	$100,000.00
393	PROJECT ABS	Reframing personal and community report back of consumer products by centering intersectionality		1R01ES036258-01	MCALLISTER, KIMBERLY A.	ZOTA, AMI R	COLUMBIA UNIVERSITY HEALTH SCIENCES	$100,000.00
394	Despite an ar	Malaysian Implementation Science Training (MIST) Program in HIV	FIC	5D43TW011324-05	BANSAL, GEETHA PARTHASARATHY	ALTICE, FREDERICK LEWIS	YALE UNIVERSITY	$100,000.00
395	Project Summ	Effects of exogenous testosterone therapy on communication in gender diverse speakers	NIDCD	5R01DC020061-04	KOPF, LISA MARIE		BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)	$100,000.00
396	PROJECT ABS	VCU National Coordinating Center for Advancing Gender Inclusive Excellence	NIDDK	1U24DK138889-01	SERRANO, KATRINA JANE		VIRGINIA COMMONWEALTH UNIVERSITY	$100,000.00
397	In the United	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$100,000.00
398	In the United	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$100,000.00
399	ABSTRACTTra	Improving the accessibility of transgender voice training with visual-acoustic biofeedback	NIDCD	5R21DC021537-02	KOPF, LISA MARIE	NOVAK, VESNA DOMINIKA	UNIVERSITY OF CINCINNATI	$100,000.00
400	PROJECT SUM	Improving service delivery models of medically assisted reproduction: A patient journey mapping study of sexual minority women	NIMHD	3R01MD015256-05S1	MUJURU, PRISCAH	CHARLTON, BRITTANY MICHELLE	HARVARD PILGRIM HEALTH CARE, INC.	$99,998.00
401	PROJECT SUM	A digital health intervention to increase condom use among adolescent sexual minority males	NIMHD	5K99MD019060-02	GARRIDO, CARLOS OSWALDO	JAVIDI, HANNAH	TRUSTEES OF INDIANA UNIVERSITY	$99,424.00
402	PROJECT SUM	Improving Measurement of Alcohol Use and Other Disparities by Sex, Sexual Orientation, and Gender Identity through Community	NIAAA	3R01AA029076-04S1	FREEMAN, ROBERT	PHILLIPS, GREGORY L.	NORTHWESTERN UNIVERSITY AT CHICAGO	$99,083.00
403	This applicati	Randomized Controlled Trial of Dyadic Financial Incentive Treatment for Dual Smoker Couples: Evaluation of Efficacy Mechanisms	NCI	3R01CA276594-02S1	RODITIS, MARIA LEIA	VANDELLEN, MICHELLE RENEE	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$95,486.00
404	Men-who-hav	Evaluating HPV Vaccination Uptake Barriers and its Efficacy in PLWH	NIMHD	3U54MD007601-38S2	LAI, GABRIEL Y	HEDGES, JERRIS ROBERT	UNIVERSITY OF HAWAII AT MANOA	$92,787.00
405	The U-RISE at	U-RISE at Spelman College	NIGMS	1T34GM149823-01A1	HARTON, MARIE DEBORAH GAYNELLE	BLANKSON, ARABA NAYENA	SPELMAN COLLEGE	$90,514.00
406	PROJECT SUM	Promoting Health and Reducing Risk among Hispanic Sexual Minority Youth and their Families	NIMHD	3R01MD017588-03S1	BARKSDALE, CRYSTAL	PRADO, GUILLERMO	UNIVERSITY OF MIAMI CORAL GABLES	$85,939.00
407	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$85,500.00
408	SUMMARYThe	Career Enhancement Program	NCI	5P20CA275734-02		MASKARINEC, GERTRAUD	UNIVERSITY OF HAWAII AT MANOA	$83,937.00
409	PROJECT SUM	Refinement of a Training Module to Improve Discussions of Sexual Orientation and Gender Identity in Cancer Clinics	NCI	1R03CA289560-01	MARCUS, PAMELA M.	CATHCART-RAKE, ELIZABETH	MAYO CLINIC ROCHESTER	$80,700.00
410	Project summ	Romantic Relationships, Discrimination Stressors, and Alcohol Use among Sexual and Gender Minority Adults	NIAAA	1R03AA031740-01	RUFFIN, BEVERLY	GREENE, KAYLIN	MONTANA STATE UNIVERSITY - BOZEMAN	$80,316.00
411	ABSTRACTIn t	A multi-level approach to improve HIV prevention and care for transgender women of color	NIMH	7R01MH129285-02	ALLISON, SUSANNAH		NEW YORK STATE PSYCHIATRIC INSTITUTE	$80,000.00

	A	B	C	D	E	F	G	H
412	Project Summ	Improving Sexual Minority Health: Differences in Substance Use, Substance Use Treatment, and Associated Chronic Diseases amo	NIDA	5R03DA052651-02	LYNCH, SEAN EDWARD WINTERS	MORGAN, ETHAN	OHIO STATE UNIVERSITY	$79,291.00
413	PROJECT SUM	Understanding the individual and combined impact of childhood sexual abuse and minority stress on hazardous drinking among s	NIAAA	5F32AA029957-03	KERRIDGE, BRADLEY TOWNSEND	BOCHICCHIO, LAUREN ANN	COLUMBIA UNIVERSITY HEALTH SCIENCES	$78,892.00
414	PROJECT SUM	Sexual Minority Mental Health During the COVID-19 Pandemic: An Intersectional, Social Epidemiologic Investigation	NIMHD	5F32MD017452-03	MUJURU, PRISCAH	BECCIA, ARIEL L	BOSTON CHILDREN'S HOSPITAL	$78,784.00
415	Project Summ	Piloting a multi-level intervention to promote viral suppression among transgender women living with HIV	NIMH	5R34MH129218-03	ALLISON, SUSANNAH	BARRINGTON, CLARE L	UNIV OF NORTH CAROLINA CHAPEL HILL	$78,491.00
416	In Malaysia th	Training in Behavioral Design Interventions to Address Stigma among Men Who have Sex with Men	NIMH	1F32MH138253-01	ALLISON, SUSANNAH	BROMBERG, DANIEL J	YALE UNIVERSITY	$77,908.00
417	Project Summ	Applying Deep Learning for Predicting Retention in PrEP Care and Effective PrEP Use among Key Populations at Risk for H	NIMH	5R03MH130275-02	SCOTT-SHELDON, LORI	LIU, FEIFAN	UNIV OF MASSACHUSETTS MED SCH WORCESTER	$76,214.00
418	Project Abstra	Sexual orientation, gender identity, and alcohol use: A multi-method analysis of developmental differences and key mechanisms	NIAAA	5F32AA030194-03	FREEMAN, ROBERT	BISHOP, MEG	UNIV OF MARYLAND, COLLEGE PARK	$76,047.00
419	Project Summ	Stigma Reduction and Gender Affirmation to Promote HIV Prevention/Testing in Trans Women	FIC	7R21TW012010-03	BANSAL, GEETHA PARTHASARATHY	OPERARIO, DON	EMORY UNIVERSITY	$75,000.00
420	ABSTRACT Th	The ADAR Summit Meeting	NIA	2R13AG066389-06	LUO, YUAN	LEVKOFF, SUE E	UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA	$74,959.00
421	The RCMI Pro	The RCMI Program in Health Disparities Research at Meharry Medical College	NIMHD	5U54MD007586-38	DAS, RINA	ADUNYAH, SAMUEL EVANS	MEHARRY MEDICAL COLLEGE	$72,750.00
422	PROJECT SUM	Development and Testing of MyPEEPS Mobile for Young Transgender Men	NIMH	5R34MH128163-03	GREENWOOD, GREGORY	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$72,743.00
423	SUMMARY/In t	Training the Long-Term Services and Supports Dementia Care Workforce in Provision of Care to Sexual and Gender Minority Residen	NIA	3R01AG075734-03S1	GERALD, MELISSA S	ROSSER, B R SIMON	UNIVERSITY OF MINNESOTA	$69,606.00
424	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$68,500.00
425	PROJECT SUM	SWG1: Sex & Gender Working Group	NIAID	5P30AI036219-28		CAMERON, CHERYL M	CASE WESTERN RESERVE UNIVERSITY	$66,771.00
426	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$66,666.00
427	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$66,666.00
428	PROJECT SUM	Population Sciences	NCI	5P30CA124435-16		JOHN, ESTHER M.	STANFORD UNIVERSITY	$66,651.00
429	PROJECT SUM	Adapting an evidence-based intervention to improve HIV testing and PrEP uptake among young men who have sex with m	FIC	1K43TW012850-01	BANSAL, GEETHA PARTHASARATHY	NGUYEN, MINH XUAN BINH	HANOI MEDICAL UNIVERSITY	$66,427.00
430	Project Summ	A culturally centered CBT protocol for suicidal ideation and suicide attempts among Latinx youth	NIMHD	3R01MD013907-05S1	DAGHER, RADA K	DUARTEVELEZ, YOVANSKA	EMMA PENDLETON BRADLEY HOSPITAL	$64,508.00
431	Project Abstra	Heavy cannabis use neurocognition and PrEP care engagement among young Black sexual minority men	NIDA	3R01DA057351-03S1	LAO, GUIFANG	SCHNEIDER, JOHN	UNIVERSITY OF CHICAGO	$62,320.00
432	PROJECT SUM	Community Engagement and Health Equity Core	NIDDK	5P30DK092949-14		PEEK, MONICA E	UNIVERSITY OF CHICAGO	$61,556.00
433	Severe inequi	ED2PrEP - patient focused low-burden strategies for PrEP uptake among emergency departments patients: a cross-over	NIAID	3R01AI169636-03S1	SHARMA, USHA K.	FELSEN, URIEL	ALBERT EINSTEIN COLLEGE OF MEDICINE	$57,967.00
434	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$56,700.00
435	PROJECT SUM	Substance use and DNA methylation at the intersection of sex and gender		5R01DA052016-04	LOSSIE, AMY C	FLENTJE, ANNESA	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$56,152.00
436	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
437	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
438	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
439	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
440	Project Abstra	Multi-Level Determinants of Sexual and Gender Minority Aging	NIA	5R36AG083386-02	NGUYEN, EMERALD THAI HAN	TRAN, NATHANIEL M	VANDERBILT UNIVERSITY	$51,650.00
441	PROJECT SUM	Dissecting the role of loneliness on substance use- and HIV-related outcomes among sexual minority men in the United	NIDA	1R36DA061635-01	DUNSTON, SHEBA KING	MARZIALI, MEGAN ELYSSA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$51,390.00
442	Project Summ	Biological Mechanisms of Suicidal Behavior among Sexual Minority Adolescents - Supplement	NIMH	3K01MH117142-05S1	BECHTHOLT, ANITA J	THOMA, BRIAN	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$50,941.00
443	PROJECT SUM	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality	NICHD	3R01HD109320-02S1	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$50,000.00
444	PROJECT SUM	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality	NICHD	3R01HD109320-02S1	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$50,000.00
445	PROJECT SUM	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality		5R01HD109320-02	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$50,000.00
446	Abstract The h	Structural Racism and Discrimination in Sexual and Gender Minority Health Inequities - Supplement	NIA	3R01AG077934-03S1	GERALD, MELISSA S	RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$50,000.00
447	Abstract The h	Structural Racism and Discrimination in Sexual and Gender Minority Health Inequities - Supplement	NIA	3R01AG077934-03S1	GERALD, MELISSA S	RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$50,000.00
448	Project Summ	Exploring the Role of Novel Aging-Focused Syndemic Conditions on HIV Risk and Quality of Life among HIV-Negative Old	NIDA	5R36DA058563-02	DUNSTON, SHEBA KING	WEINSTEIN, ELLIOTT ROYAL	UNIVERSITY OF MIAMI CORAL GABLES	$50,000.00
449	Despite an ar	Malaysian Implementation Science Training (MIST) Program in HIV	FIC	5D43TW011324-05	BANSAL, GEETHA PARTHASARATHY	ALTICE, FREDERICK LEWIS	YALE UNIVERSITY	$50,000.00
450	PROJECT ABS	Integrated Networks of Scholars in Global Health Research Training (INSIGHT)	FIC	5D43TW012274-03	HAYES, UNJA	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$50,000.00
451	Abstract Trans	Tcher Take Charge: Increasing PrEP Awareness Uptake and Adherence Through Health Care Empowerment and Address	NIMH	5R01MH128049-04		POLLARD-BRANCHARD, SUZY	PUBLIC HEALTH FOUNDATION ENTERPRISES	$50,000.00
452	In the United	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$50,000.00
453	In the United	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$50,000.00
454	PROJECT SUM	Effect of Medicaid Accountable Care Organizations on Behavioral Health Care Quality and Outcomes for Children	NIMH	3R01MH134176-02S1	HUMENSKY, JENNIFER	GOFF, SARAH L	UNIVERSITY OF MASSACHUSETTS AMHERST	$50,000.00
455	SUMMARY/AE	Kabawil: Adapting an Intervention to Reduce Intersectional Stigmas among Indigenous Sexual Minority Men and Traditional Healers	FIC	1R01TW012904-01		BANSAL, GEETHA PARTHASARATHY	UNIVERSITY OF WASHINGTON	$50,000.00
456	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$50,000.00
457	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$50,000.00
458	Project Summ	Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness / Implemen	NICHD	5UG1HD113160-02	RUSSO, DENISE	GAROFALO, ROBERT	NORTHWESTERN UNIVERSITY AT CHICAGO	$50,000.00
459	Project Summ	Dopamine Availability and Developmental Pathways of Adolescent Depression and Anhedonia - Administrative Supplement	NIMH	3R01MH127014-03S1	MURPHY, ERIC ROUSSEAU	FORBES, ERIKA E	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$50,000.00
460	ABSTRACT Ad	The role of circulating meta-inflammatory monocytes in adolescent insulin resistance	NIDDK	3R01DK130864-03S1	BASU, RAJATAVA	SINGER, KANAKADURGA	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$50,000.00
461	ABSTRACT Ad	The role of circulating meta-inflammatory monocytes in adolescent insulin resistance	NIDDK	3R01DK130864-03S1	BASU, RAJATAVA	SINGER, KANAKADURGA	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$49,999.00
462	Project Summ	Dopamine Availability and Developmental Pathways of Adolescent Depression and Anhedonia - Administrative Supplement	NIMH	3R01MH127014-03S1	MURPHY, ERIC ROUSSEAU	FORBES, ERIKA E	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$49,994.00
463	PROJECT SUM	Effect of Medicaid Accountable Care Organizations on Behavioral Health Care Quality and Outcomes for Children	NIMH	3R01MH134176-02S1	HUMENSKY, JENNIFER	GOFF, SARAH L	UNIVERSITY OF MASSACHUSETTS AMHERST	$49,974.00
464	PROJECT SUM	COVID-19 Administrative Supplement to K01: Adapting Pilot Testing a Behavioral Intervention to Incorporate Advances	NIMH	3K01MH116737-06S1	GREENWOOD, GREGORY	BUDHWANI, HENNA	FLORIDA STATE UNIVERSITY	$49,814.00
465	PROJECT SUM	Diversity in Practice: the Quest for Inclusion in Precision Medicine	NLM	5G13LM014176-03	YOON, SUNG SUG SUG	LEE, SANDRA SOO-JIN	COLUMBIA UNIVERSITY HEALTH SCIENCES	$49,795.00
466	Transgender a	Personal Healthcare Networks of Transgender and Gender-Diverse Adults After Gender-Affirming Surgery	NINR	1F31NR021239-01	WILLIS, LEIGH ANDREW	GAEDECKE, TYLER	COLUMBIA UNIVERSITY HEALTH SCIENCES	$48,974.00
467	Project Summ	Examining Proximal Associations between Minority Stress PTSD Symptoms and Alcohol Use among Bi+ College Students with Trau	NIAAA	1F31AA031420-01A1	KERRIDGE, BRADLEY TOWNSEND	BASTING, EVAN JACOB	UNIVERSITY OF TENNESSEE KNOXVILLE	$48,974.00
468	Proposal Sum	Interpersonal Protective Factors and Mental Health Symptom Self-Management Among Black Transgender Women: A Mixed-Metho	NINR	5F31NR020760-02	SEAY, JULIA SUSAN	KLEPPER, MEREDITH	JOHNS HOPKINS UNIVERSITY	$48,974.00
469	Sexual minori	Determining the role of discrimination in clinical presentation and treatment response among sexual minority people with OCD: A m	NIMH	1F31MH136729-01A1	SMITH, ASHLEY	BEZAHLER, ANDREAS	FORDHAM UNIVERSITY	$48,974.00
470	ABSTRACT Ad	Intergenerational and Cultural Drivers of Depressive Symptoms in Hispanic Sexual Minority Youth	NINR	1F31NR021243-01	SEAY, JULIA SUSAN	SCOTT, DALTON	UNIVERSITY OF MIAMI CORAL GABLES	$48,974.00
471	Project Summ	Post-Traumatic Stress and Alcohol Use as Mechanisms Explaining IPV Among Bisexual Women Who Disclose Sexual Violence to P	NIAAA	1F31AA031618-01	KERRIDGE, BRADLEY TOWNSEND	BOGEN, KATHERINE WELA	UNIVERSITY OF NEBRASKA LINCOLN	$48,974.00
472	PROJECT SUM	Aligning HIV services with gender diverse community priorities through person-centered care: a mixed methods study in	NIMH	1F31MH136856-01	ALLISON, SUSANNAH	KAPTCHUK, ROSE POLLARD	JOHNS HOPKINS UNIVERSITY	$48,974.00
473	Project Summ	Understanding Patient Level Implementation Determinants Related to Long-acting Injectable HIV Pre-Exposure Prophyl	NIMH	1F31MH134720-01A1	ALLISON, SUSANNAH	O'NEIL, ANDREW M	MEDICAL COLLEGE OF WISCONSIN	$48,974.00
474	PROPOSAL SU	Extending the Prevention Toolbox: Exploring the Acceptability and Impact of Long-acting Injectable PrEP among MSM in	NIMH	5F31MH135787-02	ALLISON, SUSANNAH	DHIR, AMIT "MICKEY"	JOHNS HOPKINS UNIVERSITY	$48,974.00
475	PROJECT SUM	Characterizing Economic Determinants of Violence and Safety Disparities Among Sexual and Gender Diverse Populations	NIMHD	1F31MD019985-01	JOHNSON, JARRETT AINSWORTH	KENNEDY, KATRINA	JOHNS HOPKINS UNIVERSITY	$48,974.00
476	PROJECT SUM	Epidemiological factors related to human monkeypox virus (MPOX) in men who have sex with men (MSM) in the United States	NIAID	1F31AI178878-01A1	CHUANG, ELEANORE JENNIFER	CARPINO, THOMAS	JOHNS HOPKINS UNIVERSITY	$48,974.00
477	PROJECT SUM	Prevention of Chlamydia trachomatis infections: Evaluation of vaccination and post-exposure prophylactic antibiotic use as popul	NIAID	1F31AI181431-01A1	CHUANG, ELEANORE JENNIFER	ZANE, GREGORY	UNIVERSITY OF WASHINGTON	$48,974.00
478	PROJECT SUM	Intersectionality Scientific Working Group	NIAID	5P30AI027763-33		SEVELIUS, JAE M.	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$48,541.00
479	PROJECT SUM	ICAP Clinical Trials Unit	NIAID	5UM1AI154468-05	GUBB, STEPHANIE MAJER		COLUMBIA UNIVERSITY HEALTH SCIENCES	$48,516.00
480	Project Summ	Employment as prevention: Adapting a structural intervention to achieve HIV equity among immigrant Latino MSM.	NIMH	1F31MH135828-01	ALLISON, SUSANNAH	JARAMILLO, JAHN	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$47,694.00
481	PA-21-151 UC	SOCIAL MEDICINE CASES FOR HEALTH EQUITY	NIMHD	1R13MD019531-01	JONES, NANCY LYNNE	HOLMES, SETH	UNIVERSITY OF CALIFORNIA BERKELEY	$47,451.00
482	Project Summ	Identifying Transdiagnostic Intervention Targets for PTSD-SUD Comorbidity in a Vulnerable Population: A Mixed-Method Study	NIDA	5R36DA058819-02	COLLIER KIDEMU, KEVA WONTORIA	LIAUTAUD, MADALYN MICHELE	HUNTER COLLEGE	$47,057.00
483	PROGRAM SU	Planning and Evaluation Core	NCI	5U54CA118638-19		RIVERS, DESIREE AVIA	MOREHOUSE SCHOOL OF MEDICINE	$46,707.00
484	Project Summ	The Use of Diversity: Managing Race and Representation in Law Politics and the Biosciences	NLM	5G13LM013533-03	YOON, SUNG SUG SUG	KAHN, JONATHAN	NORTHEASTERN UNIVERSITY	$46,437.00
485	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$45,400.00
486	PROJECT SUM	Understanding the Complex Reproductive Health Needs of Formerly Incarcerated Young Men	NICHD	5R21HD114341-02	POPKIN, RONNA	GEMMILL, ALISON	JOHNS HOPKINS UNIVERSITY	$43,519.00
487	PROJECT SUM	Exploring Acceptability & Potential Reach of Game-Based & Social Network Strategies for Improving PrEP & HIV Self-Tes	NIMH	1F31MH138212-01	ALLISON, SUSANNAH	CRAKER, LACEY	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$42,749.00
488	PROJECT SUM	Structural Stigma and Mental Health Among Transgender and Gender Diverse Adults Living in the Rural United States	NIMH	1F31MH139225-01	AVENILLA, FRANK	SIEBACH, KIRSTEN	JOHNS HOPKINS UNIVERSITY	$42,574.00
489	PROJECT SUM	Client and clinician priorities for same-day PrEP and DoxyPEP awareness uptake and persistence in primary care.	NINR	1F31NR021247-01	WILLIS, LEIGH ANDREW	ALBRIGHT, NATHANIEL	OHIO STATE UNIVERSITY	$42,104.00
490	Project Summ	Low Dose Computed Tomography (LDCT) Eligibility and Outcome differences between Sexual and Gender Minorities and their Sexu	NCI	5F31CA271474-02	VAHEDI, SHAHROOZ	ENGSTROM, CURTISS WAYNE	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$41,483.00
491	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00
492	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00
493	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00

	A	B	C	D	E	F	G	H
494	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00
495	PROJECT SUM	Applying Computational Phenotypes To Assess Mental Health Disorders Among Transgender Patients in the United States	NIMH	5F31MH132187-02	SWEENEY, MAGGIE	BELTRAN, THEO	UNIV OF NORTH CAROLINA CHAPEL HILL	$41,011.00
496	ABSTRACT/SU	Examining differential effects of state equality-promoting policies on harmful alcohol use among sexual and gender minority adults	NIAAA	5F31AA030722-02	BLOSS, GREGORY	TURNER, CAITLIN MARIE	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$40,956.00
497	PROGRAM SU	Planning and Evaluation Core	NCI	5U54CA118948-19		SCARINCI, ISABEL C	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$40,912.00
498	7. Project Sur	A Mixed Methods Study to Enhance Alcohol Treatment Help-seeking and Engagement Among Gender Diverse Adults	NIAAA	1F31AA031605-01	LITTEN, RAYE Z	COLGONIS, HANNAH ELISABETH	UNIVERSITY OF MEMPHIS	$40,769.00
499	PROJECT SUM	Social safety as a novel mechanism of risk for problematic substance use among sexual and gender minority youth	NIDA	1F31DA062473-01	DUNSTON, SHEBA KING	HAIK, AMANDA	UNIV OF NORTH CAROLINA CHAPEL HILL	$40,441.00
500	PROJECT SUM	Identifying preferences for receiving HIV prevention services among GBMSMs and for providing HIV prevention services	NIMH	5F31MH133472-02	ALLISON, SUSANNAH	RODRIGUEZ, CHRISTOFER ALFREDO	FLORIDA INTERNATIONAL UNIVERSITY	$39,535.00
501	This project w	HPV related cancers in HIV populations	NCI	1ZIACP101238-03		WENTZENSEN, NICOLAS	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS	$39,221.00
502	PROJECT SUM	Minority Stress Stimulant Use and HIV among Sexual Minority Men: A Biopsychosocial Approach	NIDA	5F31DA059345-02	BABECKI, BETH	MILLER-PERUSSE, MICHAEL JOSEPH	SAN DIEGO STATE UNIVERSITY	$38,984.00
503	Project Sumr	SWG 10: Health Equity	NIAID	5P30AI027757-37		ORELLANA, EDWIN ROBERTO	UNIVERSITY OF WASHINGTON	$36,692.00
504	ABSTRACTAge	SilverBills: A Legal Technical and Financial Tool for Aging LGBTQ+ Individuals with Impaired Cognition.	NIA	3R44AG080843-02S1	PLUDE, DANA JEFFREY	LOBEL-ESRIG, MARCI	SILVERBILLS INC.	$35,000.00
505	Transgender i	Cross Sex Steroid Therapy and Cardiovascular Risk in the Transgender Female	NHLBI	5F31HL172648-02	HUANG, LI-SHIN	CRUDUP, BRELAND	UNIVERSITY OF MISSISSIPPI MED CTR	$32,974.00
506	Project Sumr	Assessing the burden of dementia in transgender populations	NHLBI	3K01HL151902-04S1	COADY, SEAN	STREED, CARL G	BOSTON MEDICAL CENTER	$31,691.00
507	PROJECT SUM	HIV risk messaging and medical mistrust in the era of Undetectable=Untransmittable: Psychosocial and Behavioral Impl	NIMH	1F31MH139392-01	ALLISON, SUSANNAH	KALWICZ, DAVID	GEORGE WASHINGTON UNIVERSITY	$30,000.00
508	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	1R13HL173969-01	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$30,000.00
509	PROJECT SUM	Scientific Working Group	NIAID	5P30AI117943-10		PHILLIPS, GREGORY L.	NORTHWESTERN UNIVERSITY AT CHICAGO	$28,491.00
510	SUMMARY Su	Organization for the Study of Sex Differences Annual Meeting	NIA	5R13AG056135-08	WILLIAMS, JOHN	ARNOLD, ARTHUR P	UNIVERSITY OF CALIFORNIA LOS ANGELES	$24,975.00
511	POPULATION	Population Studies and Disparities Research	NCI	5P30CA022453-43		BEEBE-DIMMER, JENNIFER L	WAYNE STATE UNIVERSITY	$20,571.00
512	From both NIH	Enhancing Diversity Equity and Inclusion in Mental Health Research: American Psychopathological Association Annual Meetings	NIMH	1R13MH136663-01	MEZA-CERVERA, TATIANA	LEWIS-FERNANDEZ, ROBERTO	NEW YORK STATE PSYCHIATRIC INSTITUTE	$20,000.00
513	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	1R13HL173969-01	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$20,000.00
514	PROJECT SUM	HIV risk messaging and medical mistrust in the era of Undetectable=Untransmittable: Psychosocial and Behavioral Impl	NIMH	1F31MH139392-01	ALLISON, SUSANNAH	KALWICZ, DAVID	GEORGE WASHINGTON UNIVERSITY	$18,974.00
515	AbstractDive	Building Up	NIGMS	3U01GM132133-05S1	GAMMIE, ALISON	RUBIO, DORIS M	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$15,758.00
516	AbstractDive	Building Up	NIGMS	3U01GM132133-05S2	GAMMIE, ALISON	RUBIO, DORIS M	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$15,758.00
517	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	1R13HL173969-01	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$15,000.00
518	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	3R13HL173969-01S1	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$14,300.00
519	PROJECT SUM	Biomedical Prevention Scientific Working Group	NIAID	5P30AI064518-20		MCKELLAR, MEHRI S	DUKE UNIVERSITY	$11,307.00
520	Project Sumr	Be Curious Not Judgmental: The 4th National Symposium on Sexual Behavior of Youth	NICHD	1R13HD117635-01	GILBERT, LEAH KAYE	SILOVSKY, JANE FRANCES	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$10,000.00
521	PROJECT SUM	Boston University Conference on Language Development 2022-2026	NICHD	5R13HD090968-09	SALO, VIRGINIA CHARLOTTE	CHANG, CHARLES BOND	BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)	$10,000.00
522	From both NIH	Enhancing Diversity Equity and Inclusion in Mental Health Research: American Psychopathological Association Annual Meetings	NIMH	1R13MH136663-01	MEZA-CERVERA, TATIANA	LEWIS-FERNANDEZ, ROBERTO	NEW YORK STATE PSYCHIATRIC INSTITUTE	$10,000.00
523	PROJECT SUM	2025 Cardiac Arrhythmia Mechanisms Gordon Research Conference and Gordon Research Seminar	NHLBI	1R13HL177880-01	TJURMINA, OLGA A.	RIPPLINGER, CRYSTAL MAY	GORDON RESEARCH CONFERENCES	$5,000.00
524	SUMMARYPar	2025 Sex Differences in Immunity Gordon Research Conference and Gordon Research Seminar	NIAID	1R13AI188929-01	BARTELS, ADELINA EWURA-ABENA	OFOTOKUN, IGHOVWERHA	GORDON RESEARCH CONFERENCES	$3,100.00
525	Men who have	Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex with Men	NIAID	5U01AI156874-04	ZIMAND, LORI B.		NORTHWESTERN UNIVERSITY AT CHICAGO	$2,184.00
526	PROJECT SUM	TRANSforma Tu Salud Dejando de Fumar: Advancing smoking cessation among transgender individuals		1R21CA284313-01	PEARLMAN, PAUL C	CARTUJANO, FRANCISCO	UNIVERSITY OF ROCHESTER	$2,000.00
527	PROJECT SUM	SHINE Strong: Building the pipeline of HIV behavioral scientists with expertise in trans population health	NIMH	5R25MH119858-05	ALLISON, SUSANNAH	MCFARLAND, WILLIAM	PUBLIC HEALTH FOUNDATION ENTERPRISES	$1.00
528	Project Abstra	Enhancing dissemination and career development in sex and gender translational science in alcohol use	NIAAA	5R13AA031402-02	BALACHOVA, TATIANA NIKOLAYEVNA	MCKEE, SHERRY ANN	YALE UNIVERSITY	$1.00
529	Project Sumr	FINISHING HIV: An EHE model for Latinos Integrating One-Stop-Shop PrEP Services a Social Network Support Program a	NIAID	5R01AI169643-03	DEJLI, JAMAL	KANAMORI NISHIMURA, MARIANO JUAN	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$1.00
530	ABSTRACT | F	Pilot Project 1: Testing the effectiveness of an intervention to foster cervical cancer screening promotion for Latinx trans men among	NCI	5U54CA163068-12		SCHABATH, MATTHEW B.	H. LEE MOFFITT CANCER CTR & RES INST	$0.00
531	ABSTRACT | F	Fostering Cervical Cancer Screening Promotion for Latinx Trans Men Among Medical Students	NCI	5U54CA163071-12		RAMOS-PIBERNUS, ALIXIDA G	PONCE SCHOOL OF MEDICINE	$0.00

PDF COPY OF NIH_GRANTS_002564
NATIVE FILE PROVIDED TO COURT

	OPDIV	CFDA Number	CFDA Name	Document Number	Award Number	Grant	BAC	Statute Name	Statute Order	Recipient Organization Name	UEI	EIN	City	State	Zip	Authorized Amount	Weekly Outlays	Weekly Outlay Percentage	Drawdowns Amount	Cumulative Outlay Percentage	Remaining Balance	Period of Performance Start Date	Period of Performance End Date	Drawdowns	FFR Type	FFR Period End Date	FFR Review Status	FFR Unobligated Balance
2	NIH	93-855	Allergy and Infectious Diseases Research	GAI174708AC6	G20AI174708	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		SUNY STONY BROOK		1146013200F7	STONY BROOK	NY	11794	$2 933 079.00	0		$454 727.27	15.50%	$2 478 352	9/16/22	2/28/25	Organizations with drawdowns	Final	2/28/25	Available/Draft	
3	NIH	93-855	Allergy and Infectious Diseases Research	GAI174728AC6	G20AI174728	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF NEBRASKA MEDICAL CENTER	G15AG3BLLMH4	1470049123A6	OMAHA	NE	68198	$3 906 967.00	0		$2 339 945.00	59.89%	$1 567 022	9/16/22	2/28/25	Organizations with drawdowns	Final	2/28/25	Available/Draft	
4	NIH	93-855	Allergy and Infectious Diseases Research	GAI174740AC6	G20AI174740	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		SCRIPPS RESEARCH INSTITUTE	PHZJFZ32NKH4	1330435954A1	LA JOLLA	CA	92037	$3 869 562.00	0		$3 465 552.53	89.56%	$404 009	9/16/22	2/28/25	Organizations with drawdowns	Final	2/28/25	Available/Draft	
5	NIH	93-855	Allergy and Infectious Diseases Research	OHL156812AC5	OT2HL156812	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		RESEARCH TRIANGLE INSTITUTE	JJHCMK4NT5N3	1560686338A1	RSCH TRIANGLE PK	NC	27709	$37 709 210.00	0		$19 406 981.01	51.46%	$18 302 229	6/15/20	2/28/25	Organizations with drawdowns	Final	2/28/25	Available/Draft	
6	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	OHL156812AC3	OT2HL156812	O	CARES Act funding (P.L. 116-136) C3""	3		RESEARCH TRIANGLE INSTITUTE	JJHCMK4NT5N3	1560686338A1	RSCH TRIANGLE PK	NC	27709	$716 790 486.00	0		$288 091 694.51	40.19%	$428 698 791	6/15/20	12/31/26	Organizations with drawdowns	Final	12/31/26	Available/Draft	
7	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	OHL156812AC6	OT2HL156812	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		RESEARCH TRIANGLE INSTITUTE	JJHCMK4NT5N3	1560686338A1	RSCH TRIANGLE PK	NC	27709	$171 499 647.00	0		$59 035 115.62	34.42%	$112 464 531	6/15/20	2/28/25	Organizations with drawdowns	Final	2/28/25	Available/Draft	
8	NIH	93-855	Allergy and Infectious Diseases Research	OHL158287ACV	OT2HL158287	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		WESTAT INC	NVUWAFWQ57S5	1840529566A2	ROCKVILLE	MD	20850	$4 000 000.00			$0.00		$4 000 000	9/25/20	9/30/25	Organizations without drawdowns	Final	9/30/25	Available/Draft	
9	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	OHL161847AC6	OT2HL161847	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		NEW YORK UNIVERSITY MEDICAL CENTER		1135562309A1	NEW YORK	NY	10016	$33 203 136.00	62757.77	0.19%	$19 236 144.40	57.93%	$13 966 992	5/24/22	5/23/25	Organizations with drawdowns	Final	5/23/25	Available/Draft	
10	NIH	93-855	Allergy and Infectious Diseases Research	PAI158571AC3	P01AI158571	O	CARES Act funding (P.L. 116-136) C3""	3		Duke University	TP7EK8DZV6N5	1560532129A1	Durham	NC	277084677	$10 478 045.00	265160.42	2.53%	$3 572 008.37	34.09%	$6 906 037	9/16/21	8/31/25	Organizations with drawdowns				
11	NIH	93-855	Allergy and Infectious Diseases Research	PAI158571AC6	P01AI158571	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		Duke University	TP7EK8DZV6N5	1560532129A1	Durham	NC	277084677	$17 521 953.00	7901.85	0.05%	$16 911 285.37	96.51%	$610 668	9/16/21	8/31/25	Organizations with drawdowns				
12	NIH	93-855	Allergy and Infectious Diseases Research	PAI165072AC3	P01AI165072	O	CARES Act funding (P.L. 116-136) C3""	3		BRIGHAM & WOMEN`S HOSPITAL	QN6MS4VN7BD1	1042312909A1	BOSTON	MA	2115	$7 828 320.00	0		$399 833.55	5.11%	$7 428 486	9/16/21	8/31/25	Organizations with drawdowns				
13	NIH	93-855	Allergy and Infectious Diseases Research	PAI165072AC6	P01AI165072	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		BRIGHAM & WOMEN`S HOSPITAL	QN6MS4VN7BD1	1042312909A1	BOSTON	MA	2115	$11 809 995.00	740.85	0.01%	$11 402 533.77	96.55%	$407 461	9/16/21	8/31/25	Organizations with drawdowns				
14	NIH	93-855	Allergy and Infectious Diseases Research	PAI165075ACV	P01AI165075	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		ROCKEFELLER UNIVERSITY		1131624158A1	NEW YORK	NY	10021	$4 259 011.00	1895.37	0.04%	$1 858 158.46	43.63%	$2 400 853	1/3/22	12/31/24	Organizations with drawdowns	Final	12/31/24	Available/Draft	
15	NIH	93-855	Allergy and Infectious Diseases Research	PAI165075AC6	P01AI165075	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		ROCKEFELLER UNIVERSITY		1131624158A1	NEW YORK	NY	10021	$6 423 268.00	0		$6 078 232.72	94.63%	$345 035	1/3/22	12/31/24	Organizations with drawdowns	Final	12/31/24	Available/Draft	
16	NIH	93-855	Allergy and Infectious Diseases Research	PAI165077ACV	P01AI165077	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		UNIVERSITY OF WISCONSIN SYSTEM/BOARD OF REGENTS	LCLSJAGTNZQ7	1396006492A1	MADISON	WI	53715	$4 618 169.00			$0.00		$4 618 169	9/16/21	8/31/25	Organizations without drawdowns				
17	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	PES023513BC6	P30ES023513	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF CALIFORNIA	TX2DAGQPENZ5	1946036494A1	DAVIS	CA	95618	$1 528 426.00	0		$1 415 307.93	92.60%	$113 118	9/17/21	3/31/24	Organizations with drawdowns	Annual	3/31/24	Certified/Pending Agency Approval	
18	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	PDA048756AC6	P50DA048756	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF OREGON	Z3FGN9MF92U2	1464727800A1	EUGENE	OR	97403	$2 564 647.00	0		$957 480.42	37.33%	$1 607 167	9/15/21	6/30/25	Organizations with drawdowns	Annual	6/30/23	Agency Approved	
19	NIH	93-855	Allergy and Infectious Diseases Research	POD011092KC3	P51OD011092	O	CARES Act funding (P.L. 116-136) C3""	3		OREGON HEALTH & SCIENCE UNIVERSITY	NPSNT86JKN51	1931176109A1	PORTLAND	OR	972013098	$999 999.00	0		$98 189.00	9.82%	$901 810	5/1/21	7/31/24	Organizations with drawdowns	Annual	4/30/25	Certified/Pending Agency Approval	
20	NIH	93-855	Allergy and Infectious Diseases Research	POD011104MCV	P51OD011104	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		TULANE UNIVERSITY DELTA REGIONAL PRIMATE CENTER		1720423889A5	COVINGTON	LA	70433	$2 396 052.00	0		$1 530 545.83	63.88%	$865 506	5/31/23	4/30/24	Organizations with drawdowns	Annual	4/30/24	Certified/Pending Agency Approval	
21	NIH	93-855	Allergy and Infectious Diseases Research	POD011107LCV	P51OD011107	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		UNIVERSITY OF CALIFORNIA	TX2DAGQPENZ5	1946036494A1	DAVIS	CA	95618	$3 069 950.00	0		$941 323.58	30.66%	$2 128 626	5/31/23	4/30/24	Organizations with drawdowns	Annual	4/30/24	Certified/Pending Agency Approval	
22	NIH	93-855	Allergy and Infectious Diseases Research	POD011107KC3	P51OD011107	O	CARES Act funding (P.L. 116-136) C3""	3		UNIVERSITY OF CALIFORNIA	TX2DAGQPENZ5	1946036494A1	DAVIS	CA	95618	$5 654 777.00	0		$4 879 998.16	86.30%	$774 779	8/1/20	4/30/23	Organizations with drawdowns	Final	4/30/23	Certified/Pending Agency Approval	
23	NIH	93-855	Allergy and Infectious Diseases Research	RAI143875ACV	R01AI143875	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$6 662 234.00	0		$6 534 900.51	98.09%	$127 333	5/27/20	12/31/23	Organizations with drawdowns	Final	12/31/23	Rejected by Agency	
24	NIH	93-855	Allergy and Infectious Diseases Research	RAI153087ACV	R01AI153087	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		SEATTLE CHILDREN`S HOSPITAL	SZ32VTCXM799	1910564748A1	SEATTLE	WA	98105	$2 918 031.00	4618.32	0.16%	$2 159 050.10	73.99%	$758 981	6/4/20	5/31/25	Organizations with drawdowns	Final	5/31/25	Available/Draft	
25	NIH	93-855	Allergy and Infectious Diseases Research	RAI157253AC3	R01AI157253	O	CARES Act funding (P.L. 116-136) C3""	3		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	D3LHU66KBLD5	1566001393A1	CHAPEL HILL	NC	27599	$3 812 960.00	39702.44	1.04%	$3 495 839.21	91.68%	$317 121	9/25/20	8/31/25	Organizations with drawdowns				
26	NIH	93-855	Allergy and Infectious Diseases Research	RAI157488ACV	R01AI157488	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		YALE UNIVERSITY	FL6GV84CKN57	1060646973A1	NEW HAVEN	CT	65208047	$1 671 288.00	0		$1 399 401.34	83.73%	$271 887	7/24/20	6/30/24	Organizations with drawdowns	Final	6/30/24	Certified/Pending Agency Approval	
27	NIH	93-855	Allergy and Infectious Diseases Research	RAI158060BC3	R01AI158060	O	CARES Act funding (P.L. 116-136) C3""	3		UNIVERSITY OF CALIFORNIA IRVINE	MJC5FCYQTPE6	1952226406A1	IRVINE	CA	926971050	$727 670.00	1126.12	0.15%	$194 705.79	26.76%	$532 964	8/1/24	7/31/25	Organizations with drawdowns				
28	NIH	93-855	Allergy and Infectious Diseases Research	RAI158177ACV	R01AI158177	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		PURDUE UNIVERSITY	YRXVL4JYCEF5	1356002041A1	WEST LAFAYETTE	IN	479072040	$3 099 128.00	10437.93	0.34%	$2 747 946.46	88.67%	$351 182	8/11/20	7/31/25	Organizations with drawdowns				
29	NIH	93-855	Allergy and Infectious Diseases Research	RAI158463ACV	R01AI158463	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		UNIVERSITY OF WISCONSIN SYSTEM/BOARD OF REGENTS	LCLSJAGTNZQ7	1396006492A1	MADISON	WI	53715	$1 738 787.00	0		$1 575 848.92	90.63%	$162 938	8/5/20	7/31/25	Organizations with drawdowns				
30	NIH	93-855	Allergy and Infectious Diseases Research	RAI158775BC6	R01AI158775	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		RUTGERS THE STATE UNIVERSITY OF NEW JERSEY	YVVTQD8CJC79	1226001086A1	NEWARK	NJ	7107	$1 864 117.00	-55765.29		$1 573 961.77	84.43%	$290 155	1/4/22	7/31/25	Organizations with drawdowns	Annual	7/31/23	Agency Approved	
31	NIH	93-855	Allergy and Infectious Diseases Research	RAI161374AC6	R01AI161374	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		WASHINGTON UNIVERSITY	L6NFUM28LQM5	1430653611A1	SAINT LOUIS	MO	631121408	$1 955 860.00	15166.09	0.78%	$1 813 574.62	92.73%	$142 285	8/1/21	7/31/25	Organizations with drawdowns				
32	NIH	93-855	Allergy and Infectious Diseases Research	RAI161570AC6	R01AI161570	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$1 332 148.00	0		$1 152 656.27	86.53%	$179 492	8/19/21	7/31/23	Organizations with drawdowns	Final	7/31/23	Agency Approved	
33	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RAI169543AC3	R01AI169543	O	CARES Act funding (P.L. 116-136) C3""	3		KECK GRADUATE INSTITUTE OF APPLIED LIFE SCIENCES	GJLMWYFPMQZ7	1954625327A1	CLAREMONT	CA	91711	$3 071 572.00	0		$2 696 793.78	87.80%	$374 778	9/16/21	8/31/25	Organizations with drawdowns				
34	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RAR065493CC6	R01AR065493	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		TULANE UNIVERSITY SCHOOL OF MEDICINE		1720423889A2	NEW ORLEANS	LA	701185698	$1 370 464.00	8833.47	0.64%	$1 064 411.57	77.67%	$306 052	9/17/21	6/30/25	Organizations with drawdowns	Final	8/31/24	Available/Draft	
35	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RDE031927AC3	R01DE031927	O	CARES Act funding (P.L. 116-136) C3""	3		GENENDEAVOR LLC	JEBNJ8Y5T955	1272130385A1	FREMONT	CA	945395628	$4 504 502.00	51980.37	1.15%	$3 750 620.52	83.26%	$753 881	9/20/21	8/31/25	Organizations with drawdowns				
36	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RDK122843AC5	R01DK122843	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		OREGON HEALTH & SCIENCE UNIVERSITY	NPSNT86JKN51	1931176109A1	PORTLAND	OR	972013098	$1 286 550.00	0		$1 021 864.62	79.43%	$264 685	7/1/23	6/30/25	Organizations with drawdowns				
37	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RDK132735AC3	R01DK132735	O	CARES Act funding (P.L. 116-136) C3""	3		UNIVERSITY OF CALIFORNIA-LOS ANGELES BOARD OF REGENTS	RN64EPNH8JC6	1956006143A1	LOS ANGELES	CA	90095	$6 015 134.00	0		$4 027 523.47	66.96%	$1 987 611	9/17/21	8/31/25	Organizations with drawdowns				
38	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RHL163814BC3	R01HL163814	O	CARES Act funding (P.L. 116-136) C3""	3		BRIGHAM & WOMEN`S HOSPITAL	QN6MS4VN7BD1	1042312909A1	BOSTON	MA	2115	$3 672 336.00	91638.08	2.50%	$1 579 253.80	43.00%	$2 093 082	4/5/24	8/31/25	Organizations with drawdowns				
39	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RMD016526AC6	R01MD016526	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		WASHINGTON STATE UNIVERSITY	XRJSGX384TD6	1916001108A1	PULLMAN	WA	991640001	$1 442 425.00	1406.56	0.10%	$1 045 985.14	72.52%	$396 440	12/1/21	5/31/25	Organizations with drawdowns	Final	5/31/25	Available/Draft	
40	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	RMH125737AC6	R01MH125737	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		YALE UNIVERSITY	FL6GV84CKN57	1060646973A1	NEW HAVEN	CT	65208047	$1 933 875.00	0		$1 367 543.47	70.72%	$566 332	8/4/22	2/29/24	Organizations with drawdowns	Final	2/29/24	Certified/Pending Agency Approval	
41	NIH	93-855	Allergy and Infectious Diseases Research	RAI161501ACV	R21AI161501	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		UNIVERSITY OF MARYLAND	NPU8ULVAAS23	1520710851A1	COLLEGE PARK	MD	207423141	$414 425.00	0		$287 259.91	69.32%	$127 165	7/15/22	6/30/25	Organizations with drawdowns	Final	6/30/25	Certified/Pending Agency Approval	
42	NIH	93-855	Allergy and Infectious Diseases Research	RAI120942BC3	R24AI120942	O	CARES Act funding (P.L. 116-136) C3""	3		UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	MSPWVMXXMN76	1746000949A1	GALVESTON	TX	77550	$4 078 198.87	24948.87	0.61%	$2 935 478.98	71.98%	$1 142 720	4/12/21	3/31/26	Organizations with drawdowns	Annual	3/31/23	Available/Draft	
43	NIH	93-855	Allergy and Infectious Diseases Research	RAI186400AC3	R56AI186400	O	CARES Act funding (P.L. 116-136) C3""	3		REGENTS OF THE UNIVERSITY OF COLORADO THE	MW8JHK6ZYEX8	1846000555A7	Aurora	CO	800452571	$726 000.00	1409.85	0.19%	$177 860.02	24.50%	$548 140	8/20/24	7/31/25	Organizations with drawdowns				
44	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	SGM127983AC6	S06GM127983	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		THE CHEROKEE NATION	TBAHL1WANLF3	1730757033A1	TAHLEQUAH	OK	74464	$1 317 488.00	0		$351 917.92	26.71%	$965 570	9/1/22	9/30/25	Organizations with drawdowns	Final	9/30/25	Certified/Pending Agency Approval	
45	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	SGM127983AC4	S06GM127983	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		THE CHEROKEE NATION	TBAHL1WANLF3	1730757033A1	TAHLEQUAH	OK	74464	$2 906 085.00	0		$2 623 205.97	90.27%	$282 879	9/23/20	6/30/25	Organizations with drawdowns	Final	6/30/25	Certified/Pending Agency Approval	
46	NIH	93-855	Allergy and Infectious Diseases Research	UAI138897AC5	U01AI138897	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		JOHNS HOPKINS UNIVERSITY	FTMTDMBR29C7	1520595110A5	BALTIMORE	MD	21218	$13 641 821.00	29149.2	0.21%	$12 773 646.32	93.64%	$868 175	9/1/21	7/31/25	Organizations with drawdowns	Annual	11/30/22	Agency Approved	
47	NIH	93-855	Allergy and Infectious Diseases Research	UAI167892AC3	U01AI167892	O	CARES Act funding (P.L. 116-136) C3""	3		La Jolla Institute For Immunology	ZPAUY3FQMM26	1330328688A1	La Jolla	CA	920371387	$469 233.00	0		$128 678.02	27.42%	$340 555	5/16/24	3/31/25	Organizations with drawdowns	Final	3/31/25	Available/Draft	
48	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260462BC4	U01CA260462	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		UNIVERSITY OF ALABAMA AT BIRMINGHAM	YND4PLMC9AN7	1636005396A6	BIRMINGHAM	AL	352940111	$1 512 103.00	0		$404 750.43	26.77%	$1 107 353	6/1/23	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
49	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260469BC4	U01CA260469	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		MICHIGAN STATE UNIVERSITY	R28EKN92ZTZ9	1386005984A1	EAST LANSING	MI	48824	$964 759.00	30327.5	3.14%	$694 015.38	71.94%	$270 744	6/1/23	8/31/25	Organizations with drawdowns				
50	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260476BC4	U01CA260476	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		BETH ISRAEL HOSPITAL		1042103881A1	BOSTON	MA	2115	$897 731.00	0		$520 558.97	57.99%	$377 172	6/1/23	8/31/25	Organizations with drawdowns				
51	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260507BC4	U01CA260507	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		YALE UNIVERSITY	FL6GV84CKN57	1060646973A1	NEW HAVEN	CT	65208047	$1 137 992.00	1492.43	0.13%	$823 655.68	72.38%	$314 336	6/1/23	8/31/25	Organizations with drawdowns				
52	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260508BC4	U01CA260508	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		HEALTH RESEARCH INC.	G9H6SUM59YC4	1141402155A1	MENANDS	NY	12204	$840 583.29	12782.26	1.52%	$382 629.08	45.52%	$457 954	6/1/23	8/31/25	Organizations with drawdowns				
53	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260513BC4	U01CA260513	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		CASE WESTERN RESERVE UNIVERSITY	HJMKEF7EJW69	1341018992A1	CLEVELAND	OH	44106	$806 907.00	8181.56	1.01%	$508 224.20	62.98%	$298 683	6/1/23	8/31/25	Organizations with drawdowns				
54	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260526BC4	U01CA260526	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		UNIVERSITY OF ARKANSAS SYSTEM	VDFYLZPJEAV6	1716046242A1	Little Rock	AR	722057101	$1 269 547.69	0		$726 639.44	57.24%	$542 908	6/1/23	2/28/25	Organizations with drawdowns	Final	2/28/25	Available/Draft	
55	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260584BC4	U01CA260584	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		KAISER FOUNDATION RESEARCH INSTITUTE	P1RTMASB37B5	1941105628A1	OAKLAND	CA	946123433	$1 014 171.00	34895.8	3.44%	$386 021.94	38.06%	$628 149	6/1/23	8/31/25	Organizations with drawdowns				
56	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260588BC4	U01CA260588	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		La Jolla Institute For Immunology	ZPAUY3FQMM26	1330328688A1	La Jolla	CA	920371387	$1 130 292.00	0		$990 959.86	87.67%	$139 332	6/1/23	8/31/25	Organizations with drawdowns				
57	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA261277BC4	U01CA261277	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		HARVARD UNIVERSITY SCHOOL OF PUBLIC HEALTH	UNVDZNFA8R29	1042103580A6	BOSTON	MA	2115	$1 844 641.46	23765.85	1.29%	$1 094 037.19	59.31%	$750 604	6/1/23	9/29/25	Organizations with drawdowns				
58	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA271329AC6	U01CA271329	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF VERMONT	Z94KLERAGSV9	1030179440A1	BURLINGTON	VT	5405	$1 228 640.00	0		$1 013 247.10	82.47%	$215 393	1/18/22	12/31/24	Organizations with drawdowns	Final	12/31/24	Available/Draft	
59	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UDA040381AC6	U01DA040381	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		FLORIDA INTERNATIONAL UNIVERSITY	Q3KCVK5S9CP1	1650177616A1	MIAMI	FL	33199	$996 839.06	8534.43	0.86%	$859 343.02	86.21%	$137 496	9/30/20	7/31/25	Organizations with drawdowns				
60	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UDA053903AC6	U01DA053903	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION THE	H1HYA8Z1NTM5	1616033693C4	LEXINGTON	KY	40526	$1 546 299.00	-122.68		$1 409 773.74	91.17%	$136 525	6/1/22	5/31/25	Organizations with drawdowns	Final	5/31/25	Available/Draft	
61	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UDA057849AC4	U01DA057849	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		UNIVERSITY OF OREGON	Z3FGN9MF92U2	1464727800A1	EUGENE	OR	97403	$997 902.00	440.71	0.04%	$402 040.84	40.29%	$595 861	6/1/23	5/31/25	Organizations with drawdowns	Final	5/31/25	Available/Draft	
62	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UDK132737AC6	U01DK132737	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$2 146 671.00	0		$1 814 729.55	84.54%	$331 941	1/7/22	12/31/24	Organizations with drawdowns	Final	12/31/24	Available/Draft	
63	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UMD017412AC6	U01MD017412	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		JOHNS HOPKINS UNIVERSITY	FTMTDMBR29C7	1520595110A5	BALTIMORE	MD	21218	$2 444 726.00	8352.59	0.34%	$1 915 278.09	78.34%	$529 448	1/1/22	11/30/25	Organizations with drawdowns	Annual	11/30/22	Agency Approved	
64	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UMD017415AC6	U01MD017415	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE	YXJGGNC5J269	1481108830A3	KANSAS CITY	KS	66160	$2 458 129.00	0		$2 332 441.95	94.89%	$125 687	1/1/22	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
65	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UMD017426AC6	U01MD017426	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF PUERTO RICO - MEDICAL SCIENCE CAMPUS	KWTAB1GYM4L9	1660433762A6	SAN JUAN	PR	936	$2 091 295.00	0		$1 727 297.75	82.59%	$363 997	1/1/22	11/30/25	Organizations with drawdowns	Annual	11/30/22	Agency Approved	
66	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UMD017434AC6	U01MD017434	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		THE UNIVERSITY CORPORATION		1951992732A1	NORTHRIDGE	CA	91330	$1 044 049.00	1547.26	0.15%	$862 247.08	82.59%	$181 802	1/1/22	5/31/25	Organizations with drawdowns	Final	5/31/25	Available/Draft	
67	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UTR003780BC6	U18TR003780	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		JOHNS HOPKINS UNIVERSITY	FTMTDMBR29C7	1520595110A1	BALTIMORE	MD	21218	$1 228 745.00	3861.29	0.31%	$1 032 739.96	84.05%	$196 005	3/11/22	2/28/25	Organizations with drawdowns	Final	2/28/25	Available/Draft	
68	NIH	93-855	Allergy and Infectious Diseases Research	UAI089992BCV	U19AI089992	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		YALE UNIVERSITY	FL6GV84CKN57	1060646973A1	NEW HAVEN	CT	65208047	$7 002 260.00	25615.45	0.37%	$6 801 748.90	97.14%	$200 511	5/14/20	11/30/23	Organizations with drawdowns	Annual	11/30/23	Certified/Pending Agency Approval	
69	NIH	93-855	Allergy and Infectious Diseases Research	UAI110483BC5	U19AI110483	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$26 794 157.00	0		$26 133 076.24	97.53%	$661 081	8/27/21	4/30/24	Organizations with drawdowns	Final	4/30/24	Certified/Pending Agency Approval	
70	NIH	93-855	Allergy and Infectious Diseases Research	UAI171110AC6	U19AI171110	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF CALIFORNIA-SAN FRANCISCO	KMH5K9V7S518	1946036493A6	SAN FRANCISCO	CA	94143	$67 452 049.00	0		$55 104 444.72	81.69%	$12 347 604	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
71	NIH	93-855	Allergy and Infectious Diseases Research	UAI171292AC6	U19AI171292	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	D3LHU66KBLD5	1566001393A1	CHAPEL HILL	NC	27599	$65 483 194.00	545436.59	0.83%	$46 964 220.22	71.72%	$18 518 974	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
72	NIH	93-855	Allergy and Infectious Diseases Research	UAI171399AC6	U19AI171399	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH	KUKXRCZ6NZC2	1131624182A1	NEW YORK	NY	10021	$67 673 902.00	1126561.72	1.66%	$45 546 894.42	67.30%	$22 127 008	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
73	NIH	93-855	Allergy and Infectious Diseases Research	UAI171401AC6	U19AI171401	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		HACKENSACK MEDICAL CENTER		1221487576A1	HACKENSACK	NJ	7601	$65 141 731.00	0		$48 707 592.25	74.77%	$16 434 139	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
74	NIH	93-855	Allergy and Infectious Diseases Research	UAI171403AC6	U19AI171403	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$51 914 880.00	467106.8	0.90%	$33 562 058.42	64.65%	$18 352 822	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
75	NIH	93-855	Allergy and Infectious Diseases Research	UAI171413ACV	U19AI171413	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	MSPWVMXXMN76	1746000949A1	GALVESTON	TX	77550	$18 849 015.00			$0.00		$18 849 015	5/16/22	4/30/25	Organizations without drawdowns	Final	4/30/25	Available/Draft	
76	NIH	93-855	Allergy and Infectious Diseases Research	UAI171413AC6	U19AI171413	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	MSPWVMXXMN76	1746000949A1	GALVESTON	TX	77550	$56 163 625.00	90541.78	0.16%	$38 848 830.78	69.17%	$17 314 794	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
77	NIH	93-855	Allergy and Infectious Diseases Research	UAI171421AC6	U19AI171421	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		STANFORD UNIVERSITY	HJD6G4D6TJY5	1941156365A1	STANFORD	CA	943056215	$69 058 677.00	739906.72	1.07%	$40 327 464.21	58.40%	$28 731 213	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
78	NIH	93-855	Allergy and Infectious Diseases Research	UAI171443AC6	U19AI171443	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		SCRIPPS RESEARCH INSTITUTE	PHZJFZ32NKH4	1330435954A1	LA JOLLA	CA	92037	$67 624 156.00	118043.52	0.17%	$56 600 670.77	83.70%	$11 023 485	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
79	NIH	93-855	Allergy and Infectious Diseases Research	UAI171954AC6	U19AI171954	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF MINNESOTA	KABJZBBJ4B54	1416007513A5	MINNEAPOLIS	MN	554552070	$66 431 207.00	160868.79	0.24%	$50 612 766.05	76.19%	$15 818 441	5/16/22	4/30/25	Organizations with drawdowns	Final	4/30/25	Available/Draft	
80	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	ULM013755BC4	U24LM013755	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		YALE UNIVERSITY	FL6GV84CKN57	1060646973A1	NEW HAVEN	CT	65208047	$5 687 219.00	91033.44	1.60%	$3 813 617.03	67.06%	$1 873 602	6/1/23	11/30/25	Organizations with drawdowns				
81	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UMD016258BC6	U24MD016258	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		Duke University	TP7EK8DZV6N5	1560532129A1	Durham	NC	277084677	$86 836 635.00	53973.45	0.06%	$79 311 832.20	91.33%	$7 524 803	7/1/21	6/30/25	Organizations with drawdowns	Annual	12/31/22	Agency Approved	
82	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UMD016258BC4	U24MD016258	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		Duke University	TP7EK8DZV6N5	1560532129A1	Durham	NC	277084677	$2 000 000.00	0		$1 017 617.41	50.88%	$982 383	6/1/23	6/30/25	Organizations with drawdowns				
83	NIH	93-855	Allergy and Infectious Diseases Research	UTR001608AC6	U24TR001608	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		Duke University	TP7EK8DZV6N5	1560532129A1	Durham	NC	277084677	$115 543 799.00	10209.78	0.01%	$89 459 232.64	77.42%	$26 084 566	4/17/21	6/30/25	Organizations with drawdowns	Annual	6/30/25	Certified/Pending Agency Approval	
84	NIH	93-855	Allergy and Infectious Diseases Research	UTR001608AC3	U24TR001608	O	CARES Act funding (P.L. 116-136) C3""	3		Duke University	TP7EK8DZV6N5	1560532129A1	Durham	NC	277084677	$21 469 057.00	39050.08	0.18%	$8 859 832.47	41.27%	$12 609 225	7/15/20	6/30/25	Organizations with drawdowns	Annual	6/30/22	Rejected by Agency	
85	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260492BC4	U54CA260492	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		JOHNS HOPKINS UNIVERSITY	FTMTDMBR29C7	1520595110A1	BALTIMORE	MD	21218	$3 415 637.40	-21623.05		$3 208 375.69	93.93%	$207 262	6/1/23	8/31/25	Organizations with drawdowns				
86	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260517BC4	U54CA260517	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		STANFORD UNIVERSITY	HJD6G4D6TJY5	1941156365A1	STANFORD	CA	943056215	$2 997 978.00	23891.77	0.80%	$2 579 695.71	86.05%	$418 282	6/1/23	8/31/25	Organizations with drawdowns				
87	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260543BC4	U54CA260543	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	D3LHU66KBLD5	1566001393A1	CHAPEL HILL	NC	27599	$3 215 345.56	36721.83	1.14%	$2 149 942.44	66.87%	$1 065 403	6/1/23	8/31/25	Organizations with drawdowns				
88	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260560BC4	U54CA260560	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	C8H9CNG1VBD9	1136171197A1	MANHATTAN	NY	10029	$3 649 452.31	50673.18	1.39%	$2 669 462.93	73.15%	$979 989	6/1/23	8/31/25	Organizations with drawdowns				
89	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260563BC4	U54CA260563	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$3 057 531.00	61932.99	2.03%	$2 568 030.05	83.99%	$489 501	6/1/23	8/31/25	Organizations with drawdowns				
90	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260581BC4	U54CA260581	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		TULANE UNIVERSITY SCHOOL OF MEDICINE		1720423889A2	NEW ORLEANS	LA	701185698	$3 135 887.22	58204.63	1.86%	$2 059 202.48	65.67%	$1 076 685	6/1/23	2/28/25	Organizations with drawdowns	Final	11/30/24	Available/Draft	
91	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260582BC4	U54CA260582	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		OHIO STATE UNIVERSITY	DLWBSLWAJWR1	1316025986A1	COLUMBUS	OH	43210	$3 143 795.00	0		$2 409 280.34	76.64%	$734 515	6/1/23	8/31/25	Organizations with drawdowns				
92	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UCA260591BC4	U54CA260591	O	Paycheck Protection Program and Health Care Enhancement Act funding (P.L. 116-139) C4""	4		CEDARS-SINAI MEDICAL CENTER	NCSMA19DF7E6	1951652905A2	LOS ANGELES	CA	90048	$2 652 785.13	0		$2 174 872.82	81.98%	$477 912	6/1/23	8/31/25	Organizations with drawdowns				
93	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UEB015408CC5	U54EB015408	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		Massachusetts General Hospital The	FLJ7DQKLL226	1042697983A1	Boston	MA	21142621	$14 086 805.00	10739.5	0.08%	$13 464 952.08	95.59%	$621 853	5/1/21	5/31/25	Organizations with drawdowns	Final	5/31/25	Available/Draft	
94	NIH	93-310	TRANS-NIH RESEARCH SUPPORT	UDA050072AC6	UG1DA050072	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		YALE UNIVERSITY	FL6GV84CKN57	1060646973A1	NEW HAVEN	CT	65208047	$1 139 906.00	0		$998 605.63	87.60%	$141 300	5/15/22	11/30/23	Organizations with drawdowns	Final	11/30/23	Certified/Pending Agency Approval	
95	NIH	93-855	Allergy and Infectious Diseases Research	UAI068614DC5	UM1AI068614	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		FRED HUTCHINSON CANCER CENTER	TJFZLPP6NYL6	1911935159A2	SEATTLE	WA	98109	$31 842 477.00	18.76	0.00%	$23 804 727.63	74.76%	$8 037 749	4/1/22	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
96	NIH	93-855	Allergy and Infectious Diseases Research	UAI068614DC6	UM1AI068614	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		FRED HUTCHINSON CANCER CENTER	TJFZLPP6NYL6	1911935159A2	SEATTLE	WA	98109	$83 440 030.00	0		$76 046 756.31	91.14%	$7 393 274	4/1/22	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
97	NIH	93-855	Allergy and Infectious Diseases Research	UAI068618DC6	UM1AI068618	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		FRED HUTCHINSON CANCER CENTER	TJFZLPP6NYL6	1911935159A2	SEATTLE	WA	98109	$21 274 991.00	32105.94	0.15%	$13 771 275.53	64.73%	$7 503 715	4/1/22	6/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
98	NIH	93-855	Allergy and Infectious Diseases Research	UAI068618DCV	UM1AI068618	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		FRED HUTCHINSON CANCER CENTER	TJFZLPP6NYL6	1911935159A2	SEATTLE	WA	98109	$9 626 428.00	0		$4 626 005.62	48.06%	$5 000 422	4/1/22	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
99	NIH	93-855	Allergy and Infectious Diseases Research	UAI068618DC3	UM1AI068618	O	CARES Act funding (P.L. 116-136) C3""	3		FRED HUTCHINSON CANCER CENTER	TJFZLPP6NYL6	1911935159A2	SEATTLE	WA	98109	$4 948 110.00	2427.19	0.05%	$1 512 113.74	30.56%	$3 435 996	4/28/23	11/30/25	Organizations with drawdowns				
100	NIH	93-855	Allergy and Infectious Diseases Research	UAI068619CC3	UM1AI068619	O	CARES Act funding (P.L. 116-136) C3""	3		INTERNATIONAL FERTILITY RESEARCH PROGRAM		1237413005A1	DURHAM	NC	27709	$108 743 247.00	0		$64 554 912.05	59.36%	$44 188 335	12/1/20	11/30/23	Organizations with drawdowns	Final	11/30/23	Rejected by Agency	
101	NIH	93-855	Allergy and Infectious Diseases Research	UAI068619CC5	UM1AI068619	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		INTERNATIONAL FERTILITY RESEARCH PROGRAM		1237413005A1	DURHAM	NC	27709	$22 082 664.00	0		$13 295 422.13	60.21%	$8 787 242	7/29/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
102	NIH	93-855	Allergy and Infectious Diseases Research	UAI068635DC6	UM1AI068635	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		FRED HUTCHINSON CANCER CENTER	TJFZLPP6NYL6	1911935159A2	SEATTLE	WA	98109	$18 398 956.00	0		$17 984 780.72	97.75%	$414 175	4/1/22	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
103	NIH	93-855	Allergy and Infectious Diseases Research	UAI068635DC3	UM1AI068635	O	CARES Act funding (P.L. 116-136) C3""	3		FRED HUTCHINSON CANCER CENTER	TJFZLPP6NYL6	1911935159A2	SEATTLE	WA	98109	$12 647 369.00	0		$12 353 646.56	97.68%	$293 722	5/2/23	11/30/25	Organizations with drawdowns				
104	NIH	93-855	Allergy and Infectious Diseases Research	UAI068636EC6	UM1AI068636	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF CALIFORNIA-LOS ANGELES BOARD OF REGENTS	RN64EPNH8JC6	1956006143A1	LOS ANGELES	CA	90095	$197 887 440.00	0		$152 629 893.42	77.13%	$45 257 547	9/16/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
105	NIH	93-855	Allergy and Infectious Diseases Research	UAI068636EC3	UM1AI068636	O	CARES Act funding (P.L. 116-136) C3""	3		UNIVERSITY OF CALIFORNIA-LOS ANGELES BOARD OF REGENTS	RN64EPNH8JC6	1956006143A1	LOS ANGELES	CA	90095	$170 881 829.83	0		$126 977 579.05	74.31%	$43 904 251	1/8/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Rejected by Agency	
106	NIH	93-855	Allergy and Infectious Diseases Research	UAI068636EC5	UM1AI068636	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		UNIVERSITY OF CALIFORNIA-LOS ANGELES BOARD OF REGENTS	RN64EPNH8JC6	1956006143A1	LOS ANGELES	CA	90095	$20 566 378.00	0		$9 529 204.81	46.33%	$11 037 173	4/23/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Rejected by Agency	
107	NIH	93-855	Allergy and Infectious Diseases Research	UAI109565BC5	UM1AI109565	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	PK9FMGRDRVD5	1910653422A1	SEATTLE	WA	98101	$34 703 331.00	0		$29 066 922.63	83.76%	$5 636 408	5/13/21	1/31/25	Organizations with drawdowns	Final	1/31/25	Available/Draft	
108	NIH	93-855	Allergy and Infectious Diseases Research	UAI148373AC3	UM1AI148373	O	CARES Act funding (P.L. 116-136) C3""	3		KAISER FOUNDATION RESEARCH INSTITUTE	P1RTMASB37B5	1941105628A1	OAKLAND	CA	946123433	$9 606 309.00	138859.48	1.45%	$5 768 951.80	60.05%	$3 837 357	7/22/20	11/30/24	Organizations with drawdowns	Final	11/30/23	Rejected by Agency	
109	NIH	93-855	Allergy and Infectious Diseases Research	UAI148373AC5	UM1AI148373	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		KAISER FOUNDATION RESEARCH INSTITUTE	P1RTMASB37B5	1941105628A1	OAKLAND	CA	946123433	$7 351 141.00	77431.97	1.05%	$5 602 146.88	76.21%	$1 748 994	5/11/21	11/30/24	Organizations with drawdowns	Final	11/30/23	Rejected by Agency	
110	NIH	93-855	Allergy and Infectious Diseases Research	UAI148450AC5	UM1AI148450	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		UNIVERSITY OF ROCHESTER	F27KDXZMF9Y8	1160743209A1	ROCHESTER	NY	146113847	$10 005 677.00	0		$8 406 741.08	84.02%	$1 598 936	5/1/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Certified/Pending Agency Approval	
111	NIH	93-855	Allergy and Infectious Diseases Research	UAI148452AC5	UM1AI148452	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		VANDERBILT UNIVERSITY MEDICAL CENTER	GYLUH9UXHDX5	1352528741A1	NASHVILLE	TN	372320011	$27 356 563.00	0		$22 959 575.08	83.93%	$4 396 988	4/23/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
112	NIH	93-855	Allergy and Infectious Diseases Research	UAI148573AC5	UM1AI148573	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		UNIVERSITY OF WASHINGTON	HD1WMN6945W6	1916001537A1	SEATTLE	WA	98105	$5 394 452.00	0		$4 099 070.00	75.99%	$1 295 382	5/5/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Rejected by Agency	
113	NIH	93-855	Allergy and Infectious Diseases Research	UAI148573ACV	UM1AI148573	O	Coronavirus Supplemental funding (P.L. 116-123) CV""	1		UNIVERSITY OF WASHINGTON	HD1WMN6945W6	1916001537A1	SEATTLE	WA	98105	$9 616 028.00	0		$8 694 310.97	90.41%	$921 717	3/12/20	11/30/23	Organizations with drawdowns	Annual	11/30/23	Certified/Pending Agency Approval	
114	NIH	93-855	Allergy and Infectious Diseases Research	UAI148573AC6	UM1AI148573	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF WASHINGTON	HD1WMN6945W6	1916001537A1	SEATTLE	WA	98105	$1 561 928.00	0		$876 961.70	56.15%	$684 966	7/1/22	11/30/23	Organizations with drawdowns	Final	11/30/23	Rejected by Agency	
115	NIH	93-855	Allergy and Infectious Diseases Research	UAI148575AC5	UM1AI148575	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		BAYLOR COLLEGE OF MEDICINE	FXKMA43NTV21	1741613878A1	HOUSTON	TX	77030	$8 342 191.00	0		$6 201 452.19	74.34%	$2 140 739	5/19/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
116	NIH	93-855	Allergy and Infectious Diseases Research	UAI148576AC5	UM1AI148576	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$14 870 022.00	0		$13 831 333.45	93.01%	$1 038 689	4/26/21	11/30/24	Organizations with drawdowns	Final	11/30/24	Prepared by Grantee	
117	NIH	93-855	Allergy and Infectious Diseases Research	UAI148576AC3	UM1AI148576	O	CARES Act funding (P.L. 116-136) C3""	3		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$12 203 207.00	0		$11 407 881.77	93.48%	$795 325	7/13/20	11/30/24	Organizations with drawdowns	Final	11/30/24	Available/Draft	
118	NIH	93-855	Allergy and Infectious Diseases Research	UAI148684AC5	UM1AI148684	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		EMORY UNIVERSITY	S352L5PJLMP8	1580566256A1	ATLANTA	GA	303221620	$28 013 664.00	331097.27	1.18%	$23 871 975.71	85.22%	$4 141 688	7/27/21	5/31/25	Organizations with drawdowns	Final	5/31/25	Available/Draft	
119	NIH	93-855	Allergy and Infectious Diseases Research	UAI148689BC5	UM1AI148689	O	Coronavirus Response and Relief Supplement Appropriations Act 2021 [P.L. 116-260] C5""	5		UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL SCHOOLS	Z9CRZKD42ZT1	1526002036A1	BALTIMORE	MD	212011531	$26 702 445.00	0		$23 212 590.43	86.93%	$3 489 855	2/8/21	7/31/24	Organizations with drawdowns	Final	11/30/24	Certified/Pending Agency Approval	
120	NIH	93-855	Allergy and Infectious Diseases Research	UAI148689BC6	UM1AI148689	O	American Rescue Plan of 2021 [P.L. 117-2] C6""	6		UNIVERSITY OF MARYLAND BALTIMORE PROFESSIONAL SCHOOLS	Z9CRZKD42ZT1	1526002036A1	BALTIMORE	MD	212011531	$3 365 966.00	0		$3 200 370.90	95.08%	$165 595	8/22/22	11/30/24	Organizations with drawdowns	Final	11/30/24	Certified/Pending Agency Approval	
121	NIH	93-855	Allergy and Infectious Diseases Research	UAI151958AC3	UM1AI151958	O	CARES Act funding (P.L. 116-136) C3""	3		NATIONAL JEWISH HEALTH	VLQKFEEJ3NE9	1742044647A2	DENVER	CO	80206	$5 963 410.00	0		$5 779 160.92	96.91%	$184 249	1/28/21	3/31/24	Organizations with drawdowns	Annual	3/31/24	Rejected by Agency	

PDF COPY OF NIH_GRANTS_003123
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H
1	Project Abstra	in NJ	Administering IC	Project Number	Program Official Information	Contact PI / Project Leader	Organization Name	Total Cost
2	Poor cardiova	Cardiovascular Health and Inflammation: Intersectional Impact of Structural Racism Structural Sexism and Structural Classism	NIGMS	5P20GM135007-05		BERNAL, FEDERICO	UNIVERSITY OF VERMONT & ST AGRIC COLLEGE	
3	ABSTRACT Ch	Children's Hospital Los Angeles Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Coll	5UM2HD111076-03		BELZER, MARVIN E	WESTAT, INC.		
4	Research Pro	Administrative Core	NIMHD	2U54MD007582-39			FLORIDA AGRICULTURAL AND MECHANICAL UNIV	
5	Project Summ	Community Outreach and Engagement		2U54MD007598-16		DEL PINO, HOMERO ERWIN	CHARLES R. DREW UNIVERSITY OF MED & SCI	
6	ABSTRACT: PF	Amplifying the menthol cigarette bans impact in priority populations with a quit smoking campaign	NIDA	5U54DA060049-02			UNIV OF NORTH CAROLINA CHAPEL HILL	
7	PROJECT SUM	Recruitment and Retention Core	NINDS	5U19NS120384-04			UNIVERSITY OF CALIFORNIA AT DAVIS	
8	FIU-RCMI Adr	Administrative Core	NIMHD	5U54MD012393-08			FLORIDA INTERNATIONAL UNIVERSITY	
9	SUMMARYThe	Stanford Cancer Institute (SCI) is a national and international leader in cancer research across the cancercontrol cont	NCI	5P30CA124435-16			STANFORD UNIVERSITY	
10	PROJECT SUM	Core A: Administrative	NIAID	3P30AI050409-26S1		DEL RIO, CARLOS	EMORY UNIVERSITY	
11	PROJECT SUM	AIDS prevention;Acquired Immunodeficiency Syndrome;Address;Adherence;Adolescence;Adolescent;Adolescent and Y	NIAID	5P30AI042853-26			MIRIAM HOSPITAL	
12	PROJECT SUM	PROJECT NARRATIVEThe global HIV epidemic affects the lives of millions of individuals around the world many of whom f	NIAID	5UM1AI068619-19	DEJLI, JAMAL	COHEN, MYRON SCOTT	FAMILY HEALTH INTERNATIONAL	$12,774,001.00
13	PROJECT SUM	Clinical and Translational Science Collaborative of Northern Ohio Catalyzing Linkages to Equity in Health (CLE Health)	NCATS	5UM1TR004528-02	DOYLE, JAMIE MIHOKO	MCCOMSEY, GRACE A	CASE WESTERN RESERVE UNIVERSITY	$8,041,152.00
14	Abstract. Clir	University of Minnesota Clinical and Translational Science Institute (UMN CTSI)	NCATS	5UM1TR004405-02	KRASNOVA, IRINA N	BLAZAR, BRUCE R	UNIVERSITY OF MINNESOTA	$7,699,733.00
15	ABSTRACT O	PROJECT NARRATIVE OVERALLThe Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) will develop an	NICHD	5UM2HD111076-03	RUSSO, DENISE	DRIVER, BARBARA	WESTAT, INC.	$7,583,126.00
16	Scientific wor	Vanderbilt FIRST - Elevating Excellence and Transforming Institutional Culture	NCI	5U54CA280915-02	HUSSAIN, SHADAB FATIMA	WILKINS, CONSUELO HOPKINS	VANDERBILT UNIVERSITY MEDICAL CENTER	$5,475,798.00
17	Research sho	PURPOSE: Positively Uniting Researchers of Pain to Opine Synthesize and Engage	NINDS	1R24NS132283-01	WANDNER, LAURA DOVER	COVERSTONE, JACOB SUTTON	NEUROVATIONS	$5,142,623.00
18	PROJECT SUM	Catalyzing Systemic Change at Drexel University to Support Diverse Faculty in Health Disparities Research	NCI	5U54CA267735-04		CALZOLA, JESSICA MARIE	DREXEL UNIVERSITY	$4,642,999.00
19	SUMMARYSig	Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases (RCC RD-MCD)	NIMHD	5U24MD017250-04	STINSON, NATHANIEL	GANSKY, STUART A	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$4,475,000.00
20	The RCMI Pro	The RCMI Program in Health Disparities Research at Meharry Medical College	NIMHD	5U54MD007586-38	DAS, RINA	ADUNYAH, SAMUEL EVANS	MEHARRY MEDICAL COLLEGE	$4,434,185.00
21	No Abstract	All of Us Southern California Consortium (AoUSCC): Engagement Enrollment and Retention of Diverse Populations	OD	1OT2OD036428-01	PRABHUDAS, IRENE	ANTON-CULVER, HODA A	UNIVERSITY OF CALIFORNIA-IRVINE	$4,000,000.00
22	PROJECT SUM	Chicago Chronic Condition Equity Network (C3EN)	NIMHD	5P50MD017349-04	SOLIS SANABRIA, CAROLINA VANESSA	HUANG, ELBERT S.	UNIVERSITY OF CHICAGO	$3,998,319.00
23	ABSTRACT: O	Advancing Tobacco Regulatory Science to Reduce Health Disparities	NIDA	5U54DA060049-02	ROMBERG, ALEXA RUTH	RIBISL, KURT M.	UNIV OF NORTH CAROLINA CHAPEL HILL	$3,855,746.00
24	Project Summ	Asian Americans & Racism: Individual and Structural Experiences (ARISE)	NIA	1R56AG079510-01A1	BANDIERA, FRANK	PARK, VAN MY TA	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$3,432,146.00
25	The U.S. has s	AIDS prevention;Accounting;Address;Adherence;Administrative Supplement;African American;Age;Age Years;American	NIDA	5U01DA036926-10		JENKINS, RICHARD A	CHILDREN'S HOSPITAL OF LOS ANGELES	$2,909,986.00
26	The U.S. has s	Using Longitudinal Research to Engage African American and Latinx Sexual- and Gender-Minority Youth in the HIV Preve	NIDA	5U01DA036926-10	JENKINS, RICHARD A	KIPKE, MICHELE D.	CHILDREN'S HOSPITAL OF LOS ANGELES	$2,909,986.00
27	In this compe	20 year old;AIDS prevention;Address;Adolescence;Adolescent and Young Adult;Adult;Age;Age Years;Aging;Agreement;Ar	NIDA	5U01DA036939-10		DUNSTON, SHEBA KING	NORTHWESTERN UNIVERSITY AT CHICAGO	$2,747,259.00
28	In this compe	Multilevel Influences on HIV and Substance Use in a YMSM cohort	NIDA	5U01DA036939-10	DUNSTON, SHEBA KING	MUSTANSKI, BRIAN	NORTHWESTERN UNIVERSITY AT CHICAGO	$2,747,259.00
29	This proposal	Penn Innovation in Suicide Prevention Implementation Research (INSPIRE) Center	NIMH	5P50MH127511-04	MAVANDADI, SHAHRZAD	BROWN, GREGORY K	UNIVERSITY OF PENNSYLVANIA	$2,710,637.00
30	PROJECT SUM	Examining Social Ecological and Network Factors to Assess Epidemiological Risk in a Large National Cohort of Cisgende	NIAID	5R01AI172469-02	ROE, JOANAD'ARC C	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$2,550,380.00
31	PROJECT SUM	18 year old;AIDS prevention;Accounting;Address;Advertisements;Advertising;Affect;Age;Age Years;Alcohol consumption	NIAID	4UH3AI169658-03		ZIMAND, LORI B.	COLUMBIA UNIVERSITY HEALTH SCIENCES	$2,497,744.00
32	PROJECT SUM	MyPEEPS Mobile LITE: Limited Interaction Efficacy Trial of MyPEEPS Mobile to Reduce HIV Incidence and Better Underst	NIAID	4UH3AI169658-03	ZIMAND, LORI B.	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$2,497,744.00
33	AbstractFor p	Limited interaction cohort to identify determinants of viral suppression in MSM and transfeminine individuals living with	NIAID	5UG3AI176853-02	ZIMAND, LORI B.	SULLIVAN, PATRICK SEAN	EMORY UNIVERSITY	$2,496,734.00
34	PROJECT SUM	Examining Non-Congregate Shelter Effects on Mental Health Crises through Community Health Partnerships in Connecticut	NINR	1R01NR021461-01	MCNAMARA, KAREN MARIE	WONG, AMBROSE H	YALE UNIVERSITY	$2,432,517.00
35	PROJECT SUM	Improving mental health among the LGBTQ+ community impacted by the COVID-19 pandemic	NIMH	1RF1MH132348-01	BARRERA LOUCHEUR, ALINNE ZOE	MOITRA, ETHAN	BROWN UNIVERSITY	$2,368,492.00
36	Background:	TENTRUST - economic navigation and strengthening to realize unrestricted services for transgender women	NIDA	1DP2DA058436-01	JENKINS, RICHARD A	CYRUS, ELENA	UNIVERSITY OF CENTRAL FLORIDA	$2,280,000.00
37	Sexual minori	Harnessing the power of text messaging to reduce HIV incidence in adolescent males across the United States	NICHD	5U01HD108738-03	YATES, FRANKLIN WILLEM	YBARRA, MICHELE L.	CENTER FOR INNOVATIVE PUBLIC HEALTH RESEARCH	$2,154,708.00
38	People living v	Evaluation of anal self-sampling in HIV men-who-have-sex-with-men (HIV MSM) populations	NCI	1ZIACP101240-01		CLARKE, MEGAN	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS	$2,134,016.00
39	PROJECT SUM	Increasing financial and health equity among low income black youth and young adults	NIMHD	5U01MD019398-03	JOHNSON, JARRETT AINSWORTH	LIPPMAN, SHERI ANN	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$2,126,891.00
40	PROJECT SUM	1/4 Asian Bipolar Genetics Network (A-BIG-NET)	NIMH	5R01MH130675-03	PEVSNER, JONATHAN	HUANG, HAILIANG	BROAD INSTITUTE, INC.	$2,093,614.00
41	Project Summ	Meharry HIV/AIDS Research and Training Facility	OD	1C06OD034042-01	CHEN, YONG	BERTHAUD, VLADIMIR	MEHARRY MEDICAL COLLEGE	$2,000,000.00
42	Project Summ	Texas Minority Health Research and Outreach (MiHERO)	NIMHD	5S21MD012472-07	JONES, NANCY LYNNE	VISHWANATHA, JAMBOOR K.	UNIVERSITY OF NORTH TEXAS HLTH SCI CTR	$2,000,000.00
43	AbstractChar	Charles R. Drew University of Medicine and Science Research Endowment Program	NIMHD	5S21MD018960-02	JONES, NANCY LYNNE	CARLISLE, DAVID M	CHARLES R. DREW UNIVERSITY OF MED & SCI	$2,000,000.00
44	Project Summ	Developing a Community-Based Facility to Support Next Generation Biomedical HIV Research	OD	1C06OD034040-01	LI, XIANG-NING	RENDINA, H. JONATHON	WHITMAN-WALKER INSTITUTE, INC.	$2,000,000.00
45	Stimulant dru	RP7 Impact	NICHD	5UM2HD111102-03		HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	$1,989,068.00
46	Project Summ	Autism Center of Excellence Network: Neurodevelopmental Biomarkers of Late Diagnosis in Female and Gender Diverse Autism	NIMH	5R01MH100028-14	GILOTTY, LISA	PELPHREY, KEVIN A	UNIVERSITY OF VIRGINIA	$1,896,210.00
47	Project Summ	Establishing the science behind Alzheimer's recruitment registries: opportunities for increasing diversity and accelerating enrollmen	NIA	5R01AG063954-05	ELLIOTT, CERISE	LANGBAUM, JESSICA BROOKE	BANNER HEALTH	$1,842,475.00
48	Research sho	PURPOSE: Positively Uniting Researchers of Pain to Opine Synthesize and Engage	NINDS	1R24NS132283-01	WANDNER, LAURA DOVER	COVERSTONE, JACOB SUTTON	NEUROVATIONS	$1,739,582.00
49	PROJECT SUM	ALACRITY for Early Screening and Treatment of High Risk Youth (eSToRY)	NIMH	5P50MH126283-04	ACRI-MARRO, MARY	COOK, BENJAMIN LE	CAMBRIDGE HEALTH ALLIANCE	$1,634,609.00
50	Sexually trans	The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness investigate asso	NIAID	1R01AI181732-01A1	CHUANG, ELEANORE JENNIFER	LUETKEMEYER, ANNE FREY	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$1,628,180.00
51	Project Summ	The Optics of Health: Race Skin Tone Minority Health and Health Disparities in the U.S.	NIMH	1DP2MH132941-01	TALKOVSKY, ALEXANDER M	MONK, ELLIS	HARVARD UNIVERSITY	$1,521,000.00
52	Project Summ	Pediatric Scientist Development Program	NICHD	5K12HD000850-40	WINER, KAREN	PERMAR, SALLIE R.	WEILL MEDICAL COLL OF CORNELL UNIV	$1,501,572.00
53	PROJECT SUM	PROJECT NARRATIVEThe global HIV epidemic affects the lives of millions of individuals around the world many of whom f	NIAID	5UM1AI068619-19	DEJLI, JAMAL	COHEN, MYRON SCOTT	FAMILY HEALTH INTERNATIONAL	$1,500,000.00
54	ABSTRACT - C	Center for HIV Identification Prevention and Treatment Services	NIMH	5P30MH058107-29	GORDON, CHRISTOPHER M.	SHOPTAW, STEVEN J	UNIVERSITY OF CALIFORNIA LOS ANGELES	$1,499,315.00
55	PROJECT SUM	Center for AIDS Prevention Studies (CAPS)	NIMH	5P30MH062246-24	GORDON, CHRISTOPHER M.	JOHNSON, MALLORY O	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$1,498,873.00
56	AbstractPregi	Center to Advance Reproductive Justice and Behavioral Health among Black Pregnant/Postpartum Women and Birthing People (CO	NICHD	5U54HD113292-02	FABIYI, CAMILLE	HERNANDEZ, NATALIE DOLORES	MOREHOUSE SCHOOL OF MEDICINE	$1,474,219.00
57	In the United	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$1,411,882.00
58	In the United	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$1,411,882.00
59	Adaptable Co	Adaptable Community-Engaged Intervention for Violence Prevention: Michigan Model	NICHD	1UG3HD115253-01	GILBERT, LEAH KAYE	WU, TSU-YIN	EASTERN MICHIGAN UNIVERSITY	$1,410,608.00
60	PROJECT SUM	Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma	NIMH	1DP2MH132938-01	TALKOVSKY, ALEXANDER M	PEARL, REBECCA L	UNIVERSITY OF FLORIDA	$1,372,500.00
61	PROJECT SUM	PROJECT NARRATIVEThe global HIV epidemic affects the lives of millions of individuals around the world many of whom f	NIAID	5UM1AI068619-19	DEJLI, JAMAL	COHEN, MYRON SCOTT	FAMILY HEALTH INTERNATIONAL	$1,353,261.00
62	Transgender a	TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults Using Interventions to Drive Equity	NIMH	5U01MH136558-03	ACRI-MARRO, MARY	XU, RENA	BOSTON CHILDREN'S HOSPITAL	$1,344,044.00
63	The United St	Digital Phenotyping & Deep Learning: Substance Use Impact on PrEP Adherence among Black Sexual and Gender Minori	NIDA	1ZIADA000646-02		CURTIS, BRENDA	NATIONAL INSTITUTE ON DRUG ABUSE	$1,337,600.00
64	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$1,286,124.00
65	Project Summ	Acute;Adrenal Glands;Affect;Behavior;Biological Markers;Buffers;Cardiovascular Diseases;Cellular Phone;Chronic;Cr	NIMHD	5R01MD013495-05		DAS, RINA	JOHNS HOPKINS UNIVERSITY	$1,285,395.00
66	PROJECT ABS	Cerebral small vessel disease burden and racial disparity in vascular cognitive impairment and Alzheimers disease and its related de	NIA	5R01AG072592-04	GHALEH, MARYAM X	HYACINTH, HYACINTH IDU	UNIVERSITY OF CINCINNATI	$1,233,404.00
67	PROJECT SUM	NNLM Region 5: Reaching More People in More Ways	NLM	5UG4LM013725-04	YOON, SUNG SUG SUG	MUILENBURG, JENNY	UNIVERSITY OF WASHINGTON	$1,227,997.00
68	PROJECT SUM	Third Coast Center for AIDS Research	NIAID	3P30AI117943-10S1	REFSLAND, ERIC WILLIAM	MUSTANSKI, BRIAN	NORTHWESTERN UNIVERSITY AT CHICAGO	$1,200,000.00
69	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
70	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
71	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
72	SUMMARY/A	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$1,168,431.00
73	ABSTRACTAlz	Reducing Disparities in Dementia and VCID Outcomes in a Multicultural Rural Population	NINDS	5R01NS101483-06	YIN, XILING	GALVIN, JAMES E	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$1,143,639.00
74	AbstractThis p	Scaling Up Implementation Strategies to Improve the DIAGNOSE and PREVENT Pillars for Young MSM in Florida	NIMH	5R01MH132147-03	POLLARD-BRANCHARD, SUZY	NAAR, SYLVIE	FLORIDA STATE UNIVERSITY	$1,128,033.00
75	AbstractA ple	Leveraging a community-driven approach to address the impact of social determinants of health on structural inequities among Mi	OD	1OT2OD035935-01	MADDEN, EBONY B	IGLESIAS, ANDREA	URBAN HEALTH PARTNERSHIPS	$1,125,000.00
76	My Brothers K	Achieving Optimal Sexual and Reproductive Health (SRWH Project)	OD	1OT2OD035877-01	MADDEN, EBONY B	GIPSON, JUNE ARNESSA	MY BROTHER'S KEEPER, INC.	$1,125,000.00
77	Project Summ	Asian Community-Led Health Equity Structural Intervention (Asian CHESI)	OD	1OT2OD035669-01	MADDEN, EBONY B	WU, DUNLI	ASIAN COMMUNITY HEALTH COALITION	$1,124,986.00
78	ComPASS: Co	Addressing Systemic Barriers Impacting Health in CHC Communities	OD	1OT2OD035834-01	MADDEN, EBONY B	CARACOSTIS, ANDREA	ASIAN AMERICAN HEALTH COALITION/HOUSTON	$1,123,685.00
79	DEVELOPMEN	Developmental Core	NIAID	5P30AI027763-33		JOHNSON, MALLORY O	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$1,081,769.00
80	ABSTRACTAge	SilverBills: A Legal Technical and Financial Tool for Aging LGBTQ+ Individuals with Impaired Cognition.	NIA	5R44AG080843-02	JOHN, DINESH	LOBEL-ESRIG, MARCI	SILVERBILLS INC.	$1,080,149.00
81	Microlevel int	Macro-level Health Considerations of Community and Criminal Justice System Relationships in North Texas	OD	1OT2OD035659-01	MADDEN, EBONY B	FULMER, LINDA	HEALTHY TARRANT COUNTY COLLABORATION	$1,075,664.00
82	ABSTRACTRa	Improving Inclusivity of Alzheimers Disease and Related Dementias Research for Asian Americans and Latinx through Nationally Re	NIA	5R01AG082080-02	PHILLIPS, JOHN	LEE, SUNG-HEE	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$1,072,668.00

	A	B	C	D	E	F	G	H
83	SUMMARYIt is	NARRATIVEThe goal of this proposed research is to examine psychosocial risk and protective factors for Alzheimersdisease and rela	NIA	1R01AG087121-01A1	BANDIERA, FRANK	MEZUK, BRIANA	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$1,059,015.00
84	Project Summ	Theoretically Informed Behavioral Intervention to Enhance QOL and Prevent HIV-related Comorbidities in Ethnic and Ra	NIMHD	1R01MD019956-01	LINARES, DEBORAH ELIZABETH	RAMOS, SILVIA RAQUEL	YALE UNIVERSITY	$1,054,907.00
85	ABSTRACTIn t	A multi-level approach to improve HIV prevention and care for transgender women of color	NIMH	7R01MH129285-02	ALLISON, SUSANNAH		NEW YORK STATE PSYCHIATRIC INSTITUTE	$1,052,842.00
86	Project Summ	Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness / Implemen	NICHD	5UG1HD113160-02	RUSSO, DENISE	GAROFALO, ROBERT	NORTHWESTERN UNIVERSITY AT CHICAGO	$1,044,010.00
87	PROJECT SUM	Faithful Response II: COVID-19 Rapid Test-to-Treat with African American Churches	NIMHD	1U01MD018310-01	BARKSDALE, CRYSTAL	BERKLEY-PATTON, JANNETTE YVONNE	UNIVERSITY OF MISSOURI KANSAS CITY	$1,016,780.00
88	No Abstract	NATIONAL LATINO NETWORK (NLN) FOR PRECISION MEDICINE AND HEALTH DISPARITIES RESEARCH	OD	1OT2OD037880-01	ALFARANO, ALEXANDRIA SKYE	COLON, VIVIAN	COMPREHENSIVE CANCER CENTER/ UNIV/PR	$1,000,000.00
89	No Abstract	NATIONAL LATINO NETWORK (NLN) FOR PRECISION MEDICINE AND HEALTH DISPARITIES RESEARCH	OD	1OT2OD037880-01	ALFARANO, ALEXANDRIA SKYE		COMPREHENSIVE CANCER CENTER/ UNIV/PR	$1,000,000.00
90	The Preventio	DP24-004 PRC Core: University of Iowa Prevention Research Center for Rural Health	NCCDPHP	1U48DP006812-01	DARLING, NATALIE	AFIFI, RIMA	UNIVERSITY OF IOWA	$1,000,000.00
91	The Preventio	DP24-004 PRC Core: University of Iowa Prevention Research Center for Rural Health	NCCDPHP	1U48DP006812-01	AFIFI, RIMA	UNIVERSITY OF IOWA	IOWA CITY	$1,000,000.00
92	To respond to	DP24-004 PRC Core: UCSF Prevention Research Center: Reducing social isolation among older LGBTQ+ adults	NCCDPHP	1U48DP006806-01	RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISC	SAN FRANCISCO	$999,852.00
93	PROJECT SUM	MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM	NIMHD	5R01MD019181-02	FERNANDEZ, ANGELA R		COLUMBIA UNIVERSITY HEALTH SCIENCES	$989,833.00
94	PROJECT ABS	Integrated Networks of Scholars in Global Health Research Training (INSIGHT)	FIC	5D43TW012274-03	HAYES, UNJA	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$986,244.00
95	PROJECT SUM	Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals with Eating Disorders	NIMH	1R61MH133710-01A1	CHAVEZ, MARK		AUBURN UNIVERSITY AT AUBURN	$978,986.00
96	Abstract:The	Screening strategies and social determinants of health among people with high risk of anal cancer	NCI	5R01CA285198-02	SAHASRABUDDHE, VIKRANT V		EMORY UNIVERSITY	$976,498.00
97	ABSTRACTThe	Center for Health Equity Research (CHER)	NIMHD	3U54MD012523-05S1	STINSON, NATHANIEL		UNIVERSITY OF ILLINOIS AT CHICAGO	$950,000.00
98	ABSTRACTBa	Phase IIB: Development of TruT Algorithm for Commercialization in Androgen Disorders	NIA	5R44AG045011-05	JOSEPH, LYNDON		FUNCTION PROMOTING THERAPIES, LLC	$948,808.00
99	7. Project Sur	Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication	NIAID	5UM1AI069463-19	SANNE, IAN MATTHIAS	WITS HEALTH CONSORTIUM (PTY), LTD	PARKTOWN	$943,730.00
100	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$927,251.00
101	ABSTRACT: W	NARRATIVE: We propose to conduct research that will determine the impact of relevant behaviors on HIVprevention am	NIDA	5R01DA057351-03	LAO, GUIFANG		UNIVERSITY OF CHICAGO	$924,073.00
102	AbstractIn th	Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substanc	NIDA	5R01DA056888-03	WEBB, CANDACE KARONDELETTE		FRIENDS RESEARCH INSTITUTE, INC.	$912,089.00
103	AbstractTrans	Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women	NIDA	5R01DA056287-02	REBACK, CATHY J	FRIENDS RESEARCH INSTITUTE, INC.	BALTIMORE	$896,441.00
104	ABSTRACTIn t	RP4 LEAP	NICHD	5UM2HD111102-03	HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	TALLAHASSEE	$895,147.00
105	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$887,718.00
106	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$887,718.00
107	Enter the text	Promoting Inclusive Excellence	NIGMS	1R01GM155395-01	NELSON, SHAKIRA M		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$879,690.00
108	ABSTRACTDe	AIDS prevention;Address;Adherence;Adolescent and Young Adult;Age;Area;Articulation;Award;Behavior;Biological;Bise	NIAID	4UH3AI169631-03		ZIMAND, LORI B.	UNIVERSITY OF ILLINOIS AT CHICAGO	$877,431.00
109	ABSTRACTDe	Keeping it LITE 2: Exploring HIV Risk in Vulnerable Youth with Limited Interaction and Digital Health Intervention (LITE-2)	NIAID	4UH3AI169631-03	ZIMAND, LORI B.	HOSEK, SYBIL	UNIVERSITY OF ILLINOIS AT CHICAGO	$877,431.00
110	Project Abstr	Step UP for STEM and Health Careers: An Intervention to Reduce STEM-related biases and improve high school STEM learning envi	NICHD	5R44HD103517-03	GALLEN, COURTNEY LEIGH		RESILIENT GAMES STUDIO, LLC	$863,909.00
111	PROJECT SUM	CE24-001 Injury Prevention Research Center at Emory (IPRCE).	NCIPC	1R49CE003553-01	RUPP, JONATHAN D.	EMORY UNIVERSITY	ATLANTA	$850,000.00
112	Sexually trans	Doxy4STICare - Doxycycline for Sexually Transmitted Infections; A Comprehensive Assessment of Antimicrobial Resista	NIAID	1R56AI182347-01A1	HUEBNER, ROBIN E		COLUMBIA UNIVERSITY HEALTH SCIENCES	$837,185.00
113	PROJECT SUM	Still Climbin': A Randomized Controlled Trial of an Intervention to Improve Coping with Discrimination Address Medical Mistrust an	NIMHD	5R01MD014722-05	GILLMAN, ARIELLE SAMANTHA		RAND CORPORATION	$829,836.00
114	PROJECT SUM	Bisexual adolescents' and young adults' risk for depression and suicidal ideation: Developmental trajectories risk and protective fac	NIMH	1R01MH138335-01	MURPHY, ERIC ROUSSEAU		OHIO STATE UNIVERSITY	$815,881.00
115	PROJECT SUM	Bisexual adolescents' and young adults' risk for depression and suicidal ideation: Developmental trajectories risk and protective fac	NIMH	1R01MH138335-01		DYAR, CHRISTINA	OHIO STATE UNIVERSITY	$815,881.00
116	Hypertension	A daily diary examination of the influence of intersectional stigma on blood pressure	NHLBI	1R01HL168489-01A1	CAMPO, REBECCAA.		COLUMBIA UNIVERSITY HEALTH SCIENCES	$813,579.00
117	Project Summ	Identifying socioecological profiles that impact changes in care outcomes among Black Sexual minority men living with	NIMH	5UG3MH133258-02	STIRRATT, MICHAEL J		GEORGE WASHINGTON UNIVERSITY	$811,432.00
118	PROJECT SUM	Sexual orientation-related disparities in obstetrical and perinatal health	NIMHD	5R01MD015256-05	MUJURU, PRISCAH		HARVARD PILGRIM HEALTH CARE, INC.	$802,428.00
119	PROJECT SUM	Sexual orientation-related disparities in obstetrical and perinatal health	NIMHD	5R01MD015256-05		CHARLTON, BRITTANY MICHELLE	HARVARD PILGRIM HEALTH CARE, INC.	$802,428.00
120	AbstractThe h	Structural Racism and Discrimination in Older Men's Health Inequities	NIA	5R01AG077934-03	GERALD, MELISSA S		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$800,878.00
121	Transgender a	The effects of gender-affirming sex steroids on brain development in adolescents	NICHD	1R01HD115921-01	WINER, KAREN		BOSTON CHILDREN'S HOSPITAL	$800,403.00
122	PROJECT SUM	Implementing sustainable evidence-based mental healthcare in low-resource community settings nationwide to advance mental h	NIMH	5R01MH133543-02	MAVANDADI, SHAHRZAD		YALE UNIVERSITY	$798,034.00
123	PROJECT SUM	Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)	NIAID	5R01AI174862-03	SHARMA, USHA K.		HARVARD PILGRIM HEALTH CARE, INC.	$790,624.00
124	Project Summ	Resource Centers for Minority Aging Research National Coordinating Center (RCMARs NCC)	NIA	5U24AG083253-02	GERALD, MELISSA S		GERONTOLOGICAL SOCIETY OF AMERICA	$789,806.00
125	Abstract. In re	Leveraging a Strategic Alliance of Community-Based Implementers and Researchers to Characterize Protocolize and S	NIMH	1R01MH138237-01	POLLARD-BRANCHARD, SUZY		UNIVERSITY OF MIAMI CORAL GABLES	$788,119.00
126	PROJECT SUM	Trans/Forming Genomics: Guidance for Research Involving Transgender and Gender Diverse People	NHGRI	5R01HG013145-02	LOCKHART, NICOLE C		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	$787,406.00
127	Sexual minori	Young Sexual Minority Women's Mental Health: Developmental Trajectories Mechanisms of Risk and Protective Factors.	NIMH	5R01MH132692-02	MORRIS, SARAH E		UNIVERSITY OF CINCINNATI	$786,630.00
128	PROJECT SUM	Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP	NIAID	1R01AI186641-01	SPINELLI, MATTHEW A.	UNIVERSITY OF CALIFORNIA, SAN FRANCISC	SAN FRANCISCO	$781,821.00
129	PROJECT SUM	Promoting Reductions in Intersectional Stigma to Improve HIV Testing and PrEP Use Among Latino Sexual Minority Men	NIMH	5R01MH121256-05	GREENWOOD, GREGORY		RAND CORPORATION	$780,958.00
130	AbstractThe d	Public Health Relevance StatementLatinx gay/bisexual men and men who have sex with men experience disproportiona	NIMH	5U01MH136574-02	POLLARD-BRANCHARD, SUZY		SAN FRANCISCO STATE UNIVERSITY	$780,747.00
131	Transgender a	Cardiometabolic Impact of Gender-Affirming Hormone Therapy in Transmasculine Young Adults	NHLBI	1R01HL177518-01	WIDLANSKY, MICHAEL E	MEDICAL COLLEGE OF WISCONSIN	MILWAUKEE	$779,771.00
132	Project Summ	Michigan Center for Diabetes Translational Research	NIDDK	5P30DK092926-14	HEISLER, MARY ELLEN MICHELE	UNIVERSITY OF MICHIGAN AT ANN ARBOR	ANN ARBOR	$779,000.00
133	PROJECT SUM	Behavior;Black race;Chicago;Cities;Collaborations;Communicable Diseases;Communities;Complex;Data;Disadvanta	NIDA	1R01DA061247-01		BIRKETT, MICHELLE	NORTHWESTERN UNIVERSITY AT CHICAGO	$777,568.00
134	PROJECT SUM	Characterizing Sleep ART Adherence and Viral Suppression Among Black Sexual Minority Men	NHLBI	5R01HL160325-04	DIXIT, SHILPY		COLUMBIA UNIVERSITY HEALTH SCIENCES	$774,324.00
135	ABSTRACT CH	Optimizing a Just-in-Time Adaptive Intervention to Increase Uptake of Chemsex Harm Reduction Services in MSM: A Mic	NIDA	1R01DA061661-01	JENKINS, RICHARD A		UNIVERSITY OF CONNECTICUT STORRS	$773,845.00
136	PROJECT SUM	ICAP Clinical Trials Unit	NIAID	5UM1AI154468-05	GUBB, STEPHANIE MAJER		COLUMBIA UNIVERSITY HEALTH SCIENCES	$772,420.00
137	Project Summ	Network-based study design statistical and modeling solutions for HIV among populations that use illicit substances: Int	NIDA	1R01DA058994-01A1	JENKINS, RICHARD A		UNIVERSITY OF RHODE ISLAND	$771,618.00
138	Summary/Abs	Impact of Gender Affirming Hormone Therapy on HIV Viral Dynamics and Immune Responses in Transgender Women	NIAID	1R01AI189309-01	SCULLY, EILEEN PATRICIA	JOHNS HOPKINS UNIVERSITY	BALTIMORE	$771,490.00
139	PROJECT SUM	Investigating and identifying the heterogeneity in COVID-19 misinformation exposure on social media among Black and Rural comm	NIMHD	5R01MD018340-03	GILLMAN, ARIELLE SAMANTHA		UNIVERSITY OF PENNSYLVANIA	$771,159.00
140	Chlamydia tra	A seek test and treat intervention to reduce Chlamydia trachomatis disparities in Black youth living in the deep South	NIAID	1R01AI186142-01A1	CHUANG, ELEANORE JENNIFER		TULANE UNIVERSITY OF LOUISIANA	$770,842.00
141	The goal of thi	Characterizing intersecting sexual gender and race-based stigmas affecting communities of US transgender women and	NINR	5R01NR020437-04	WILLIS, LEIGH ANDREW		JOHNS HOPKINS UNIVERSITY	$768,731.00
142	Project Summ	Building mobile HIV prevention and mental health support in low-resource settings	NIMH	7R01MH116829-06	LELUTIU-WEINBERGER, CORINA		COLUMBIA UNIVERSITY HEALTH SCIENCES	$768,346.00
143	What we know	A Multilevel Multiphase Optimization Strategy for PrEP: Patients and Providers in Primary Care	NIMHD	5R01MD018523-02	BARKSDALE, CRYSTAL		HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCE	$768,126.00
144	Project Summ	Developing and pilot testing an eHealth decision support tool for young trans women to improve informed decision maki	NIMH	1R34MH137753-01	SENN, THERESA ELAINE		TEMPLE UNIV OF THE COMMONWEALTH	$766,765.00
145	7.PROJECTSU	Acquired Immunodeficiency Syndrome;Adult;Affect;Age;Aging;Alzheimer's disease related dementia;Alzheimer's dise	NIA	5R01AG069041-04		BOCKTING, WALTER O.	NEW YORK STATE PSYCHIATRIC INSTITUTE	$765,460.00
146	7.PROJECTSU	Social Convoys Cognitive Reserve and Resilience and Risk for Alzheimer's Disease and Related Dementias	NIA	5R01AG069041-04	GERALD, MELISSA S		NEW YORK STATE PSYCHIATRIC INSTITUTE	$765,460.00
147	SUMMARYAd	Assessing intersectional multilevel and multidimensional structural racism for English- and Spanish-speaking populations in the U	NIMHD	5R01MD019029-02	GILLMAN, ARIELLE SAMANTHA		UNIVERSITY OF MARYLAND BALTIMORE	$764,870.00
148	PROJECT SUM	The Institute for Health Equity Research Catalyst Center	NIMHD	1P50MD019475-01	STINSON, NATHANIEL		ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	$759,917.00
149	Project Summ	Feasibility acceptability and preliminary efficacy of an adapted group-based and online HIV prevention intervention for	NIMH	1R34MH134603-01A1	POLLARD-BRANCHARD, SUZY		UNIVERSITY OF ILLINOIS AT CHICAGO	$759,489.00
150	Project Summ	Social-Affective Vulnerability to Suicidality among LGBTQ Young Adults: Proximal and Distal Factors	NIMH	5R01MH124900-04	LEITMAN, DAVID I		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$759,447.00
151	PROJECT SUM	Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV	NIDA	5R01DA058965-02	WEBB, CANDACE KARONDELETTE		UNIVERSITY OF CHICAGO	$758,812.00
152	PROJECT SUM	A Strengths-Based Intersectional Approach to Suicide Prevention Among Black Sexual and Gender Minority Youth	NIMH	5R01MH134051-02	MURPHY, ERIC ROUSSEAU		UNIVERSITY OF CENTRAL FLORIDA	$756,237.00
153	PROJECT SUM	A Strengths-Based Intersectional Approach to Suicide Prevention Among Black Sexual and Gender Minority Youth	NIMH	5R01MH134051-02		TALIAFERRO, LINDSAY A	UNIVERSITY OF CENTRAL FLORIDA	$756,237.00
154	Project Abstra	A randomized clinical trial of client-centered care coordination to improve pre-exposure prophylaxis use for Black men	NIMH	5R01MH134721-02	STIRRATT, MICHAEL J		UNIVERSITY OF MARYLAND BALTIMORE	$753,802.00
155	In this Resear	Engaging Diverse Stakeholders in Genomic/Precision Medicine Research: The All of Us Research Program Engagement Core	OD	3OT2OD035980-01S1	ALTON, ANGELICA SUZETTE		VANDERBILT UNIVERSITY MEDICAL CENTER	$750,528.00
156	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$750,000.00
157	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01	GERALD, MELISSA S	BOGART, LAURA M	RAND CORPORATION	$750,000.00
158	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01		GERALD, MELISSA S	RAND CORPORATION	$750,000.00
159	ABSTRACTDe	AIDS prevention;Address;Adherence;Adolescent and Young Adult;Age;Area;Articulation;Award;Behavior;Biological;Bise	NIAID	4UH3AI169631-03		ZIMAND, LORI B.	UNIVERSITY OF ILLINOIS AT CHICAGO	$750,000.00
160	ABSTRACTDe	Keeping it LITE 2: Exploring HIV Risk in Vulnerable Youth with Limited Interaction and Digital Health Intervention (LITE-2)	NIAID	4UH3AI169631-03	ZIMAND, LORI B.	HOSEK, SYBIL	UNIVERSITY OF ILLINOIS AT CHICAGO	$750,000.00
161	Project Summ	THE IMPACT OF PUBERTAL SUPPRESSION ON ADOLESCENT NEURAL AND MENTAL HEALTH TRAJECTORIES - Resubmission - 1	NIMH	5R01MH123746-04	MURPHY, ERIC ROUSSEAU		RESEARCH INST NATIONWIDE CHILDREN'S HOSP	$738,171.00
162	PROJECT SUM	A unified protocol to address sexual minority women's minority stress mental health and hazardous drinking	NIAAA	5R01AA029088-03	FREEMAN, ROBERT		YALE UNIVERSITY	$737,885.00
163	PROJECT ABS	Synergistic epidemics of non-communicable diseases stigma depression and material insecurities among sexual and ge	NHLBI	5R01HL165686-03	KUNZ, JOHN FREDERIC		UNIVERSITY OF MARYLAND BALTIMORE	$734,579.00
164	Project Summ	Enhancing Structural Competency in School-Based Health Centers to Address LGBTQ+ Adolescent Health Equity	NINR	5R01NR021019-03	GODETTE, DIONNE		PACIFIC INSTITUTE FOR RES AND EVALUATION	$734,567.00

	A	B	C	D	E	F	G	H
165	PROJECT SUM	Long-term and Daily Associations among Intersectional Minority Stress Structural Oppression and Alcohol Use and Misuse among	NIAAA	5R01AA029989-04	RUFFIN, BEVERLY		UNIV OF MARYLAND, COLLEGE PARK	$729,606.00
166	AbstractBy 2(	Building Community and Research Engagement among Sexual and Gender Minority Older Adults at Risk for Alzheimers Disease and	NIA	5R24AG066599-03	GERALD, MELISSA S		EMORY UNIVERSITY	$727,284.00
167	PROJECT SUM	A longitudinal and experience sampling investigation of rejection sensitivity and its role in sexual minority adolescents' mental healt	NIMH	5R01MH130375-02	SMITH, ASHLEY		ROSALIND FRANKLIN UNIV OF MEDICINE & SCI	$726,126.00
168	PROJECT SUM	Suicide Prevention for Sexual and Gender Minority Youth	NIMH	5R33MH120236-04	O'CONNOR, STEPHEN		SAN DIEGO STATE UNIVERSITY	$724,430.00
169	PROJECT SUM	Mental Health Effects of Marriage Policy: Evidence from Linked Administrative Data in New Zealand	NIMH	1R01MH140023-01	TALKOVSKY, ALEXANDER M		VANDERBILT UNIVERSITY	$722,293.00
170	PROJECT SUM	Understanding multilevel predictors affecting family formation among sexual and gender minority couples	NICHD	1R01HD115551-01	POPKIN, RONNA		NORTHWESTERN UNIVERSITY AT CHICAGO	$718,900.00
171	PROJECT SUM	A Multi-Level Integrated Strategy to Optimize PrEP Adherence for Black MSM and Accelerate Implementation at Scale	NIMH	1R01MH138225-01	POLLARD-BRANCHARD, SUZY		YALE UNIVERSITY	$709,213.00
172	Project Summ	Sex hormone effects on neurodevelopment: Controlled puberty in transgender adolescents	NIMH	5R01MH115349-05	SMITH, ASHLEY		STANFORD UNIVERSITY	$707,054.00
173	SUMMARYSe	Enhancing Measurement and Characterization of Roles and Experiences of Sexual and Gender Minority Caregivers of Persons living	NIA	5R01AG083177-02	GERALD, MELISSA S		UNIVERSITY OF NEVADA LAS VEGAS	$702,329.00
174	PROJECT SUM	Characterizing Intersectional Geospatial Stigma and Affirmation Landscapes and Their Influence on Black and Latino Bi	NIDA	1R01DA059240-01A1	DUNSTON, SHEBA KING		FLORIDA STATE UNIVERSITY	$701,204.00
175	PROJECT SUM	Equitable Measurement of Care Disparities and Needs in Intersex Youth/Youth with Variations in Sex Development	NICHD	5R01HD114134-02	POPKIN, RONNA		CHILDREN'S RESEARCH INSTITUTE	$699,796.00
176	Project Summ	Intervention to improve parent communication about sexuality with sexual minority male adolescents	NICHD	1R01HD111516-01A1	POPKIN, RONNA		UNIVERSITY OF PENNSYLVANIA	$698,557.00
177	PROJECT SUM	A Randomized Controlled Trial of a Game-Based Intervention to Reduce Alcohol Use among Sexual and Gender Minority Youth	NIAAA	5R01AA030017-02	KERRIDGE, BRADLEY TOWNSEND		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$695,237.00
178	AbstractRece	Testing Effective Methods to Recruit Sexual and Gender Minority Cancer Patients for Cancer Studies	NCI	5R01CA265945-03	BERRIGAN, DAVID		UNIVERSITY OF MINNESOTA	$694,803.00
179	PROJECT SUM	Structural Influences on Methamphetamine Use among Black Gay and Bisexual Men in Atlanta	NIDA	5R01DA056235-03	DUNSTON, SHEBA KING		EMORY UNIVERSITY	$683,730.00
180	PROJECT SUM	A multidimensional investigation of social support for transgender and nonbinary people and its impacts on health and well-being	NIMHD	5R01MD018571-02	BARKSDALE, CRYSTAL		UNIVERSITY OF WISCONSIN-MADISON	$681,042.00
181	ABSTRACT Th	Preventing Drug Abuse among Sexual-Minority Youth	NIDA	5R01DA043512-05	ROMBERG, ALEXA RUTH		COLUMBIA UNIV NEW YORK MORNINGSIDE	$680,444.00
182	220.7 PROJEC	NEXUS: A novel social network approach to study the effects of intersectional stigma on HIV prevention among Latino MS	NIMH	5R01MH123282-05	GREENWOOD, GREGORY		UNIVERSITY OF CALIFORNIA, SAN DIEGO	$678,582.00
183	Project Summ	Long-term trajectories of psychosocial functioning among transgender youth and their parents.	NICHD	5R01HD112418-02	POPKIN, RONNA		UT SOUTHWESTERN MEDICAL CENTER	$678,490.00
184	PROJECT SUM	Strategies to Prevent HIV Acquisition Among Transgender MSM in the US	NIMH	7R01MH129175-03	STIRRATT, MICHAEL J		UNIVERSITY OF MICHIGAN AT ANN ARBOR	$676,347.00
185	Project Summ	The Collaborative Care PrTNER (Prevention Treatment NavigationEngagement Resource) Project	NIDA	7R01DA059022-02	WEBB, CANDACE KARONDELETTE		CHILDREN'S HOSP OF PHILADELPHIA	$674,186.00
186	ABSTRACTNo	The Role of Local Structural Stigma in Alcohol Related Inequities among SGM Young Adults	NIAAA	1R01AA031637-01A1	FREEMAN, ROBERT		PACIFIC INSTITUTE FOR RES AND EVALUATION	$668,532.00
187	Project Summ	An Online Family-based Program to Prevent Alcohol Use and Dating and Sexual Violence among Sexual and Gender Minority Youth	NIAAA	1R34AA030662-01A1	BALACHOVA, TATIANA NIKOLAYEVNA		UNIVERSITY OF COLORADO	$653,281.00
188	PROJECT SUM	Biopsychosocial mechanisms underlying internalizing psychopathology in a prospective population-based cohort of sexual minor	NIMH	5R01MH118245-05	MORRIS, SARAH E		YALE UNIVERSITY	$652,487.00
189	PROJECT SUM	Measuring and Mapping Trajectories of Risk and Resilience for Suicidal Thoughts and Behaviors in Sexual and Gender Minority Prete	NIMH	1R01MH137695-01	MURPHY, ERIC ROUSSEAU		VANDERBILT UNIVERSITY	$651,915.00
190	Project Summ	Sexual Assault Recovery Among Sexual Minority Women: A Longitudinal Multi-Level Study	NIMHD	5R01MD017573-03	MUJURU, PRISCAH		UNIVERSITY OF WASHINGTON	$645,353.00
191	PROJECT SUM	Geographically-Explicit Ecological Momentary Assessment Protocol to Assess the Linkages Between Intersectional Discrimination,	NHLBI	1R01HL169503-01A1	BROWN, ALISON GWENDOLYN MARY		NEW YORK UNIVERSITY	$636,567.00
192	PROJECT SUM	Sexual minority couples' health during the transition to marriage	NIMHD	5R01MD018167-03	GILLMAN, ARIELLE SAMANTHA		UNIVERSITY OF DENVER (COLORADO SEMINARY)	$632,717.00
193	7. PROJECT S	Female Sexual Orientation GWAS	NICHD	5R01HD100180-05	POPKIN, RONNA		ENDEAVOR HEALTH CLINICAL OPERATIONS	$624,192.00
194	Project Summ	Cardiovascular Health of Sexual and Gender Minorities in the Hispanic Community Health Study/Study of Latinos (SGM HCHS/SOL	NHLBI	5R01HL149778-05	KUNZ, JOHN FREDERIC		UNIV OF NORTH CAROLINA CHAPEL HILL	$615,646.00
195	PROJECT SUM	Social Connectedness and Health among Gender Minority People of Color	NIMHD	5R01MD017085-03	HERREN, OLGA MARINA		COLUMBIA UNIVERSITY HEALTH SCIENCES	$612,485.00
196	PROJECT SUM	Project Recognize: Improving Measurement of Alcohol Use and Other Disparities by Sex Sexual Orientation and Gender Identity thro	NIAAA	5R01AA029076-04	FREEMAN, ROBERT		NORTHWESTERN UNIVERSITY AT CHICAGO	$604,760.00
197	PROJECT SUM	Examining the Mechanisms and Consequences of Sleep Health Inequities Affecting Black Sexual Minority Men	NIMHD	5R01MD019278-02	GILLMAN, ARIELLE SAMANTHA		RAND CORPORATION	$599,087.00
198	PROJECT SUM	AIDS/HIV problem;Accidental Injury;Address;Adult;Affect;Age;Alcohol consumption;Alcohols;Area;Biological Markers;Bisexual;B	NIDA	5R01DA045773-05		DUNSTON, SHEBA KING	GEORGE WASHINGTON UNIVERSITY	$592,421.00
199	Project Summ	Psychosocial Predictors of Risk for Suicidal Behavior Among Gender Minority Adolescents	NIMHD	1R01MD018582-01A1	BURNS, PAUL ANTHONY		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$585,097.00
200	Improving the	Looking Back to Look Forward: Social Environment Across the Life Course Epigenetics and Birth Outcomes in Black Families	NIA	7R01AG069003-04	BRAUDT, DAVID BRUCE		UNIV OF NORTH CAROLINA CHAPEL HILL	$584,035.00
201	PROJECT SUM	Understanding the Role of Structural Oppression for Suicide Risk among Black Sexual and Gender Minority Adolescents and Young	NIMHD	5R01MD018679-02	BARKSDALE, CRYSTAL		RUTGERS BIOMEDICAL AND HEALTH SCIENCES	$582,847.00
202	PROJECT SUM	Violence and viral suppression among men living with HIV	NIMH	5R01MH123388-05	SENN, THERESA ELAINE		UNIVERSITY OF MICHIGAN AT ANN ARBOR	$582,129.00
203	People living \	Evaluation of anal self-sampling in HIV men-who-have-sex-with-men (HIV MSM) populations	NCI	1ZIACP101240-01		CLARKE, MEGAN	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS	$580,000.00
204	Project Abstra	Feasibility and Effectiveness of Gamified Digital Intervention to Prevent Alcohol and Mental Health Risks	NIAAA	5R01AA031175-02	KERRIDGE, BRADLEY TOWNSEND		LOYOLA MARYMOUNT UNIVERSITY	$576,285.00
205	Transgender (	AIDS prevention;Address;Adherence;Adult;Affect;Anus;Behavioral;Biological;Birth;Blood;Caring;Categories;Centers fo	NIMH	5R01MH115765-05		ALLISON, SUSANNAH	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$573,588.00
206	PROJECT SUM	AIDS prevention;Ablation;Address;Adherence;Adult;Age;Anal Sex;Area;Behavioral;Blood;Caring;Clinical;Clinical Trials;	NIAID	5R01AI145675-05		PORTER, KRISTEN AMY	JOHNS HOPKINS UNIVERSITY	$567,621.00
207	PROJECT SUM	UnBIASED: Understanding Biased patient-provider Interaction And Supporting Enhanced Discourse	NLM	5R01LM013301-05	MISQUITTA, LEONIE		UNIVERSITY OF WASHINGTON	$561,008.00
208	Abstract Lesb	Peer Victimization and Risky Alcohol Use among Sexual Minority Youth: Understanding Mechanisms and Contexts	NIAAA	5R01AA028810-04	FREEMAN, ROBERT		STATE UNIVERSITY OF NEW YORK AT BUFFALO	$553,693.00
209	Project Abstra	Public Health Relevance Health disparities adversely affecting sexual and gender minority (SGM) adolescents and youth of colorare	NIMHD	5R01MD015722-04	BARKSDALE, CRYSTAL		UNIVERSITY OF MINNESOTA	$550,391.00
210	Project Summ	Autism Center of Excellence Network: Neurodevelopmental Biomarkers of Late Diagnosis in Female and Gender Diverse Autism	NIMH	5R01MH100028-14	GILOTTY, LISA	PELPHREY, KEVIN A	UNIVERSITY OF VIRGINIA	$550,000.00
211	PROJECT SUM	Examining Health Comorbidities and Healthcare Utilization Disparities among Older Transgender and Cisgender Adults in the U.S.	NIA	5R01AG073440-03	NOVAK, PRISCILLA JOY		BROWN UNIVERSITY	$538,794.00
212	PROJECT SUM	Health and economic consequences of changing federal and state policies on reproductive health.	NICHD	1R01HD112464-01A1	POPKIN, RONNA		UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$538,719.00
213	Project Summ	The Impact of Minority Stress on Alcohol-Related Sexual Assault among Sexual Minority College Students: An Intersectional Mixed	NIAAA	5R01AA031213-02	FREEMAN, ROBERT		UNIVERSITY OF WISCONSIN MILWAUKEE	$538,377.00
214	PROJECT SUM	Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Messag	NCI	5R01CA237670-06	BLAKE, KELLY D		UNIVERSITY OF PENNSYLVANIA	$536,922.00
215	ABSTRACTThe	Modeling Resilience as a Multidimensional Protective Factor for Transgender Health Disparities: Measure Development and Longitu	NIMHD	5R01MD018051-03	GILLMAN, ARIELLE SAMANTHA		MICHIGAN STATE UNIVERSITY	$534,452.00
216	Recent data e	Reproductive Consequences of Steroid Hormone Administration	NICHD	5R01HD098233-05	JOHNSTON, DANIEL STEPHEN		UNIVERSITY OF MICHIGAN AT ANN ARBOR	$532,185.00
217	Project Summ	Sex Gender and the Immunopathogenesis of HIV	NIAID	5R01AI154541-04		NOVAK, LEIA KAYE	JOHNS HOPKINS UNIVERSITY	$531,596.00
218	AbstractUpta	Evaluating the effectiveness of a mobile HIV prevention app to increase HIV and STI testing and PrEP initiation among run	NIMH	5R01MH134267-02	POLLARD-BRANCHARD, SUZY		EMORY UNIVERSITY	$531,589.00
219	Project Summ	Addressing the continuum of care among high-risk Thai men	NIMH	5R01MH119015-05	GREENWOOD, GREGORY		MAHIDOL UNIVERSITY	$531,153.00
220	PROJECT SUM	Intersectional Approaches to Population-Level Health Research: Role of HIV Risk and Mental Health in Alcohol Use Disp	NIAAA	5R01AA029044-04	FREEMAN, ROBERT		NORTHWESTERN UNIVERSITY AT CHICAGO	$530,894.00
221	ABSTRACTTra	Skeletal Health and Bone Marrow Composition Among Youth	NICHD	5R01HD101421-05		RUSSO, DENISE	BOSTON CHILDREN'S HOSPITAL	$529,742.00
222	PROJECT SUM	PrEParados: A Multi-Level Social Network Model to Increase PrEP Enrollment by Latino MSM Self-Identified as Gay Bisex	NIMH	5R01MH125727-03	STIRRATT, MICHAEL J		UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$524,517.00
223	Project Summ	MyPrEP Plus: Development and Pilot Testing of Novel Pre-Exposure Prophylaxis Support Tools for Transgender Women	NIMH	1R34MH132405-01	STIRRATT, MICHAEL J		PUBLIC HEALTH FOUNDATION ENTERPRISES	$521,875.00
224	PROJECT SUM	Stress hazardous drinking and intimate partner aggression in a diverse sample of women and their partners	NIAAA	5R01AA027252-05	FREEMAN, ROBERT		COLUMBIA UNIVERSITY HEALTH SCIENCES	$520,468.00
225	Project Summ	Alcohol minority stress and intimate partner violence: Temporal and prospective associations in sexual minority young adults	NIAAA	5R01AA027248-05	FREEMAN, ROBERT		UNIVERSITY OF WISCONSIN MILWAUKEE	$519,398.00
226	ABSTRACTSTI	STI Response and Recommendations Under PrEP (STIRRUP)	NIMH	5R01MH128130-04	SCOTT-SHELDON, LORI		EMORY UNIVERSITY	$518,619.00
227	SUMMARYThe	Community Outreach and Engagement	NCI	5P30CA124435-16			STANFORD UNIVERSITY	$512,726.00
228	Men who have	Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex with Men	NIAID	5U01AI156874-04	ZIMAND, LORI B.		NORTHWESTERN UNIVERSITY AT CHICAGO	$500,000.00
229	AbstractThe c	RFA-PS-23-006 De Confianza: Creating Medical Trust with Latinx Communities	NCHHSTP	5U01PS005248-02		RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$499,674.00
230	ABSTRACTOv	Acquired Immunodeficiency Syndrome;Address;Adherence;Aging;Area;Biological Markers;Blood;Caring;Chronic;Cohort Studies;Complex;C	NIH	5R01HL160326-05	COADY, SEAN	FRIEDMAN, MACKEY R	RUTGERS BIOMEDICAL AND HEALTH SCIENCES	$497,040.00
231	Enhancing Po	Confidentiality in use of health insurance coverage for reproductive health services	NICHD	1R21HD116080-01	POPKIN, RONNA	JANIAK, ELIZABETH	BRIGHAM AND WOMEN'S HOSPITAL	$495,307.00
232	PROJECT SUM	A Randomized Controlled Trial of an HPV Vaccine Intervention for Young Sexual Minority Men	NCI	5R37CA226682-06	KOBRIN, SARAH	REITER, PAUL L	OHIO STATE UNIVERSITY	$490,264.00
233	PROJECT SUM	Over-the-Counter PrEP: Acceptability Feasibility and Potential Impact of Access without a Prescription (OFFSCRIPT)		1R21MH136855-01	STIRRATT, MICHAEL J	MARCUS, JULIA L.	HARVARD PILGRIM HEALTH CARE, INC.	$489,120.00
234	PROJECT SUM	Choice-Based PrEP Delivery for Transgender People in Uganda	NIMH	5R01MH130208-02	STIRRATT, MICHAEL J	MUJUGIRA, ANDREW	INFECTIOUS DISEASES INSTITUTE	$478,540.00
235	Estimates sug	Harnessing the power of technology to develop a population-based HIV prevention program for trans girls	NINR	5R01NR020309-04	WILLIS, LEIGH ANDREW	YBARRA, MICHELE L.	CENTER FOR INNOVATIVE PUBLIC HEALTH RESEARCH	$472,086.00
236	Project Summ	3-Dimensional;AIDS prevention;Accounting;Address;Adherence;Affect;Age;Area;Behavioral;Black race;Blood;California;Clinic;Clinic Visits	5R01MH119956-05	STIRRATT, MICHAEL J	BUCHBINDER, SUSAN	PUBLIC HEALTH FOUNDATION ENTERPRISES	$471,332.00	
237	Project Summ	AIDS prevention;Address;Adherence;Africa;Age;Bisexual;Caring;Clinical;Communities;Consultations;Control Groups;Country;Data;Discrir	5R01NR021170-02	WILLIS, LEIGH ANDREW	ABU-BA'ARE, GAMJI RABIU	UNIVERSITY OF ROCHESTER	$465,030.00	
238	PROJECT SUM	Development and Initial Trial of Brief Interventions to Help Parents of Stigmatized Youth Reduce Distress and Strengthen Attachmer	NICHD	1R21HD110617-01A1	POPKIN, RONNA	PACHANKIS, JOHN EDWARD	YALE UNIVERSITY	$463,689.00
239		Development and Evaluation of a Multilevel Socio-Culturally Contextualized Digital Health Decision Intervention to Reduce Medical Mistru		5U01PS005283-02			GUILAMO-RAMOS, VINCENT M.	$460,246.00
240	PROJECT SUM	Implementation of PrEP Care Among Women in Family Planning Clinics	NIMH	5R01MH134264-02	POLLARD-BRANCHARD, SUZY		RUSH UNIVERSITY MEDICAL CENTER	$458,824.00
241	Project Abstra	Sampling Strategies and Measure Development for the LGBT Aging Project (SAMLAP)		5R01AG070059-03	PHILLIPS, JOHN	O'MUIRCHEARTAIGH, COLM AONGUS	NATIONAL OPINION RESEARCH CENTER	$458,823.00
242	Summary: Sex	Reconstruction of an SGM-specific sexual violence peer support program (SSS+)		1R15AA030898-01A1	ROACH, DEIDRA	MOXIE, JESSAMYN	UNIVERSITY OF NORTH CAROLINA CHARLOTTE	$458,269.00
243	ABSTRACTKn	STEM-Coaching and Resources for Entrepreneurial Women (CREW)		5R25GM147291-03	BLATCH, SYDELLA ANNE	FEGHALI-BOSTWICK, CAROL A.	MEDICAL UNIVERSITY OF SOUTH CAROLINA	$457,484.00
244	Hispanic/Lati	Exploring and Intervening on Multilevel Factors of Medical Mistrust among Hispanic/Latino Gay Bisexual and Other Men Who Have Sex with I		5U01PS005250-02			RHODES, SCOTT D	$456,915.00
245	ABSTRACTYou	AIDS prevention;Acquired Immunodeficiency Syndrome;Adolescent Development;Adverse event;Affect;Age;Area;Attention;Awareness;Beha	1R21MH130302-01A1	ALLISON, SUSANNAH	BOYD, DONTE T	OHIO STATE UNIVERSITY	$450,125.00	
246	AbstractThe c	Building a Diverse Network to Support and Build Pathways for Historically Underrepresented Students in Quantitative-Focused Research Areas Within the A	1OT2OD037655-01	ALFARANO, ALEXANDRIA SKYE	COOK, STEPHANIE HAZEL	NEW YORK UNIVERSITY	$450,000.00	

	A	B	C	D	E	F	G	H
247	PROJECT SUN	Activities of Daily Living;Address;Adherence;Advocate;Age;Ally;Anti-Retroviral Agents;Bereavement;Bisexual;Caring;Child;Cognitive;Cognitive Therapy;Co		1R21AG087792-01	GERALD, MELISSA S	BATCHELDER, ABIGAIL WINSTON	FENWAY COMMUNITY HEALTH CENTER	$443,875.00
248	Despite the S	Adapting and testing a smoking cessation intervention for transgender and gender-diverse individuals	NCI	1R21CA292185-01	RODITIS, MARIA LEIA	O'CLEIRIGH, CONALL MICHAEL	MASSACHUSETTS GENERAL HOSPITAL	$439,966.00
249	Appalachia is	Harnessing the power of peer navigation and mHealth to reduce health disparities in Appalachia		5R01NR019512-05	GODETTE, DIONNE	RHODES, SCOTT D	WAKE FOREST UNIVERSITY HEALTH SCIENCES	$439,496.00
250	ABSTRACTIt is	Race & Place: The Impacts of Racial Inequality on Substance Use and HIV Outcomes in Los Angeles		1R01DA061345-01	WEBB, CANDACE KARONDELETTE	GORBACH, PAMINA MAE	UNIVERSITY OF CALIFORNIA LOS ANGELES	$439,153.00
251	PROJECT SUN	RP3 PrEP Choice	NICHD	5UM2HD111102-03		HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	$429,460.00
252	PROJECT SUN	Feasibility study for assessing processes and outcomes related to gender affirming care		1R21HD115838-01	POPKIN, RONNA	HUTCHENS, KENDRA	UNIVERSITY OF COLORADO DENVER	$429,000.00
253	Project Summ	Restoring equity to measuring and preventing perinatal intimate partner violence (Remap-IPV)	NICHD	1R25HD116367-01	CHINN, JUANITA JEANNE	HATCHER, ABIGAIL MAE	UNIV OF NORTH CAROLINA CHAPEL HILL	$428,270.00
254	PROJECT SUN	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality		5R01HD109320-02	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$427,618.00
255	ABSTRACTBla	One Ballroom: Understanding Intersectional Stigma to Optimize the HIV Prevention Continuum among Vulnerable Populations in the United States		5DP2AI164315-04	SHARP, GERALD B.	ARAYASIRIKUL, SEAN	UNIVERSITY OF CALIFORNIA-IRVINE	$426,660.00
256	Project Abstra	The Next Generation of Black Women Scientists		5R25GM060566-22	HARTON, MARIE DEBORAH GAYNELLE	BLANKSON, ARABA NAYENA	SPELMAN COLLEGE	$424,969.00
257	Project Summ	Using digital photovoice to explore the relationships between social media content and suicidality among transgender adolescents	NIMH	1R01MH135498-01A1	MURPHY, ERIC ROUSSEAU	NAMBISAN, PRIYA	UNIVERSITY OF WISCONSIN MILWAUKEE	$423,369.00
258	PROJECT ABS	VCU National Coordinating Center for Advancing Gender Inclusive Excellence	NIDDK	1U24DK138889-01	SERRANO, KATRINA JANE		VIRGINIA COMMONWEALTH UNIVERSITY	$421,354.00
259	SUMMARYThi	AIDS prevention;Address;Adherence;Affect;Affordable Care Act;Architecture;Behavioral;Black race;Caring;Clinic;Computer Assisted;Comp		1R21DA062591-01	JENKINS, RICHARD A	GROV, CHRISTIAN	GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY	$420,319.00
260	ABSTRACTSe	Cultural Consensus Modeling to Identify Culturally Relevant Risk and Protective Factors for Suicide among Sexual Minority Youth		1R21MH135130-01A1	MURPHY, ERIC ROUSSEAU	HILL, RYAN	LOUISIANA STATE UNIV A&M COL BATON ROUGE	$417,730.00
261	PROJECT SUN	RP5 MPT Study	NICHD	5UM2HD111102-03		HIGHTOW-WEIDMAN, LISA B	FLORIDA STATE UNIVERSITY	$416,416.00
262	PROJECT SUN	Design of a Lay Health Worker Training Intervention to Promote Mental Health Care Access for Racially Diverse Transgender Youth	NIMH	1R21MH135234-01A1	LUSHIN, VICTOR	BARNETT, MIYA	UNIVERSITY OF CALIFORNIA SANTA BARBARA	$416,299.00
263	Project Summ	Effects of exogenous testosterone therapy on communication in gender diverse speakers	NIDCD	5R01DC020061-04	KOPF, LISA MARIE		BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)	$415,942.00
264	PROJECT SUN	Abstinence;Arousal;Attenuated;Behavior Therapy;Behavioral;Clinical;Cocaine use disorder;Control Groups;Cues;Development;Drug usage;Electroence		5R61DA056779-02	PARIYADATH, VANI	PARVAZ, MUHAMMAD ADEEL	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	$415,322.00
265	PROJECT SUN	Substance use and DNA methylation at the intersection of sex and gender		5R01DA052016-04	LOSSIE, AMY C	FLENTJE, ANNESA	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$415,223.00
266	PROJECT SUN	Center for AIDS Prevention Studies (CAPS)	NIMH	5P30MH062246-24	GORDON, CHRISTOPHER M.	JOHNSON, MALLORY O	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$411,982.00
267	ABSTRACTThe	Recruiting & Retaining Older African Americans into Research (ROAR)		5R24AG065151-03	ELLIOTT, CERISE	MITCHELL, JAYMIA ANN	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$410,803.00
268	PROJECT SUN	18 year old;Address;Adult;Age;Awareness;Behavioral Risk Factor Surveillance System;Bisexual;Cessation of life;Cigarette Smoker;Data;Data Set;Data Sou		5R01CA276500-02	REYES-GUZMAN, CAROLYN	VELIZ, PHILIP T	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$407,963.00
269	PROJECT SUN	Using mixed methods to evaluate self- and other-generated TDM content as predictors of socioemotional well-being in sexual and g	NICHD	5P01HD109850-03		SELKIE, ELLEN MARIE	UNIVERSITY OF WISCONSIN-MADISON	$407,284.00
270	SUMMARY/AB	Elucidating minority stress influences on tobacco use at the intersection of sexual orientation and rurality		1R01DA059480-01A1	DUNSTON, SHEBA KING	ROMM, KATELYN	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$406,246.00
271	PROJECT SUN	Social and structural violence and HIV care continuum outcomes: Developing a trauma-informed HIV care intervention	NIMH	5R01MH123349-05	SENN, THERESA ELAINE	SHANNON, KATE	UNIVERSITY OF BRITISH COLUMBIA	$401,871.00
272	PROJECT SUN	Boosting Mentor Effectiveness iN Training of Research Scientists (MENTORS) Using Social Cognitive Career Theory to Support Entry of Women & Minorities		5U01GM132375-05	GAMMIE, ALISON	ARORA, VINEET	UNIVERSITY OF CHICAGO	$400,242.00
273	Project Summ	Charting Trajectories of Sexual Identity Development and Mental Health Disparities Among Sexual Minority Youth		5R01MD015109-04	BARKSDALE, CRYSTAL	HALL, WILLIAM JAMES	UNIV OF NORTH CAROLINA CHAPEL HILL	$386,605.00
274	PROJECT SUN	Intervention to Enhance PrepPersistence Among African American Men Who Have Sex With Men	NIMH	5R01MH131475-02	STIRRATT, MICHAEL J		BROWN UNIVERSITY	$379,617.00
275	Abstract My B	Achieving Optimal Sexual and Reproductive Health (SRWH Project)	OD	3OT2OD035877-01S1	MADDEN, EBONY B	GIPSON, JUNE ARNESSA	MY BROTHER'S KEEPER, INC.	$375,000.00
276	Virginia Tech	Virginia Tech Postbaccalaureate Research Education Program (VT PREP)		5R25GM066534-20	AKACEM, LAMEESE DANA	SMITH, EDWARD J	VIRGINIA POLYTECHNIC INST AND ST UNIV	$374,968.00
277	PROJECT SUN	Intermountain PREP		5R25GM144253-03	STEPANEK, LAURIE ELIZABETH	MURTAUGH, LEWIS C	UNIVERSITY OF UTAH	$369,845.00
278	PROJECT SUN	Experiences of Rural Sexual and Gender Minority Couples: Does Alcohol Use Explain the Link Between Minority Stress and Intimate	NIAAA	5R01AA030558-02	FREEMAN, ROBERT		UNIVERSITY OF NEBRASKA LINCOLN	$350,000.00
279	PROJECT SUN	Intervention to Enhance PrepPersistence Among African American Men Who Have Sex With Men	NIMH	5R01MH131475-02	STIRRATT, MICHAEL J		BROWN UNIVERSITY	$350,000.00
280	PROJECT SUN	Examining Social Ecological and Network Factors to Assess Epidemiological Risk in a Large National Cohort of Cisgende	NIAID	5R01AI172469-02	ROE, JOANAD'ARC C	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$350,000.00
281		Sailing PrEP: Tailoring PrEP navigation for sexual and gender minorities in Puerto Rico		1U01PS005284-01			KARVER, TAHILIN SANCHEZ	$349,959.00
282	ABSTRACTPol	A novel approach for equitable characterization of gender and its use in exposing subgroup discrepancies in polygenic score associ	NHGRI	5R01HG012697-03	RIVERS, ROBERT C		UNIVERSITY OF IOWA	$348,982.00
283	Abstract:Orop	HPV Oropharyngeal cancer and screening in Gay and Bisexual Men		5R01CA253244-03	CHOLLETTE, VERONICA	ROSS, MICHAEL W	UNIVERSITY OF MINNESOTA	$347,351.00
284	The RCMI Pro	The RCMI Program in Health Disparities Research at Meharry Medical College	NIMHD	5U54MD007586-38	DAS, RINA	ADUNYAH, SAMUEL EVANS	MEHARRY MEDICAL COLLEGE	$345,550.00
285	Project Summ	Stanford Women's Reproductive Health Research Career Development Program		5K12HD103084-05	KAUFMAN, STEVEN	SUBAK, LESLEE L	STANFORD UNIVERSITY	$336,279.00
286	AbstractDeca	How Spouses Influence Each Other's Health in Same- and Different-Sex Marriages: A Dyadic and Longitudinal Assessment from Mid to Later Life		5R37AG076057-04	GERALD, MELISSA S	UMBERSON, DEBRA J.	UNIVERSITY OF TEXAS AT AUSTIN	$329,102.00
287	There is a den	Supporting the Tufts BIRCWH Program with an Additional Scholar Position		3K12AR084217-09S1	TIGNO, XENIA	FREUND, KAREN	TUFTS UNIVERSITY BOSTON	$327,390.00
288	ABSTRACTThi	UCSF-Kaiser Department of Research Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Program		3K12AR084219-26S1	TIGNO, XENIA	HARPER, CYNTHIA C	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$325,591.00
289	SUMMARY MI	PREP-MT: Providing Research Education for Postbaccalaureate Trainees in Montana		5R25GM152359-02	STEPANEK, LAURIE ELIZABETH	BIMCZOK, DIANE	MONTANA STATE UNIVERSITY - BOZEMAN	$325,205.00
290	PROJECT SUN	A Multidimensional Aging Science Program: MSTEM Scholars Trained in Aging Research (MSTEM STAR)		5R25AG076390-03	TORRES, DELANY	PIAZZA, JENNIFER	CALIFORNIA STATE UNIVERSITY FULLERTON	$325,034.00
291	Belonging is a	Bridges: A digital intervention to increase workplace belonging		1R43MD019197-01	JOHNSON, JARRETT AINSWORTH	EVERS, KERRY	PRO-CHANGE BEHAVIOR SYSTEMS, INC.	$324,381.00
292	PROJECT SUN	TRANSforma Tu Salud Dejando de Fumar: Advancing smoking cessation among transgender individuals		1R21CA284313-01	PEARLMAN, PAUL C	CARTUJANO, FRANCISCO	UNIVERSITY OF ROCHESTER	$323,032.00
293	Abstract HIV (	AIDS prevention;Address;Adherence;Affect;Birth;Bisexual;Caring;Central America;Communities;Complex;Country;Data;Destinations;Diag		1R21MH136915-01A1	STENSON, ANAIS FERN	TIEU, HONG VAN NHU	NEW YORK BLOOD CENTER	$308,371.00
294	Our committr	Bachelor's Degree;Behavioral;Biology;Biomedical Research;CCL7 gene;Career Choice;Collaborations;County;Data;Development Plans;Disciplin		5R25GM050070-22	STEPANEK, LAURIE ELIZABETH	MOLONEY, DANIEL J	STATE UNIVERSITY NEW YORK STONY BROOK	$305,137.00
295	Abstract Mala	Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM	FIC	5R33TW011665-06	NEWSOME, BRAD	SHRESTHA, ROMAN	UNIVERSITY OF CONNECTICUT STORRS	$293,778.00
296	Contextual D	Contextual Determinants of Sexual Minority Health in the United States	NIMHD	5R01MD016417-03		MUJURU, PRISCAH	UNIVERSITY OF TEXAS SAN ANTONIO	$291,186.00
297	ABSTRACT Ga	GHB Toxicokinetics: Role of sex hormone dependent monocarboxylate transporter regulation and potential for altered overdose ris	NIDA	5SC1DA052120-04	LE, HOANG VAN	FELMLEE, MELANIE	UNIVERSITY OF THE PACIFIC-STOCKTON	$290,624.00
298	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01	GERALD, MELISSA S	BOGART, LAURA M	RAND CORPORATION	$290,387.00
299	SUMMARY/AB	Social Connectedness Loneliness and Health Among Aging Black Sexual Minority Men	NIA	1R56AG087032-01		GERALD, MELISSA S	RAND CORPORATION	$290,387.00
300	Project Summ	18 year old;Advertisements;Affect;Age;Baltimore;Bisexual;Black race;Caring;Clinic;Communication;Communities;Cyb	NIMH	5R21MH129186-02		ALLISON, SUSANNAH	JOHNS HOPKINS UNIVERSITY	$286,563.00
301	Abstract Hist	Evidence-based Parent Training for Diverse Families (PTDF)	NICHD	1R44HD106855-01A1		GALLEN, COURTNEY LEIGH	IRIS MEDIA, INC.	$283,526.00
302	PROJECT SUN	Sexual Fluidity and Longitudinal Changes in Alcohol Misuse and Associated Health Consequences	NIAAA	5R01AA030243-03		KERRIDGE, BRADLEY TOWNSEND	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$280,253.00
303	In the general	Youth Empowerment and Safety Intervention for Systems-involved Sexual and Gender Minority Youth at Risk of Suicide	NIMH	1R34MH134912-01A1		O'CONNOR, STEPHEN	CASE WESTERN RESERVE UNIVERSITY	$279,366.00
304	Transgender v	Optimizing an mHealth intervention to improve uptake and adherence of the HIV pre-exposure prophylaxis (PrEP) in vuln	NICHD	5R33HD107988-04	YATES, FRANKLIN WILLEM	WANG, BO	UNIV OF MASSACHUSETTS MED SCH WORCESTER	$278,952.00
305	A health work	Sexual and Gender Minority Cancer Curricular Advances for Research and Education (SGM Cancer CARE)	NCI	5R25CA265802-03		RADAEV, SERGEY	UNIVERSITY OF TX MD ANDERSON CAN CTR	$277,181.00
306	PROJECT SUN	Integrated Alcohol and Sexual Assault Prevention for Bisexual Women	NIAAA	5R34AA030035-03		KERRIDGE, BRADLEY TOWNSEND	RHODE ISLAND HOSPITAL	$275,273.00
307	Project Summ	14 year old;Address;Adolescent;Age;Attitude;Behavior;Cause of Death;Child;Communities;Complex;Data;Development;Distress	NIMHD	1R21MD019829-01		GOGINENI, ARUNDHATI	UNIVERSITY OF SOUTHERN CALIFORNIA	$269,438.00
308	PROJECT SUN	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$267,000.00
309	PROJECT SUN	Cardiometabolic effects of gender-affirming hormone therapy in transgender adolescents	NICHD	5R21HD107609-02	WINER, KAREN	WEINZIMER, STUART ALAN	YALE UNIVERSITY	$266,081.00
310	Project Abstra	Examining reproductive and sexual health during the transition to adulthood	NICHD	1R56HD113725-01A1		POPKIN, RONNA	INNOVATION RESEARCH AND TRAINING, INC.	$263,996.00
311	PROJECT ABS	The BH-Works Suicide Prevention Program for Sexual and Gender Minority Youth	NIMH	5R34MH129785-03		O'CONNOR, STEPHEN	VIRGINIA POLYTECHNIC INST AND ST UNIV	$263,102.00
312	PROJECT ABS	Adapting the FOCUS Program for Sexual and Gender Minority (SGM) Cancer Patients and Caregivers	NCI	5R34CA283408-02		DEAN, DAVID WORTH	UNIVERSITY OF ROCHESTER	$261,095.00
313	PROJECT SUN	AIDS prevention;Address;Adherence;Adult;Age;Awareness;Cicatrix;Continuity of Patient Care;Data;Decision Making;D	NIAID	1R21AI183907-01A1		MATHIAS, CHERLYNN	UNIVERSITY OF WASHINGTON	$259,807.00
314	Project Summ	Adaptation and feasibility of Many Men Many Voices (3MV) an HIV prevention intervention to reduce intersectional stigr	FIC	5R01TW012671-02		BANSAL, GEETHA PARTHASARATHY	UNIVERSITY OF ROCHESTER	$257,515.00
315	PROJECT SUN	Training in Genomics Research (TiGeR)	NHGRI	5R25HG012330-03	XIRASAGAR, SANDHYA		ARIZONA STATE UNIVERSITY-TEMPE CAMPUS	$252,692.00
316	Project Summ	Advancing help-seeking and recovery measures for sexual and gender minority survivors of gender-based violence	NIMHD	1R21MD019089-01A1		MUJURU, PRISCAH	TEMPLE UNIV OF THE COMMONWEALTH	$250,709.00
317	PROJECT SUN	ADVANCE SGM Health for Research Diversity	NIMHD	1T32MD019780-01		BARKSDALE, CRYSTAL	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$250,060.00
318	Men who have	Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex with Men	NIAID	5U01AI156874-04	ZIMAND, LORI B.		NORTHWESTERN UNIVERSITY AT CHICAGO	$250,000.00
319	PROJECT SUN	Development and Preliminary Trial of a Digital Transdiagnostic CBT Intervention for Transgender Adolescents	NIMH	1R34MH133768-01A1	BURSTEIN, MARCY ELLEN	CHEN, DIANE	LURIE CHILDREN'S HOSPITAL OF CHICAGO	$249,765.00
320	Individuals ra	Transdisciplinary Health Disparities Research Training for Native Hawaiians and Pacific Students	NIMHD	5T37MD008636-10	OLADEINDE, YEWANDE A	SY, ANGELA U	UNIVERSITY OF HAWAII AT MANOA	$249,400.00
321	PROJECT	Event-level Antecedents of Heavy Drinking Among Bisexual and Heterosexual Women with and without Histories of Sexual Assault	NIAAA	4R00AA030079-03	KERRIDGE, BRADLEY TOWNSEND	LOPEZ, GABRIELA	RHODE ISLAND HOSPITAL	$249,000.00
322	PROJECT SUN	Event-level Antecedents of Heavy Drinking Among Bisexual and Heterosexual Women with and without Histories of Sexual Assault	NIAAA	4R00AA030079-03		KERRIDGE, BRADLEY TOWNSEND	RHODE ISLAND HOSPITAL	$249,000.00
323	PROJECT SUN	Sexually Transmited Infection Testing Risk and Prevention among Trans Women (STRIP-T)	NIMHD	4R00MD017967-03		HERREN, OLGA MARINA	UNIVERSITY OF CENTRAL FLORIDA	$249,000.00
324	PROJECT SUN	Stigma Romantic Relationships and Alcohol Use Among Transgender and Nonbinary Young Adults	NIAAA	4R00AA030601-03	KERRIDGE, BRADLEY TOWNSEND	MURCHISON, GABRIEL R	BOSTON UNIVERSITY MEDICAL CAMPUS	$249,000.00
325	The applicant	AIDS prevention;Address;Area;Attitude;Award;Behavior;Behavior Therapy;Behavioral;Caring;Collaborations;Communi	NIDA	4R00DA055508-03		JENKINS, RICHARD A	ILLINOIS INSTITUTE OF TECHNOLOGY	$249,000.00
326	PROJECT SUN	Testing the effect of anti-tobacco message framing on polytobacco use in lesbian gay bisexual and transgender young adults	NCI	5R00CA260718-04		MAYER, MARGARET ELIZABETH	OHIO STATE UNIVERSITY	$248,993.00
327	PROJECT SUN	AIDS prevention;Achievement;Acquired Immunodeficiency Syndrome;Address;Admission activity;Affect;Area;Arts;Awar	NIMH	5R25MH126703-04		ALLISON, SUSANNAH	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$247,641.00
328	ABSTRACT AN	The Role of Testosterone on Mediating Sex and Gender Influences on Chronic Orofacial Pain Conditions	NIDCR	5R01DE032225-02	GHIM, MELISSA M	RO, JIN Y	UNIVERSITY OF MARYLAND BALTIMORE	$246,556.00
329	PROJECT SUN	Population-Specific Eating Disorder Risk Factors in Sexual Minority Women	NIMHD	5R00MD015770-04		JOHNSON, JARRETT AINSWORTH	UNIVERSITY OF COLORADO DENVER	$244,716.00

	A	B	C	D	E	F	G	H
330	Project Summ	Enhancing Engagement with Online Health Messaging about Oral and Injectable PrEP Among Young-Adult MSM	NIMH	5R21MH133487-02		GREENWOOD, GREGORY	PENNSYLVANIA STATE UNIVERSITY, THE	$241,500.00
331	Project Summ	Defining the neovaginal microbiome after gender affirming vaginoplasty	NIAID	1R21AI178840-01A1	CHUANG, ELEANORE JENNIFER	FARR ZUEND, CHRISTINA	CASE WESTERN RESERVE UNIVERSITY	$241,500.00
332	PROJECT SUM	A mixed-methods approach to understanding stress and hazardous drinking among same-sex female couples	NIAAA	5R00AA028049-05		ZHA, WENXING	NORTHWESTERN UNIVERSITY AT CHICAGO	$241,466.00
333	PROJECT SUM	An intervention to promote healthy relationships among transgender and gender expansive youth	NICHD	5R21HD107311-02		POPKIN, RONNA	SEATTLE CHILDREN'S HOSPITAL	$240,544.00
334	The aim of thi	In-depth Understanding of HIV Risk Behavior among Men Who Have Sex With Men in Sub-Saharan Africa: Secondary Ana	NIMH	5R21MH130217-02		SCOTT-SHELDON, LORI	NEW YORK STATE PSYCHIATRIC INSTITUTE	$240,219.00
335	AbstractTrans	Tcher Take Charge: Increasing PrEP Awareness Uptake and Adherence Through Health Care Empowerment and Addressi	NIMH	5R01MH128049-04	POLLARD-BRANCHARD, SUZY		PUBLIC HEALTH FOUNDATION ENTERPRISES	$237,100.00
336	AbstractTrans	Tcher Take Charge: Increasing PrEP Awareness Uptake and Adherence Through Health Care Empowerment and Addressi	NIMH	5R01MH128049-04	POLLARD-BRANCHARD, SUZY		PUBLIC HEALTH FOUNDATION ENTERPRISES	$237,100.00
337	PROJECT SUM	Brothers building brothers by breaking barriers (B6): A resilience-focused intervention for young Black gay and bisexual men living w	NIMH	5R34MH129187-03		ALLISON, SUSANNAH	EMORY UNIVERSITY	$234,600.00
338	PROJECT SUM	ESTEEMED Scholars Program at the University of Rhode Island	NIBIB	5R25EB034489-02		GATLIN, TINA L.	UNIVERSITY OF RHODE ISLAND	$234,392.00
339	Project Summ	Proud to Quit (P2Q): A Person-centered mobile technology intervention for smoking cessation among transgender adults	NIDA	5R34DA058191-02	FITZ-RANDOLPH, MARCY ESTHER	SUN, CHRISTINA JIAYI	UNIVERSITY OF COLORADO DENVER	$234,262.00
340	Project Summ	Identifying Community-Informed DoxyPEP Implementation Strategies to Guide Equitable Delivery of Syphilis Prevention	NIMHD	5R21MD018707-02		FERNANDEZ, ANGELA R	UNIVERSITY OF CHICAGO	$232,669.00
341	Pre-exposure	AIDS prevention;Address;Adherence;Agreement;Appointment;Awareness;Behavioral;Biological;Bisexual;Black race;Bl	NIMH	5R34MH129279-03		STIRRATT, MICHAEL J	SAN DIEGO STATE UNIVERSITY	$230,997.00
342	PROJECT ABS	Reframing personal and community report back of consumer products by centering intersectionality		1R01ES036258-01	MCALLISTER, KIMBERLY A.	ZOTA, AMI R	COLUMBIA UNIVERSITY HEALTH SCIENCES	$230,305.00
343	Project Summ	Buddhism and HIV Stigma in Thailand: An Intervention Study	FIC	5R01TW012392-03	BANSAL, GEETHA PARTHASARATHY	CHEN, WEI-TI	UNIVERSITY OF CALIFORNIA LOS ANGELES	$224,971.00
344	PROJECT SUM	AIDS prevention;Adherence;Appointment;Behavioral;Cities;Code;Data;Data Collection;Development;Effectiveness;E	NIDA	7R21DA058575-02		JENKINS, RICHARD A	HARVARD PILGRIM HEALTH CARE, INC.	$220,370.00
345	Project Summ	Daily Impact of Sexual Minority Stress on Alcohol-Related Intimate Partner Violence among Bisexual+ Young Adults: A Couples' Da	NIAAA	1R21AA031548-01A1		FREEMAN, ROBERT	VIRGINIA POLYTECHNIC INST AND ST UNIV	$218,293.00
346	Project Summ	The All-or-Nothing Marriage? Marital Functioning and Health Among Individuals in Same and Different-Gender Marriages	NIA	5R01AG060944-05		BRAUDT, DAVID BRUCE	UNIVERSITY OF MINNESOTA	$218,169.00
347	Project Abstra	Strengthening the HIV care continuum for transgender women living with HIV in Malaysia	NIMH	5R21MH128114-02	ALLISON, SUSANNAH	WICKERSHAM, JEFFREY ALLEN	YALE UNIVERSITY	$218,127.00
348	PROJECT SUM	Ecological momentary assessment of daily minority stressors and cannabis and tobacco co-use among sexual minority young adu	NIMHD	1R21MD019345-01A1		GOGINENI, ARUNDHATI	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$216,772.00
349	PROJECT SUM	Short Trainings on Methods for Recruiting Sampling and Counting Hard-to-Reach Populations: The H2R Training Program	NIMH	5R25MH129290-03	ALLISON, SUSANNAH	MIRZAZADEH, ALI	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$216,249.00
350	ABSTRACT AN	The Role of Testosterone on Mediating Sex and Gender Influences on Chronic Orofacial Pain Conditions	NIDCR	5R01DE032225-02	GHIM, MELISSA M	RO, JIN Y	UNIVERSITY OF MARYLAND BALTIMORE	$215,441.00
351	ABSTRACTSui	CA-LINC: A Culturally Adapted Care Coordination Suicide Detection and Intervention Model for Black Youth	NIMH	5R34MH129782-03		ACRI-MARRO, MARY	UNIVERSITY OF NORTH CAROLINA CHARLOTTE	$214,271.00
352	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$214,000.00
353	PROJECT SUM	AIDS prevention;Adoption;Advocate;Bisexual;Caring;Chlamydia;Clinic;Collaborations;Communication difficulty;Comm	NIMH	5R34MH129208-03		SENN, THERESA ELAINE	MEDICAL COLLEGE OF WISCONSIN	$213,959.00
354	PROJECT SUM	Intersectional minority stress mental health and HIV treatment and care among MSM living with HIV in Ghana	NIMH	5K01MH130270-03		SENN, THERESA ELAINE	STATE UNIVERSITY OF NEW YORK AT BUFFALO	$211,430.00
355	ABSTRACTIn S	Formative work for the development of an intervention to support combined HIV/syphilis self-testing and linkage to prev	NIMH	1R21MH135779-01A1	GREENWOOD, GREGORY	RAEL, CHRISTINE TAGLIAFERRI	UNIVERSITY OF COLORADO DENVER	$211,326.00
356	PROJECT SUM	18 year old;Address;Adopted;Adult;Advisory Committees;Affect;Anxiety;Anxiety Disorders;Area;Attention;Bisexual;Clinical;Clinica	NIMH	1K23MH137389-01		SWEENEY, MAGGIE	HUNTER COLLEGE	$211,103.00
357	PROJECT SUM	Understanding Breast Cancer Risk and Screening in Transgender Persons through a Pilot Breast Cancer Screening Program	NCI	5K08CA276706-02		BIAN, YANSONG	MEDICAL COLLEGE OF WISCONSIN	$210,062.00
358	Men who have	Integration of Electronic SBI(RT) into an HIV Testing Program to Reduce Substance Use and HIV risk Behavior among MS	NIDA	5R34DA055503-03	LEE-WINN, ANGELA EUNJI	BALAN, IVAN C	FLORIDA STATE UNIVERSITY	$209,449.00
359	ABSTRACTIn t	Formative work to develop differentiated communication tools to facilitate transgender women's recruitment enrollme	NIMH	5R21MH132421-02	STIRRATT, MICHAEL J	RAEL, CHRISTINE TAGLIAFERRI	UNIVERSITY OF COLORADO DENVER	$208,242.00
360	7. Project Sun	Intersectional discrimination and linkage to HIV prevention and care in transgender women in Ecuador	NIMH	5K01MH134764-02	GREENWOOD, GREGORY	AGUAYO ROMERO, RODRIGO ARMANDO	WHITMAN-WALKER INSTITUTE, INC.	$207,691.00
361	PROJECT SUM	Building Interdisciplinary Research Careers in Women's Health at UC Davis	NIAMS	3K12AR084220-21S1	TIGNO, XENIA	LANE, NANCY E	UNIVERSITY OF CALIFORNIA AT DAVIS	$206,172.00
362	PROJECT SUM	Using youth-engaged methods to develop and evaluate a measure for disordered eating behaviors in transgender and gender-divers	NIMH	1K23MH134111-01		BECHTHOLT, ANITA J	VIRGINIA COMMONWEALTH UNIVERSITY	$205,308.00
363	Young men ha	Adapting effective mhealth interventions to improve uptake and adherence of the HIV pre- exposure prophylaxis (PrEP) i	NIMH	5R34MH124081-03	ALLISON, SUSANNAH	WANG, BO	UNIV OF MASSACHUSETTS MED SCH WORCESTER	$202,639.00
364	Project Summ	Building an interprofessional and diverse workforce in substance use and pain	NIDA	1T32DA057926-01A1		LIN, YU	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$202,337.00
365	PROJECT SUM	CHAMPION - Combining HIV And Stimulant Prevention and Treatment Interventions Optimized for HIV-Negative MSM	NIDA	1R21DA060856-01A1	JENKINS, RICHARD A	TSUYUKI, KIYOMI	UNIVERSITY OF CALIFORNIA, SAN DIEGO	$202,308.00
366	Background. S	19 year old;Address;Adherence;Age;Agreement;Anti-Retroviral Agents;Appointment;Attention;Behavioral;Behavioral M	NIMH	5R34MH126894-03		ALLISON, SUSANNAH	BROWN UNIVERSITY	$202,013.00
367	Project Summ	Data-driven peer-led messaging using social media influencers to increase PrEP awareness and uptake among transgen	NIMH	5R34MH129189-03	SCOTT-SHELDON, LORI	BASS, SARAH B	TEMPLE UNIV OF THE COMMONWEALTH	$201,803.00
368	Significance.	AIDS prevention;AIDS/HIV problem;Address;Adherence;Affect;Back;Behavior;Behavior Therapy;Behavioral Research;B	NIDA	5R21DA053156-02		HARTSOCK, PETER	NEW YORK STATE PSYCHIATRIC INSTITUTE	$200,782.00
369	Project Summ	Psychosocial Predictors of Risk for Suicidal Behavior Among Gender Minority Adolescents	NIMHD	1R01MD018582-01A1	BURNS, PAUL ANTHONY		UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$200,000.00
370	Project Summ	Two-Spirit Films in Indigenous Cancer Health	NCI	3P30CA016056-47S1		HE, MIN	ROSWELL PARK CANCER INSTITUTE CORP	$200,000.00
371	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$200,000.00
372	In the United S	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$200,000.00
373	In the United S	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$200,000.00
374	AbstractUpta	Evaluating the effectiveness of a mobile HIV prevention app to increase HIV and STI testing and PrEP initiation among rur	NIMH	5R01MH134267-02	POLLARD-BRANCHARD, SUZY		EMORY UNIVERSITY	$200,000.00
375	PROJECT SUM	Experiences of Rural Sexual and Gender Minority Couples: Does Alcohol Use Explain the Link Between Minority Stress and Intimate	NIAAA	5R01AA030558-02	FREEMAN, ROBERT		UNIVERSITY OF NEBRASKA LINCOLN	$177,063.00
376	ABSTRACTPol	A novel approach for equitable characterization of gender and its use in exposing subgroup discrepancies in polygenic score associ	NHGRI	5R01HG012697-03	RIVERS, ROBERT C		UNIVERSITY OF IOWA	$160,444.00
377	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$160,000.00
378	SUMMARY/AE	Kabawil: Adapting an Intervention to Reduce Intersectional Stigmas among Indigenous Sexual Minority Men and Traditional Healers	FIC	1R01TW012904-01		BANSAL, GEETHA PARTHASARATHY	UNIVERSITY OF WASHINGTON	$157,738.00
379	PROJECT SUM	Sexual Fluidity and Longitudinal Changes in Alcohol Misuse and Associated Health Consequences	NIAAA	3R01AA030243-03S1	KERRIDGE, BRADLEY TOWNSEND	EVANS-POLCE, REBECCA J.	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$155,941.00
380	PROJECT SUM	Multilevel strategies to understand and modify the role of structural and environmental context on HIV inequities for sex	NIAID	4UH3AI169655-03	ZIMAND, LORI B.	RENDINA, H. JONATHON	GEORGE WASHINGTON UNIVERSITY	$150,000.00
381	PROJECT SUM	Examining Social Ecological and Network Factors to Assess Epidemiological Risk in a Large National Cohort of Cisgende	NIAID	5R01AI172469-02	ROE, JOANAD'ARC C	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$150,000.00
382	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$150,000.00
383	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$150,000.00
384	Project Summ	Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness / Implemen	NICHD	5UG1HD113160-02	RUSSO, DENISE	GAROFALO, ROBERT	NORTHWESTERN UNIVERSITY AT CHICAGO	$150,000.00
385	Despite an ar	Malaysian Implementation Science Training (MIST) Program in HIV	FIC	5D43TW011324-05	BANSAL, GEETHA PARTHASARATHY	ALTICE, FREDERICK LEWIS	YALE UNIVERSITY	$147,920.00
386	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$147,825.00
387	PROJECT SUM	Predicting acute and dynamic suicide risk in rural sexual minorities	NIMHD	5K08MD019314-03	JONES, NANCY LYNNE	FORREST, LAUREN NICOLE	UNIVERSITY OF OREGON	$139,738.00
388	Project Summ	Stigma Reduction and Gender Affirmation to Promote HIV Prevention/Testing in Trans Women	FIC	7R21TW012010-03	BANSAL, GEETHA PARTHASARATHY	OPERARIO, DON	EMORY UNIVERSITY	$139,298.00
389	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$118,365.00
390	ABSTRACTTra	Improving the accessibility of transgender voice training with visual-acoustic biofeedback	NIDCD	5R21DC021537-02	KOPF, LISA MARIE	NOVAK, VESNA DOMINIKA	UNIVERSITY OF CINCINNATI	$114,998.00
391	PROJECT SUM	Implementation of PrEP Care Among Women in Family Planning Clinics	NIMH	5R01MH134264-02	POLLARD-BRANCHARD, SUZY		RUSH UNIVERSITY MEDICAL CENTER	$100,000.00
392	PROJECT ABS	Reframing personal and community report back of consumer products by centering intersectionality		1R01ES036258-01	MCALLISTER, KIMBERLY A.	ZOTA, AMI R	COLUMBIA UNIVERSITY HEALTH SCIENCES	$100,000.00
393	PROJECT ABS	Reframing personal and community report back of consumer products by centering intersectionality		1R01ES036258-01	MCALLISTER, KIMBERLY A.	ZOTA, AMI R	COLUMBIA UNIVERSITY HEALTH SCIENCES	$100,000.00
394	Despite an ar	Malaysian Implementation Science Training (MIST) Program in HIV	FIC	5D43TW011324-05	BANSAL, GEETHA PARTHASARATHY	ALTICE, FREDERICK LEWIS	YALE UNIVERSITY	$100,000.00
395	Project Summ	Effects of exogenous testosterone therapy on communication in gender diverse speakers	NIDCD	5R01DC020061-04	KOPF, LISA MARIE		BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)	$100,000.00
396	PROJECT ABS	VCU National Coordinating Center for Advancing Gender Inclusive Excellence	NIDDK	1U24DK138889-01	SERRANO, KATRINA JANE		VIRGINIA COMMONWEALTH UNIVERSITY	$100,000.00
397	In the United S	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$100,000.00
398	In the United S	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$100,000.00
399	ABSTRACTTra	Improving the accessibility of transgender voice training with visual-acoustic biofeedback	NIDCD	5R21DC021537-02	KOPF, LISA MARIE	NOVAK, VESNA DOMINIKA	UNIVERSITY OF CINCINNATI	$100,000.00
400	PROJECT SUM	Improving service delivery models of medically assisted reproduction: A patient journey mapping study of sexual minority women	NIMHD	3R01MD015256-05S1	MUJURU, PRISCAH	CHARLTON, BRITTANY MICHELLE	HARVARD PILGRIM HEALTH CARE, INC.	$99,998.00
401	PROJECT SUM	A digital health intervention to increase condom use among adolescent sexual minority males	NIMHD	5K99MD019060-02	GARRIDO, CARLOS OSWALDO	JAVIDI, HANNAH	TRUSTEES OF INDIANA UNIVERSITY	$99,424.00
402	PROJECT SUM	Improving Measurement of Alcohol Use and Other Disparities by Sex, Sexual Orientation, and Gender Identity through Community	NIAAA	3R01AA029076-04S1	FREEMAN, ROBERT	PHILLIPS, GREGORY L.	NORTHWESTERN UNIVERSITY AT CHICAGO	$99,083.00
403	This applicati	Randomized Controlled Trial of Dyadic Financial Incentive Treatment for Dual Smoker Couples: Evaluation of Efficacy Mechanisms	NCI	3R01CA276594-02S1	RODITIS, MARIA LEIA	VANDELLEN, MICHELLE RENEE	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$95,486.00
404	Men-who-hav	Evaluating HPV Vaccination Uptake Barriers and its Efficacy in PLWH	NIMHD	3U54MD007601-38S2	LAI, GABRIEL Y	HEDGES, JERRIS ROBERT	UNIVERSITY OF HAWAII AT MANOA	$92,787.00
405	The U-RISE at	U-RISE at Spelman College	NIGMS	1T34GM149823-01A1	HARTON, MARIE DEBORAHGAYNELLE	BLANKSON, ARABA NAYENA	SPELMAN COLLEGE	$90,514.00
406	PROJECT SUM	Promoting Health and Reducing Risk among Hispanic Sexual Minority Youth and their Families	NIMHD	3R01MD017588-03S1	BARKSDALE, CRYSTAL	PRADO, GUILLERMO	UNIVERSITY OF MIAMI CORAL GABLES	$85,939.00
407	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$85,500.00
408	SUMMARYThe	Career Enhancement Program	NCI	5P20CA275734-02		MASKARINEC, GERTRAUD	UNIVERSITY OF HAWAII AT MANOA	$83,937.00
409	PROJECT SUM	Refinement of a Training Module to Improve Discussions of Sexual Orientation and Gender Identity in Cancer Clinics	NCI	1R03CA289560-01	MARCUS, PAMELA M.	CATHCART-RAKE, ELIZABETH	MAYO CLINIC ROCHESTER	$80,700.00
410	Project summ	Romantic Relationships, Discrimination Stressors, and Alcohol Use among Sexual and Gender Minority Adults	NIAAA	1R03AA031740-01	RUFFIN, BEVERLY	GREENE, KAYLIN	MONTANA STATE UNIVERSITY - BOZEMAN	$80,316.00
411	ABSTRACTIn t	A multi-level approach to improve HIV prevention and care for transgender women of color	NIMH	7R01MH129285-02	ALLISON, SUSANNAH		NEW YORK STATE PSYCHIATRIC INSTITUTE	$80,000.00

	A	B	C	D	E	F	G	H
412	Project Summ	Improving Sexual Minority Health: Differences in Substance Use, Substance Use Treatment, and Associated Chronic Diseases amo	NIDA	5R03DA052651-02	LYNCH, SEAN EDWARD WINTERS	MORGAN, ETHAN	OHIO STATE UNIVERSITY	$79,291.00
413	PROJECT SUM	Understanding the individual and combined impact of childhood sexual abuse and minority stress on hazardous drinking among s	NIAAA	5F32AA029957-03	KERRIDGE, BRADLEY TOWNSEND	BOCHICCHIO, LAUREN ANN	COLUMBIA UNIVERSITY HEALTH SCIENCES	$78,892.00
414	PROJECT SUM	Sexual Minority Mental Health During the COVID-19 Pandemic: An Intersectional, Social Epidemiologic Investigation	NIMHD	5F32MD017452-03	MUJURU, PRISCAH	BECCIA, ARIEL L	BOSTON CHILDREN'S HOSPITAL	$78,784.00
415	Project Summ	Piloting a multi-level intervention to promote viral suppression among transgender women living with HIV	NIMH	5R34MH129218-03	ALLISON, SUSANNAH	BARRINGTON, CLARE L	UNIV OF NORTH CAROLINA CHAPEL HILL	$78,491.00
416	In Malaysia th	Training in Behavioral Design Interventions to Address Stigma among Men Who have Sex with Men	NIMH	1F32MH138253-01	ALLISON, SUSANNAH	BROMBERG, DANIEL J	YALE UNIVERSITY	$77,908.00
417	Project Summ	Applying Deep Learning for Predicting Retention in PrEP Care and Effective PrEP Use among Key Populations at Risk for H	NIMH	5R03MH130275-02	SCOTT-SHELDON, LORI	LIU, FEIFAN	UNIV OF MASSACHUSETTS MED SCH WORCESTER	$76,214.00
418	Project Abstra	Sexual orientation, gender identity, and alcohol use: A multi-method analysis of developmental differences and key mechanisms	NIAAA	5F32AA030194-03	FREEMAN, ROBERT	BISHOP, MEG	UNIV OF MARYLAND, COLLEGE PARK	$76,047.00
419	Project Summ	Stigma Reduction and Gender Affirmation to Promote HIV Prevention/Testing in Trans Women	FIC	7R21TW012010-03	BANSAL, GEETHA PARTHASARATHY	OPERARIO, DON	EMORY UNIVERSITY	$75,000.00
420	ABSTRACT Th	The ADAR Summit Meeting	NIA	2R13AG066389-06	LUO, YUAN	LEVKOFF, SUE E	UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA	$74,959.00
421	The RCMI Pro	The RCMI Program in Health Disparities Research at Meharry Medical College	NIMHD	5U54MD007586-38	DAS, RINA	ADUNYAH, SAMUEL EVANS	MEHARRY MEDICAL COLLEGE	$72,750.00
422	PROJECT SUM	Development and Testing of MyPEEPS Mobile for Young Transgender Men	NIMH	5R34MH128163-03	GREENWOOD, GREGORY	SCHNALL, REBECCA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$72,743.00
423	SUMMARY/In t	Training the Long-Term Services and Supports Dementia Care Workforce in Provision of Care to Sexual and Gender Minority Residen	NIA	3R01AG075734-03S1	GERALD, MELISSA S	ROSSER, B R SIMON	UNIVERSITY OF MINNESOTA	$69,606.00
424	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$68,500.00
425	PROJECT SUM	SWG1: Sex & Gender Working Group	NIAID	5P30AI036219-28		CAMERON, CHERYL M	CASE WESTERN RESERVE UNIVERSITY	$66,771.00
426	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$66,666.00
427	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$66,666.00
428	PROJECT SUM	Population Sciences	NCI	5P30CA124435-16		JOHN, ESTHER M.	STANFORD UNIVERSITY	$66,651.00
429	PROJECT SUM	Adapting an evidence-based intervention to improve HIV testing and PrEP uptake among young men who have sex with m	FIC	1K43TW012850-01	BANSAL, GEETHA PARTHASARATHY	NGUYEN, MINH XUAN BINH	HANOI MEDICAL UNIVERSITY	$66,427.00
430	Project Summ	A culturally centered CBT protocol for suicidal ideation and suicide attempts among Latinx youth	NIMHD	3R01MD013907-05S1	DAGHER, RADA K	DUARTEVELEZ, YOVANSKA	EMMA PENDLETON BRADLEY HOSPITAL	$64,508.00
431	Project Abstra	Heavy cannabis use neurocognition and PrEP care engagement among young Black sexual minority men	NIDA	3R01DA057351-03S1	LAO, GUIFANG	SCHNEIDER, JOHN	UNIVERSITY OF CHICAGO	$62,320.00
432	PROJECT SUM	Community Engagement and Health Equity Core	NIDDK	5P30DK092949-14		PEEK, MONICA E	UNIVERSITY OF CHICAGO	$61,556.00
433	Severe inequi	ED2PrEP - patient focused low-burden strategies for PrEP uptake among emergency departments patients: a cross-over	NIAID	3R01AI169636-03S1	SHARMA, USHA K.	FELSEN, URIEL	ALBERT EINSTEIN COLLEGE OF MEDICINE	$57,967.00
434	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$56,700.00
435	PROJECT SUM	Substance use and DNA methylation at the intersection of sex and gender		5R01DA052016-04	LOSSIE, AMY C	FLENTJE, ANNESA	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$56,152.00
436	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
437	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
438	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
439	PROJECT SUM	Center for AIDS Research at Emory University	NIAID	5P30AI050409-26	REFSLAND, ERIC WILLIAM	DEL RIO, CARLOS	EMORY UNIVERSITY	$51,700.00
440	Project Abstra	Multi-Level Determinants of Sexual and Gender Minority Aging	NIA	5R36AG083386-02	NGUYEN, EMERALD THAI HAN	TRAN, NATHANIEL M	VANDERBILT UNIVERSITY	$51,650.00
441	PROJECT SUM	Dissecting the role of loneliness on substance use- and HIV-related outcomes among sexual minority men in the United	NIDA	1R36DA061635-01	DUNSTON, SHEBA KING	MARZIALI, MEGAN ELYSSA	COLUMBIA UNIVERSITY HEALTH SCIENCES	$51,390.00
442	Project Summ	Biological Mechanisms of Suicidal Behavior among Sexual Minority Adolescents - Supplement	NIMH	3K01MH117142-05S1	BECHTHOLT, ANITA J	THOMA, BRIAN	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$50,941.00
443	PROJECT SUM	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality	NICHD	3R01HD109320-02S1	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$50,000.00
444	PROJECT SUM	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality	NICHD	3R01HD109320-02S1	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$50,000.00
445	PROJECT SUM	Advancing novel survey tools to increase participation and improve sexual and reproductive health data quality		5R01HD109320-02	POPKIN, RONNA	MOSESON LIDOW, HEIDI SERENE	IBIS REPRODUCTIVE HEALTH	$50,000.00
446	Abstract The h	Structural Racism and Discrimination in Sexual and Gender Minority Health Inequities - Supplement	NIA	3R01AG077934-03S1	GERALD, MELISSA S	RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$50,000.00
447	Abstract The h	Structural Racism and Discrimination in Sexual and Gender Minority Health Inequities - Supplement	NIA	3R01AG077934-03S1	GERALD, MELISSA S	RAMIREZ-VALLES, JESUS	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$50,000.00
448	Project Summ	Exploring the Role of Novel Aging-Focused Syndemic Conditions on HIV Risk and Quality of Life among HIV-Negative Old	NIDA	5R36DA058563-02	DUNSTON, SHEBA KING	WEINSTEIN, ELLIOTT ROYAL	UNIVERSITY OF MIAMI CORAL GABLES	$50,000.00
449	Despite an ar	Malaysian Implementation Science Training (MIST) Program in HIV	FIC	5D43TW011324-05	BANSAL, GEETHA PARTHASARATHY	ALTICE, FREDERICK LEWIS	YALE UNIVERSITY	$50,000.00
450	PROJECT ABS	Integrated Networks of Scholars in Global Health Research Training (INSIGHT)	FIC	5D43TW012274-03	HAYES, UNJA	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$50,000.00
451	Abstract Trans	Tcher Take Charge: Increasing PrEP Awareness Uptake and Adherence Through Health Care Empowerment and Address	NIMH	5R01MH128049-04		POLLARD-BRANCHARD, SUZY	PUBLIC HEALTH FOUNDATION ENTERPRISES	$50,000.00
452	In the United	AIDS prevention;Address;Adherence;Age;Alcohol abuse;Area;Attention;Automobile Driving;Black race;Cessation of life;	NIAID	5R01AI172092-03		HUEBNER, ROBIN E	JOHNS HOPKINS UNIVERSITY	$50,000.00
453	In the United	Enhanced COhort methods for HIV Research and Epidemiology (ENCORE) among transgender women in the United Stat	NIAID	5R01AI172092-03	HUEBNER, ROBIN E	WIRTZ, ANDREA L	JOHNS HOPKINS UNIVERSITY	$50,000.00
454	PROJECT SUM	Effect of Medicaid Accountable Care Organizations on Behavioral Health Care Quality and Outcomes for Children	NIMH	3R01MH134176-02S1	HUMENSKY, JENNIFER	GOFF, SARAH L	UNIVERSITY OF MASSACHUSETTS AMHERST	$50,000.00
455	SUMMARY/AE	Kabawil: Adapting an Intervention to Reduce Intersectional Stigmas among Indigenous Sexual Minority Men and Traditional Healers	FIC	1R01TW012904-01		BANSAL, GEETHA PARTHASARATHY	UNIVERSITY OF WASHINGTON	$50,000.00
456	PROJECT SUM	AIDS prevention;Acceleration;Address;Affect;Africa;Africa South of the Sahara;African;Age;Baltimore;Behavioral;Case	NICHD	5UG1HD113162-02		RUSSO, DENISE	UNIVERSITY OF MARYLAND BALTIMORE	$50,000.00
457	PROJECT SUM	Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research	NICHD	5UG1HD113162-02	RUSSO, DENISE	CHARURAT, MANHATTAN E	UNIVERSITY OF MARYLAND BALTIMORE	$50,000.00
458	Project Summ	Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness / Implemen	NICHD	5UG1HD113160-02	RUSSO, DENISE	GAROFALO, ROBERT	NORTHWESTERN UNIVERSITY AT CHICAGO	$50,000.00
459	Project Summ	Dopamine Availability and Developmental Pathways of Adolescent Depression and Anhedonia - Administrative Supplement	NIMH	3R01MH127014-03S1	MURPHY, ERIC ROUSSEAU	FORBES, ERIKA E	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$50,000.00
460	ABSTRACT Ad	The role of circulating meta-inflammatory monocytes in adolescent insulin resistance	NIDDK	3R01DK130864-03S1	BASU, RAJATAVA	SINGER, KANAKADURGA	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$50,000.00
461	ABSTRACT Ad	The role of circulating meta-inflammatory monocytes in adolescent insulin resistance	NIDDK	3R01DK130864-03S1	BASU, RAJATAVA	SINGER, KANAKADURGA	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$49,999.00
462	Project Summ	Dopamine Availability and Developmental Pathways of Adolescent Depression and Anhedonia - Administrative Supplement	NIMH	3R01MH127014-03S1	MURPHY, ERIC ROUSSEAU	FORBES, ERIKA E	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$49,994.00
463	PROJECT SUM	Effect of Medicaid Accountable Care Organizations on Behavioral Health Care Quality and Outcomes for Children	NIMH	3R01MH134176-02S1	HUMENSKY, JENNIFER	GOFF, SARAH L	UNIVERSITY OF MASSACHUSETTS AMHERST	$49,974.00
464	PROJECT SUM	COVID-19 Administrative Supplement to K01: Adapting Pilot Testing a Behavioral Intervention to Incorporate Advances	NIMH	3K01MH116737-06S1	GREENWOOD, GREGORY	BUDHWANI, HENNA	FLORIDA STATE UNIVERSITY	$49,814.00
465	PROJECT SUM	Diversity in Practice: the Quest for Inclusion in Precision Medicine	NLM	5G13LM014176-03	YOON, SUNG SUG SUG	LEE, SANDRA SOO-JIN	COLUMBIA UNIVERSITY HEALTH SCIENCES	$49,795.00
466	Transgender a	Personal Healthcare Networks of Transgender and Gender-Diverse Adults After Gender-Affirming Surgery	NINR	1F31NR021239-01	WILLIS, LEIGH ANDREW	GAEDECKE, TYLER	COLUMBIA UNIVERSITY HEALTH SCIENCES	$48,974.00
467	Project Summ	Examining Proximal Associations between Minority Stress PTSD Symptoms and Alcohol Use among Bi+ College Students with Trau	NIAAA	1F31AA031420-01A1	KERRIDGE, BRADLEY TOWNSEND	BASTING, EVAN JACOB	UNIVERSITY OF TENNESSEE KNOXVILLE	$48,974.00
468	Proposal Sum	Interpersonal Protective Factors and Mental Health Symptom Self-Management Among Black Transgender Women: A Mixed-Metho	NINR	5F31NR020760-02	SEAY, JULIA SUSAN	KLEPPER, MEREDITH	JOHNS HOPKINS UNIVERSITY	$48,974.00
469	Sexual minori	Determining the role of discrimination in clinical presentation and treatment response among sexual minority people with OCD: A m	NIMH	1F31MH136729-01A1	SMITH, ASHLEY	BEZAHLER, ANDREAS	FORDHAM UNIVERSITY	$48,974.00
470	ABSTRACT Ad	Intergenerational and Cultural Drivers of Depressive Symptoms in Hispanic Sexual Minority Youth	NINR	1F31NR021243-01	SEAY, JULIA SUSAN	SCOTT, DALTON	UNIVERSITY OF MIAMI CORAL GABLES	$48,974.00
471	Project Summ	Post-Traumatic Stress and Alcohol Use as Mechanisms Explaining IPV Among Bisexual Women Who Disclose Sexual Violence to P	NIAAA	1F31AA031618-01	KERRIDGE, BRADLEY TOWNSEND	BOGEN, KATHERINE WELA	UNIVERSITY OF NEBRASKA LINCOLN	$48,974.00
472	PROJECT SUM	Aligning HIV services with gender diverse community priorities through person-centered care: a mixed methods study in	NIMH	1F31MH136856-01	ALLISON, SUSANNAH	KAPTCHUK, ROSE POLLARD	JOHNS HOPKINS UNIVERSITY	$48,974.00
473	Project Summ	Understanding Patient Level Implementation Determinants Related to Long-acting Injectable HIV Pre-Exposure Prophyl	NIMH	1F31MH134720-01A1	ALLISON, SUSANNAH	O'NEIL, ANDREW M	MEDICAL COLLEGE OF WISCONSIN	$48,974.00
474	PROPOSAL SU	Extending the Prevention Toolbox: Exploring the Acceptability and Impact of Long-acting Injectable PrEP among MSM in	NIMH	5F31MH135787-02	ALLISON, SUSANNAH	DHIR, AMIT "MICKEY"	JOHNS HOPKINS UNIVERSITY	$48,974.00
475	PROJECT SUM	Characterizing Economic Determinants of Violence and Safety Disparities Among Sexual and Gender Diverse Populations	NIMHD	1F31MD019985-01	JOHNSON, JARRETT AINSWORTH	KENNEDY, KATRINA	JOHNS HOPKINS UNIVERSITY	$48,974.00
476	PROJECT SUM	Epidemiological factors related to human monkeypox virus (MPOX) in men who have sex with men (MSM) in the United States	NIAID	1F31AI178878-01A1	CHUANG, ELEANORE JENNIFER	CARPINO, THOMAS	JOHNS HOPKINS UNIVERSITY	$48,974.00
477	PROJECT SUM	Prevention of Chlamydia trachomatis infections: Evaluation of vaccination and post-exposure prophylactic antibiotic use as popul	NIAID	1F31AI181431-01A1	CHUANG, ELEANORE JENNIFER	ZANE, GREGORY	UNIVERSITY OF WASHINGTON	$48,974.00
478	PROJECT SUM	Intersectionality Scientific Working Group	NIAID	5P30AI027763-33		SEVELIUS, JAE M.	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$48,541.00
479	PROJECT SUM	ICAP Clinical Trials Unit	NIAID	5UM1AI154468-05	GUBB, STEPHANIE MAJER		COLUMBIA UNIVERSITY HEALTH SCIENCES	$48,516.00
480	Project Summ	Employment as prevention: Adapting a structural intervention to achieve HIV equity among immigrant Latino MSM.	NIMH	1F31MH135828-01	ALLISON, SUSANNAH	JARAMILLO, JAHN	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$47,694.00
481	PA-21-151 UC	SOCIAL MEDICINE CASES FOR HEALTH EQUITY	NIMHD	1R13MD019531-01	JONES, NANCY LYNNE	HOLMES, SETH	UNIVERSITY OF CALIFORNIA BERKELEY	$47,451.00
482	Project Summ	Identifying Transdiagnostic Intervention Targets for PTSD-SUD Comorbidity in a Vulnerable Population: A Mixed-Method Study	NIDA	5R36DA058819-02	COLLIER KIDEMU, KEVA WONTORIA	LIAUTAUD, MADALYN MICHELE	HUNTER COLLEGE	$47,057.00
483	PROGRAM SU	Planning and Evaluation Core	NCI	5U54CA118638-19		RIVERS, DESIREE AVIA	MOREHOUSE SCHOOL OF MEDICINE	$46,707.00
484	Project Summ	The Use of Diversity: Managing Race and Representation in Law Politics and the Biosciences	NLM	5G13LM013533-03	YOON, SUNG SUG SUG	KAHN, JONATHAN	NORTHEASTERN UNIVERSITY	$46,437.00
485	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$45,400.00
486	PROJECT SUM	Understanding the Complex Reproductive Health Needs of Formerly Incarcerated Young Men	NICHD	5R21HD114341-02	POPKIN, RONNA	GEMMILL, ALISON	JOHNS HOPKINS UNIVERSITY	$43,519.00
487	PROJECT SUM	Exploring Acceptability & Potential Reach of Game-Based & Social Network Strategies for Improving PrEP & HIV Self-Tes	NIMH	1F31MH138212-01	ALLISON, SUSANNAH	CRAKER, LACEY	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$42,749.00
488	PROJECT SUM	Structural Stigma and Mental Health Among Transgender and Gender Diverse Adults Living in the Rural United States	NIMH	1F31MH139225-01	AVENILLA, FRANK	SIEBACH, KIRSTEN	JOHNS HOPKINS UNIVERSITY	$42,574.00
489	PROJECT SUM	Client and clinician priorities for same-day PrEP and DoxyPEP awareness uptake and persistence in primary care.	NINR	1F31NR021247-01	WILLIS, LEIGH ANDREW	ALBRIGHT, NATHANIEL	OHIO STATE UNIVERSITY	$42,104.00
490	Project Summ	Low Dose Computed Tomography (LDCT) Eligibility and Outcome differences between Sexual and Gender Minorities and their Sexu	NCI	5F31CA271474-02	VAHEDI, SHAHROOZ	ENGSTROM, CURTISS WAYNE	UNIVERSITY OF MICHIGAN AT ANN ARBOR	$41,483.00
491	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00
492	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00
493	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00

	A	B	C	D	E	F	G	H
494	PROJECT SUM	Providence/Boston Center for AIDS Research (CFAR)	NIAID	5P30AI042853-26	SCHOONMAKER, ANNALISE ROSA	CU-UVIN, SUSAN	MIRIAM HOSPITAL	$41,400.00
495	PROJECT SUM	Applying Computational Phenotypes To Assess Mental Health Disorders Among Transgender Patients in the United States	NIMH	5F31MH132187-02	SWEENEY, MAGGIE	BELTRAN, THEO	UNIV OF NORTH CAROLINA CHAPEL HILL	$41,011.00
496	ABSTRACT/SU	Examining differential effects of state equality-promoting policies on harmful alcohol use among sexual and gender minority adults	NIAAA	5F31AA030722-02	BLOSS, GREGORY	TURNER, CAITLIN MARIE	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	$40,956.00
497	PROGRAM SU	Planning and Evaluation Core	NCI	5U54CA118948-19		SCARINCI, ISABEL C	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$40,912.00
498	7. Project Sur	A Mixed Methods Study to Enhance Alcohol Treatment Help-seeking and Engagement Among Gender Diverse Adults	NIAAA	1F31AA031605-01	LITTEN, RAYE Z	COLGONIS, HANNAH ELISABETH	UNIVERSITY OF MEMPHIS	$40,769.00
499	PROJECT SUM	Social safety as a novel mechanism of risk for problematic substance use among sexual and gender minority youth	NIDA	1F31DA062473-01	DUNSTON, SHEBA KING	HAIK, AMANDA	UNIV OF NORTH CAROLINA CHAPEL HILL	$40,441.00
500	PROJECT SUM	Identifying preferences for receiving HIV prevention services among GBMSMs and for providing HIV prevention services	NIMH	5F31MH133472-02	ALLISON, SUSANNAH	RODRIGUEZ, CHRISTOFER ALFREDO	FLORIDA INTERNATIONAL UNIVERSITY	$39,535.00
501	This project w	HPV related cancers in HIV populations	NCI	1ZIACP101238-03		WENTZENSEN, NICOLAS	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS	$39,221.00
502	PROJECT SUM	Minority Stress Stimulant Use and HIV among Sexual Minority Men: A Biopsychosocial Approach	NIDA	5F31DA059345-02	BABECKI, BETH	MILLER-PERUSSE, MICHAEL JOSEPH	SAN DIEGO STATE UNIVERSITY	$38,984.00
503	Project Summ	SWG 10: Health Equity	NIAID	5P30AI027757-37		ORELLANA, EDWIN ROBERTO	UNIVERSITY OF WASHINGTON	$36,692.00
504	ABSTRACTAge	SilverBills: A Legal Technical and Financial Tool for Aging LGBTQ+ Individuals with Impaired Cognition.	NIA	3R44AG080843-02S1	PLUDE, DANA JEFFREY	LOBEL-ESRIG, MARCI	SILVERBILLS INC.	$35,000.00
505	Transgender i	Cross Sex Steroid Therapy and Cardiovascular Risk in the Transgender Female	NHLBI	5F31HL172648-02	HUANG, LI-SHIN	CRUDUP, BRELAND	UNIVERSITY OF MISSISSIPPI MED CTR	$32,974.00
506	Project Summ	Assessing the burden of dementia in transgender populations	NHLBI	3K01HL151902-04S1	COADY, SEAN	STREED, CARL G	BOSTON MEDICAL CENTER	$31,691.00
507	PROJECT SUM	HIV risk messaging and medical mistrust in the era of Undetectable=Untransmittable: Psychosocial and Behavioral Impl	NIMH	1F31MH139392-01	ALLISON, SUSANNAH	KALWICZ, DAVID	GEORGE WASHINGTON UNIVERSITY	$30,000.00
508	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	1R13HL173969-01	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$30,000.00
509	PROJECT SUM	Scientific Working Group	NIAID	5P30AI117943-10		PHILLIPS, GREGORY L.	NORTHWESTERN UNIVERSITY AT CHICAGO	$28,491.00
510	SUMMARY Su	Organization for the Study of Sex Differences Annual Meeting	NIA	5R13AG056135-08	WILLIAMS, JOHN	ARNOLD, ARTHUR P	UNIVERSITY OF CALIFORNIA LOS ANGELES	$24,975.00
511	POPULATION	Population Studies and Disparities Research	NCI	5P30CA022453-43		BEEBE-DIMMER, JENNIFER L	WAYNE STATE UNIVERSITY	$20,571.00
512	From both NIH	Enhancing Diversity Equity and Inclusion in Mental Health Research: American Psychopathological Association Annual Meetings	NIMH	1R13MH136663-01	MEZA-CERVERA, TATIANA	LEWIS-FERNANDEZ, ROBERTO	NEW YORK STATE PSYCHIATRIC INSTITUTE	$20,000.00
513	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	1R13HL173969-01	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$20,000.00
514	PROJECT SUM	HIV risk messaging and medical mistrust in the era of Undetectable=Untransmittable: Psychosocial and Behavioral Impl	NIMH	1F31MH139392-01	ALLISON, SUSANNAH	KALWICZ, DAVID	GEORGE WASHINGTON UNIVERSITY	$18,974.00
515	AbstractDive	Building Up	NIGMS	3U01GM132133-05S1	GAMMIE, ALISON	RUBIO, DORIS M	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$15,758.00
516	AbstractDive	Building Up	NIGMS	3U01GM132133-05S2	GAMMIE, ALISON	RUBIO, DORIS M	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	$15,758.00
517	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	1R13HL173969-01	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$15,000.00
518	PROJECT ABS	Society of Behavioral Medicine 2024 Annual Meeting & Scientific Sessions	NHLBI	3R13HL173969-01S1	SHIROMA, ERIC JITSUO	FUEMMELER, BERNARD F	SOCIETY OF BEHAVIORAL MEDICINE	$14,300.00
519	PROJECT SUM	Biomedical Prevention Scientific Working Group	NIAID	5P30AI064518-20		MCKELLAR, MEHRI S	DUKE UNIVERSITY	$11,307.00
520	Project Summ	Be Curious Not Judgmental: The 4th National Symposium on Sexual Behavior of Youth	NICHD	1R13HD117635-01	GILBERT, LEAH KAYE	SILOVSKY, JANE FRANCES	UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR	$10,000.00
521	PROJECT SUM	Boston University Conference on Language Development 2022-2026	NICHD	5R13HD090968-09	SALO, VIRGINIA CHARLOTTE	CHANG, CHARLES BOND	BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)	$10,000.00
522	From both NIH	Enhancing Diversity Equity and Inclusion in Mental Health Research: American Psychopathological Association Annual Meetings	NIMH	1R13MH136663-01	MEZA-CERVERA, TATIANA	LEWIS-FERNANDEZ, ROBERTO	NEW YORK STATE PSYCHIATRIC INSTITUTE	$10,000.00
523	PROJECT SUM	2025 Cardiac Arrhythmia Mechanisms Gordon Research Conference and Gordon Research Seminar	NHLBI	1R13HL177880-01	TJURMINA, OLGA A.	RIPPLINGER, CRYSTAL MAY	GORDON RESEARCH CONFERENCES	$5,000.00
524	SUMMARYPar	2025 Sex Differences in Immunity Gordon Research Conference and Gordon Research Seminar	NIAID	1R13AI188929-01	BARTELS, ADELINA EWURA-ABENA	OFOTOKUN, IGHOVWERHA	GORDON RESEARCH CONFERENCES	$3,100.00
525	Men who have	Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex with Men	NIAID	5U01AI156874-04	ZIMAND, LORI B.		NORTHWESTERN UNIVERSITY AT CHICAGO	$2,184.00
526	PROJECT SUM	TRANSforma Tu Salud Dejando de Fumar: Advancing smoking cessation among transgender individuals		1R21CA284313-01	PEARLMAN, PAUL C	CARTUJANO, FRANCISCO	UNIVERSITY OF ROCHESTER	$2,000.00
527	PROJECT SUM	SHINE Strong: Building the pipeline of HIV behavioral scientists with expertise in trans population health	NIMH	5R25MH119858-05	ALLISON, SUSANNAH	MCFARLAND, WILLIAM	PUBLIC HEALTH FOUNDATION ENTERPRISES	$1.00
528	Project Abstra	Enhancing dissemination and career development in sex and gender translational science in alcohol use	NIAAA	5R13AA031402-02	BALACHOVA, TATIANA NIKOLAYEVNA	MCKEE, SHERRY ANN	YALE UNIVERSITY	$1.00
529	Project Summ	FINISHING HIV: An EHE model for Latinos Integrating One-Stop-Shop PrEP Services a Social Network Support Program a	NIAID	5R01AI169643-03	DEJLI, JAMAL	KANAMORI NISHIMURA, MARIANO JUAN	UNIVERSITY OF MIAMI SCHOOL OF MEDICINE	$1.00
530	ABSTRACT | F	Pilot Project 1: Testing the effectiveness of an intervention to foster cervical cancer screening promotion for Latinx trans men among	NCI	5U54CA163068-12		SCHABATH, MATTHEW B.	H. LEE MOFFITT CANCER CTR & RES INST	$0.00
531	ABSTRACT | F	Fostering Cervical Cancer Screening Promotion for Latinx Trans Men Among Medical Students	NCI	5U54CA163071-12		RAMOS-PIBERNUS, ALIXIDA G	PONCE SCHOOL OF MEDICINE	$0.00

PDF COPY OF NIH_GRANTS_003463
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
1	Project Title	Public Health Relevance	Administering	Application ID	Award Notice	Opportunity Number	Project Numb	Serial Numbe	Program Official Informa	Project Start I	Project End D	Study Section	Contact PI Pe	Contact PI / P	Other PI or Pr	Department	Organization I	Budget Start I	Budget End Da	Funding Mech	Fiscal Year	Total Cost	Funding IC(s)	Direct Cost IC	Indirect Cost	Total Cost IC
2	Creation of an Institution	n/a	OD	10129786	9/19/20	PAR-20-086	1C06OD0301	30152	CHEN, YONG	9/21/20	5/31/25	Scientific and	6205023	REILLY, MURE	Not Applicab	INTERNAL ME	COLUMBIA U	9/21/20	5/31/25	Construction	2020	$8,000,000	OD	$8,000,000	$0	$8,000,000
3	Center to Improve Chron	NARRATIVE:The COMMU	NIMHD	10897775	8/1/24	RFA-MD-21-007	5P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$4,048,432	NIMHD	$2,674,989	$1,373,443	$4,048,432
4	Center for Environmenta	PROJECT NARRATIVE OV	NIEHS	10851719	5/10/24	RFA-ES-20-006	5P30ES00908	9089	THOMPSON, CLAUDIA	7/1/98	4/30/28	Environmenta	7839598	PERZANOWS	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$1,631,206	NIEHS	$1,020,275	$610,931	$1,631,206
5	Climate and Health: Acti	Overall NarrativeClimat	NIA	10981243	9/20/24	RFA-ES-23-007	1P20AG0939	93975	KWOK, RICHARD K	9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	BERHANE, KI	PUBLIC HEAL	COLUMBIA U	9/30/24	8/31/25	Research Ce	2024	$1,397,411	NIA	$849,890	$547,521	$1,397,411
6	Advanced training in env	Project NarrativeColum	NIEHS	10843247	6/7/24	PA-18-403	5T32ES00732	7322	SHREFFLER, CAROL A.	7/1/00	6/30/25	Environmenta	1862308	MILLER, GARY	FACTOR-LITV	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$1,343,565	NIEHS	$1,561,132	$95,611	$1,343,565
7	Anga Center for Climate	PROJECT NARRATIVE Eas	FIC	10982425	9/19/24	RFA-ES-23-007	1P20TW0128	12808	NEWSOME, BRAD	9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	NDETEI, DAV	Unavailable	COLUMBIA U	9/23/24	8/31/25	Research Ce	2024	$1,061,973	NIEHS	$860,247	$201,725	$1,061,972
8	Center to Improve Chron	NARRATIVE:The COMMU	NIMHD	10939527	8/27/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,025,313	NIMHD	$787,662	$237,651	$1,025,313
9	Resilient Emotion Regula	Project NarrativeResilie	NIMH	10898037	7/15/24	PA-20-185	5R01MH1305	130578	SMITH, ASHLEY	8/2/23	6/30/28	Child Psycho	9514113	TOTTENHAM,	SEEDAT, SOR	PSYCHOLOG	COLUMBIA U	7/15/24	6/30/25	Non-SBIR/ST	2024	$992,759	NIMH	$904,808	$87,951	$992,759
10	Comparing a Novel Teleh	PROJECT NARRATIVECar	NIMHD	10981223	9/17/24	PA-20-183	1R01MD0191	19189	PADGETT, LYNNE SLAU	9/20/24	5/31/29	Clinical Mana	15008881	DURAN, AND	Not Applicab	INTERNAL ME	COLUMBIA U	9/20/24	5/31/25	Non-SBIR/ST	2024	$821,694	NIMHD	$499,510	$322,184	$821,694
11	A daily diary examination	PROJECT NARRATIVEStig	NHLBI	10801457	1/22/24	PA-20-185	1R01HL1684	168489	CAMPO, REBECCA A.	9/1/24	5/31/28	Biobehaviora	12508902	CACERES, BI	Not Applicab	OTHER HEAL	COLUMBIA U	9/1/24	5/31/25	Non-SBIR/ST	2024	$813,579	NHLBI	$494,577	$319,002	$813,579
12	Ending the HIV Epidemic	Project NarrativeThe pro	NINR	10819558	4/16/24	RFA-MD-21-004	5R01NR0205	20583	WILLIS, LEIGH ANDREW	7/1/22	4/30/27	ZMD1-KNL(J	10397136	LELUTIU-WEI	BROWNE, FE	OTHER HEAL	COLUMBIA U	5/1/24	4/30/25	Non-SBIR/ST	2024	$798,648	NINR	$615,060	$183,588	$798,648
13	Disability diversity and tr	Project NarrativeStudies	NHGRI	10653189	9/1/23	PA-17-444	5R01HG0108	10868	KAUFMAN, DAVE J	3/12/21	6/30/25	Special Emph	12453587	SABATELLO, M	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/23	6/30/25	Non-SBIR/ST	2023	$795,723	NHGRI	$498,920	$296,803	$795,723
14	Just Inclusion and Equity	PROJECT NARRATIVEThis	NHGRI	10910148	9/23/24	PAR-20-254	5R01HG0128	12841	STERLING, RENE	9/1/23	6/30/27	Special Emph	6597920	LEE, SANDRA	CALLIER, SHA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$737,573	NHGRI	$577,866	$159,707	$737,573
15	Estimating the impact of	PROJECT NARRATIVEAgg	NIDA	10840302	3/12/24	PA-20-185	5R01DA0580	58028	DUNSTON, SHEBA KIN	5/15/23	3/31/28	Social Scienc	11076659	PRINS, SETH	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$716,003	NIDA	$473,109	$242,894	$716,003
16	Harnessing digital health	Only one in four depresse	NCI	10945367	8/26/24	PAR-22-105	1R01CA2940	294004	RANDHAWA, GURVAN	9/1/24	7/31/29	Science of Im	12100576	MOISE, NATH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/24	7/31/25	Non-SBIR/ST	2024	$696,140	NCI	$436,637	$259,503	$696,140
17	SPECTRUM (Studying PR	NARRATIVEThe SPECTRU	NCI	10801508	4/5/24	PA-20-185	1R01CA2791	279145	DEAN, DAVID WORTH	4/5/24	3/31/29	Cancer and H	14146562	HOUGHTON,	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/5/24	3/31/25	Non-SBIR/ST	2024	$694,771	NCI	$532,535	$162,236	$694,771
18	Late Life Learning Demer	Project NarrativeThis pro	NIA	10845557	6/13/24	PAR-21-311	5R01AG0740	74076	CHATTERJI, MINKI	9/1/22	5/31/27	Special Emph	11055051	ZEKI AL HAZZ	ELBEJJANI , M	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$704,282	NIA	$592,671	$101,611	$694,282
19	Reducing Health Dispari	PROJECT NARRATIVEThe	NINR	10864979	5/22/24	PA-20-142	5T32NR0079	7969	KEHL, KAREN	8/1/02	6/30/27	ZNR1-REV-M	9765581	SCHNALL, RE	BAKKEN, SUZ	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$691,597	NINR	$689,848	$44,588	$691,597
20	GENETIC ATTRIBUTIONS	The proposed research w	NHGRI	10932235	8/7/24	PAR-20-254	5R01HG0128	12868	KAUFMAN, DAVE J	9/20/23	6/30/27	Special Emph	14884731	LEBOWITZ, M	PEARL, REBE	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$689,893	NHGRI	$634,610	$55,283	$689,893
21	Preventing Drug Abuse ar	PROJECT NARRATIVE Add	NIDA	10425383	7/7/22	PA-15-261	5R01DA0435	43512	ROMBERG, ALEXA RUT	7/1/18	6/30/25	Interventions	8585554	SCHWINN, T	Not Applicab	OTHER HEAL	COLUMBIA U	7/1/22	6/30/25	Non-SBIR/ST	2022	$680,444	NIDA	$433,039	$247,405	$680,444
22	Health Disparities in Hos	PROJECT NARRATIVERac	NINR	10912788	6/17/24	PA-20-185	5R01NR0206	20601	KEHL, KAREN	8/23/23	6/30/27	Healthcare a	1872031	STONE, PATR	DHINGRA, LA	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$655,106	NINR	$545,221	$109,885	$655,106
23	Intervention toiMProveAd	RELEVANCEThere are lor	NIMHD	10897800	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	6405748	HERSHMAN,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$654,071		$405,673	$248,398	$654,071
24	Evaluating Medicaid Post	Project NarrativeSustain	NIMHD	11003869	4/8/24	PA-21-268	7R01MD0181	18180	OLADEINDE, YEWAND	6/4/23	11/30/28	Organization	8963719	JANEVIC, TER	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/8/24	11/30/25	Non-SBIR/ST	2024	$642,775	NIMHD	$563,130	$79,645	$642,775
25	Project 1: Addressing Sle	NARRATIVE:Sleep health	NIMHD	10897794	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	12346337	MAKAREM, N	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$628,419		$396,689	$231,730	$628,419
26	Temperature shade and a	Temperatures are rising	NIMH	10863844	6/20/24	PA-20-185	5R01MH1287	128734	THOMAS, LAURA A.	9/15/21	6/30/26	Behavioral G	9555896	KEYES, KATHE	RUNDLE, AND	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$621,780	NIMH	$408,959	$212,821	$621,780
27	Social Connectedness a	PROJECT NARRATIVEGer	NIMHD	11004310	12/22/24	PAR-21-350	5R01MD0170	17085	HERREN, OLGA MARIN	7/15/23	12/31/27	Special Emph	6832127	BOCKTING, W	Not Applicab	OTHER HEAL	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$612,485	NIMHD	$449,844	$162,641	$612,485
28	Assessing Cervical Canc	PROJECT NARRATIVEThe	NIMHD	10982514	12/17/24	PAR-20-310	5R01MD0182	18250	PADGETT, LYNNE SLAU	5/5/23	11/30/27	Organization	10513738	LLANOS, ADA	TSUI, JENNIF	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$610,020	NIMHD	$528,633	$81,387	$610,020
29	Policy levers to reduce ra	Project NarrativeGestat	NIDDK	11094148	2/21/25	PA-20-185	5R01DK1347	134725	LAWRENCE, JEAN M	12/9/23	2/29/28	Community I	8963719	JANEVIC, TER	Not Applicab	PUBLIC HEAL	COLUMBIA U	3/1/25	2/28/26	Non-SBIR/ST	2025	$570,471	NIDDK	$391,471	$179,000	$570,471
30	Enhancing Alzheimer's-re	PROJECT NARRATIVEIncr	NIA	11033614	1/31/25	RFA-AG-24-027	1UG3AG0905	90558	GHALEH, MARYAM X	2/1/25	1/31/28	Special Emph	7891222	BRICKMAN, A	MNGOMEZU	NEUROLOGY	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$539,352	NIA	$420,681	$118,671	$539,352
31	Impact of Social Cohesio	PROJECT NARRATIVEThis	NIMHD	10397977	5/8/22	RFA-MD-18-003	5R01MD0135	13554	STINSON, NATHANIEL	9/11/18	4/30/25	ZMD1-RP(O1	11872940	DUNCAN, DU	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/22	4/30/25	Non-SBIR/ST	2022	$507,062	NIMHD	$340,488	$166,574	$507,062
32	Policy solutions for addre	n/a	NICHD	10908630	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	1970408	LI, GUOHUA	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$503,613		$365,317	$138,296	$503,613
33	2/3 Genomics of Schizop	PROJECT NARRATIVEAfri	NIMH	11085137	12/19/24	PAR-20-027	5U01MH1250	125058	PEVSNER, JONATHAN	1/1/21	12/31/25	ZMH1-ERB-C	1911330	SUSSER, EZR	Not Applicab	PUBLIC HEAL	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$447,238	NIMH	$336,053	$111,185	$447,238
34	The Behavioral Cost of C	PROJECT NARRATIVEThe	OD	10923510	9/18/24	RFA-RM-23-007	1DP5OD0374	37400	MILLER, BECKY	9/18/24	7/31/29	Special Emph	78943744	MINOR, KELT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/24	7/31/25	Non-SBIR/ST	2024	$411,250	OD	$249,999	$161,250	$411,249
35	Network biology-based m	n/a	NIA	10981246	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	1862308	MILLER, GARY	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$384,800		$233,921	$150,879	$384,800
36	Columbia Population Re	Project NarrativeThe Co	NICHD	10895753	8/14/24	RFA-HD-24-008	2P2CHD0584	58486	CLARK, REBECCA L	8/15/09	6/30/29	Special Emph	1892638	TEITLER, JULI	HIRSCH, JEN	OTHER HEAL	COLUMBIA U	9/1/24	6/30/25	Other Resear	2024	$359,265	NICHD	$218,398	$140,867	$359,265
37	Cannabis use PrEP and H	PROJECT NARRATIVEThis	NIDA	10838513	8/6/24	RFA-DA-21-024	5R01DA0545	54553	JENKINS, RICHARD A	8/1/21	5/31/26	ZDA1-TXT-V(	11872940	DUNCAN, DU	KNOX, JUSTIN	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$715,456	NIAID	$297,359	$60,370	$357,729
38	Cannabis use PrEP and H	PROJECT NARRATIVEThis	NIDA	10838513	8/6/24	RFA-DA-21-024	5R01DA0545	54553	JENKINS, RICHARD A	8/1/21	5/31/26	ZDA1-TXT-V(	11872940	DUNCAN, DU	KNOX, JUSTIN	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$715,456	NIDA	$297,358	$60,369	$357,727
39	Training in Health Equity	NarrativeThe mission of t	NCI	10884327	7/22/24	RFA-CA-21-020	5R25CA2741	274180	GHOSH, SANGEETA AH	8/15/22	7/31/27	Institutional	10534314	MCDONALD,	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$342,806	NCI	$317,416	$25,393	$342,806
40	Nationwide Associations	n/a	NIA	10981245	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$281,937		$171,790	$110,147	$281,937
41	Investigating pathways b	n/a	FIC	10982427	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$275,863		$218,939	$56,924	$275,863
42	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	OD	$242,040	$7,885	$249,925
43	Novel Assessments of the	PROJECT NARRATIVEIn t	NIEHS	10832126	4/1/24	PA-20-188	5R00ES0337	33742	LAWRENCE, KAITLYN G	5/1/23	4/30/26	NSS	77863179	PARKS, ROBB	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Non-SBIR/ST	2024	$249,000	NIEHS	$151,368	$97,632	$249,000
44	Training West African Pul	Project narrative:We pro	FIC	10899280	9/2/24	PAR-21-120	1D43TW0127	12737	SINA, BARBARA J	9/1/24	4/30/29	Special Emph	6434515	WICKISER, JO	DOUMBIA, SE	PUBLIC HEAL	COLUMBIA U	9/1/24	4/30/25	Other Resear	2024	$248,793	NIAID	$240,575	$5,946	$246,521
45	Racial Disparity in Diagn	Uterine cancer is the mo	NIMHD	10831829	4/19/24	PA-20-185	5R01MD0163	16386	PADGETT, LYNNE SLAU	8/27/21	4/30/26	Healthcare a	7568885	XU, XIAO	WRIGHT, JAS	OBSTETRICS	COLUMBIA U	5/1/24	4/30/26	Non-SBIR/ST	2024	$232,654	NIMHD	$152,337	$80,317	$232,654
46	Center to Improve Chron	NARRATIVE:The COMMU	NIMHD	10939526	8/26/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$226,727	NIMHD	$137,828	$88,899	$226,727
47	India - Factors of CKDu ir	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	NIDDK	$205,661	$79,103	$199,334
48	Youth-PRIDES: Implemer	Mental disorders are the	NIMH	10669228	7/19/23	PA-18-363	5K01MH1202	120258	ALLISON, SUSANNAH	8/15/19	7/31/25	Mental Healt	9614976	LOVERO, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/23	7/31/25	Other Resear	2023	$181,675	NIMH	$169,700	$11,975	$181,675
49	Racial Inequities in Opio	PROJECT NARRATIVEThe	NIDA	10821454	3/21/24	PA-20-190	5K01DA0580	58085	ZUR, JULIA BETH	4/15/23	3/31/28	Social Scienc	12407723	PAMPLIN, JOH	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Other Resear	2024	$177,962	NIDA	$164,780	$13,182	$177,962
50	Subtyping sepsis in Ugan	PROJECT NARRATIVEThe	NIAID	11009064	1/17/25	PA-20-205	5K23AI16336	163364	ERNST, NANCY L.	2/2/22	1/31/26	Microbiology	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	2/1/25	1/31/26	Other Resear	2025	$173,996	NIAID	$161,107	$12,889	$173,996
51	Just Inclusion and Equity	PROJECT NARRATIVEThis	NHGRI	11064335	9/24/24	PA-20-272	3R01HG0128	12841	STERLING, RENE	9/1/23	6/30/27	Special Emph	6597920	LEE, SANDRA	CALLIER, SHA	INTERNAL ME	COLUMBIA U	9/24/24	6/30/25	Non-SBIR/ST	2024	$164,087	NHGRI	$115,703	$48,384	$164,087
52	Leveraging Latinx Adoles	PROJECT NARRATIVECur	NIMH	10919831	8/26/24	RFA-MH-23-116	5R21MH1354	135489	SMITH, ASHLEY	9/4/23	8/31/25	ZMH1-ERB-R	11732940	DUPONT, ME	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	$163,665	NIMH	$110,800	$52,865	$163,665
53	Establishing a unified eva	Project NarrativeExtrem	NIEHS	11055056	12/13/24	PAR-21-172	1K01ES03620	36202	QUINN, ASHLINN KO	12/16/24	11/30/27	Special Emph	78417944	WU, XIAO	Not Applicab	BIOSTATISTIC	COLUMBIA U	12/16/24	11/30/25	Other Resear	2025	$157,841	NIEHS	$146,149	$11,692	$157,841
54	Investigating association	PROJECT NARRATIVEClin	NIMH	10592335	3/23/23	PA-21-235	5R21MH1273	127356	CAMPBELL-ROSEN, HC	4/1/22	3/31/25	Community I	16325196	WINTER, SAM	Not Applicab	OTHER HEAL	COLUMBIA U	4/1/23	3/31/25	Non-SBIR/ST	2023	$157,500	NIMH	$125,000	$32,500	$157,500
55	India - Factors of CKDu ir	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	NIEHS	$150,290	$57,804	$145,666
56	Summer Program for Und	PROJECT NARRATIVEThe	NINDS	11004622	12/23/24	PAR-21-168	5R25NS0764	76445	MATTHEWS, MARGUER	4/1/12	12/31/27	ZNS1-SRB-D	8613268	GRUEBER, W	SIEGELBAUM	PHYSIOLOGY	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$135,000	NINDS	$125,000	$10,000	$135,000
57	Support Mentoring of Ear	The regulation of body we	NIDDK	10917344	5/21/24	RFA-DK-22-012	5K26DK1384	138418	SASLOWSKY, DAVID E	9/1/23	5/31/28	ZDK1-GRB-1	1869280	GALLAGHER,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$132,845	NIDDK	$123,116	$9,729	$132,845
58	DYnamics of Contracept	PROJECT NARRATIVEAdo	NICHD	10846589	5/17/24	PA-20-190	5K01HD1086	108636	CHINN, JUANITA JEANN	5/24/23	4/30/28	Population Sc	14766811	GREENLEAF,	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Other Resear	2024	$130,810	NICHD	$121,120	$9,690	$130,810
59	Advancing equitable imp	Project narrative/Public	NIDDK	10906807	8/28/24	PA-20-190	5K01DK1324	132495	RANKIN, TRACY L	9/15/22	8/31/27	Kidney, Urolo	14313406	MILO RASOU	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$128,938	NIDDK	$119,743	$9,195	$128,938
60	Spatiotemporal effects a	PROJECT NARRATIVEWil	NIEHS	10984277	7/24/24	PAR-21-271	1K99ES03589	35895	CUI, YUXIA	8/1/24	7/31/26	Special Emph	78428836	CERNA-TURO	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$126,333	NIEHS	$116,975	$9,358	$126,333
61	Mentoring clinical invest	PROJECT NARRATIVEThe	NIDA	10863840	6/4/24	PA-19-122	5K24DA0513	51328	LAO, GUIFANG	4/1/23	6/30/25	Population a	9421939	SEVELIUS, JAE	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Other Resear	2024	$125,114	NIDA	$115,846	$9,268	$125,114
62	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	NIEHS	$96,846	$3,154	$100,000
63	BEST-DP: Biostatistics &	Biomedical scientists es	NHLBI	10658980	5/3/23	RFA-HL-16-008	5R25HL0962	96260	WOLZ, MICHAEL	5/15/09	4/30/25	ZHL1-CSR-M	10781196	GOLDSMITH,	BEGG, MELIS	BIOSTATISTIC	COLUMBIA U	5/1/23	4/30/25	Other Resear	2023	$82,944	NHLBI	$76,800	$6,144	$82,944
64	Development and Testing	PROJECT NARRATIVETra	NIMH	10744754	11/15/23	PA-20-141	5R34MH1281	128163	GREENWOOD, GREGO	1/1/22	11/30/25	HIV/AIDS Intr	9765581	SCHNALL, RE	GAROFALO, R	OTHER HEAL	COLUMBIA U	12/1/23	11/30/25	Non-SBIR/ST	2024	$72,743	NIMH	$62,125	$10,618	$72,743
65	Disparities in Deaths of D	PROJECT NARRATIVEThe	NIEHS	11100635	8/8/24	PA-23-189	3R00ES0337	33742	LAWRENCE, KAITLYN G	5/1/23	4/30/26		77863179	PARKS, ROBB	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/9/24	4/30/25	Non-SBIR/ST	2024	$67,927	NIEHS	$44,672	$23,255	$67,927
66	Youth-PRIDES: Implemer	Mental disorders are the	NIMH	10900850	8/31/23	PA-20-272	3K01MH1202	120258	ALLISON, SUSANNAH	8/15/19	7/31/25	Mental Healt	9614976	LOVERO, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/23	7/31/25	Other Resear	2023	$65,315	NIMH	$60,477	$4,838	$65,315
67	Skeletal Health in Youth	Our parent study is show	NIDDK	10772814	8/28/23	PA-20-272	3R01DK1225	122564	MALOZOWSKI, SAUL N	9/12/19	6/30/25	ZDK1(M3)-S	7373765	RUBIN, MISH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/23	6/30/25	Non-SBIR/ST	2023	$100,000	NIDDK	$30,395	$19,605	$50,000
68	Skeletal Health in Youth	Our parent study is show	NIDDK	10772814	8/28/23	PA-20-272	3R01DK1225	122564	MALOZOWSKI, SAUL N	9/12/19	6/30/25	ZDK1(M3)-S	7373765	RUBIN, MISH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/23	6/30/25	Non-SBIR/ST	2023	$100,000	OD	$30,395	$19,605	$50,000
69	Diversity in Practice: the	PROJECT NARRATIVEThis	NLM	11009933	12/13/24	PAR-21-046	5G13LM0141	14176	YOON, SUNG SUG SUG	1/1/23	12/31/25	ZLM1-JL-P(01	6597920	LEE, SANDRA	SHIM, JANET	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$49,795	NLM	$49,795	$0	$49,795
70	Personal Healthcare Net	PROJECT NARRATIVETra	NINR	10900078	6/24/24	PA-21-051	1F31NR0212	21239	WILLIS, LEIGH ANDREW	7/1/24	3/31/26	National Inst	79192449	GAEDECKE, T	Not Applicab	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NINR	$48,974	$0	$48,974
71	Applying a multidimensio	PROJECT NARRATIVEMo	NIMH	10909057	8/15/24	PA-21-051	5F31MH1346	134699	ALLISON, SUSANNAH	9/1/23	8/31/25	Special Emph	16592276	KHALIFA, ALE	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$47,324	NIMH	$47,324	$0	$47,324
72	Neighborhood Social Env	PROJECT NARRATIVEDep	NIMH	10833481	4/25/24	PA-21-051	5F31MH1322	132290	AVENILLA, FRANK	5/1/23	4/30/25	Special Emph	15898106	DIAZ, SARAH	Not Applicab	NONE	COLUMBIA U	5/1/24	4/30/25	Training, Indiv	2024	$39,146	NIMH	$39,146	$0	$39,146
73	An equity-focused evalua	PROJECT NARRATIVEThis	NIEHS	10930696	8/9/24	PA-21-052	5F31ES03528	35280	LAWRENCE, KAITLYN G	9/15/23	8/14/25	Special Emph	77847681	FLORES, NIN	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/15/24	8/14/25	Training, Indiv	2024	$36,053	NIEHS	$36,053	$0	$36,053
74	Late Life Learning Demer	Project NarrativeThis pro	NIA	10845557	6/13/24	PAR-21-311	5R01AG0740	74076	CHATTERJI, MINKI	9/1/22	5/31/27	Special Emph	11055051	ZEKI AL HAZZ	ELBEJJANI , M	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$704,282	FIC	$8,537	$1,463	$10,000
75	India - Factors of CKDu ir	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	FIC	$5,158	$1,984	$5,000
76	Training West African Pul	Project narrative:We pro	FIC	10899280	9/2/24	PAR-21-120	1D43TW0127	12737	SINA, BARBARA J	9/1/24	4/30/29	Special Emph	6434515	WICKISER, JO	DOUMBIA, SE	PUBLIC HEAL	COLUMBIA U	9/1/24	4/30/25	Other Resear	2024	$248,793	FIC	$2,218	$54	$2,272
77	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	FIC	$2	$0	$2
78	Anga Center for Climate	PROJECT NARRATIVE Eas	FIC	10982425	9/19/24	RFA-ES-23-007	1P20TW0128	12808	NEWSOME, BRAD	9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	NDETEI, DAV	Unavailable	COLUMBIA U	9/23/24	8/31/25	Research Ce	2024	$1,061,973	FIC	$1	$0	$1
79	The Behavioral Cost of C	PROJECT NARRATIVEThe	OD	10923510	9/18/24	RFA-RM-23-007	1DP5OD0374	37400	MILLER, BECKY	9/18/24	7/31/29	Special Emph	78943744	MINOR, KELT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/24	7/31/25	Non-SBIR/ST	2024	$411,250	NIDCR	$1	$0	$1
80	Medical Scientist Trainin	PROJECT NARRATIVEThe	NIGMS	10877873	6/4/24	PAR-21-189	5T32GM1454	145440	MCINTYRE, JEREMY CO	7/1/22	6/30/27	Training and V	1864040	REINER, STEV	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$1,558,334	NIGMS	$1,489,124	$69,210	$1,558,334
81	Postdoctoral Training in (	Our training program see	NHLBI	10890104	7/15/24	PA-18-403	5T32HL00785	7854	WEBB, STEPHANIE JOH	7/1/96	6/30/26	NHLBI Institu	8052876	MARX, STEVE	ABDALLA, MA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$900,800	NHLBI	$862,704	$58,096	$900,800
82	Training in Cellular Mole	PROJECT NARRATIVEThe	NIGMS	10868599	4/22/24	PAR-20-213	5T32GM1457	145766	AIYEGBO, MOHAMMED	7/1/22	6/30/27	Training and V	1884281	LIEM, RONAL	HAEUSLER, R	PATHOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$878,975	NIGMS	$836,384	$42,591	$878,975
83	NRSA Training Core	n/a	NCATS	10894261	6/12/24	PAR-18-940	5TL1TR00187	1875	ATIENZA, AUDIE A	7/1/16	5/31/26	ZTR1-SRC(99	8870151	SPANN, MAR	TAYLOR, JAC	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Inst	2024	$749,022	NCATS	$895,872	$53,150	$749,022
84	Postdoctoral Training in A	Project NarrativeThis is a	NHLBI	10824211	8/5/24	PA-20-142	5T32HL00734	7343	WANG, WAYNE C.	7/1/78	7/31/28	NHLBI Institu	1857723	GINSBERG, H	REILLY, MURE	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$673,488	NHLBI	$698,140	$50,131	$673,488
85	Patient Safety and Healt	Despite a heightened foc	AHRQ	10875422	6/26/24	RFA-HS-22-010	5T32HS02612	26121	DESOTO, MAUSHAMI	7/1/18	6/30/28	ZHS1-HSR-A	10386412	ADELMAN, JA	BARR, R GRA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$620,443	AHRQ	$596,592	$38,847	$620,443
86	Training Program on HIV a	PROJECT NARRATIVE Thi	NIDA	10918691	5/16/24	PA-23-048	2T32DA0378	37801	DUCHARME, LORI	7/1/14	6/30/29	Special Emph	1891871	EL-BASSEL, N	METSCH, LIS	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$557,156	NIDA	$522,404	$34,752	$557,156
87	Substance Abuse Epidem	Substance use and subst	NIDA	10836582	5/20/24	PA-20-142	5T32DA0310	31099	LOPEZ, MARSHA	7/1/12	6/30/27	ZDA1-SKM-D	1879601	HASIN, DEBO	MARTINS, SIL	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$510,748	NIDA	$545,048	$35,700	$510,748
88	Behavioral Sciences Res	Major biomedical advanc	NIMH	10874650	6/28/24	PA-18-403	5T32MH0191	19139	ALLISON, SUSANNAH	7/1/89	6/30/25	ZMH1-ERB-M	8188389	MELLINS, CLA	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$500,315	NIMH	$564,140	$43,451	$500,315
89	Systems Science and Co	PROJECT NARRATIVEThe	NINR	10861745	5/16/24	PA-20-142	5T32NR0142	14205	KEHL, KAREN	7/1/13	6/30/28	ZNR1-REV-W	9844694	POGHOSYAN	STONE, PATR	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$487,419	NINR	$485,994	$31,920	$487,419
90	Molecular Oncology Trai	PROJECT NARRATIVECar	NCI	10880432	6/25/24	PA-18-403	5T32CA2037	203703	LIM, SUSAN E	7/18/16	6/30/26	Institutional	6405748	HERSHMAN,	CREW, KATH	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$483,880	NCI	$514,752	$39,740	$483,880
91	Translational Research T	We urgently need to sust	NIMH	10836376	6/3/24	PA-18-403	5T32MH0164	16434	BECHTHOLT, ANITA J	9/25/80	6/30/25	ZMH1-ERB-G	8746379	VEENSTRA-V	FITZGERALD,	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$462,630	NIMH	$514,596	$37,568	$462,630
92	Training in Schizophrenia	PROJECT NARRATIVEThis	NIMH	10894080	6/7/24	PA-18-403	5T32MH0188	18870	CHAVEZ, MARK	8/1/88	6/30/25	ZMH1-ERB-G	9574679	KELLENDONK	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$458,786	NIMH	$532,584	$39,007	$458,786
93	Global Mental Health (G	People in Low and Middle	NIMH	10911009	8/19/24	PA-20-142	5T32MH0967	96724	ALLISON, SUSANNAH	8/21/12	7/31/28	ZMH1-ERB-E	6072016	WAINBERG, M	Not Applicab	PSYCHIATRY	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$443,114	NIMH	$416,948	$31,532	$443,114
94	Genetic Approaches to D	PROJECT NARRATIVEThis	NIGMS	10866352	4/9/24	PAR-17-341	5T32GM1418	141882	STAMM, JOYCE CHIN-(	7/1/21	6/30/26	Training and V	1940239	SHIRASU-HIZ	BERCHOWIT	GENETICS	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$439,487	NIGMS	$418,192	$21,295	$439,487
95	Research Training Progra	Project narrativePsychia	NIMH	10863869	6/20/24	PA-20-142	5T32MH0130	13043	CHAVEZ, MARK	7/1/72	6/30/27	ZMH1-ERB-M	9555896	KEYES, KATHE	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$432,394	NIMH	$423,188	$29,069	$432,394

A2751

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
96	Translational Clinical Re	Project Narrative:Substa	NIDA	10837720	5/22/24	PA-20-142	5T32DA0072	7294	LAO, GUIFANG	7/20/93	6/30/28	Career Deve	1866589	LEVIN, FRAN(	MARTINEZ, D	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$412,899	NIDA	$542,736	$40,163	$412,899
97	Multidisciplinary Training	Project NarrativeWhile d	NIDDK	10849176	6/26/24	PA-23-048	2T32DK08325	83256	DENSMORE, CHRISTIN	7/1/09	6/30/29	Special Emph	1873597	WANG, TIMO	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$400,571	NIDDK	$487,904	$32,352	$400,571
98	Genome and Epigenome	Two fundamental but me	NCI	10910046	8/6/24	PA-20-142	5T32CA26582	265828	LIM, SUSAN E	9/1/22	8/31/27	Institutional T	7931342	ZHANG, ZHIG	SYMINGTON,	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$373,349	NCI	$409,146	$26,372	$373,349
99	Neuroepidemiology Train	The goal of this proposal	NINDS	10620288	7/24/23	PA-18-403	5T32NS00715	7153	WEIGAND, LETITIA ALE	7/1/80	6/30/25	ZNS1-SRB-L(	9875866	WILLEY, JOSH	GU, YIAN	NEUROLOGY	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$373,048	NINDS	$348,916	$24,132	$373,048
100	Research Training in Mod	PROJECT NARRATIVEThis	NIMH	10849196	6/5/24	PA-23-048	2T32MH0151	15144	CHAVEZ, MARK	7/1/78	6/30/29	Special Emph	1925580	LEONARDO,	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$363,642	NIMH	$443,432	$32,475	$363,642
101	Anesthesiology Research	NarrativeThe proposed p	NIGMS	10876234	6/18/24	PA-20-142	5T32GM0084	8464	PAUL, MOUSHUMI	7/1/92	6/30/28	ZGM1-TWD-X	1864643	EMALA, CHAR	HUA, MAY	ANESTHESIO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$350,862	NIGMS	$326,028	$24,834	$350,862
102	Dental-Biomedical Engin	Project NarrativeIn the U	NIDCR	10880369	6/27/24	PAR-20-056	5T90DE03212	32123	MCGUIRL, MICHELE	7/1/23	6/30/28	ZDE1-NB(13)	6952080	WADHWA, SU	LU, HELEN H	DENTISTRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$329,548	NIDCR	$312,804	$16,744	$329,548
103	Graduate Training in Nut	The discipline of nutritio	NIDDK	10887599	8/8/24	PA-18-403	5T32DK00764	7647	DENSMORE, CHRISTIN	9/15/90	8/31/25	ZDK1-GRB-T	1952696	FERRANTE, A	ZELTSER, LOR	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$319,578	NIDDK	$317,844	$16,308	$319,578
104	The Columbia University	PROJECT NARRATIVEThe	NHLBI	10899556	7/15/24	PA-20-142	5T32HL10532	105323	KALANTARI, ROYA	7/1/11	6/30/26	NHLBI Institu	1861590	BHATTACHAR	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$309,544	NHLBI	$384,180	$26,702	$309,544
105	Training in Translational	Project NarrativeThe aim	NIAID	10744233	11/7/23	PA-18-403	5T32AI14809	148099	GONDRE-LEWIS, TIMO	2/1/20	8/31/25	Allergy, Immu	1887410	SYKES, MEGA	Not Applicab	INTERNAL ME	COLUMBIA U	2/1/24	8/31/25	Training, Inst	2024	$302,148	NIAID	$317,734	$23,948	$302,148
106	Research Training in Late	Project NarrativeThere i	NIMH	10591549	6/9/23	PA-18-403	5T32MH0200	20004	CHAVEZ, MARK	7/1/98	6/30/25	ZMH1-ERB-G	10355138	BROWN, PAT	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$299,068	NIMH	$322,536	$24,139	$299,068
107	Training Grant in Diabete	The Training Grant in Dia	NIDDK	10848883	6/17/24	PA-23-048	1T32DK13195	131952	CASTLE, ARTHUR	7/1/24	5/31/29	Diabetes, End	6564579	ACCILI, DOM	PAJVANI, UTP	INTERNAL ME	COLUMBIA U	7/1/24	5/31/25	Training, Inst	2024	$298,427	NIDDK	$279,692	$18,735	$298,427
108	Global HIV Implementati	PROJECT NARRATIVEDes	NIAID	11006928	7/9/24	PA-23-048	2T32AI11439	114398	REFSLAND, ERIC WILL	9/1/14	8/31/29	Acquired Imm	8438960	HOWARD, AN	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$286,928	NIAID	$317,844	$16,308	$286,928
109	Neurobiology and Behav	PROJECT NARRATIVENeu	NIMH	10917221	8/23/24	PAR-17-096	5T32MH1260	126036	VAN'T VEER, ASHLEE V	9/1/20	8/31/25	ZNS1-SRB-X	8613268	GRUEBER, W	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$425,050	NIGMS	$265,646	$13,078	$267,698
110	Training Grant in Pediatr	NARRATIVEMore pediatr	NIDDK	10865098	6/12/24	PA-18-403	5T32DK06552	65522	CASTLE, ARTHUR	7/1/05	6/30/25	Diabetes, End	1918410	OBERFIELD, S	Not Applicab	PEDIATRICS	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$260,271	NIDDK	$260,040	$19,003	$260,271
111	Social Determinants of H	Columbia University Mai	NIMH	10873117	6/14/24	PA-20-142	5T32MH1283	128395	ALLISON, SUSANNAH	7/1/21	6/30/26	ZAA1-GG(35)	2109075	WINGOOD, G	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$259,320	NIMH	$263,620	$13,490	$259,320
112	Hormones: Molecular Me	Project NarrativeThe goa	NIDDK	10849844	6/21/24	PA-20-142	5T32DK00732	7328	CASTLE, ARTHUR	9/15/78	6/30/26	Diabetes, End	7752388	KOUSTENI, ST	Not Applicab	PHYSIOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$225,297	NIDDK	$232,870	$13,590	$225,297
113	Vision Sciences Training	Project NarrativeThe goa	NEI	10909050	9/6/24	PA-20-142	5T32EY01393	13933	CLAYTON, EDWIN C	9/30/01	8/31/26	ZEY1-VSN(04	1879090	MASON, CAR	TROY, CAROL	PATHOLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$222,768	NEI	$211,896	$10,872	$222,768
114	Advanced Graduate Train	The complexity of neuros	NINDS	10615158	7/10/23	PA-18-403	5T32NS06492	64929	WEIGAND, LETITIA ALE	7/1/09	6/30/25	ZNS1-SRB-L(	2201944	ABBOTT, LAU	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$213,078	NINDS	$202,776	$10,302	$213,078
115	Columbia University Gra	This competing renewal	NIAID	10841618	5/15/24	PA-18-403	5T32AI10671	106711	GONDRE-LEWIS, TIMO	6/1/14	6/30/25	Allergy, Immu	9235902	BASU, UTTIYA	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$212,360	NIAID	$211,896	$10,872	$212,360
116	Short Term Training Gran	PROJECT NARRATIVEThis	NHLBI	10833526	4/4/24	PA-18-404	5T35HL00761	7616	HILL-PRYOR, CRYSTAL	5/1/81	4/30/26	ZHL1-CSR-B	7057421	LEIBEL, RUD(	Not Applicab	PEDIATRICS	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$210,933	NHLBI	$195,308	$15,625	$210,933
117	Training in Pediatric Infe	Project NarrativeThis is a	NIAID	10661019	7/21/23	PA-18-403	5T32AI00753	7531	COOMES, STEPHANIE	9/30/98	8/31/25	Microbiology	1935964	SAIMAN, LISA	PRINCE, ALIC	PEDIATRICS	COLUMBIA U	9/1/23	8/31/25	Training, Inst	2023	$206,884	NIAID	$282,096	$18,128	$206,884
118	Advanced Graduate Train	The goal of the proposed	NINDS	10878700	6/19/24	PAR-19-211	5T32NS06492	64928	WEIGAND, LETITIA ALE	7/1/10	6/30/25	ZNS1-SRB-D	8737737	HENGST, ULF	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$200,104	NINDS	$249,288	$13,863	$200,104
119	Obesity Research Cente	Obesity is now among the	NIDDK	10896924	6/28/24	PA-20-142	5T32DK00755	7559	DENSMORE, CHRISTIN	7/1/89	7/31/27	ZDK1-GRB-T	1869280	GALLAGHER,	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$197,244	NIDDK	$289,676	$19,174	$197,244
120	Integrated Musculoskele	PROJECT NARRATIVEThe	NIAMS	10804662	5/3/24	PA-20-142	5T32AR08074	80744	VINCENT, ISAAH S	5/1/23	4/30/28	ZAR1-KM(M1	1880521	GUO, X. EDW	CHAHINE, NA	BIOMEDICAL	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$197,168	NIAMS	$186,296	$10,872	$197,168
121	Multidisciplinary Training	PROJECT NARRATIVEGas	NCI	10769254	8/23/24	PA-20-142	1T32CA28527	285274	LIM, SUSAN E	9/1/24	8/31/29	Institutional T	9047196	ABRAMS, JUL	RUSTGI, ANIL	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$193,144	NCI	$180,800	$12,344	$193,144
122	Columbia Integrated Tra	PROJECT NARRATIVEThis	NIAID	10814938	5/7/24	PA-20-142	5T32AI10085	100852	COOMES, STEPHANIE	6/1/13	5/31/28	Microbiology	9733196	UHLEMANN,	SOBIESZCZY	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Inst	2024	$188,707	NIAID	$198,216	$12,817	$188,707
123	Brief Research In Aging a	Project NarrativeThe Bri	NIA	10834985	6/6/24	PA-20-162	5T35AG04430	44303	WAGSTER, MOLLY V.	5/1/13	4/30/28	ZAG1-ZIJ-U(J	9773845	NOBLE, JAME	AGARWAL, SA	NEUROLOGY	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$187,816	NIA	$173,904	$13,912	$187,816
124	Research Training in Biol	PROJECT NARRATIVEThis	NIMH	10844537	7/1/24	PA-20-142	5T32MH0966	96679	CHAVEZ, MARK	6/1/13	6/30/28	ZMH1-ERB-E	6487748	ATTIA, EVELYN	WALSH, B. TI	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$176,220	NIMH	$265,308	$19,425	$176,220
125	Neurobiology and Behav	PROJECT NARRATIVENeu	NIMH	10917221	8/23/24	PAR-17-096	5T32MH1260	126036	VAN'T VEER, ASHLEE V	9/1/20	8/31/25	ZNS1-SRB-X	8613268	GRUEBER, W	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$425,050	NIMH	$156,146	$7,686	$157,352
126	Multidisciplinary Training	Project NarrativeThe aim	NIAMS	10849865	6/26/24	PA-20-142	5T32AR07695	76953	VINCENT, ISAAH S	7/1/21	6/30/26	ZAR1-FY(M1)	1964244	BATHON, JOA	WINCHESTER	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$137,882	NIAMS	$169,720	$12,378	$137,882
127	GSH Training Grant	PROJECT NARRATIVENat	NICHD	10892748	5/29/24	PA-20-142	5T32HD0493	49339	CAPPS, RANDOLPH CH	5/9/06	4/30/27	ZHD1-DSR-R	1950424	HIRSCH, JEN	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$115,696	NICHD	$209,896	$10,712	$115,696
128	Research Training Progra	Project Narrative:Menta	NIMH	10847982	6/5/24	PA-23-048	1T32MH1358	135856	CHAVEZ, MARK	7/1/24	6/30/29	Special Emph	8874378	WANG, YUAN	OGDEN, TOD	BIOSTATISTIC	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$110,844	NIMH	$105,448	$5,396	$110,844
129	Training Medical Student	Project NarrativeThe ma	NIDDK	10820478	5/1/24	PA-20-162	5T35DK09343	93430	CASTLE, ARTHUR	3/15/12	4/30/27	Kidney, Urolo	1860269	AL-AWQATI, Q	PAJVANI, UTP	INTERNAL ME	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$103,318	NIDDK	$98,922	$7,914	$103,318
130	Functional interrogation	PROJECT NARRATIVEThis	NIMH	10915447	8/28/24	RFA-MH-20-620	5F32MH1300	130023	VAN'T VEER, ASHLEE V	9/1/22	8/31/25	ZMH1-ERB-L	78260336	YI, JANE	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$84,254	NINDS	$84,254	$0	$84,254
131	Unraveling the neural me	PROJECT NARRATIVETo r	NIDA	10902676	3/14/24	PA-21-048	1F32DA0607	60751	LIN, YU	5/1/24	4/30/27	Special Emph	77856830	SHEN, JIA	Not Applicab	NEUROSCIEN	COLUMBIA U	5/1/24	4/30/25	Training, Indiv	2024	$82,192	NIDA	$82,192	$0	$82,192
132	Understanding the indivi	PROJECT NARRATIVEHaz	NIAAA	10867417	8/7/24	PA-21-048	5F32AA02995	29957	KERRIDGE, BRADLEY T	8/1/22	7/31/25	ZAA1-GG(32)	14982558	BOCHICCHI(	Not Applicab	OTHER HEALT	COLUMBIA U	8/1/24	7/31/25	Training, Indiv	2024	$78,892	NIAAA	$78,892	$0	$78,892
133	Fast and Flexible Conjun	Project NarrativeThe hur	NEI	10809777	4/3/24	PA-21-048	5F32EY03365	33654	AGARWAL, NEERAJ	4/16/22	4/15/25	Special Emph	78107930	TAYLOR, JOH	Not Applicab	PSYCHOLOG	COLUMBIA U	4/16/24	4/15/25	Training, Indiv	2024	$74,284	NEI	$74,284	$0	$74,284
134	Photocatalytic Generati	PROJECT NARRATIVE Ne	NIGMS	11014961	12/23/24	PA-21-048	5F32GM1530	153032	STAMM, JOYCE CHIN-(	1/10/24	1/9/27	Special Emph	15873294	KARIOFILLIS,	Not Applicab	CHEMISTRY	COLUMBIA U	1/10/25	1/9/26	Training, Indiv	2025	$74,284	NIGMS	$74,284	$0	$74,284
135	Caregiver influences on i	PROJECT NARRATIVEMe	NICHD	10997094	8/22/24	PA-23-262	1F32HD1144	114417	MANN KOEPKE, KATHY	11/1/24	10/31/27	Special Emph	79078686	YATES, TRIST	Not Applicab	PSYCHOLOG	COLUMBIA U	11/1/24	10/31/25	Training, Indiv	2024	$73,828	NICHD	$73,828	$0	$73,828
136	Discovering how emergin	PROJECT NARRATIVE We	NICHD	10996977	7/27/24	PA-23-262	1F32HD1166	116657	MILLER, BRETT	11/16/24	11/15/27	Special Emph	16076737	FOREST, TESS	Not Applicab	PSYCHOLOG	COLUMBIA U	11/16/24	11/15/25	Training, Indiv	2024	$73,828	NICHD	$73,828	$0	$73,828
137	Integrating biomaterials	Project NarrativeGlycan	NIBIB	11071622	11/27/24	PA-23-262	1F32EB03692	36927	GUTEKUNST, DAVID JO	1/1/25	12/31/28	Special Emph	12489535	HINCAPIE, R(	Not Applicab	BIOMEDICAL	COLUMBIA U	1/1/25	12/31/25	Training, Indiv	2025	$73,828	NIBIB	$73,828	$0	$73,828
138	Striatal Dopamine's Role	Project NarrativeImpaire	NIMH	10824454	9/13/23	PA-21-048	1F32MH1355	135597	PINARD, COURTNEY	3/2/24	10/31/28	Special Emph	14218632	DECORTE, BE	Not Applicab	PSYCHIATRY	COLUMBIA U	3/2/24	10/31/26	Training, Indiv	2023	$73,580	NIMH	$73,580	$0	$73,580
139	Resting state connectivit	PROJECT NARRATIVEObs	NIMH	10904864	8/7/24	PA-21-049	5F30MH1265	126504	BECHTHOLT, ANITA J	9/1/21	8/31/25	Special Emph	15267921	SHI, TRACEY	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$56,974	NIMH	$56,974	$0	$56,974
140	Alzheimer's Disease Gen	PROJECT NARRATIVEGen	NIA	10906795	8/30/24	PA-21-049	5F30AG0746	74618	SARE, RACHEL	9/1/21	8/31/25	Special Emph	15267909	CHATILA, ZEN	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$53,974	NIA	$53,974	$0	$53,974
141	Quantifying the interacti	NarrativePreterm birth i	NICHD	10914690	8/8/24	PA-21-049	5F30HD1088	108886	GIRARDI, GUILLERMIN	9/15/22	9/14/26	Special Emph	15827843	KINDSCHUH	Not Applicab	BIOCHEMIST	COLUMBIA U	9/15/24	9/14/25	Training, Indiv	2024	$53,974	NICHD	$53,974	$0	$53,974
142	Contribution of PAG to In	PROJECT NARRATIVEDes	NCI	10888994	6/17/24	PA-21-049	5F30CA2716	271624	ODEH, HANA M	7/15/22	7/14/26	Special Emph	15827894	MOORE, EMI	Not Applicab	INTERNAL ME	COLUMBIA U	7/15/24	7/14/25	Training, Indiv	2024	$53,974	NCI	$53,974	$0	$53,974
143	Leveraging CRISPR RNA-(	PROJECT NARRATIVEDes	NHLBI	11005254	12/23/24	PA-21-052	5F31HL16753	167530	REYES, MADELYN	2/1/23	1/31/27	Special Emph	15074693	KING, REBEC	Not Applicab	BIOCHEMIST	COLUMBIA U	2/1/25	1/31/26	Training, Indiv	2025	$53,974	NHLBI	$53,974	$0	$53,974
144	Targeting Neuron-Microg	PROJECT NARRATIVENea	NCI	10875397	5/31/24	PA-19-191	5F30CA2577	257768	PURI, ANU	6/15/21	6/14/25	Special Emph	15271056	GOLDBERG,	Not Applicab	PATHOLOGY	COLUMBIA U	6/15/24	6/14/25	Training, Indiv	2024	$53,974	NCI	$53,974	$0	$53,974
145	Deciphering mechanism	PROJECT NARRATIVEPat	NIDCD	10906823	8/27/24	PA-21-049	5F30DC0209	20900	SCHURMAN, JACLYN R	9/1/22	8/31/26	ZDC1-SRB-E	15827862	POURMORAD	Not Applicab	BIOCHEMIST	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$53,974	NIDCD	$53,974	$0	$53,974
146	Adipocyte-derived exoso	Project NarrativeAdipose	NIDDK	10902095	8/7/24	PA-21-049	5F30DK1290	129008	CASTLE, ARTHUR	9/15/21	9/14/25	ZDK1-GRB-2	15267915	GOODMAN, J	Not Applicab	INTERNAL ME	COLUMBIA U	9/15/24	9/14/25	Training, Indiv	2024	$53,974	NIDDK	$53,974	$0	$53,974
147	Elucidating the role of Fr	PROJECT NARRATIVEAcu	NIDDK	10862718	6/17/24	PA-21-049	5F30DK1341	134109	DENSMORE, CHRISTIN	7/1/22	6/30/26	ZDK1-GRB-7	15827849	LI, ALINA LIN	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$53,974	NIDDK	$53,974	$0	$53,974
148	Modulation of Heterome	PROJECT NARRATIVEThe	NINDS	11031948	2/13/25	PA-21-051	5F31NS1325	132554	UMANAH, GEORGE KW	2/1/24	1/31/27	Special Emph	77858962	YEN, LAURA Y	Not Applicab	PHYSIOLOGY	COLUMBIA U	2/1/25	1/31/26	Training, Indiv	2025	$51,974	NINDS	$51,974	$0	$51,974
149	Induction and maintenar	PROJECT NARRATIVEVac	NIAID	10891422	6/4/24	PA-21-049	5F30AI17478	174785	ARNOLD, MICHELLE M	7/1/23	6/30/27	Special Emph	16529540	DAVIS-PORAD	Not Applicab	SURGERY	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$50,974	NIAID	$50,974	$0	$50,974
150	Multiscale imaging of cor	PROJECT NARRATIVERea	NIMH	10901194	3/8/24	PA-21-049	1F30MH1356	135661	VAN'T VEER, ASHLEE V	3/15/24	3/14/28	Special Emph	16529550	GRUSKIN, DA	Not Applicab	NEUROSCIEN	COLUMBIA U	3/15/24	3/14/25	Training, Indiv	2024	$50,937	NIMH	$50,937	$0	$50,937
151	Impact of Species-Specif	PROJECT NARRATIVESyn	NIMH	10899947	3/8/24	PA-21-049	1F30MH1366	136683	DRISCOLL, JAMIE	7/1/24	6/30/27	Special Emph	78213242	RECUPERO, A	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$50,937	NIMH	$50,937	$0	$50,937
152	Engineering a strategy for	PROJECT NARRATIVEThe	NHLBI	10998065	9/10/24	PA-23-260	1F30HL1740	174098	MEADOWS, TAWANNA	9/15/24	9/14/27	Special Emph	78213224	CORDOVES,	Not Applicab	INTERNAL ME	COLUMBIA U	9/15/24	9/14/25	Training, Indiv	2024	$50,937	NHLBI	$50,937	$0	$50,937
153	Mechanisms of reverse t	PROJECT NARRATIVE Wit	NIAID	10901546	1/25/24	PA-21-049	1F30AI18383	183830	ERNST, NANCY L.	7/1/24	6/30/27	Special Emph	78213245	TANG, STEPH	Not Applicab	BIOCHEMIST	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$50,937	NIAID	$50,937	$0	$50,937
154	Targeting Purinergic Sign	PROJECT NARRATIVEGlid	NCI	10825218	3/11/24	PA-21-049	1F30CA2880	288006	PURI, ANU	3/15/24	3/14/28	Special Emph	16529573	PEREIRA, BRI	Not Applicab	PATHOLOGY	COLUMBIA U	3/15/24	3/14/25	Training, Indiv	2024	$50,937	NCI	$50,937	$0	$50,937
155	Improving bacterial canc	PROJECT NARRATIVEBac	NCI	11112287	2/28/25	PA-21-049	5F30CA2877	287792	PURI, ANU	3/1/24	2/28/28	Special Emph	16529535	CHEN, NOAH	Not Applicab	MICROBIOLO	COLUMBIA U	3/1/25	2/28/26	Training, Indiv	2025	$50,937	NCI	$50,937	$0	$50,937
156	Disentangling the roles o	PROJECT NARRATIVECel	NIDCD	11165197	12/9/24	PA-23-260	1F30DC0227	22796	SCHURMAN, JACLYN R	1/15/25	1/14/29	Special Emph	78213239	MIHAILA, TIBE	Not Applicab	BIOCHEMIST	COLUMBIA U	1/15/25	1/14/26	Training, Indiv	2025	$50,928	NIDCD	$50,928	$0	$50,928
157	Investigating the Impacts	PROJECT NARRATIVEAlzh	NIA	10902945	7/3/24	PA-21-049	1F30AG0843	84312	MACKIEWICZ, MIROSL	7/3/24	7/2/28	Special Emph	16529554	JIN, MICHELL	Not Applicab	PSYCHIATRY	COLUMBIA U	7/3/24	7/2/25	Training, Indiv	2024	$50,414	NIA	$50,414	$0	$50,414
158	Epigenetic and Neuronal	PROJECT NARRATIVERet	NICHD	10902891	9/10/24	PA-21-049	1F30HD1153	115371	OREILLY, JULIA JIAQI	9/16/24	9/15/28	Special Emph	16529563	PAN, RICHAR	Not Applicab	PHYSIOLOGY	COLUMBIA U	9/16/24	9/15/25	Training, Indiv	2024	$50,414	NICHD	$50,414	$0	$50,414
159	RNA Decay of LINE-1 Ret	PROJECT NARRATIVEIn o	NIAID	10902832	7/9/24	PA-21-049	1F30AI17918	179182	GONDRE-LEWIS, TIMO	7/15/24	7/14/27	Special Emph	16529555	LAURING, MA	Not Applicab	MICROBIOLO	COLUMBIA U	7/15/24	7/14/25	Training, Indiv	2024	$50,414	NIAID	$50,414	$0	$50,414
160	Transcriptional regulatio	PROJECT NARRATIVEHur	NIDCR	10908411	7/26/24	PA-21-051	5F31DE0319	31970	FUQUA, CHANTEL FAYS	9/1/22	8/31/25	National Inst	16077152	ANDERSON,	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$49,774	NIDCR	$49,774	$0	$49,774
161	ECM remodeling and cro	PROJECT NARRATIVE Joi	NIDCR	10979141	7/26/24	PA-21-051	5F31DE0332	33220	FUQUA, CHANTEL FAYS	9/1/23	8/31/26	Special Emph	77792546	MO, JULIA	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$49,774	NIDCR	$49,774	$0	$49,774
162	Testing competing mode	Project Narrative:Halluc	NIMH	10869925	6/21/24	PA-21-051	5F31MH1346	134617	AVENILLA, FRANK	7/1/23	6/30/25	Special Emph	16104095	BUCK, JUSTIN	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,994	NIMH	$48,994	$0	$48,994
163	Acetylation as a novel po	PROJECT NARRATIVE-ce	NIDDK	10903057	2/14/24	PA-21-051	1F31DK1376	137600	CASTLE, ARTHUR	6/1/24	5/31/26	Fellowships i	77823297	CHIRIKJIAN,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Indiv	2024	$48,974	NIDDK	$48,974	$0	$48,974
164	Immature neutrophil mig	PROJECT NARRATIVEObe	NIDDK	11071091	12/24/24	PA-23-272	1F31DK1425	142531	CASTLE, ARTHUR	12/24/24	12/23/26	Fellowships i	77812251	QUIN WATER	Not Applicab	INTERNAL ME	COLUMBIA U	12/24/24	12/23/25	Training, Indiv	2025	$48,974	NIDDK	$48,974	$0	$48,974
165	The genomic and synapti	Project NarrativeLearne	NIDCD	11071726	8/20/24	PA-23-272	1F31DC0221	22183	SCHURMAN, JACLYN R	9/1/24	8/31/27	Special Emph	79511585	NARAYANAN,	Not Applicab	ENGINEERIN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIDCD	$48,974	$0	$48,974
166	Synergistic contributions	PROJECT NARRATIVEThis	NIA	10998809	8/13/24	PA-23-272	1F31AG0900	90091	SARE, RACHEL	9/1/24	8/31/27	Special Emph	79142637	EDWARDS, N	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
167	The impact of Alzheimer'	PROJECT NARRATIVEAlzh	NIA	10997953	8/19/24	PA-23-272	1F31AG0900	90071	WAGSTER, MOLLY V.	9/1/24	8/31/26	Special Emph	15977956	BULTHUIS, N	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
168	Brain-wide neural mecha	PROJECT NARRATIVE Cry	NICHD	10903156	4/5/24	PA-21-052	1F31HD1144	114466	MANN KOEPKE, KATHY	4/5/24	9/4/26	Special Emph	77842692	MCRAE, BRIA	Not Applicab	NEUROSCIEN	COLUMBIA U	4/5/24	4/4/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
169	Impact of developmenta	PROJECT NARRATIVEPre	NIMH	11071345	8/30/24	PA-23-271	1F31MH1381	138134	PINARD, COURTNEY	9/1/24	2/28/27	Special Emph	78316229	ANQUEIRA, A	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIMH	$48,974	$0	$48,974
170	Impact of social environ	PROJECT NARRATIVEThe	NIMH	10902956	3/5/24	PA-21-052	1F31MH1368	136812	PINARD, COURTNEY	7/1/24	6/30/27	Special Emph	78640196	BRAVO, ISAB	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NIMH	$48,974	$0	$48,974
171	Regeneration of Thalamo	Project Narra+veThis pro	NINDS	11070946	11/21/24	PA-23-272	1F31NS1416	141628	OSBORNE, LESLIE CAR	12/1/24	9/30/27	Special Emph	79678097	CHUA, JIANM	Not Applicab	BIOLOGY	COLUMBIA U	12/1/24	11/30/25	Training, Indiv	2025	$48,974	NINDS	$48,974	$0	$48,974
172	The Cellular and Neural (	PROJECT NARRATIVEFlex	NINDS	10903100	3/20/24	PA-21-051	1F31NS1377	137735	GREENWELL, THOMAS	4/1/24	3/31/27	Special Emph	77842705	WOOD, ABBY	Not Applicab	NEUROSCIEN	COLUMBIA U	4/1/24	3/31/25	Training, Indiv	2024	$48,974	NINDS	$48,974	$0	$48,974
173	Determining how a single	Project Narrative1. PKR	NINDS	10997698	6/27/24	PA-23-271	1F31NS1396	139626	SIEBER, BETH-ANNE	7/1/24	6/30/28	Special Emph	14938537	GERTIE, JAKE	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NINDS	$48,974	$0	$48,974
174	Interrogation of non-can(	PROJECT NARRATIVEVolt	NINDS	10902910	3/29/24	PA-21-052	1F31NS1377	137770	MATOS GALICIA, HEIDI	9/1/24	8/31/27	Special Emph	15147704	HELMS, KYLE	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NINDS	$48,974	$0	$48,974
175	Elucidating the complex	PROJECT NARRATIVEAllo	NIAID	10903188	8/6/24	PA-21-051	1F31AI18413	184134	XU, ZUOYU	9/1/24	8/31/27	Special Emph	78329645	SUNDBERG,	Not Applicab	BIOCHEMIST	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
176	Mechanistic insights into	Project NarrativePhosph	NIAID	10826774	7/22/24	PA-21-051	1F31AI18155	181556	GU, XIN-XING	9/1/24	8/31/26	Special Emph	16104164	ZINKLE, ALLE	Not Applicab	PHYSIOLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
177	Biomechanics and mech	PROJECT NARRATIVEUte	NICHD	10902995	8/8/24	PA-21-051	1F31HD1144	114449	AHN, HELENA HYESOO	9/1/24	8/31/26	Special Emph	15967517	FODERA, DAN	Not Applicab	BIOMEDICAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
178	Investigating the role of c	PROJECT NARRATIVEThe	NIAID	11071146	11/26/24	PA-23-272	1F31AI18888	188882	GONDRE-LEWIS, TIMO	12/1/24	11/30/27	Special Emph	79078562	WHISENANT,	Not Applicab	MICROBIOLO	COLUMBIA U	12/1/24	11/30/25	Training, Indiv	2025	$48,974	NIAID	$48,974	$0	$48,974
179	Host Factors Required by	Project NarrativeThe Par	NIAID	10824958	3/6/24	PA-21-051	1F31AI17676	176760	KIM, SONNIE	3/6/24	3/5/26	Special Emph	77858958	STEARNS, KY	Not Applicab	PHYSIOLOGY	COLUMBIA U	3/6/24	3/5/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
180	Investigating the Genetic	PROJECT NARRATIVEBas	NHLBI	10998862	8/13/24	PA-23-272	1F31HL17616	176168	SOOD, BEENA G	9/1/24	8/31/27	Special Emph	78335692	DIRVIN, BRO	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NHLBI	$48,974	$0	$48,974
181	Type I Interferon Mediate	PROJECT NARRATIVEVas	NINDS	11003276	12/9/24	PA-21-051	5F31NS1309	130983	HEWETT, SANDRA JEAN	1/15/23	1/14/26	Special Emph	15827872	TUOHY, MARY	Not Applicab	NEUROLOGY	COLUMBIA U	1/15/25	1/14/26	Training, Indiv	2025	$48,974	NINDS	$48,974	$0	$48,974
182	Therapeutic Editing of Ro	PROJECT NARRATIVEPho	NEI	11042742	1/22/25	PA-21-051	5F31EY03366	33660	AGARWAL, NEERAJ	2/1/23	1/31/26	Special Emph	78103980	NOLAN, NICH	Not Applicab	OPHTHALMO	COLUMBIA U	2/1/25	1/31/26	Training, Indiv	2025	$48,974	NEI	$48,974	$0	$48,974
183	Interactions between mo	PROJECT NARRATIVEThe	NIMH	10928756	8/29/24	PA-21-051	5F31MH1333	133351	PINARD, COURTNEY	9/8/23	9/7/25	Special Emph	16366203	GASSER, CAM	Not Applicab	PSYCHOLOG	COLUMBIA U	9/8/24	9/7/25	Training, Indiv	2024	$48,974	NIMH	$48,974	$0	$48,974
184	Inhibition of CD33-sialic	PROJECT NARRATIVEWh	NIA	10928124	8/27/24	PA-21-051	5F31AG0796	79613	SARE, RACHEL	9/1/23	8/31/26	Special Emph	16177782	GREEN, JENN	Not Applicab	PHARMACOL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
185	Understanding and Contr	Project NarrativeMecha	NICHD	10914666	8/7/24	PA-20-246	5F31HD1054	105405	MUKHOPADHYAY, MAH	9/1/21	8/31/25	Special Emph	16124527	CUPO, CHRIS	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
186	Mechanisms underlying t	Project Narrative While	NIA	10909146	8/26/24	PA-21-051	5F31AG0796	79601	FRIDELL, YIH-WOEI	9/1/22	8/31/25	Special Emph	16077168	GATTO, JARED	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
187	A Novel Long Noncoding	PROJECT NARRATIVESys	NIAID	10886817	6/5/24	PA-21-051	5F31AI17231	172316	GONDRE-LEWIS, TIMO	7/1/22	6/30/25	Special Emph	78206283	TIAN, RUXIAO	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
188	Mechanisms controlling	Project narrativeMany tr	NICHD	11099655	7/9/24	PA-21-051	5F31HD1102	110242	STEIN, KATHRYN K	7/1/23	6/30/26	Special Emph	16027869	MUNCE, ROS	Not Applicab	GENETICS	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
189	Chromosomal instability	PROJECT NARRATIVEBra	NCI	10842249	6/6/24	PA-21-049	5F30CA2811	281104	BIAN, YANSONG	7/1/23	6/30/28	Special Emph	16529522	CAPRIO, LIND	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NCI	$48,974	$0	$48,974
190	Prenatal exposure to pht	PROJECT NARRATIVEPht	NIEHS	10923843	7/25/24	PA-21-051	5F31ES03497	34972	BOYLES, ABEE	9/1/23	8/31/25	Special Emph	78596921	SIDDIQ, SHA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIEHS	$48,974	$0	$48,974

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
191	Examining Individuals' Ex	PROJECT NARRATIVERes	NIAAA	10908296	8/2/24	PA-21-051	5F31AA03119	31193	BLOSS, GREGORY	9/1/23	8/31/25	ZAA1-GG(32)	78548327	MEHRANBOD	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIAAA	$48,974	$0	$48,974
192	Auditory cortical tuning t	Project Narrative Deficit	NIDCD	10904727	7/10/24	PA-21-051	5F31DC0209	20904	SCHURMAN, JACLYN R	9/1/22	8/31/25	ZDC1-SRB-Y	78565715	EDWARDS, JA	Not Applicab	PSYCHOLOG	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIDCD	$48,974	$0	$48,974
193	Data-Driven Discovery o	PROJECT NARRATIVEThis	NIA	10915420	8/9/24	PA-21-051	5F31AG0796	79627	MARTIN, DAMALI	9/1/23	8/31/25	Special Emph	16354815	JAWADEKAR,	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,214	NIA	$48,214	$0	$48,214
194	Regulation and function c	Project NarrativeMitoch	NINDS	10888185	6/17/24	PA-21-051	5F31NS1291	129199	MILLER, DANIEL L	7/1/22	6/30/25	Special Emph	16486772	DONOVAN, E	Not Applicab	BIOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,123	NINDS	$48,123	$0	$48,123
195	Associations among mate	PROJECT NARRATIVETho	NICHD	10898330	7/23/24	PA-21-051	1F31HD1153	115324	GRIFFIN, JAMES	8/1/24	7/31/26	Special Emph	78158033	SPERBER, JES	Not Applicab	PSYCHOLOG	COLUMBIA U	8/1/24	7/31/25	Training, Indiv	2024	$42,574	NICHD	$42,574	$0	$42,574
196	Linking endoplasmic retic	Project NarrativeNeurot	NEI	11002649	11/29/24	PA-21-052	5F31EY03516	35165	AGARWAL, NEERAJ	12/16/23	12/15/26	Special Emph	15050727	DELGADO, KA	Not Applicab	BIOLOGY	COLUMBIA U	12/16/24	12/15/25	Training, Indiv	2025	$42,574	NEI	$42,574	$0	$42,574
197	Parent-adolescent inforr	PROJECT NARRATIVESuic	NICHD	10996097	2/20/25	PA-21-051	5F31HD1112	111295	ESPOSITO, LAYLA E	1/1/24	1/1/27	Special Emph	78597909	SPEARS, ANG	Not Applicab	PSYCHOLOG	COLUMBIA U	1/2/25	1/1/26	Training, Indiv	2025	$41,294	NICHD	$41,294	$0	$41,294
198	Investigating the potentia	PROJECT NARRATIVEMat	NIAID	10824991	3/22/24	PA-21-051	1F31AI17685	176851	BOZICK, BROOKE ALLIS	8/1/24	7/31/26	Special Emph	77847671	GORIN, EMM	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Training, Indiv	2024	$36,053	NIAID	$36,053	$0	$36,053
199	Long-term exposure to ar	PROJECT NARRATIVEThis	NIEHS	10922694	8/12/24	PA-21-051	5F31ES03530	35306	JOUBERT, BONNIE	9/1/23	8/31/26	Special Emph	78344631	MEDGYESI, D	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$35,958	NIEHS	$35,958	$0	$35,958
200	Examining Social Ecologi	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEAL	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NIAID	$1,700,392	$849,988	$2,550,380
201	Examining Social Ecologi	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEAL	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NICHD	$233,353	$116,647	$350,000
202	Examining Social Ecologi	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEAL	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NIAAA	$100,009	$49,991	$150,000
203	NY Community-Hospital-	OVERALL PROJECT NARR	NICHD	10908625	7/17/24	RFA-HD-23-035	5U54HD1131	113172	FABIYI, CAMILLE	8/17/23	7/31/30	Special Emph	15745999	REDDY, UMA	BROWN, SEV	OBSTETRICS	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$2,265,444	NICHD	$1,825,476	$439,968	$2,265,444
204	The Empilisweni Center f	Project NarrativeAlthoug	NCI	10931463	7/29/24	RFA-CA-22-019	5U54CA2840	284030	SIVARAM, SUDHA	9/19/23	8/31/28	ZCA1-SRB-2	7012821	CASTOR, DEL	ARENDSE, JU	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,068,363	NCI	$850,447	$217,916	$1,068,363
205	MyPEEPS Mobile Plus: A N	PROJECT NARRATIVEHIV	NIMHD	10933040	3/22/24	RFA-MD-23-008	5R01MD0191	19181	FERNANDEZ, ANGELA	9/21/23	3/31/28	ZMD1-IN(A1)	9765581	SCHNALL, RE	GAROFALO, R	OTHER HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$989,833	NIMHD	$754,827	$235,006	$989,833
206	Integrated Supportive Ca	Policy solutions that cen	NINR	10933006	6/26/24	RFA-NR-23-002	5R01NR0211	21108	GIVENS-BRADLEY, SHA	9/21/23	6/30/28	Special Emph	15823607	DAW, JAMIE R	DORVAL-MO	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$743,447	NINR	$505,099	$238,348	$743,447
207	Mental Health of Latino A	Exposures to deprivation	NIMHD	10839331	11/29/23	PAR-21-080	5R01MD0172	17273	STINSON, NATHANIEL	5/9/23	11/30/28	Psychosocia	1869481	ORJUELA, MA	LEWIS-FERN	PUBLIC HEAL	COLUMBIA U	12/1/23	11/30/25	Non-SBIR/ST	2024	$687,188	NIMHD	$422,830	$264,358	$687,188
208	Multidimensional and lor	PROJECT NARRATIVEThe	NIAID	10938759	9/12/24	PA-20-185	1R01AI18499	184997	MINNICOZZI, MICHAE	9/12/24	7/31/29	Population ba	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	9/12/24	7/31/25	Non-SBIR/ST	2024	$615,891	NIAID	$425,191	$190,700	$615,891
209	Strategies for Reaching a	Project NarrativeAdvanc	NCI	10856030	3/13/24	PAR-22-105	1R01CA2892	289295	MARCUS, PAMELA M.	4/1/24	3/31/29	Special Emph	9837872	SHELTON, RA	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$542,964	NCI	$396,853	$146,111	$542,964
210	Reframing personal and c	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RC	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	NIEHS	$159,622	$70,683	$230,305
211	Reframing personal and c	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RC	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	NHGRI	$69,309	$30,691	$100,000
212	Reframing personal and c	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RC	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	OD	$69,309	$30,691	$100,000
213	CADRE Program for Postb	PROJECT NARRATIVEIt is	NINDS	10987061	11/29/24	RFA-NS-22-035	5R25NS1309	130961	MATTHEWS, MARGUER	12/1/22	11/30/26	ZNS1-SRB-D	8613268	GRUEBER, W	HENGST, ULF	PHYSIOLOGY	COLUMBIA U	12/1/24	11/30/25	Other Resear	2025	$424,202	NINDS	$392,780	$31,422	$424,202
214	SEARCH: SMS Electronic	PUBLIC HEALTH RELEVAN	NCI	10919236	7/19/24	PAR-19-376	5R33CA2536	253604	PEARLMAN, PAUL C	8/1/20	7/31/26	Special Emph	9013927	STOCKWELL,	KITAKA, SABR	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$246,609	NCI	$195,292	$46,317	$241,609
215	SEARCH: SMS Electronic	PUBLIC HEALTH RELEVAN	NCI	10919236	7/19/24	PAR-19-376	5R33CA2536	253604	PEARLMAN, PAUL C	8/1/20	7/31/26	Special Emph	9013927	STOCKWELL,	KITAKA, SABR	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$246,609	FIC	$4,042	$958	$5,000
216	Multimodal immune prof	PROJECT NARRATIVEThe	NIAID	10651894	5/16/23	PA-20-195	5R21AI17124	171249	PLIMACK, MARY KATHE	6/23/22	5/31/25	Clinical Rese	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$236,190	NIAID	$151,692	$84,498	$236,190
217	Training in Cardiovascula	PROJECT NARRATIVEThe	NHLBI	10863934	4/1/24	RFA-HL-19-024	5R25HL1560	156002	MEADOWS, TAWANNA	5/1/21	4/30/26	ZHL1-CSR-A	1859027	MARKS, AND	Not Applicab	PHYSIOLOGY	COLUMBIA U	5/1/24	4/30/25	Other Resear	2024	$123,984	NHLBI	$114,800	$9,184	$123,984
218	The Role of Social Detern	PROJECT NARRATIVEOve	NINR	10995462	7/2/24	PA-23-272	1F31NR0213	21330	WILLIS, LEIGH ANDREW	9/1/24	8/31/26	National Inst	15467797	HAHN, ALEXA	Not Applicab	OTHER HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$51,974	NINR	$51,974	$0	$51,974
219	Does self-reported psych	PROJECT NARRATIVEHyp	NICHD	11105757	8/6/24	PA-21-052	5F31HD1102	110257	MITCHELL, MEGAN S	9/1/23	8/31/25	Special Emph	15784692	CLEMONS, A	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,214	NICHD	$48,214	$0	$48,214
220	Brain Research Apprenti	PROJECT NARRATIVEThe	NINDS	11058915	12/20/24	PAR-21-168	2R25NS1155	115551	MATTHEWS, MARGUER	12/5/20	1/31/30	Special Emph	9307525	SHOHAMY, D	EL-SHAMAYL	PSYCHOLOG	COLUMBIA U	2/1/25	1/31/26	Other Resear	2025	$135,000	NINDS	$125,000	$10,000	$135,000
221	Summer Institute for Trai	PROJECT NARRATIVETec	NHLBI	11011475	1/2/25	RFA-HL-22-009	5R25HL1617	161786	COADY, SEAN	1/15/22	12/31/26	ZHL1-CSR-A	7347011	BERHANE, KI	MAURO, CHR	BIOSTATISTIC	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$238,222	NHLBI	$155,181	$8,041	$163,222
222	Summer Institute for Trai	PROJECT NARRATIVETec	NHLBI	11011475	1/2/25	RFA-HL-22-009	5R25HL1617	161786	COADY, SEAN	1/15/22	12/31/26	ZHL1-CSR-A	7347011	BERHANE, KI	MAURO, CHR	BIOSTATISTIC	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$238,222	OD	$71,306	$3,694	$75,000
223	The linkage between Rac	Elevated expression of th	NCI	10891394	9/11/24	PAR-18-654	5R01CA2533	253368	MERCER, NATALIA	9/24/20	6/30/25	Special Emph	1926891	GARDNER, K	Not Applicab	PATHOLOGY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$625,704	NCI	$482,854	$142,850	$625,704
224	A Multilevel Investigation	Project NarrativeMexico	NIA	10979824	8/26/24	RFA-AG-24-028	1R01AG0891	89174	BANDIERA, FRANK	9/1/24	5/31/29	Special Emph	11055051	ZEKI AL HAZZ	GLYMOUR, M	PUBLIC HEAL	COLUMBIA U	9/1/24	5/31/25	Non-SBIR/ST	2024	$839,262	NIA	$608,095	$231,167	$839,262
225	The SDOH-Homecare Int	Project Narrative: Stroke	NINDS	11012850	2/19/25	PA-20-183	5U01NS1355	135533	SANKAR, CHERYSE A	2/1/24	1/31/29	Health Servic	8840097	WILLIAMS, OL	MARSHALL, R	NEUROLOGY	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$1,086,080	NINDS	$710,421	$375,659	$1,086,080
226	CE24-001 Columbia Cen	Columbia Center for Inju	NCIPC	10762286	7/29/24	RFA-CE-24-001	1R49CE0035	3555		8/1/24	7/31/29	Special Emph	1974739	BRANAS, CH	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other	2023	$849,985	NCIPC			$849,985
227	Dissecting the role of lon	PROJECT NARRATIVELon	NIDA	11003839	7/22/24	PAR-23-194	1R36DA0616	61635	DUNSTON, SHEBA KIN	8/1/24	7/31/26	Special Emph	78302176	MARZIALI, ME	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$51,390	NIDA	$48,116	$3,274	$51,390
228	Drinking water contamin	PROJECT NARRATIVEClin	NIEHS	10727706	9/8/23	PA-20-200	1R03ES03550	35509	BOYLES, ABEE	9/10/23	8/31/25	Reproductive	14259321	GOIN, DANA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/10/23	8/31/25	Non-SBIR/ST	2023	$185,979	NIEHS	$124,036	$61,943	$185,979
229	HIV Intervention Science	PROJECT NARRATIVE The	NIMH	10442449	8/21/23	PAR-15-145	5R25MH0806	80665	ALLISON, SUSANNAH	4/16/07	6/30/25	ZMH1-ERB-X	1891871	EL-BASSEL, N	WU, ELWIN	OTHER HEAL	COLUMBIA U	7/1/23	6/30/25	Other Resear	2023	$132,524	NIMH	$245,414	$19,633	$132,524
230	GLASS-AD: Global Latino	NARRATIVE.Hispanics/La	NIA	10935947	8/29/24	PAR-21-212	5U01AG0818	81817	BENNANI-BAITI, MICH	9/30/23	8/31/28	ZAG1-ZIJ-4(J2	11677901	TOSTO, GIUS	MARTIN, EDE	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	$2,682,382	NIA	$2,341,785	$340,597	$2,682,382
231	Pediatric Heart Network	PROJECT NARRATIVEThe	NHLBI	11005047	12/24/24	RFA-HL-24-001	5UM1HL1727	172720	OJESE, OLANREWAJU C	1/1/24	12/31/30	ZHL1-CSR-Q	14396086	RICHMOND,	ANDERSON,	PEDIATRICS	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$419,349	NHLBI	$298,514	$120,835	$419,349
232	Prenatal Exposure to Air	NARRATIVEThis proposal	NIEHS	10981407	9/5/24	PA-20-185	1R01ES0357	35792	GRAY, KIMBERLY A	9/6/24	6/30/29	Social and En	10550576	MARGOLIS, A	FOX, NATHAN	PSYCHIATRY	COLUMBIA U	9/6/24	6/30/25	Non-SBIR/ST	2024	$701,902	NIEHS	$494,571	$207,331	$701,902
233	Strengthening Healthcar	Project NarrativeThe pro	NINDS	11062246	9/10/24	PA-20-272	3R01NS1236	123639	YIN, XILING	6/15/21	6/30/25	Acute Neura	11309584	MASTERSON	GAUDINO, M	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$157,869	OD	$95,969	$61,900	$157,869
234	Summer Biomechanics B	NARRATIVEThe 2023-202	NIBIB	10836043	5/29/24	PA-21-151	5R13EB0350	35037	GUTEKUNST, DAVID JO	6/1/23	5/31/26	ZEB1-OSR-E	7075581	THOMOPOUL	Not Applicab	ORTHOPEDIC	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$10,000	NIBIB	$10,000	$0	$10,000
235	Doxy4STICare - Doxycyc	Narrative: This study aim	NIAID	11035852	3/11/24	PA-20-185	1R56AI18234	182347	HUEBNER, ROBIN E	3/11/24	2/28/26	HIV Comorbid	14634337	ZUCKER, JASO	Not Applicab	INTERNAL ME	COLUMBIA U	3/11/24	2/28/26	Non-SBIR/ST	2024	$837,185	NIAID	$508,927	$328,258	$837,185
236	Characterizing Sleep ART	PROJECT NARRATIVEUsi	NHLBI	10920401	8/27/24	RFA-HL-21-018	5R01HL1603	160325	DIXIT, SHILPY	9/15/21	7/31/26	ZHL1-CSR-Q	11872940	DUNCAN, DU	SCHNEIDER,	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$774,324	NHLBI	$654,575	$119,749	$774,324
237	The impact of a culturally	Preterm birth occurs at u	NIMHD	10992173	11/28/24	PAR-21-100	5R01MD0168	16899	MUJURU, PRISCAH	4/16/23	11/30/27	ZNS1-SRB-E	1916168	CORWIN, ELI	LOEWY, JOAN	OTHER HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$618,862	NIMHD	$530,964	$87,898	$618,862
238	A randomized trial of Imp	PROJECT NARRATIVENea	NIMH	10615902	6/7/23	PA-18-274	5R01MH1180	118004	SENN, THERESA ELAIN	8/23/19	5/31/25	Population a	1893302	SIKKEMA, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$607,390	NIMH	$480,303	$127,087	$607,390
239	Preparing for pre-exposu	Project NarrativeTo stem	FIC	10884348	7/8/24	PAR-19-376	5R33TW0117	11752	NEWSOME, BRAD	9/9/20	6/30/25	Special Emph	10397136	LELUTIU-WEI	PACHANKIS,	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$327,558	FIC	$246,265	$81,293	$327,558
240	Stress hazardous drinking a	PROJECT NARRATIVEStudi	NIAAA	10911104	8/5/24	PA-20-190	5K01AA02853	28532	FREEMAN, ROBERT	9/1/21	8/31/26	Clinical, Treatn	14429074	FORD, JESSIE	Not Applicable	PUBLIC HEALT	COLUMBIA UN	9/1/24	8/31/25	Other Research	2024	$140,687	NIAAA	$130,266	$10,421	$140,687
241	MyPEEPS Mobile LITE: Lin	PROJECT NARRATIVEAdd	NIAID	11081972	8/1/24	RFA-AI-21-018	4UH3AI16965	169658	ZIMAND, LORI B.	9/1/22	7/31/27	ZAI1-KSW-A(J	9765581	SCHNALL, RE	DUNCAN, DU	OTHER HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$2,497,744	NIAID	$2,615,064	$1,015,363	$2,497,744
242	Building mobile HIV preven	Project NarrativeThis projec	NIMH	10632778	8/10/22	PA-21-268	7R01MH1168	116829	GREENWOOD, GREGORY	9/5/18	6/30/25	Behavioral and	10397136	LELUTIU-WEIN	PACHANKIS, J	OTHER HEALT	COLUMBIA UN	8/11/22	6/30/25	Non-SBIR/STT	2022	$768,346	NIMH	$542,762	$225,584	$768,346
243																										
244	Obesogenic origins of ma	PROJECT NARRATIVEThe	NICHD	10850865	7/15/24	PA-19-056	5R01HD1045	104599	MAJJI, SAI PRASANNA	9/25/20	6/30/25	Special Emph	8345946	ABRAMS, ELA	JAO, JENNIFE	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$2,452,419	NICHD	$2,380,040	$72,379	$2,452,419
245	Trial of Human Milk Oligo	Project Narrative:Childr	NICHD	10857315	6/21/24	PA-18-480	5R01HD1054	105492	MAJJI, SAI PRASANNA	6/1/21	5/31/26	HIV Comorbid	12518193	SHIVAKOTI, R	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$732,299	NICHD	$580,457	$151,842	$732,299
246	Targeting TB transmission h	Project NarrativeA critical ba	NIAID	10827921	5/6/24	PA-20-185	5R01AI15117	151173	LACOURCIERE, KAREN A	5/11/21	4/30/26	Infectious Dise	10783316	MATHEMA, BA	NAIDOO, KOG	PUBLIC HEALT	COLUMBIA UN	5/1/24	4/30/25	Non-SBIR/STT	2024	$632,098	NIAID	$525,367	$106,731	$632,098
247	Automated Digital Imagin	Project NarrativeWe pro	NCI	10880245	6/5/24	PA-19-056	5R01CA2545	254576	VILLALOBOS, AUBREY V	7/6/20	6/30/25	HIV Comorbid	1872852	KUHN, LOUIS	Not Applicab	NEUROLOGY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$470,853	NCI	$329,527	$141,326	$470,853
248	Strengthening informed co	Public Health Relevance: S	NICHD	11008251	8/6/24	PA-20-194	1R21HD1154	115480	ESBER, ALLAHNA LAURE	8/6/24	7/31/26	Population an	1872852	KUHN, LOUISE	Not Applicable	NEUROLOGY	COLUMBIA UN	8/6/24	7/31/25	Non-SBIR/STT	2024	$295,355	NICHD	$238,798	$56,557	$295,355
249	Emergence of bedaquilin	PROJECT NARRATIVEBed	NIAID	10977076	10/30/24	PA-20-185	5R01AI16993	169938	LACOURCIERE, KAREN	11/25/22	10/31/27	Special Emph	10783316	MATHEMA, BA	GANDHI, NEE	PUBLIC HEAL	COLUMBIA U	11/1/24	10/31/25	Non-SBIR/ST	2025	$722,084	NIAID	$585,910	$136,174	$722,084
250	mHealth and Mobile Ultras	PROJECT NARRATIVEThe p	NICHD	10693537	8/3/23	PA-21-268	7R21HD1030	103053	WEINBERG, DAVID H.	9/3/22	8/31/25	Special Empha	11309584	MASTERSON C	Not Applicable	Unavailable	COLUMBIA UN	9/3/22	8/31/25	Non-SBIR/STT	2022	$174,031	NICHD	$120,785	$48,246	$169,031
251	Sleep health of preschoo	This K01 International Re	FIC	10931620	9/14/24	PAR-21-105	5K01TW0124	12425	HAYES, UNJA	9/21/23	8/31/28	Special Emph	12203848	SANIA, AYESH	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$151,698	FIC	$141,855	$9,843	$151,698
252	International Workshops	PROJECT NARRATIVEThe	NICHD	10884394	6/26/24	PA-21-151	5R13HD1103	110322	LEE, SONIA S	8/1/22	7/31/25	Pediatrics St	8345946	ABRAMS, ELA	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$74,999	NICHD	$74,999	$0	$74,999
253	Fragile Families Summer	PROJECT NARRATIVEThis	NICHD	10919203	7/15/24	PAR-18-217	5R25HD0745	74544	JEKIELEK, SUSAN	2/7/13	7/31/25	Population Sc	10237406	MINCY, RON	GARFINKEL, I	OTHER HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$161,460	NICHD	$149,592	$11,868	$161,460
254	mHealth and Mobile Ultr	PROJECT NARRATIVEThe	NICHD	10693537	8/3/23	PA-21-268	7R21HD1030	103053	WEINBERG, DAVID H.	9/3/22	8/31/25	Special Emph	11309584	MASTERSON	Not Applicab	Unavailable	COLUMBIA U	9/3/22	8/31/25	Non-SBIR/ST	2022	$174,031	FIC	$3,573	$1,427	$5,000
255	An effectiveness trial of WIN	The proposed study interve	NIAAA	10923881	8/5/24	RFA-AA-21-016	7R01AA03046	30462	FREEMAN, ROBERT	9/1/22	6/30/27	ZAA1-DD(17)V	11496912	DASGUPTA, A	GILBERT, LOU	PUBLIC HEALT	COLUMBIA UN	7/1/24	6/30/25	Non-SBIR/STT	2024	$717,423	NIAAA	$454,525	$262,898	$717,423
256	The TAIL-PrEP Study: Acce	Project NarrativePotent	NIMH	10700242	9/18/23	PA-20-145	1R21MH1337	133755	STIRRATT, MICHAEL J	9/18/23	9/17/25	HIV/AIDS Intr	11019999	MEYERS, KAT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/23	9/17/25	Non-SBIR/ST	2023	$483,983	OD	$164,981	$100,051	$265,032
257	Guyana Research in Injur	Although Guyana has the	FIC	10900711	8/16/24	RFA-TW-21-003	5D43TW0121	12189	LEVINTOVA, MARYA	9/15/21	8/31/26	Special Emph	7947406	HOVEN, CHR	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$262,065	FIC	$253,858	$8,207	$262,065
258	The TAIL-PrEP Study: Acce	Project NarrativePotent	NIMH	10700242	9/18/23	PA-20-145	1R21MH1337	133755	STIRRATT, MICHAEL J	9/18/23	9/17/25	HIV/AIDS Intr	11019999	MEYERS, KAT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/23	9/17/25	Non-SBIR/ST	2023	$483,983	NIMH	$136,297	$82,654	$218,951
259	Using wastewater survei	Project NarrativeSARS-C	NIAID	10762470	12/12/23	PA-20-195	5R21AI17574	175747	BOZICK, BROOKE ALLIS	1/10/23	12/31/25	Modeling and	11805024	YANG, WAN	Not Applicab	PUBLIC HEAL	COLUMBIA U	1/1/24	12/31/25	Non-SBIR/ST	2024	$205,625	NIAID	$125,000	$80,625	$205,625
260	Harnessing Bioinformatics f	Project Narrative:Pre-expos	NIAID	10886003	7/12/24	PA-19-119	5K23AI15037	150378	MCKAIG, ROSEMARY G	8/1/20	7/31/25	Acquired Imm	14634337	ZUCKER, JASO	Not Applicable	INTERNAL ME	COLUMBIA UN	8/1/24	7/31/25	Other Research	2024	$192,024	NIAID	$178,200	$13,824	$192,024
261	Bronx Environmental Healt	Project NarrativeThe propo	NIEHS	11058265	1/30/25	PAR-21-168	1R25ES03601	36012	HUMBLE, MICHAEL C.	2/1/25	1/31/30	Special Empha	11722514	HILPERT, MAR	VAN HORNE, Y	PUBLIC HEALT	COLUMBIA UN	2/1/25	1/31/26	Other Research	2025	$132,347	NIEHS	$124,988	$7,359	$132,347
262	A Multi-site Multi-Setting RC	Public Health RelevanceInj	NIDA	10217065	8/3/22	PAS-16-018	5R01DA0457	45713	LAO, GUIFANG	9/30/17	7/31/25	ZDA1-HXO-H(	1955316	METSCH, LISA	BRUNEAU, JUL	PUBLIC HEALT	COLUMBIA UN	8/1/22	7/31/25	Non-SBIR/STT	2022	$1,217,167	NIDA	$1,156,400	$60,767	$1,217,167
263	RFA-PS-21-003: PrEP Cho	PROJECT NARRATIVEMe	NCHHSTP	10844338	6/25/24	RFA-PS-21-003	5U01PS00522	5229		9/30/21	9/29/26	ZPS1-GCA(48	9765581	SCHNALL, RE	Not Applicab	NONE	COLUMBIA U	9/30/24	9/29/25	Non-SBIR/ST	2024	$1,038,792	NCHHSTP			$1,038,792
264	ICAP Clinical Trials Unit	PROJECT NARRATIVEThe	NIAID	10975364	11/11/24	RFA-AI-19-045	5UM1AI15446	154468	GUBB, STEPHANIE MAJ	12/1/20	11/30/27	ZAI1-RCU-A(S	1871336	EL-SADR, WA	JUSTMAN, JES	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$820,936	NIAID	$615,399	$157,021	$772,420
265	ICAP Clinical Trials Unit	PROJECT NARRATIVEThe	NIAID	10975364	11/11/24	RFA-AI-19-045	5UM1AI15446	154468	GUBB, STEPHANIE MAJ	12/1/20	11/30/27	ZAI1-RCU-A(S	1871336	EL-SADR, WA	JUSTMAN, JES	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$820,936	NIDA	$38,654	$9,862	$48,516
266	Center for High-Throughp	This Program represents	NIAID	10891553	7/19/24	RFA-AI-19-012	5U19AI06777	67773	TALIAFERRO, LANYN P.	8/31/05	7/31/25	ZAI1-JA-I(J1)	1868601	BRENNER, D	Not Applicab	RADIATION-D	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$5,348,648	OD	$4,286,746	$1,061,902	$5,348,648
267	A Tolerance Approach to	Project NarrativeThis is a	NIAID	10991705	12/20/24	PAR-20-072	5P01AI04589	45897	NABAVI, NASRIN N.	9/15/00	12/31/26	ZAI1-LAR-X(M	1887410	SYKES, MEGA	SACHS, DAVI	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$3,181,738	NIAID	$1,964,036	$1,217,702	$3,181,738
268	Opportunities Fund Mana	n/a	NIAID	10891556	7/19/24	RFA-AI-19-012	5U19AI06777	67773		8/31/05	7/31/25	ZAI1-JA-I	1942267	AMUNDSON,	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024			$2,781,929	$391,796	$3,173,725
269	Engineering protease-res	The outbreak of SARS-Co	NIAID	11177103	9/4/24	PAR-20-178	4R01AI16096	160961	PLIMACK, MARY KATHE	8/1/21	7/31/26	ZAI1-ZL-W(J2	1878831	MOSCONA, A	Not Applicab	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$714,282	NIAID	$569,159	$145,123	$714,282
270	Fusion inhibitors that blo	The recent and ongoing o	NIAID	11177101	9/4/24	PAR-20-178	4R01AI16095	160953	BASU, DIPANWITA	8/1/21	7/31/26	ZAI1-ZL-W(J2	8439631	POROTTO, M	DE SWART, R	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$711,960	NIAID	$545,111	$166,849	$711,960
271	Quantifying Error Growth	PROJECT NARRATIVEIn t	NIAID	10623347	5/3/23	PA-20-185	5R01AI16302	163023	GEZMU, MISRAK	6/9/21	5/31/27	Special Emph	8466769	SHAMAN, JEF	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$649,085	NIAID	$403,484	$245,601	$649,085
272	COVID-19 Mother Baby C	NARRATIVEThe devastat	NIMH	11073000	1/22/25	PA-20-185	5R01MH1265	126531	ZEHR, JULIA L	4/12/21	1/31/26	Development	8077959	DUMITRIU, D	MARSH, RAC	PEDIATRICS	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$644,816	NIMH	$455,455	$189,361	$644,816
273	Immunologic and Predict	Multisystem inflammato	NICHD	10866496	8/7/24	PA-20-185	5R01HD1084	108467	MAJJI, SAI PRASANNA	7/18/22	6/30/27	Special Emph	10812148	BOGUNOVIC	Not Applicab	PEDIATRICS	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$531,183	NICHD	$359,936	$171,247	$531,183
274	Elucidating the impact of	PROJECT NARRATIVE:The	NIAID	10785394	8/15/24	PA-20-203	1K08AI18034	180347	ARNOLD, MICHELLE M	8/15/24	7/31/29	Allergy, Immu	10786718	BOWEN, ANT	Not Applicab	INTERNAL ME	COLUMBIA U	8/15/24	7/31/25	Other Resear	2024	$193,644	NIAID	$179,300	$14,344	$193,644
275	Evaluating the Epidemiol	PROJECT NARRATIVENeu	NIAID	10894841	8/22/24	PA-20-205	5K23AI17126	171263	GONDRE-LEWIS, TIMO	8/16/22	7/31/26	Microbiology	15670222	PURPURA, LA	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$192,260	NIAID	$178,200	$14,060	$192,260
276	Neurocognitive & neurop	Public Health Relevance	NIDCD	10846774	5/22/24	PA-20-205	5K23DC0196	19678	RIVERA-RENTAS, ALBE	6/1/21	5/31/26	Communicat	9698876	OVERDEVEST	Not Applicab	OTOLARYNG	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$178,610	NIDCD	$165,380	$13,230	$178,610
277	Enhancing Nurse Practit	PROJECT NARRATIVEAdd	NINR	11012314	2/14/25	PAR-20-310	5R01NR0210	21007	MCNAMARA, KAREN M	4/7/23	1/31/27	Healthcare a	9844694	POGHOSYAN	Not Applicab	OTHER HEAL	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$717,434	NINR	$476,613	$240,821	$717,434
278	Communicating Narrativ	Project NarrativeIn this r	NINR	11018608	1/28/25	PA-20-185	5R01NR0169	16941	MCNAMARA, KAREN M	4/6/17	1/31/27	Clinical Infor	8414539	ROSSETTI, SA	CATO, KENRI	INTERNAL ME	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$715,057	NINR	$569,395	$145,662	$715,057
279	Clinical Operations and	n/a	NIA	10924048	8/20/24	PAR-19-374	5U19AG0785	78558		9/1/22	8/31/27	ZAG1-ZIJ-5	10523321	TEMPROSA, M	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	##########		##########	$115,984	##########
280	Clinical and Translationa	Project Narrative Page 2	NCATS	10893961	6/12/24	PAR-18-940	5UL1TR00187	1873	ATIENZA, AUDIE A	8/1/22	5/31/26		6205023	REILLY, MURE	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	##########	NCATS	$6,379,791	$3,908,575	##########
281	Cancer Center Support C	OVERALL: NARRATIVECa	NCI	10880379	6/6/24	PAR-17-095	5P30CA0136	13696	BELIN, PRECILLA L.	7/4/97	6/30/25	Cancer Cent	1868587	RUSTGI, ANIL	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$5,302,111	NCI	$3,272,908	$2,029,203	$5,302,111
282	Alzheimer's Disease Rese	OVERALL NARRATIVEThe	NIA	10885042	6/21/24	RFA-AG-20-004	5P30AG0664	66462	SILVERBERG, NINA B.	6/15/20	4/30/25	ZAG1-ZIJ-G(J	1884949	SMALL, SCOT	Not Applicab	NEUROLOGY	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$3,035,934	NIA	$1,926,030	$1,109,904	$3,035,934
283	A Multi-scale Atlas of Ser	OVERALL: PROJECT NAR	NIA	10898652	8/12/24	RFA-RM-21-008	5U54AG0760	76040	FRIDELL, YIH-WOEI	9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	CHRISTIANO	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,587,409	OD	$2,156,497	$925,931	$2,587,409
284	Prospective Genetic Risk	PROJECT NARRATIVEThe	NICHD	10916374	8/26/24	RFA-HD-22-008	5P50HD1098	109879	KAU, ALICE S	9/6/22	8/31/27	Special Emph	8746379	VEENSTRA-VA	CHUNG, WEN	PEDIATRICS	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,373,156	NICHD	$1,481,345	$641,811	$2,123,156
285	Prospective Genetic Risk	PROJECT NARRATIVEThe	NICHD	10916374	8/26/24	RFA-HD-22-008	5P50HD1098	109879	KAU, ALICE S	9/6/22	8/31/27	Special Emph	8746379	VEENSTRA-VA	CHUNG, WEN	PEDIATRICS	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,373,156	NIEHS	$174,428	$75,572	$250,000

A2753

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
286	Center for Solutions for N	NARRATIVEThe Center fo	NINDS	10878252	9/2/24	RFA-NS-24-022	1U54NS1371	137199	DALEY, WILLIAM PATRI	9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/3/24	8/31/25	Research Ce	2024	$1,968,142	NINDS	$697,351	$270,791	$968,142
287	Center for Solutions for N	NARRATIVEThe Center fo	NINDS	10878252	9/2/24	RFA-NS-24-022	1U54NS1371	137199	DALEY, WILLIAM PATRI	9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/3/24	8/31/25	Research Ce	2024	$1,968,142	NCCIH	$180,075	$69,925	$250,000
288	Columbia University and	NarrativeHazardous met	NIEHS	10877756	6/25/24	RFA-ES-20-014	5P42ES03371	33719	CARLIN, DANIELLE J.	9/21/22	6/30/27	ZES1-LAT-S(S	8696712	NAVAS-ACIEN	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,791,523	NIEHS	$1,273,206	$518,317	$1,791,523
289	Center for Cancer Syster	PROJECT NARRATIVEThe	NCI	10931548	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	7827402	CALIFANO, A	HONIG, BARR	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,736,052	NCI	$1,093,908	$642,144	$1,736,052
290	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NINDS	$1,573,209	$635,680	$796,311
291	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NCATS	$1,036,744	$418,912	$524,769
292	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NICHD	$395,124	$159,655	$200,000
293	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	OD	$98,781	$39,913	$50,000
294	New York Obesity Resear	PROJECT NARRATIVEThe	NIDDK	10817164	5/9/24	RFA-DK-19-002	5P30DK0266	26687	EVANS, MARY	12/1/96	3/31/26	ZDK1-GRB-2	1869280	GALLAGHER,	FERRANTE, A	INTERNAL ME	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,221,081	NIDDK	$820,033	$401,048	$1,221,081
295	The Columbia University	NARRATIVEThe Columbia	NIDDK	10818417	5/7/24	RFA-DK-19-004	5P30DK1327	132710	SERRANO, KATRINA JA	4/30/22	3/31/27	ZDK1-GRB-7	8447367	SCHWABE, R	Not Applicab	INTERNAL ME	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,204,298	NIDDK	$732,096	$472,202	$1,204,298
296	Investigating the Genetic	OVERALL: NARRATIVELov	NIDDK	10897733	7/24/24	RFA-DK-20-008	5U54DK1043	104309	NIHALANI, DEEPAK	9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	BARASCH, JC	UROLOGY	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$1,200,000	NIDDK	$769,851	$430,149	$1,200,000
297	Molecular Correlates of	PROJECT NARRATIVEPeo	NINDS	10878254	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,186,570		$777,943	$408,627	$1,186,570
298	NAMDC Clinical Registry	n/a	NINDS	10699998	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,179,830		$840,296	$339,534	$1,179,830
299	Columbia Roybal Center	Project NarrativeMost a	NIA	10875092	8/12/24	RFA-AG-24-006	2P30AG0641	64198	ONKEN, LISA	9/15/19	5/31/29	Special Emph	9193205	KRONISH, IAN	MOISE, NATH	INTERNAL ME	COLUMBIA U	8/15/24	5/31/25	Research Ce	2024	$1,121,471	NIA	$817,721	$303,750	$1,121,471
300	Administrative Core	n/a	NIMHD	11177217	8/27/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	7/1/24	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,025,313		$787,662	$237,651	$1,025,313
301	Project 3: Developmenta	n/a	NICHD	10916387	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	8465923	AMSO, DIMA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,009,214		$613,504	$395,710	$1,009,214
302	Columbia-Cornell-Einste	Disparities in healthcare	AHRQ	11004283	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	10386412	ADELMAN, JA	ALCANTARA,	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$996,724	AHRQ	$699,385	$297,339	$996,724
303	Biological Analysis Core	n/a	NIA	10898662	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$967,665		$626,730	$340,935	$967,665
304	Living Healthy for Moms	n/a	NICHD	10908626	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	11628850	OSBORNE, L	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$941,193		$803,483	$137,710	$941,193
305	Clinical Core	n/a	NIA	10885045	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	9773845	NOBLE, JAME	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$841,656		$519,541	$322,115	$841,656
306	Roybal Center for Fearle	n/a	NIA	10875094	8/12/24	RFA-AG-24-006	2P30AG0641	64198		9/15/19	5/31/29	Special Emph	12100576	MOISE, NATH	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$827,484		$639,005	$188,479	$827,484
307	Core Facilities for Vision	Project NarrativeVision i	NEI	10896239	8/23/24	PAR-20-051	5P30EY0190	19007	GOVER, TONY DOUGLA	7/1/10	6/30/26	ZEY1-VSN(07	7367717	GOLDBERG,	Not Applicab	OPHTHALMO	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$808,380	NEI	$499,000	$309,380	$808,380
308	Administrative Core	n/a	NIA	10898653	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$778,367		$480,474	$297,893	$778,367
309	Administrative Core	n/a	NIA	10885044	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	1884949	SMALL, SCOT	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$769,214		$474,823	$294,391	$769,214
310	Research and Data Analy	n/a	AHRQ	11004299	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	11309584	MASTERSON	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$767,567		$543,123	$224,444	$767,567
311	Administrative Core	n/a	NINDS	10699995	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$755,914		$538,375	$217,539	$755,914
312	Investigator Developmer	n/a	NIMHD	10897790	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	7120933	SHIMBO, DAI	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$654,700		$419,210	$235,490	$654,700
313	Columbia Center for Inte	PROJECT NARRATIVEThe	NIA	10909374	7/25/24	RFA-AG-23-025	5P30AG0593	59303	BANDIERA, FRANK	9/1/18	6/30/28	ZAG1-ZIJ-4(M	2261261	MANLY, JENN	BRICKMAN, A	NEUROLOGY	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$641,307	NIA	$515,243	$126,064	$641,307
314	Project 3-CommunityHe	NARRATIVEThe CHURCH	NIMHD	10897805	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	8840097	WILLIAMS, OL	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$634,066		$425,098	$208,968	$634,066
315	Administrative Core	n/a	NIMHD	10897780	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$633,012		$406,263	$226,749	$633,012
316	CONNECTOME-Commu	n/a	NIMHD	10897786	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$629,596		$490,982	$138,614	$629,596
317	Career Enhancement Pro	n/a	NINDS	10700016	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880694	HAAS, RICHA	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$615,493		$438,365	$177,128	$615,493
318	Translational Research S	n/a	NIEHS	10851724	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8853211	CHILLRUD, S	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$532,335		$328,674	$203,661	$532,335
319	Mitochondrial functiona	n/a	NINDS	10700003	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1973197	VAN HOVE, JO	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$497,390		$354,250	$143,140	$497,390
320	Biospecimen Core	n/a	NIA	10898656	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	1894412	OWENS, DAV	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$455,184		$307,959	$147,225	$455,184
321	Tissue Engineering Resou	n/a	NIBIB	10848083	6/6/24	PAR-20-169	2P41EB02706	27062		9/16/19	2/28/29	Special Emph	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$445,884		$307,242	$138,642	$445,884
322	Administrative Core	n/a	NIEHS	10851720	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8651962	BACCARELLI,	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$440,749		$267,933	$172,816	$440,749
323	Genotypic Analysis of ME	PROJECT NARRATIVEA he	NINDS	10878255	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	11229447	PONTING, CH	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$437,634		$431,876	$5,758	$437,634
324	NY-CHAMP Community E	n/a	NICHD	10908634	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	9403946	HALL, KELLI S	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$435,249		$355,191	$80,058	$435,249
325	Project 1: Identifying and	n/a	NICHD	10916384	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	1890713	CHUNG, WEN	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$400,487		$243,457	$157,030	$400,487
326	Data Analysis Core	n/a	NIA	10898660	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	14885882	MENON, VILA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$386,193		$296,267	$89,926	$386,193
327	Career Development and	n/a	NICHD	10908637	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	9807979	TAYLOR, JAC	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$385,389		$301,485	$83,904	$385,389
328	Genomic Testing for Mole	n/a	NINDS	10700001	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	11003865	KARAA, AMEL	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$374,245		$266,544	$107,701	$374,245
329	Human phenotype (Core	n/a	NIDDK	10817169	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1869280	GALLAGHER,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$356,448		$229,999	$126,449	$356,448
330	Tissue Engineering Resou	n/a	NIBIB	10848082	6/6/24	PAR-20-169	2P41EB02706	27062		9/16/19	2/28/29	Special Emph	1943583	HUNG, CLAR	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$352,774		$218,392	$134,382	$352,774
331	Biomarker Core	n/a	NIA	10885054	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	7891222	BRICKMAN, A	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$343,652		$212,131	$131,521	$343,652
332	Expanded Access Deoxyr	There are no FDA-approv	NINDS	10700011	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$334,868		$238,499	$96,369	$334,868
333	Administrative and Engag	n/a	NCI	10931473	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	7012821	CASTOR, DEL	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$331,893		$238,874	$93,019	$331,893
334	Advanced Genetic Study	n/a	NINDS	10700006	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1927769	BEDOYAN, JI	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$331,873		$236,366	$95,507	$331,873
335	Imaging Histology and Fu	n/a	NEI	10896247	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	1933579	SPARROW, JA	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$322,638		$199,159	$123,479	$322,638
336	Research Project 1	n/a	NCI	10931482	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	16051833	SAIDU, RAKIY	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$318,356		$268,072	$50,284	$318,356
337	Neuropathology Core	n/a	NIA	10885050	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	10450717	TEICH, ANDR	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$312,508		$192,906	$119,602	$312,508
338	Tissue Engineering Resou	n/a	NIBIB	10848081	6/6/24	PAR-20-169	2P41EB02706	27062		9/16/19	2/28/29	Special Emph	2059300	KAPLAN, DAV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$304,639		$288,514	$16,125	$304,639
339	Roybal Center for Fearle	n/a	NIA	10875093	8/12/24	RFA-AG-24-006	2P30AG0641	64198		9/15/19	5/31/29	Special Emph	9193205	KRONISH, IAN	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$293,987		$178,716	$115,271	$293,987
340	Research Education Con	n/a	NIA	10909378	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	7033495	AIELLO, ALLIS	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$291,715		$278,009	$13,706	$291,715
341	Anga Center Capacity Bu	n/a	FIC	10982429	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	79487238	MUITA, RICH	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$277,209		$237,419	$39,790	$277,209
342	High Resolution Models	Project 1 NarrativeThere	NIEHS	10877757	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	8853211	CHILLRUD, S	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$272,919		$172,836	$100,083	$272,919
343	Anga Center Community	n/a	FIC	10982428	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	79391762	MUHANGUZI	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$271,971		$215,850	$56,121	$271,971
344	Causal Molecular Mecha	Project 4 NarrativeArsen	NIEHS	10877761	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	10403982	PEARSON, BF	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$270,683		$176,497	$94,186	$270,683
345	Pilot	n/a	NINDS	10700012	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$268,405		$191,163	$77,242	$268,405
346	Computer Core	n/a	NEI	10896243	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	6619355	ALLIKMETS, R	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$267,182		$164,927	$102,255	$267,182
347	Pilot Project Program	n/a	NIEHS	10851731	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8875879	RE, DIANE BE	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$262,970		$159,860	$103,110	$262,970
348	Advanced Single Cell Tec	n/a	NCI	11171868	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	10946359	SIMS, PETER	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$259,748		$157,902	$101,846	$259,748
349	Leadership and Administ	n/a	NIA	10909375	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	2261261	MANLY, JENN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$257,034		$170,438	$86,596	$257,034
350	Administrative Core	n/a	NIDDK	10817165	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	7057421	LEIBEL, RUD	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$254,749		$167,223	$87,526	$254,749
351	Administrative Core	n/a	NIDDK	10897735	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$253,820		$156,679	$97,141	$253,820
352	Integrated Data and Exp	n/a	NIA	10981248	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	7347011	BERHANE, KI	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$250,250		$152,128	$98,122	$250,250
353	The Administrative Core	n/a	NIDDK	10818418	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	8447367	SCHWABE, R	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$246,248		$149,695	$96,553	$246,248
354	Core C: Assessment Core	n/a	NICHD	10916382	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	1884921	KANNE, STEP	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$245,768		$170,672	$75,096	$245,768
355	A Novel Metabolic Pathw	n/a	NIDDK	10897761	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	8228433	BARASCH, JC	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$243,194		$160,708	$82,486	$243,194
356	Administrative Core	n/a	NIA	10981244	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$242,814		$147,607	$95,207	$242,814
357	Human genetic approach	n/a	NIDDK	10897749	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	3169385	GHARAVI, ALI	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$241,161		$159,121	$82,040	$241,161
358	Research Capacity Build	n/a	NCI	10931477	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	14456149	DENNY, LYNE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$238,827		$192,143	$46,684	$238,827
359	Community Engagement	n/a	NIA	10981247	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	9509976	ZOTA, AMI R	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$237,610		$144,444	$93,166	$237,610
360	Anga Center Administrat	n/a	FIC	10982426	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	14103745	MUSYIMI, CH	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$236,930		$188,040	$48,890	$236,930
361	Community Engagement	n/a	NIEHS	10851729	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	9509976	ZOTA, AMI R	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$235,283		$166,623	$68,660	$235,283
362	Microbial Genomics Bior	n/a	NIDDK	10897744	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	9733196	UHLEMANN,	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$233,244		$143,978	$89,266	$233,244
363	Transcriptional regulatio	n/a	NIDDK	10897757	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$228,581		$149,365	$79,216	$228,581
364	Administrative Core	n/a	NINDS	10878253	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$228,352		$137,986	$90,366	$228,352
365	Administrative Core	n/a	NIMHD	11177216	8/26/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	7/1/24	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$226,727		$137,828	$88,899	$226,727
366	Data Management and A	NarrativeThe DMAC will	NIEHS	10877764	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	10781196	GOLDSMITH,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$221,085		$146,163	$74,922	$221,085
367	The Bioimaging Core	n/a	NIDDK	10818427	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	3127300	OLIVE, KENN	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$216,525		$131,626	$84,899	$216,525
368	The Clinical Biospecime	n/a	NIDDK	10818421	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9047196	ABRAMS, JUL	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$216,188		$131,421	$84,767	$216,188
369	Admin Core	n/a	NIMHD	10934597	8/1/24	RFA-MD-21-007	5P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	HERSHMAN,	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$214,568		$131,074	$83,494	$214,568
370	Molecular Biology/Molec	n/a	NIDDK	10817183	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	14183064	EGLI, DIETER	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$207,281		$147,276	$60,005	$207,281
371	Core B: Statistical and C	n/a	NICHD	10916379	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	7740764	WALL, MELAN	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$205,785		$145,313	$60,472	$205,785
372	Light-Based Approaches	Project 5 NarrativeExpos	NIEHS	10877762	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	8270461	BOSTICK, BE	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$195,766		$143,409	$52,357	$195,766
373	Pilot and Feasibility Prog	n/a	NIDDK	10817190	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1927452	KORNER, JUD	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$194,306		$129,913	$64,393	$194,306
374	Instrumentation Fabricat	n/a	NEI	10896241	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	2093726	SILVERMAN,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$191,176		$118,010	$73,166	$191,176
375	Project 2: Psychosocial i	n/a	NICHD	10916385	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	8236828	APPELBAUM,	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$186,214		$144,914	$41,300	$186,214
376	Administrative Core	n/a	AHRQ	11004290	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	10386412	ADELMAN, JA	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$183,870		$123,085	$60,785	$183,870
377	Research Project 2	n/a	NCI	10931485	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	12114400	MOODLEY, JE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$179,287		$151,358	$27,929	$179,287
378	Neuroimmunology Core	n/a	NIA	10885057	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	1925223	DE JAGER, PH	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$176,063		$108,681	$67,382	$176,063
379	Isotopic Tracing of Sourc	Project 2 NarrativeProje	NIEHS	10877759	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	77993292	HALLIDAY, AL	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$175,669		$141,496	$34,173	$175,669
380	Data Management and S	n/a	NIA	10885048	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	2076195	ANDREWS, H	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$173,189		$125,570	$47,619	$173,189

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
381	The Bioinformatics and S	n/a	NIDDK	10818422	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	10946359	SIMS, PETER	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$169,960		$103,319	$66,641	$169,960
382	Core D: Dissemination a	n/a	NICHD	10916377	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Empl	8746379	VEENSTRA-V	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$165,343		$103,404	$61,939	$165,343
383	The Organoid and Cell Cu	n/a	NIDDK	10818425	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	7132013	NAKAGAWA,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$165,030		$100,322	$64,708	$165,030
384	Studying the evolution of	PROJECT NARRATIVEThe	NCI	11072772	9/3/24	PA-20-272	3U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1(M2)	7827402	CALIFANO, A	HONIG, BARR	INTERNAL MB	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$164,500	NCI	$100,000	$64,500	$164,500
385	Genetics Core	n/a	NIA	10885056	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	9349727	REITZ, CHRIS	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$164,206		$101,362	$62,844	$164,206
386	Clinical and Translationa	Project NarrativeIn this a	NCATS	11064191	8/7/24	PA-20-272	3UL1TR0018	1873	ATIENZA, AUDIE A	8/1/22	5/31/26		6205023	REILLY, MUR	Not Applicab	INTERNAL MB	COLUMBIA U	8/7/24	5/31/25	Research Ce	2024	$161,384	OD	$98,106	$63,278	$161,384
387	Core A: Administrative C	n/a	NICHD	10916375	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Empl	1890713	CHUNG, WE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$160,345		$97,474	$62,871	$160,345
388	Study Design and Data S	n/a	NIEHS	10851726	5/10/24	RFA-ES-20-006	5P30ES0090	9089		7/1/98	4/30/28	Environmenta	2409522	FACTOR-LITV	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$159,869		$97,185	$62,684	$159,869
389	Animal Phenotyping (Cor	n/a	NIDDK	10817174	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	6361245	SCHWARTZ,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$151,772		$100,760	$51,012	$151,772
390	Outreach Recruitment a	n/a	NIA	10885052	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	12570380	ARCE, MIGUI	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$147,446		$91,016	$56,430	$147,446
391	Administrative Core	Administrative Core - Na	NIEHS	10877763	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8696712	NAVAS-ACIEN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$133,652		$83,031	$50,621	$133,652
392	Pathogen Discovery Thro	NARRATIVEWhat causes	NINDS	10878256	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Empl	12386930	MISHRA, NIS	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$115,586		$69,845	$45,741	$115,586
393	Pilot and Feasibility Prog	n/a	NIDDK	10818429	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9695780	PAJVANI, UTP	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$113,773		$69,163	$44,610	$113,773
394	Research Education Cor	n/a	NIA	10885058	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	8152373	COSENTINO,	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$108,000		$100,000	$8,000	$108,000
395	Outreach Core	n/a	NCI	11171867	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	1878184	MURRAY, DIA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$106,850		$64,955	$41,895	$106,850
396	Tissue Engineering Resou	n/a	NIBIB	10848080	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Empl	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$96,810		$58,851	$37,959	$96,810
397	Analysis Core	n/a	NIA	10909376	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	8735029	TERESI, JEAN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$92,558		$66,796	$25,762	$92,558
398	Community Engagement	Community Engagement	NIEHS	10877765	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	7698320	O'LEARY, MA	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$77,823		$73,818	$4,005	$77,823
399	The Enrichment Program	n/a	NIDDK	10818430	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9365956	QUE, JIANWE	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$76,574		$46,550	$30,024	$76,574
400	Enrichment Program	n/a	NIDDK	10817197	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1952696	FERRANTE, A	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$56,525		$44,862	$11,663	$56,525
401	Tissue Engineering Resou	n/a	NIBIB	10848084	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Empl	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$55,247		$33,585	$21,662	$55,247
402	Research Experience and	RETCC NarrativeThe Res	NIEHS	10877766	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8696712	NAVAS-ACIEN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$53,698		$33,360	$20,338	$53,698
403	Administrative Core	n/a	NCI	11171863	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	7827402	CALIFANO, A	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$49,932		$30,353	$19,579	$49,932
404	Research Education Cor	n/a	AHRQ	11004294	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	12100576	MOISE, NATH	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$45,287		$33,177	$12,110	$45,287
405	Administrative Core	n/a	NEI	10896240	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	7367717	GOLDBERG,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$27,384		$16,904	$10,480	$27,384
406																										
407																										
408																					Total	##########				

PDF COPY OF NIH_GRANTS_003512
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H	I
1	**Project Abstract**	**Project Title**	**Administering IC**	**Project Number**	**Program Official Information**	**Contact PI / Project Leader**	**Organization Name**	**Total Cost**	**MAX SCORE**
2	PROJECT SUMMARY/ABSTRACT Sexual minority women (e.g. lesbian bisexual queer women) and gender di	Testing a multistage model of risk factors for cannabis use utilizing a measurement burst design among s	NIDA	5R01DA058642-02	DUNSTON, SHEBA KING		OHIO STATE UNIVERSITY	$ 699,139	0.569017112
3	PROJECT SUMMARY/ABSTRACTRates of sexually transmitted infections (STIs) in California have reached ep	Social influences on sexual health among Latinx adolescents and emerging adults who identify as LGBTQ	NICHD	3R01HD075787-08S1	POPKIN, RONNA	MINNIS, ALEXANDRA M	RESEARCH TRIANGLE INSTITUTE	$ 50,000	0.50308311
4	Youth who are assigned female at birth (AFAB) and identify as transgender (e.g. as non-binary or astrans bo	#TranscendentHealth - Adapting an LGB+ inclusive teen pregnancy prevention program for transgender	NINR	5R01NR020846-02	WILLIS, LEIGH ANDREW		CENTER FOR INNOVATIVE PUBLIC HEALTH RESEARCH	$ 620,288	0.493396372
5	Project SummaryThis proposed study aligned with RFA-AG-24-025 aims to address how interpersonal pro	Social Networks and Cognitive Health among Black and Latino sexual minority men in NJ	NIA	1R01AG089099-01	GERALD, MELISSA S		RUTGERS BIOMEDICAL AND HEALTH SCIENCES	$ 739,827	0.37393868
6	SUMMARYAdvancing racial equity in the U.S. starts by collecting valid and reliable data on structural racis	Assessing intersectional multilevel and multidimensional structural racism for English- and Spanish-spea	NIMHD	3R01MD019029-02S1	GILLMAN, ARIELLE SAMANTHA	VILLALONGA OLIVES, ESTER	UNIVERSITY OF MARYLAND BALTIMORE	$ 75,405	0.386453331
7	Project Summary Transgender individuals experience persistent psychological distress caused by an incon	Understanding how chromosomal makeup and cross-sex hormone administration affect wound healing	NIGMS	1F31GM153136-01	STAMM, JOYCE CHIN-CHIN NG	SOARES, VANCE	JOHNS HOPKINS UNIVERSITY	$ 48,974	0.558771551

PDF COPY OF NIH_GRANTS_003588
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E
1					
2		Sex Hormones and Identity affect Nociceptive Expression (SHINE)	3R01NR019417-(	UNIVERSITY OF ALABAMA AT BIRMINGH	$50,000
3	Project SummaryThe COVID-19 pandemic and the co-occurrin	Unequal Parenthoods: Population Perspectives on Gender Race and Sexual Minority Disparities in Family Stress and Health During Crises	5U01HD108779-	UNIVERSITY OF MINNESOTA	$225,000
4	PROJECT SUMMARYThis project seeks to use real-time geospat	Impact of Social Cohesion and Social Capital in PrEP Uptake and Adherence Among Transwomen of Color	5R01MD013554-(	COLUMBIA UNIVERSITY HEALTH SCIEN(	$507,062
5	PROJECT SUMMARYThe goal of the proposed research is to dev	Measures of structural stigmatization and discrimination for HIV research with Latine sexual and gender minorities	1R01MD020284-	DREXEL UNIVERSITY	$812,946
6	PROJECT SUMMARY/ABSTRACTDisparities continue to persist	Exploring Stigma Social Support and Cancer Screenings among Sexual and Gender Diverse People Living with HIV in Georgia	3R01NR020154-(	EMORY UNIVERSITY	$87,833
7	The All of Us Research Program has an explicit goal to enroll at	PRIDEnet for the All of Us Research Program	4OT2OD025276-	STANFORD UNIVERSITY	$1,444,263
8	PROJECT SUMMARY/ABSTRACT An unprecedented number of n	Supportive and restrictive factors and mental health in LGBT adolescent and young adult populations	1R61HD117134-	HARVARD PILGRIM HEALTH CARE, INC.	$838,837
9	PROJECT SUMMARY.Sexual and gender minority (SGM) youth i	Project SMART: Social Media Anti-vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens	5R01DA054236-(	UNIVERSITY OF PENNSYLVANIA	$681,337
10	Project SummaryTransgender and other gender minority youth	Development and Pilot Evaluation of an Online Mentoring Program to Prevent Adversities Among Trans and Other Gender Minority Youth	5R21MD018509-	UNIVERSITY OF NEBRASKA LINCOLN	$236,949
11	Project summary/abstractThe 2024 National LGBTQ Health Co	National LGBT Health Conference 2024	1R13MH138043-	EMORY UNIVERSITY	$20,000
12	The All of Us Research Program has an explicit goal to enroll at	PRIDEnet for the All of Us Research Program	4OT2OD025276-	STANFORD UNIVERSITY	$1,444,263
13	Project SummaryBackground/Objective: Transgender adolesce	Development of a School-Based Prevention Intervention to Promote Adolescent Mental Health Equity	1R34MH136018-	BOSTON COLLEGE	$139,551
14	PROJECT SUMMARYNo changes being proposed.INTRODUCTIO	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	3R01AG063771-(	VANDERBILT UNIVERSITY	$99,998
15	Project SummaryThe goal of this study is to test the efficacy of a theo	Efficacy of a Multi-level School Intervention for LGBTQ Youth	5R01MD016082-(	WASHINGTON UNIVERSITY	$565,297
16	Project SummarySexual and gender minorities (SGM) are heav	Training Program in Translational Science HIV and Sexual and Gender Minority Health	5T32MH130325-(	NORTHWESTERN UNIVERSITY AT CHICA	$497,664
17	Project SummaryNearly half of sexual minority (SM) men exper	An Innovative Prospective Model to Understand Risk and Protective Factors for Sexual Assault Experiences and Outcomes Among Sexual Minority Men	5R01MD016384-	UNIVERSITY OF NEBRASKA LINCOLN	$767,135
18	The "Patient-Responsive Initiatives for Diverse Engagement LG	PRIDE-CARES Center: Patient-Responsive Initiatives for Diverse Engagement - LGBTQ+ Community Action in Research to Eliminate Substance Use Disorder	1R24DA061190-(	UNIVERSITY OF SOUTH CAROLINA AT C(	$503,095
19	Project SummaryCategorization is a fundamental aspect of hu	Views of Gender in Adolescence	3R01HD092347-	PRINCETON UNIVERSITY	$97,554
20	ABSTRACTOne in two Black men who have sex with men (MSM)	Intersectional Discrimination and Sexual Health Among Young Black Men who Have Sex with Men: A Mixed Methods Study	1F31MH138075-	DUKE UNIVERSITY	$42,014
21	PROJECT SUMMARYRacial ethnic and sexual and gender minor	SILOS: Structural Inequities across Layers Of Social-Context as Drivers of HIV and Substance Use	1R01DA061247-(	NORTHWESTERN UNIVERSITY AT CHICA	$777,568
22	Project Summary/AbstractThe Stanford Genomics Diversity Su	Genomics Diversity Summer Program (GDSP) at Stanford	5R25HG010857-	STANFORD UNIVERSITY	$285,283
23	Project SummaryThis proposal seeks continued support to exp	A Longitudinal Examination of Mechanisms Underlying Intersectional Health Disparities in the United States	2R01HD094081-	UNIVERSITY OF MINNESOTA	$672,168
24	PROJECT SUMMARYTHIRD COAST CFAR DEi PROGRAM CORE	Partnering and Programming for a BIPOC SGM Pathway to HIV Research	3P30AI117943-1(	NORTHWESTERN UNIVERSITY AT CHICA	
25	PROJECT SUMMARYDiversity enhances creativity and innovati	Faculty Initiative for Improved Recruitment Retention and Experience (FIIRRE)	5U54CA272171-(	UNIVERSITY OF SOUTH CAROLINA AT C(	$4,386,670
26	Project SummaryThe scope of this study is to engage Ryan Whit	Ending the HIV Epidemic with Equity: An All-facility Intervention to Reduce Structural Racism and Discrimination and Its Impact on Patient and Healthcare Staff Wellbeing	5R01NR020583-(	COLUMBIA UNIVERSITY HEALTH SCIEN(	$798,648
27	The University at Buffalo (UB) NIMHD Center of Excellence in I	Igniting Hope in Buffalo New York communities: Training the Next Generation of Health Equity Researchers	1P50MD019473-	STATE UNIVERSITY OF NEW YORK AT BU	
28	Project Summary/AbstractBackground: Structural racism defir	Developing Modules to Address Microaggressions and Discriminatory Behaviors	5R25GM149980-	CHILDREN'S HOSP OF PHILADELPHIA	$91,048
29	Background: Black women represent the largest group of wome	Monitoring Microaggressions and Adversities to Generate Interventions for Change (MMAGIC) for Black Women Living with HIV	3R01MH121194-	UNIVERSITY OF MIAMI CORAL GABLES	$72,588
30	Background: Black women represent the largest group of wome	Monitoring Microaggressions and Adversities to Generate Interventions for Change (MMAGIC) for Black Women Living with HIV	5R01MH121194-	UNIVERSITY OF MIAMI CORAL GABLES	$642,346
31	Project SummaryStress is associated with HIV risk behaviors in	Health disparities stress pathways and stress-related comorbidities among MSM living with HIV	5R01MD013495-	JOHNS HOPKINS UNIVERSITY	$1,285,395
32	Project Summary Overdose deaths are exponentially rising for	Exploring Historical Trauma Racial Discrimination PTSD and Substance Use Among Black Young Adults	1R36DA058830-(	NEW SCHOOL UNIVERSITY	$53,501

	A	B	C	D	E
33	AbstractTransgender and gender diverse adults (TGDAs) experience s	An intersectional approach linking Minority Stressors Experienced by Transgender and Gender Diverse Adults to Alcohol and Drug Use and comorbid Mental and Physical Health Outcomes	5R01AA030275-0	GEORGIA STATE UNIVERSITY	$501,825
34	PROJECT SUMMARY/ABSTRACTStructural racism and discrimi	Universal basic income and structural racism in the US South: Differences in health service utilization between older African American men with and without experiences of recent incarceration	5R01MD017509-	UNIV OF ARKANSAS FOR MED SCIS	$760,276
35	Project Summary/ AbstractSocial justice is the primary ethical	Securing Health Equity: Philosophical Foundations for Equality and Social Justice in Public Health and Health Care	1G13LM014426-(	UNIVERSITY OF WASHINGTON	$47,535
36	Project SummaryBlack and Latinx gay and bisexual men are at highes	Theoretically Informed Behavioral Intervention to Enhance QOL and Prevent HIV-related Comorbidities in Ethnic and Racial Sexual Minority Men	1R01MD019956-0	YALE UNIVERSITY	$1,054,907
37	Project Summary/Abstract The goal of this R01 is to build upon	Identifying multilevel facilitators of care outcomes among Positive Deviants to design an intervention for Black sexual minority men living with HIV	1R01NR021691-(	GEORGE WASHINGTON UNIVERSITY	$676,457
38	PROJECT SUMMARY Inequities in health manifest as a result of	Multilevel Racism & Discrimination and PrEP Outcomes Among Black SMM in the Southeastern U.S.	5R01MH130166-	US HELPING US, PEOPLE INTO LIVING, I	$601,194
39	PROJECT SUMMARY/ABSTRACTIt is estimated that more than (	Understanding the effects of cross-sex hormone therapy on vaginal mucosal immunity	5R21AI178913-01	BOSTON MEDICAL CENTER	$222,500
40	Project SummaryBlack cisgender women (hereafter Black wor	A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation among Black Women	5R01MD019178-	JOHNS HOPKINS UNIVERSITY	$1,105,281
41	PROJECT SUMMARY/ABSTRACTThere is evidence of a growing h	A multi-level study of the link between fear of deportation and mental health in Latinx young adults: The role of systemic inflammation and related risk and protective factors	1F31MD019521-	UNIVERSITY OF HOUSTON	$36,978
42	Sex differences in immunity are dynamic throughout the lifespan and	Understanding transgender women's immune and behavioral responses to seasonal COVID-19 vaccines to improve their uptake	1R21AI183544-01	NEW YORK BLOOD CENTER	$267,121
43	PROJECT ABSTRACTHeadache has been one of the top three causes	Effect of pubertal hormones on Headache in Transmasculine Adolescents	5K23NS130143-0	UNIVERSITY OF COLORADO DENVER	$224,924
44	Project SummaryThis project will elucidate the psychological proces	The psychological underpinnings of gender disparities in adolescent mental health	5F32MH135634-0	PRINCETON UNIVERSITY	$73,828
45	Sex Hormones and Identity affect Nociceptive Expression (SHINE)Pro	Sex Hormones and Identity affect Nociceptive Expression (SHINE)	5R01NR019417-0	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$473,872
46	PROJECT SUMMARYThis R01 proposal responds to Notice of Sp	Androgen effects on the reproductive neuroendocrine axis	5R01HD111650-	UNIVERSITY OF CALIFORNIA, SAN DIEG	$581,671
47	This proposal will undertake preclinical studies to address brea	Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes	1R56CA284564-(	BETH ISRAEL DEACONESS MEDICAL CE	$299,940
48	PROJECT ABSTRACTWounds have a sizable impact on public he	Molecular Mechanisms of Hormone-Mediated Sex Differences in Wound Healing	1R35GM157032-	BRIGHAM AND WOMEN'S HOSPITAL	$442,444
49	The University of Georgia (UGA) proposes a renewal of PREP@UGA th	PREP at University of Georgia	2R25GM109435-1	UNIVERSITY OF GEORGIA	$343,158
50	Project Summary/Abstract Science is failing minorities in the US by 1)	Culturally-focused HIV Advancements through the Next Generation for Equity (CHANGE) Training Program	5T32MH126772-0	UNIVERSITY OF MIAMI SCHOOL OF MEDIC	$286,511
51	ABSTRACTThe vision of the Utah Clinical & Translational Science Inst	CTSA UM1 Program at University of Utah	5UM1TR004409-0	UNIVERSITY OF UTAH	$5,424,809
52	Project SummaryThe goal of this study is to test the efficacy of a	Efficacy of a Multi-level School Intervention for LGBTQ Youth	5R01MD016082-	WASHINGTON UNIVERSITY	$565,297
53	PROJECT SUMMARY/ABSTRACTSexual minorities (i.e. individua	The Socioecology of Sexual Minority Stigma: Data Harmonization to Address Confounding Bias and Investigate Cross-Level MentalHealth Effects	5R01MH133821-	SAN DIEGO STATE UNIVERSITY	$447,178
54					$32,563,719

PDF COPY OF NIH_GRANTS_003632
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E
1					
2		Sex Hormones and Identity affect Nociceptive Expression (SHINE)	3R01NR019417-(	UNIVERSITY OF ALABAMA AT BIRMINGH	$50,000
3	Project SummaryThe COVID-19 pandemic and the co-occurrin	Unequal Parenthoods: Population Perspectives on Gender Race and Sexual Minority Disparities in Family Stress and Health During Crises	5U01HD108779-	UNIVERSITY OF MINNESOTA	$225,000
4	PROJECT SUMMARYThis project seeks to use real-time geospat	Impact of Social Cohesion and Social Capital in PrEP Uptake and Adherence Among Transwomen of Color	5R01MD013554-(	COLUMBIA UNIVERSITY HEALTH SCIEN(	$507,062
5	PROJECT SUMMARYThe goal of the proposed research is to dev	Measures of structural stigmatization and discrimination for HIV research with Latine sexual and gender minorities	1R01MD020284-	DREXEL UNIVERSITY	$812,946
6	PROJECT SUMMARY/ABSTRACTDisparities continue to persist	Exploring Stigma Social Support and Cancer Screenings among Sexual and Gender Diverse People Living with HIV in Georgia	3R01NR020154-(	EMORY UNIVERSITY	$87,833
7	The All of Us Research Program has an explicit goal to enroll at	PRIDEnet for the All of Us Research Program	4OT2OD025276-	STANFORD UNIVERSITY	$1,444,263
8	PROJECT SUMMARY/ABSTRACT An unprecedented number of n	Supportive and restrictive factors and mental health in LGBT adolescent and young adult populations	1R61HD117134-	HARVARD PILGRIM HEALTH CARE, INC.	$838,837
9	PROJECT SUMMARY.Sexual and gender minority (SGM) youth i	Project SMART: Social Media Anti-vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens	5R01DA054236-(	UNIVERSITY OF PENNSYLVANIA	$681,337
10	Project SummaryTransgender and other gender minority youth	Development and Pilot Evaluation of an Online Mentoring Program to Prevent Adversities Among Trans and Other Gender Minority Youth	5R21MD018509-	UNIVERSITY OF NEBRASKA LINCOLN	$236,949
11	Project summary/abstractThe 2024 National LGBTQ Health Co	National LGBT Health Conference 2024	1R13MH138043-	EMORY UNIVERSITY	$20,000
12	The All of Us Research Program has an explicit goal to enroll at	PRIDEnet for the All of Us Research Program	4OT2OD025276-	STANFORD UNIVERSITY	$1,444,263
13	Project SummaryBackground/Objective: Transgender adolesce	Development of a School-Based Prevention Intervention to Promote Adolescent Mental Health Equity	1R34MH136018-	BOSTON COLLEGE	$139,551
14	PROJECT SUMMARYNo changes being proposed.INTRODUCTIO	Effects of Social Networks and Policy Context on Health among Older Sexual and Gender Minorities in the US South	3R01AG063771-(	VANDERBILT UNIVERSITY	$99,998
15	Project SummaryThe goal of this study is to test the efficacy of a theo	Efficacy of a Multi-level School Intervention for LGBTQ Youth	5R01MD016082-(	WASHINGTON UNIVERSITY	$565,297
16	Project SummarySexual and gender minorities (SGM) are heav	Training Program in Translational Science HIV and Sexual and Gender Minority Health	5T32MH130325-(	NORTHWESTERN UNIVERSITY AT CHICA	$497,664
17	Project SummaryNearly half of sexual minority (SM) men exper	An Innovative Prospective Model to Understand Risk and Protective Factors for Sexual Assault Experiences and Outcomes Among Sexual Minority Men	5R01MD016384-	UNIVERSITY OF NEBRASKA LINCOLN	$767,135
18	The "Patient-Responsive Initiatives for Diverse Engagement LG	PRIDE-CARES Center: Patient-Responsive Initiatives for Diverse Engagement - LGBTQ+ Community Action in Research to Eliminate Substance Use Disorder	1R24DA061190-(	UNIVERSITY OF SOUTH CAROLINA AT C(	$503,095
19	Project SummaryCategorization is a fundamental aspect of hu	Views of Gender in Adolescence	3R01HD092347-	PRINCETON UNIVERSITY	$97,554
20	ABSTRACTOne in two Black men who have sex with men (MSM)	Intersectional Discrimination and Sexual Health Among Young Black Men who Have Sex with Men: A Mixed Methods Study	1F31MH138075-	DUKE UNIVERSITY	$42,014
21	PROJECT SUMMARYRacial ethnic and sexual and gender minor	SILOS: Structural Inequities across Layers Of Social-Context as Drivers of HIV and Substance Use	1R01DA061247-(	NORTHWESTERN UNIVERSITY AT CHICA	$777,568
22	Project Summary/AbstractThe Stanford Genomics Diversity Su	Genomics Diversity Summer Program (GDSP) at Stanford	5R25HG010857-	STANFORD UNIVERSITY	$285,283
23	Project SummaryThis proposal seeks continued support to exp	A Longitudinal Examination of Mechanisms Underlying Intersectional Health Disparities in the United States	2R01HD094081-	UNIVERSITY OF MINNESOTA	$672,168
24	PROJECT SUMMARYTHIRD COAST CFAR DEi PROGRAM CORE	Partnering and Programming for a BIPOC SGM Pathway to HIV Research	3P30AI117943-1(	NORTHWESTERN UNIVERSITY AT CHICA	
25	PROJECT SUMMARYDiversity enhances creativity and innovati	Faculty Initiative for Improved Recruitment Retention and Experience (FIIRRE)	5U54CA272171-(	UNIVERSITY OF SOUTH CAROLINA AT C(	$4,386,670
26	Project SummaryThe scope of this study is to engage Ryan Whit	Ending the HIV Epidemic with Equity: An All-facility Intervention to Reduce Structural Racism and Discrimination and Its Impact on Patient and Healthcare Staff Wellbeing	5R01NR020583-(	COLUMBIA UNIVERSITY HEALTH SCIEN(	$798,648
27	The University at Buffalo (UB) NIMHD Center of Excellence in I	Igniting Hope in Buffalo New York communities: Training the Next Generation of Health Equity Researchers	1P50MD019473-	STATE UNIVERSITY OF NEW YORK AT BU	
28	Project Summary/AbstractBackground: Structural racism defir	Developing Modules to Address Microaggressions and Discriminatory Behaviors	5R25GM149980-	CHILDREN'S HOSP OF PHILADELPHIA	$91,048
29	Background: Black women represent the largest group of wome	Monitoring Microaggressions and Adversities to Generate Interventions for Change (MMAGIC) for Black Women Living with HIV	3R01MH121194-	UNIVERSITY OF MIAMI CORAL GABLES	$72,588
30	Background: Black women represent the largest group of wome	Monitoring Microaggressions and Adversities to Generate Interventions for Change (MMAGIC) for Black Women Living with HIV	5R01MH121194-	UNIVERSITY OF MIAMI CORAL GABLES	$642,346
31	Project SummaryStress is associated with HIV risk behaviors in	Health disparities stress pathways and stress-related comorbidities among MSM living with HIV	5R01MD013495-	JOHNS HOPKINS UNIVERSITY	$1,285,395
32	Project Summary Overdose deaths are exponentially rising for	Exploring Historical Trauma Racial Discrimination PTSD and Substance Use Among Black Young Adults	1R36DA058830-(	NEW SCHOOL UNIVERSITY	$53,501

	A	B	C	D	E
33	AbstractTransgender and gender diverse adults (TGDAs) experience s	An intersectional approach linking Minority Stressors Experienced by Transgender and Gender Diverse Adults to Alcohol and Drug Use and comorbid Mental and Physical Health Outcomes	5R01AA030275-0	GEORGIA STATE UNIVERSITY	$501,825
34	PROJECT SUMMARY/ABSTRACTStructural racism and discrimi	Universal basic income and structural racism in the US South: Differences in health service utilization between older African American men with and without experiences of recent incarceration	5R01MD017509-	UNIV OF ARKANSAS FOR MED SCIS	$760,276
35	Project Summary/ AbstractSocial justice is the primary ethical	Securing Health Equity: Philosophical Foundations for Equality and Social Justice in Public Health and Health Care	1G13LM014426-(	UNIVERSITY OF WASHINGTON	$47,535
36	Project SummaryBlack and Latinx gay and bisexual men are at highes	Theoretically Informed Behavioral Intervention to Enhance QOL and Prevent HIV-related Comorbidities in Ethnic and Racial Sexual Minority Men	1R01MD019956-0	YALE UNIVERSITY	$1,054,907
37	Project Summary/Abstract The goal of this R01 is to build upon	Identifying multilevel facilitators of care outcomes among Positive Deviants to design an intervention for Black sexual minority men living with HIV	1R01NR021691-(	GEORGE WASHINGTON UNIVERSITY	$676,457
38	PROJECT SUMMARY Inequities in health manifest as a result of	Multilevel Racism & Discrimination and PrEP Outcomes Among Black SMM in the Southeastern U.S.	5R01MH130166-	US HELPING US, PEOPLE INTO LIVING, I	$601,194
39	PROJECT SUMMARY/ABSTRACTIt is estimated that more than (	Understanding the effects of cross-sex hormone therapy on vaginal mucosal immunity	5R21AI178913-01	BOSTON MEDICAL CENTER	$222,500
40	Project SummaryBlack cisgender women (hereafter Black wor	A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation among Black Women	5R01MD019178-	JOHNS HOPKINS UNIVERSITY	$1,105,281
41	PROJECT SUMMARY/ABSTRACTThere is evidence of a growing h	A multi-level study of the link between fear of deportation and mental health in Latinx young adults: The role of systemic inflammation and related risk and protective factors	1F31MD019521-	UNIVERSITY OF HOUSTON	$36,978
42	Sex differences in immunity are dynamic throughout the lifespan and	Understanding transgender women's immune and behavioral responses to seasonal COVID-19 vaccines to improve their uptake	1R21AI183544-01	NEW YORK BLOOD CENTER	$267,121
43	PROJECT ABSTRACTHeadache has been one of the top three causes	Effect of pubertal hormones on Headache in Transmasculine Adolescents	5K23NS130143-0	UNIVERSITY OF COLORADO DENVER	$224,924
44	Project SummaryThis project will elucidate the psychological proces	The psychological underpinnings of gender disparities in adolescent mental health	5F32MH135634-0	PRINCETON UNIVERSITY	$73,828
45	Sex Hormones and Identity affect Nociceptive Expression (SHINE)Pro	Sex Hormones and Identity affect Nociceptive Expression (SHINE)	5R01NR019417-0	UNIVERSITY OF ALABAMA AT BIRMINGHAM	$473,872
46	PROJECT SUMMARYThis R01 proposal responds to Notice of Sp	Androgen effects on the reproductive neuroendocrine axis	5R01HD111650-	UNIVERSITY OF CALIFORNIA, SAN DIEG	$581,671
47	This proposal will undertake preclinical studies to address brea	Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes	1R56CA284564-(	BETH ISRAEL DEACONESS MEDICAL CE	$299,940
48	PROJECT ABSTRACTWounds have a sizable impact on public he	Molecular Mechanisms of Hormone-Mediated Sex Differences in Wound Healing	1R35GM157032-	BRIGHAM AND WOMEN'S HOSPITAL	$442,444
49	The University of Georgia (UGA) proposes a renewal of PREP@UGA th	PREP at University of Georgia	2R25GM109435-1	UNIVERSITY OF GEORGIA	$343,158
50	Project Summary/Abstract Science is failing minorities in the US by 1)	Culturally-focused HIV Advancements through the Next Generation for Equity (CHANGE) Training Program	5T32MH126772-0	UNIVERSITY OF MIAMI SCHOOL OF MEDIC	$286,511
51	ABSTRACTThe vision of the Utah Clinical & Translational Science Inst	CTSA UM1 Program at University of Utah	5UM1TR004409-0	UNIVERSITY OF UTAH	$5,424,809
52	Project SummaryThe goal of this study is to test the efficacy of a	Efficacy of a Multi-level School Intervention for LGBTQ Youth	5R01MD016082-	WASHINGTON UNIVERSITY	$565,297
53	PROJECT SUMMARY/ABSTRACTSexual minorities (i.e. individua	The Socioecology of Sexual Minority Stigma: Data Harmonization to Address Confounding Bias and Investigate Cross-Level MentalHealth Effects	5R01MH133821-	SAN DIEGO STATE UNIVERSITY	$447,178
54					$32,563,719

PDF COPY OF NIH_GRANTS_003807
NATIVE FILE PROVIDED TO COURT

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
1	Project Title	Public Health Relevance	Administering	Application ID	Award Notice	Opportunity Number	Project Numb	Serial Numbe	Program Official Informa	Project Start I	Project End D	Study Section	Contact PI Pe	Contact PI / P	Other PI or Pr	Department	Organization I	Budget Start I	Budget End Da	Funding Mech	Fiscal Year	Total Cost	Funding IC(s)	Direct Cost IC	Indirect Cost	Total Cost IC
2	Creation of an Institution	n/a	OD	10129786	9/19/20	PAR-20-086	1C06OD0301	30152	CHEN, YONG	9/21/20	5/31/25	Scientific and	6205023	REILLY, MURE	Not Applicab	INTERNAL ME	COLUMBIA U	9/21/20	5/31/25	Construction	2020	$8,000,000	OD	$8,000,000	$0	$8,000,000
3	Center to Improve Chron	NARRATIVE:The COMMU	NIMHD	10897775	8/1/24	RFA-MD-21-007	5P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$4,048,432	NIMHD	$2,674,989	$1,373,443	$4,048,432
4	Center for Environmenta	PROJECT NARRATIVE OV	NIEHS	10851719	5/10/24	RFA-ES-20-006	5P30ES00908	9089	THOMPSON, CLAUDIA	7/1/98	4/30/28	Environmenta	7839598	PERZANOWS	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$1,631,206	NIEHS	$1,020,275	$610,931	$1,631,206
5	Climate and Health: Acti	Overall NarrativeClimat	NIA	10981243	9/20/24	RFA-ES-23-007	1P20AG0939	93975	KWOK, RICHARD K	9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	BERHANE, KI	PUBLIC HEAL	COLUMBIA U	9/30/24	8/31/25	Research Ce	2024	$1,397,411	NIA	$849,890	$547,521	$1,397,411
6	Advanced training in env	Project NarrativeColum	NIEHS	10843247	6/7/24	PA-18-403	5T32ES00732	7322	SHREFFLER, CAROL A.	7/1/00	6/30/25	Environmenta	1862308	MILLER, GARY	FACTOR-LITV	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$1,343,565	NIEHS	$1,561,132	$95,611	$1,343,565
7	Anga Center for Climate	PROJECT NARRATIVE Eas	FIC	10982425	9/19/24	RFA-ES-23-007	1P20TW0128	12808	NEWSOME, BRAD	9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	NDETEI, DAV	Unavailable	COLUMBIA U	9/23/24	8/31/25	Research Ce	2024	$1,061,973	NIEHS	$860,247	$201,725	$1,061,972
8	Center to Improve Chron	NARRATIVE:The COMMU	NIMHD	10939527	8/27/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,025,313	NIMHD	$787,662	$237,651	$1,025,313
9	Resilient Emotion Regula	Project NarrativeResilie	NIMH	10898037	7/15/24	PA-20-185	5R01MH1305	130578	SMITH, ASHLEY	8/2/23	6/30/28	Child Psycho	9514113	TOTTENHAM,	SEEDAT, SOR	PSYCHOLOG	COLUMBIA U	7/15/24	6/30/25	Non-SBIR/ST	2024	$992,759	NIMH	$904,808	$87,951	$992,759
10	Comparing a Novel Teleh	PROJECT NARRATIVECar	NIMHD	10981223	9/17/24	PA-20-183	1R01MD0191	19189	PADGETT, LYNNE SLAU	9/20/24	5/31/29	Clinical Mana	15008881	DURAN, AND	Not Applicab	INTERNAL ME	COLUMBIA U	9/20/24	5/31/25	Non-SBIR/ST	2024	$821,694	NIMHD	$499,510	$322,184	$821,694
11	A daily diary examination	PROJECT NARRATIVEStig	NHLBI	10801457	1/22/24	PA-20-185	1R01HL1684	168489	CAMPO, REBECCA A.	9/1/24	5/31/28	Biobehaviora	12508902	CACERES, BI	Not Applicab	OTHER HEAL	COLUMBIA U	9/1/24	5/31/25	Non-SBIR/ST	2024	$813,579	NHLBI	$494,577	$319,002	$813,579
12	Ending the HIV Epidemic	Project NarrativeThe pro	NINR	10819558	4/16/24	RFA-MD-21-004	5R01NR0205	20583	WILLIS, LEIGH ANDREW	7/1/22	4/30/27	ZMD1-KNL(J	10397136	LELUTIU-WEI	BROWNE, FE	OTHER HEAL	COLUMBIA U	5/1/24	4/30/25	Non-SBIR/ST	2024	$798,648	NINR	$615,060	$183,588	$798,648
13	Disability diversity and tr	Project NarrativeStudies	NHGRI	10653189	9/1/23	PA-17-444	5R01HG0108	10868	KAUFMAN, DAVE J	3/12/21	6/30/25	Special Emph	12453587	SABATELLO, N	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/23	6/30/25	Non-SBIR/ST	2023	$795,723	NHGRI	$498,920	$296,803	$795,723
14	Just Inclusion and Equity	PROJECT NARRATIVEThis	NHGRI	10910148	9/23/24	PAR-20-254	5R01HG0128	12841	STERLING, RENE	9/1/23	6/30/27	Special Emph	6597920	LEE, SANDRA	CALLIER, SHA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$737,573	NHGRI	$577,866	$159,707	$737,573
15	Estimating the impact of	PROJECT NARRATIVEAgg	NIDA	10840302	3/12/24	PA-20-185	5R01DA0580	58028	DUNSTON, SHEBA KIN	5/15/23	3/31/28	Social Scienc	11076659	PRINS, SETH	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$716,003	NIDA	$473,109	$242,894	$716,003
16	Harnessing digital health	Only one in four depresse	NCI	10945367	8/26/24	PAR-22-105	1R01CA2940	294004	RANDHAWA, GURVAN	9/1/24	7/31/29	Science of Im	12100576	MOISE, NATH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/24	7/31/25	Non-SBIR/ST	2024	$696,140	NCI	$436,637	$259,503	$696,140
17	SPECTRUM (Studying PR	NARRATIVEThe SPECTRU	NCI	10801508	4/5/24	PA-20-185	1R01CA2791	279145	DEAN, DAVID WORTH	4/5/24	3/31/29	Cancer and H	14146562	HOUGHTON,	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/5/24	3/31/25	Non-SBIR/ST	2024	$694,771	NCI	$532,535	$162,236	$694,771
18	Late Life Learning Demer	Project NarrativeThis pro	NIA	10845557	6/13/24	PAR-21-311	5R01AG0740	74076	CHATTERJI, MINKI	9/1/22	5/31/27	Special Emph	11055051	ZEKI AL HAZZ	ELBEJJANI , M	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$704,282	NIA	$592,671	$101,611	$694,282
19	Reducing Health Dispari	PROJECT NARRATIVEThe	NINR	10864979	5/22/24	PA-20-142	5T32NR0079	7969	KEHL, KAREN	8/1/02	6/30/27	ZNR1-REV-M	9765581	SCHNALL, RE	BAKKEN, SUZ	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$691,597	NINR	$689,848	$44,588	$691,597
20	GENETIC ATTRIBUTIONS	The proposed research w	NHGRI	10932235	8/7/24	PAR-20-254	5R01HG0128	12868	KAUFMAN, DAVE J	9/20/23	6/30/27	Special Emph	14884731	LEBOWITZ, M	PEARL, REBE	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$689,893	NHGRI	$634,610	$55,283	$689,893
21	Preventing Drug Abuse ar	PROJECT NARRATIVE Add	NIDA	10425383	7/7/22	PA-15-261	5R01DA0435	43512	ROMBERG, ALEXA RUT	7/1/18	6/30/25	Interventions	8585554	SCHWINN, T	Not Applicab	OTHER HEAL	COLUMBIA U	7/1/22	6/30/25	Non-SBIR/ST	2022	$680,444	NIDA	$433,039	$247,405	$680,444
22	Health Disparities in Hos	PROJECT NARRATIVERad	NINR	10912788	6/17/24	PA-20-185	5R01NR0206	20601	KEHL, KAREN	8/23/23	6/30/27	Healthcare a	1872031	STONE, PATR	DHINGRA, LA	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$655,106	NINR	$545,221	$109,885	$655,106
23	Intervention toiMProveAc	RELEVANCEThere are lor	NIMHD	10897800	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	6405748	HERSHMAN,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$654,071		$405,673	$248,398	$654,071
24	Evaluating Medicaid Post	Project NarrativeSustain	NIMHD	11003869	4/8/24	PA-21-268	7R01MD0181	18180	OLADEINDE, YEWAND	6/4/23	11/30/28	Organization	8963719	JANEVIC, TER	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/8/24	11/30/25	Non-SBIR/ST	2024	$642,775	NIMHD	$563,130	$79,645	$642,775
25	Project 1: Addressing Sle	NARRATIVE:Sleep health	NIMHD	10897794	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	12346337	MAKAREM, N	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$628,419		$396,689	$231,730	$628,419
26	Temperature shade and a	Temperatures are rising (	NIMH	10863844	6/20/24	PA-20-185	5R01MH1287	128734	THOMAS, LAURA A.	9/15/21	6/30/26	Behavioral G	9555896	KEYES, KATHE	RUNDLE, AND	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$621,780	NIMH	$408,959	$212,821	$621,780
27	Social Connectedness a	PROJECT NARRATIVEGer	NIMHD	11004310	12/22/24	PAR-21-350	5R01MD0170	17085	HERREN, OLGA MARIN	7/15/23	12/31/27	Special Emph	6832127	BOCKTING, W	Not Applicab	OTHER HEAL	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$612,485	NIMHD	$449,844	$162,641	$612,485
28	Assessing Cervical Canc	PROJECT NARRATIVEThe	NIMHD	10982514	12/17/24	PAR-20-310	5R01MD0182	18250	PADGETT, LYNNE SLAU	5/5/23	11/30/27	Organization	10513738	LLANOS, ADA	TSUI, JENNIF	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$610,020	NIMHD	$528,633	$81,387	$610,020
29	Policy levers to reduce ra	Project NarrativeGestat	NIDDK	11094148	2/21/25	PA-20-185	5R01DK1347	134725	LAWRENCE, JEAN M	12/9/23	2/29/28	Community I	8963719	JANEVIC, TER	Not Applicab	PUBLIC HEAL	COLUMBIA U	3/1/25	2/28/26	Non-SBIR/ST	2025	$570,471	NIDDK	$391,471	$179,000	$570,471
30	Enhancing Alzheimer's-re	PROJECT NARRATIVEIncr	NIA	11033614	1/31/25	RFA-AG-24-027	1UG3AG0905	90558	GHALEH, MARYAM X	2/1/25	1/31/28	Special Emph	7891222	BRICKMAN, A	MNGOMEZU	NEUROLOGY	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$539,352	NIA	$420,681	$118,671	$539,352
31	Impact of Social Cohesio	PROJECT NARRATIVEThis	NIMHD	10397977	5/8/22	RFA-MD-18-003	5R01MD0135	13554	STINSON, NATHANIEL	9/11/18	4/30/25	ZMD1-RP(O1	11872940	DUNCAN, DU	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/22	4/30/25	Non-SBIR/ST	2022	$507,062	NIMHD	$340,488	$166,574	$507,062
32	Policy solutions for addre	n/a	NICHD	10908630	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	1970408	LI, GUOHUA	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$503,613		$365,317	$138,296	$503,613
33	2/3 Genomics of Schizop	PROJECT NARRATIVEAfri	NIMH	11085137	12/19/24	PAR-20-027	5U01MH1250	125058	PEVSNER, JONATHAN	1/1/21	12/31/25	ZMH1-ERB-C	1911330	SUSSER, EZR	Not Applicab	PUBLIC HEAL	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$447,238	NIMH	$336,053	$111,185	$447,238
34	The Behavioral Cost of C	PROJECT NARRATIVEThe	OD	10923510	9/18/24	RFA-RM-23-007	1DP5OD0374	37400	MILLER, BECKY	9/18/24	7/31/29	Special Emph	78943744	MINOR, KELT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/24	7/31/25	Non-SBIR/ST	2024	$411,250	OD	$249,999	$161,250	$411,249
35	Network biology-based m	n/a	NIA	10981246	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	1862308	MILLER, GARY	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$384,800		$233,921	$150,879	$384,800
36	Columbia Population Re	Project NarrativeThe Co	NICHD	10895753	8/14/24	RFA-HD-24-008	2P2CHD0584	58486	CLARK, REBECCA L	8/15/09	6/30/29	Special Emph	1892638	TEITLER, JULI	HIRSCH, JEN	OTHER HEAL	COLUMBIA U	9/1/24	6/30/25	Other Resear	2024	$359,265	NICHD	$218,398	$140,867	$359,265
37	Cannabis use PrEP and H	PROJECT NARRATIVEThis	NIDA	10838513	8/6/24	RFA-DA-21-024	5R01DA0545	54553	JENKINS, RICHARD A	8/1/21	5/31/26	ZDA1-TXT-V((	11872940	DUNCAN, DU	KNOX, JUSTIN	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$715,456	NIAID	$297,359	$60,370	$357,729
38	Cannabis use PrEP and H	PROJECT NARRATIVEThis	NIDA	10838513	8/6/24	RFA-DA-21-024	5R01DA0545	54553	JENKINS, RICHARD A	8/1/21	5/31/26	ZDA1-TXT-V((	11872940	DUNCAN, DU	KNOX, JUSTIN	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$715,456	NIDA	$297,358	$60,369	$357,727
39	Training in Health Equity	NarrativeThe mission of t	NCI	10884327	7/22/24	RFA-CA-21-020	5R25CA2741	274180	GHOSH, SANGEETA AH	8/15/22	7/31/27	Institutional	10534314	MCDONALD,	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$342,806	NCI	$317,416	$25,393	$342,806
40	Nationwide Associations	n/a	NIA	10981245	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$281,937		$171,790	$110,147	$281,937
41	Investigating pathways b	n/a	FIC	10982427	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$275,863		$218,939	$56,924	$275,863
42	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	OD	$242,040	$7,885	$249,925
43	Novel Assessments of the	PROJECT NARRATIVEIn t	NIEHS	10832126	4/1/24	PA-20-188	5R00ES0337	33742	LAWRENCE, KAITLYN G	5/1/23	4/30/26	NSS	77863179	PARKS, ROBB	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Non-SBIR/ST	2024	$249,000	NIEHS	$151,368	$97,632	$249,000
44	Training West African Pub	Project narrative:We pro	FIC	10899280	9/2/24	PAR-21-120	1D43TW0127	12737	SINA, BARBARA J	9/1/24	4/30/29	Special Emph	6434515	WICKISER, JO	DOUMBIA, SE	PUBLIC HEAL	COLUMBIA U	9/1/24	4/30/25	Other Resear	2024	$248,793	NIAID	$240,575	$5,946	$246,521
45	Racial Disparity in Diagn	Uterine cancer is the mo	NIMHD	10831829	4/19/24	PA-20-185	5R01MD0163	16386	PADGETT, LYNNE SLAU	8/27/21	4/30/26	Healthcare a	7568885	XU, XIAO	WRIGHT, JAS	OBSTETRICS	COLUMBIA U	5/1/24	4/30/26	Non-SBIR/ST	2024	$232,654	NIMHD	$152,337	$80,317	$232,654
46	Center to Improve Chron	NARRATIVE:The COMMU	NIMHD	10939526	8/26/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$226,727	NIMHD	$137,828	$88,899	$226,727
47	India - Factors of CKDu ir	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	NIDDK	$205,661	$79,103	$199,334
48	Youth-PRIDES: Implemer	Mental disorders are the	NIMH	10669228	7/19/23	PA-18-363	5K01MH1202	120258	ALLISON, SUSANNAH	8/15/19	7/31/25	Mental Healt	9614976	LOVERO, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/23	7/31/25	Other Resear	2023	$181,675	NIMH	$169,700	$11,975	$181,675
49	Racial Inequities in Opio	PROJECT NARRATIVEThe	NIDA	10821454	3/21/24	PA-20-190	5K01DA0580	58085	ZUR, JULIA BETH	4/15/23	3/31/28	Social Scienc	12407723	PAMPLIN, JOH	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Other Resear	2024	$177,962	NIDA	$164,780	$13,182	$177,962
50	Subtyping sepsis in Ugand	PROJECT NARRATIVEThe	NIAID	11009064	1/17/25	PA-20-205	5K23AI16336	163364	ERNST, NANCY L.	2/2/22	1/31/26	Microbiology	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	2/1/25	1/31/26	Other Resear	2025	$173,996	NIAID	$161,107	$12,889	$173,996
51	Just Inclusion and Equity	PROJECT NARRATIVEThis	NHGRI	11064335	9/24/24	PA-20-272	3R01HG0128	12841	STERLING, RENE	9/1/23	6/30/27	Special Emph	6597920	LEE, SANDRA	CALLIER, SHA	INTERNAL ME	COLUMBIA U	9/24/24	6/30/25	Non-SBIR/ST	2024	$164,087	NHGRI	$115,703	$48,384	$164,087
52	Leveraging Latinx Adoleso	PROJECT NARRATIVECur	NIMH	10919831	8/26/24	RFA-MH-23-116	5R21MH1354	135489	SMITH, ASHLEY	9/4/23	8/31/25	ZMH1-ERB-R	11732940	DUPONT, ME	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	$163,665	NIMH	$110,800	$52,865	$163,665
53	Establishing a unified eva	Project NarrativeExtrem	NIEHS	11055056	12/13/24	PAR-21-172	1K01ES0362	36202	QUINN, ASHLINN KO	12/16/24	11/30/27	Special Emph	78417944	WU, XIAO	Not Applicab	BIOSTATISTIC	COLUMBIA U	12/16/24	11/30/25	Other Resear	2025	$157,841	NIEHS	$146,149	$11,692	$157,841
54	Investigating association	PROJECT NARRATIVEClin	NIMH	10592335	3/23/23	PA-21-235	5R21MH1273	127356	CAMPBELL-ROSEN, HC	4/1/22	3/31/25	Community I	16325196	WINTER, SAM	Not Applicab	OTHER HEAL	COLUMBIA U	4/1/23	3/31/25	Non-SBIR/ST	2023	$157,500	NIMH	$125,000	$32,500	$157,500
55	India - Factors of CKDu ir	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	NIEHS	$150,290	$57,804	$145,666
56	Summer Program for Und	PROJECT NARRATIVEThe	NINDS	11004622	12/23/24	PAR-21-168	5R25NS0764	76445	MATTHEWS, MARGUER	4/1/12	12/31/27	ZNS1-SRB-D	8613268	GRUEBER, W	SIEGELBAUM	PHYSIOLOGY	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$135,000	NINDS	$125,000	$10,000	$135,000
57	Support Mentoring of Ear	The regulation of body we	NIDDK	10917344	5/21/24	RFA-DK-22-012	5K26DK1384	138418	SASLOWSKY, DAVID E	9/1/23	5/31/28	ZDK1-GRB-1	1869280	GALLAGHER,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$132,845	NIDDK	$123,116	$9,729	$132,845
58	DYnamics of Contracept	PROJECT NARRATIVEAdo	NICHD	10846589	5/17/24	PA-20-190	5K01HD1086	108636	CHINN, JUANITA JEANN	5/24/23	4/30/28	Population Sc	14766811	GREENLEAF,	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Other Resear	2024	$130,810	NICHD	$121,120	$9,690	$130,810
59	Advancing equitable imp	Project narrative/Public	NIDDK	10906807	8/28/24	PA-20-190	5K01DK1324	132495	RANKIN, TRACY L	9/15/22	8/31/27	Kidney, Urolo	14313406	MILO RASOU	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$128,938	NIDDK	$119,743	$9,195	$128,938
60	Spatiotemporal effects a	PROJECT NARRATIVEWil	NIEHS	10984277	7/24/24	PAR-21-271	1K99ES0358	35895	CUI, YUXIA	8/1/24	7/31/26	Special Emph	78428836	CERNA-TURO	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$126,333	NIEHS	$116,975	$9,358	$126,333
61	Mentoring clinical invest	PROJECT NARRATIVEThe	NIDA	10863840	6/4/24	PA-19-122	5K24DA0513	51328	LAO, GUIFANG	4/1/23	6/30/25	Population a	9421939	SEVELIUS, JAE	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Other Resear	2024	$125,114	NIDA	$115,846	$9,268	$125,114
62	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	NIEHS	$96,846	$3,154	$100,000
63	BEST-DP: Biostatistics &	Biomedical scientists es	NHLBI	10658980	5/3/23	RFA-HL-16-008	5R25HL0962	96260	WOLZ, MICHAEL	5/15/09	4/30/25	ZHL1-CSR-M	10781196	GOLDSMITH,	BEGG, MELIS	BIOSTATISTIC	COLUMBIA U	5/1/23	4/30/25	Other Resear	2023	$82,944	NHLBI	$76,800	$6,144	$82,944
64	Development and Testing	PROJECT NARRATIVETra	NIMH	10744754	11/15/23	PA-20-141	5R34MH1281	128163	GREENWOOD, GREGO	1/1/22	11/30/25	HIV/AIDS Intr	9765581	SCHNALL, RE	GAROFALO, F	OTHER HEAL	COLUMBIA U	12/1/23	11/30/25	Non-SBIR/ST	2024	$72,743	NIMH	$62,125	$10,618	$72,743
65	Disparities in Deaths of D	PROJECT NARRATIVEThe	NIEHS	11100635	8/8/24	PA-23-189	3R00ES0337	33742	LAWRENCE, KAITLYN G	5/1/23	4/30/26		77863179	PARKS, ROBB	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/9/24	4/30/25	Non-SBIR/ST	2024	$67,927	NIEHS	$44,672	$23,255	$67,927
66	Youth-PRIDES: Implemer	Mental disorders are the	NIMH	10900850	8/31/23	PA-20-272	3K01MH1202	120258	ALLISON, SUSANNAH	8/15/19	7/31/25	Mental Healt	9614976	LOVERO, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/23	7/31/25	Other Resear	2023	$65,315	NIMH	$60,477	$4,838	$65,315
67	Skeletal Health in Youth	Our parent study is show	NIDDK	10772814	8/28/23	PA-20-272	3R01DK1225	122564	MALOZOWSKI, SAUL N	9/12/19	6/30/25	ZDK1(M3)-S	7373765	RUBIN, MISH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/23	6/30/25	Non-SBIR/ST	2023	$100,000	NIDDK	$30,395	$19,605	$50,000
68	Skeletal Health in Youth	Our parent study is show	NIDDK	10772814	8/28/23	PA-20-272	3R01DK1225	122564	MALOZOWSKI, SAUL N	9/12/19	6/30/25	ZDK1(M3)-S	7373765	RUBIN, MISH	Not Applicab	INTERNAL ME	COLUMBIA U	9/1/23	6/30/25	Non-SBIR/ST	2023	$100,000	OD	$30,395	$19,605	$50,000
69	Diversity in Practice: the	PROJECT NARRATIVEThis	NLM	11009933	12/13/24	PAR-21-046	5G13LM0141	14176	YOON, SUNG SUG SUG	1/1/23	12/31/25	ZLM1-JL-P(01	6597920	LEE, SANDRA	SHIM, JANET	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$49,795	NLM	$49,795	$0	$49,795
70	Personal Healthcare Net	PROJECT NARRATIVETra	NINR	10900078	6/24/24	PA-21-051	1F31NR0212	21239	WILLIS, LEIGH ANDREW	7/1/24	3/31/26	National Inst	79192449	GAEDECKE, T	Not Applicab	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NINR	$48,974	$0	$48,974
71	Applying a multidimensio	PROJECT NARRATIVEMo	NIMH	10909057	8/15/24	PA-21-051	5F31MH1346	134699	ALLISON, SUSANNAH	9/1/23	8/31/25	Special Emph	16592276	KHALIFA, ALE	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$47,324	NIMH	$47,324	$0	$47,324
72	Neighborhood Social Env	PROJECT NARRATIVEDep	NIMH	10833481	4/25/24	PA-21-051	5F31MH1322	132290	AVENILLA, FRANK	5/1/23	4/30/25	Special Emph	15898106	DIAZ, SARAH	Not Applicab	NONE	COLUMBIA U	5/1/24	4/30/25	Training, Indiv	2024	$39,146	NIMH	$39,146	$0	$39,146
73	An equity-focused evalua	PROJECT NARRATIVEThis	NIEHS	10930696	8/9/24	PA-21-052	5F31ES0352	35280	LAWRENCE, KAITLYN G	9/15/23	8/14/25	Special Emph	77847681	FLORES, NIN	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/15/24	8/14/25	Training, Indiv	2024	$36,053	NIEHS	$36,053	$0	$36,053
74	Late Life Learning Demer	Project NarrativeThis pro	NIA	10845557	6/13/24	PAR-21-311	5R01AG0740	74076	CHATTERJI, MINKI	9/1/22	5/31/27	Special Emph	11055051	ZEKI AL HAZZ	ELBEJJANI , M	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$704,282	FIC	$8,537	$1,463	$10,000
75	India - Factors of CKDu ir	NARRATIVEChronic kidne	NIDDK	10886697	8/6/24	RFA-DK-20-017	5U01DK1300	130058	NIHALANI, DEEPAK	8/25/21	6/30/26	ZDK1-GRB-J	10051988	MOHAN, SUM	JHA, VIVEKAN	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$350,000	FIC	$5,158	$1,984	$5,000
76	Training West African Pub	Project narrative:We pro	FIC	10899280	9/2/24	PAR-21-120	1D43TW0127	12737	SINA, BARBARA J	9/1/24	4/30/29	Special Emph	6434515	WICKISER, JO	DOUMBIA, SE	PUBLIC HEAL	COLUMBIA U	9/1/24	4/30/25	Other Resear	2024	$248,793	FIC	$2,218	$54	$2,272
77	Advancing Public Health	NARRATIVEThe unpreced	FIC	10891645	8/2/24	RFA-RM-20-016	5U2RTW0121	12123	POVLICH, LAURA	9/22/21	7/31/26	Special Emph	7347011	BERHANE, KI	BEKELE, RAH	BIOSTATISTIC	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$349,927	FIC	$2	$0	$2
78	Anga Center for Climate	PROJECT NARRATIVE Eas	FIC	10982425	9/19/24	RFA-ES-23-007	1P20TW0128	12808	NEWSOME, BRAD	9/23/24	8/31/27	Special Emph	16325196	WINTER, SAM	NDETEI, DAV	Unavailable	COLUMBIA U	9/23/24	8/31/25	Research Ce	2024	$1,061,973	FIC	$1	$0	$1
79	The Behavioral Cost of C	PROJECT NARRATIVEThe	OD	10923510	9/18/24	RFA-RM-23-007	1DP5OD0374	37400	MILLER, BECKY	9/18/24	7/31/29	Special Emph	78943744	MINOR, KELT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/24	7/31/25	Non-SBIR/ST	2024	$411,250	NIDCR	$1	$0	$1
80	Medical Scientist Trainin	PROJECT NARRATIVEThe	NIGMS	10877873	6/4/24	PAR-21-189	5T32GM1454	145440	MCINTYRE, JEREMY CC	7/1/22	6/30/27	Training and V	1864040	REINER, STEV	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$1,558,334	NIGMS	$1,489,124	$69,210	$1,558,334
81	Postdoctoral Training in (	Our training program see	NHLBI	10890104	7/15/24	PA-18-403	5T32HL0078	7854	WEBB, STEPHANIE JOH	7/1/96	6/30/26	NHLBI Institu	8052876	MARX, STEVE	ABDALLA, MA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$900,800	NHLBI	$862,704	$58,096	$900,800
82	Training in Cellular Molec	PROJECT NARRATIVEThe	NIGMS	10868599	4/22/24	PAR-20-213	5T32GM1457	145766	AIYEGBO, MOHAMMED	7/1/22	6/30/27	Training and V	1884281	LIEM, RONAL	HAEUSLER, R	PATHOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$878,975	NIGMS	$836,384	$42,591	$878,975
83	NRSA Training Core	n/a	NCATS	10894261	6/12/24	PAR-18-940	5TL1TR00187	1875	ATIENZA, AUDIE A	7/1/16	5/31/26	ZTR1-SRC(99	8870151	SPANN, MAR	TAYLOR, JAC	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Inst	2024	$749,022	NCATS	$895,872	$53,150	$749,022
84	Postdoctoral Training in A	Project NarrativeThis is a	NHLBI	10824211	8/5/24	PA-20-142	5T32HL00734	7343	WANG, WAYNE C.	7/1/78	7/31/28	NHLBI Institu	1857723	GINSBERG, H	REILLY, MURE	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$673,488	NHLBI	$698,140	$50,131	$673,488
85	Patient Safety and Healt	Despite a heightened foo	AHRQ	10875422	6/26/24	RFA-HS-22-010	5T32HS0261	26121	DESOTO, MAUSHAMI	7/1/18	6/30/28	ZHS1-HSR-A	10386412	ADELMAN, JA	BARR, R GRA	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$620,443	AHRQ	$596,592	$38,847	$620,443
86	Training Program on HIV a	PROJECT NARRATIVE Thi	NIDA	10918691	5/16/24	PA-23-048	2T32DA0378	37801	DUCHARME, LORI	7/1/14	6/30/29	Special Emph	1891871	EL-BASSEL, N	METSCH, LIS	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$557,156	NIDA	$522,404	$34,752	$557,156
87	Substance Abuse Epidem	Substance use and subst	NIDA	10836582	5/20/24	PA-20-142	5T32DA0310	31099	LOPEZ, MARSHA	7/1/12	6/30/27	ZDA1-SKM-D	1879601	HASIN, DEBO	MARTINS, SIL	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$510,748	NIDA	$545,048	$35,700	$510,748
88	Behavioral Sciences Res	Major biomedical advanc	NIMH	10874650	6/28/24	PA-18-403	5T32MH0191	19139	ALLISON, SUSANNAH	7/1/89	6/30/25	ZMH1-ERB-M	8188389	MELLINS, CLA	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$500,315	NIMH	$564,140	$43,451	$500,315
89	Systems Science and Co	PROJECT NARRATIVEThe	NINR	10861745	5/16/24	PA-20-142	5T32NR0142	14205	KEHL, KAREN	7/1/13	6/30/28	ZNR1-REV-W	9844694	POGHOSYAN	STONE, PATR	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$487,419	NINR	$485,994	$31,920	$487,419
90	Molecular Oncology Trai	PROJECT NARRATIVECar	NCI	10880432	6/25/24	PA-18-403	5T32CA2037	203703	LIM, SUSAN E	7/18/16	6/30/26	Institutional	6405748	HERSHMAN,	CREW, KATH	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$483,880	NCI	$514,752	$39,740	$483,880
91	Translational Research T	We urgently need to sust	NIMH	10836376	6/3/24	PA-18-403	5T32MH0164	16434	BECHTHOLT, ANITA J	9/25/80	6/30/25	ZMH1-ERB-G	8746379	VEENSTRA-VA	FITZGERALD,	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$462,630	NIMH	$514,596	$37,568	$462,630
92	Training in Schizophrenia	PROJECT NARRATIVEThis	NIMH	10894080	6/7/24	PA-18-403	5T32MH0188	18870	CHAVEZ, MARK	8/1/88	6/30/25	ZMH1-ERB-G	9574679	KELLENDONK	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$458,786	NIMH	$532,584	$39,007	$458,786
93	Global Mental Health (G	People in Low and Middle	NIMH	10911009	8/19/24	PA-20-142	5T32MH0967	96724	ALLISON, SUSANNAH	8/21/12	7/31/28	ZMH1-ERB-E	6072016	WAINBERG, M	Not Applicab	PSYCHIATRY	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$443,114	NIMH	$416,948	$31,532	$443,114
94	Genetic Approaches to D	PROJECT NARRATIVEThis	NIGMS	10866352	4/9/24	PAR-17-341	5T32GM1418	141882	STAMM, JOYCE CHIN-(	7/1/21	6/30/26	Training and V	1940239	SHIRASU-HIZ	BERCHOWIT	GENETICS	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$439,487	NIGMS	$418,192	$21,295	$439,487
95	Research Training Progra	Project narrativePsychia	NIMH	10863869	6/20/24	PA-20-142	5T32MH0130	13043	CHAVEZ, MARK	7/1/72	6/30/27	ZMH1-ERB-M	9555896	KEYES, KATHE	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$432,394	NIMH	$423,188	$29,069	$432,394

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
96	Translational Clinical Re	Project Narrative:Substa	NIDA	10837720	5/22/24	PA-20-142	5T32DA0072	7294	LAO, GUIFANG	7/20/93	6/30/28	Career Deve	1866589	LEVIN, FRAN	MARTINEZ, D	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$412,899	NIDA	$542,736	$40,163	$412,899
97	Multidisciplinary Training	Project NarrativeWhile d	NIDDK	10849176	6/26/24	PA-23-048	2T32DK0832	83256	DENSMORE, CHRISTIN	7/1/09	6/30/29	Special Emph	1873597	WANG, TIMO	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$400,571	NIDDK	$487,904	$32,352	$400,571
98	Genome and Epigenome	Two fundamental but me	NCI	10910046	8/6/24	PA-20-142	5T32CA2658	265828	LIM, SUSAN E	9/1/22	8/31/27	Institutional T	7931342	ZHANG, ZHIG	SYMINGTON,	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$373,349	NCI	$409,146	$26,372	$373,349
99	Neuroepidemiology Train	The goal of this proposal	NINDS	10620288	7/24/23	PA-18-403	5T32NS0071	7153	WEIGAND, LETITIA ALE	7/1/80	6/30/25	ZNS1-SRB-L(	9875866	WILLEY, JOSH	GU, YIAN	NEUROLOGY	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$373,048	NINDS	$348,916	$24,132	$373,048
100	Research Training in Mod	PROJECT NARRATIVEThis	NIMH	10849196	6/5/24	PA-23-048	2T32MH0151	15144	CHAVEZ, MARK	7/1/78	6/30/29	Special Emph	1925580	LEONARDO,	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$363,642	NIMH	$443,432	$32,475	$363,642
101	Anesthesiology Research	NarrativeThe proposed p	NIGMS	10876234	6/18/24	PA-20-142	5T32GM0084	8464	PAUL, MOUSHUMI	7/1/92	6/30/28	ZGM1-TWD-X	1864643	EMALA, CHAR	HUA, MAY	ANESTHESIO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$350,862	NIGMS	$326,028	$24,834	$350,862
102	Dental-Biomedical Engin	Project NarrativeIn the U	NIDCR	10880369	6/27/24	PAR-20-056	5T90DE0321	32123	MCGUIRL, MICHELE	7/1/23	6/30/28	ZDE1-NB(13)	6952080	WADHWA, SU	LU, HELEN H	DENTISTRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$329,548	NIDCR	$312,804	$16,744	$329,548
103	Graduate Training in Nut	The discipline of nutritio	NIDDK	10887599	8/8/24	PA-18-403	5T32DK0076	7647	DENSMORE, CHRISTIN	9/15/90	8/31/25	ZDK1-GRB-T	1952696	FERRANTE, A	ZELTSER, LOR	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$319,578	NIDDK	$317,844	$16,308	$319,578
104	The Columbia University	PROJECT NARRATIVEThe	NHLBI	10899556	7/15/24	PA-20-142	5T32HL1053	105323	KALANTARI, ROYA	7/1/11	6/30/26	NHLBI Institu	1861590	BHATTACHAR	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$309,544	NHLBI	$384,180	$26,702	$309,544
105	Training in Translational	Project NarrativeThe aim	NIAID	10744233	11/7/23	PA-18-403	5T32AI14809	148099	GONDRE-LEWIS, TIMO	2/1/20	8/31/25	Allergy, Immu	1887410	SYKES, MEGA	Not Applicab	INTERNAL ME	COLUMBIA U	2/1/24	8/31/25	Training, Inst	2024	$302,148	NIAID	$317,734	$23,948	$302,148
106	Research Training in Late	Project NarrativeThere i	NIMH	10591549	6/9/23	PA-18-403	5T32MH0200	20004	CHAVEZ, MARK	7/1/98	6/30/25	ZMH1-ERB-G	10355138	BROWN, PAT	Not Applicab	PSYCHIATRY	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$299,068	NIMH	$322,536	$24,139	$299,068
107	Training Grant in Diabete	The Training Grant in Dia	NIDDK	10848883	6/17/24	PA-23-048	1T32DK1319	131952	CASTLE, ARTHUR	7/1/24	5/31/29	Diabetes, End	6564579	ACCILI, DOM	PAJVANI, UTP	INTERNAL ME	COLUMBIA U	7/1/24	5/31/25	Training, Inst	2024	$298,427	NIDDK	$279,692	$18,735	$298,427
108	Global HIV Implementati	PROJECT NARRATIVEDes	NIAID	11006928	7/9/24	PA-23-048	2T32AI11439	114398	REFSLAND, ERIC WILL	9/1/14	8/31/29	Acquired Imm	8438960	HOWARD, AN	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$286,928	NIAID	$317,844	$16,308	$286,928
109	Neurobiology and Behav	PROJECT NARRATIVENeu	NIMH	10917221	8/23/24	PAR-17-096	5T32MH1260	126036	VAN'T VEER, ASHLEE V	9/1/20	8/31/25	ZNS1-SRB-X	8613268	GRUEBER, W	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$425,050	NIGMS	$265,646	$13,078	$267,698
110	Training Grant in Pediatr	NARRATIVEMore pediatr	NIDDK	10865098	6/12/24	PA-18-403	5T32DK0655	65522	CASTLE, ARTHUR	7/1/05	6/30/25	Diabetes, End	1918410	OBERFIELD, S	Not Applicab	PEDIATRICS	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$260,271	NIDDK	$260,040	$19,003	$260,271
111	Social Determinants of H	Columbia University Mai	NIMH	10873117	6/14/24	PA-20-142	5T32MH1283	128395	ALLISON, SUSANNAH	7/1/21	6/30/26	ZAA1-GG(35)	2109075	WINGOOD, G	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$259,320	NIMH	$263,620	$13,490	$259,320
112	Hormones: Molecular Me	Project NarrativeThe goa	NIDDK	10849844	6/21/24	PA-20-142	5T32DK0073	7328	CASTLE, ARTHUR	9/15/78	6/30/26	Diabetes, End	7752388	KOUSTENI, ST	Not Applicab	PHYSIOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$225,297	NIDDK	$232,870	$13,590	$225,297
113	Vision Sciences Training	Project NarrativeThe goa	NEI	10909050	9/6/24	PA-20-142	5T32EY0139	13933	CLAYTON, EDWIN C	9/30/01	8/31/26	ZEY1-VSN(04	1879090	MASON, CAR	TROY, CAROL	PATHOLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$222,768	NEI	$211,896	$10,872	$222,768
114	Advanced Graduate Train	The complexity of neuros	NINDS	10615158	7/10/23	PA-18-403	5T32NS0649	64929	WEIGAND, LETITIA ALE	7/1/09	6/30/25	ZNS1-SRB-L(	2201944	ABBOTT, LAU	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/23	6/30/25	Training, Inst	2023	$213,078	NINDS	$202,776	$10,302	$213,078
115	Columbia University Gra	This competing renewal	NIAID	10841618	5/15/24	PA-18-403	5T32AI10671	106711	GONDRE-LEWIS, TIMO	6/1/14	6/30/25	Allergy, Immu	9235902	BASU, UTTIYA	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$212,360	NIAID	$211,896	$10,872	$212,360
116	Short Term Training Gran	PROJECT NARRATIVEThis	NHLBI	10833526	4/4/24	PA-18-404	5T35HL0076	7616	HILL-PRYOR, CRYSTAL	5/1/81	4/30/26	ZHL1-CSR-B	7057421	LEIBEL, RUD	Not Applicab	PEDIATRICS	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$210,933	NHLBI	$195,308	$15,625	$210,933
117	Training in Pediatric Infe	Project NarrativeThis is a	NIAID	10661019	7/21/23	PA-18-403	5T32AI00753	7531	COOMES, STEPHANIE	9/30/98	8/31/25	Microbiology	1935964	SAIMAN, LISA	PRINCE, ALIC	PEDIATRICS	COLUMBIA U	9/1/23	8/31/25	Training, Inst	2023	$206,884	NIAID	$282,096	$18,128	$206,884
118	Advanced Graduate Train	The goal of the proposed	NINDS	10878700	6/19/24	PAR-19-211	5T32NS0649	64928	WEIGAND, LETITIA ALE	7/1/10	6/30/25	ZNS1-SRB-D	8737737	HENGST, ULR	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$200,104	NINDS	$249,288	$13,863	$200,104
119	Obesity Research Cente	Obesity is now among the	NIDDK	10896924	6/28/24	PA-20-142	5T32DK0075	7559	DENSMORE, CHRISTIN	7/1/89	7/31/27	ZDK1-GRB-T	1869280	GALLAGHER,	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Training, Inst	2024	$197,244	NIDDK	$289,676	$19,174	$197,244
120	Integrated Musculoskele	PROJECT NARRATIVEThe	NIAMS	10804662	5/3/24	PA-20-142	5T32AR0807	80744	VINCENT, ISAAH S	5/1/23	4/30/28	ZAR1-KM(M1	1880521	GUO, X. EDW	CHAHINE, NA	BIOMEDICAL	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$197,168	NIAMS	$186,296	$10,872	$197,168
121	Multidisciplinary Training	PROJECT NARRATIVEGas	NCI	10769254	8/23/24	PA-20-142	1T32CA2852	285274	LIM, SUSAN E	9/1/24	8/31/29	Institutional T	9047196	ABRAMS, JUL	RUSTGI, ANIL	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$193,144	NCI	$180,800	$12,344	$193,144
122	Columbia Integrated Tra	PROJECT NARRATIVEThis	NIAID	10814938	5/7/24	PA-20-142	5T32AI10085	100852	COOMES, STEPHANIE	6/1/13	5/31/28	Microbiology	9733196	UHLEMANN,	SOBIESZCZY	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Inst	2024	$188,707	NIAID	$198,216	$12,817	$188,707
123	Brief Research In Aging a	Project NarrativeThe Bri	NIA	10834985	6/6/24	PA-20-162	5T35AG0443	44303	WAGSTER, MOLLY V.	5/1/13	4/30/28	ZAG1-ZIJ-U(J	9773845	NOBLE, JAME	AGARWAL, SA	NEUROLOGY	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$187,816	NIA	$173,904	$13,912	$187,816
124	Research Training in Biol	PROJECT NARRATIVEThis	NIMH	10844537	7/1/24	PA-20-142	5T32MH0966	96679	CHAVEZ, MARK	6/1/13	6/30/28	ZMH1-ERB-E	6487748	ATTIA, EVELYN	WALSH, B. TIM	PSYCHIATRY	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$176,220	NIMH	$265,308	$19,425	$176,220
125	Neurobiology and Behav	PROJECT NARRATIVENeu	NIMH	10917221	8/23/24	PAR-17-096	5T32MH1260	126036	VAN'T VEER, ASHLEE V	9/1/20	8/31/25	ZNS1-SRB-X	8613268	GRUEBER, W	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Inst	2024	$425,050	NIMH	$156,146	$7,686	$157,352
126	Multidisciplinary Training	Project NarrativeThe aim	NIAMS	10849865	6/26/24	PA-20-142	5T32AR0769	76953	VINCENT, ISAAH S	7/1/21	6/30/26	ZAR1-FY(M1)	1964244	BATHON, JOA	WINCHESTER	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$137,882	NIAMS	$169,720	$12,378	$137,882
127	GSH Training Grant	PROJECT NARRATIVENat	NICHD	10892748	5/29/24	PA-20-142	5T32HD0493	49339	CAPPS, RANDOLPH CH	5/9/06	4/30/27	ZHD1-DSR-R	1950424	HIRSCH, JEN	Not Applicab	PUBLIC HEAL	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$115,696	NICHD	$209,896	$10,712	$115,696
128	Research Training Progra	Project Narrative:Menta	NIMH	10847982	6/5/24	PA-23-048	1T32MH1358	135856	CHAVEZ, MARK	7/1/24	6/30/29	Special Emph	8874378	WANG, YUAN	OGDEN, TOD	BIOSTATISTIC	COLUMBIA U	7/1/24	6/30/25	Training, Inst	2024	$110,844	NIMH	$105,448	$5,396	$110,844
129	Training Medical Student	Project NarrativeThe ma	NIDDK	10820478	5/1/24	PA-20-162	5T35DK0934	93430	CASTLE, ARTHUR	3/15/12	4/30/27	Kidney, Urolo	1860269	AL-AWQATI, Q	PAJVANI, UTP	INTERNAL ME	COLUMBIA U	5/1/24	4/30/25	Training, Inst	2024	$103,318	NIDDK	$98,922	$7,914	$103,318
130	Functional interrogation	PROJECT NARRATIVEThis	NIMH	10915447	8/28/24	RFA-MH-20-620	5F32MH1300	130023	VAN'T VEER, ASHLEE V	9/1/22	8/31/25	ZMH1-ERB-L	78260336	YI, JANE	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$84,254	NINDS	$84,254	$0	$84,254
131	Unraveling the neural me	PROJECT NARRATIVETo r	NIDA	10902676	3/14/24	PA-21-048	1F32DA0607	60751	LIN, YU	5/1/24	4/30/27	Special Emph	77856830	SHEN, JIA	Not Applicab	NEUROSCIEN	COLUMBIA U	5/1/24	4/30/25	Training, Indiv	2024	$82,192	NIDA	$82,192	$0	$82,192
132	Understanding the indivi	PROJECT NARRATIVEHaz	NIAAA	10867417	8/7/24	PA-21-048	5F32AA0299	29957	KERRIDGE, BRADLEY T	8/1/22	7/31/25	ZAA1-GG(32)	14982558	BOCHICCHI	Not Applicab	OTHER HEALT	COLUMBIA U	8/1/24	7/31/25	Training, Indiv	2024	$78,892	NIAAA	$78,892	$0	$78,892
133	Fast and Flexible Conjun	Project NarrativeThe hur	NEI	10809777	4/3/24	PA-21-048	5F32EY0336	33654	AGARWAL, NEERAJ	4/16/22	4/15/25	Special Emph	78107930	TAYLOR, JOH	Not Applicab	PSYCHOLOG	COLUMBIA U	4/16/24	4/15/25	Training, Indiv	2024	$74,284	NEI	$74,284	$0	$74,284
134	Photocatalytic Generati	PROJECT NARRATIVE Ne	NIGMS	11014961	12/23/24	PA-21-048	5F32GM1530	153032	STAMM, JOYCE CHIN-	1/10/24	1/9/27	Special Emph	15873294	KARIOFILLIS,	Not Applicab	CHEMISTRY	COLUMBIA U	1/10/25	1/9/26	Training, Indiv	2025	$74,284	NIGMS	$74,284	$0	$74,284
135	Caregiver influences on i	PROJECT NARRATIVEMe	NICHD	10997094	8/22/24	PA-23-262	1F32HD1144	114417	MANN KOEPKE, KATHY	11/1/24	10/31/27	Special Emph	79078686	YATES, TRIST	Not Applicab	PSYCHOLOG	COLUMBIA U	11/1/24	10/31/25	Training, Indiv	2024	$73,828	NICHD	$73,828	$0	$73,828
136	Discovering how emergin	PROJECT NARRATIVE We	NICHD	10996977	7/27/24	PA-23-262	1F32HD1166	116657	MILLER, BRETT	11/16/24	11/15/27	Special Emph	16076737	FOREST, TESS	Not Applicab	PSYCHOLOG	COLUMBIA U	11/16/24	11/15/25	Training, Indiv	2024	$73,828	NICHD	$73,828	$0	$73,828
137	Integrating biomaterials	Project NarrativeGlycan	NIBIB	11071622	11/27/24	PA-23-262	1F32EB0369	36927	GUTEKUNST, DAVID JO	1/1/25	12/31/28	Special Emph	12489535	HINCAPIE, R	Not Applicab	BIOMEDICAL	COLUMBIA U	1/1/25	12/31/25	Training, Indiv	2025	$73,828	NIBIB	$73,828	$0	$73,828
138	Striatal Dopamine's Role	Project NarrativeImpaire	NIMH	10824454	9/13/23	PA-21-048	1F32MH1355	135597	PINARD, COURTNEY	3/2/24	10/31/28	Special Emph	14218632	DECORTE, BE	Not Applicab	PSYCHIATRY	COLUMBIA U	3/2/24	10/31/26	Training, Indiv	2023	$73,580	NIMH	$73,580	$0	$73,580
139	Resting state connectivit	PROJECT NARRATIVEObs	NIMH	10904864	8/7/24	PA-21-049	5F30MH1265	126504	BECHTHOLT, ANITA J	9/1/21	8/31/25	Special Emph	15267921	SHI, TRACEY	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$56,974	NIMH	$56,974	$0	$56,974
140	Alzheimer's Disease Gen	PROJECT NARRATIVEGer	NIA	10906795	8/30/24	PA-21-049	5F30AG0746	74618	SARE, RACHEL	9/1/21	8/31/25	Special Emph	15267909	CHATILA, ZEN	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$53,974	NIA	$53,974	$0	$53,974
141	Quantifying the interacti	NarrativePreterm birth i	NICHD	10914690	8/8/24	PA-21-049	5F30HD1088	108886	GIRARDI, GUILLERMIN	9/15/22	9/14/26	Special Emph	15827843	KINDSCHUH	Not Applicab	BIOCHEMIST	COLUMBIA U	9/15/24	9/14/25	Training, Indiv	2024	$53,974	NICHD	$53,974	$0	$53,974
142	Contribution of PAG to In	PROJECT NARRATIVEDes	NCI	10888994	6/17/24	PA-21-049	5F30CA2716	271624	ODEH, HANA M	7/15/22	7/14/26	Special Emph	15827894	MOORE, EMI	Not Applicab	INTERNAL ME	COLUMBIA U	7/15/24	7/14/25	Training, Indiv	2024	$53,974	NCI	$53,974	$0	$53,974
143	Leveraging CRISPR RNA-	PROJECT NARRATIVEDes	NHLBI	11005254	12/23/24	PA-21-052	5F31HL1675	167530	REYES, MADELYN	2/1/23	1/31/27	Special Emph	15074693	KING, REBEC	Not Applicab	BIOCHEMIST	COLUMBIA U	2/1/25	1/31/26	Training, Indiv	2025	$53,974	NHLBI	$53,974	$0	$53,974
144	Targeting Neuron-Microg	PROJECT NARRATIVENea	NCI	10875397	5/31/24	PA-19-191	5F30CA2577	257768	PURI, ANU	6/15/21	6/14/25	Special Emph	15271056	GOLDBERG,	Not Applicab	PATHOLOGY	COLUMBIA U	6/15/24	6/14/25	Training, Indiv	2024	$53,974	NCI	$53,974	$0	$53,974
145	Deciphering mechanism	PROJECT NARRATIVEPat	NIDCD	10906823	8/27/24	PA-21-049	5F30DC0209	20900	SCHURMAN, JACLYN R	9/1/22	8/31/26	ZDC1-SRB-E	15827862	POURMORAD	Not Applicab	BIOCHEMIST	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$53,974	NIDCD	$53,974	$0	$53,974
146	Adipocyte-derived exoso	Project NarrativeAdipose	NIDDK	10902095	8/7/24	PA-21-049	5F30DK1290	129008	CASTLE, ARTHUR	9/15/21	9/14/25	ZDK1-GRB-2	15267915	GOODMAN, J	Not Applicab	INTERNAL ME	COLUMBIA U	9/15/24	9/14/25	Training, Indiv	2024	$53,974	NIDDK	$53,974	$0	$53,974
147	Elucidating the role of Fra	PROJECT NARRATIVEAcu	NIDDK	10862718	6/17/24	PA-21-049	5F30DK1341	134109	DENSMORE, CHRISTIN	7/1/22	6/30/26	ZDK1-GRB-7	15827849	LI, ALINA LIN	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$53,974	NIDDK	$53,974	$0	$53,974
148	Modulation of Heterome	PROJECT NARRATIVEThe	NINDS	11031948	2/13/25	PA-21-051	5F31NS1325	132554	UMANAH, GEORGE KW	2/1/24	1/31/27	Special Emph	77858962	YEN, LAURA Y	Not Applicab	PHYSIOLOGY	COLUMBIA U	2/1/25	1/31/26	Training, Indiv	2025	$51,974	NINDS	$51,974	$0	$51,974
149	Induction and maintenan	PROJECT NARRATIVEVac	NIAID	10891422	6/4/24	PA-21-049	5F30AI17478	174785	ARNOLD, MICHELLE M	7/1/23	6/30/27	Special Emph	16529540	DAVIS-PORAD	Not Applicab	SURGERY	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$50,974	NIAID	$50,974	$0	$50,974
150	Multiscale imaging of cor	PROJECT NARRATIVERea	NIMH	10901194	3/8/24	PA-21-049	1F30MH1356	135661	VAN'T VEER, ASHLEE V	3/15/24	3/14/28	Special Emph	16529550	GRUSKIN, DA	Not Applicab	NEUROSCIEN	COLUMBIA U	3/15/24	3/14/25	Training, Indiv	2024	$50,937	NIMH	$50,937	$0	$50,937
151	Impact of Species-Specif	PROJECT NARRATIVESyn	NIMH	10899947	3/8/24	PA-21-049	1F30MH1366	136683	DRISCOLL, JAMIE	7/1/24	6/30/27	Special Emph	78213242	RECUPERO, A	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$50,937	NIMH	$50,937	$0	$50,937
152	Engineering a strategy for	PROJECT NARRATIVEThe	NHLBI	10998065	9/10/24	PA-23-260	1F30HL1740	174098	MEADOWS, TAWANNA	9/15/24	9/14/27	Special Emph	78213224	CORDOVES,	Not Applicab	INTERNAL ME	COLUMBIA U	9/15/24	9/14/25	Training, Indiv	2024	$50,937	NHLBI	$50,937	$0	$50,937
153	Mechanisms of reverse tr	PROJECT NARRATIVE Wit	NIAID	10901546	1/25/24	PA-21-049	1F30AI18383	183830	ERNST, NANCY L.	7/1/24	6/30/27	Special Emph	78213245	TANG, STEPH	Not Applicab	BIOCHEMIST	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$50,937	NIAID	$50,937	$0	$50,937
154	Targeting Purinergic Sign	PROJECT NARRATIVEGlic	NCI	10825218	3/11/24	PA-21-049	1F30CA2880	288006	PURI, ANU	3/15/24	3/14/28	Special Emph	16529573	PEREIRA, BRI	Not Applicab	PATHOLOGY	COLUMBIA U	3/15/24	3/14/25	Training, Indiv	2024	$50,937	NCI	$50,937	$0	$50,937
155	Improving bacterial canc	PROJECT NARRATIVEBac	NCI	11112287	2/28/25	PA-21-049	5F30CA2877	287792	PURI, ANU	3/1/24	2/28/28	Special Emph	16529535	CHEN, NOAH	Not Applicab	MICROBIOLO	COLUMBIA U	3/1/25	2/28/26	Training, Indiv	2025	$50,937	NCI	$50,937	$0	$50,937
156	Disentangling the roles o	PROJECT NARRATIVECel	NIDCD	11165197	12/9/24	PA-23-260	1F30DC0227	22796	SCHURMAN, JACLYN R	1/15/25	1/14/29	Special Emph	78213239	MIHAILA, TIBE	Not Applicab	BIOCHEMIST	COLUMBIA U	1/15/25	1/14/26	Training, Indiv	2025	$50,928	NIDCD	$50,928	$0	$50,928
157	Investigating the Impacts	PROJECT NARRATIVEAlzh	NIA	10902945	7/3/24	PA-21-049	1F30AG0843	84312	MACKIEWICZ, MIROSL	7/3/24	7/2/28	Special Emph	16529554	JIN, MICHELL	Not Applicab	PSYCHIATRY	COLUMBIA U	7/3/24	7/2/25	Training, Indiv	2024	$50,414	NIA	$50,414	$0	$50,414
158	Epigenetic and Neuronal	PROJECT NARRATIVERet	NICHD	10902891	9/10/24	PA-21-049	1F30HD1153	115371	OREILLY, JULIA JIAQI	9/16/24	9/15/28	Special Emph	16529563	PAN, RICHAR	Not Applicab	PHYSIOLOGY	COLUMBIA U	9/16/24	9/15/25	Training, Indiv	2024	$50,414	NICHD	$50,414	$0	$50,414
159	RNA Decay of LINE-1 Ret	PROJECT NARRATIVEIn o	NIAID	10902832	7/9/24	PA-21-049	1F30AI17918	179182	GONDRE-LEWIS, TIMO	7/15/24	7/14/27	Special Emph	16529555	LAURING, MA	Not Applicab	MICROBIOLO	COLUMBIA U	7/15/24	7/14/25	Training, Indiv	2024	$50,414	NIAID	$50,414	$0	$50,414
160	Transcriptional regulatio	PROJECT NARRATIVEHur	NIDCR	10908411	7/26/24	PA-21-051	5F31DE0319	31970	FUQUA, CHANTEL FAYS	9/1/22	8/31/25	National Inst	16077152	ANDERSON,	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$49,774	NIDCR	$49,774	$0	$49,774
161	ECM remodeling and cro	PROJECT NARRATIVE Joi	NIDCR	10979141	7/26/24	PA-21-051	5F31DE0332	33220	FUQUA, CHANTEL FAYS	9/1/23	8/31/26	Special Emph	77792546	MO, JULIA	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$49,774	NIDCR	$49,774	$0	$49,774
162	Testing competing mode	Project Narrative:Halluc	NIMH	10869925	6/21/24	PA-21-051	5F31MH1346	134617	AVENILLA, FRANK	7/1/23	6/30/25	Special Emph	16104095	BUCK, JUSTIN	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,994	NIMH	$48,994	$0	$48,994
163	Acetylation as a novel po	PROJECT NARRATIVE-ce	NIDDK	10903057	2/14/24	PA-21-051	1F31DK1376	137600	CASTLE, ARTHUR	6/1/24	5/31/26	Fellowships i	77823297	CHIRIKJIAN,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Training, Indiv	2024	$48,974	NIDDK	$48,974	$0	$48,974
164	Immature neutrophil mig	PROJECT NARRATIVEObe	NIDDK	11071091	12/24/24	PA-23-272	1F31DK1425	142531	CASTLE, ARTHUR	12/24/24	12/23/26	Fellowships i	77812251	QUIN WATER	Not Applicab	INTERNAL ME	COLUMBIA U	12/24/24	12/23/25	Training, Indiv	2025	$48,974	NIDDK	$48,974	$0	$48,974
165	The genomic and synapti	Project NarrativeLearne	NIDCD	11071726	8/20/24	PA-23-272	1F31DC0221	22183	SCHURMAN, JACLYN R	9/1/24	8/31/27	Special Emph	79511585	NARAYANAN,	Not Applicab	ENGINEERIN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIDCD	$48,974	$0	$48,974
166	Synergistic contributions	PROJECT NARRATIVEThis	NIA	10998809	8/13/24	PA-23-272	1F31AG0900	90091	SARE, RACHEL	9/1/24	8/31/27	Special Emph	79142637	EDWARDS, N	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
167	The impact of Alzheimer'	PROJECT NARRATIVEAlzh	NIA	10997953	8/19/24	PA-23-272	1F31AG0900	90071	WAGSTER, MOLLY V.	9/1/24	8/31/26	Special Emph	15977956	BULTHUIS, N	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
168	Brain-wide neural mecha	PROJECT NARRATIVE Cry	NICHD	10903156	4/5/24	PA-21-052	1F31HD1144	114466	MANN KOEPKE, KATHY	4/5/24	9/4/26	Special Emph	77842692	MCRAE, BRIA	Not Applicab	NEUROSCIEN	COLUMBIA U	4/5/24	4/4/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
169	Impact of developmenta	PROJECT NARRATIVEPre	NIMH	11071345	8/30/24	PA-23-271	1F31MH1381	138134	PINARD, COURTNEY	9/1/24	2/28/27	Special Emph	78316229	ANQUEIRA, A	Not Applicab	NEUROSCIEN	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIMH	$48,974	$0	$48,974
170	Impact of social environm	PROJECT NARRATIVEThe	NIMH	10902956	3/5/24	PA-21-052	1F31MH1368	136812	PINARD, COURTNEY	7/1/24	6/30/27	Special Emph	78640196	BRAVO, ISAB	Not Applicab	NEUROSCIEN	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NIMH	$48,974	$0	$48,974
171	Regeneration of Thalamo	Project Narra+veThis pro	NINDS	11070946	11/21/24	PA-23-272	1F31NS1416	141628	OSBORNE, LESLIE CAR	12/1/24	9/30/27	Special Emph	79678097	CHUA, JIANM	Not Applicab	BIOLOGY	COLUMBIA U	12/1/24	11/30/25	Training, Indiv	2025	$48,974	NINDS	$48,974	$0	$48,974
172	The Cellular and Neural (	PROJECT NARRATIVEFlex	NINDS	10903100	3/20/24	PA-21-051	1F31NS1377	137735	GREENWELL, THOMAS	4/1/24	3/31/27	Special Emph	77842705	WOOD, ABBY	Not Applicab	NEUROSCIEN	COLUMBIA U	4/1/24	3/31/25	Training, Indiv	2024	$48,974	NINDS	$48,974	$0	$48,974
173	Determining how a single	Project Narrative1. PKR	NINDS	10997698	6/27/24	PA-23-271	1F31NS1396	139626	SIEBER, BETH-ANNE	7/1/24	6/30/28	Special Emph	14938537	GERTIE, JAKE	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NINDS	$48,974	$0	$48,974
174	Interrogation of non-can	PROJECT NARRATIVEVolt	NINDS	10902910	3/29/24	PA-21-052	1F31NS1377	137770	MATOS GALICIA, HEIDI	9/1/24	8/31/27	Special Emph	15147704	HELMS, KYLE	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NINDS	$48,974	$0	$48,974
175	Elucidating the complex	PROJECT NARRATIVEAllo	NIAID	10903188	8/6/24	PA-21-051	1F31AI18413	184134	XU, ZUOYU	9/1/24	8/31/27	Special Emph	78329645	SUNDBERG,	Not Applicab	BIOCHEMIST	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
176	Mechanistic insights into	Project NarrativePhosph	NIAID	10826774	7/22/24	PA-21-051	1F31AI18155	181556	GU, XIN-XING	9/1/24	8/31/26	Special Emph	16104164	ZINKLE, ALLE	Not Applicab	PHYSIOLOGY	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
177	Biomechanics and mech	PROJECT NARRATIVEUte	NICHD	10902995	8/8/24	PA-21-051	1F31HD1144	114449	AHN, HELENA HYESOO	9/1/24	8/31/26	Special Emph	15967517	FODERA, DAN	Not Applicab	BIOMEDICAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
178	Investigating the role of c	PROJECT NARRATIVEThe	NIAID	11071146	11/26/24	PA-23-272	1F31AI18888	188882	GONDRE-LEWIS, TIMO	12/1/24	11/30/27	Special Emph	79078562	WHISENANT,	Not Applicab	MICROBIOLO	COLUMBIA U	12/1/24	11/30/25	Training, Indiv	2025	$48,974	NIAID	$48,974	$0	$48,974
179	Host Factors Required by	Project NarrativeThe Par	NIAID	10824958	3/6/24	PA-21-051	1F31AI17676	176760	KIM, SONNIE	3/6/24	3/5/26	Special Emph	77858958	STEARNS, KY	Not Applicab	PHYSIOLOGY	COLUMBIA U	3/6/24	3/5/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
180	Investigating the Genetic	PROJECT NARRATIVEBas	NHLBI	10998862	8/13/24	PA-23-272	1F31HL1761	176168	SOOD, BEENA G	9/1/24	8/31/27	Special Emph	78335692	DIRVIN, BRO	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NHLBI	$48,974	$0	$48,974
181	Type I Interferon Mediate	PROJECT NARRATIVEVas	NINDS	11003276	12/9/24	PA-21-051	5F31NS1309	130983	HEWETT, SANDRA JEAN	1/15/23	1/14/26	Special Emph	15827872	TUOHY, MARY	Not Applicab	NEUROLOGY	COLUMBIA U	1/15/25	1/14/26	Training, Indiv	2025	$48,974	NINDS	$48,974	$0	$48,974
182	Therapeutic Editing of Ro	PROJECT NARRATIVEPho	NEI	11042742	1/22/25	PA-21-051	5F31EY0336	33660	AGARWAL, NEERAJ	2/1/23	1/31/26	Special Emph	78103980	NOLAN, NICH	Not Applicab	OPHTHALMO	COLUMBIA U	2/1/25	1/31/26	Training, Indiv	2025	$48,974	NEI	$48,974	$0	$48,974
183	Interactions between mo	PROJECT NARRATIVEThe	NIMH	10928756	8/29/24	PA-21-051	5F31MH1333	133351	PINARD, COURTNEY	9/8/23	9/7/25	Special Emph	16366203	GASSER, CAN	Not Applicab	PSYCHOLOG	COLUMBIA U	9/8/24	9/7/25	Training, Indiv	2024	$48,974	NIMH	$48,974	$0	$48,974
184	Inhibition of CD33-sialic	PROJECT NARRATIVEWh	NIA	10928124	8/27/24	PA-21-051	5F31AG0796	79613	SARE, RACHEL	9/1/23	8/31/26	Special Emph	16177782	GREEN, JENN	Not Applicab	PHARMACOL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
185	Understanding and Contr	Project NarrativeMecha	NICHD	10914666	8/7/24	PA-20-246	5F31HD1054	105405	MUKHOPADHYAY, MAH	9/1/21	8/31/25	Special Emph	16124527	CUPO, CHRIS	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
186	Mechanisms underlying t	Project Narrative While	NIA	10909146	8/26/24	PA-21-051	5F31AG0796	79601	FRIDELL, YIH-WOEI	9/1/22	8/31/25	Special Emph	16077168	GATTO, JARED	Not Applicab	GENETICS	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIA	$48,974	$0	$48,974
187	A Novel Long Noncoding	PROJECT NARRATIVESys	NIAID	10886817	6/5/24	PA-21-051	5F31AI17231	172316	GONDRE-LEWIS, TIMO	7/1/22	6/30/25	Special Emph	78206283	TIAN, RUXIAO	Not Applicab	MICROBIOLO	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NIAID	$48,974	$0	$48,974
188	Mechanisms controlling	Project narrativeMany tr	NICHD	11099655	7/9/24	PA-21-051	5F31HD1102	110242	STEIN, KATHRYN K	7/1/23	6/30/26	Special Emph	16027869	MUNCE, ROS	Not Applicab	GENETICS	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NICHD	$48,974	$0	$48,974
189	Chromosomal instability	PROJECT NARRATIVEBra	NCI	10842249	6/6/24	PA-21-049	5F30CA2811	281104	BIAN, YANSONG	7/1/23	6/30/28	Special Emph	16529522	CAPRIO, LIND	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Training, Indiv	2024	$48,974	NCI	$48,974	$0	$48,974
190	Prenatal exposure to pht	PROJECT NARRATIVEPht	NIEHS	10923843	7/25/24	PA-21-051	5F31ES0349	34972	BOYLES, ABEE	9/1/23	8/31/25	Special Emph	78596921	SIDDIQ, SHA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indiv	2024	$48,974	NIEHS	$48,974	$0	$48,974

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
191	Examining Individuals' Ex	PROJECT NARRATIVERes	NIAAA	10908296	8/2/24	PA-21-051	5F31AA0311	31193	BLOSS, GREGORY	9/1/23	8/31/25	ZAA1-GG(32)	78548327	MEHRANBOD	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIAAA	$48,974	$0	$48,974
192	Auditory cortical tuning t	Project Narrative Deficit	NIDCD	10904727	7/10/24	PA-21-051	5F31DC0209	20904	SCHURMAN, JACLYN R	9/1/22	8/31/25	ZDC1-SRB-Y	78565715	EDWARDS, J	Not Applicab	PSYCHOLOG	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,974	NIDCD	$48,974	$0	$48,974
193	Data-Driven Discovery o	PROJECT NARRATIVEThis	NIA	10915420	8/9/24	PA-21-051	5F31AG0796	79627	MARTIN, DAMALI	9/1/23	8/31/25	Special Emph	16354815	JAWADEKAR,	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,214	NIA	$48,214	$0	$48,214
194	Regulation and function (	Project NarrativeMitoch	NINDS	10888185	6/17/24	PA-21-051	5F31NS1291	129199	MILLER, DANIEL L	7/1/22	6/30/25	Special Emph	16486772	DONOVAN, E	Not Applicab	BIOLOGY	COLUMBIA U	7/1/24	6/30/25	Training, Indi	2024	$48,123	NINDS	$48,123	$0	$48,123
195	Associations among mate	PROJECT NARRATIVETho	NICHD	10898330	7/23/24	PA-21-051	1F31HD1153	115324	GRIFFIN, JAMES	8/1/24	7/31/26	Special Emph	78158033	SPERBER, JE	Not Applicab	PSYCHOLOG	COLUMBIA U	8/1/24	7/31/25	Training, Indi	2024	$42,574	NICHD	$42,574	$0	$42,574
196	Linking endoplasmic reti	Project NarrativeNeurot	NEI	11002649	11/29/24	PA-21-052	5F31EY03516	35165	AGARWAL, NEERAJ	12/16/23	12/15/26	Special Emph	15050727	DELGADO, K	Not Applicab	BIOLOGY	COLUMBIA U	12/16/24	12/15/25	Training, Indi	2025	$42,574	NEI	$42,574	$0	$42,574
197	Parent-adolescent inforr	PROJECT NARRATIVESui	NICHD	10996097	2/20/25	PA-21-051	5F31HD1112	111295	ESPOSITO, LAYLA E	1/1/24	1/1/27	Special Emph	78597909	SPEARS, ANG	Not Applicab	PSYCHOLOG	COLUMBIA U	1/2/25	1/1/26	Training, Indi	2025	$41,294	NICHD	$41,294	$0	$41,294
198	Investigating the potenti	PROJECT NARRATIVEMat	NIAID	10824991	3/22/24	PA-21-051	1F31AI17685	176851	BOZICK, BROOKE ALLIS	8/1/24	7/31/26	Special Emph	77847671	GORIN, EMM	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Training, Indi	2024	$36,053	NIAID	$36,053	$0	$36,053
199	Long-term exposure to ar	PROJECT NARRATIVEThis	NIEHS	10922694	8/12/24	PA-21-051	5F31ES03530	35306	JOUBERT, BONNIE	9/1/23	8/31/26	Special Emph	78344631	MEDGYESI, D	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$35,958	NIEHS	$35,958	$0	$35,958
200	Examining Social Ecologi	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEAL	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NIAID	$1,700,392	$849,988	$2,550,380
201	Examining Social Ecologi	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEAL	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NICHD	$233,353	$116,647	$350,000
202	Examining Social Ecologi	PROJECT NARRATIVECis	NIAID	10686266	7/17/23	RFA-AI-21-058	5R01AI17246	172469	ROE, JOANAD'ARC C	8/18/22	7/31/28	ZAI1-KSW-A(	9765581	SCHNALL, RE	JOHNSON, A	OTHER HEAL	COLUMBIA U	8/1/23	7/31/25	Non-SBIR/ST	2023	$3,050,380	NIAAA	$100,009	$49,991	$150,000
203	NY Community-Hospital-	OVERALL PROJECT NARR	NICHD	10908625	7/17/24	RFA-HD-23-035	5U54HD1131	113172	FABIYI, CAMILLE	8/17/23	7/31/30	Special Emph	15745999	REDDY, UMA	BROWN, SEV	OBSTETRICS	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$2,265,444	NICHD	$1,825,476	$439,968	$2,265,444
204	The Empilisweni Center f	Project NarrativeAlthoug	NCI	10931463	7/29/24	RFA-CA-22-019	5U54CA2840	284030	SIVARAM, SUDHA	9/19/23	8/31/28	ZCA1-SRB-2	7012821	CASTOR, DEL	ARENDSE, JU	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,068,363	NCI	$850,447	$217,916	$1,068,363
205	MyPEEPS Mobile Plus: A N	PROJECT NARRATIVEHIV	NIMHD	10933040	3/22/24	RFA-MD-23-008	5R01MD0191	19181	FERNANDEZ, ANGELA	9/21/23	3/31/28	ZMD1-IN(A1)	9765581	SCHNALL, RE	GAROFALO, F	OTHER HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$989,833	NIMHD	$754,827	$235,006	$989,833
206	Integrated Supportive Ca	Policy solutions that cen	NINR	10933006	6/26/24	RFA-NR-23-002	5R01NR0211	21108	GIVENS-BRADLEY, SHA	9/21/23	6/30/28	Special Emph	15823607	DAW, JAMIE F	DORVAL-MO	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$743,447	NINR	$505,099	$238,348	$743,447
207	Mental Health of Latino A	Exposures to deprivation	NIMHD	10839331	11/29/23	PAR-21-080	5R01MD0172	17273	STINSON, NATHANIEL	5/9/23	11/30/28	Psychosocia	1869481	ORJUELA, MA	LEWIS-FERN	PUBLIC HEAL	COLUMBIA U	12/1/23	11/30/25	Non-SBIR/ST	2024	$687,188	NIMHD	$422,830	$264,358	$687,188
208	Multidimensional and lor	PROJECT NARRATIVEThe	NIAID	10938759	9/12/24	PA-20-185	1R01AI18499	184997	MINNICOZZI, MICHAE	9/12/24	7/31/29	Population ba	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	9/12/24	7/31/25	Non-SBIR/ST	2024	$615,891	NIAID	$425,191	$190,700	$615,891
209	Strategies for Reaching a	Project NarrativeAdvanc	NCI	10856030	3/13/24	PAR-22-105	1R01CA2892	289295	MARCUS, PAMELA M.	4/1/24	3/31/29	Special Emph	9837872	SHELTON, RA	Not Applicab	PUBLIC HEAL	COLUMBIA U	4/1/24	3/31/25	Non-SBIR/ST	2024	$542,964	NCI	$396,853	$146,111	$542,964
210	Reframing personal and (	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RC	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	NIEHS	$159,622	$70,683	$230,305
211	Reframing personal and (	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RC	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	NHGRI	$69,309	$30,691	$100,000
212	Reframing personal and (	PROJECT NARRATIVERad	NIEHS	10869406	6/25/24	RFA-ES-23-006	1R01ES03625	36258	MCALLISTER, KIMBERL	6/25/24	5/31/28	Special Emph	9509976	ZOTA, AMI R	DODSON, RC	PUBLIC HEAL	COLUMBIA U	6/25/24	5/31/25	Non-SBIR/ST	2024	$430,305	OD	$69,309	$30,691	$100,000
213	CADRE Program for Postb	PROJECT NARRATIVEIt is	NINDS	10987061	11/29/24	RFA-NS-22-035	5R25NS1309	130961	MATTHEWS, MARGUER	12/1/22	11/30/26	ZNS1-SRB-D	8613268	GRUEBER, W	HENGST, ULF	PHYSIOLOGY	COLUMBIA U	12/1/24	11/30/25	Other Resear	2025	$424,202	NINDS	$392,780	$31,422	$424,202
214	SEARCH: SMS Electronic	PUBLIC HEALTH RELEVAN	NCI	10919236	7/19/24	PAR-19-376	5R33CA2536	253604	PEARLMAN, PAUL C	8/1/20	7/31/26	Special Emph	9013927	STOCKWELL,	KITAKA, SABR	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$246,609	NCI	$195,292	$46,317	$241,609
215	SEARCH: SMS Electronic	PUBLIC HEALTH RELEVAN	NCI	10919236	7/19/24	PAR-19-376	5R33CA2536	253604	PEARLMAN, PAUL C	8/1/20	7/31/26	Special Emph	9013927	STOCKWELL,	KITAKA, SABR	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$246,609	FIC	$4,042	$958	$5,000
216	Multimodal immune prof	PROJECT NARRATIVEThe	NIAID	10651894	5/16/23	PA-20-195	5R21AI17124	171249	PLIMACK, MARY KATHE	6/23/22	5/31/25	Clinical Rese	14609840	CUMMINGS,	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$236,190	NIAID	$151,692	$84,498	$236,190
217	Training in Cardiovascula	PROJECT NARRATIVEThe	NHLBI	10863934	4/1/24	RFA-HL-19-024	5R25HL1560	156002	MEADOWS, TAWANNA	5/1/21	4/30/26	ZHL1-CSR-A	1859027	MARKS, AND	Not Applicab	PHYSIOLOGY	COLUMBIA U	5/1/24	4/30/25	Other Resear	2024	$123,984	NHLBI	$114,800	$9,184	$123,984
218	The Role of Social Determ	PROJECT NARRATIVEOve	NINR	10995462	7/2/24	PA-23-272	1F31NR0213	21330	WILLIS, LEIGH ANDREW	9/1/24	8/31/26	National Inst	15467797	HAHN, ALEXA	Not Applicab	OTHER HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$51,974	NINR	$51,974	$0	$51,974
219	Does self-reported psych	PROJECT NARRATIVEHyp	NICHD	11105757	8/6/24	PA-21-052	5F31HD1102	110257	MITCHELL, MEGAN S	9/1/23	8/31/25	Special Emph	15784692	CLEMONS, A	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/1/24	8/31/25	Training, Indi	2024	$48,214	NICHD	$48,214	$0	$48,214
220	Brain Research Apprenti	PROJECT NARRATIVEThe	NINDS	11058915	12/20/24	PAR-21-168	2R25NS1155	115551	MATTHEWS, MARGUER	12/5/20	1/31/30	Special Emph	9307525	SHOHAMY, D	EL-SHAMAYL	PSYCHOLOG	COLUMBIA U	2/1/25	1/31/26	Other Resear	2025	$135,000	NINDS	$125,000	$10,000	$135,000
221	Summer Institute for Trai	PROJECT NARRATIVETec	NHLBI	11011475	1/2/25	RFA-HL-22-009	5R25HL1617	161786	COADY, SEAN	1/15/22	12/31/26	ZHL1-CSR-A	7347011	BERHANE, KI	MAURO, CHR	BIOSTATISTIC	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$238,222	NHLBI	$155,181	$8,041	$163,222
222	Summer Institute for Trai	PROJECT NARRATIVETec	NHLBI	11011475	1/2/25	RFA-HL-22-009	5R25HL1617	161786	COADY, SEAN	1/15/22	12/31/26	ZHL1-CSR-A	7347011	BERHANE, KI	MAURO, CHR	BIOSTATISTIC	COLUMBIA U	1/1/25	12/31/25	Other Resear	2025	$238,222	OD	$71,306	$3,694	$75,000
223	The linkage between Rac	Elevated expression of th	NCI	10891394	9/11/24	PAR-18-654	5R01CA2533	253368	MERCER, NATALIA	9/24/20	6/30/25	Special Emph	1926891	GARDNER, K	Not Applicab	PATHOLOGY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$625,704	NCI	$482,854	$142,850	$625,704
224	A Multilevel Investigation	Project NarrativeMexico	NIA	10979824	8/26/24	RFA-AG-24-028	1R01AG0891	89174	BANDIERA, FRANK	9/1/24	5/31/29	Special Emph	11055051	ZEKI AL HAZZ	GLYMOUR, M	PUBLIC HEAL	COLUMBIA U	9/1/24	5/31/25	Non-SBIR/ST	2024	$839,262	NIA	$608,095	$231,167	$839,262
225	The SDOH-Homecare Int	Project Narrative: Stroke	NINDS	11012850	2/19/25	PA-20-183	5U01NS1355	135533	SANKAR, CHERYSE A	2/1/24	1/31/29	Health Servic	8840097	WILLIAMS, OL	MARSHALL, R	NEUROLOGY	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$1,086,080	NINDS	$710,421	$375,659	$1,086,080
226	CE24-001 Columbia Cen	Columbia Center for Inju	NCIPC	10762286	7/29/24	RFA-CE-24-001	1R49CE0035	3555		8/1/24	7/31/29	Special Emph	1974739	BRANAS, CH	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other	2023	$849,985	NCIPC			$849,985
227	Dissecting the role of lon	PROJECT NARRATIVELon	NIDA	11003839	7/22/24	PAR-23-194	1R36DA0616	61635	DUNSTON, SHEBA KIN	8/1/24	7/31/26	Special Emph	78302176	MARZIALI, ME	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$51,390	NIDA	$48,116	$3,274	$51,390
228	Drinking water contamin	PROJECT NARRATIVEClir	NIEHS	10727706	9/8/23	PA-20-200	1R03ES0355	35509	BOYLES, ABEE	9/10/23	8/31/25	Reproductive	14259321	GOIN, DANA	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/10/23	8/31/25	Non-SBIR/ST	2023	$185,979	NIEHS	$124,036	$61,943	$185,979
229	HIV Intervention Science	PROJECT NARRATIVE The	NIMH	10442449	8/21/23	PAR-15-145	5R25MH0806	80665	ALLISON, SUSANNAH	4/16/07	6/30/25	ZMH1-ERB-X	1891871	EL-BASSEL, N	WU, ELWIN	OTHER HEAL	COLUMBIA U	7/1/23	6/30/25	Other Resear	2023	$132,524	NIMH	$245,414	$19,633	$132,524
230	GLASS-AD: Global Latino	NARRATIVE.Hispanics/La	NIA	10935947	8/29/24	PAR-21-212	5U01AG0818	81817	BENNANI-BAITI, MICH	9/30/23	8/31/28	ZAG1-ZIJ-4(J2	11677901	TOSTO, GIUS	MARTIN, EDE	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	$2,682,382	NIA	$2,341,785	$340,597	$2,682,382
231	Pediatric Heart Network	PROJECT NARRATIVEThe	NHLBI	11005047	12/24/24	RFA-HL-24-001	5UM1HL1727	172720	OJESE, OLANREWAJU (	1/1/24	12/31/30	ZHL1-CSR-Q	14396086	RICHMOND,	ANDERSON,	PEDIATRICS	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$419,349	NHLBI	$298,514	$120,835	$419,349
232	Prenatal Exposure to Air	NARRATIVEThis proposal	NIEHS	10981407	9/5/24	PA-20-185	1R01ES0357	35792	GRAY, KIMBERLY A	9/6/24	6/30/29	Social and En	10550576	MARGOLIS, A	FOX, NATHAN	PSYCHIATRY	COLUMBIA U	9/6/24	6/30/25	Non-SBIR/ST	2024	$701,902	NIEHS	$494,571	$207,331	$701,902
233	Strengthening Healthcar	Project NarrativeThe pro	NINDS	11062246	9/10/24	PA-20-272	3R01NS1236	123639	YIN, XILING	6/15/21	6/30/25	Acute Neura	11309584	MASTERSON	GAUDINO, M	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$157,869	OD	$95,969	$61,900	$157,869
234	Summer Biomechanics B	NARRATIVEThe 2023-202	NIBIB	10836043	5/29/24	PA-21-151	5R13EB0350	35037	GUTEKUNST, DAVID JO	6/1/23	5/31/26	ZEB1-OSR-E	7075581	THOMOPOUL	Not Applicab	ORTHOPEDIC	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$10,000	NIBIB	$10,000	$0	$10,000
235	Doxy4STICare - Doxycyc	Narrative: This study aim	NIAID	11035852	3/11/24	PA-20-185	1R56AI18234	182347	HUEBNER, ROBIN E	3/11/24	2/28/26	HIV Comorbic	14634337	ZUCKER, JAS	Not Applicab	INTERNAL ME	COLUMBIA U	3/11/24	2/28/26	Non-SBIR/ST	2024	$837,185	NIAID	$508,927	$328,258	$837,185
236	Characterizing Sleep ART	PROJECT NARRATIVEUsi	NHLBI	10920401	8/27/24	RFA-HL-21-018	5R01HL1603	160325	DIXIT, SHILPY	9/15/21	7/31/26	ZHL1-CSR-Q	11872940	DUNCAN, DU	SCHNEIDER,	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$774,324	NHLBI	$654,575	$119,749	$774,324
237	The impact of a culturally	Preterm birth occurs at u	NIMHD	10992173	11/28/24	PAR-21-100	5R01MD0168	16899	MUJURU, PRISCAH	4/16/23	11/30/27	ZNS1-SRB-E	1916168	CORWIN, ELI	LOEWY, JOAN	OTHER HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$618,862	NIMHD	$530,964	$87,898	$618,862
238	A randomized trial of Imp	PROJECT NARRATIVENea	NIMH	10615902	6/7/23	PA-18-274	5R01MH1180	118004	SENN, THERESA ELAIN	8/23/19	5/31/25	Population a	1893302	SIKKEMA, KAT	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$607,390	NIMH	$480,303	$127,087	$607,390
239	Preparing for pre-exposu	Project NarrativeTo stem	FIC	10884348	7/8/24	PAR-19-376	5R33TW0117	11752	NEWSOME, BRAD	9/9/20	6/30/25	Special Emph	10397136	LELUTIU-WEI	PACHANKIS,	OTHER HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$327,558	FIC	$246,265	$81,293	$327,558
240	Stress hazardous drinking a	PROJECT NARRATIVEStudi	NIAAA	10911104	8/5/24	PA-20-190	5K01AA02853	28532	FREEMAN, ROBERT	9/1/21	8/31/26	Clinical, Treatn	14429074	FORD, JESSIE	Not Applicable	PUBLIC HEALT	COLUMBIA UN	9/1/24	8/31/25	Other Research	2024	$140,687	NIAAA	$130,266	$10,421	$140,687
241	MyPEEPS Mobile LITE: Lir	PROJECT NARRATIVEAdd	NIAID	11081972	8/1/24	RFA-AI-21-018	4UH3AI16965	169658	ZIMAND, LORI B.	9/1/22	7/31/27	ZAI1-KSW-A(J	9765581	SCHNALL, RE	DUNCAN, DU	OTHER HEAL	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$2,497,744	NIAID	$2,615,064	$1,015,363	$2,497,744
242	Building mobile HIV preven	Project NarrativeThis projec	NIMH	10632778	8/10/22	PA-21-268	7R01MH1168	116829	GREENWOOD, GREGORY	9/5/18	6/30/25	Behavioral and	10397136	LELUTIU-WEIN	PACHANKIS, J	OTHER HEALT	COLUMBIA UN	8/11/22	6/30/25	Non-SBIR/STT	2022	$768,346	NIMH	$542,762	$225,584	$768,346
243																										
244	Obesogenic origins of ma	PROJECT NARRATIVEThe	NICHD	10850865	7/15/24	PA-19-056	5R01HD1045	104599	MAJJI, SAI PRASANNA	9/25/20	6/30/25	Special Emph	8345946	ABRAMS, ELA	JAO, JENNIFE	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$2,452,419	NICHD	$2,380,040	$72,379	$2,452,419
245	Trial of Human Milk Oligo	Project Narrative:Childre	NICHD	10857315	6/21/24	PA-18-480	5R01HD1054	105492	MAJJI, SAI PRASANNA	6/1/21	5/31/26	HIV Comorbic	12518193	SHIVAKOTI, R	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/24	5/31/25	Non-SBIR/ST	2024	$732,299	NICHD	$580,457	$151,842	$732,299
246	Targeting TB transmission h	Project NarrativeA critical ba	NIAID	10827921	5/6/24	PA-20-185	5R01AI15117	151173	LACOURCIERE, KAREN A	5/11/21	4/30/26	Infectious Dise	10783316	MATHEMA, BA	NAIDOO, KOG	PUBLIC HEALT	COLUMBIA UN	5/1/24	4/30/25	Non-SBIR/STT	2024	$632,098	NIAID	$525,367	$106,731	$632,098
247	Automated Digital Imagir	Project NarrativeWe pro	NCI	10880245	6/5/24	PA-19-056	5R01CA2545	254576	VILLALOBOS, AUBREY V	7/6/20	6/30/25	HIV Comorbic	1872852	KUHN, LOUIS	Not Applicab	NEUROLOGY	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$470,853	NCI	$329,527	$141,326	$470,853
248	Strengthening informed co	Public Health Relevance: S	NICHD	11008251	8/6/24	PA-20-194	1R21HD1154	115480	ESBER, ALLAHNA LAURE	8/6/24	7/31/26	Population an	1872852	KUHN, LOUISE	Not Applicable	NEUROLOGY	COLUMBIA UN	8/6/24	7/31/25	Non-SBIR/STT	2024	$295,355	NICHD	$238,798	$56,557	$295,355
249	Emergence of bedaquilin	PROJECT NARRATIVEBed	NIAID	10977076	10/30/24	PA-20-185	5R01AI16993	169938	LACOURCIERE, KAREN	11/25/22	10/31/27	Special Emph	10783316	MATHEMA, B	GANDHI, NE	PUBLIC HEAL	COLUMBIA U	11/1/24	10/31/25	Non-SBIR/ST	2025	$722,084	NIAID	$585,910	$136,174	$722,084
250	mHealth and Mobile Ultras	PROJECT NARRATIVEThe p	NICHD	10693537	8/3/23	PA-21-268	7R21HD1030	103053	WEINBERG, DAVID H.	9/3/22	8/31/25	Special Empha	11309584	MASTERSON (	Not Applicable	Unavailable	COLUMBIA UN	9/3/22	8/31/25	Non-SBIR/STT	2022	$174,031	NICHD	$120,785	$48,246	$169,031
251	Sleep health of preschoo	This K01 International Re	FIC	10931620	9/14/24	PAR-21-105	5K01TW0124	12425	HAYES, UNJA	9/21/23	8/31/28	Special Emph	12203848	SANIA, AYESH	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$151,698	FIC	$141,855	$9,843	$151,698
252	International Workshops	PROJECT NARRATIVEThe	NICHD	10884394	6/26/24	PA-21-151	5R13HD1103	110322	LEE, SONIA S	8/1/22	7/31/25	Pediatrics St	8345946	ABRAMS, ELA	Not Applicab	PUBLIC HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$74,999	NICHD	$74,999	$0	$74,999
253	Fragile Families Summer	PROJECT NARRATIVEThis	NICHD	10919203	7/15/24	PAR-18-217	5R25HD0745	74544	JEKIELEK, SUSAN	2/7/13	7/31/25	Population Sc	10237406	MINCY, RON	GARFINKEL, I	OTHER HEAL	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$161,460	NICHD	$149,592	$11,868	$161,460
254	mHealth and Mobile Ultr	PROJECT NARRATIVEThe	NICHD	10693537	8/3/23	PA-21-268	7R21HD1030	103053	WEINBERG, DAVID H.	9/3/22	8/31/25	Special Emph	11309584	MASTERSON	Not Applicab	Unavailable	COLUMBIA U	9/3/22	8/31/25	Non-SBIR/ST	2022	$174,031	FIC	$3,573	$1,427	$5,000
255	An effectiveness trial of WIN	The proposed study interve	NIAAA	10923881	8/5/24	RFA-AA-21-016	7R01AA03046	30462	FREEMAN, ROBERT	9/1/22	6/30/27	ZAA1-DD(17)V	11496912	DASGUPTA, A	GILBERT, LOU	PUBLIC HEALT	COLUMBIA UN	7/1/24	6/30/25	Non-SBIR/STT	2024	$717,423	NIAAA	$454,525	$262,898	$717,423
256	The TAIL-PrEP Study: Acc	Project NarrativePotent	NIMH	10700242	9/18/23	PA-20-145	1R21MH1337	133755	STIRRATT, MICHAEL J	9/18/23	9/17/25	HIV/AIDS Intr	11019999	MEYERS, KAT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/23	9/17/25	Non-SBIR/ST	2023	$483,983	OD	$164,981	$100,051	$265,032
257	Guyana Research in Injur	Although Guyana has the	FIC	10900711	8/16/24	RFA-TW-21-003	5D43TW0121	12189	LEVINTOVA, MARYA	9/15/21	8/31/26	Special Emph	7947406	HOVEN, CHR	Not Applicab	PSYCHIATRY	COLUMBIA U	9/1/24	8/31/25	Other Resear	2024	$262,065	FIC	$253,858	$8,207	$262,065
258	The TAIL-PrEP Study: Acc	Project NarrativePotent	NIMH	10700242	9/18/23	PA-20-145	1R21MH1337	133755	STIRRATT, MICHAEL J	9/18/23	9/17/25	HIV/AIDS Intr	11019999	MEYERS, KAT	Not Applicab	INTERNAL ME	COLUMBIA U	9/18/23	9/17/25	Non-SBIR/ST	2023	$483,983	NIMH	$136,297	$82,654	$218,951
259	Using wastewater survei	Project NarrativeSARS-C	NIAID	10762470	12/12/23	PA-20-195	5R21AI17574	175747	BOZICK, BROOKE ALLIS	1/10/23	12/31/25	Modeling and	11805024	YANG, WAN	Not Applicab	PUBLIC HEAL	COLUMBIA U	1/1/24	12/31/25	Non-SBIR/ST	2024	$205,625	NIAID	$125,000	$80,625	$205,625
260	Harnessing Bioinformatics f	Project Narrative:Pre-expos	NIAID	10886003	7/12/24	PA-19-119	5K23AI15037	150378	MCKAIG, ROSEMARY G	8/1/20	7/31/25	Acquired Imm	14634337	ZUCKER, JASO	Not Applicable	INTERNAL ME	COLUMBIA UN	8/1/24	7/31/25	Other Research	2024	$192,024	NIAID	$178,200	$13,824	$192,024
261	Bronx Environmental Healt	Project NarrativeThe propo	NIEHS	11058265	1/30/25	PAR-21-168	1R25ES03601	36012	HUMBLE, MICHAEL C.	2/1/25	1/31/30	Special Empha	11722514	HILPERT, MAR	VAN HORNE, Y	PUBLIC HEALT	COLUMBIA UN	2/1/25	1/31/26	Other Research	2025	$132,347	NIEHS	$124,988	$7,359	$132,347
262	A Multi-site Multi-Setting RC	Public Health RelevanceInj	NIDA	10217065	8/3/22	PAS-16-018	5R01DA0457	45713	LAO, GUIFANG	9/30/17	7/31/25	ZDA1-HXO-H(	1955316	METSCH, LISA	BRUNEAU, JUL	PUBLIC HEALT	COLUMBIA UN	8/1/22	7/31/25	Non-SBIR/STT	2022	$1,217,167	NIDA	$1,156,400	$60,767	$1,217,167
263	RFA-PS-21-003: PrEP Cho	PROJECT NARRATIVEMe	NCHHSTP	10844338	6/25/24	RFA-PS-21-003	5U01PS00522	5229		9/30/21	9/29/26	ZPS1-GCA(48	9765581	SCHNALL, RE	Not Applicab	NONE	COLUMBIA U	9/30/24	9/29/25	Non-SBIR/ST	2024	$1,038,792	NCHHSTP			$1,038,792
264	ICAP Clinical Trials Unit	PROJECT NARRATIVEThe	NIAID	10975364	11/11/24	RFA-AI-19-045	5UM1AI15446	154468	GUBB, STEPHANIE MAJ	12/1/20	11/30/27	ZAI1-RCU-A($	1871336	EL-SADR, WA	JUSTMAN, JES	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$820,936	NIAID	$615,399	$157,021	$772,420
265	ICAP Clinical Trials Unit	PROJECT NARRATIVEThe	NIAID	10975364	11/11/24	RFA-AI-19-045	5UM1AI15446	154468	GUBB, STEPHANIE MAJ	12/1/20	11/30/27	ZAI1-RCU-A($	1871336	EL-SADR, WA	JUSTMAN, JES	PUBLIC HEAL	COLUMBIA U	12/1/24	11/30/25	Non-SBIR/ST	2025	$820,936	NIDA	$38,654	$9,862	$48,516
266	Center for High-Throughp	This Program represents	NIAID	10891553	7/19/24	RFA-AI-19-012	5U19AI06777	67773	TALIAFERRO, LANYN P.	8/31/05	7/31/25	ZAI1-JA-I(J1)	1868601	BRENNER, D	Not Applicab	RADIATION-D	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$5,348,648	OD	$4,286,746	$1,061,902	$5,348,648
267	A Tolerance Approach to	Project NarrativeThis is a	NIAID	10991705	12/20/24	PAR-20-072	5P01AI04589	45897	NABAVI, NASRIN N.	9/15/00	12/31/26	ZAI1-LAR-X(M	1887410	SYKES, MEGA	SACHS, DAVI	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Non-SBIR/ST	2025	$3,181,738	NIAID	$1,964,036	$1,217,702	$3,181,738
268	Opportunities Fund Mana	n/a	NIAID	10891556	7/19/24	RFA-AI-19-012	5U19AI06777	67773		8/31/05	7/31/25	ZAI1-JA-I	1942267	AMUNDSON,	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024			$2,781,929	$391,796	$3,173,725
269	Engineering protease-res	The outbreak of SARS-Co	NIAID	11177103	9/4/24	PAR-20-178	4R01AI16096	160961	PLIMACK, MARY KATHE	8/1/21	7/31/26	ZAI1-ZL-W(J2	1878831	MOSCONA, A	Not Applicab	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$714,282	NIAID	$569,159	$145,123	$714,282
270	Fusion inhibitors that blo	The recent and ongoing o	NIAID	11177101	9/4/24	PAR-20-178	4R01AI16095	160953	BASU, DIPANWITA	8/1/21	7/31/26	ZAI1-ZL-W(J2	8439631	POROTTO, M	DE SWART, R	PEDIATRICS	COLUMBIA U	8/1/24	7/31/25	Non-SBIR/ST	2024	$711,960	NIAID	$545,111	$166,849	$711,960
271	Quantifying Error Growth	PROJECT NARRATIVEIn t	NIAID	10623347	5/3/23	PA-20-185	5R01AI16302	163023	GEZMU, MISRAK	6/9/21	5/31/27	Special Emph	8466769	SHAMAN, JEF	Not Applicab	PUBLIC HEAL	COLUMBIA U	6/1/23	5/31/25	Non-SBIR/ST	2023	$649,085	NIAID	$403,484	$245,601	$649,085
272	COVID-19 Mother Baby (	NARRATIVEThe devastat	NIMH	11073000	1/22/25	PA-20-185	5R01MH1265	126531	ZEHR, JULIA L	4/12/21	1/31/26	Development	8077959	DUMITRIU, D	MARSH, RAC	PEDIATRICS	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$644,816	NIMH	$455,455	$189,361	$644,816
273	Immunologic and Predict	Multisystem inflammato	NICHD	10866496	8/7/24	PA-20-185	5R01HD1084	108467	MAJJI, SAI PRASANNA	7/18/22	6/30/27	Special Emph	10812148	BOGUNOVIC	Not Applicab	PEDIATRICS	COLUMBIA U	7/1/24	6/30/25	Non-SBIR/ST	2024	$531,183	NICHD	$359,936	$171,247	$531,183
274	Elucidating the impact of	PROJECT NARRATIVE:The	NIAID	10785394	8/15/24	PA-20-203	1K08AI18034	180347	ARNOLD, MICHELLE M	8/15/24	7/31/29	Allergy, Immu	10786718	BOWEN, ANT	Not Applicab	INTERNAL ME	COLUMBIA U	8/15/24	7/31/25	Other Resear	2024	$193,644	NIAID	$179,300	$14,344	$193,644
275	Evaluating the Epidemiol	PROJECT NARRATIVENeu	NIAID	10894841	8/22/24	PA-20-205	5K23AI17126	171263	GONDRE-LEWIS, TIMO	8/16/22	7/31/26	Microbiology	15670222	PURPURA, LA	Not Applicab	INTERNAL ME	COLUMBIA U	8/1/24	7/31/25	Other Resear	2024	$192,260	NIAID	$178,200	$14,060	$192,260
276	Neurocognitive & neurop	Public Health Relevance	NIDCD	10846774	5/22/24	PA-20-205	5K23DC0196	19678	RIVERA-RENTAS, ALBE	6/1/21	5/31/26	Communicat	9698876	OVERDEVEST	Not Applicab	OTOLARYNG	COLUMBIA U	6/1/24	5/31/25	Other Resear	2024	$178,610	NIDCD	$165,380	$13,230	$178,610
277	Enhancing Nurse Practit	PROJECT NARRATIVEAdd	NINR	11012314	2/14/25	PAR-20-310	5R01NR0210	21007	MCNAMARA, KAREN M	4/7/23	1/31/27	Healthcare a	9844694	POGHOSYAN	Not Applicab	OTHER HEAL	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$717,434	NINR	$476,613	$240,821	$717,434
278	Communicating Narrativ	Project NarrativeIn this r	NINR	11018608	1/28/25	PA-20-185	5R01NR0169	16941	MCNAMARA, KAREN M	4/6/17	1/31/27	Clinical Infor	8414539	ROSSETTI, SA	CATO, KENRI	INTERNAL ME	COLUMBIA U	2/1/25	1/31/26	Non-SBIR/ST	2025	$715,057	NINR	$569,395	$145,662	$715,057
279	Clinical Operations and	n/a	NIA	10924048	8/20/24	PAR-19-374	5U19AG0785	78558		9/1/22	8/31/27	ZAG1-ZIJ-5	10523321	TEMPROSA, N	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Non-SBIR/ST	2024	##########		##########	$115,984	##########
280	Clinical and Translationa	Project Narrative Page 2	NCATS	10893961	6/12/24	PAR-18-940	5UL1TR00187	1873	ATIENZA, AUDIE A	8/1/22	5/31/26		6205023	REILLY, MURE	Not Applicab	INTERNAL ME	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	##########	NCATS	$6,379,791	$3,908,575	##########
281	Cancer Center Support (	OVERALL: NARRATIVECa	NCI	10880379	6/6/24	PAR-17-095	5P30CA0136	13696	BELIN, PRECILLA L.	7/4/97	6/30/25	Cancer Cent	1868587	RUSTGI, ANIL	Not Applicab	INTERNAL ME	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$5,302,111	NCI	$3,272,908	$2,029,203	$5,302,111
282	Alzheimer's Disease Rese	OVERALL NARRATIVEThe	NIA	10885042	6/21/24	RFA-AG-20-004	5P30AG0664	66462	SILVERBERG, NINA B.	6/15/20	4/30/25	ZAG1-ZIJ-G(J	1884949	SMALL, SCOT	Not Applicab	NEUROLOGY	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$3,035,934	NIA	$1,926,030	$1,109,904	$3,035,934
283	A Multi-scale Atlas of Ser	OVERALL: PROJECT NAR	NIA	10898652	8/12/24	RFA-RM-21-008	5U54AG0760	76040	FRIDELL, YIH-WOEI	9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	CHRISTIANO	NEUROLOGY	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,587,409	OD	$2,156,497	$925,931	$2,587,409
284	Prospective Genetic Risk	PROJECT NARRATIVEThe	NICHD	10916374	8/26/24	RFA-HD-22-008	5P50HD1098	109879	KAU, ALICE S	9/6/22	8/31/27	Special Emph	8746379	VEENSTRA-V	CHUNG, WEN	PEDIATRICS	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,373,156	NICHD	$1,481,345	$641,811	$2,123,156
285	Prospective Genetic Risk	PROJECT NARRATIVEThe	NICHD	10916374	8/26/24	RFA-HD-22-008	5P50HD1098	109879	KAU, ALICE S	9/6/22	8/31/27	Special Emph	8746379	VEENSTRA-V	CHUNG, WEN	PEDIATRICS	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$2,373,156	NIEHS	$174,428	$75,572	$250,000

A2767

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
286	Center for Solutions for N	NARRATIVEThe Center fo	NINDS	10878252	9/2/24	RFA-NS-24-022	1U54NS1371	137199	DALEY, WILLIAM PATRI	9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/3/24	8/31/25	Research Ce	2024	$1,968,142	NINDS	$697,351	$270,791	$968,142
287	Center for Solutions for N	NARRATIVEThe Center fo	NINDS	10878252	9/2/24	RFA-NS-24-022	1U54NS1371	137199	DALEY, WILLIAM PATRI	9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	PUBLIC HEAL	COLUMBIA U	9/3/24	8/31/25	Research Ce	2024	$1,968,142	NCCIH	$180,075	$69,925	$250,000
288	Columbia University and	NarrativeHazardous met	NIEHS	10877756	6/25/24	RFA-ES-20-014	5P42ES03371	33719	CARLIN, DANIELLE J.	9/21/22	6/30/27	ZES1-LAT-S(S	8696712	NAVAS-ACIEN	Not Applicab	PUBLIC HEAL	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,791,523	NIEHS	$1,273,206	$518,317	$1,791,523
289	Center for Cancer Syster	PROJECT NARRATIVEThe	NCI	10931548	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	7827402	CALIFANO, A	HONIG, BARR	INTERNAL ME	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,736,052	NCI	$1,093,908	$642,144	$1,736,052
290	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NINDS	$1,573,209	$635,680	$796,311
291	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NCATS	$1,036,744	$418,912	$524,769
292	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	NICHD	$395,124	$159,655	$200,000
293	The North American Mito	As research on the mitoc	NINDS	10699986	9/18/23	RFA-TR-18-020	5U54NS0780	78059	HARTMAN, ADAM L.	9/30/11	8/31/25	ZTR1-RD-8(0	1880690	HIRANO, MIC	Not Applicab	NEUROLOGY	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,571,080	OD	$98,781	$39,913	$50,000
294	New York Obesity Resear	PROJECT NARRATIVEThe	NIDDK	10817164	5/9/24	RFA-DK-19-002	5P30DK0266	26687	EVANS, MARY	12/1/96	3/31/26	ZDK1-GRB-2	1869280	GALLAGHER,	FERRANTE, A	INTERNAL ME	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,221,081	NIDDK	$820,033	$401,048	$1,221,081
295	The Columbia University	NARRATIVEThe Columbia	NIDDK	10818417	5/7/24	RFA-DK-19-004	5P30DK1327	132710	SERRANO, KATRINA JA	4/30/22	3/31/27	ZDK1-GRB-7	8447367	SCHWABE, R	Not Applicab	INTERNAL ME	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,204,298	NIDDK	$732,096	$472,202	$1,204,298
296	Investigating the Genetic	OVERALL: NARRATIVELov	NIDDK	10897733	7/24/24	RFA-DK-20-008	5U54DK1043	104309	NIHALANI, DEEPAK	9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	BARASCH, JC	UROLOGY	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$1,200,000	NIDDK	$769,851	$430,149	$1,200,000
297	Molecular Correlates of S	PROJECT NARRATIVEPeo	NINDS	10878254	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$1,186,570		$777,943	$408,627	$1,186,570
298	NAMDC Clinical Registry	n/a	NINDS	10699998	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$1,179,830		$840,296	$339,534	$1,179,830
299	Columbia Roybal Center	Project NarrativeMost ad	NIA	10875092	8/12/24	RFA-AG-24-006	2P30AG0641	64198	ONKEN, LISA	9/15/19	5/31/29	Special Emph	9193205	KRONISH, IAN	MOISE, NATH	INTERNAL ME	COLUMBIA U	8/15/24	5/31/25	Research Ce	2024	$1,121,471	NIA	$817,721	$303,750	$1,121,471
300	Administrative Core	n/a	NIMHD	11177217	8/27/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	7/1/24	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$1,025,313		$787,662	$237,651	$1,025,313
301	Project 3: Developmenta	n/a	NICHD	10916387	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	8465923	AMSO, DIMA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$1,009,214		$613,504	$395,710	$1,009,214
302	Columbia-Cornell-Einste	Disparities in healthcare	AHRQ	11004283	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	10386412	ADELMAN, JA	ALCANTARA,	INTERNAL ME	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$996,724	AHRQ	$699,385	$297,339	$996,724
303	Biological Analysis Core	n/a	NIA	10898662	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$967,665		$626,730	$340,935	$967,665
304	Living Healthy for Moms	n/a	NICHD	10908626	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	11628850	OSBORNE, L	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$941,193		$803,483	$137,710	$941,193
305	Clinical Core	n/a	NIA	10885045	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	9773845	NOBLE, JAME	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$841,656		$519,541	$322,115	$841,656
306	Roybal Center for Fearle	n/a	NIA	10875094	8/12/24	RFA-AG-24-006	2P30AG0641	64198		9/15/19	5/31/29	Special Emph	12100576	MOISE, NATH	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$827,484		$639,005	$188,479	$827,484
307	Core Facilities for Vision	Project NarrativeVision i	NEI	10896239	8/23/24	PAR-20-051	5P30EY0190	19007	GOVER, TONY DOUGLA	7/1/10	6/30/26	ZEY1-VSN(07	7367717	GOLDBERG,	Not Applicab	OPHTHALMO	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$808,380	NEI	$499,000	$309,380	$808,380
308	Administrative Core	n/a	NIA	10898653	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	10321663	PHATNANI, H	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$778,367		$480,474	$297,893	$778,367
309	Administrative Core	n/a	NIA	10885044	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	1884949	SMALL, SCOT	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$769,214		$474,823	$294,391	$769,214
310	Research and Data Analy	n/a	AHRQ	11004299	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	11309584	MASTERSON	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$767,567		$543,123	$224,444	$767,567
311	Administrative Core	n/a	NINDS	10699995	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$755,914		$538,375	$217,539	$755,914
312	Investigator Developmer	n/a	NIMHD	10897790	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	7120933	SHIMBO, DAI	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$654,700		$419,210	$235,490	$654,700
313	Columbia Center for Inte	PROJECT NARRATIVEThe	NIA	10909374	7/25/24	RFA-AG-23-025	5P30AG0593	59303	BANDIERA, FRANK	9/1/18	6/30/28	ZAG1-ZIJ-4(M	2261261	MANLY, JENN	BRICKMAN, A	NEUROLOGY	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$641,307	NIA	$515,243	$126,064	$641,307
314	Project 3-CommunityHe	NARRATIVEThe CHURCH	NIMHD	10897805	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	8840097	WILLIAMS, OL	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$634,066		$425,098	$208,968	$634,066
315	Administrative Core	n/a	NIMHD	10897780	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$633,012		$406,263	$226,749	$633,012
316	CONNECTOME-Commu	n/a	NIMHD	10897786	8/1/24	RFA-MD-21-007	5P50MD0173	17341		9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$629,596		$490,982	$138,614	$629,596
317	Career Enhancement Pro	n/a	NINDS	10700016	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880694	HAAS, RICHA	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$615,493		$438,365	$177,128	$615,493
318	Translational Research S	n/a	NIEHS	10851724	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8853211	CHILLRUD, S	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$532,335		$328,674	$203,661	$532,335
319	Mitochondrial functiona	n/a	NINDS	10700003	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1973197	VAN HOVE, JO	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$497,390		$354,250	$143,140	$497,390
320	Biospecimen Core	n/a	NIA	10898656	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	1894412	OWENS, DAV	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$455,184		$307,959	$147,225	$455,184
321	Tissue Engineering Resou	n/a	NIBIB	10848083	6/6/24	PAR-20-169	2P41EB02706	27062		9/16/19	2/28/29	Special Emph	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$445,884		$307,242	$138,642	$445,884
322	Administrative Core	n/a	NIEHS	10851720	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8651962	BACCARELLI,	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$440,749		$267,933	$172,816	$440,749
323	Genotypic Analysis of ME	PROJECT NARRATIVEA he	NINDS	10878255	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	11229447	PONTING, CH	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$437,634		$431,876	$5,758	$437,634
324	NY-CHAMP Community E	n/a	NICHD	10908634	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	9403946	HALL, KELLI S	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$435,249		$355,191	$80,058	$435,249
325	Project 1: Identifying and	n/a	NICHD	10916384	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	1890713	CHUNG, WEN	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$400,487		$243,457	$157,030	$400,487
326	Data Analysis Core	n/a	NIA	10898660	8/12/24	RFA-RM-21-008	5U54AG0760	76040		9/30/21	8/31/26	Special Emph	14885882	MENON, VILA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$386,193		$296,267	$89,926	$386,193
327	Career Development and	n/a	NICHD	10908637	7/17/24	RFA-HD-23-035	5U54HD1131	113172		8/17/23	7/31/30	Special Emph	9807979	TAYLOR, JACO	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$385,389		$301,485	$83,904	$385,389
328	Genomic Testing for Mole	n/a	NINDS	10700001	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	11003865	KARAA, AMEL	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$374,245		$266,544	$107,701	$374,245
329	Human phenotype (Core	n/a	NIDDK	10817169	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1869280	GALLAGHER,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$356,448		$229,999	$126,449	$356,448
330	Tissue Engineering Resou	n/a	NIBIB	10848082	6/6/24	PAR-20-169	2P41EB02706	27062		9/16/19	2/28/29	Special Emph	1943583	HUNG, CLAR	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$352,774		$218,392	$134,382	$352,774
331	Biomarker Core	n/a	NIA	10885054	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	7891222	BRICKMAN, A	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$343,652		$212,131	$131,521	$343,652
332	Expanded Access Deoxyr	There are no FDA-approv	NINDS	10700011	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$334,868		$238,499	$96,369	$334,868
333	Administrative and Engag	n/a	NCI	10931473	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	7012821	CASTOR, DEL	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$331,893		$238,874	$93,019	$331,893
334	Advanced Genetic Study	n/a	NINDS	10700006	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1927769	BEDOYAN, JI	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$331,873		$236,366	$95,507	$331,873
335	Imaging Histology and Fu	n/a	NEI	10896247	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	1933579	SPARROW, JA	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$322,638		$199,159	$123,479	$322,638
336	Research Project 1	n/a	NCI	10931482	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	16051833	SAIDU, RAKIY	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$318,356		$268,072	$50,284	$318,356
337	Neuropathology Core	n/a	NIA	10885050	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	10450717	TEICH, ANDR	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$312,508		$192,906	$119,602	$312,508
338	Tissue Engineering Resou	n/a	NIBIB	10848081	6/6/24	PAR-20-169	2P41EB02706	27062		9/16/19	2/28/29	Special Emph	2059300	KAPLAN, DAV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$304,639		$288,514	$16,125	$304,639
339	Roybal Center for Fearle	n/a	NIA	10875093	8/12/24	RFA-AG-24-006	2P30AG0641	64198		9/15/19	5/31/29	Special Emph	9193205	KRONISH, IAN	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$293,987		$178,716	$115,271	$293,987
340	Research Education Con	n/a	NIA	10909378	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	7033495	AIELLO, ALLIS	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$291,715		$278,009	$13,706	$291,715
341	Anga Center Capacity Bu	n/a	FIC	10982429	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	79487238	MUITA, RICH	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$277,209		$237,419	$39,790	$277,209
342	High Resolution Models c	Project 1 NarrativeThere	NIEHS	10877757	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	8853211	CHILLRUD, S	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$272,919		$172,836	$100,083	$272,919
343	Anga Center Community	n/a	FIC	10982428	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	79391762	MUHANGUZI	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$271,971		$215,850	$56,121	$271,971
344	Causal Molecular Mecha	Project 4 NarrativeArsen	NIEHS	10877761	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	10403982	PEARSON, BF	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$270,683		$176,497	$94,186	$270,683
345	Pilot	n/a	NINDS	10700012	9/18/23	RFA-TR-18-020	5U54NS0780	78059		9/30/11	8/31/25	ZTR1-RD-8	1880690	HIRANO, MIC	Not Applicab	Unavailable	COLUMBIA U	9/1/23	8/31/25	Research Ce	2023	$268,405		$191,163	$77,242	$268,405
346	Computer Core	n/a	NEI	10896243	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	6619355	ALLIKMETS, R	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$267,182		$164,927	$102,255	$267,182
347	Pilot Project Program	n/a	NIEHS	10851731	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	8875879	RE, DIANE BE	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$262,970		$159,860	$103,110	$262,970
348	Advanced Single Cell Tec	n/a	NCI	11171868	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	10946359	SIMS, PETER	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$259,748		$157,902	$101,846	$259,748
349	Leadership and Administ	n/a	NIA	10909375	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	2261261	MANLY, JENN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$257,034		$170,438	$86,596	$257,034
350	Administrative Core	n/a	NIDDK	10817165	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	7057421	LEIBEL, RUDO	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$254,749		$167,223	$87,526	$254,749
351	Administrative Core	n/a	NIDDK	10897735	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$253,820		$156,679	$97,141	$253,820
352	Integrated Data and Expo	n/a	NIA	10981248	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	7347011	BERHANE, KI	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$250,250		$152,128	$98,122	$250,250
353	The Administrative Core	n/a	NIDDK	10818418	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	8447367	SCHWABE, R	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$246,248		$149,695	$96,553	$246,248
354	Core C: Assessment Core	n/a	NICHD	10916382	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	1884921	KANNE, STEP	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$245,768		$170,672	$75,096	$245,768
355	A Novel Metabolic Pathw	n/a	NIDDK	10897761	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	8228433	BARASCH, JO	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$243,194		$160,708	$82,486	$243,194
356	Administrative Core	n/a	NIA	10981244	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	11035327	KIOUMOURTZ	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$242,814		$147,607	$95,207	$242,814
357	Human genetic approach	n/a	NIDDK	10897749	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	3169385	GHARAVI, ALI	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$241,161		$159,121	$82,040	$241,161
358	Research Capacity Build	n/a	NCI	10931477	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	14456149	DENNY, LYNE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$238,827		$192,143	$46,684	$238,827
359	Community Engagement	n/a	NIA	10981247	9/20/24	RFA-ES-23-007	1P20AG0939	93975		9/30/24	8/31/27	Special Emph	9509976	ZOTA, AMI R	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$237,610		$144,444	$93,166	$237,610
360	Anga Center Administrat	n/a	FIC	10982426	9/19/24	RFA-ES-23-007	1P20TW0128	12808		9/23/24	8/31/27	Special Emph	14103745	MUSYIMI, CH	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$236,930		$188,040	$48,890	$236,930
361	Community Engagement	n/a	NIEHS	10851729	5/10/24	RFA-ES-20-006	5P30ES00908	9089		7/1/98	4/30/28	Environmenta	9509976	ZOTA, AMI R	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$235,283		$166,623	$68,660	$235,283
362	Microbial Genomics Bior	n/a	NIDDK	10897744	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	9733196	UHLEMANN,	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$233,244		$143,978	$89,266	$233,244
363	Transcriptional regulatio	n/a	NIDDK	10897757	7/24/24	RFA-DK-20-008	5U54DK1043	104309		9/24/14	7/31/26	ZDK1-GRB-T	1909897	MENDELSOH	Not Applicab	Unavailable	COLUMBIA U	8/1/24	7/31/25	Research Ce	2024	$228,581		$149,365	$79,216	$228,581
364	Administrative Core	n/a	NINDS	10878253	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Emph	6916278	LIPKIN, W. IAN	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$228,352		$137,986	$90,366	$228,352
365	Administrative Core	n/a	NIMHD	11177216	8/26/24	PA-23-044	3P50MD0173	17341	STINSON, NATHANIEL	7/1/24	6/30/26	ZMD1-MLS(A	1884501	TERRY, MARY	COHN, ELIZA	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$226,727		$137,828	$88,899	$226,727
366	Data Management and A	NarrativeThe DMAC will	NIEHS	10877764	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	10781196	GOLDSMITH,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$221,085		$146,163	$74,922	$221,085
367	The Bioimaging Core	n/a	NIDDK	10818427	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	3127300	OLIVE, KENN	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$216,525		$131,626	$84,899	$216,525
368	The Clinical Biospecime	n/a	NIDDK	10818421	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9047196	ABRAMS, JUL	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$216,188		$131,421	$84,767	$216,188
369	Admin Core	n/a	NIMHD	10934597	8/1/24	RFA-MD-21-007	5P50MD0173	17341	STINSON, NATHANIEL	9/24/21	6/30/26	ZMD1-MLS	1884501	TERRY, MARY	HERSHMAN,	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$214,568		$131,074	$83,494	$214,568
370	Molecular Biology/Molec	n/a	NIDDK	10817183	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	14183064	EGLI, DIETER	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$207,281		$147,276	$60,005	$207,281
371	Core B: Statistical and C	n/a	NICHD	10916379	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	7740764	WALL, MELAN	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$205,785		$145,313	$60,472	$205,785
372	Light-Based Approaches	Project 5 NarrativeExpos	NIEHS	10877762	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	8270461	BOSTICK, BE	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$195,766		$143,409	$52,357	$195,766
373	Pilot and Feasibility Prog	n/a	NIDDK	10817190	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1927452	KORNER, JUD	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$194,306		$129,913	$64,393	$194,306
374	Instrumentation Fabricat	n/a	NEI	10896241	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	2093726	SILVERMAN,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$191,176		$118,010	$73,166	$191,176
375	Project 2: Psychosocial i	n/a	NICHD	10916385	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Emph	8236828	APPELBAUM,	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$186,214		$144,914	$41,300	$186,214
376	Administrative Core	n/a	AHRQ	11004290	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	10386412	ADELMAN, JA	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$183,870		$123,085	$60,785	$183,870
377	Research Project 2	n/a	NCI	10931485	7/29/24	RFA-CA-22-019	5U54CA2840	284030		9/19/23	8/31/28	ZCA1-SRB-2	12114400	MOODLEY, JE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$179,287		$151,358	$27,929	$179,287
378	Neuroimmunology Core	n/a	NIA	10885057	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	1925223	DE JAGER, PH	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$176,063		$108,681	$67,382	$176,063
379	Isotopic Tracing of Sourc	Project 2 NarrativeProje	NIEHS	10877759	6/25/24	RFA-ES-20-014	5P42ES03371	33719		9/21/22	6/30/27	ZES1-LAT-S	77993292	HALLIDAY, AL	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$175,669		$141,496	$34,173	$175,669
380	Data Management and S	n/a	NIA	10885048	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	2076195	ANDREWS, H	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$173,189		$125,570	$47,619	$173,189

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
381	The Bioinformatics and S	n/a	NIDDK	10818422	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	10946359	SIMS, PETER	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$169,960		$103,319	$66,641	$169,960
382	Core D: Dissemination a	n/a	NICHD	10916377	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Empl	8746379	VEENSTRA-V	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$165,343		$103,404	$61,939	$165,343
383	The Organoid and Cell Cu	n/a	NIDDK	10818425	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	7132013	NAKAGAWA,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$165,030		$100,322	$64,708	$165,030
384	Studying the evolution of	PROJECT NARRATIVEThe	NCI	11072772	9/3/24	PA-20-272	3U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1(M2)	7827402	CALIFANO, A	HONIG, BARR	INTERNAL MB	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$164,500	NCI	$100,000	$64,500	$164,500
385	Genetics Core	n/a	NIA	10885056	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	9349727	REITZ, CHRIS	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$164,206		$101,362	$62,844	$164,206
386	Clinical and Translationa	Project NarrativeIn this a	NCATS	11064191	8/7/24	PA-20-272	3UL1TR0018	1873	ATIENZA, AUDIE A	8/1/22	5/31/26		6205023	REILLY, MUR	Not Applicab	INTERNAL MB	COLUMBIA U	8/7/24	5/31/25	Research Ce	2024	$161,384	OD	$98,106	$63,278	$161,384
387	Core A: Administrative C	n/a	NICHD	10916375	8/26/24	RFA-HD-22-008	5P50HD1098	109879		9/6/22	8/31/27	Special Empl	1890713	CHUNG, WE	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$160,345		$97,474	$62,871	$160,345
388	Study Design and Data S	n/a	NIEHS	10851726	5/10/24	RFA-ES-20-006	5P30ES0090	9089		7/1/98	4/30/28	Environmenta	2409522	FACTOR-LITV	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$159,869		$97,185	$62,684	$159,869
389	Animal Phenotyping (Cor	n/a	NIDDK	10817174	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	6361245	SCHWARTZ,	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$151,772		$100,760	$51,012	$151,772
390	Outreach Recruitment a	n/a	NIA	10885052	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	12570380	ARCE, MIGUE	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$147,446		$91,016	$56,430	$147,446
391	Administrative Core	Administrative Core - Na	NIEHS	10877763	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8696712	NAVAS-ACIEN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$133,652		$83,031	$50,621	$133,652
392	Pathogen Discovery Thro	NARRATIVEWhat causes	NINDS	10878256	9/2/24	RFA-NS-24-022	1U54NS1371	137199		9/3/24	8/31/29	Special Empl	12386930	MISHRA, NIS	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$115,586		$69,845	$45,741	$115,586
393	Pilot and Feasibility Prog	n/a	NIDDK	10818429	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9695780	PAJVANI, UTP	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$113,773		$69,163	$44,610	$113,773
394	Research Education Cor	n/a	NIA	10885058	6/21/24	RFA-AG-20-004	5P30AG0664	66462		6/15/20	4/30/25	ZAG1-ZIJ-G	8152373	COSENTINO,	Not Applicab	Unavailable	COLUMBIA U	5/1/24	4/30/25	Research Ce	2024	$108,000		$100,000	$8,000	$108,000
395	Outreach Core	n/a	NCI	11171867	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	1878184	MURRAY, DIA	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$106,850		$64,955	$41,895	$106,850
396	Tissue Engineering Resou	n/a	NIBIB	10848080	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Empl	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$96,810		$58,851	$37,959	$96,810
397	Analysis Core	n/a	NIA	10909376	7/25/24	RFA-AG-23-025	5P30AG0593	59303		9/1/18	6/30/28	ZAG1-ZIJ-4	8735029	TERESI, JEAN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$92,558		$66,796	$25,762	$92,558
398	Community Engagement	Community Engagement	NIEHS	10877765	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	7698320	O'LEARY, MA	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$77,823		$73,818	$4,005	$77,823
399	The Enrichment Program	n/a	NIDDK	10818430	5/7/24	RFA-DK-19-004	5P30DK1327	132710		4/30/22	3/31/27	ZDK1-GRB-7	9365956	QUE, JIANWE	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$76,574		$46,550	$30,024	$76,574
400	Enrichment Program	n/a	NIDDK	10817197	5/9/24	RFA-DK-19-002	5P30DK0266	26687		12/1/96	3/31/26	ZDK1-GRB-2	1952696	FERRANTE, A	Not Applicab	Unavailable	COLUMBIA U	4/1/24	3/31/25	Research Ce	2024	$56,525		$44,862	$11,663	$56,525
401	Tissue Engineering Resou	n/a	NIBIB	10848084	6/6/24	PAR-20-169	2P41EB0270	27062		9/16/19	2/28/29	Special Empl	6912764	VUNJAK-NOV	Not Applicab	Unavailable	COLUMBIA U	6/1/24	5/31/25	Research Ce	2024	$55,247		$33,585	$21,662	$55,247
402	Research Experience and	RETCC NarrativeThe Res	NIEHS	10877766	6/25/24	RFA-ES-20-014	5P42ES0337	33719		9/21/22	6/30/27	ZES1-LAT-S	8696712	NAVAS-ACIEN	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$53,698		$33,360	$20,338	$53,698
403	Administrative Core	n/a	NCI	11171863	8/31/24	RFA-CA-21-048	5U54CA2745	274506	ZAMISCH, MONICA	9/19/23	8/31/28	ZCA1-RTRB-	7827402	CALIFANO, A	Not Applicab	Unavailable	COLUMBIA U	9/1/24	8/31/25	Research Ce	2024	$49,932		$30,353	$19,579	$49,932
404	Research Education Cor	n/a	AHRQ	11004294	12/5/24	RFA-HS-23-001	5P30HS0297	29763	GRIFFIOEN, MARI	1/1/24	12/31/28	ZHS1-HSR-B	12100576	MOISE, NATH	Not Applicab	Unavailable	COLUMBIA U	1/1/25	12/31/25	Research Ce	2025	$45,287		$33,177	$12,110	$45,287
405	Administrative Core	n/a	NEI	10896240	8/23/24	PAR-20-051	5P30EY0190	19007		7/1/10	6/30/26	ZEY1-VSN	7367717	GOLDBERG,	Not Applicab	Unavailable	COLUMBIA U	7/1/24	6/30/25	Research Ce	2024	$27,384		$16,904	$10,480	$27,384
406																										
407																										
408																					Total	##########				